

000950170-24-08932610-Q BridgeBio Pharma, Inc. 2024080120240801162446162446162446 0 0000950170-24-089326 10-Q 97 20240630 20240801 20240801 BridgeBio Pharma, Inc. 0001743881 2834 000000000 DE 1231 10-Q 34 0001-38959 241167124 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 BridgeBio Pharma LLC 20180618 10-Q 1 bbio-20240630.htm 10-Q 10 -12-310001743881Qfalsehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrent

gaap:CommonStockMemberbbio:TwoThousandAndTwentyOneStockOptionAndIncentivePlanMember2024-06-012024-06-300001743881us-gaap:BridgeBioServicesIncMember2023-01-012023-06-300001743881us-gaap:OtherConsolidatedEntitiesMember2023-04-012023-06-300001743881us-gaap:EmployeeStockOptionMemberbbio:TwoThousandAndNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2023-01-012023-06-300001743881us-gaap:FoundationMedicineDiagnosticsAgreementMemberbbio:FoundationMedicineIncMemberbbio:QEDTherapeuticsIncMember2018-11-302018-11-300001743881us-gaap:RegularEquityProgramMemberbbio:TwoThousandAndNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2023-12-310001743881us-gaap:LeaseAgreementsAndLettersOfCreditMember2024-06-300001743881us-gaap:StockCompensationPlanMemberus-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001743881us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-06-300001743881us-gaap:FairValueInputsLevel2Membersus-gaap:FairValueMeasurementsRecurringMember2024-06-300001743881us-gaap:OtherConsolidatedEntitiesMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-04-012023-06-300001743881us-gaap:ParentMemberus-gaap:StockCompensationPlanMember2023-01-012023-03-310001743881us-gaap:TreasuryStockCommonMember2022-12-310001743881us-gaap:OtherConsolidatedEntitiesMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001743881us-gaap:LicenseAndCollaborationAgreementMemberbbio:BristolMyersSquibbCompanyMember2022-06-300001743881us-gaap:FairValueInputsLevel1Membersus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2024-06-300001743881us-gaap:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember2020-03-090001743881us-gaap:InterestAdjustOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember2024-06-300001743881us-gaap:ParentMember2024-04-012024-06-300001743881us-gaap:RestrictedStockUnitsRSUMemberbbio:TwoThousandAndNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2024-04-012024-06-300001743881us-gaap:LicenseAndCollaborationAgreementMemberbbio:BristolMyersSquibbCompanyMember2024-06-300001743881us-gaap:FinancingAgreementMember2024-01-172024-01-170001743881us-gaap:AdditionalPaidInCapitalMember2024-06-300001743881us-gaap:USTreasuryBillSecuritiesMember2024-06-300001743881us-gaap:UnvestedPerformanceBasedRestrictedStockUnitMember2023-01-012023-06-300001743881us-gaap:OtherRSAsMemberbbio:TwoThousandAndNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2023-01-012023-06-300001743881us-gaap:UnvestedRestrictedStockAwardMember2024-01-012024-06-300001743881us-gaap:QEDTherapeuticsIncMember2023-12-310001743881us-gaap:EmployeeStockOptionMemberbbio:TwoThousandAndNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2024-01-012024-06-300001743881us-gaap:ShareRepurchaseTransactionsMemberbbio:TwoThousandAndTwentyOneCappedCallTransactionsMember2021-01-252021-01-250001743881us-gaap:FairValueInputsLevel3Membersus-gaap:FairValueMeasurementsRecurringMember2023-12-310001743881us-gaap:ShareRepurchaseTransactionsMemberbbio:TwoThousandAndTwentyOneCappedCallTransactionsMember2021-01-250001743881us-gaap:AssumedConversionOffTwoThousandAndTwentyNineNotesMember2023-01-012023-06-300001743881us-gaap:ParentMember2023-04-012023-06-300001743881us-gaap:CommonStockOptionsIssuedAndOutstandingMember2023-01-012023-06-300001743881us-gaap:USTreasuryBillSecuritiesMember2023-12-310001743881us-gaap:FoundationMedicineDiagnosticsAgreementMemberbbio:FoundationMedicineIncMemberbbio:QEDTherapeuticsIncMember2024-03-012024-03-310001743881us-gaap:CappedCallTransactionsMemberbbio:ShareRepurchaseTransactionsMember2020-03-042020-03-040001743881us-gaap:LicenseAndCollaborationAgreementMemberbbio:HelsinnTherapeuticsMember2021-03-292021-03-290001743881us-gaap:RestrictedStockMemberbbio:TwoThousandAndNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2024-06-300001743881us-gaap:ShortTermInvestmentsMember2024-06-300001743881us-gaap:EidosTherapeuticsIncMemberbbio:BayerExclusiveLicenseAgreementMemberbbio:SellerPartiesMember2024-05-012024-05-010001743881us-gaap:TwoThousandAndTwentyStockAndEquityAwardExchangeProgramMember2020-11-180001743881us-gaap:LoanAgreementMember2021-11-012021-11-300001743881us-gaap:QEDTherapeuticsIncMember2024-06-300001743881us-gaap:PrincipalValueOfConvertibleSeniorNotesDueTwoThousandAndTwentyNineAndTwoThousandAndTwentySevenMember2024-06-300001743881us-gaap:AdditionalPaidInCapitalMember2023-06-300001743881us-gaap:TwoThousandAndTwentyStockAndEquityAwardExchangeProgramMember2024-04-012024-06-300001743881us-gaap:CommonStockMember2022-12-310001743881us-gaap:EidosTherapeuticsIncMemberbbio:BayerExclusiveLicenseAgreementMember2024-04-012024-06-300001743881us-gaap:HelsinnTherapeuticsMemberbbio:QEDTherapeuticsIncMember2024-04-012024-06-300001743881us-gaap:QEDTherapeuticsIncMemberbbio:HelsinnMember2024-01-012024-06-300001743881us-gaap:PrincipalValueOnTwoPointFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember2024-06-300001743881us-gaap:EidosTherapeuticsIncMemberbbio:LelandStanfordJuniorUniversityMemberbbio:StanfordLicenseAgreementMember2023-01-012023-06-300001743881us-gaap:SatisfyTaxWithholdingMemberus-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001743881us-gaap:CommonStockMember2023-01-012023-03-310001743881us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001743881us-gaap:RedeemableConvertibleNoncontrollingInterestsMember2023-01-012023-03-310001743881us-gaap:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember2023-01-012023-06-300001743881us-gaap:AlexionLicenseAgreementsMembersrt:MaximumMember2019-09-300001743881us-gaap:TwoThousandAndTwentyOneCappedCallTransactionsMember2021-01-250001743881us-gaap:RetainedEarningsMember2023-12-310001743881us-gaap:TwoThousandAndNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMemberbbio:TwoThousandAndTwentyStockAndEquityAwardExchangeProgramMember2023-01-012023-06-300001743881us-gaap:EidosTherapeuticsIncMemberbbio:BayerExclusiveLicenseAgreementMemberbbio:SellerPartiesMember2024-03-010001743881us-gaap:LianBioMemberbbio:EquityMethodInvesteesIpoMember2023-04-012023-06-300001743881us-gaap:TheRasIncMemberbbio:BridgeBioOncologyTherapeuticsMember2024-04-302024-04-300001743881us-gaap:LianBioMemberbbio:EquityMethodInvesteesIpoMember2023-01-012023-06-300001743881us-gaap:BayerConsumerCareAgAndKyowaKirinCoLtdMemberbbio:FinancingAgreementMember2024-04-012024-06-300001743881us-gaap:AccruedCompensationAndBenefitsMember2024-06-300001743881us-gaap:BridgeBioServicesIncMemberbbio:TwoThousandAndNineteenEmployeeStockPurchasePlanMember2023-01-012023-06-300001743881us-gaap:FairValueInputsLevel1Membersus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001743881us-gaap:CappedCallTransactionsMember2020-03-042020-03-040001743881us-gaap:FoundationMedicineIncMember2024-01-012024-06-300001743881us-gaap:KyowaKirinExclusiveLicenseMemberbbio:QEDTherapeuticsIncMember2024-06-300001743881us-gaap:FinancingAgreementMemberbbio:LoanAgreementMember2024-01-172024-01-170001743881us-gaap:TwoPointFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember2021-01-282021-01-280001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001743881us-gaap:AgencyDiscountNotesMembersus-gaap:FairValueMeasurementsRecurringMember2024-06-300001743881us-gaap:RestructuringImpairmentAndRelatedChargesMember2024-01-012024-06-300001743881us-gaap:LoanAgreementMember2021-11-300001743881us-gaap:CommonStockMember2023-04-012023-06-300001743881us-gaap:BridgeBioServicesIncMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-04

3100001743881bbio:FoundationMedicineDiagnosticsAgreementMemberbbio:FoundationMedicineIncMemberbbio:QEDTherapeuticsIncMember2024-03-3100001743881bbio:KyowaKirinExclusiveLicenseMemberbbio:QEDTherapeuticsIncMember2024-02-0700001743881us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2023-12-3100001743881us-gaap:SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMemberbbio:FinancingAgreementMember2024-01-172024-01-170001743881us-gaap:ParentMember2022-12-3100001743881us-gaap:RestrictedStockMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2023-01-012023-06-300001743881bbio:HelsinnTherapeuticsMember2023-04-012023-06-300001743881bbio:OtherRSAsMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2023-04-012023-06-300001743881us-gaap:CommonStockMemberbbio:TwoThousandTwentyFourFollowOnOfferingMember2024-03-3100001743881bbio:RestructuringImpairmentAndRelatedChargesMemberbbio:OtherConsolidatedEntitiesMember2024-04-012024-06-300001743881bbio:EidosTherapeuticsIncMemberbbio:TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlanMember2024-06-300001743881srt:MaximumMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2020-04-222020-04-220001743881bbio:EidosTherapeuticsIncMemberbbio:TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlanMember2024-01-012024-06-300001743881bbio:AccountingStandardUpdate201818Memberbbio:LicenseAndCollaborationAgreementMemberbbio:HelsinnTherapeuticsMemberbbio:QEDTherapeuticsIncMember2023-04-012023-06-300001743881us-gaap:NoncontrollingInterestMember2024-03-310001743881bbio:EidosTherapeuticsIncMemberbbio:BayerExclusiveLicenseAgreementMember2024-06-300001743881bbio:EidosTherapeuticsIncMemberbbio:BayerExclusiveLicenseAgreementMemberus-gaap:LicenseMember2024-04-012024-06-300001743881bbio:EidosTherapeuticsIncMemberbbio:LelandStanfordJuniorUniversityMemberbbio:StanfordLicenseAgreementMember2024-01-012024-06-300001743881bbio:TwoThousandNineteenStockOptionAndIncentivePlanMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2020-11-182020-11-180001743881bbio:SoftPlusInterestMemberbbio:FinancingAgreementMember2024-01-172024-01-170001743881us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012024-06-300001743881bbio:LoanAgreementMembersrt:MaximumMember2021-11-012021-11-300001743881us-gaap:CommonStockMemberbbio:TwoThousandTwentyThreeAtTheMarketAgreementMemberbbio:AtTheMarketOfferingMembersrt:MaximumMember2023-05-012023-05-310001743881us-gaap:CommonStockMember2023-03-310001743881bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember2021-02-020001743881bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2024-01-012024-06-300001743881us-gaap:RetainedEarningsMember2022-12-310001743881bbio:BridgeBioServicesIncMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-04-012023-06-300001743881us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001743881us-gaap:CommonStockMemberus-gaap:StockCompensationPlanMember2024-01-012024-03-3100001743881us-gaap:CommonStockMemberbbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMember2024-06-300001743881bbio:UnvestedMarketBasedRestrictedStockUnitMember2023-01-012023-06-300001743881bbio:LianBioMemberbbio:BridgeBioPharmaLimitedLiabilityCompanyMember2024-03-012024-03-3100001743881bbio:SatisfyTaxWithholdingMemberus-gaap:ParentMember2024-04-012024-06-300001743881bbio:LicenseAndCollaborationAgreementMemberbbio:QEDTherapeuticsIncMember2021-03-292021-03-290001743881us-gaap:RetainedEarningsMember2023-06-300001743881bbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMemberbbio:BridgeBioServicesIncMemberbbio:MarketBasedRestrictedStockUnitsRsusMembersrt:MaximumMember2020-01-012023-12-3100001743881bbio:ReceivableFromLicensingAndCollaborationAgreementsMemberbbio:LicenseAndCollaborationAgreementMember2023-12-310001743881us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001743881srt:MinimumMember2024-03-310001743881bbio:TrancheTwoAdvanceMemberbbio:LoanAgreementMembersrt:MaximumMember2021-11-300001743881bbio:LianBioMemberbbio:BridgeBioPharmaLimitedLiabilityCompanyMember2024-01-012024-06-300001743881us-gaap:SalesMemberbbio:LicenseAndCollaborationAgreementMemberbbio:NavirePharmaIncMemberbbio:BristolMyersSquibbCompanyMember2023-01-012023-06-300001743881bbio:FundingAgreementMember2024-01-172024-01-170001743881bbio:LianBioMember2024-06-300001743881bbio:LicenseAgreementMemberbbio:LianBioMembersrt:MaximumMember2020-08-012020-08-310001743881us-gaap:FairValueMeasurementsRecurringMember2024-06-3000017438812023-01-012023-03-310001743881bbio:RedeemableConvertibleNoncontrollingInterestsMember2023-12-310001743881bbio:TwoThousandNineteenStockOptionAndIncentivePlanMemberus-gaap:CommonStockMember2023-12-310001743881bbio:FinancingAgreementMemberbbio:IncrementalTermLoanMember2024-01-170001743881us-gaap:FairValueInputsLevel1Member2023-12-310001743881us-gaap:CommonStockMemberus-gaap:StockCompensationPlanMember2023-04-012023-06-300001743881bbio:TheRasIncMemberbbio:BridgeBioOncologyTherapeuticsMemberbbio:TransitionServiceAgreementMember2024-06-300001743881bbio:BridgeBioServicesIncMember2024-04-012024-06-300001743881us-gaap:EmployeeStockOptionMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2024-01-012024-06-300001743881bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMemberus-gaap:EmployeeStockOptionMember2024-06-300001743881bbio:OtherRSAsMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2024-01-012024-06-300001743881us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-06-300001743881us-gaap:CommonStockMemberbbio:EidosAwardExchangePlanMember2021-12-310001743881bbio:HelsinnTherapeuticsMember2023-12-310001743881bbio:EidosTherapeuticsIncMemberbbio:KyowaKirinExclusiveLicenseMember2024-01-012024-06-3000017438812023-12-310001743881bbio:RestructuringImpairmentAndRelatedChargesMember2024-04-012024-06-300001743881bbio:AssumedConversionOfTwoThousandTwentySevenNotesMember2024-01-012024-06-300001743881bbio:LicenseAndCollaborationAgreementMemberbbio:NavirePharmaIncMemberbbio:BristolMyersSquibbCompanyMember2024-06-300001743881us-gaap:StockCompensationPlanMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001743881bbio:AccountingStandardUpdate201818Memberbbio:LicenseAndCollaborationAgreementMemberbbio:HelsinnTherapeuticsMemberbbio:QEDTherapeuticsIncMember2023-01-012023-06-300001743881bbio:EidosTherapeuticsIncMemberbbio:BayerExclusiveLicenseAgreementMember2024-05-310001743881bbio:RedeemableConvertibleNoncontrollingInterestsMember2022-12-310001743881bbio:ReceivableFromLicensingAndCollaborationAgreementsMemberbbio:LicenseAndCollaborationAgreementMember2024-06-300001743881us-gaap:EmployeeStockOptionMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMembersrt:MaximumMember2024-01-012024-06-300001743881bbio:ResilienceAgreementsMember2024-01-012024-06-300001743881srt:MinimumMemberbbio:LoanAgreementMember2021-11-012021-11-300001743881bbio:UnvestedRestrictedStockUnitMember2023-01-012023-06-300001743881bbio:BridgeBioOncologyTherapeuticsMember2024-04-012024-06-300001743881srt:MinimumMember2024-01-012024-06-300001743881us-gaap:StockCompensationPlanMember2024-04-012024-06-300001743881bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenAndTwoThousandAndTwentyNineMember2024-01-012024-06-300001743881bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2023-12-310001743881us-gaap:SalesMemberbbio:LicenseAndCollaborationAgreementMemberbbio:NavirePharmaIncMemberbbio:BristolMyersSquibbCompanyMember2024-01-012024-06-300001743881bbio:FinancingAgreementMember2024-01-012024-06-300001743881bbio:ProjectAgreementMemberbbio:AspaTherapeuticsIncMember2023-09-012023-09-300001743881bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2020-04-220001743881us-gaap:RetainedEarningsMember2023-01-012023-03-310001743881bbio:QEDTherapeuticsIncMember2023-04-012023-06-300001743881bbio:HelsinnTherapeuticsMemberbbio:QEDTherapeuticsIncMember2024-01-012024-06-300001743881bbio:EidosTherapeuticsIncMemberbbio:CommercialProductSupplyMemberbbio:BayerExclusiveLicenseAgreementMember2024-01-012024-06-300001743881bbio:OriginAndSentynlTherapeuticsIncMember2022-03-012022-03-310001743881bbio:Other

300001743881bbio:QEDTherapeuticsIncMemberbbio:FoundationMedicineDiagnosticsAgreementMemberbbio:FoundationMedicineIncMember2023-01-012023-06-300001743881bbio:ResilienceAgreementsMember2024-04-012024-06-300001743881bbio:LoanAgreementMember2024-01-172024-01-170001743881us-gaap:ParentMem2024-03-310001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001743881bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember2024-06-300001743881bbio:OtherConsolidatedEntitiesMember2024-01-012024-06-300001743881us-gaap:NoncontrollingInterestMember2023-04-06-300001743881bbio:LicenseAgreementMemberbbio:LianBioMember2020-08-012020-08-310001743881us-gaap:CommonStockMemberbbio:FollowOnOfferingMember2023-03-102023-03-100001743881bbio:SatisfyTaxWithholdingMemberus-gaap:CommonStockMember2024-01-012024-03-310001743881bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2023-04-012023-06-300001743881bbio:BaseRatePlusInterestMemberbbio:FinancingAgreementMember2024-01-172024-01-170001743881bbio:InterestAdjustOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember2024-06-300001743881us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001743881bbio:BridgeBioServicesIncMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001743881bbio:TheRasIncMemberbbio:BridgeBioOncologyTherapeuticsMember2024-04-300001743881us-gaap:RetainedEarningsMember2023-04-012023-06-300001743881us-gaap:RestrictedStockMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2020-04-222020-04-220001743881us-gaap:ParentMember2023-03-3100017438812023-09-012023-09-300001743881bbio:EidosTherapeuticsIncMemberus-gaap:CommonStockMemberbbio:AlexionAgreementsMember2019-09-012019-09-300001743881bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember2024-04-012024-06-300001743881bbio:BridgeBioServicesIncMemberbbio:TwoThousandNineteenEmployeeStockPurchasePlanMember2024-01-012024-06-300001743881bbio:BridgeBioServicesIncMemberbbio:TwoThousandNineteenEmployeeStockPurchasePlanMember2024-06-300001743881us-gaap:TreasuryStockCommonMember2024-03-310001743881bbio:AccruedCompensationAndBenefitsMember2023-12-3100017438812023-01-012023-12-310001743881bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2024-06-300001743881bbio:FoundationMedicineDiagnosticsAgreementMemberbbio:FoundationMedicineIncMemberbbio:QEDTherapeuticsIncMember2018-11-300001743881us-gaap:NoncontrollingInterestMember2022-12-310001743881us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001743881us-gaap:RestrictedStockMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2023-04-012023-06-300001743881bbio:TwoThousandNineteenEmployeeStockPurchasePlanMember2024-01-012024-06-300001743881bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2024-01-012024-06-300001743881bbio:BridgeBioServicesIncMemberbbio:TwoThousandNineteenEmployeeStockPurchasePlanMember2019-06-222019-06-220001743881bbio:OtherConsolidatedEntitiesMember2024-04-012024-06-300001743881bbio:LianBioMemberbbio:EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMemberbbio:BridgeBioPharmaLimitedLiabilityCompanyMember2024-02-012024-02-290001743881us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2024-06-300001743881bbio:SatisfyTaxWithholdingMemberus-gaap:ParentMember2024-01-012024-03-310001743881us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001743881bbio:TrancheOneAdvanceMemberbbio:LoanAgreementMembersrt:MaximumMember2021-11-300001743881bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember2020-03-092020-03-090001743881bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember2023-06-300001743881us-gaap:CommonStockMemberus-gaap:StockCompensationPlanMember2024-04-012024-06-300001743881us-gaap:CommonStockMemberus-gaap:EmployeeStockMember2024-01-012024-03-310001743881bbio:AssumedConversionOfTwoThousandTwentyNineNotesMember2024-01-012024-06-300001743881bbio:UnvestedPerformanceBasedRestrictedStockUnitMember2024-01-012024-06-300001743881us-gaap:NoncontrollingInterestMember2023-06-300001743881bbio:LoanSecurityAgreementMember2023-12-310001743881us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001743881bbio:EidosTherapeuticsIncMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2023-01-012023-12-310001743881bbio:TheRasIncMemberbbio:BridgeBioOncologyTherapeuticsMember2024-04-012024-06-300001743881bbio:OtherConsolidatedEntitiesMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012024-06-300001743881us-gaap:EmployeeStockMember2024-01-012024-03-310001743881us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001743881us-gaap:CommonStockMemberbbio:TwoThousandTwentyThreeAtTheMarketAgreementMemberbbio:AtTheMarketOfferingMember2023-05-310001743881us-gaap:TreasuryStockCommonMember2023-12-310001743881bbio:EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMemberbbio:LianBioMemberbbio:BridgeBioPharmaLimitedLiabilityCompanyMember2024-02-012024-02-290001743881us-gaap:CommonStockMemberbbio:FollowOnOfferingMember2023-03-310001743881us-gaap:RestrictedStockUnitsRSUMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2024-06-300001743881bbio:TheRasIncMemberbbio:BridgeBioOncologyTherapeuticsMember2024-06-300001743881bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember2023-06-300001743881bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember2024-06-300001743881bbio:UnvestedMarketBasedRestrictedStockUnitMember2024-01-012024-06-300001743881us-gaap:CommonStockMember2024-06-300001743881bbio:ProjectAgreementMemberbbio:AdrenasTherapeuticsIncMember2023-09-012023-09-300001743881bbio:LicenseAndCollaborationAgreementMemberbbio:FoundationMedicineIncMembersrt:MaximumMemberbbio:QEDTherapeuticsIncMember2024-01-012024-06-300001743881bbio:CappedCallTransactionsMember2020-01-012020-12-310001743881bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMembersrt:MaximumMember2021-01-282021-01-280001743881us-gaap:EmployeeStockOptionMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2020-04-222020-04-220001743881us-gaap:NoncontrollingInterestMember2023-04-012023-06-300001743881bbio:LicenseAndCollaborationAgreementMemberbbio:NavirePharmaIncMemberbbio:BristolMyersSquibbCompanyMember2023-12-310001743881us-gaap:SalesMemberbbio:LicenseAndCollaborationAgreementMemberbbio:NavirePharmaIncMemberbbio:BristolMyersSquibbCompanyMember2024-04-012024-06-300001743881bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember2023-12-310001743881srt:MaximumMember2024-03-310001743881us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001743881bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2024-04-012024-06-300001743881bbio:AccruedProfessionalAndOtherAccruedLiabilitiesMember2024-06-300001743881srt:MinimumMemberbbio:FoundationMedicineIncMemberbbio:QEDTherapeuticsIncMember2024-01-012024-06-300001743881us-gaap:AdditionalPaidInCapitalMember2022-12-310001743881us-gaap:CommonStockMemberbbio:FollowOnOfferingMember2023-03-012023-03-310001743881us-gaap:AdditionalPaidInCapitalMember2024-03-310001743881bbio:HelsinnTherapeuticsMember2024-06-300001743881us-gaap:CommonStockMemberbbio:FollowOnOfferingMembersrt:MinimumMember2023-03-310001743881bbio:LeaseAgreementsAndLettersOfCreditMember2023-12-310001743881bbio:CommonStockOptionsIssuedAndOutstandingMember2024-01-012024-06-300001743881bbio:BridgeBioServicesIncMemberbbio:TwoThousandNineteenEmployeeStockPurchasePlanMember2024-04-012024-06-300001743881us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100017438812024-01-012024-03-310001743881bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember2021-01-280001743881bbio:CappedCallTransactionsMemberbbio:ShareRepurchaseTransactionsMember2020-03-040001743881us-gaap:StockCompensationPlanMember2024-01-012024-03-310001743881us-gaap:RestrictedStockUnitsRSUMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2023-01-012023-06-300001743881us-gaap:AccountsPayableMember2024-06-300001743881bbio:BridgeBioServicesIncMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012024-06-300001743881us-gaap:RetainedEarningsMember2024-04-012024-06-300001743881us-gaap:CommonStockMemberbbio:FollowOnOfferingMember2023-04-032023-04-030001743881srt:MinimumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-06-300001743881us-gaap:RestrictedStockMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2024-01-012024-06-300001743881us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001743881bbio:OriginBiosciencesIncMembersrt:MaximumMember2018-12-310001743881bbio:FinancingAgreementMemberus-gaap:CashMember2024-01-012024-06-3000017438812023-01-012023-06-300001743881srt:MinimumMemberbbio:FinancingAgreementMember2024-01-170001743881bbio:LoanAgreementMembersrt:MaximumMember2021-11-300001743881us-gaap:ParentMemberus-gaap:EmployeeStockMember2024-01-012024-03-310001743881us-gaap:RestrictedStockMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2023-04-012023-06-300001743881bbio:FinancingAgreementMembersrt:MaximumMember2024-01-012024-06-300001743881bbio:PerformanceBasedMilestoneAwardsMember2024-06-300001743881bbio:HelsinnTherapeuticsMember2023-01-012023-06-3000017438812024-01-012024-06-300001743881bbio:LicenseAgreementMemberbbio:LianBioMemberus-gaap:LicenseMember2021-01-012021-12-310001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001743881bbio:FundingAgreementMember2024-06-300001743881us-gaap:CommonStockMember2023-12-310001743881bbio:FinancingAgreementMember2024-04-012024-06-300001743881bbio:OtherConsolidatedEntitiesMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001743881bbio:BridgeBioServicesIncMemberbbio:RestructuringImpairmentAndRelatedChargesMember2024-01-012024-06-300001743881bbio:FinancingAgreementMembersrt:MaximumMember2024-01-170001743881bbio:EstimatedSharesIssuablePerformanceBasedMilestoneCompensationArrangementMember2024-01-012024-06-300001743881bbio:PrincipalValueAndInterestOnTwoThousandAndTwentySevenAndTwoThousandAndTwentyNineMember2024-06-300001743881bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember2023-04-012023-06-300001743881us-gaap:MoneyMarketFundsMember2023-12-310001743881us-gaap:RetainedEarningsMember2024-06-300001743881bbio:SatisfyTaxWithholdingMemberus-gaap:CommonStockMember2023-04-012023-06-300001743881bbio:InterestTwoThousandAndTwentySevenAndTwoThousandAndTwentyNineMember2024-06-300001743881bbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMemberbbio:BridgeBioServicesIncMemberbbio:MarketBasedRestrictedStockUnitsRusMember2024-06-300001743881bbio:DevelopmentAndManufacturingServicesAgreementMember2023-09-012023-09-300001743881bbio:EidosTherapeuticsIncMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2023-12-3100017438812023-04-012023-06-300001743881us-gaap:ParentMemberus-gaap:StockCompensationPlanMember2024-04-012024-06-300001743881us-gaap:RestrictedStockMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2023-12-310001743881us-gaap:FairValueInputsLevel3Memberbbio:AgencyDiscountNotesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001743881us-gaap:RestrictedStockMemberbbio:RegularEquityProgramMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2024-01-012024-06-3000017438812024-07-250001743881bbio:PerformanceBasedStockOptionsMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2020-11-182020-11-180001743881us-gaap:StockCompensationPlanMember2023-01-012023-03-310001743881us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001743881us-gaap:RestrictedStockMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2024-01-012024-06-300001743881us-gaap:CommonStockMemberbbio:FollowOnOfferingMembersrt:MaximumMember2023-03-310001743881bbio:OtherConsolidatedEntitiesMember2023-01-012023-06-300001743881us-gaap:CommonStockMemberus-gaap:EmployeeStockMember2023-01-012023-03-310001743881bbio:LicenseAndCollaborationAgreementMemberbbio:QEDTherapeuticsIncMember2024-01-012024-06-300001743881bbio:TrancheTwoAdvanceMemberbbio:LoanAgreementMembersrt:MaximumMember2022-05-310001743881bbio:UnvestedRestrictedStockAwardMember2023-01-012023-06-300001743881bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2024-06-300001743881bbio:PerformanceBasedRestrictedStockAwardsMemberbbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2020-04-222020-04-220001743881bbio:OtherConsolidatedEntitiesMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-06-300001743881us-gaap:NoncontrollingInterestMember2023-12-310001743881us-gaap:RetainedEarningsMember2024-03-310001743881us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001743881bbio:AccruedResearchAndDevelopmentLiabilitiesMember2024-06-300001743881bbio:InitialTermLoanMemberbbio:FinancingAgreementMember2024-01-012024-06-300001743881bbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMemberbbio:BridgeBioServicesIncMemberbbio:MarketBasedRestrictedStockUnitsRusMember2024-01-012024-06-300001743881us-gaap:AdditionalPaidInCapitalMember2023-12-310001743881us-gaap:StockCompensationPlanMember2023-04-012023-06-300001743881bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMemberus-gaap:EmployeeStockOptionMember2023-04-012023-06-300001743881us-gaap:RestrictedStockMember2024-01-012024-06-300001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001743881bbio:LoanAgreementMemberus-gaap:PaymentInKindPIKNoteMember2023-01-012023-06-300001743881bbio:HelsinnMemberbbio:QEDTherapeuticsIncMember2024-06-300001743881bbio:RestructuringImpairmentAndRelatedChargesMemberbbio:OtherConsolidatedEntitiesMember2024-01-012024-06-300001743881us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001743881bbio:BridgeBioServicesIncMemberbbio:RestructuringImpairmentAndRelatedChargesMember2024-04-012024-06-300001743881bbio:BridgeBioServicesIncMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-06-300001743881bbio:InitialTermLoanMemberbbio:FinancingAgreementMember2024-01-170001743881bbio:KyowaKirinExclusiveLicenseMemberus-gaap:LicenseMemberbbio:QEDTherapeuticsIncMember2024-01-012024-06-300001743881bbio:KyowaKirinExclusiveLicenseMember2024-06-300001743881bbio:PrincipalValueAndInterestOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember2024-06-300001743881bbio:EidosTherapeuticsIncMemberbbio:BayerExclusiveLicenseAgreementMemberus-gaap:LicenseMember2024-01-012024-06-

000001743881bbio:OriginAndSentryInTherapeuticsIncMember2022-03-3100001743881bbio:LoanAgreementMember2022-11-3000001743881bbio:LoanAgreementMember2024-01-012024-06-3000001743881bbio:PrincipalValueAndInterestOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember2024-06-3000001743881bbio:UnvestedRestrictedStockUnitMember2024-01-012024-06-3000001743881us-gaap:ParentMember2023-01-012023-03-3100001743881bbio:SatisfyTaxWithholdingMemberus-gaap:CommonStockMember2023-01-012023-03-3100001743881bbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMemberbbio:BridgeBioServicesIncMemberbbio:MarketBasedRestrictedStockUnitsRsumMembersrt:MinimumMember2020-01-012023-12-31000017438812024-04-012024-06-3000001743881us-gaap:StockCompensationPlanMemberus-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000001743881bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember2023-01-012023-06-3000001743881us-gaap:CommonStockMemberbbio:TwoThousandTwentyFourFollowOnOfferingMember2024-03-012024-03-3100001743881bbio:SatisfyTaxWithholdingMember2024-04-012024-06-3000001743881us-gaap:ParentMember2024-01-012024-03-3100001743881us-gaap:CommonStockMember2024-03-3100001743881bbio:ExclusiveLicenseAgreementsWithBayerConsumerCareAgAndKyowaKirinCoLtdMember2024-01-012024-03-31000017438812024-06-3000001743881bbio:AgencyDiscountNotesMember2024-06-3000001743881bbio:TheRasIncMemberbbio:BridgeBioOncologyTherapeuticsMember2024-05-012024-06-3000001743881us-gaap:TreasuryBillSecuritiesMember2023-03-3100001743881bbio:SatisfyTaxWithholdingMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100001743881us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2023-12-3100001743881bbio:SatisfyTaxWithholdingMemberus-gaap:ParentMember2023-04-012023-06-3000001743881us-gaap:CommonStockMemberbbio:TwoThousandNineteenInducementEquityPlansMember2024-06-3000001743881us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100001743881sr:MinimumMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMemberus-gaap:EmployeeStockOptionMember2024-01-012024-06-3000001743881bbio:LianBioMemberbbio:EquityMethodInvesteeIpoMember2024-01-012024-06-3000001743881us-gaap:RetainedEarningsMember2023-03-3100001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-3000001743881bbio:EidosTherapeuticsIncMemberus-gaap:CommonStockMemberbbio:AlexionAgreementsMember2019-09-3000001743881us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2024-06-3000001743881bbio:LianBioMemberbbio:EquityMethodInvesteeIpoMember2024-04-012024-06-3000001743881bbio:LicenseAndCollaborationAgreementMember2023-12-3100001743881bbio:RedeemableConvertibleNoncontrollingInterestsMember2023-06-3000001743881bbio:CappedCallTransactionsMember2020-03-0400001743881us-gaap:NoncontrollingInterestMember2023-03-3100001743881bbio:KyowaKirinExclusiveLicenseMemberus-gaap:LicenseMemberbbio:QEDTherapeuticsIncMember2024-04-012024-06-3000001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100001743881us-gaap:RestrictedStockUnitsRSUMemberbbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember2024-01-012024-06-3000001743881bbio:TheRasIncMemberbbio:TransitionServiceAgreementMemberbbio:BridgeBioOncologyTherapeuticsMember2024-04-012024-06-3000001743881us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-06-30xbrl:purexbrl:sharesbio:TradingDaybio:Installmentiso4217:USDxbrl:sharesbio:Employeebbio:Granteeiso4217:USD A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 A FORM 10-Q (Mark One) a QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or a TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 A BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) A Delaware A 84-1850815 (State or other jurisdiction of incorporation or organization) A (I.R.S. Employer Identification No.) 3160 Porter Drive, Suite 250, Palo Alto, CA A 94304 (Address of principal executive offices) A (Zip Code) (650) 391-9740 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: A Title of each class A TradingSymbol(s) A Name of each exchange on which registered Common Stock, par value \$0.001 per share A BBIO A The Nasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes A No A Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (A32.32.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes A No A Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act. A Large accelerated filer A Accelerated filer A Non-accelerated filer A Smaller reporting company A Emerging growth company A If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. A Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes A No A As of July 25, 2024, the registrant had 188,032,738 shares of common stock, \$0.001 par value per share, outstanding. A A Table of Contents A A Page PART I. A FINANCIAL INFORMATION A Item 1. A Financial Statements (Unaudited) A A Condensed Consolidated Balance Sheets A 3 A Condensed Consolidated Statements of Operations A 4 A Condensed Consolidated Statements of Comprehensive Loss A 5 A A Condensed Consolidated Statements of Redeemable Convertible Noncontrolling Interests and Stockholders' Deficit A 6 A Condensed Consolidated Statements of Cash Flows A 8 A Notes to Condensed Consolidated Financial Statements A 10 Item 2. A Management's Discussion and Analysis of Financial Condition and Results of Operations A 47 Item 3. A Quantitative and Qualitative Disclosures About Market Risk A 60 Item 4. A Controls and Procedures A 60 PART II. A OTHER INFORMATION A Item 1. A Legal Proceedings A 61 Item 1A. A Risk Factors A 61 Item 2. A Unregistered Sales of Equity Securities and Use of Proceeds A 63 Item 3. A Defaults Upon Senior Securities A 63 Item 4. A Mine Safety Disclosures A 63 Item 5. A Other Information A 63 Item 6. A Exhibits A 64 Signatures A 66 A 2 A BRIDGEBIO PHARMA, INC. Condensed Consolidated Balance Sheets (in thousands, except shares and per share amounts) A A A June 30, A A December 31, A A A 2024 A A 2023 A A A (Unaudited) A A (1) A Assets A A A A Current assets: A A A A Cash and cash equivalents A \$ 407,958 A A \$ 375,935 A Marketable securities A A 39,813 A A A A Investments in equity securities A A A A 58,949 A Receivables from licensing and collaboration agreements A A 660 A A A 1,751 A Restricted cash A A 139,409 A A A 16,653 A Prepaid expenses and other current assets A A 28,396 A A A 24,305 A Total current assets A A 616,236 A A A 477,593 A Investment in nonconsolidated entity A A 117,006 A A A A Property and equipment, net A A 9,840 A A A 11,816 A Operating lease right-of-use assets A A 7,267 A A A 8,027 A Intangible assets, net A A 25,123 A A A 26,319 A Other assets A A 18,903 A A A 22,625 A Total assets A \$ 794,375 A A \$ 546,380 A Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders' Deficit A A A A Current liabilities: A A A A Accounts payable A \$ 18,126 A A A 10,655 A Accrued compensation and benefits A A 29,056 A A A 57,370 A Accrued research and development liabilities A A 33,178 A A A 29,765 A Operating lease liabilities, current portion A A 4,623 A A A 4,128 A Deferred revenue, current portion A A 15,098 A A A 6,096 A Accrued professional and other accrued liabilities A A 34,283 A A A 35,830 A Total current liabilities A A 134,364 A A A 143,844 A 2029 Notes, net A A 737,882 A A A 736,905 A 2027 Notes, net A A 544,270 A A A 543,379 A Term loan, net A A 435,447 A A A 446,445 A Operating lease liabilities, net of current portion A A 7,059 A A A 8,981 A Deferred revenue, net of current portion A A 16,961 A A A 3,727 A Other long-term liabilities A A 485 A A A 5,634 A Total liabilities A A 1,876,468 A A A 1,888,915 A Commitments and contingencies (Note 8) A A A A Redeemable convertible noncontrolling interests A A (223) A A A 478 A Stockholders' deficit: A A A A Undesignated preferred stock, \$0.001A par value; 25,000,000A shares A A authorized; noA shares issued and outstanding A A A A A A A A Common stock, \$0.001A par value; 500,000,000A shares authorized; A A 194,224,499A shares issued and 188,032,738A shares outstanding as of A A June 30, 2024, 181,274,712A shares issued and 175,082,951A shares A A A A outstanding as of December 31, 2023 A A 194 A A A 181 A Treasury stock, at cost; 6,191,761A shares as of June 30, 2024 and A A December 31, 2023 A A A (275,000) A A (275,000) A Additional paid-in capital A A 1,851,058 A A A 1,481,032 A Accumulated other comprehensive income A A (4) A A 31 A Accumulated deficit A A (2,669,173) A A (2,560,501) A Total BridgeBio stockholders' deficit A A (1,092,925) A A (1,354,257) A Noncontrolling interests A A 11,055 A A A 11,244 A Total stockholders' deficit A A (1,081,870) A A (1,343,013) A Total liabilities, redeemable convertible noncontrolling interests and A A stockholders' deficit A \$ 794,375 A A \$ 546,380 A The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. A (1)The condensed consolidated balance sheet as of December 31, 2

available-for-sale securities at December 31, 2023, net loss attributable to noncontrolling interests is \$1,147,931. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. (2) The consolidated balances as of December 31, 2023 and 2022 are derived from the audited consolidated financial statements as of those dates. A 7 BRIDGEBIO PHARMA, INC. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) A 6 Six Months Ended June 30, A 4 2024 A 2023 A Operating activities: A 4 Net loss A \$ (111,704) A \$ (303,435) Adjustments to reconcile net loss to net cash used in operating activities: A 4 Stock-based compensation A 38,511 A 49,085 Loss on extinguishment of debt A 26,590 A accretion of debt A 3,683 A 4,580 Depreciation and amortization A 3,170 A 3,270 Noncash lease expense A 2,093 A 2,024 Accrual of payment-in-kind interest on term loan A 6,742 A 7,742 Net loss from equity method investment A 7,925 A 7,925 Loss (gain) on deconsolidation of subsidiaries A (126,294) A 1,241 Gain from investment in equity securities, net A (8,136) A (2,399) Fair value adjustment of warrants A (222) Other noncash adjustments A (1,911) A (328) Changes in operating assets and liabilities: A 4 Receivables from licensing and collaboration agreements A 1,091 A 8,466 Prepaid expenses and other current assets A (6,506) A 1,057 Other assets A 942 A 32 Accounts payable A 8,858 A (4,098) Accrued compensation and benefits A (8,378) A (11,071) Accrued research and development liabilities A 7,067 A (11,322) Operating lease liabilities A (2,981) A (2,443) Deferred revenue A 22,236 A 4 (3,184) Accrued professional and other liabilities A (1,090) A 4,330 Net cash used in operating activities A (144,834) A (257,675) Investing activities: A 4 Purchases of marketable securities A (93,811) A (19,754) Maturities of marketable securities A 55,000 A 41,550 Purchases of investments in equity securities A (20,271) A (71,504) Proceeds from sales of investments in equity securities A 63,229 A 67,068 Proceeds from special cash dividends received from investments in equity securities A 25,682 A 26,582 Payment for an intangible asset A (3,190) A 26,582 Purchases of property and equipment A (749) A (440) Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries A (98) A (503) Net cash provided by investing activities A 25,792 A 16,417 Financing activities: A 4 Proceeds from term loan under Financing Agreement A 450,000 A 4 Issuance costs and discounts associated with term loan under Financing Agreement A (15,986) A 4 Repayment of term loan under Loan and Security Agreement A (473,417) A 4 Proceeds from issuance of common stock through public offerings, net A 314,759 A 144,049 Proceeds from BridgeBio common stock issuances under ESPP A 2,364 A 1,809 Proceeds from stock option exercises, net of repurchases A 778 A 312 Repurchase of RSU shares to satisfy tax withholding A (4,679) A (1,715) Other financing activities A 4 4,563 Net cash provided by financing activities A 273,819 A 149,018 Net increase (decrease) in cash, cash equivalents and restricted cash A 154,777 A (92,240) Cash, cash equivalents and restricted cash at beginning of period A 394,732 A 416,884 Cash, cash equivalents and restricted cash at end of period A 549,509 A 324,644 A The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. A 8 BRIDGEBIO PHARMA, INC. Condensed Consolidated Statements of Cash Flows (Continued) (Unaudited) (in thousands) A 6 Six Months Ended June 30, A 4 2024 A 2023 A Supplemental Disclosure of Cash Flow Information: A 4 Cash paid for interest A 49,046 A 28,738 Supplemental Disclosures of Noncash Investing and Financing Information: A 4 Unpaid public offering issuance costs A 18 A 4 Deferred and unpaid issuance costs recorded to "Accrued professional and other accrued liabilities" A 74 A 4 Unpaid property and equipment A 70 A 4 131 Transfers to noncontrolling interests A (1,929) A (5,940) Reconciliation of Cash, Cash Equivalents and Restricted Cash: A 4 Cash and cash equivalents A 407,958 A 302,438 Restricted cash A 139,409 A 19,930 Restricted cash included in Other assets A 2,142 A 2,276 A Total cash, cash equivalents and restricted cash at end of periods shown in the condensed consolidated statements of cash flows A 549,509 A 324,644 A The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. A 9 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) 1. Organization and Description of Business BridgeBio Pharma, Inc. (the "Company" or the "Company") is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. Since inception, BridgeBio has either created wholly-owned subsidiaries or has made investments in certain controlled entities, including partially-owned subsidiaries for which BridgeBio has a majority voting interest, and variable interest entities (the "VIEs") for which BridgeBio is the primary beneficiary (collectively, the "VIEs"). BridgeBio is headquartered in Palo Alto, California. 2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The condensed consolidated financial statements include the accounts of BridgeBio Pharma, Inc. and its wholly-owned subsidiaries and controlled entities, substantially all of which are denominated in U.S. dollars. All intercompany balances and transactions have been eliminated in consolidation. For nonconsolidated entities where we own or are exposed to less than 100% of the economics, we record net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests in our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. In determining whether an entity is considered a controlled entity, we applied the VIE and Voting Interest Entity ("VIE") models. We assess whether we are the primary beneficiary of a VIE based on our power to direct the activities of the VIE that most significantly impact the VIE's economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Entities that do not qualify as a VIE are assessed for consolidation under the VOE model. Under the VOE model, BridgeBio consolidates the entity if it determines that it has a controlling financial interest in the entity through its ownership of greater than 50% of the outstanding voting shares of the entity and that other equity holders do not have substantive voting, participating or liquidation rights. We assess whether we are the primary beneficiary of a VIE or whether we have a majority voting interest for entities consolidated under the VOE model at the inception of the arrangement and at each reporting date. The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles ("GAAP") in the United States and applicable rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC. The condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of our financial position, our results of operations and comprehensive loss, stockholders' deficit and our cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim periods. Cash, Cash Equivalents and Marketable Securities We consider all highly liquid investments purchased with original maturities of 90 days or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market instruments, such as money market funds and U.S. treasury bills. 10 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) A Our marketable securities consist of high investment grade fixed income securities that are primarily invested in U.S. treasury bills. We classify our marketable securities as available-for-sale securities and report them at fair value in Cash and cash equivalents or Marketable securities on the condensed consolidated balance sheets with related unrealized gains and losses included as a component of stockholders' deficit. We classify our marketable securities as either short-term or long-term based on each instrument's underlying contractual maturity date. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity which is included in Other income on the condensed consolidated statements of operations. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in Other income (expense), net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. Our cash, cash equivalents and marketable securities are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as commercial paper, U.S. government obligations, treasury bills, and money market funds, and places restrictions on maturities and concentrations by type and issuer. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown on the condensed consolidated statements of cash flows: A June 30, 2024 A December 31, 2023 A (in thousands) A Cash and cash equivalents A 407,958 A 375,935 Restricted cash A 139,409 A 16,653 Restricted cash, non-current included in Other assets A 2,142 A 2,144 A Total cash, cash equivalents and restricted cash A 549,509 A 394,732 Restricted Cash Restricted cash primarily represents funds in a controlled account that was established in connection with the Company's Term Loans described in Note 9. Under the terms of the Financing Agreement (as defined in Note 9), the Company is required to deposit 75% of proceeds, net of certain permitted costs, received from certain asset sale transactions into escrow accounts to be controlled by the Administrative Agent. During the three months ended June 30, 2024, we received \$235.0 million in aggregate from Bayer Consumer Care AG and Kyowa Kirin Co., Ltd. and deposited net proceeds of \$159.3 million into the escrow accounts, which was classified as restricted cash on the condensed consolidated balance sheet as of June 30, 2024. Furthermore, under the terms of the Amended Financing Agreement (as defined in Note 9), between June 20, 2024 and through the earlier of the FDA approval date of a first NDA for acoramidis and November 30, 2024, the Company is able to request a release of funds in an aggregate amount not to exceed 50% of the original net cash proceeds received from asset sale transactions. As of June 30, 2024, \$20.0 million was released from the escrow accounts and classified as cash, with a remaining balance of \$139.3 million in the escrow accounts classified as restricted cash on the condensed consolidated balance sheet. Refer to Note 9 and Note 11 for further details regarding the Financing Agreement and the exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd. As of December 31, 2023, the use of such non-interest-bearing cash was restricted per the terms of the underlying amended Loan and Security Agreement and was to be used solely for certain research and development expenses directly attributable to the performance of obligations associated with the Navire-BMS License Agreement, which is further described in Note 11. As of December 31, 2023, restricted cash related to this agreement was \$16.5 million, which is presented as part of restricted cash on the condensed consolidated balance sheet. Upon the termination of the Loan and Security Agreement and full repayment of the term loan in January 2024 (refer to Note 9 for details), the non-interest-bearing cash was no longer restricted as of June 30, 2024. Additionally, under certain lease agreements and letters of credit, we have pledged cash and cash equivalents as collateral. As of June 30, 2024, restricted cash related to such agreements was \$0.1 million and \$2.1 million, which is presented as part of restricted cash and Other assets, respectively, on the condensed consolidated balance sheets. As of December 31, 2023, restricted cash related to such agreements was \$0.1 million and \$2.1 million, which is presented as part of restricted cash and Other assets, respectively, on the condensed consolidated balance sheets. 11 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) A Equity Method and Other Equity Investments We use the equity method to account for any of our investments under the scope of ASC 323 Investments. Equity Method and Joint Ventures, where we may not be the primary beneficiary, but may still exercise significant influence over operating activities of the investee. Our consolidated net loss includes our Company's proportionate share of the net income or loss from equity method investment and amortization of any in-process research and development (the "IPR&D assets"). Our judgment regarding the level of influence over each equity method investee includes considering key factors such as our ownership interest, representation on the board of directors, participation in policy-making decisions, and other material transactions. Since inception through April 29, 2024, TheRas, Inc. (the "Ras") has been a majority-owned subsidiary of the Company that had been consolidated. On April 30, 2024, the Company completed a \$200.0 million private equity financing with external investors of TheRas, Inc., to accelerate the development of its oncology portfolio. Upon completion of the private equity financing, Company ownership was reduced to approximately 37.9% of TheRas' equity. As part of the private equity financing transaction, TheRas' Certificate of Incorporation and Investors' Rights Agreement were amended and restated to reflect a change in TheRas' governance structure and composition of the board of directors, which was determined to be a VIE reconsideration event. Based on the VIE reconsideration assessment, TheRas was deemed a VIE. As a result of the change in governance structure and composition of the board of directors, BridgeBio is no longer the primary beneficiary, as it no longer has the power over key decisions that significantly impact TheRas' economic performance. Accordingly, BridgeBio deconsolidated TheRas, Inc. and accounted for BridgeBio's retained investment in TheRas, Inc., for which it has significant influence through its ownership interest, using the equity method of accounting as of April 30, 2024. As of December 31, 2020, we had an equity method and equity security investments in PellePharm. The equity security investments in PellePharm were without a readily determinable fair value and were carried at cost less impairment plus or minus observable price changes. PellePharm became a consolidated VIE in April 2021 under ASC 810, Consolidation. On January 16, 2023, PellePharm's board of directors authorized the assignment of all PellePharm's assets to PellePharm ABC, LLC for liquidation and distribution under the General Assignment for the Benefit of Creditors (the "ABC"). As part of the ABC proceedings, PellePharm's board of directors resigned effective March 6, 20

We also require any collateral receivables from license and collaboration agreements are recorded net of allowance for credit losses, if any. We are subject to certain risks and uncertainties and we believe that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing, regulatory approval and market acceptance of, and reimbursement for, product candidates, performance of third-party contract research organizations and manufacturers upon which we rely, development of sales channels, protection of our intellectual property, litigation or claims against us based on intellectual property, patent, product, regulatory, clinical or other factors, and our ability to attract and retain employees necessary to support our growth. We are dependent on third-party manufacturers to supply products for research and development activities in our programs. In particular, we rely and expect to continue to rely on a small number of manufacturers to supply us with our requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to:

- Allowance for credit losses; accruals for research and development activities, such as clinical, development, regulatory, and sales-based milestone payments in our in-licensing agreements and asset acquisitions;
- Accruals for performance-based milestone compensation arrangements; determining and allocating the transaction price to performance obligations for transactions accounted for under ASC 606, Revenue from Contracts with Customers; the expected recoverability and estimated useful lives of our long-lived assets; and additional charges as a result of, or that are associated with, any restructuring initiative as well as impairment and related charges.

We base our estimates on historical experience and on various other assumptions that we believe are reasonable. Actual results may differ from those estimates or assumptions.

13 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited)

3. Fair Value Measurements

The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation:

	June 30, 2024	Total	Level 1	Level 2	Level 3	(in thousands)	Assets	Cash equivalents	Money market funds	Treasury bills	Marketable securities	LianBio Warrant	Embedded derivative	Total financial assets
As of June 30, 2024	\$139,282	\$139,282	\$139,282	\$0	\$0	\$139,282	\$85,605	\$85,605	\$0	\$0	\$0	\$0	\$0	\$139,282
As of December 31, 2023	\$139,282	\$139,282	\$139,282	\$0	\$0	\$139,282	\$85,605	\$85,605	\$0	\$0	\$0	\$0	\$0	\$139,282

The fair values of our 2.25% convertible senior notes due 2029 (the "2029 Notes") and our 2.50% convertible senior notes due 2027 (the "2027 Notes") (collectively, the "Notes"), which differ from their respective carrying values, are determined by prices for the Notes observed in market trading. The market for trading of the Notes is not considered to be an active market and therefore the estimate of fair value is based on Level 2 inputs. As of June 30, 2024, the estimated fair value of our 2029 Notes and 2027 Notes, which have aggregate face values of \$747.5 million and \$550.0 million, respectively, were \$604.1 million and \$553.7 million, respectively, based on their market prices on the last trading day for the period. As of December 31, 2023, the estimated fair value of our 2029 Notes and 2027 Notes was \$638.7 million and \$695.8 million, respectively, based on their market prices on the last trading day for the period. Term Loan The fair value of our outstanding term loan (refer to Note 9) is estimated using the net present value of the payments, discounted at an interest rate that is consistent with a market interest rate, which is a Level 2 input. The estimated fair value of our outstanding term loan under the Financing Agreement (as defined in Note 9 below) as of June 30, 2024 was \$464.9 million and under the Loan Agreement (as defined in Note 9 below) as of December 31, 2023 was \$389.1 million.

4. Cash Equivalents and Marketable Securities

Cash equivalents consist primarily of amounts invested in money market instruments, such as money market funds and U.S. treasury bills. Our marketable securities consist of high investment grade fixed income securities that are invested in U.S. treasury bills. Cash equivalents and marketable securities classified as available-for-sale consisted of the following:

	June 30, 2024	Amortized Cost Basis	Unrealized Gains	Unrealized Losses	Estimated Fair Value	(in thousands)	Cash equivalents	Money market funds	Treasury bills	Marketable securities	LianBio Warrant	Embedded derivative	Total financial assets
As of June 30, 2024	\$139,282	\$139,282	\$0	\$0	\$139,282	\$139,282	\$85,605	\$85,605	\$0	\$0	\$0	\$0	\$139,282
As of December 31, 2023	\$139,282	\$139,282	\$0	\$0	\$139,282	\$139,282	\$85,605	\$85,605	\$0	\$0	\$0	\$0	\$139,282

There have been no significant realized gains or losses on available-for-sale securities for the periods presented. There were no available-for-sale securities that have been in a continuous unrealized loss position for more than 12 months. We believe that we have the ability to realize the full value of all of these investments upon their respective maturities.

5. Noncontrolling Interests

As of June 30, 2024 and December 31, 2023, we had both redeemable convertible noncontrolling interests and noncontrolling interests in consolidated partially-owned entities, for which BridgeBio is the primary beneficiary under the VIE model. These balances are reported as separate components outside stockholders' deficit in Redeemable convertible noncontrolling interests and as part of stockholders' deficit in Noncontrolling interests on the condensed consolidated balance sheets. We adjust the carrying value of noncontrolling interests to reflect the book value attributable to noncontrolling stockholders of consolidated partially-owned entities when there is a change in the ownership during the respective reporting period and such adjustments are recorded to Additional paid-in capital. For the three and six months ended June 30, 2024, the adjustments in the aggregate amounted to \$(0.1) million and \$(1.9) million, respectively. For the three and six months ended June 30, 2023, the adjustments in the aggregate amounted to \$(3.1) million and \$(5.9) million, respectively. All such adjustments are disclosed within the Transfers from (to) noncontrolling interests line item on the condensed consolidated statements of redeemable convertible noncontrolling interests and stockholders' deficit.

6. Equity Method Investment and Other Equity Investments

Ras On April 30, 2024, The Ras, Inc., doing business as BridgeBio Oncology Therapeutics (BBOT), a majority-owned subsidiary of the Company, completed a \$200.0 million private equity financing with external investors to accelerate the development of its oncology portfolio. Upon completion of the private equity financing, the Company's ownership of BBOT's equity was reduced to approximately 37.9%. As part of the private equity financing transaction, BBOT's Certificate of Incorporation and Investors' Rights Agreement were amended and restated to reflect a change to BBOT's governance structure and composition of the board of directors, which was determined to be a VIE reconsideration event. Based on the VIE reconsideration assessment, BBOT was deemed a VIE. As a result of the change in governance structure and composition of the board of directors, BridgeBio is no longer the primary beneficiary of BBOT, as it no longer has the power over key decisions that significantly impact BBOT's economic performance. Accordingly, BridgeBio deconsolidated BBOT on April 30, 2024. During the three months ended June 30, 2024, we recognized a \$126.3 million net gain from deconsolidation of a subsidiary, which is presented on the condensed consolidated statements of operations for the three and six months ended June 30, 2024. The gain on deconsolidation represents the difference between BridgeBio's equity investment in BBOT, valued at \$124.9 million upon deconsolidation and the carrying value of the net assets held by BBOT on April 30, 2024. Upon the deconsolidation of BBOT, BridgeBio accounted for its retained investment in BBOT, for which it has significant influence through its ownership interest, using the equity method of accounting under ASC 323 - Investments. Equity Method and Joint Ventures. BBOT was also deemed a related party. BridgeBio's equity investment in BBOT, valued at \$124.9 million upon deconsolidation, was compared to BridgeBio's percentage of underlying equity in net assets of BBOT, which includes an implied difference of \$49.6 million between the fair value of the equity investment and the underlying equity in the net assets of BBOT (referred to as a basis difference). The basis difference was attributed to BBOT's in-process research and development (IPR&D assets), and is amortized as a component of net loss from equity method investment over the estimated useful life of the IPR&D asset. The amortization of the IPR&D asset for the period from May 1, 2024 through June 30, 2024 was immaterial. For the period from May 1, 2024 through June 30, 2024, we recognized a net loss from equity method investment of \$7.9 million. As of June 30, 2024, the aggregate carrying amount of our equity method investment in BBOT is \$117.0 million and is presented as Investment in nonconsolidated entity on our condensed consolidated balance sheets.

16 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited)

In addition, on April 30, 2024, the Company and BBOT entered into an 18-month transition service agreement (the "Transition Service Agreement") for the provision of certain transitional consulting services to be provided by the Company and BBOT. Under the Transition Service Agreement, the Company recognized \$0.8 million in other income during the three and six months ended June 30, 2024, and \$0.1 million in prepaid expenses and other current assets as of June 30, 2024 for transitional consulting services provided by BridgeBio to BBOT. The Company also recognized \$0.3 million in research and development liabilities during the three and six months ended June 30, 2024, and \$0.3 million in accrued research and development liabilities for transitional consulting services provided by BBOT to BridgeBio as of June 30, 2024.

LianBio In October 2019, our subsidiary, BridgeBio Pharma LLC (BBP LLC), entered into an exclusivity agreement with LianBio, an exempt company organized under the laws of the Cayman Islands (together with its subsidiaries, LianBio), pursuant to which BBP LLC received equity in LianBio (the "LianBio Exclusivity Agreement"). We account for BBP LLC's equity interest in LianBio under ASC 321 Investments - Equity Securities as an investment in equity securities. For the three months ended June 30, 2024 and 2023, we recorded an unrealized gain of nil and \$1.6 million, respectively, for the ongoing mark-to-market adjustments of the investment. For the six months ended June 30, 2024 and 2023, we recorded an unrealized gain of nil and \$3.2 million, respectively, for the ongoing mark-to-market adjustments of the investment (refer to Note 3).

As of December 31, 2023, QED also held warrants which entitled QED to purchase 347,569 shares of LianBio. The LianBio Warrant was measured at fair value on a recurring basis, with changes in fair value recognized in our condensed consolidated statements of operations as part of Other income (expense), net. The LianBio Warrant, which is presented as part of Other assets on our condensed consolidated balance sheets, had a fair value of \$1.6 million as of December 31, 2023. In February 2024, QED exercised the 347,569 shares of LianBio warrants it held for an immaterial amount. In March 2024, we received net proceeds of \$25.7 million as special cash dividends and recognized net realized gains of \$1.8 million from our investment in LianBio equity securities. As of June 30, 2024, the Company held 5,350,361 shares of LianBio common stock. PellePharm As of April 15, 2021, BridgeBio had been the primary beneficiary of PellePharm as it had power over key decisions that significantly impact PellePharm's economic performance. BridgeBio also had the obligation to absorb losses or the right to receive benefits from PellePharm that could potentially be significant to PellePharm through its common and preferred stock interest in PellePharm. Accordingly, BridgeBio had consolidated PellePharm during the period April 15, 2021 through December 31, 2022. On January 16, 2023, PellePharm's board of directors authorized the assignment of all PellePharm's assets to PellePharm ABC, LLC for liquidation and distribution under the General Assignment for the Benefit of Creditors (ABC proceedings). As part of the ABC proceedings, PellePharm's board of directors resigned effective March 6, 2023. The date the board of directors resigned was determined to be a VIE reconsideration event. Based on the changes to PellePharm's governance structure and composition of the board of directors as a result of the ABC, BridgeBio was no longer the primary beneficiary, as it no longer had the power over key decisions that significantly impact PellePharm's economic performance. Accordingly, during the three months ended March 31, 2023, BridgeBio deconsolidated PellePharm and recognized a loss of \$1.2 million which is presented as part of Other income (expense), net on the condensed consolidated statements of operations for the six months ended June 30, 2023.

7. Intangible Assets, net

The following table summarizes our recognized intangible assets as a result of the arrangements described in the following sections:

	June 30, 2024	December 31, 2023	Weighted-average Estimated Useful Lives	Amount	(in thousands)	Gross amount	Accumulated amortization	Net amount

[illegible]

\$82.2 A \$ 544,270 A \$ 736,905 A \$ 545,379 A A 22 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited)A The following table sets forth the total interest expense recognized and effective interest rates related to the Notes for the periods presented:A A Three Months Ended June 30, 2024 A A Six Months Ended June 30, 2024 A A 2029 Notes A A 2027 Notes A A Total A A 2029 Notes A A 2027 Notes A A Total A A (in thousands) A A A Contractual interest expense A \$ 4,204 A A \$ 4,347 A A \$ 7,641 A A \$ 8,409 A A \$ 6,875 A A \$ 15,284 A Amortization of debt discount and issuance costs A 490 A A 447 A A 937 A A 977 A A A 891 A A 1,868 A Total interest and amortization expense A \$ 4,694 A A \$ 3,884 A A \$ 8,578 A A \$ 9,386 A A \$ 7,766 A A \$ 17,152 A A A A A A A A A Effective interest rate A 2.6 % A 2.8 % A A A 2.6 % A 2.8 % A A A Three Months Ended June 30, 2023 A A Six Months Ended June 30, 2023 A A 2029 Notes A A 2027 Notes A A Total A A 2029 Notes A A 2027 Notes A A Total A A (in thousands) A A A Contractual interest expense A \$ 4,204 A A \$ 4,347 A A \$ 7,641 A A \$ 8,409 A A \$ 6,875 A A \$ 15,284 A Amortization of debt discount and issuance costs A 477 A A 436 A A 913 A A 952 A A 867 A A 1,819 A Total interest and amortization expense A \$ 4,681 A A \$ 3,873 A A \$ 8,554 A A \$ 9,361 A A \$ 7,742 A A \$ 17,103 A A A A A A A A Effective interest rate A 2.6 % A 2.8 % A A A 2.6 % A 2.8 % A A As of June 30, 2024, interest payable on the 2029 and 2027 Notes amounted to \$7.0 million and \$4.0 million, respectively. As of December 31, 2023, interest payable on the 2029 and 2027 Notes amounted to \$7.0 million and \$4.0 million, respectively.Future minimum payments under the Notes as of June 30, 2024 are as follows: A A 2029 Notes A A 2027 Notes A A Total A A (in thousands) A Remainder of 2024 A \$ 8,409 A A \$ 6,875 A A \$ 15,284 A Year ending December 31: A A A A A A 2025 A \$ 16,819 A A 13,750 A A 30,569 A 2026 A \$ 16,819 A A 13,750 A A 30,569 A 2027 A \$ 16,819 A A 16,819 A A 556,875 A A 573,694 A 2028 A \$ 16,819 A A æ A A 16,819 A Thereafter A \$ 755,909 A A æ A A 755,909 A Total future payments A \$ 831,594 A A \$ 591,250 A A 1,422,844 A Less amounts representing interest A \$ (84,094) A A (41,250) A A (125,344) Total principal amount A \$ 747,500 A A \$ 550,000 A A \$ 1,297,500 A A 23 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited)A Capped Call and Share Repurchase Transactions with Respect to the NotesOn each of January 25, 2021 and March 4, 2020, concurrently with the pricing of the 2029 Notes and 2027 Notes, respectively, we entered into separate privately negotiated capped call transactions (the æ2021 Capped Call Transactionsæ and the æ2020 Capped Call Transactionsæ, respectively), or, together, the Capped Call Transactions, with certain financial institutions, or the Capped Call Counterparties. We used approximately \$61.3 million and \$49.3 million of the net proceeds from the 2021 Note Offering and 2020 Note Offering, respectively, to pay for the cost of the respective Capped Call Transactions. The Capped Call Transactions are expected generally to reduce the potential dilution to BridgeBioÆ™'s common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap initially equal to \$131.58 for the 2021 Capped Call Transactions and \$62.12 for the 2020 Capped Call Transactions (both of which represented a premium of 100% over the last reported sale price of BridgeBioÆ™'s common stock on the date of the Capped Call Transactions) and are subject to certain adjustments under the terms of the Capped Call Transactions. The 2021 Capped Calls and 2020 Capped Calls cover 7,702,988 shares and 12,878,305 shares, respectively, of our common stock (subject to anti-dilution and certain other adjustments), which are the same number of shares of common stock that initially underlie the Notes. The 2021 Capped Calls have an initial strike price of approximately \$97.04 per share, which corresponds to the initial conversion price of the 2029 Notes. The 2020 Capped Calls have an initial strike price of approximately \$42.71 per share, which corresponds to the initial conversion price of the 2027 Notes. The Capped Call Transactions are separate transactions, entered into by us with the Capped Call Counterparties, and are not part of the terms of the Notes.These Capped Call instruments meet the conditions outlined in ASC 815-40, Derivatives and Hedging, to be classified in stockholdersÆ™ equity and are not subsequently remeasured as long as the conditions for equity classification continue to be met. We recorded a reduction to additional paid-in capital of approximately \$61.3 million and \$49.3 million for the years ended December 31, 2021 and 2020, respectively, related to the premium payments for the Capped Call Transactions. Additionally, we used approximately \$50.0 million and \$75.0 million of the net proceeds from the 2021 Note Offering and 2020 Note Offering to repurchase 759,993 shares and 2,414,681 shares, respectively, of our common stock concurrently with the closing of the Note Offerings from certain of the NotesÆ™ Initial Purchasers in privately negotiated transactions. The agreed purchase price per share of common stock in the repurchases were \$65.79 and \$31.06, which were the last reported sale prices per share of our common stock on The Nasdaq Global Select Market, or Nasdaq, on January 25, 2021 and March 4, 2020, respectively. The shares repurchased were recorded as æTreasury stock.æTerm Loan, netLoan and Security Agreement In November 2021, we entered into a Loan and Security Agreement (the æLoan Agreement,æ and as amended by the First Amendment (as defined below) and the Second Amendment (as defined below), the æAmended Loan Agreementæ), by and among (i) U.S. Bank National Association, in its capacity as administrative agent (in such capacity, the æAdministrative Agentæ) and collateral agent (in such capacity, the æCollateral Agentæ), (ii) certain lenders (the æLendersæ), (iii) BridgeBio, as a borrower, and (iv) certain subsidiaries of BridgeBio, as guarantors (the æGuarantorsæ). In May 2022, we entered into the first amendment to the Loan Agreement (the æFirst Amendmentæ) and in November 2022, we entered into the second amendment to the Loan Agreement (the æSecond Amendmentæ), as further described below. In January 2024, we fully repaid the term loan under the Loan Agreement as further described below.Pursuant to the original terms and conditions of the Loan Agreement, the Lenders agreed to extend term loans to us in an aggregate principal amount of up to \$750.0 million, comprised of (i) a tranche 1 advance of \$450.0 million (the æTranche 1 Advanceæ), and (ii) a tranche 2 advance of \$300.0 million (the æTranche 2 Advanceæ) (collectively, the æTerm Loan Advancesæ). The Tranche 1 Advance under the Loan Agreement was funded on November 17, 2021. The Tranche 2 Advance remained available for funding until December 31, 2022, which was available at our election after the occurrence of certain milestone events relating to data from our clinical trials. The terms related to the Tranche 2 Advance were modified in the First Amendment and Second Amendment as further discussed below. The First AmendmentÆ™ s term included the reduction of the aggregate amount of the Tranche 2 Advance from \$300.0 million to \$100.0 million. The Second Amendment eliminated the \$100.0 million Tranche 2 Advance. As a result of the Second Amendment, the total aggregate principal amount of the loan is \$450.0 million before any mandatory prepayment.A 24 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited)A As security for our obligations under the Loan Agreement, each of BridgeBio and the Guarantors granted the Collateral Agent, for the benefit of the Lenders, a continuing security interest in substantially all of the assets of BridgeBio and the Guarantors (including all equity interests owned or hereafter acquired by BridgeBio and the Guarantors), subject to certain customary exceptions. Upon exceeding certain investment and disposition thresholds, additional subsidiaries of BridgeBio will be required to join as guarantors.Any outstanding principal on the Term Loan Advances will accrue interest at a fixed rate equal to 9.0% per annum. 3.0% of which can be a payment-in-kind (æPIKæ) until January 1, 2025. Interest payments are payable quarterly following the funding of a Term Loan Advance. We would be required to make principal payments on the outstanding balance of the Term Loan Advances commencing on January 2, 2025 (the æTerm Loan Amortization Dateæ) in nine quarterly installments, plus interest. If we have achieved certain milestone events relating to data from the clinical trial of acoramidis (the æAcoramidis Milestoneæ) on or prior to January 1, 2025, then the Term Loan Amortization Date would be automatically extended to January 2, 2026. Any amounts outstanding under the Term Loan Advances are due and payable on November 17, 2026 (the æMaturity Dateæ).We may prepay the outstanding principal amount of the Term Loan Advances at any time (in whole, but not in part), plus accrued and unpaid interest and a prepayment premium ranging from 1.0% to 3.0% of the principal amount outstanding depending on the timing of payment (plus a customary make-whole amount if prepaid on or prior to November 17, 2022).At the LendersÆ™ election, we were also required to make mandatory prepayments upon the occurrence of certain prepayment events related to the repurchase or redemption of pledged collateral, entry into certain royalty transactions, disposition of other assets or subsidiaries, and entry into licensing and other monetization transactions (all such events are referred to as prepayment events), which could be 50.0% or 75.0% of net cash proceeds from such transaction depending on achievement of the Acoramidis Milestone. Subject to the mandatory prepayment requirements for certain prepayment events, the Loan Agreement contains customary affirmative and limited negative covenants which, among other things, limit our ability to (i) incur additional indebtedness, (ii) pay dividends or make certain distributions, (iii) dispose of our assets, grant liens, license or encumber our assets or (iv) fundamentally alter the nature of our business. BridgeBio and the Guarantors have broad ability to license our intellectual property, dispose of other assets and enter into monetization and royalty transactions, subject in each case to the requirement to make a mandatory prepayment described above. The Loan Agreement provides that BridgeBio and the Guarantors may, subject to certain limitations, (x) repurchase BridgeBioÆ™ s equity interest and the equity interest of any of its subsidiaries, (y) enter into any joint ventures or similar investments, and (z) make other investments and acquisitions. Subject to the mandatory prepayment requirement described above, portfolio companies owned by BridgeBio that are not parties to the Loan Agreement are, subject to certain exceptions, not subject to any covenants or limitations under the Loan Agreement. The Loan Agreement also contains customary events of default, including among other things, our failure to make any principal or interest payments when due, the occurrence of certain bankruptcy or insolvency events or the breach of the covenants under the Loan Agreement. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate our obligations under the Loan Agreement.We received net proceeds from the Tranche 1 Advance of \$431.3 million, after deducting debt discount and issuance costs of \$18.7 million, of which approximately \$1.1 million of debt issuance costs were incurred for professional services provided by KKR Capital Markets LLC. KKR Capital Markets LLC is an affiliate of KKR Genetic Disorder L.P., a related party being a principal stockholder of BridgeBio. In May 2022, we entered into the First Amendment, which, among other things:æpermitted the sale of our priority revenue voucher (æPRVæ, refer to Note 12) and, generally, future dispositions of other PRVs; æreduced the aggregate amount of the Tranche 2 Advance from \$300.0 million to \$100.0 million and modified certain conditions to the availability thereof, as mentioned above; æamended the principal payments such that the entire outstanding principal balance of the Term Loan Advances is due and payable at the Maturity Date or upon early termination; andæmodified the terms and conditions governing when certain entities into which we have made investments will be required to become guarantors under the Amended Loan Agreement.A 25 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited)A In June 2022, the receipt of an upfront payment under the license development and commercialization agreement that our subsidiary, Navire Pharma, Inc. (æNavireæ), entered into with Bristol-Myers Squibb Company (æBMSæ), which is further described in Note 11, triggered certain mandatory prepayment provisions of the Amended Loan Agreement. As a result, we paid \$20.5 million to the Lenders in June 2022, of which \$20.1 million and \$0.4 million were applied to principal and exit fee, respectively.Pursuant to the terms of the Loan Agreement, we exercised our option to convert \$3.4 million and \$6.7 million of accrued interest into principal via PIK for the three and six months ended June 30, 2023, respectively.In November 2022, we entered into the Second Amendment, which, among other things: æacknowledged that our prior prepayment made with certain cash proceeds received in connection the receipt of an upfront payment under the Navire-BMS License Agreement, which is further described in Note 11, satisfied the mandatory prepayment requirement under the Amended Loan Agreement, on the terms and conditions specified in the Amended Loan Agreement;æpermitted certain budgeted expenses to be excluded from the definition of cash proceeds subject to the CompanyÆ™ s mandatory prepayment obligations, on the terms and conditions specified in the Amended Loan Agreement, refer to Note 2 under Restricted Cash section for further discussion;æremoved certain threshold amounts applicable to certain prepayment events; andæterminated the LendersÆ™ \$100.0 million Tranche 2 Advance. The balances of our borrowing under the Amended Loan Agreement consisted of the following: A A December 31, 2023 A A (in thousands) A Principal value of term loan A \$ 429,916 A PIK added to principal A 25,531 A Debt discount, issuance costs and exit fee accretion A (9,002) Term loan, net A \$ 446,445 A For the three and six months ended June 30, 2024, we recognized interest expense related to the Amended Loan Agreement of nil and \$3.0 million, respectively, of which nil and \$0.

three months ended June 30, 2024, we received \$235.0 million in aggregate from Bayer Consumer Care AG and Kyowa Kirin Co., Ltd, and deposited net proceeds of \$159.3 million into the escrow accounts. Refer to Note 11 for further details regarding the exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd. The completion of the \$200.0 million private equity financing with external investors of BBOT was considered an asset sale transaction that was subject to a disposition fee under the Financing Agreement. Accordingly, we paid a disposition fee of \$1.1 million to the Administrative Agent during the three months ended June 30, 2024. Refer to Note 6 for further details regarding the BBOT private equity financing transaction. The Financing Agreement contains affirmative covenants and negative covenants applicable to the Company and its subsidiaries that are customary for financings of this type. Such covenants, among other items, limit the Company's and its subsidiaries' ability to (i) incur additional permitted indebtedness, (ii) pay dividends or make certain distributions, (iii) dispose of its and their assets, grant liens and license or permit other encumbrances on its and their assets, (iv) fundamentally alter the nature of their businesses and (v) enter into certain transactions with affiliates. The Company and the Guarantors are also required to maintain a minimum qualified cash balance of \$70.0 million, at all times. The Company and its subsidiaries are permitted to license their intellectual property, dispose of other assets and enter into monetization and royalty transactions, in each case, subject to satisfaction of certain terms and conditions. The Financing Agreement also includes representations, warranties, indemnities and events of default that are customary for financings of this type, including an event of default relating to a change of control of the Company. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate the Company's obligations under the Financing Agreement. A 27 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) On June 20, 2024, the Company and each of the guarantors entered into the Second Amendment to the Financing Agreement (the Financing Agreement, as amended by the Second Amendment, the Amended Financing Agreement). Under the Amended Financing Agreement, between June 20, 2024 and through the earlier of the date the FDA approves a first NDA for acoramidis and November 30, 2024, the Company is able to request a release of funds in an aggregate amount not to exceed 50% of the original net cash proceeds received from asset sale transactions. As of June 30, 2024, \$20.0 million was released from the escrow accounts and classified as cash, with a remaining balance of \$139.3 million in the escrow accounts classified as restricted cash on the condensed consolidated balance sheet. Furthermore, under the Amended Financing Agreement, the minimum qualified cash balance was amended from \$70.0 million to \$70.0 million plus 40% of any cash released by the Company from the escrow accounts, at all times. As of June 30, 2024, the minimum unrestricted qualified cash balance was \$78.0 million. We received net proceeds from the Initial Term Loan of \$434.0 million, after deducting debt discount and issuance costs of \$160.0 million. The balances of our borrowing under the Amended Financing Agreement consisted of the following: A June 30, 2024 A (in thousands) A Principal value of term loan A \$ 450,000 A Debt discount, issuance costs and exit fee accretion A (14,553) Term loan, net A \$ 435,447 A For the three and six months ended June 30, 2024, we recognized interest expense related to the Amended Financing Agreement of \$14.3 million and \$26.2 million, respectively, of which \$0.7 million and \$1.4 million, respectively, relates to amortization of debt discount and issuance costs. As of June 30, 2024, interest payable under the Amended Financing Agreement included in Accrued professional and other accrued liabilities in our condensed consolidated balance sheet amounted to \$0.3 million. Future minimum payments under the Amended Financing Agreement as of June 30, 2024 are as follows: A A Amount A (in thousands) A Remainder of 2024 A \$ 27,515 A Year Ending December 31: A A 2025 A \$ 53,995 A 2026 A \$ 53,995 A 2027 A \$ 119,454 A 2028 A \$ 131,732 A 2029 A \$ 294,327 A Total future payments A \$ 681,018 A Less amounts representing interest A (231,018) Total principal amount of term loan payments A \$ 450,000 A The amounts in the table above do not take into account any changes due to mandatory payments under the terms of the Amended Financing Agreement. 10. Funding Agreement On January 17, 2024, the Company and its subsidiaries, Eidos Therapeutics, Inc., BridgeBio Europe B.V. and BridgeBio International GmbH (collectively, the Seller Parties), entered into a Funding Agreement (the Funding Agreement) with LSI Financing 1 Designated Activity Company and CPEIB Credit Europe S.A. r.l. (together, the Purchasers), and Alter Domus (US) LLC, as the collateral agent. Pursuant to the Funding Agreement, the Purchasers agreed to pay to the Company \$500.0 million (net of certain transaction expenses) (the Investment Amount) upon the first FDA approval of acoramidis, subject to certain conditions relating to the FDA approval and other customary conditions (such date of payment, the Funding Date). In return, the Company granted the Purchasers the right to receive payments (the Royalty Interest Payments) equal to 5% of the global Net Sales of acoramidis (the Net Sales). Each Royalty Interest Payment will become payable to the Purchasers on a quarterly A 28 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) A basis after the Funding Date. In addition, the Seller Parties granted the collateral agent, for the benefit of the Purchasers, a security interest in specific assets related to acoramidis. The Purchasers' rights to the Royalty Interest Payments and ownership interest in Net Sales will terminate upon the earlier of the Purchasers' receipt of (a) Royalty Interest Payments equal to \$950.0 million (the Cap Amount) and (b) a buy-out payment (the Buy-Out Payment) in an amount determined in accordance with the Funding Agreement but that will not exceed the Cap Amount. In the event that a change in control (as customarily defined in the Funding Agreement) occurs on or after the effective date of the Funding Agreement and prior to FDA approval of acoramidis, either party may terminate the Funding Agreement and the Seller Parties shall make a one-time payment of \$25.0 million (in the aggregate) to the Purchasers. Under certain conditions, including conditions relating to sales performance of acoramidis by or on behalf of the Company, the rate of the Royalty Interest Payments may adjust to a maximum rate of 10% in 2027. The Funding Agreement will terminate upon customary events, and also in the event the Funding Date does not occur on or prior to May 15, 2025 (in which case either party may terminate the Funding Agreement at no charge and without premium or penalty). Under the Funding Agreement, the Seller Parties are required to comply with various covenants, including using commercially reasonable efforts to obtain regulatory approval for and commercialize acoramidis, providing the Purchasers with certain clinical, commercial, regulatory and intellectual property updates and certain financial statements, and providing notices upon the occurrence of certain events, each as agreed under the Funding Agreement. The Funding Agreement also contains certain representations and warranties, indemnification obligations, put-option events and other provisions that are customary for transactions of this nature. As of June 30, 2024, the Company has not received proceeds under the Funding Agreement. As of June 30, 2024, we recognized deferred issuance costs of \$5.8 million in Prepaid expenses and other current assets in our condensed consolidated balance sheet. 11. License and Collaboration Agreements Bayer Exclusive License On March 1, 2024, certain subsidiaries of the Company, including Eidos Therapeutics, Inc., BridgeBio International GmbH and BridgeBio Europe B.V., (collectively the Seller Parties), entered into an exclusive license agreement (the Bayer Agreement) with Bayer Consumer Care AG, a wholly-owned subsidiary of Bayer AG (the Bayer), to develop and commercialize acoramidis as a treatment for transthyretin amyloidosis in the European Union and all member and extension states of the European Patent Organization (the Licensed Territory). Under the terms of the Bayer Agreement, the Seller Parties granted Bayer an exclusive license, effective upon the date that certain antitrust clearances have been obtained, or March 26, 2024, to certain of the Seller Parties' intellectual property rights to develop, manufacture and commercialize acoramidis (previously known as AG10) in the Licensed Territory. In consideration for the license grant, the Seller Parties are entitled to receive an upfront payment of \$135.0 million, which was received in full in May 2024, and will be eligible to receive up to \$175.0 million in regulatory and sales milestone payments through 2026, and additional payments up to \$450.0 million subject to the achievement of certain sales milestones. In addition, the Seller Parties are entitled to receive royalties according to a tiered structure starting in the low-thirties percent on net sales by Bayer of acoramidis in the Licensed Territory, subject to reduction under certain circumstances as provided in the Bayer Agreement. Unless earlier terminated, the Bayer Agreement will expire at the end of the royalty term for a licensed product, provided that the licenses granted to Bayer for such licensed product survive such expiration on a non-exclusive basis. Either party may terminate the Agreement in the event of a material breach or insolvency of the other party or in the event merger control proceedings are started and clearances are not obtained. Additionally, Bayer may terminate the Bayer Agreement for convenience upon at least 270 days' prior written notice, and the Seller Parties may terminate the Bayer Agreement in the event Bayer ceases exploitation of acoramidis under certain circumstances or challenges the validity or enforceability of the Seller Parties' patent rights. We determined that the Bayer Agreement falls within the scope of ASC 606 as Bayer is a customer in this arrangement, and we identified the following performance obligations in the agreement: an exclusive license to develop and commercialize acoramidis in the Licensed Territory and the related know-how; and research and development services to conduct ongoing clinical trials. A 29 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) We determined that the performance obligations outlined above are capable of being distinct and distinct with the context of the contract given such rights and activities are independent of each other. The license can be used by Bayer without the development services. Similarly, those services provide a distinct benefit to Bayer within the context of the contract, separate from the license, as the services could be provided by Bayer or another third party without our assistance. We determined the initial transaction price at inception of the Bayer Agreement to be \$135.0 million, which is comprised of the fixed and non-refundable upfront payment. No additional development or sales milestone payments are included in the transaction price, as all such payments are variable consideration that are fully constrained as of June 30, 2024. We include variable consideration in our transaction price to the extent that it is probable that it will not result in a significant revenue reversal when the uncertainty associated with the variable consideration is subsequently resolved. As part of management's evaluation of the variable consideration, we considered numerous factors, including the fact that achievement of the milestones is outside of our control, contingent upon the success of our existing clinical trials, Bayer's efforts, and receipt of regulatory approval that is subject to scientific risks of success. Royalty arrangements and commercial-based milestones will be recognized when the sales occur or the milestones are achieved pursuant to the sales-based royalty exception under ASC 606 because the license is the predominant item to which the royalties or commercial-based milestones relate. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. We allocated the transaction price of \$135.0 million based on the stand-alone selling prices (the SSP) of each of the performance obligations as follows: \$130.5 million for the upfront transfer of the license; and \$4.5 million for the research and development services to conduct the ongoing clinical trials. The SSP for the license was determined using an approach that considered discounted, probability-weighted cash flows related to the license transferred. The SSP for the ongoing research and development services were based on estimates of the associated effort and cost of these services, adjusted for a reasonable gross profit margin that would be expected to be realized under similar contracts. We recognize revenue for each of the two performance obligations as follows: We recognized revenue related to the license at a point in time upon transfer of the rights and control of the license to Bayer. The transfer of the rights and control of the license occurred in March 2024, thus we recognized the full amount allocated to the license and related know-how during the three months ended March 31, 2024. We are recognizing revenue related to the research and development services for the ongoing clinical trials over time using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. We expect the research and development services for ongoing clinical trials to extend through 2028. We have recognized \$0.4 million of revenue relating to this performance obligation during the three and six months ended June 30, 2024. As of June 30, 2024, there are no outstanding receivables from licensing and collaboration agreements relating to the Bayer Agreement within our condensed consolidated balance sheet. During the three and six months ended June 30, 2024 we recognized license revenue of \$0.4 million and \$130.9 million, respectively, under the Bayer Agreement. Our condensed consolidated balance sheet as of June 30, 2024 includes a deferred revenue balance of \$4.1 million (\$1.4 million presented as Deferred revenue, current portion and \$2.7 million included in Deferred revenue, net of current portion) related to our research and development services obligations. In addition, under the terms of the Financing Agreement, the Bayer Agreement represents an asset sale transaction that requires the Company to deposit 75% of proceeds, net of certain permitted costs, received from the transaction into an escrow account to be controlled by the Administrative Agent. In May 2024, we deposited \$84.7 million into the escrow account from the receipt of the \$135.0 million from Bayer. Refer to Note 9 for further details regarding the Financing Agreement. In June 2024, BridgeBio Europe B.V. (the BridgeBio B.V.) entered into a commercial supply agreement with Bayer (the Bayer Supply Agreement) with an initial 30-month term ending in December 2026, for which BridgeBio B.V. will manufacture and supply to Bayer the commercial product ordered by Bayer solely for the use in the commercialization in the Licensed Territory under the Bayer Agreement. Under the Bayer Supply Agreement, Bayer shall pay to BridgeBio B.V. a commercial product per unit price equal to the applicable fully burdened manufacturing cost per unit of product, which shall include the cost of the active pharmaceutical ingredient (the API) used to manufacture the product and the packaging price. As of June 30, 2024, there have been no commercial product supply sales to Bayer. A 30 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) A Kyowa Kirin Exclusive License On February 7, 2024, the Company's subsidiary, QED, and Kyowa Kirin Co., Ltd (the Kyowa Kirin) or (the KKC) entered into a partnership wherein QED granted Kyowa Kirin an exclusive license to develop, manufacture, and commercialize ifenegratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan, in accordance with the terms therein (the KKC Agreement). In exchange, QED received an upfront payment of \$100.0 million in June 2024, and will be eligible to receive royalties up to the mid-twenties percent on sales of ifenegratinib in Japan, with the potential to receive up to \$81.4 million in development and sales-based milestone payments. Unless earlier terminated, the KKC Agreement will expire at the end of the royalty term for a licensed product, provided that the licenses granted to Kyowa Kirin for such licensed product survive such expiration on a non-exclusive basis. Either party may terminate the KKC Agreement in the event of a material breach or insolvency of the other party. Additionally, Kyowa Kirin may terminate the KKC Agreement for convenience upon at least 180 days' prior written notice, and QED may terminate the KKC Agreement in the event Kyowa Kirin ceases exploitation of ifenegratinib under certain circumstances or challenges the validity or enforceability of Kyowa Kirin's patent rights. We determined that the KKC Agreement falls within the scope of ASC 606 as Kyowa Kirin is a customer in this arrangement, and we identified the following performance obligations in the agreement: an exclusive license to develop and commercialize ifenegratinib for achondroplasia, hypochondroplasia and other skeletal dysplasias in Japan and the related know-how; and research and development services to conduct ongoing clinical trials. We determined that the performance obligations outlined above are capable of being distinct and distinct with the context of the contract given such rights and activities are independent of each other. The license can be used by Kyowa Kirin without any development activities. Similarly, those services provide a distinct benefit to Kyowa Kirin within the context of the contract, separate from the license, as the services could be provided by Kyowa Kirin or another third party without our assistance. We determined the initial transaction price at inception of the KKC Agreement to be \$100.0 million, which is comprised of the fixed and non-refundable upfront payment. No additional development or sales milestone payments are included in the transaction price, as all such payments are variable consideration that are fully constrained as of June 30, 2024. We include variable consideration in our transaction price to the extent that it is probable that it will not result in a significant revenue reversal when the uncertainty associated with the variable consideration is subsequently resolved. As part of management's evaluation of the variable consideration, we considered numerous factors, including the fact that achievement of the milestones is outside of our control, contingent upon the success of our existing and future clinical trials, Kyowa Kirin's efforts, and receipt of regulatory approval that is subject to scientific risks of success. Royalty arrangements and commercial-based milestones will be recognized when the sales occur or the milestones are achieved pursuant to the sales-based royalty exception under ASC 606 because the license is the predominant item to which the royalties or commercial-based milestones relate. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. We allocated the transaction price of \$100.0 million based on the SSP of each of the performance obligations as follows: \$69.1 million for the upfront transfer of the license; and \$30.9 million for research and development services to conduct the ongoing clinical trials. The SSP for the license was determined using an approach that considered discounted, probability-weighted cash flows related to the license transferred. The SSP for the ongoing research and development services were based on estimates of the associated effort and cost of these services, adjusted for a reasonable gross profit margin that would be expected to be realized under similar contracts. We recognize revenue for each of the two performance obligations as follows: We recognized revenue related to the license at a point in time upon transfer of the rights and control of the license to KKC. The transfer of the rights and control of the license occurred in February 2024, thus we recognized the full amount allocated to the license and related know-how during the three months ended March 31, 2024. We are recognizing revenue relating to the research and development services for the ongoing clinical trials over time using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. We expect the development services to extend through 2029. We have recognized \$1.3 million and \$2.9 million of revenue relating to this performance obligation during the three and six months ended June 30, 2024, respectively. A 31 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) As of June 30, 2024, there are no outstanding receivables from licensing and collaboration agreements relating to the KKC Agreement within our condensed consolidated balance sheet. During the three and six months ended June 30, 2024, we recognized license revenue of \$1.3 million and \$72.1 million under the KKC Agreement. Our condensed consolidated balance sheet as of June 30, 2024 includes a deferred revenue balance of \$28.0 million (\$13.7 million presented as Deferred revenue, current portion and \$14.3 million included in Deferred revenue, net of current portion) related to our research and development

services obligation. In addition, under the terms of the Financing Agreement, the KKC Agreement represents an asset sale transaction that requires the Company to deposit 75% of proceeds, net of certain permitted costs, received from the transaction into an escrow account to be controlled by the Administrative Agent. In June 2024, we deposited \$74.6 million into the escrow account from the receipt of the \$100.0 million from KKC. Refer to Note 9 for further details regarding the Financing Agreement. License, Development and Commercialization Agreement with BMS On May 12, 2022, BridgeBio and our subsidiary, Navire, entered into an exclusive license, development and commercialization agreement with BMS (the “Navire-BMS License Agreement”), pursuant to which Navire granted BMS exclusive rights to develop and commercialize Navire’s product candidate, BBP-398, in all indications worldwide, except for the People’s Republic of China, Macau, Hong Kong, Taiwan, Thailand, Singapore, and South Korea (the “Asia Region”). The development and commercialization of BBP-398 within the Asia Region is governed under the Navire-LianBio License Agreement (as discussed below). The Navire-BMS License Agreement expands an earlier agreement between Navire and BMS that was executed in July 2021 to study BBP-398 in a combination therapy trial to treat advanced solid tumors with KRAS mutations (the “2021 Navire-BMS Agreement”). The Navire-BMS License Agreement does not alter the terms of the 2021 Navire-BMS Agreement. Under the terms of the Navire-BMS License Agreement, Navire was entitled to receive a non-refundable, upfront payment of \$90.0 million, which Navire received in full in June 2022. Additionally, Navire is eligible to receive additional payments totaling up to approximately \$815.0 million in the aggregate, subject to the achievement of development, regulatory and commercial milestones, as well as tiered royalties in the low-to-mid teens as a percentage of adjusted net sales by BMS of the licensed products sold worldwide, outside of the Asia Region. Navire will retain the option to acquire higher royalties in the United States in connection with funding a portion of development costs upon the initiation of registrational studies. Based on the terms of the Navire-BMS License Agreement, Navire will continue to lead its ongoing Phase 1 monotherapy and combination therapy trials (collectively, the “Phase 1 Trials”), and BMS will lead and fund all other development and commercialization activities. Navire is fully funding the Phase 1 trials with the exception of the combination therapy governed under the 2021 Navire-BMS Agreement. In accordance with the 2021 Navire-BMS Agreement, both parties are sharing all research and development costs equally for this trial. We have recorded all research and development costs for the Phase 1 Trials, as well as the reimbursement for the costs associated with the trial governed by the 2021 Navire-BMS Agreement within “Research and development” in our condensed consolidated statement of operations. In March 2024, we received written notice from BMS for the termination of the Navire-BMS License Agreement effective June 2024, and all rights and obligations thereunder. In April 2024, Navire and BMS entered into a Clinical Collaboration Termination Agreement which terminated the 2021 Navire-BMS Agreement. Navire and BMS agreed to pursue reasonable efforts to wind down activities under both the Navire-BMS License Agreement and the 2021 Navire-BMS Agreement. As a result of the termination, Navire is no longer entitled to any future unearned development, regulatory or sales-based milestone and royalty payments. However, we may in the future be eligible to receive earned payments for any milestones already achieved prior to termination and for achieving any milestones while closing out the remaining services. We determined that the Navire-BMS License Agreement falls within the scope of ASC 606 as BMS is a customer in this arrangement, and we identified the following performance obligations in the agreement: “an exclusive license to develop and commercialize BBP-398 and the related know-how; and research and development services to complete the Phase 1 Trials for BBP-398. We determined that the performance obligations outlined above are capable of being distinct and distinct with the context of the contract given such rights and activities are independent of each other. The license can be used by BMS without the research and development services. Similarly, those services provide a distinct benefit to BMS within the context of the contract, separate from the license, as the services could be provided by BMS or another third party without our assistance. We may enter into clinical and commercial supply agreements for the licensed territory. We determined that the optional right to future products under these supply agreements does not represent a material right. In March 2023, Navire and BMS entered into a clinical supply agreement for the supply of clinical quantities of the licensed product. Navire has supplied insignificant amounts to BMS as part of the clinical supply agreement for the three and six months ended June 30, 2024 and 2023. A 32 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) We determined the initial transaction price at inception of the Navire-BMS License Agreement to be \$90.0 million, which is comprised of the fixed and non-refundable upfront payment. No additional development, regulatory, or sales milestone payments are included in the transaction price, as all such payments are variable consideration that are fully constrained as of June 30, 2024. We include variable consideration in our transaction price to the extent that it is probable that it will not result in a significant revenue reversal when the uncertainty associated with the variable consideration is subsequently resolved. As part of management’s evaluation of the variable consideration, we considered numerous factors, including the fact that achievement of the milestones is outside of our control, contingent upon the success of our existing and future clinical trials, BMS’s efforts, and receipt of regulatory approval that is subject to scientific risks of success. Royalty arrangements and commercial-based milestones will be recognized when the sales occur or the milestones are achieved pursuant to the sales-based royalty exception under ASC 606 because the license is the predominant item to which the royalties or commercial-based milestones relate. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. We allocated the transaction price of \$90.0 million based on the SSP of each of the performance obligations as follows: \$70.2 million for the upfront transfer of the license; and \$19.8 million for research and development services to complete the Phase 1 Trials of BBP-398. The SSP for the license was determined using an approach that considered discounted, probability-weighted cash flows related to the license transferred. The SSP for the ongoing research and development services were based on estimates of the associated effort and cost of these services, adjusted for a reasonable gross profit margin that would be expected to be realized under similar contracts. We recognize revenue for each of the two performance obligations as follows: We recognize revenue related to the license at a point in time upon transfer of the rights and control of the license to BMS. The transfer of the rights and control of the license occurred in June 2022, thus we recognized the full amount allocated to the license and related know-how during the three months ended June 30, 2022. We are recognizing revenue related to the research and development services to complete the Phase 1 Trials for BBP-398 over time using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. As a result of the Navire-BMS License Agreement termination, the research and development services performance obligation is complete and there are no remaining performance obligations. As such, the remaining revenue allocated to this performance obligation was recognized during the three months ended March 31, 2024. Revenue recognized related to this performance obligation for the three and six months ended June 30, 2024 was nil and \$9.9 million, respectively. Revenue recognized related to this performance obligation for the three and six months ended June 30, 2023, was \$1.5 million and \$3.2 million, respectively. For the three and six months ended June 30, 2024, we have recognized nil and \$9.9 million, respectively, in revenue relating to the Navire-BMS Agreement. For the three and six months ended June 30, 2023, we have recognized \$1.5 million and \$3.2 million in revenue, respectively, relating to the Navire-BMS Agreement. As of June 30, 2024, there are no remaining balances in deferred revenue within our condensed consolidated balance sheet. Our condensed consolidated balance sheet as of December 31, 2023 includes a deferred revenue balance of \$9.9 million (\$6.1 million presented as “Deferred revenue, current portion” and \$3.8 million included in “Deferred revenue, net of current portion”) related to our research and development services obligation. License and Collaboration Agreement with Helsinn On March 29, 2021, QED entered into a license and collaboration agreement with Helsinn Healthcare S.A. (“HHC”) and Helsinn Therapeutics (U.S.), Inc. (“HTU”), and collectively with HHC, “Helsinn”) (the “QED-Helsinn License and Collaboration Agreement”), pursuant to which QED granted to HHC exclusive licenses to develop, manufacture and commercialize QED’s product candidate, ifingratinib, in oncology and all other indications except achondroplasia or any other skeletal dysplasias, worldwide, except for the People’s Republic of China, Hong Kong and Macau (“Greater China”), and under which QED received a co-exclusive license to co-commercialize ifingratinib in the United States in the licensed indications. The QED-Helsinn License and Collaboration Agreement became effective on April 16, 2021. Upon approval by the FDA in May 2021, QED and HTU co-commercialized ifingratinib in the licensed indications in the United States and shared profits and losses on a 50:50 basis. Additionally, QED and Helsinn shared global, excluding Greater China, research and development costs for ifingratinib in the licensed indications at a rate of 40% for QED and 60% for Helsinn. A 33 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) On February 28, 2022, QED and Helsinn amended the QED-Helsinn License and Collaboration Agreement (the “Amended QED-Helsinn License and Collaboration Agreement”) effective on March 1, 2022. Under the terms of the Amended QED-Helsinn License and Collaboration Agreement, Helsinn had an exclusive license to commercialize ifingratinib in the United States and was responsible for solely developing, manufacturing and commercializing ifingratinib in oncology indications except for achondroplasia or any other skeletal dysplasias worldwide, outside of Greater China. QED retains all rights to develop, manufacture and commercialize ifingratinib in skeletal dysplasia, including achondroplasia. The Amended QED-Helsinn License and Collaboration Agreement also provided for a transitional period, which extended from the effective date through August 31, 2022, for which QED was contracted to assist in research and development and commercialization activities. The costs related to QED’s contracted activities incurred during the transitional period were fully reimbursable by Helsinn and were due to QED subsequent to the transitional period. Helsinn also agreed to reimburse QED’s obligation to FMI described in Note 7 as part of the Amended QED-Helsinn License and Collaboration Agreement. In recording this transaction, we recognized a corresponding gain as part of “Other income (expense), net” for the three months ended September 30, 2022. Effective December 21, 2022, QED and Helsinn (the “Helsinn Parties”), entered into a Mutual Termination Agreement (“MTA”), which terminates the Amended QED-Helsinn License and Collaboration Agreement and all rights and obligations thereunder. The Helsinn Parties agreed to perform certain close-out services to enable QED to pursue the development, manufacture and commercialization of ifingratinib as a potential treatment of non-oncology indications, such as in achondroplasia worldwide, excluding China, Hong Kong, and Macau. As a result of the termination, QED is no longer entitled to any future regulatory or sales-based milestone payments. QED was subject to royalties on net sales of TRUSELTQTM through March 31, 2023, at which date Helsinn no longer sold the licensed product. Helsinn permanently discontinued the distribution of TRUSELTQTM and the FDA announced the withdrawal of the NDA approval in May 2023, additionally, all clinical investigations under the associated IND are discontinued. Helsinn completed sales of the licensed product during the three months ended March 31, 2023, and the associated revenue recognized was immaterial. The Helsinn Parties developed a Close-Out Plan, as defined within the MTA. Activities within the Close-Out Plan are to be shared equally subsequent to the lower of the first \$11.0 million of costs, or QED’s obligation to FMI, which are the responsibility of QED. QED reached the threshold of \$11.0 million in January 2023. The activities within the Close-Out Plan were substantially completed in 2023. Upon the effective date of the MTA, outstanding obligations of \$31.3 million (\$18.8 million relating to contracted research and development and commercial activities and \$12.5 million relating to the reimbursement of QED’s obligation to FMI) under the Amended QED-Helsinn License and Collaboration Agreement related to the contracted services during the transitional period became due, of which all payments have been paid in full. In March 2024, QED reduced its obligation to FMI to \$9.6 million and therefore, pursuant to the MTA, QED’s responsibility for close-out activities was lowered to this amount and Helsinn’s reimbursement of QED’s obligation to FMI was reduced from \$11.0 million to \$9.6 million. As a result of the reduced FMI obligation, Helsinn is required to share evenly an additional \$1.4 million of close-out costs and QED is required to reimburse Helsinn \$1.4 million relating to the FMI obligation, resulting in a net payable position to Helsinn from QED of \$0.7 million. For the three and six months ended June 30, 2024, QED has incurred immaterial close out costs and the net costs are subject to 50% reimbursement from Helsinn. For the three and six months ended June 30, 2023, QED has incurred \$2.1 million and \$5.7 million of close-out costs, respectively, of which \$2.1 million and \$4.5 million are subject to 50% reimbursement from Helsinn, respectively. As of June 30, 2024, there is no outstanding receivable balance due from Helsinn. As of December 31, 2023, the outstanding receivable due from Helsinn was \$0.6 million. The outstanding receivables are presented in “Receivables from licensing and collaboration agreements” within our condensed consolidated balance sheets. Close-out costs incurred, including Helsinn’s reimbursements, are recorded in “Restructuring, impairment and related charges” for the three and six months ended June 30, 2024 and 2023, respectively, within our condensed consolidated statement of operations (refer to Note 16). The QED-Helsinn License and Collaboration Agreement, the Amended QED-Helsinn License Collaboration Agreement, and the MTA are considered to be within the scope of ASC 808 as the parties are active participants and are exposed to the significant risks and rewards of the collaborative activity. The QED-Helsinn License and Collaboration Agreement and the Amended QED-Helsinn License and Collaboration Agreement are also partially within the scope of ASC 606 for the units of account where Helsinn is identified as a customer. For the units of account in the collaboration arrangement that do not represent a vendor-customer relationship, including the performance of collaborative research and development and commercialization services, we determined that ASC 606 is not appropriate to apply by analogy and applied a reasonable and rational accounting policy election that faithfully depicts the transfer of services to the collaboration partner over the estimated performance period. Reimbursement payments from Helsinn associated with the collaborative research and development and commercialization services are recognized as the related expense is incurred and classified as an offset to the underlying expense and excluded from the transaction price. A 34 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) We evaluated the terms of the QED-Helsinn License and Collaboration Agreement and identified Helsinn as a customer with the following two distinct performance obligations: (1) exclusive licenses to develop, manufacture, and commercialize the underlying product, and (2) transfer of inventory within the transitional supply period. The Amended QED-Helsinn License and Collaboration Agreement did not give rise to any additional performance obligations. All of the license revenue relating to these units of account accounted for under ASC 606 were recognized in the year ended December 31, 2021. For the unit of account that is within the scope of ASC 808 relating to collaborative research and development services, pursuant to the QED-Helsinn License and Collaboration Agreement, the Amended QED-Helsinn License Collaboration Agreement, and the MTA, we have recognized an immaterial amount of Helsinn’s share of research and development expenses for the three and six months ended June 30, 2024 as a reduction to restructuring, impairment and related charges. We have recognized Helsinn’s share of research and development expenses of \$1.0 million and \$2.2 million for the three and six months ended June 30, 2023, respectively. License Agreement with LianBio Navire In August 2020, Navire entered into an exclusive license agreement with LianBio (“the Navire-LianBio License Agreement”). Pursuant to the Navire-LianBio License Agreement, Navire granted to LianBio an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize SHP2 inhibitor BBP-398, or BBP-398, for tumors driven by RAS and receptor tyrosine kinase mutations. Under the terms of the Navire-LianBio License Agreement, LianBio will receive commercial rights in China and selected Asian markets and participate in clinical development activities for BBP-398. In consideration for the rights granted to LianBio, we received a nonrefundable \$8.0 million upfront payment, which we recognized as license revenue in 2020. We will also have the right to receive future development and sales milestone payments of up to \$382.1 million, and tiered royalty payments from single-digit to low-teens on net sales of the product in licensed territories. We recognized \$8.5 million in license revenue, representing a regulatory milestone payment in 2021. We accounted for the Navire-LianBio License Agreement under ASC 606 and identified the exclusive license as a distinct performance obligation since LianBio can benefit from the license on its own by developing and commercializing the underlying product using its own resources. In addition, we may enter into clinical and commercial supply agreements for the licensed territory. We determined that the optional right to future products under these supply agreements does not represent a material right. In July 2022, Navire and LianBio entered into a clinical supply agreement for the manufacture and supply of clinical quantities of the licensed product. During the three and six months ended June 30, 2024 and 2023, Navire has not provided any clinical supply to LianBio. QED In October 2019, QED entered into an exclusive license agreement with LianBio (the “QED-LianBio License Agreement”). Pursuant to the QED-LianBio License Agreement, QED granted to LianBio an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize ifingratinib for any and all human prophylactic and therapeutic uses in all cancer indications (including in combination with other therapies) in certain territories outside the United States. Under the QED-LianBio License Agreement, QED received a nonrefundable upfront payment of \$10.0 million and is eligible to receive development and sales milestones payments of up to \$132.5 million and tiered royalties on net sales ranging from the low to mid-teens. In addition, QED also received warrants which entitled QED to purchase 10% of the then-fully diluted shares of one of the subsidiaries of LianBio upon achievement of certain contingent development milestones (refer to Note 6). We accounted for the QED-LianBio License Agreement and the LianBio Exclusivity Agreement as a single transaction under ASC 606 and identified the exclusive license as a distinct performance obligation since LianBio can benefit from the license on its own by developing and commercializing the underlying product using its own resources. In addition, we may enter into clinical and commercial supply agreements for the licensed territory. We determined that LianBio’s optional right to future products under these supply agreements is not considered to represent a material right. A clinical supply agreement was entered into in November 2021. QED has not provided any clinical supplies to LianBio during the three and six months ended June 30, 2024. QED provided insignificant amounts of clinical supplies to LianBio during the three and six months ended June 30, 2023 and has recorded such amounts within “Revenue” in our condensed consolidated statement of operations. License Agreement with Alexion In September 2019, Eidos Therapeutics, Inc. (“Eidos”), entered into

an exclusive license agreement with Alexion Pharma International Operations Unlimited Company, a subsidiary of Alexion Pharmaceuticals, Inc., or together Alexion (the “Alexion-Alexion License Agreement”), to develop, manufacture, and commercialize in Japan the compound known as acoramidis (previously known as AG10) and any of its various chemical forms and any pharmaceutical products containing acoramidis. Under the Eidos-Alexion A 35 BRIDGEIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited)A License Agreement, Eidos received an upfront nonrefundable payment of \$25.0 million and is eligible to receive \$30.0 million in regulatory milestone payments and royalties in the low-teens based on net sales of acoramidis in Japan. The royalty rate is subject to reduction if Alexion is required to obtain intellectual property rights from third parties to develop, manufacture or commercialize acoramidis in Japan, or upon the introduction of generic competition into market.Eidos also entered into a stock purchase agreement with Alexion, under which Eidos sold to Alexion 556,173 shares of Eidos common stock at a price per share of \$44.95, for an aggregate purchase price of approximately \$25.0 million. The excess of the purchase price over the value of the Eidos shares, determined based on the closing price of a share of Eidos’s common stock of \$41.91 as reported on Nasdaq as of the date of execution, was \$1.7 million and recognized in revenue as part of the upfront payment as discussed below.Eidos accounted for the Eidos-Alexion License Agreement under ASC 606 and identified the exclusive license as a distinct performance obligation since Alexion can benefit from the license on its own by developing and commercializing the underlying product using its own resources. Eidos recognized the \$25.0 million upfront fee and \$1.7 million premium paid for Eidos’s common stock for a total upfront payment of \$26.7 million in license revenue upon the effective date of the license agreement in September 2019. Eidos determined that the license was a right to use its intellectual property and as of the effective date, it had provided all necessary information to Alexion to benefit from the license and the license term had begun. In addition, Eidos entered into a clinical supply agreement in July 2020 and may enter into a commercial supply agreement for the licensed territory. Eidos determined that the optional right to future products under these supply agreements is not considered to represent a material right. Eidos has supplied insignificant amounts to Alexion as part of the clinical supply agreement during the three and six months ended June 30, 2024 and 2023, respectively, and has recorded such amounts within Revenues in our condensed consolidated statements of operations.Receivables from Licensing and Collaboration Agreements Receivables from licensing and collaboration agreements represent valid claims against our partners, customers, biopharmaceutical companies including unbilled receivables and royalty payments due from third parties for licensing the Company’s technologies. Unbilled receivables include balances due from our biopharmaceutical customers related to development services and transition-related receivables that are recognized upon incurrence of the costs for the partnered programs but prior to the achievement of contractual billing rights. As of June 30, 2024 and December 31, 2023, the Company had unbilled receivables of \$0.2 million and \$0.9 million, respectively, of which 70.6% and 61.9%, respectively, of total unbilled receivables related to one partner. Total receivables from licensing and collaboration agreements as of June 30, 2024 and December 31, 2023 are \$0.7 million and \$1.8 million, respectively, and are presented as Receivables from licensing and collaboration agreements within our condensed consolidated balance sheets.The Company evaluates the collectability of its receivables from licensing and collaboration agreements based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management’s best estimate of the amount of probable credit losses. As of June 30, 2024 and December 31, 2023, the Company did not have an allowance for credit losses. 12.In-licensing and Other Research and Development Agreements Stanford License Agreement In April 2016, Eidos entered into a license agreement with the Board of Trustees of the Leland Stanford Junior University, (Stanford University), relating to Eidos’s drug discovery and development initiatives. Under this agreement and its amendments, Eidos has been granted certain worldwide exclusive licenses to make, use, and sell products that are covered by licensed patent rights. In March 2017, Eidos paid a license fee of \$10,000, which was recorded as research and development expense during the year ended December 31, 2017, as the acquired assets did not have any alternative future use. Eidos may also be required to make future payments of up to approximately \$1.0 million to Stanford University upon achievement of specific intellectual property, clinical and regulatory milestone events, and pay royalties of up to low single-digit percentages on future net sales, if any. In addition, Eidos is obligated to pay Stanford University a percentage of non-royalty revenue received by Eidos from its sublicensees, with the amount owed decreasing annually for three years based on when the applicable sublicense agreement is executed. Additionally, under the license agreement with Stanford University, we will pay Stanford University a portion of all nonroyalty sublicensing consideration attributable to the sublicense of the licensed compounds. For the six months ended June 30, 2024, we A 36 BRIDGEIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited)A incurred and paid \$8.1 million of licensing fees due to Stanford University related to the Company entering into an exclusive license agreement with Bayer in March 2024. For the three and six months ended June 30, 2023, the licensing fees incurred were not material. Diagnostics Agreement with Foundation Medicine As discussed in Note 7, QED and FMI entered into a diagnostics agreement relating to QED’s drug discovery and development initiatives. For the three and six months ended June 30, 2024 and 2023, the research and development expenses QED recognized were not material in connection with this agreement.Resilience Development and Manufacturing Service AgreementsIn September 2023, Aspa Therapeutics, Inc. (Aspa) and Adrenas Therapeutics Inc. (AspaAdrenas), each entered into a Development and Manufacturing Services Agreement (collectively the “Resilience DMSAs”) and a Project Agreement (collectively the “Resilience PAs”), (collectively the “Resilience Agreements”) with Resilience US, Inc. (Resilience), for Resilience to provide contract development, manufacturing, testing and related services with respect to therapeutic and pharmaceutical products for the clinical development applications of BBP-812 and BBP-631, respectively. BBP-812 is an intravenous AAV9 investigational drug product intended for the treatment of children with Canavan Disease, under the age of five years. BBP-631 is an intravenous AAV5 investigational drug product intended for the treatment of adults and children with congenital adrenal hyperplasia. The Resilience DMSAs have ten-year terms and may each be extended for additional two-year periods. Under the Resilience PAs, Resilience will provide Aspa with a cost sharing credit of the lesser of a fixed percentage of certain agreed upon service costs or \$15.5 million. Under the Resilience PAs, Resilience will provide Adrenas with a cost sharing credit of the lesser of a fixed percentage of certain agreed upon service costs or \$29.3 million. In addition to the payments for their share of services performed by Resilience, Aspa and Adrenas may each be required to make future payments of up to \$10.0 million upon achievement of certain development and approval milestone events, and royalty payments (mid-single digit for BBP-812 and low-single digit for BBP-631) based on achievement of certain net sales metrics.For the three and six months ended June 30, 2024, \$0.4 million and \$0.9 million, respectively, in research and development expenses was incurred, which was net of \$0.5 million and \$1.1 million, respectively, in cost sharing credits received in connection with the Resilience Agreements.Other License and Collaboration AgreementsIn addition to the agreements described above, we have also entered into other license and collaboration agreements with various institutions and business entities on terms similar to those described above, none of which are material individually or in the aggregate. 13.LeasesWe have operating leases for our corporate headquarters, office spaces and laboratory facilities. One of our office space leases has a finance lease component representing lessor provided furniture and office equipment. Our finance lease, which is presented as part of Property and equipment, net in our condensed consolidated balance sheets, is not material.Certain leases include renewal options at our election and we include the renewal options when we are reasonably certain that the renewal option will be exercised. The lease liabilities were measured using a weighted-average discount rate based on the most recent borrowing rate as of the calculation of the respective lease liability, adjusted for the remaining lease term and aggregate amount of the lease. The components of lease cost are as follows: A Three Months Ended June 30, A Six Months Ended June 30, A A 2024 A 2023 A 2024 A 2023 A A (in thousands) A (in thousands) A Straight line operating lease costs A \$ 1,024 A A \$ 992 A A \$ 2,093 A A \$ 2,024 A Finance lease costs A A 100 A A 105 A A 201 A A 213 A Variable lease costs A 1,477 A A 1,700 A A 3,490 A A 3,418 A Total lease cost A \$ 2,601 A A \$ 2,797 A A \$ 5,784 A A \$ 5,655 A A 37 BRIDGEIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited)A Supplemental cash flow information related to leases are as follows: A Six Months Ended June 30, A A 2024 A 2023 A A (in thousands) A Cash paid for amounts included in the measurement of lease liabilities: A A A A Operating cash flows for operating leases A \$ 2,981 A A \$ 2,443 A Operating cash flows for finance lease A 222 A A 217 A Operating lease right-of-use assets obtained in exchange A A A for operating lease obligations A 1,292 A A 828 A Supplemental information related to the remaining lease term and discount rate are as follows: A A June 30, A A 2024 A 2023 A Weighted-average remaining lease term (in years) A A A A Operating leases A 4.0 A A 5.2 A Finance lease A 1.6 A A 2.6 A Weighted-average discount rate A A A A Operating leases A 6.24 A A 6.34 A Finance lease A 6.62 A A 6.62 A As of June 30, 2024, future minimum lease payments for our noncancelable operating leases are as follows. Future minimum lease payments under our finance lease are not material.A A Amount A A (in thousands) A Remainder of 2024 A \$ 2,509 A Year ending December 31: A A 2025 A \$ 1,033 A 2026 A 2,276 A 2027 A 459 A 2028 A 459 A Thereafter A 2,179 A Total future minimum lease payments A 12,985 A Imputed interest A (1,303) Total A \$ 11,682 A A Reported as of June 30, 2024 A A Operating lease liabilities, current portion A \$ 4,623 A Operating lease liabilities, net of current portion A 7,059 A Total operating lease liabilities A \$ 11,682 A The impairment loss recognized was not material for the three and six months ended June 30, 2024. No impairment loss was recognized during the three and six months ended June 30, 2023. 14.Public Offerings2023 Follow-on OfferingIn March 2023, we entered into an Underwriting Agreement (the “2023 Follow-on Agreement”) with Goldman Sachs & Co. LLC, Evercore Group L.L.C., Morgan Stanley & Co. LLC and KKR Capital Markets LLC (collectively, as representatives of several underwriters (collectively, the “2023 Underwriters”), relating to an underwritten public offering (the “2023 Follow-on offering”) of 8,823,530 shares of the Company’s common stock, \$0.001 par value per share (the “Common Stock”), at a public offering price of \$17.00 per share. The Company also granted the Underwriters a 30-day option to purchase, at the public offering price less A 38 BRIDGEIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited)A underwriting discounts and commissions, up to an additional 1,323,529 shares of Common Stock. The Company paid the Underwriters a commission of 4.3% of the aggregate gross proceeds received from all sales of the common stock under the 2023 Follow-on Agreement. The Underwriters included KCM, which is an affiliate of KKR Genetic Disorder L.P., a related party being a stockholder who beneficially owns greater than 5% of our outstanding securities. KCM received a commission of 0.315% of the aggregate gross proceeds received from all sales of the common stock under the 2023 Follow-on Agreement. In March 2023, 8,823,530 shares were issued under the 2023 Follow-on Agreement, for net proceeds of \$143.0 million, after deducting underwriting fees and commissions of \$6.5 million (of which \$0.5 million related to commissions paid to KCM) and offering costs of \$0.5 million. In April 2023, the Underwriters partially exercised their 30-day option to purchase additional shares, for which 63,470 shares were issued for net proceeds of \$1.0 million, after deducting underwriting fees and commissions of less than \$0.1 million.2023 Shelf Registration Statement and ATM AgreementIn May 2023, we filed a shelf registration statement on Form S-3 (the “2023 Shelf”) with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and units or any combination thereof. We also concurrently entered into an Equity Distribution Agreement (the “ATM Agreement”) with Goldman Sachs & Co. LLC and SVB Securities LLC (collectively, the “ATM Sales Agents”), with respect to an “at-the-market” offering program under which we may issue and sell, from time to time at our sole discretion and pursuant to a prospectus supplement, shares of our common stock, par value \$0.001 per share, having an aggregate offering price of up to \$450.0 million through the ATM Sales Agents. We will pay the ATM Sales Agents a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. During the year ended December 31, 2023, 2,171,217 shares were issued under the ATM Agreement, for net proceeds of \$65.0 million, after deducting sales agent fees and commissions of \$1.0 million. During the six months ended June 30, 2024, 1,061,991 shares were issued under the ATM Agreement, for net proceeds of \$38.1 million, after deducting sales agent fees and commissions of \$0.6 million. As of June 30, 2024, we are still eligible to sell up to \$345.3 million of our common stock pursuant to the ATM Agreement under the 2023 Shelf. 2024 Follow-on OfferingIn March 2024, we entered into an Underwriting Agreement (the “2024 Follow-on Agreement”) with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of several underwriters (collectively, the “2024 Underwriters”), relating to an underwritten public offering (the “2024 Follow-on offering”) of 8,620,690 shares of the Company’s common stock, \$0.001 par value per share, at a public offering price of \$29.00 per share. The Company also granted the 2024 Underwriters a 30-day option to purchase, at the public offering price less underwriting discounts and commissions, up to an additional 1,293,103 shares of Common Stock, which the 2024 Underwriters exercised in full on the closing of the 2024 Follow-on offering. The Company paid the Underwriters a commission of 3.6% of the aggregate gross proceeds received from all sales of the common stock under the Follow-on Agreement. In March 2024, 9,913,793 shares (including the 1,293,103 shares issued upon exercise of the 2024 Underwriters’ option to purchase additional shares) were issued under the 2024 Follow-on Agreement, for net proceeds of \$276.6 million, after deducting underwriting fees and commissions of \$10.3 million and offering costs of \$0.6 million. 15.Stock-Based Compensation Under each of the legal entity’s equity plans, we recorded stock-based compensation in the following expense categories in our condensed consolidated statements of operations for employees and non-employees: A Three Months Ended June 30, 2024 A Six Months Ended June 30, 2024 A A BridgeBioEquity Plan A OtherSubsidiariesEquity Plan A Total A A BridgeBioEquity Plan A A OtherSubsidiariesEquity Plan A Total A A A A A (in thousands) A A A A Research and development A \$ 4,937 A A \$ 4,937 A A \$ 17,679 A A \$ 37 A A \$ 17,716 A Selling, general and administrative A 16,471 A A 16,471 A A 32,542 A A 32,542 A Restructuring, impairment and related charges A 43 A A 43 A A 43 A A 43 A Total stock-based compensation A \$ 21,451 A A \$ 21,451 A A \$ 50,264 A A \$ 50,264 A A 39 BRIDGEIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited)A A Three Months Ended June 30, 2023 A A Six Months Ended June 30, 2023 A A BridgeBioEquity Plan A A OtherSubsidiariesEquity Plan A Total A A BridgeBioEquity Plan A A OtherSubsidiariesEquity Plan A Total A A A A A (in thousands) A A A A Research and development A \$ 13,188 A A \$ 13,229 A A \$ 24,925 A A \$ 83 A A \$ 25,008 A Selling, general and administrative A 13,947 A A 13,947 A A 25,645 A A 25,645 A Total stock-based compensation A \$ 27,135 A A \$ 27,135 A A \$ 50,570 A A \$ 50,570 A A We recorded nil and \$11.8 million of stock-based compensation expense for the three and six months ended June 30, 2024, respectively, for performance-based milestone awards that were achieved during the periods and were settled in cash. We recorded nil and \$1.6 million of stock-based compensation expense for the three and six months ended June 30, 2023, respectively, for performance-based milestone awards that were achieved during the periods and were settled in cash. Equity-Based Awards of BridgeBioIn December 2023, the 2019 Inducement Equity Plan was amended and restated to increase the number of shares authorized for issuance from 2,000,000 shares to 3,750,000 shares. In June 2024, our stockholders approved an amendment and restatement of our 2021 Amended and Restated Stock Option and Incentive Plan (the “2021 A&R Plan”), to, among other things, increase the number of shares authorized for issuance by 6,500,000 shares. As of June 30, 2024, 9,855,774 shares and 1,486,257 shares were reserved for future issuances under the 2021 A&R Plan and the Amended and Restated 2019 Inducement Equity Plan (the “2019 Inducement Plan”), respectively. Pursuant to the Merger Transactions, we also reserved 2,802,644 shares in 2021 specifically under the Eidos Award Exchange (the “Eidos Award Exchange Plan”), all of which were issued upon execution of the Eidos Award Exchange as discussed below. The 2021 A&R Plan, the A&R 2019 Inducement Plan and the Eidos Award Exchange Plan are collectively referred herein as the “Plans.” 2020 Stock and Equity Award Exchange Program (Exchange Program) On April 22, 2020, we completed our 2020 Stock and Equity Award Exchange Program (the “Exchange Program”) for certain subsidiaries, which was an opportunity for eligible controlled entities’ employees and consultants to exchange their subsidiary equity (including common stock, vested and unvested stock options and RSAs) for BridgeBio equity (including common stock, vested and unvested stock options and RSAs) and/or performance-based milestone awards tied to the achievement of certain development and regulatory milestones. The Exchange Program aligns our incentive compensation structure for employees and consultants across the BridgeBio group of companies to be consistent with the achievement of our overall corporate goals. In connection with the Exchange Program, we issued awards of BridgeBio equity under the then 2019 Amended and Restated Stock Option and Incentive Plan (the “2019 A&R Plan”), which was amended and restated in December 2021 into the 2021 A&R Plan and further amended and restated in June 2024, as mentioned above, to 149 grantees covering 554,064 shares of common stock, 1,268,110 stock options to purchase common stock, 50,145 shares of RSAs and 22,611 shares of performance-based RSAs. The exchange also included performance-based milestone awards of up to \$183.4 million to be settled in fully-vested RSAs in the future upon achievement of the milestones. In consideration for all the subsidiaries’ shares tendered, BridgeBio increased its ownership in controlled entities included in the Exchange Program and the corresponding noncontrolling interest decreased. On November 18, 2020, we completed a stock and equity award under our Exchange Program for a subsidiary. We issued awards of BridgeBio equity under the then 2019 A&R Plan to 16 grantees covering 24,924 shares of common stock, 70,436 stock options to purchase common stock, and 10,772 shares of performance-based stock options to purchase common stock. The exchange also included performance-based milestone awards of up to \$11.7 million to be settled in fully-vested RSAs in the future upon achievement of the milestones.We evaluated the exchange of the controlled entities’ outstanding common stock and equity

awards for BridgeBio awards as a modification under ASC 718, Share Based Payments. Under ASC 718, a modification is a change in the terms or conditions of a stock-based compensation award. In assessing the accounting treatment, we consider the fair value, vesting conditions and classification as an equity or liability award of the controlled entity equity before the exchange, compared to the BridgeBio equity received as part of the exchange to determine whether modification accounting must be applied. When applying modification accounting, we considered the type of modification to determine the appropriate stock-based compensation cost to be recognized on April 22 and November 18, 2020, (each the “Modification Date”), and subsequent to the Modification Date. 40 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) We considered the total shares of common stock and equity awards, whether vested or unvested, held by each participant in each controlled entity as the unit of account. The controlled entity’s common stock and equity awards in each unit of account was exchanged for a combination of BridgeBio’s common stock, time-based vesting equity awards and/or performance-based milestone awards. Other than the exchange of the controlled entity equity awards for performance-based milestone awards, all other exchanged BridgeBio equity awards retained the original vesting conditions. As a result, there was no incremental stock-based compensation expense resulting from the exchange of time-based equity awards. At the completion of the Exchange Program, we determined \$17.4 million of the performance-based milestone awards were probable of achievement and represented the incremental stock-based compensation cost resulting from the modification of time-based equity awards to performance-based milestone awards. These performance-based milestone awards were to be recognized over a period ranging from 0.7 year to 1.7 years. There was no incremental stock-based compensation cost arising from the completion of the Exchange Program on November 18, 2020. Under ASC 718, we account for such performance-based milestone awards as a liability in “Accrued compensation and benefits” and in “Other long-term liabilities” on the condensed consolidated balance sheets due to the fixed milestone amount that will be converted into a variable number of shares of BridgeBio’s common stock to be granted upon the achievement date. For the three and six months ended June 30, 2024 we recognized reversals of \$8.9 million and \$8.7 million, respectively, of stock-based compensation cost associated with performance-based milestone awards as of June 30, 2024 as the obligation was no longer determined to be probable. For the three and six months ended June 30, 2023 we recognized \$0.5 million and \$2.2 million, respectively, of stock-based compensation cost associated with performance-based milestone awards whereby the milestones were determined to be probable of achievement as of June 30, 2023. Refer to Note 8 for contingent compensation accrued associated with performance-based milestones that are determined to be probable as of June 30, 2024. Performance-based Milestone Awards Apart from the Exchange Program discussed above, we have performance-based milestone compensation arrangements with certain employees and consultants whose vesting is contingent upon meeting various regulatory and development milestones, with fixed monetary amounts known at inception that can be settled in the form of cash or equity at our sole discretion, upon achievement of each contingent milestone. Upon achievement of a contingent milestone and if such performance-based milestone awards are settled in the form of equity, these are satisfied in the form of fully-vested RSAs. We recognize such contingent stock-based compensation expense when the milestone is probable of achievement. For the three and six months ended June 30, 2024, we recognized \$(1.0) million and \$0.9 million, respectively, of stock-based compensation cost associated with performance-based milestone awards whereby the milestones were determined to be probable of achievement as of June 30, 2024. The \$(1.0) million and \$0.9 million in stock-based compensation associated with performance-based milestone awards during the three and six months ended June 30, 2024, respectively, includes reversals totaling \$1.6 million as the obligation was no longer determined to be probable. For the three and six months ended June 30, 2023, we recognized \$2.0 million and \$3.0 million, respectively, of stock-based compensation cost associated with performance-based milestone awards whereby the milestones were determined to be probable of achievement as of June 30, 2023. Refer to Note 8 for contingent compensation accrued associated with performance-based milestone awards that are determined to be probable as of June 30, 2024. 41 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) A Stock Option Grants of BridgeBio The following table summarizes BridgeBio’s stock option activity under the Plans for the six months ended June 30, 2024: A A Options Outstanding A A Weighted-Average Exercise Price per Option A A Weighted-Average Remaining Contractual Life (years) A A Aggregate Intrinsic Value (in thousands) A A Outstanding as of December 31, 2023 A A A A 12,332,442 A A A A A A Regular equity program A A 10,793,862 A A A A \$ 25.69 A A 7.1 A A \$ 178,594 A A Eidos Awards Exchange A A 1,221,942 A A A A \$ 14.60 A A 4.7 A A \$ 31,580 A A Exchange Program A A 316,638 A A A A \$ 2.19 A A 5.3 A A \$ 12,105 A A Granted A A A A 398,764 A A A A A A A A Regular equity program A A 398,764 A A A A \$ 27.56 A A A A A A Exercised A A A A (49,982) A A A A A A A A Regular equity program A A (14,066) A A A A \$ 19.04 A A A A A A Eidos Awards Exchange A A (35,916) A A A A \$ 14.21 A A A A A A Cancelled A A A A (3,867) A A A A A A Eidos Awards Exchange A A (3,867) A A A A \$ 63.38 A A A A A A Outstanding as of June 30, 2024 A A A A \$ 12,677,357 A A A A A A A A Regular equity program A A 11,178,560 A A A A \$ 25.76 A A A A \$ 66,111 A A Eidos Awards Exchange A A 1,182,159 A A A A \$ 14.45 A A A A 4.2 A A \$ 13,513 A A Exchange Program A A 316,638 A A A A \$ 2.19 A A 4.8 A A \$ 7,436 A A Exercisable as of June 30, 2024 A A A A 10,018,943 A A A A A A A A Regular equity program A A 8,525,576 A A A A \$ 26.82 A A 6.2 A A \$ 45,274 A A Eidos Awards Exchange A A 1,179,149 A A A A \$ 14.43 A A A A 4.2 A A \$ 13,508 A A Exchange Program A A 314,218 A A A A \$ 2.18 A A 4.8 A A \$ 7,382 A A The options granted to employees and non-employees are exercisable at the price of BridgeBio’s common stock at the respective grant dates. The options granted have a service condition and generally vest over a period of three to four years. The weighted-average grant date fair value of options granted during the six months ended June 30, 2024 was \$21.30. The aggregate intrinsic value of options outstanding and exercisable as of June 30, 2024 in the table above are calculated based on the difference between the exercise price and the current fair value of BridgeBio’s common stock. The total intrinsic value of options exercised for the six months ended June 30, 2024 was \$0.9 million. For the three and six months ended June 30, 2024, we recognized stock-based compensation expense of \$5.9 million and \$12.2 million, respectively, related to stock options under the Plans. For the three and six months ended June 30, 2023, we recognized stock-based compensation expense of \$8.1 million and \$15.0 million, respectively, related to stock options under the Plans. As of June 30, 2024, there was \$32.3 million of total unrecognized compensation cost related to stock options under the Plans that is expected to be recognized over a weighted-average period of 1.9 years. Restricted Stock Units (RSUs) of BridgeBio The following table summarizes BridgeBio’s RSU activity under the Plans for the six months ended June 30, 2024: A A Unvested Shares of RSUs Outstanding A A Weighted-Average Grant Date Fair Value A A Balance as of December 31, 2023 A A 8,942,813 A A \$ 16.27 A A Granted A A 3,899,497 A A \$ 28.28 A A Vested A A (1,957,694) A A \$ 17.73 A A Cancelled A A (329,776) A A \$ 20.39 A A Balance as of June 30, 2024 A A 10,554,840 A A \$ 20.31 A A 42 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) A For the three and six months ended June 30, 2024, we recognized stock-based compensation expense of \$22.5 million and \$39.3 million, respectively, related to RSUs under the Plans. For the three and six months ended June 30, 2023 we recognized stock-based compensation expense of \$15.1 million and \$27.4 million, respectively, related to RSUs under the Plans. As of June 30, 2024, there was \$197.7 million of total unrecognized compensation cost related to RSUs under the Plans that is expected to be recognized over a weighted-average period of 2.9 years. Market-Based RSUs of BridgeBio In December 2023, the Company approved and granted performance restricted stock units under the 2021 A&R Plan to certain employees with vesting based on achievement of market capitalization targets (“market-based RSUs”), which are subject to the continued service of the employees through the vest date and are subject to accelerated vesting upon a change in control event. The achievement of the market capitalization targets will be measured based on BridgeBio market capitalization data (available on the Nasdaq.com website) meeting the targets for 20-consecutive trading days during the performance period of up to six years from the date of grant. The respective grant-date fair value of the market-based RSUs, which aggregated to \$10.8 million, was determined using the Monte Carlo valuation model and are recognized as compensation expense over the derived service period of the awards. The assumptions used in the Monte Carlo valuation included expected volatility ranging from 96.8% - 113.7%, risk free rate ranging from 4.22% - 4.35%, no expected dividend yield, expected term of three to six years and possible future market capitalization over the derived service period based on historical stock prices and market capitalization. As of June 30, 2024, 375,000 market-based RSUs were outstanding with a weighted average grant date fair value of \$28.73. For three and six months ended June 30, 2024, we recognized stock-based compensation expense of \$2.4 million and \$4.8 million, respectively, related to market-based RSU awards. As of June 30, 2024, there was \$5.2 million of total unrecognized compensation cost related to market-based RSUs under the Plans that is expected to be recognized over a weighted-average period of 0.8 year. Restricted Stock Awards (RSAs) of BridgeBio The following table summarizes our RSA activity under the Plans for the six months ended June 30, 2024: A A Unvested Shares of RSAs Outstanding A A Weighted-Average Grant Date Fair Value A A Balance as of December 31, 2023 A A 85,453 A A \$ 7.27 A A Granted A A 8,057 A A \$ 38.74 A A Vested A A (8,057) A A \$ 38.74 A A Vested A A Regular equity program A A (85,453) A A \$ 7.27 A A Balance as of June 30, 2024 A A A A \$ A A For the three and six months ended June 30, 2024 and 2023, we recognized stock-based compensation expense related to RSAs under the Plans as follows: A A Three Months Ended June 30, A A Six Months Ended June 30, A A 2024 A A 2023 A A 2024 A A 2023 A A (in thousands) A A Exchange Program A A A A \$ A A \$ A A \$ 312 A A \$ 3,605 A A Other RSAs A A A A \$ 1,023 A A 621 A A 2,049 A A Total stock-based compensation expense A A A A \$ A A \$ 1,023 A A \$ 933 A A \$ 5,654 A A As of June 30, 2024, there was no unrecognized compensation cost related to RSAs under the Plans. The balance of unvested RSAs as of December 31, 2023 is included as outstanding shares disclosed on the condensed consolidated balance sheets as the shares were issued but were subject to forfeiture per the terms of the awards. 43 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) A 2019 Employee Stock Purchase Plan (ESPP) of BridgeBio On June 22, 2019, we adopted the 2019 ESPP, which became effective on June 25, 2019 and was amended and restated effective as of December 12, 2019. The ESPP initially reserves and authorizes the issuance of up to a total of 2,000,000 shares of common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2020, by the lower of: (i) 1% of the outstanding number of shares of common stock on the immediately preceding December 31, (ii) 2,000,000 shares or (iii) such lesser number of shares as determined by the Compensation Committee. Under the ESPP, eligible employees may purchase shares of BridgeBio’s common stock through payroll deductions at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or the end of six-month offering periods. An employee’s payroll deductions under the ESPP are limited to 15% of the employee’s compensation and employees may not purchase more than 3,500 shares of BridgeBio’s common stock during any offering period. For the three and six months ended June 30, 2024, stock-based compensation expense related to our ESPP was \$0.5 million and \$1.1 million, respectively. For the three and six months ended June 30, 2023, stock-based compensation expense related to our ESPP was \$0.4 million and \$0.9 million, respectively. As of June 30, 2024, 3,462,568 shares were reserved for future issuance under the ESPP. Valuation Assumptions We used the Black-Scholes model to estimate the fair value of stock options and stock purchase rights under the ESPP. For the six months ended June 30, 2024, we used the following weighted-average assumptions in the Black-Scholes calculations: A A Stock Options A A ESPP A Expected term (in years) A 6.00 A 6.03 A 0.50 A Expected volatility A 92.0% - 92.3% A 55.8% - 122.1% A Risk-free interest rate A 4.2% - 4.3% A 5.3% - 5.5% A Dividend yield A A A A A A A A Weighted-average fair value of stock-based awards granted A \$ 21.30 A \$ 14.14 A Equity Awards of Eidos Prior to the Eidos Merger Transactions in 2021, Eidos issued its own equity-based awards under the Eidos 2016 Equity Incentive Plan and the Eidos 2018 Stock Option and Incentive Plan (collectively, the “Eidos Plans”). Upon closing of the Eidos Merger Transactions, we issued 2,776,672 stock options to purchase common stock of BridgeBio and 25,972 shares of BridgeBio RSUs to 88 employees of Eidos under the Eidos Award Exchange in exchange for their then outstanding common stock options and RSUs under the Eidos Plans (the “Replaced Awards”). The awards issued in the Eidos Award Exchange have the same vesting terms and conditions as the Replaced Awards. We evaluated the exchange of the awards as a modification under ASC 718 and recognized no incremental compensation cost from such modification. 16. Restructuring, Impairment and Related Charges In January 2022, we committed to a restructuring initiative designed to drive operational changes in our business processes, efficiencies and cost savings to advance our corporate strategy and development programs. The restructuring initiative included, among other components, consolidation and rationalization of our facilities, reprioritization of development programs and the reduction in our workforce. In March 2024, upon entering into the Bayer Agreement and termination of the Navire-BMS License Agreement (refer to Note 11 for details regarding these transactions), we have committed to additional restructuring plans to reprioritize and advance our corporate strategy and development programs. We estimate that we will incur a remaining \$12.0 million to \$16.0 million in restructuring charges, consisting primarily of winding down costs, exit and other related costs, and severance and employee-related costs. Our estimate of the costs is subject to certain assumptions and actual results may differ from those estimates or assumptions. We may also incur additional costs that are not currently foreseeable as we continue to evaluate our restructuring alternatives to drive operational changes in business processes, efficiencies and cost savings. 44 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) A Restructuring, impairment and related charges included in our condensed consolidated statements of operations for the three and six months ended June 30, 2024 and 2023 consisted of the following: A A Three Months Ended June 30, A A Six Months Ended June 30, A A 2024 A A 2023 A A 2024 A A 2023 A A (in thousands) A A Long-lived assets impairments and write-offs A A A A \$ A A \$ A A \$ 271 A A \$ A A Severance and employee-related costs A A 538 A A 572 A A 2,503 A A 715 A A Winding down, exit and other related costs A A 2,353 A A 2,959 A A 3,517 A A 6,185 A A Total A A \$ 2,891 A A \$ 3,531 A A \$ 6,291 A A \$ 6,900 A A The following table summarizes the activity related to the restructuring liabilities associated with our restructuring initiatives for the six months ended June 30, 2024 and 2023: A A Six Months Ended June 30, A A 2024 A A 2023 A A (in thousands) A A Beginning balance A \$ 55 A \$ 6,826 A Restructuring, impairment and related charges A \$ 6,291 A A 6,900 A Cash payments A (3,121) A (1,526) A Noncash activities A (318) A A A A Ending balance A \$ 2,907 A A \$ 2,200 A A Restructuring liabilities are presented in our condensed consolidated balance sheets as follows: A A June 30, 2024 A A December 31, 2023 A A (in thousands) A A Accounts payable A \$ 1,314 A A \$ 48 A A Accrued compensation and benefits A \$ 780 A A A A Accrued research and development liabilities A 651 A A 7 A Accrued professional and other accrued liabilities A 162 A A A A Total A \$ 2,907 A A \$ 55 A A 17. Income Taxes BridgeBio is subject to U.S. federal, state and foreign income taxes as a corporation. BridgeBio’s tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate adjusted for the effect of discrete items arising in that quarter. There was no provision for income tax for the three and six months ended June 30, 2024 and 2023. Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, we have recorded a full valuation allowance against our otherwise recognizable net deferred tax assets. Our policy is to recognize interest and penalties associated with uncertain tax benefits as part of the income tax provision and include accrued interest and penalties with the related income tax liability on the condensed consolidated balance sheets. To date, we have not recognized any interest and penalties in our condensed consolidated statements of operations, nor have we accrued for or made payments for interest and penalties. Our unrecognized gross tax benefits would not reduce the estimated annual effective tax rate if recognized because we have recorded a full valuation allowance on its deferred tax assets. 45 BRIDGEBIO PHARMA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) A 18. Net Loss Per Share Basic net loss per share attributable to common stockholders of BridgeBio is computed by dividing net loss attributable to common stockholders of BridgeBio by the weighted-average number of shares of common stock outstanding. Diluted net loss per share attributable to common stockholders of BridgeBio is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, plus all additional common shares that would have been outstanding, assuming dilutive potential common shares had been issued for other dilutive securities. For the three and six months ended June 30, 2024 and 2023, diluted and basic net loss per share attributable to common stockholders of BridgeBio were identical since potential common shares were excluded from the calculation, as their effect was anti-dilutive. The following table summarizes the common stock equivalents that were anti-dilutive: A A As of June 30, A A 2024 A A 2023 A A Unvested RSAs A A A A 363,022 A A Unvested RSUs A 10,554,840 A A 10,250,071 A A Unvested performance-based RSUs A 3,326 A A 7,875 A A Unvested market-based RSUs A 375,000 A A A A Common stock options issued and outstanding A 12,677,357 A A 12,850,536 A A Estimated shares issuable under performance-based milestone A A compensation arrangements A 3,811,055 A A 11,438,950 A A Estimated shares issuable under the ESPP A 106,012 A A 123,340 A A Assumed conversion of 2027 Notes A 12,878,305 A A 12,878,305 A A Assumed conversion of 2029 Notes A 7,702,988 A A 7,702,988 A A 48,108,883 A A 55,615,087 A A Our 2029 Notes and 2027 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. As discussed in Notes 8 and 15, we have performance-based milestone compensation arrangements, whose vesting is contingent upon meeting various regulatory and development milestones, with fixed monetary amounts known at inception that can be settled in

the form of cash or equity at our sole election, upon achievement of each contingent milestone. The common stock equivalents of such arrangements were estimated as if the contingent milestones were achieved as of the reporting date and the arrangements were all settled in equity. A 46 A Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes thereto for the year ended December 31, 2023 included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the U.S. Securities and Exchange Commission (the "SEC") on February 22, 2024. This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, you can identify these statements by forward-looking words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "should," "estimate," "continue," and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, as updated by the information, if any, in Part II, Item 1A, "Risk Factors" included in this Quarterly Report on Form 10-Q. The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. Except as may be required by law, we assume no obligation to update these forward-looking statements or the reasons that results could differ from these forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q. Overview BridgeBio Pharma, Inc. (the "Company" or the "Company") is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. Since inception, BridgeBio has created 17 Investigational New Drug applications, or INDs, and had two products approved by the U.S. Food and Drug Administration. We worked across over 20 disease states at various stages of development. Several of our programs target indications that we believe present the potential for our product candidates, if approved, to target portions of market opportunities of at least \$1.0 billion in annual sales. We focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology. Our approach is to translate research pioneered at academic laboratories and leading medical institutions into products that we hope will ultimately reach patients. We are able to realize this opportunity through a confluence of scientific advances: (i) identification of the genetic underpinnings of disease as more cost-efficient genome and exome sequencing becomes available; (ii) progress in molecular biology; and (iii) the development and maturation of longitudinal data and retrospective studies that enable the linkage of genes to diseases. We believe that this early-stage innovation represents one of the greatest practical sources for new drug creation. Since our inception in 2015, we have focused substantially all of our efforts and financial resources on acquiring and developing product and technology rights, building our intellectual property portfolio and conducting research and development activities for our product candidates within our wholly-owned subsidiaries and controlled entities, including partially-owned subsidiaries and subsidiaries we consolidate based on our deemed majority control of such entities as determined using either the variable interest entity, or VIE model, or the voting interest entity, or VOE model. To support these activities, we and our wholly-owned subsidiary, BridgeBio Services, Inc., (i) identify and secure new programs, (ii) set up new wholly-owned subsidiaries or controlled entities, (iii) recruit key management team members, (iv) raise and allocate capital across the portfolio and (v) provide certain shared services, including accounting, legal, information technology, administrative, and human resources, as well as workshops. We have not generated any significant revenue from product sales. To date, we have funded our operations with proceeds from the sale of our equity securities, issuance of convertible notes, debt borrowings, sale of certain assets and, to a lesser extent, upfront and milestone payments from licensing arrangements. We have incurred significant operating losses since our inception. For the six months ended June 30, 2024 and 2023, we incurred net losses of \$111.7 million and \$303.4 million, respectively. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of our product candidates at our wholly-owned subsidiaries and controlled entities. While we have undertaken activities in preparation for commercial launch readiness for our late-stage programs and a restructuring initiative to drive operational change in business processes, efficiencies and cost savings, we expect to continue to incur significant operating and net losses for at least the next several years. In addition, we have very limited experience with commercialization, and we may not be able to generate significant revenues from product sales, if any, even if any of our product candidates are approved for commercial sale. Further, we may not realize the anticipated efficiencies and other benefits of our past and any future restructuring initiatives. Additionally, failure to secure FDA approval for acoramidis will result in our inability to receive a \$500.0 million milestone payment pursuant to the Funding Agreement, which would significantly harm our business, prospects, financial condition and results of operations. In June 2024, BridgeBio Europe B.V. (the "BridgeBio B.V.") entered into a commercial supply agreement with Bayer (the "Bayer Supply Agreement") with an initial 30-month term ending in December 2026, for which BridgeBio B.V. will manufacture and supply to Bayer the commercial product ordered by Bayer solely for the use in the commercialization in the Licensed Territory under the Bayer Agreement. Under the Bayer Supply Agreement, Bayer shall pay to BridgeBio B.V. a commercial product per unit price equal to the applicable fully burdened manufacturing cost per unit of product, which shall include the cost of the API used to manufacture the product and the packaging price. As of June 30, 2024 there have been no commercial product supply sales to Bayer. On April 30, 2024, TheRas, Inc., doing business as BridgeBio Oncology Therapeutics (BBOT), a majority-owned subsidiary of the Company, completed a \$200.0 million private equity financing with external investors to accelerate the development of its oncology portfolio. As part of the private equity financing transaction, BBOT's Certificate of Incorporation and Investors' Rights Agreement were amended and restated to reflect a change in BBOT's governance structure and composition of the board of directors, which was determined to be a VIE reconsideration event. Based on the VIE reconsideration assessment, BBOT was deemed a VIE. As a result of the change in the governance structure and composition of the board of directors, BridgeBio is no longer the primary beneficiary of BBOT, as it no longer has the power over key decisions that significantly impact BBOT's economic performance. Accordingly, BridgeBio deconsolidated BBOT on April 30, 2024. During the three months ended June 30, 2024, we recognized a \$126.3 million net gain from deconsolidation of a subsidiary which is presented on the condensed consolidated statements of operations for the three and six months ended June 30, 2024. Upon the deconsolidation of BBOT, BridgeBio accounted for its retained investments in BBOT, for which it has significant influence through its ownership interest, using the equity method of accounting. BBOT was also deemed a related party. For the period May 1, 2024 through June 30, 2024, we recognized a net loss from equity method investment of \$7.9 million. As of June 30, 2024, the aggregate carrying amount of our equity method investment in BBOT is \$117.0 million and is presented as investment in nonconsolidated entity on our condensed consolidated balance sheets. On March 1, 2024, certain subsidiaries of the Company, including Eidos Therapeutics, Inc., BridgeBio International GmbH and BridgeBio Europe B.V. (collectively the "Seller Parties"), entered into an exclusive license agreement (the "Bayer Agreement") with Bayer Consumer Care AG, a wholly-owned subsidiary of Bayer AG (the "Bayer"), to develop and commercialize acoramidis as a treatment for transthyretin amyloidosis in the European Union and all member states of the European Patent Organization (the "Licensed Territory"). Under the terms of the Bayer Agreement, the Seller Parties granted Bayer an exclusive license, effective upon the date that certain antitrust clearances have been obtained, to certain of the Seller Parties' intellectual property rights to develop, manufacture and commercialize acoramidis (previously known as AG10) in the Licensed Territory. In consideration for the license grant, the Seller Parties are entitled to receive an upfront payment of \$135.0 million and will be eligible to receive up to \$175.0 million in regulatory and sales milestone payments through 2026, and additional payments up to \$450.0 million subject to the achievement of certain sales milestones. In addition, the Seller Parties are entitled to receive royalties according to a tiered structure starting in the low-thirties percent on net sales by Bayer of acoramidis in the Licensed Territory, subject to reduction under certain circumstances as provided in the Bayer Agreement. On February 7, 2024, our subsidiary, QED, and Kyowa Kirin Co., Ltd. (the "Kyowa Kirin" or the "KKC") entered into a partnership wherein QED granted Kyowa Kirin an exclusive license to develop, manufacture, and commercialize infratrinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan in accordance with the terms therein (the "KKC Agreement"). In exchange, QED will receive an upfront payment of \$100.0 million and will be eligible to receive royalties up to the mid-twenties percent on sales of infratrinib in Japan, with the potential to receive up to \$81.4 million in development and sales-based milestone payments. On January 17, 2024, the Company and each of the guarantors entered into a Financing Agreement, which was amended on February 12, 2024 (the "Financing Agreement") and June 20, 2024 (the "Financing Agreement, as amended by the Second Amendment, the "Amended Financing Agreement"), with the lenders party thereto (the "Lenders") and Blue Owl Capital Corporation, as administrative agent for the Lenders (the "Administrative Agent"). Pursuant to the terms and conditions of the Amended Financing Agreement, the Lenders have agreed to extend a senior secured credit facility to the Company in an aggregate principal amount of up to \$750.0 million comprised of (i) an initial term loan in an aggregate principal amount of \$450.0 million (the "Initial Term Loan") and (ii) one or more incremental term loans in an aggregate amount not to exceed \$300.0 million (collectively, the "Incremental Term Loan," and together with the Initial Term Loan, collectively, the "Term Loans"), subject to the satisfaction of certain terms and conditions set forth in the Amended Financing Agreement. The Initial Term Loan was funded on January 17, 2024. Incremental Term Loans are available at the Company's and the Lenders' mutual consent from time to time after January 17, 2024. Refer to the "Liquidity and Capital Resources" section for additional details regarding this agreement. On January 17, 2024, we and our subsidiaries entered into a Funding Agreement with LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.A. r.l. together, (the "Purchasers"). Pursuant to the Funding Agreement, the Purchasers agreed to pay to the Company \$500.0 million (net of certain transaction expenses) upon the first FDA approval of acoramidis, subject to certain conditions relating to the FDA approval and other customary conditions (such date of payment, the "Funding Date"). In return, we granted the Purchasers the right to receive payments (the "Royalty Interest Payments") equal to 5% of the global net sales of acoramidis (the "Net Sales"), which under certain conditions may adjust to a maximum rate of 10% in 2027. Each Royalty Interest Payment will become a 48 A payable to the Purchasers on a quarterly basis after the Funding Date. In addition, the Seller Parties granted the collateral agent, for the benefit of the Purchasers, a security interest in specific assets related to acoramidis. The Funding Agreement will terminate upon customary events, and also in the event the Funding Date does not occur on or prior to May 15, 2025 (in which case either party may terminate the Funding Agreement at no charge and without premium or penalty). As of June 30, 2024, the Company has not received proceeds under the Funding Agreement. Refer to the "Liquidity and Capital Resources" section for additional details regarding this agreement. Due to the inherently unpredictable nature of preclinical and clinical development, and given our novel therapeutic approaches and the stage of development of our product candidates, we cannot determine and are unable to estimate with certainty the timelines we will require and the costs we will incur for the development of our product candidates. Clinical and preclinical development timelines and costs, and the potential of development success, can differ materially from expectations due to a variety of factors. In January 2022, we committed to a restructuring initiative designed to drive operational changes in our business processes, efficiencies and cost savings to advance our corporate strategy and development programs. The restructuring initiative included, among other components, consolidation and rationalization of our facilities, reprioritization of development programs and the reduction in our workforce. In March 2024, upon entering into the Bayer Agreement and termination of the Navire-BMS License Agreement (refer to Note 11 for details regarding these transactions), we have committed to additional restructuring plans to reprioritize and advance our corporate strategy and development programs. We estimate that we will incur a remaining \$12.0 million to \$16.0 million in restructuring charges, consisting primarily of winding down costs, exit and other related costs, and severance and employee-related costs. Our estimate of the costs is subject to certain assumptions and actual results may differ from those estimates or assumptions. We may also incur additional costs that are not currently foreseeable as we continue to evaluate our restructuring alternatives to drive operational changes in business processes, efficiencies and cost savings. During the six months ended June 30, 2024 and 2023, our restructuring, impairment and related charges amounted to \$6.3 million and \$6.9 million, respectively, which consisted primarily of winding down costs, exit and other related costs, impairments and write-offs of long-lived assets, and severance and employee-related costs. Results of Operations The following table summarizes the results of our operations for the periods indicated: A A Three Months Ended June 30, A A Six Months Ended June 30, A A 2024 A A 2023 A A 2024 A A 2023 A A (in thousands) A Revenue A \$ 2,168 A A \$ 1,641 A A \$ 213,288 A A \$ 3,467 A A Cost of revenue A A 598 A A 599 A A 1,196 A A 1,250 A A Research and development A A 114,695 A A A 107,488 A A 255,667 A A A 200,349 A A Selling, general and administrative A A 59,523 A A 36,122 A A 125,330 A A 67,230 A A Restructuring, impairment and related charges A A 2,891 A A 3,531 A A 6,291 A A 6,900 A A Loss from operations A A (175,539) A A (146,099) A A (175,196) A A (272,262) A A Interest income A A 5,195 A A 4,514 A A 9,270 A A 8,667 A A Interest expense A A (22,937) A A (20,594) A A (46,408) A A (40,715) A A Gain on deconsolidation of a subsidiary A A 126,294 A A A A A 126,294 A A A A Loss on extinguishment of debt A A A A A A (26,590) A A A A Net loss from equity method investment A A (7,925) A A A A (7,925) A A A A Other income (expense), net A A (632) A A 1,476 A A 8,851 A A 8,755 A A Net loss A A (75,544) A A (160,703) A A (111,704) A A (303,435) A A Net loss attributable to redeemable convertible noncontrolling A A interests and noncontrolling interests A A 2,088 A A 2,804 A A 3,032 A A 5,380 A A Net loss attributable to common stockholders of BridgeBio A A (73,456) A A (157,899) A A (108,672) A A (298,055) A A A A June 30, 2024 A A December 31, 2023 A A A A (in thousands) A Cash, cash equivalents and marketable securities A A A A 447,771 A A \$ 375,935 A A Restricted cash A A A A 139,409 A A A 16,653 A A Investments in equity securities A A A A A A 58,949 A A 49 A A Cash, Cash Equivalents, Marketable Securities, Restricted Cash and Investments in Equity Securities As of June 30, 2024, we had cash, cash equivalents and marketable securities of \$447.8 million and restricted cash of \$139.4 million, compared to cash, cash equivalents and marketable securities of \$375.9 million, restricted cash of \$16.7 million and investments in equity securities of \$58.9 million as of December 31, 2023. Under the terms of the Amended Financing Agreement, the Company is required to deposit 75% of proceeds, net of certain permitted costs, received from certain asset sale transactions into an escrow account to be controlled by the Administrative Agent. During the three months ended June 30, 2024, we received \$235.0 million in aggregate from Bayer and Kyowa Kirin, and deposited net proceeds of \$159.3 million into the escrow accounts, which was classified as restricted cash on the condensed consolidated balance sheet as of June 30, 2024. Furthermore, under the terms of Amended Financing Agreement, between June 20, 2024 and through the earlier of the FDA approval date and November 30, 2024, the Company is able to request a release of funds in an aggregate amount not to exceed 50% of the original net cash proceeds received from asset sale transactions. As of June 30, 2024, \$20.0 million was released from the escrow accounts and classified as cash on the condensed consolidated balance sheet, with a remaining balance of \$139.3 million in the escrow accounts classified as restricted cash. Refer to Note 9 and Note 11 for further details regarding the Amended Financing Agreement, the Bayer Agreement and KKC Agreement. Restricted cash as of December 31, 2023 primarily represents funds in a controlled account that was established in connection with the Loan and Security Agreement (the "Amended Loan Agreement") that is described in Note 9. The use of such non-interest-bearing cash was restricted per the terms of the underlying amended loan agreement and was to be used solely for certain research and development expenses directly attributable to the performance of obligations associated with the Navire-BMS License Agreement, which is further described in Note 11. Upon the termination of the Amended Loan Agreement and full repayment of the term loan in January 2024 (refer to Note 9 for details), the non-interest-bearing cash was no longer restricted. Revenue The following table summarizes our revenue for the following periods: A A Three Months Ended June 30, A A A A Six Months Ended June 30, A A A A 2024 A A 2023 A A Change A A 2024 A A 2023 A A Change A A (in thousands) A Revenue A \$ 2,168 A A \$ 1,641 A A \$ 527 A A \$ 213,288 A A \$ 3,467 A A \$ 209,821 A A Revenue for the three months ended June 30, 2024 consists mainly of the recognition of services revenue under the Bayer Agreement and the KKC Agreement. Revenue for the three months ended June 30, 2023 was primarily related to the recognition of services revenue under the Navire-BMS License Agreement. Revenue for the six months ended June 30, 2024 consists mainly of \$202.9 million from the recognition of the upfront license fee and services revenue under the Bayer Agreement and the KKC Agreement. An additional \$9.9 million of revenue was attributable to the remaining services revenue in connection with the Navire-BMS License Agreement as a result of the termination of the agreement. Revenue for the six months ended June 30, 2023 was primarily related to the recognition of services revenue under the Navire-BMS License Agreement. The level of revenue, including license and service revenue, that we recognize depends in part upon the estimated recognition period of the upfront payments allocated to continuing performance obligations, the achievement of milestones and other contingent events, the level of effort incurred for research and development contracted services, and

the impact of entering into new licensing and collaboration agreements, if any. Operating Costs and Expenses Research and Development Expenses The following table summarizes our research and development expenses for the following periods:

	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	2023	Change 2024	
Research and development	\$ 114,695	\$ 107,488	\$ 7,207	\$ 255,667	
Research and development expenses increased by	\$ 7.2 million	for the three months ended June 30, 2024, compared to the same period in 2023.	This change was primarily due to an increase in personnel costs of \$11.9 million and external costs of \$2.4 million to support the advancement of research and development for our key programs, an increase in licensing fees of \$1.3 million, which was offset by a decrease in stock-based compensation of \$8.3 million.	\$ 50	
Research and development expenses increased by	\$ 55.3 million	for the six months ended June 30, 2024, compared to the same period in 2023.	This change was primarily due to an increase in personnel costs of \$28.4 million and external costs of \$24.1 million to support the advancement of research and development for our key programs, an increase in licensing fees of \$10.1 million, which was offset by a decrease in stock-based compensation of \$7.3 million.	Research and development costs consist primarily of external costs, such as fees paid to consultants, contractors, contract manufacturing organizations (CMOs), and contract research organizations, or CROs, purchase of active pharmaceutical ingredients, or APIs, in connection with our preclinical, contract manufacturing and clinical development activities and are tracked on a program-by-program basis.	
License fees and other costs incurred after a product candidate has been designated and that are directly related to the product candidate are included in the specific program expense. License fees and other costs incurred prior to designating a product candidate are included in early-stage research programs. The following table summarizes our research and development expenses by program incurred for the following periods:	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	2023	Change 2023	
(in thousands)	ATTR Amyloidosis - TTR stabilizer (acoramidis)	\$ 36,798	\$ 26,218	\$ 76,540	\$ 47,549
Achondroplasia - low-dose FGFRi (infigratinib)	\$ 17,927	\$ 11,096	\$ 36,358	\$ 23,453	
LGMD2I/R9 - Glycosylation substrate (BBP-418)	\$ 10,773	\$ 9,043	\$ 20,791	\$ 15,377	
ADH1 - CaSR antagonist (encaleret)	\$ 10,608	\$ 11,650	\$ 23,152	\$ 21,062	
Other development programs	\$ 13,864	\$ 22,106	\$ 48,902	\$ 41,745	
Other research programs	\$ 24,725	\$ 27,375	\$ 49,924	\$ 51,163	
Total	\$ 114,695	\$ 107,488	\$ 255,667	\$ 200,349	

Selling, General and Administrative Expenses The following table summarizes our selling, general and administrative expenses for the following periods:

	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	2023	Change 2023		
Selling, general and administrative	\$ 59,523	\$ 36,122	\$ 23,401	\$ 125,330		
Selling, general and administrative expenses increased by	\$ 23.4 million	for the three months ended June 30, 2024, compared to the same period in 2023, mainly due to an increase in external costs of \$10.9 million and personnel related expense of \$10.0 million to support commercialization readiness efforts, and an increase in stock-based compensation expense of \$2.5 million.	Selling, general and administrative expenses increased by \$58.1 million for the six months ended June 30, 2024, compared to the same period in 2023, mainly due to an increase in external costs of \$19.5 million and personnel related expense of \$17.7 million to support commercialization readiness efforts, nonrecurring deal-related expenses of \$14.0 million, and an increase in stock-based compensation expense of \$6.9 million.			
Restructuring, Impairment and Related Charges The following table summarizes our restructuring, impairment and related charges during the periods indicated:	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	2023	Change 2023		
(in thousands)	Restructuring, impairment and related charges	\$ 2,891	\$ 3,531	\$ (640)	\$ 6,291	
As discussed in Note 16 to our condensed consolidated financial statements, in January 2022, we committed to a restructuring initiative designed to drive operational changes in our business processes, efficiencies and cost savings to advance our corporate strategy and development programs. The restructuring initiative included, among other components, consolidation and rationalization of our facilities, reprioritization of development programs and the reduction in our workforce. In March 2024, upon entering into the Bayer Agreement and termination of the Navire-BMS License Agreement (refer to Note 11 for details regarding these transactions), we have committed to additional restructuring plans to reprioritize and advance our corporate strategy and development programs. We estimate that we will incur a remaining \$12.0 million to \$16.0 million in restructuring charges, consisting primarily of winding down costs, exit and other related costs, and severance and employee-related costs. Our estimate of the costs is subject to certain assumptions and actual results may differ from those estimates or assumptions. We may also incur additional costs that are not currently foreseeable as we continue to evaluate our restructuring alternatives to drive operational changes in business processes, efficiencies and cost savings. Other Income (Expense), Net Interest Income The following table summarizes our interest income during the periods indicated:	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	2023	Change 2023		
(in thousands)	Interest income	\$ 5,195	\$ 4,514	\$ 681	\$ 9,270	
As compared to the same period in 2023 was generally consistent. Generally, increases and decreases in interest income are attributable to changes in the interest-bearing average balances of our cash equivalents and marketable securities and fluctuations in interest rates. Interest Expense The following table summarizes our interest expense during the periods indicated:	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	2023	Change 2023		
(in thousands)	Interest expense	\$ (22,937)	\$ (20,594)	\$ (2,343)	\$ (46,408)	
Interest expense consists primarily of interest expense incurred under our 2029 Notes issued in January 2021, our 2027 Notes issued in March 2020, our term loan under the Amended Financing Agreement and our term loan under the Amended Loan Agreement. Our outstanding term loan principal balance under our Amended Loan Agreement was fully repaid on January 17, 2024 upon receiving proceeds from the Financing Agreement plus additional cash from our operations, for which we were extended a senior secured credit facility of \$450.0 million in an aggregate principal amount for the Initial Term Loan, which is subject to variable interest rates (refer to the Liquidity and Capital Resources section below and Notes 9 for details regarding the Term Loan and the Amended Financing Agreement). As a result of the variable interest rates under our Amended Financing Agreement we expect our interest expense will continue to fluctuate in the future. Gain on Deconsolidation of a Subsidiary The following table summarizes our gain on deconsolidation of a subsidiary during the periods indicated:	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	2023	Change 2023		
(in thousands)	Gain on deconsolidation of a subsidiary	\$ 126,294	\$ 126,294	\$ 126,294	\$ 126,294	
On April 30, 2024, BBOT, a majority-owned subsidiary of the Company, completed a \$200.0 million private equity financing with external investors. As a result of the private equity financing transaction, BridgeBio deconsolidated BBOT on April 30, 2024 and recognized a net gain from deconsolidation of \$126.3 million for the three and six months ended June 30, 2024. Refer to Note 6 for further details regarding the BBOT private equity financing transaction.	52	Loss on Extinguishment of Debt The following table summarizes our loss on extinguishment of debt during the periods indicated:	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	2023	Change 2023
(in thousands)	Loss on extinguishment of debt	\$ (26,590)	\$ (26,590)	\$ (26,590)	\$ (26,590)	
On January 17, 2024, upon receiving proceeds from the Financing Agreement, we fully repaid the term loan under the Amended Loan Agreement and recognized a loss on extinguishment of debt of \$26.6 million in our condensed consolidated statements of operations. Refer to Note 9 to our condensed consolidated financial statements. Net Loss from Equity Method Investment The following table summarizes our share in net loss of equity method investment during the periods indicated:	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	2023	Change 2023		
(in thousands)	Net loss from equity method investment	\$ (7,925)	\$ (7,925)	\$ (7,925)	\$ (7,925)	
Upon the deconsolidation of BBOT, BridgeBio accounted for its retained investment in BBOT using the equity method of accounting. For the period May 1, 2024 through June 30, 2024, we recorded a net loss from equity method investment of \$7.9 million. Other Income (Expense), Net The following table summarizes our other income (expense), net during the periods indicated:	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	2023	Change 2023		
(in thousands)	Other income (expense), net	\$ 875	\$ 7,976	\$ 875	\$ 7,976	
Other income (expense), net for the three months ended June 30, 2024 consists mainly of a \$1.1 million disposition fee incurred under the Amended Financing Agreement in relation to the BBOT private equity financing transaction, partially offset by \$0.8 million in other income recognized under the Transition Service Agreement with BBOT. Other income (expense), net for the three months ended June 30, 2023 consists mainly of the net realized and unrealized gains from changes in fair value of our equity security investments of \$1.4 million. Other income (expense), net for the six months ended June 30, 2024 consists mainly of the net realized gain of \$8.1 million from our investments in equity securities. Other income (expense), net for the six months ended June 30, 2023 consists mainly of the net realized and unrealized gains from changes in fair value of our investments in equity securities of \$2.4 million, partially offset by a \$1.2 million loss from the deconsolidation of PellePharm. Net Loss Attributable to Redeemable Convertible Noncontrolling Interests and Noncontrolling Interests The following table summarizes our net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests during the periods indicated:	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	2023	Change 2023		
(in thousands)	Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests	\$ 2,088	\$ 2,804	\$ (716)	\$ 3,032	
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests in our condensed consolidated statements of operations consists of the portion of the net loss of those consolidated entities that is not allocated to us. Changes in the amount of net loss attributable to noncontrolling interests are directly impacted by changes in the net loss of our consolidated entities and are the result of ownership percentage changes. Refer to Note 5 to our condensed consolidated financial statements.	53	Liquidity and Capital Resources We have historically financed our operations primarily through the sale of our equity securities, issuance of convertible notes, debt borrowings, and revenue from certain licensing and collaboration agreements and sales of certain assets. As of June 30, 2024, we had cash, cash equivalents and marketable securities of \$447.8 million and restricted cash of \$139.4 million, including funds held by our wholly-owned subsidiaries and controlled entities, which are available only for specific entity usage. As of June 30, 2024, our outstanding debt was \$1.7 billion, net of debt discounts and issuance costs and accretion. Since inception, we have incurred significant operating losses. For the six months ended June 30, 2024, we incurred net losses of \$111.7 million. We had an accumulated deficit as of June 30, 2024 of \$2.7 billion. While we have undertaken activities in preparation for commercial launch readiness for our late-stage programs and a restructuring initiative to drive operational change in business processes, efficiencies and cost savings, we expect to continue to incur significant operating and net losses over the next several years as we continue to fund our drug development and discovery efforts. In particular, to the extent we advance our programs into and through later-stage clinical trials without a partner, we will incur substantial expenses. In addition, we have very limited experience with commercialization, and we may not be able to generate significant revenues from product sales, if any, even if any of our product candidates are approved for commercial sale. Further, we may not realize the anticipated efficiencies and other benefits of our past and any future restructuring initiatives. Our current business plan is also subject to significant uncertainties and risks as a result of, among other factors, our ability to generate product sales sufficient to achieve profitability, which will depend heavily on the successful development and eventual commercialization of product candidates at our consolidated entities as well as our ability to partner in the development of certain clinical programs, as well as the levels of our operating expenses. Additionally, failure to secure FDA approval for acoramidis will result in our inability to receive a \$500.0 million milestone payment pursuant to the Funding Agreement, which would significantly harm our business, prospects, financial condition and results of operations. Our short-term and long-term liquidity requirements include contractual payments related to our 2029 Notes, 2027 Notes and term loan (refer to Note 9 to our condensed consolidated financial statements), obligations under our real estate leases (refer to Note 13 to our condensed consolidated financial statements), accounts payable, accrued liabilities and the remaining liabilities under our restructuring initiative (refer to Note 16 to our condensed consolidated financial statements). We also have performance-based milestone compensation arrangements with certain employees and consultants, whose vesting is contingent upon meeting various regulatory and development milestones, with fixed monetary amounts known at inception that can be settled in the form of cash or equity at our sole election, upon achievement of each contingent milestone (refer to Note 8 to our condensed consolidated financial statements). Additionally, we have certain contingent payment obligations under various license and collaboration agreements in which we are required to make milestone payments upon successful completion and achievement of certain intellectual property, clinical, regulatory and sales milestones. We also enter into agreements in the normal course of business with CROs and other vendors for clinical trials and with vendors for preclinical studies and other services and products for operating purposes, which are generally cancelable upon written notice with potential termination charges. We expect our cash and cash equivalents, marketable securities and restricted cash will fund our operations for at least the next 12 months from the date of filing of this Quarterly Report on Form 10-Q based on current operating plans and financial forecasts. If our current operating plans or financial forecasts change, including as a result of general market and economic conditions, inflationary pressures, supply chain issues on our research and development activities, we may require additional funding sooner in the form of public or private equity offerings, debt financings or additional collaborations and licensing arrangements. However, future financing may not be available in amounts or on terms acceptable to us, if at all. In addition, we are closely monitoring macroeconomic events, including inflationary pressures and supply chain issues, which may negatively impact our financial and operating results. We will continue to assess our operating costs and expenses and our cash and cash equivalents and, if circumstances warrant, we will make appropriate adjustments to our operating plan. Sources of Liquidity Receivables from licensing and collaboration agreements. On March 1, 2024, certain subsidiaries of the Company, including Eidos Therapeutics, Inc., BridgeBio International GmbH and BridgeBio Europe B.V. (collectively the Seller Parties), entered into an exclusive license agreement (the Bayer Agreement) with Bayer Consumer Care AG, a wholly-owned subsidiary of Bayer AG (Bayer), to develop and commercialize acoramidis as a treatment for transthyretin amyloidosis in the European Union and all member states of the European Patent Organization (the Licensed Territory). Under the terms of the Bayer Agreement, the Seller Parties granted Bayer an exclusive license, effective upon the date that certain antitrust clearances have been obtained, to certain of the Seller Parties' intellectual property rights to develop, manufacture and commercialize acoramidis (previously known as AG10) in the Licensed Territory. In consideration for the license grant, the Seller Parties are entitled to receive an upfront payment of \$135.0 million and will be eligible to receive up to \$175.0 million in regulatory and sales milestone payments through 2026, and additional payments up to \$450.0 million subject to the 54 achievement of certain sales milestones. In addition, the Seller Parties are entitled to receive royalties according to a tiered structure starting in the low-thirties percent on net sales by Bayer of acoramidis in the Licensed Territory, subject to reduction under certain circumstances as provided in the Bayer Agreement. On February 7, 2024, our subsidiary, QED, and Kyowa Kirin Co., Ltd (Kyowa Kirin) or KKC entered into a partnership wherein QED granted Kyowa Kirin an exclusive license to develop, manufacture, and commercialize infigratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan in accordance with the terms therein (the KKC Agreement). In exchange, QED will receive an upfront payment of \$100.0 million and will be eligible to receive royalties up to the mid-twenties percent on sales of infigratinib in Japan, with the potential to receive up to \$81.4 million in development and sales-based milestone payments. Furthermore, under the terms of the Amended Financing Agreement, the Company is required to deposit 75% of proceeds, net of certain permitted costs, received from certain asset sale transactions into an escrow account to be controlled by the Administrative Agent. The Bayer and KKC agreements meet the requirements of asset sale transactions under the terms of the Amended Financing Agreement. During the three months ended June 30, 2024, we received \$235.0 million in aggregate from Bayer and KKC, and deposited net proceeds of \$159.3 million into the escrow accounts, which was classified as restricted cash on the condensed consolidated balance sheet as of June 30, 2024. Refer to the Term Loan, net section below for details regarding the escrow accounts deposits required for asset sales transactions under the Amended Financing Agreement. Public offerings In March 2024, we entered into an Underwriting Agreement (the 2024 Follow-on Agreement) with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of several underwriters (collectively, the 2024 Underwriters), relating to an underwritten public offering (the 2024 Follow-on offering) of 8,620,690 shares of the Company's common stock, \$0.001 par value per share, at a public offering price of \$29.00 per share. The Company also granted the 2024 Underwriters a 30-day option to purchase, at the public offering price less underwriting discounts and commissions, up to an additional 1,293,103 shares of Common Stock, which the 2024 Underwriters exercised in full on the closing of the 2024 Follow-on offering. The Company paid the Underwriters a commission of 3.6% of the aggregate gross proceeds received from all sales of the common stock under the Follow-on Agreement. In March 2024, 9,913,793 shares (including the 1,293,103 shares issued upon exercise of the 2024 Underwriters' option to purchase additional shares) were issued under the 2024 Follow-on Agreement, for				

net proceeds of \$276.6 million, after deducting underwriting fees and commissions of \$10.3 million and deferred offering costs of \$0.6 million. In May 2023, we filed a shelf registration statement on Form S-3ASR, or the 2023 Shelf, with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and units or any combination thereof. We also concurrently entered into the 2023 ATM Agreement, with Goldman Sachs & Co. LLC and SVB Securities LLC or collectively, the ATM Sales Agents, with respect to an at-the-market offering program under which we may issue and sell, from time to time at our sole discretion and pursuant to a prospectus supplement, shares of our common stock, par value \$0.001 per share, having an aggregate offering price of up to \$450.0 million through the ATM Sales Agents. We will pay the ATM Sales Agents a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the 2023 ATM Agreement. During the three and six months ended June 30, 2024, 1,061,991 shares were issued under the ATM Agreement, for net proceeds of \$38.1 million, after deducting sales agent fees and commissions of \$0.6 million. As of June 30, 2024, we are still eligible to sell up to \$345.3 million of our common stock pursuant to the ATM Agreement under the 2023 Shelf. Debt As of June 30, 2024, we have borrowings under the 2029 Notes, the 2027 Notes and the Term Loan under the Amended Financing Agreement, which are discussed below. 2029 Notes, net In January and February 2021, we issued an aggregate principal amount of \$747.5 million of our 2029 Notes, pursuant to an Indenture dated January 28, 2021, or the 2029 Notes Indenture, between us and U.S. Bank National Association, as trustee, or the 2029 Notes Trustee, in a private offering to qualified institutional buyers, or the 2021 Note Offering, pursuant to Rule 144A under the Securities Act. The 2029 Notes accrue interest payable semiannually in arrears on February 1 and August 1 of each year, beginning on August 1, 2021, at a rate of 2.25% per year. The 2029 Notes will mature on February 1, 2029, unless earlier converted, redeemed or repurchased. The 2029 Notes are convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. We received net proceeds from the 2021 Note Offering of approximately \$731.4 million, after deducting the 2029 Notes Initial Purchasers' discount. There were no direct offering expenses borne by us for the 2029 Notes. We used approximately \$61.3 million of the net proceeds from the 2021 Note Offering to pay for the cost of the 2021 Capped Call Transactions and approximately \$50.0 million to pay for the repurchase of shares of our common stock. A 55 A holder of 2029 Notes may convert all or any portion of its 2029 Notes at its option at any time prior to the close of business on the business day immediately preceding November 1, 2028 only under certain circumstances. On or after November 1, 2028 until the close of business on the second scheduled trading day immediately preceding the maturity date, a holder may convert all or any portion of its 2029 Notes at any time. We may not redeem the 2029 Notes prior to February 6, 2026. We may redeem for cash all or any portion of the 2029 Notes, at our option, on a redemption date occurring on or after February 6, 2026 and on or before the 41st scheduled trading day immediately before the maturity date, under certain circumstances. No sinking fund is provided for the 2029 Notes. If we undergo a fundamental change (as defined in the 2029 Notes Indenture), holders may require us to repurchase for cash all or any portion of their 2029 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2029 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The 2029 Notes Indenture contains customary terms and covenants, including that upon certain events of default occurring and continuing, either the 2029 Notes Trustee or the holders of not less than 25% in aggregate principal amount of the 2029 Notes then outstanding may declare the entire principal amount of all the Notes plus accrued special interest, if any, to be immediately due and payable. The 2029 Notes are our general unsecured obligations and rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2029 Notes; equal in right of payment with all of our liabilities that are not so subordinated, including our 2027 Notes; effectively junior to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. Refer to Note 9 in our condensed consolidated financial statements for other details, including our future minimum payments under the 2029 Notes. 2027 Notes, net In March 2020, we issued an aggregate principal amount of \$550.0 million of our 2027 Notes, pursuant to an Indenture dated March 9, 2020, or the Indenture, between BridgeBio and U.S. Bank National Association, as trustee, or the Trustee, in a private offering to qualified institutional buyers, or the 2020 Note Offering, pursuant to Rule 144A under the Securities Act. The 2027 Notes are senior, unsecured obligations of BridgeBio and accrue interest payable semiannually in arrears on March 15 and September 15 of each year, beginning on September 15, 2020, at a rate of 2.50% per year. The 2027 Notes will mature on March 15, 2027, unless earlier converted or repurchased. Upon conversion, the 2027 Notes are convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. We received net proceeds from the 2020 Note Offering of approximately \$537.0 million, after deducting the Initial Purchasers' discount and offering expenses. We used approximately \$49.3 million of the net proceeds from the 2020 Note Offering to pay for the cost of the Capped Call Transactions, and approximately \$75.0 million to pay for the repurchases of shares of our common stock in connection with the 2020 Note Offering. A holder of 2027 Notes may convert all or any portion of its 2027 Notes at its option at any time prior to the close of business on the business day immediately preceding December 15, 2026 only under certain circumstances. On or after December 15, 2026 until the close of business on the second scheduled trading day immediately preceding the maturity date, a holder may convert all or any portion of its 2027 Notes at any time. We may not redeem the 2027 Notes prior to the maturity date, and no sinking fund is provided for the 2027 Notes. If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or any portion of their 2027 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary terms and covenants, including that upon certain events of default occurring and continuing, either the Trustee or the holders of not less than 25% in aggregate principal amount of the 2027 Notes then outstanding may declare the entire principal amount of all the Notes plus accrued special interest, if any, to be immediately due and payable. The 2027 Notes are our general unsecured obligations and rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2027 Notes; equal in right of payment with all of our liabilities that are not so subordinated; effectively junior to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. Refer to Note 9 in our condensed consolidated financial statements for other details, including our future minimum payments under the 2027 Notes. Term Loan, net On January 17, 2024, we entered into the Financing Agreement with certain of our subsidiaries party thereto as guarantors, the Lenders and the Administrative Agent, which was amended on February 12, 2024. A 56 A Pursuant to the terms and conditions of the Financing Agreement, the Lenders have agreed to extend a senior secured credit facility to the Company in an aggregate principal amount of up to \$750.0 million, comprised of (i) an Initial Term Loan in an aggregate principal amount of \$450.0 million and (ii) one or more Incremental Term Loans in an aggregate amount not to exceed \$300.0 million, subject to the satisfaction of certain terms and conditions set forth in the Financing Agreement. The Initial Term Loan was funded on January 17, 2024. Incremental Term Loans are available at the Company's and the Lenders' mutual consent from time to time after January 17, 2024. The obligations of the Company under the Financing Agreement are and will be guaranteed by certain of the Company's existing and future direct and indirect subsidiaries, subject to certain exceptions (such subsidiaries, collectively, the Guarantors). As security for the obligations of the Company and the Guarantors, each of the Company and the Guarantors are required to grant to the Administrative Agent, for the benefit of the Lenders and secured parties, a continuing first priority security interest in substantially all of the assets of the Company and the Guarantors (including all equity interests owned or hereafter acquired by the Company and the Guarantors), subject to certain customary exceptions. Any outstanding principal on the Term Loans will initially bear interest at a rate per annum equal to (A) in the case of Term Loans bearing interest based on the base rate defined in the Financing Agreement (and which base rate will not be less than 2.00%), the sum of (i) the base rate plus (ii) 5.75% and (B) in the case of Term Loans bearing interest based on the three-month forward-looking term secured overnight financing rate administered by the Federal Reserve Bank of New York (the Term SOFR), the sum of (i) three-month Term SOFR (subject to 1.00% per annum floor), plus (ii) 6.75%. Accrued interest is payable quarterly following the funding of the Initial Term Loan on the Closing Date, on any date of prepayment or repayment of the Term Loans and at maturity. The Company may prepay the Term Loans at any time (in whole or in part) or be required to make mandatory prepayments upon the occurrence of certain customary prepayment events. The mandatory prepayment events include certain permitted asset sales transactions (which include certain sales, leases, assignments, conveyances, transfers, licenses or exchanges of property) that occur prior to the date the FDA approves a first NDA for acoramidis, which would require the Company to deposit 75% of net cash received from such transactions into an escrow account controlled by the Administrative Agent, and the Company may also be subject to a specified disposition fee per transaction for certain asset sale transactions. In certain instances and during certain time periods, prepayments will be subject to customary prepayment fees. The amount of any prepayment fee may vary, but the maximum amount that may be due with any such prepayment would be an amount equal to 3.00% of the Term Loans being prepaid at such time, plus a customary make whole amount. We have entered into asset sales transactions that occurred during the three months ended March 31, 2024 for the exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd, for which the Company is required to deposit 75% of the proceeds, net of certain permitted costs, upon receipt of the upfront payments from Bayer Consumer Care AG and Kyowa Kirin Co., Ltd, into the escrow accounts. During the three months ended June 30, 2024, we received \$235.0 million in aggregate from Bayer Consumer Care AG and Kyowa Kirin Co., Ltd, and deposited net proceeds of \$159.3 million into the escrow accounts. Refer to Note 11 for further details regarding the exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd. The completion of the \$200.0 million private equity financing with external investors of BBOT, was considered an asset sale transaction that was subject to a disposition fee under the Financing Agreement. Accordingly, we paid a disposition fee of \$1.1 million to the Administrative Agent during the three months ended June 30, 2024. Refer to Note 6 for further details regarding the BBOT private equity financing transaction. The Financing Agreement contains affirmative covenants and negative covenants applicable to the Company and its subsidiaries that are customary for financings of this type. Such covenants, among other items, limit the Company's and its subsidiaries' ability to (i) incur additional permitted indebtedness, (ii) pay dividends or make certain distributions, (iii) dispose of its and their assets, grant liens and license or permit other encumbrances on its and their assets, (iv) fundamentally alter the nature of their businesses and (v) enter into certain transactions with affiliates. The Company and the Guarantors are also required to maintain a minimum unrestricted cash balance of \$70.0 million at all times. The Company and its subsidiaries are permitted to license their intellectual property, dispose of other assets and enter into monetization and royalty transactions, in each case, subject to satisfaction of certain terms and conditions. The Financing Agreement also includes representations, warranties, indemnities and events of default that are customary for financings of this type, including an event of default relating to a change of control of the Company. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate the Company's obligations under the Financing Agreement. On June 20, 2024, the Company and each of the guarantors entered into the Second Amendment to the Financing Agreement. Under the Amended Financing Agreement, between June 20, 2024 and through the earlier of the FDA approval date and November 30, 2024, the Company is able to request a release of funds in an aggregate amount not to exceed 50% of the original net cash proceeds received from asset sale transactions. As of June 30, 2024, \$20.0 million was released from the escrow accounts and classified as cash, with a remaining balance of \$139.3 million in the escrow accounts classified as restricted cash on the condensed consolidated balance sheet. Furthermore, under the Amended Financing Agreement, the minimum qualified cash balance was amended from \$70.0 million to \$70.0 million plus 40% of any cash released by the Company from the escrow accounts, at all times. As of June 30, 2024, the minimum unrestricted qualified cash balance was \$78.0 million. A 57 A Cash Flows The following table summarizes our cash flows during the periods indicated: A Six Months Ended June 30, A A A 2024 A 2023 A Change A A A (in thousands) A A A Net cash used in operating activities \$ (144,834) A \$ (257,675) A \$ 112,841 A Net cash provided by investing activities A 25,792 A A 16,417 A A 9,375 A Net cash provided by financing activities A 273,819 A A 149,018 A A 124,801 A Net increase (decrease) in cash, cash equivalents and A A A restricted cash A 154,777 A \$ (92,240) A \$ 247,017 A A Net Cash Flows Used in Operating Activities Net cash used in operating activities was \$144.8 million for the six months ended June 30, 2024, consisting primarily of our net loss of \$111.7 million, adjusted for non-cash items totaling \$54.4 million, which primarily includes a \$126.3 million net gain on the deconsolidation of a subsidiary, \$8.1 million net realized gain from investment in equity securities, offset by \$38.5 million in stock-based compensation expense, \$26.6 million in loss on extinguishment of debt from the repayment of the term loan under the Amended Loan Agreement, net loss from equity method investment of \$7.9 million, and \$3.7 million in accretion of debt; and \$21.3 million in net cash inflow related to changes in operating assets and liabilities. The \$21.3 million net cash inflow related to changes in operating assets and liabilities was attributed mainly to an increase in deferred revenue of \$22.2 million primarily related to the Bayer Agreement and KKC Agreement, an increase of \$8.9 million in accounts payable, and an increase of \$7.1 million in accrued research and development liabilities, partially offset by a decrease of \$8.4 million in accrued compensation and benefits and a decrease in prepaid expenses and other current assets of \$6.5 million, which are primarily due to timing of payments. Net cash used in operating activities was \$257.7 million for the six months ended June 30, 2023, consisting primarily of our net loss of \$303.4 million, adjusted for non-cash items totaling \$64.0 million, which primarily includes \$49.1 million in stock-based compensation expense, \$6.7 million in accrued payment-in-kind interest, and \$4.6 million in accretion of debt, as well as \$18.2 million net cash outflow related to changes in operating assets and liabilities. The \$18.2 million net cash outflow related to changes in operating assets and liabilities was attributed mainly to a decrease of \$11.3 million in accrued research and development liabilities and a decrease of \$11.1 million in accrued compensation and benefits mainly due to timing of payments, a decrease of \$4.1 million in accounts payable due to timing of payments, partially offset by a decrease of \$8.5 million from licensing and collaboration agreements receivables primarily due to collections. Net Cash Flows Provided by Investing Activities Net cash provided by investing activities was \$25.8 million for the six months ended June 30, 2024, attributable primarily to \$63.2 million in proceeds from the sale of equity securities, \$55.0 million in proceeds from the maturities of marketable securities, \$25.7 million in special cash dividends received from equity securities, partially offset by purchases of marketable securities of \$93.8 million and purchases of investments in equity securities of \$20.3 million. Net cash provided by investing activities was \$16.4 million for the six months ended June 30, 2023, attributable primarily to \$67.1 million in proceeds from the sale of equity securities, \$41.6 million in maturities of marketable securities, partially offset by purchases of investment in equity securities of \$71.5 million and purchases of marketable securities of \$19.8 million. Net Cash Flows Provided by Financing Activities Net cash provided by financing activities was \$273.8 million for the six months ended June 30, 2024, consisting primarily of \$450.0 million in proceeds from the term loan under the Financing Agreement, \$314.8 million in net proceeds from the issuance of common stock through public offerings, and partially offset by \$473.4 million repayment of the term loan under the Amended Loan Agreement, and \$16.0 million in issuance costs and discounts associated with the Amended Financing Agreement. Net cash provided by financing activities was \$149.0 million for the six months ended June 30, 2023, consisting primarily of \$144.0 million in net proceeds from the issuance of common stock through the Follow-on offering. A 58 A Critical Accounting Policies Our management's discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as revenues, if any, and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in the section titled "Management's Discussion and Analysis of Financial Condition and Operations" included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC, except for certain updates to our accounting policy as discussed in Note 2 in our condensed consolidated financial statements as of and for the six months ended June 30, 2024. Recent Accounting Pronouncements There have been no significant changes in recently adopted or issued accounting pronouncements from those disclosed in the section titled "Financial Statements and Supplementary Data" included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. A 59 A Item 3. Quantitative and Qualitative Disclosures About Market Risk As of June 30, 2024, we held cash, cash equivalents, marketable securities and restricted cash (current) of \$587.2 million. Our cash equivalents consist of amounts invested in money market funds; agency discount notes; and high investment grade fixed income securities that are primarily invested in commercial paper, U.S. government securities and treasury bills. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure. We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. We do not believe that our cash and cash equivalents have a significant risk of default or illiquidity. As of June 30, 2024, our 2029 Notes and 2027 Notes had principal balances of \$747.5 million and \$550.0 million, respectively, which bear fixed interest

[illegible]

SECOND AMENDMENT TO FINANCING AGREEMENT (this ~~à~~Amendmentà), dated as of June 20, 2024, is entered into by and among BRIDGEBIO PHARMA, INC., a Delaware corporation (the ~~à~~Borrowerà), the Guarantors party hereto, the Lenders party hereto, and BLUE OWL CAPITAL CORPORATION, as administrative agent for the Lenders (in such capacity, the ~~à~~Administrative Agentà). WHEREAS, the Borrower, certain Subsidiaries of the Borrower from time to time party as guarantors (the ~~à~~Guarantorsà), the Lenders from time to time party thereto and the Administrative Agent have entered into that certain Financing Agreement, dated as of January 17, 2024 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the ~~à~~Financing Agreementà); WHEREAS, the parties hereto wish to make certain amendments to the Financing Agreement as set forth herein; and WHEREAS, the Administrative Agent and each of the Lenders party hereto (collectively constituting the Required Lenders under the Financing Agreement as of the date hereof) are willing, on the terms and subject to the conditions set forth below, to consent to the amendments to the Financing Agreement set forth herein. NOW, THEREFORE, in consideration of the promises and the mutual agreements contained herein and in the Financing Agreement, the parties hereto agree as follows: Section 1. Definitions. All capitalized terms used but not otherwise defined herein (including, without limitation, in the preamble and recitals hereto) are used as defined in the Financing Agreement. Section 2. Amendments to the Financing Agreement. As of the Second Amendment Effective Date (as defined below): 2.1. the Financing Agreement is hereby amended to delete or move the stricken text (indicated textually in the same manner as the following examples: stricken text or moved text), as applicable and to add or move the double underlined text (indicated textually in the same manner as the following examples: added text or moved text) as set forth in the pages of the Financing Agreement attached as Exhibit A hereto; 2.2. Exhibit B (Form of Compliance Certificate) and Exhibit D (Reserved) to the Financing Agreement are hereby deleted in their entirety and the Exhibits attached as Exhibit B and Exhibit C hereto are substituted therefor, respectively; and 2.3. A new Schedule 1.2 (Designated Assets) and Schedule 1.3 ([***] Subsidiaries), as set forth on Exhibit D and Exhibit E hereto, respectively, shall be added to the Financing Agreement. Section 3. Conditions Precedent. The effectiveness of this Amendment shall be subject to the prior or concurrent satisfaction or waiver of each of the following conditions precedent (the date on which such conditions are satisfied or waived, the ~~à~~Second Amendment Effective Dateà): | À 3.1. The Loan Parties and the Lenders constituting the Required Lenders shall have duly executed and delivered counterparts of this Amendment to the Administrative Agent. 3.2. No event shall have occurred and be continuing or would result from the consummation of the transactions contemplated herein that would constitute an Event of Default or a Default. 3.3. The Loan Parties shall have paid all fees, costs and expenses then due and payable by the Loan Parties pursuant to the Financing Agreement and the other Loan Documents, including, without limitation, Section 10.2 of the Financing Agreement. 3.4. [***]. Section 4. Representations and Warranties. Each Loan Party hereby represents and warrants to the Administrative Agent and the Lenders as follows: 4.1. This Amendment constitutes a legal valid and binding obligation of each Loan Party hereto, enforceable against such Loan Party in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditorsà™ rights generally or by general equitable principles relating to enforceability (whether enforcement is sought by proceedings in equity or at law). 4.2. The representations and warranties contained in the Financing Agreement (as amended hereby) and in each other Loan Document, certificate or other writing delivered to Administrative Agent or any Lender pursuant thereto on or prior to the date hereof are true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified as to ~~à~~materialityà or ~~à~~Material Adverse Effectà in the text thereof, which representations and warranties are true and correct in all respects subject to such qualification) on and as of the date hereof to the same extent as though made on and as of the date hereof, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties are true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified as to ~~à~~materialityà or ~~à~~Material Adverse Effectà in the text thereof, which representations and warranties are true and correct in all respects subject to such qualification) on and as of such earlier date. 4.3. No event has occurred and is continuing or would result from the transactions contemplated by this Amendment that would constitute an Event of Default or a Default. 4.4. None of the [***] Subsidiaries own, control or hold any rights involving, relating to or affecting any Product of BridgeBio and its Subsidiaries other than the Designated Assets. Section 5. Miscellaneous. 5.1. Amendment is a ~~à~~Loan Documentà. This Amendment is a Loan Document and all references to a ~~à~~Loan Documentà in the Financing Agreement and the other Loan Documents shall be deemed to include this Amendment. 5.2. References to the Financing Agreement. Upon the effectiveness of this Amendment, each reference in the Financing Agreement to ~~à~~this Agreement,à ~~à~~hereunder,à ~~à~~hereof,à ~~à~~herein,à or words of like import shall mean and be a reference to the Financing Agreement as amended hereby, and each reference in the other Loan Documents or in any other document, instrument or agreement executed and/or delivered in connection with the Financing Agreement to ~~à~~Financing Agreementà, ~~à~~thereunderà, ~~à~~thereofà 2| À or words of like import referring to the Financing Agreement shall mean and be a reference to the Financing Agreement as amended hereby. 5.3. Reaffirmation of Obligations. Each of the Loan Parties (a) acknowledges and consents to all of the terms and conditions of this Amendment, (b) reaffirms all of its obligations under the Loan Documents to which it is a party and acknowledges and agrees that all of its obligations under the Loan Documents to which it is a party remain in full force and effect on a continuous basis, and (c) agrees that this Amendment and all documents executed in connection herewith do not operate to reduce or discharge any of the Loan Partyà™s obligations under the Loan Documents to which it is a party and do not constitute a novation of such obligations. 5.4. Reaffirmation of Security Interests. Each of the Loan Parties (a) affirms that each of the Liens granted, and each of the guaranties made, in or pursuant to the Loan Documents are valid and subsisting, (b) acknowledges and agrees that the grants of security interests by and the guaranties of the Guarantors contained in the Financing Agreement and the other Loan Documents are, and shall remain, in full force and effect after giving effect to this Amendment, and (c) acknowledges and agrees that this Amendment shall in no manner impair or otherwise adversely affect any of the Liens or security interests granted, or any of the guaranties made, in or pursuant to the Loan Documents. 5.5. No Other Changes. Except as specifically amended by this Amendment, the Financing Agreement, the other Loan Documents and all other documents, instruments and agreements executed and/or delivered in connection therewith shall remain in full force and effect and are hereby ratified and confirmed. 5.6. No Waiver. The execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the Administrative Agent or any Lender under the Financing Agreement or any other document, instrument or agreement executed in connection therewith, nor constitute a waiver of any provision contained therein, except as specifically set forth herein. 5.7. Governing Law. This Amendment AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN THE STATE OF NEW YORK. 5.8. Counterparts. This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Amendment by facsimile or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Amendment. The words ~~à~~execution,à ~~à~~executeà, ~~à~~signed,à ~~à~~signature,à and words of like import in or related to any document to be signed in connection with this Amendment and the other Loan Documents and the transactions contemplated hereby and thereby shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act. For the purposes of this Section 5.8, ~~à~~electronic signatureà shall be construed so as to include the electronic signature of each witness, if any, of an electronic signature used to execute this Amendment. [Signature Pages Follow] 3| À IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the day and year first above written. À BRIDGEBIO PHARMA, INC., as the Borrower À À By:À /s/ Neil Kumar À Name: Neil Kumar À Title: President À À À BRIDGEBIO PHARMA LLC, as a Guarantor SubsidiaryÀ À By:À /s/ Neil KumarName: Neil KumarTitle: President À À BRIDGEBIO SERVICES INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: President À À EIDOS THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: President À À PHOENIX TISSUE REPAIR, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: PresidentÀ À [Signature Page to Second Amendment to Financing Agreement] À À ADRENAS THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: TreasurerÀ À QED THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: PresidentÀ À ORIGIN BIOSCIENCES, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: PresidentÀ À CALCILYTIX THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: President À À ML BIO SOLUTIONS INC., as a Guarantor SubsidiaryÀ À By: /s/ Christine SuiName: Christine SuiTitle: President À À [Signature Page to Second Amendment to Financing Agreement] À À BRIDGEBIO GENE THERAPY LLC, as a Guarantor SubsidiaryÀ À By: /s/ Eric DavidName: Eric DavidTitle: Chief Executive OfficerÀ À BRIDGEBIO CHEMISTRY, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: PresidentÀ À BRIDGEBIO GENE THERAPY RESEARCH, INC., as a Guarantor SubsidiaryÀ À By: /s/ Eric DavidName: Eric DavidTitle: Chief Executive OfficerÀ À CANTERO THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Thomas TrimarchiName: Thomas TrimarchiTitle: PresidentÀ À [Signature Page to Second Amendment to Financing Agreement] À À COA THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Thomas TrimarchiName: Thomas TrimarchiTitle: President À À CYAN THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Thomas TrimarchiName: Thomas TrimarchiTitle: PresidentÀ À DTD THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: PresidentÀ À FERRO THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Thomas TrimarchiName: Thomas TrimarchiTitle: PresidentÀ À G PROTEIN THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: PresidentÀ À [Signature Page to Second Amendment to Financing Agreement] À À MOLECULAR SKIN THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: TreasurerÀ À NAVIRE PHARMA, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: President À À PORTAL THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Thomas TrimarchiName: Thomas TrimarchiTitle: PresidentÀ À SUB21, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: President À À SUB22, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: President À À [Signature Page to Second Amendment to Financing Agreement] À À VENTHERA, INC., as a Guarantor SubsidiaryÀ À By: /s/ Thomas TrimarchiName: Thomas TrimarchiTitle: President À À EULAMIN THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: President À À SEN THERAPEUTICS, INC., as a Guarantor SubsidiaryÀ À By: /s/ Neil KumarName: Neil KumarTitle: PresidentÀ À BB SQUARE CAPITAL, LLC, as a Guarantor SubsidiaryÀ À By: /s/ Nikhilesh ChandName: Nikhilesh ChandTitle: Chief Executive OfficerÀ À BB SQUARE INVESTORS GP I, LLC, as a Guarantor SubsidiaryÀ À By: /s/ Nikhilesh ChandName: Nikhilesh ChandTitle: Chief Executive OfficerÀ À [Signature Page to Second Amendment to Financing Agreement] À À BB SQUARE LP INVESTMENT, LLC, as a Guarantor SubsidiaryÀ À By: /s/ Nikhilesh ChandName: Nikhilesh ChandTitle: Chief Executive OfficerÀ À BB SQUARE CAPITAL INVESTORS I LP, as a Guarantor SubsidiaryBy: BB Square Investors GP I, LLCÀ À By: /s/ Nikhilesh ChandName: Nikhilesh ChandTitle: Chief Executive OfficerÀ À BB SQUARE HOLDINGS, LLC, as a Guarantor SubsidiaryÀ À By: /s/ Nikhilesh ChandName: Nikhilesh ChandTitle: Chief Executive OfficerÀ À BRIDGEBIO INTERNATIONAL GMBH, as a Guarantor SubsidiaryÀ À By: /s/ Giuseppe CodonesuName: Giuseppe CodonesuTitle: Manager & Authorized SignatoryÀ À BRIDGEBIO EUROPE B.V., as a Guarantor SubsidiaryÀ À By: /s/ Giuseppe CodonesuName: Giuseppe CodonesuTitle: Authorised SignatoryÀ À [Signature Page to Second Amendment to Financing Agreement] À À À BLUE OWL CAPITAL CORPORATION, as Administrative Agent À By: Blue Owl Credit Advisors LLC, its Investment AdvisorÀ À By: /s/ Meenal Mehta À Name: Meenal Mehta À Title: Authorized Signatory À À [Signature Page to Second Amendment to Financing Agreement] À À BLUE OWL CAPITAL CORPORATION À as a LenderÀ By: Blue Owl Credit Advisors LLC, its Investment Advisor À À By: /s/ Meenal Mehta À Name: Meenal Mehta À Title: Authorized Signatory À À À BLUE OWL CAPITAL CORPORATION II À as a LenderÀ By: Blue Owl Credit Advisors LLC, its Investment Advisor À À By: /s/ Meenal Mehta À Name: Meenal Mehta À Title: Authorized Signatory À À À BLUE OWL CAPITAL CORPORATION III À as a LenderÀ By: Blue Owl Diversified Credit Advisors LLC, its Investment Advisor À À By: /s/ Meenal Mehta À Name: Meenal Mehta À Title: Authorized Signatory À À À BLUE OWL CREDIT INCOME CORP. À as a LenderÀ By: Blue Owl Credit Advisors LLC, its Investment Advisor À À By: /s/ Meenal Mehta À Name: Meenal Mehta À Title: Authorized Signatory À À [Signature Page to Second Amendment to Financing Agreement] À À À BLUE OWL TECHNOLOGY FINANCE CORP. À as a LenderÀ By: Blue Owl Technology Credit Advisors LLC, its Investment Advisor À À By: /s/ Meenal Mehta À Name: Meenal Mehta À Title: Authorized Signatory À À À BLUE OWL TECHNOLOGY FINANCE CORP. II À as a LenderÀ By: Blue Owl Technology Credit Advisors II LLC, its Investment Advisor À À By: /s/ Meenal Mehta À Name: Meenal Mehta À Title: Authorized Signatory À À À BLUE OWL TECHNOLOGY FINANCE CORP. À as a LenderÀ By: Blue Owl Technology Credit Advisors II LLC, its Investment Advisor À À By: /s/ Meenal Mehta À Name: Meenal Mehta À Title: Authorized Signatory À À [Signature Page to Second Amendment to Financing Agreement] À À CPPIB CREDIT INVESTMENTS III INC. À as a LenderÀ À À By: /s/ David Colla À Name: David Colla À Title: Authorized Signatory À À À By: /s/ David Melkuev À Name: David Melkuev À Title: Authorized Signatory À [Signature Page to Second Amendment to Financing Agreement] Execution VersionÀ EXHIBIT A CONFORMED FINANCING AGREEMENT (see attached) | Execution VersionÀ À À À FINANCING AGREEMENT dated as of January 17, 2024, as amended by the First Amendment to Financing Agreement dated as of February 12, 2024 and the Second Amendment to Financing Agreement dated as of June 20, 2024 among BRIDGEBIO PHARMA, INC., as the Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER FROM TIME TO TIME PARTY HERETO, as Guarantors, VARIOUS LENDERS FROM TIME TO TIME PARTY HERETO, AND BLUE OWL CAPITAL CORPORATIONAs Administrative Agent | À TABLE OF CONTENTS Page Article IÀ DEFINITIONS AND INTERPRETATION 6 Section 1.1 Definitions 6 Section 1.2 Accounting and Other Terms 67 Section 1.3 Interpretation, Etc. 58 Section 1.4 Time References 59 Section 1.5 Certain Matters of Construction 59 Section 1.6 Dutch Terms 59 Article IIÀ LOANS 61 Section 2.1 Term Loans 61 Section 2.2 Use of Proceeds 62 Section 2.3 Evidence of Debt; Register; Lendersà™ Books and Records; Notes 62 Section 2.4 Interest 63 Section 2.5 Conversion/Continuation 65 Section 2.6 Default Interest 65 Section 2.7 Fees 65 Section 2.8 Repayment of Term Loans 65 Section 2.9 Voluntary Prepayments 66 Section 2.10 Mandatory Prepayments 67 Section 2.11 Application of Prepayments 69 Section 2.12 General Provisions Regarding Payments 70 Section 2.13 Ratable Sharing 72 Section 2.14 Increased Costs; Capital Adequacy 72 Section 2.15 Taxes; Withholding, Etc 73 Section 2.16 Obligation to Mitigate 77 Section 2.17 Defaulting Lenders 77 Section 2.18 Removal or Replacement of a Lender 78 Section 2.19 Making or Maintaining SOFR Loans 78 Section 2.20 Benchmark Replacement Setting 80 Section 2.21 Incremental Term Loans 81 Article IIIÀ CONDITIONS PRECEDENT 82 Section 3.1 Closing Date 82 Section 3.2 Conditions to Each Subsequent Credit Extension 85 Article IVÀ REPRESENTATIONS AND WARRANTIES 86 Section 4.1 Organization; Requisite Power and Authority; Qualification 86 Section 4.2 Capital Stock and Ownership 86 Section 4.3 Due Authorization 87 Section 4.4 No Conflict 87 Section 4.5 Governmental Consents 87 Section 4.6 Binding Obligation 87 Section 4.7 Historical Financial Statements 87 Section 4.8 Initial Projections 88 Section 4.9 No Material Adverse Effect 88 Section 4.10 Adverse Proceedings, Etc 88 À -iÀ - À À Section 4.11 Payment of Taxes 88 Section 4.12 Properties, Title 88 Section 4.13 Environmental Matters 89 Section 4.14 No Defaults 89 Section 4.15 Material Contracts 89 Section 4.16 Governmental Regulation 89 Section 4.17 Margin Stock 90 Section 4.18 Employee Benefit Plans 90 Section 4.19 Certain Fees 90 Section 4.20 Solvency 90 Section 4.21 ERISA 90 Section 4.22 Compliance with Statutes, Etc 90 Section 4.23 Intellectual Property 90 Section 4.24 Insurance 92 Section 4.25 Common Enterprise 92 Section 4.26 Permits, Etc 93 Section 4.27 Bank Accounts and Securities Accounts 93 Section 4.28 Security Interests 93 Section 4.29 PATRIOT ACT and FCPA 93 Section 4.30 Reserved 94 Section 4.31 Disclosure 94 Section 4.32 Use of Proceeds 94 Section 4.33 Regulatory Compliance 94 Section 4.34 Government Contracts 95 Section 4.35 Healthcare Regulatory Laws. 96 Section 4.36 Data Protection 96 Section 4.37 Centre of Main Interests 97 Article VÀ AFFIRMATIVE COVENANTS 97 Section 5.1 Financial Statements and Other Reports 97 Section 5.2 Existence 103 Section 5.3 Payment of Taxes and Claims 103 Section 5.4 Maintenance of Properties 103 Section 5.5 Insurance 103 Section 5.6 Books and Records; Inspections 104 Section 5.7 Lenders Meetings and Conference Calls 104 Section 5.8 Compliance with Laws 105 Section 5.9 Environmental 105 Section 5.10 Subsidiaries 105 Section 5.11 Real Estate Assets 106 Section 5.12 Further Assurances 106 Section 5.13 Control Agreements, Blocked Accounts, Etc 107 Section 5.14 DAC6. 107 Section 5.15 Post-Closing Matters 108 Article VIÀ NEGATIVE COVENANTS 108 Section 6.1 Indebtedness 108 Section 6.2 Liens 108 Section 6.3 Material Contracts 108 Section 6.4 No Further Negative Pledges 108 Section 6.5 Restricted Junior Payments 109 À -iÀ - À | À Section 6.6 Restrictions on Subsidiary Distributions 110 Section 6.7 Investments 110 Section 6.8 Minimum Qualified Cash 111 Section 6.9 Fundamental Changes; Disposition of Assets 111 Section 6.10 Disposal of Subsidiary Interests 113 Section 6.11 Sales and Lease Backs 113 Section 6.12 Transactions with Shareholders and Affiliates 113 Section 6.13 Conduct of Business 114 Section 6.14 Changes to Organizational Documents 114 Section 6.15 Accounting Methods 114

Section 6.16 Deposit Accounts and Securities Accounts 114 Section 6.17 Prepayments of Certain Indebtedness 116 Section 6.18 Anti-Terrorism Laws 116 Section 6.19 Anti-Corruption Laws 116 Section 6.20 Use of Proceeds 115 Article VIIA GUARANTY 116 Section 7.1 Guaranty of the Obligations 116 Section 7.2 Contribution by Guarantors 116 Section 7.3 Payment by Guarantors 116 Section 7.4 Liability of Guarantors Absolute 117 Section 7.5 Waivers by Guarantors 118 Section 7.6 Guarantors' Rights of Subrogation, Contribution, Etc. 119 Section 7.7 Subordination of Other Obligations 119 Section 7.8 Continuing Guaranty 120 Section 7.9 Authority of Guarantors or Borrower 120 Section 7.10 Financial Condition of Borrower 120 Section 7.11 Bankruptcy, Etc. 120 Section 7.12 Discharge of Guaranty Upon Sale of Guarantor 121 Section 7.13 Swiss Guaranty Limitations 121 Article VIIIA EVENTS OF DEFAULT 124 Section 8.1 Events of Default 124 Section 8.2 Remedies 127 Section 8.3 Rights Not Exclusive 127 Article IXA ADMINISTRATIVE AGENT 127 Section 9.1 Appointment of Administrative Agent 127 Section 9.2 Powers and Duties 129 Section 9.3 General Immunity 129 Section 9.4 Administrative Agent Entitled to Act as Lender 130 Section 9.5 Lenders' Representations, Warranties and Acknowledgment 130 Section 9.6 Right to Indemnity 131 Section 9.7 Successor Administrative Agent 131 Section 9.8 Collateral Documents and Guaranty 133 Section 9.9 Agency for Perfection 133 Section 9.10 Reports and Other Information; Confidentiality; Disclaimers 133 Section 9.11 Protective Advances 134 Section 9.12 Erroneous Payments 135 Section 9.13 Parallel Liability 137 A - iiiA - A | A Article XA MISCELLANEOUS 137 Section 10.1 Notices 137 Section 10.2 Expenses 138 Section 10.3 Indemnity 139 Section 10.4 Set-Off 139 Section 10.5 Amendments and Waivers 140 Section 10.6 Successors and Assigns; Participations 141 Section 10.7 Independence of Covenants 144 Section 10.8 Survival of Representations, Warranties and Agreements 144 Section 10.9 No Waiver; Remedies Cumulative 144 Section 10.10 Marshalling; Payments Set Aside 144 Section 10.11 Severability 145 Section 10.12 Obligations Several; Independent Nature of Lenders' Rights 145 Section 10.13 Headings 145 Section 10.14 APPLICABLE LAW 145 Section 10.15 CONSENT TO JURISDICTION 145 Section 10.16 WAIVER OF JURY TRIAL 146 Section 10.17 Confidentiality 146 Section 10.18 Usury Savings Clause 147 Section 10.19 Counterparts 148 Section 10.20 Effectiveness 148 Section 10.21 PATRIOT Act Notice 148 Section 10.22 Service of Process 148 Section 10.23 Waiver of Immunity 148 Section 10.24 Acknowledgment and Consent to Bail-In of Affected Financial Institutions 149 Section 10.25 Representation of Dutch Guarantors 149 Section 10.26 Intercreditor Agreements 149 A - A - ivA - A | A APPENDICES: A Initial Term Loan Commitments A B Notice Addresses A A A A A SCHEDULES: 1.1 Immaterial Subsidiaries A 1.2 Designated Assets A 1.3 [***] Subsidiaries A 4.1 Jurisdictions of Organization and Qualification A 4.2 Capital Stock and Ownership A 4.12 Real Property A 4.15 Material Contracts A 4.23 Intellectual Property A 4.24 Insurance A 4.27 Bank Accounts and Securities Accounts A 4.34 Government Contracts A 5.15 Certain Post Closing Matters A 6.1 Certain Indebtedness A 6.2 Certain Liens A 6.7 Certain Investments A 6.12 Certain Affiliate Transactions A A A A A EXHIBITS: A-1 Funding Notice A-2 Conversion/Continuation Notice A B Compliance Certificate A C Assignment Agreement A D [***] Request A E Closing Date Certificate A F Solvency Certificate A G Counterpart Agreement A | A FINANCING AGREEMENT This FINANCING AGREEMENT, dated as of January 17, 2024, is entered into by and among BRIDGE BIO PHARMA, INC., a Delaware corporation (the "Borrower"), certain Subsidiaries of the Borrower from time to time party hereto, as Guarantors, the Lenders from time to time party hereto, and Blue Owl Capital Corporation (the "Blue Owl"), as administrative agent for the Lenders (in such capacity, the "Administrative Agent"). W I T N E S S E T H WHEREAS, capitalized terms used in these Recitals shall have the respective meanings set forth for such terms in Section 1.1 hereof; WHEREAS, on the Closing Date the Lenders have agreed to extend a term loan facility to the Borrower in an aggregate principal amount equal to \$450,000,000, the proceeds of which will be used as described in Section 2.2; WHEREAS, the Borrower has agreed to secure all of its Obligations by granting to Administrative Agent, for the benefit of Secured Parties, a First Priority Lien on all of its assets (except as otherwise set forth in the Collateral Documents), including a pledge or mortgage (as applicable) of all of the Capital Stock of each of its Subsidiaries (except as otherwise set forth in the Collateral Documents); and WHEREAS, the Guarantors have agreed to guarantee the Obligations of Borrower hereunder and to secure their respective Obligations by granting to Administrative Agent, for the benefit of Secured Parties, a First Priority Lien on all of their respective assets (except as otherwise set forth in the Collateral Documents), including a pledge or mortgage (as applicable) of all of the Capital Stock of each of their respective Subsidiaries (except as otherwise set forth in the Collateral Documents). NOW, THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained, the parties hereto agree as follows: Article I DEFINITIONS AND INTERPRETATION Section 1.1 Definitions. The following terms used herein, including in the preamble, recitals, exhibits and schedules hereto, shall have the following meanings: "2027 Notes" means the 2.50% Convertible Senior Notes due 2027 issued by the Borrower under the 2027 Notes Indenture. "2027 Notes Indenture" means that certain Indenture, dated as of March 9, 2020, by and between the Borrower and U.S. Bank National Association, as trustee, as amended, restated, supplemented or otherwise modified and in effect on the Closing Date and as further amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms hereof. "2029 Notes" means the 2.25% Convertible Senior Notes due 2029 issued by the Borrower under the 2029 Notes Indenture. "2029 Notes Indenture" means that certain Indenture, dated as of January 28, 2021, by and between the Borrower and U.S. Bank National Association, as trustee, as amended, restated, supplemented or A | A otherwise modified and in effect on the Closing Date and as further amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms hereof. "Acceptable Intercreditor Agreement" means, with respect to any applicable Permitted Royalty Monetization Transaction, an intercreditor agreement (a) substantially consistent with the Acoramidis Intercreditor Agreement or (b) if not substantially consistent with the Acoramidis Intercreditor Agreement, either (x) having terms not materially less favorable to the Administrative Agent and the Lenders (taken as a whole) than those set forth in the Acoramidis Intercreditor Agreement or (y) that is otherwise reasonably acceptable to the Administrative Agent (such approval not to be unreasonably withheld, delayed or conditioned). "Account Charge" means, with respect to any Cash and Cash Equivalents of a Loan Party maintained in a jurisdiction other than the United States, an agreement executed and delivered by the applicable Loan Party and Administrative Agent (or the Intercreditor Agent (Swiss), as applicable) that creates in favor of the Administrative Agent (or the Intercreditor Agent (Swiss), as applicable) for the benefit of the Secured Parties, a valid, perfected First Priority security interest (subject to any exceptions permitted in the Collateral Documents) in such Cash and Cash Equivalents. "Acoramidis" means any product that contains the pharmaceutical compound known by the name acoramidis (and any salt, free acid/base, solvate, hydrate, stereoisomer, crystalline or polymorphic form, prodrug, conjugate or complex of acoramidis) in all forms, presentations, doses and formulations (including any improvements and modifications to, metabolites or analogs of or any derivatives therefrom), whether used as a single agent or in combination with other therapeutically active agents. "Acoramidis Intercreditor Agreement" means that certain Intercreditor Agreement, dated as of the date hereof, by between the Administrative Agent and the Acoramidis Revenue Transaction Agent, as collateral agent for the Acoramidis Purchasers, and acknowledged and agreed to by the Loan Parties, as amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with its terms. "Acoramidis Revenue Transaction" means the Royalty Monetization Transaction contemplated under the Acoramidis Revenue Transaction Documents. "Acoramidis Revenue Transaction Agent" means Alter Domus (US) LLC and any successor or assigns acting as collateral agent for the Acoramidis Purchasers. "Acoramidis Revenue Transaction Agreement" means that certain Funding Agreement, dated as of the date hereof, by and among, (i) each of Borrower, Eidos Therapeutics, Inc., a Delaware corporation, BridgeBio International GmbH, a Swiss limited liability company, and BridgeBio Euro B.V., a private company with limited liability incorporated under Dutch law registered with the Dutch trade register under number 82337527, as seller parties, (ii) each of LSI Financing 1 Designation Activity Company, a designated activity company limited by shares duly incorporated under the laws of Ireland and CPPIB CREDIT EUROPE S.A. R.L., a private limited liability company (société à responsabilité limitée) incorporated and organized under the laws of the Grand Duchy of Luxembourg, as purchasers (collectively, the "Acoramidis Purchasers"), and (iii) the Acoramidis Revenue Transaction Agent, as collateral agent for the Acoramidis Purchasers. "Acoramidis Revenue Transaction Documents" means, collectively, the Acoramidis Revenue Transaction Agreement, the Acoramidis Intercreditor Agreement and the other Transaction Documents (as defined in the Acoramidis Revenue Transaction Documents). A - 7A - A | A "Additional Equity Proceeds" means the Net Proceeds of any sale, after the Closing Date, of Qualified Capital Stock of Borrower. "Adjusted EBITDA" shall mean, for any period, Net Income for such period: (a) increased, without duplication, by the following, in each case, to the extent (and in the same proportion) deducted (and not added back or excluded) in determining Net Income for such period: (i) consolidated interest expense of the Borrower and its Subsidiaries for such period, determined on a consolidated basis in accordance with GAAP, with respect to all outstanding Indebtedness of the Borrower and its Subsidiaries; (ii) all amounts attributable to depreciation and amortization for such period; (iii) consolidated income tax expense for such period; (iv) any non-cash charges or adjustments, including any equity-based or non-cash compensation charges or expenses, including any such charges or expenses arising from grants of stock appreciation or similar rights, stock options, restricted stock or other rights, retention charges (including charges or expenses in respect of incentive plans) and any write-offs or write-downs reducing Net Income for such period (provided that if any such non-cash charges represent an accrual or reserve for potential cash items in any future period, (A) the Borrower may elect not to add back such non-cash charge in the current period and (B) to the extent the Borrower elects to add back such non-cash charge, the cash payment in respect thereof in such future period shall be subtracted from Adjusted EBITDA to such extent), and excluding amortization of a prepaid cash item that was paid in a prior period; and (v) the amount of restructuring charges or any reasonable and documented out-of-pocket costs, fees or expenses incurred in connection with any Permitted Acquisitions or other similar Permitted Investment, any permitted issuance of Capital Stock or Indebtedness or any permitted Asset Sale during such period; provided, that, the aggregate amount of costs, fees, expenses, and charges added back to Adjusted EBITDA pursuant to this clause (a)(v) for any consecutive four fiscal quarter period shall not exceed the greater of: (x) \$[***] and [***]% of Adjusted EBITDA (calculated prior to giving effect to this clause (a)(v)); and (b) decreased, without duplication, and to the extent included in arriving at such Net Income: (i) interest income for such period; (ii) income tax credits and refunds for such period; (iii) non-cash gains or adjustments (excluding any non-cash gain to the extent it represents the reversal of an accrual or reserve for a potential cash item that reduced Adjusted EBITDA in any prior period) and all other non-cash items of income for such period; and (iv) all cash payments made during such period on account of accruals, reserves and other non-cash charges added to Net Income in a previous period pursuant to clause (a)(iv) above. "Administrative Agent" has the meaning specified in the preamble hereto. A - 8A - A | A "Administrative Agent's Account" means an account at a bank designated by Administrative Agent from time to time as the account into which the Loan Parties shall make all payments to Administrative Agent under this Agreement and the other Loan Documents. "Adverse Proceeding" means any action, suit, proceeding (whether administrative, judicial or otherwise), governmental investigation or arbitration (whether or not purportedly on behalf of the Borrower or any of its Subsidiaries) at law or in equity, or before or by any Governmental Authority, domestic or foreign (including any Environmental Claims) or other regulatory body or any mediator or arbitrator, whether pending or, to the knowledge of the Borrower or any of its Subsidiaries, threatened in writing against the Borrower or any of its Subsidiaries or any property of the Borrower or any of its Subsidiaries. "Affected Financial Institution" means (a) any EEA Financial Institution or (b) any UK Financial Institution. "Affected Lender" has the meaning specified in Section 2.19(a). "Affected Loans" has the meaning specified in Section 2.19(a). "Affected Product" has the meaning specified in Section 8.1(o). "Affiliate" means, as applied to any Person, any other Person directly or indirectly controlling (including any member of the senior management group of such Person), controlled by, or under common control with, that Person. For the purposes of this definition, "control" (including, with correlative meanings, the terms "controlling," "controlled by" and "under common control with"), as applied to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of that Person, whether through the ownership of voting securities or Capital Stock, by contract or otherwise. Notwithstanding anything herein to the contrary, in no event shall Administrative Agent or any Lender or any of their Affiliates or Related Funds be considered an "Affiliate" of any Loan Party. Any reference to an Affiliate of Blue Owl (or its Affiliates) shall include any Person that is controlled or managed by Blue Owl, or where Blue Owl has a direct or indirect majority economic interest therein. "Aged Payables Amount" means, as of any date of determination, the aggregate amount of the Loan Parties' total accounts payable (under GAAP) that, as of such date, has not been paid by the 120th day after the due date associated with such accounts. "Aggregate Amounts Due" has the meaning specified in Section 2.13. "Aggregate Payments" has the meaning specified in Section 7.2. "Agreement" means this Financing Agreement and any annexes, exhibits and schedules attached hereto. "Anti-Corruption Laws" means all Requirements of Law concerning or relating to bribery or corruption, including, without limitation, the United States Foreign Corrupt Practices Act of 1977, and the anti-bribery and anti-corruption laws and regulations of those jurisdictions in which the Loan Parties do business. "Anti-Terrorism Laws" means any Requirement of Law relating to terrorism or money laundering, including, without limitation, (a) the Money Laundering Control Act of 1986 (i.e., 18 U.S.C. §§ 1956 and 1957), (b) the Currency and Foreign Transactions Reporting Act (31 U.S.C. §§ 5311-5330 and 12 U.S.C. A - 9

management with respect to any Intellectual Property Rights and (y) any Royalty Monetization Transaction shall be deemed to be an Asset Sale; (vi) the non-exclusive lease, assignment or sublease of any real or personal property (other than any Intellectual Property Rights or any property pursuant to a Royalty Monetization Transaction) in the ordinary course of business which do not materially interfere with the ordinary conduct of the business of the Borrower or any of its Subsidiaries and which are otherwise permitted under this Agreement; and (vii) the discontinuation of development or abandonment of any Product (other than any Specified Product) that, in the reasonable good faith judgment of the Borrower, is no longer commercially desirable or economically practical. **Assignment Agreement** means an Assignment and Assumption Agreement substantially in the form of Exhibit C, with such amendments or modifications as may be approved by Administrative Agent. **Authorized Officer** means, as applied to any Person, any individual holding the position of chairman of the board (if an officer), (managing) director, chief executive officer, president or one of its vice presidents (or the equivalent thereof), and such Person's chief financial officer or treasurer. **Available Investment Amount** means, as of any date of determination, an amount equal to the sum of: (a) \$[***], plus (b) an amount equal to the greater of (x) [***] of Adjusted EBITDA for the most recently ended Measurement Period and (y) \$[***], plus (c) the amount of Additional Equity Proceeds which, as of such date: (i) are not held in a Blocked Account for purposes of complying with the Net Outstanding Amount requirements in the definition of Term Loan Maturity Date and (ii) have not otherwise been applied, including, without limitation, in connection with any Investment permitted under clause (s) of the definition of Permitted Investment or an investment under clause (d) of the definition of Permitted Intercompany Investments, minus (d) the aggregate amount of Investments, Restricted Junior Payments and prepayments of Indebtedness previously made using the Available Investment Amount. **Available Tenor** means, as of any date of determination and with respect to the then-current Benchmark, as applicable, if such Benchmark is a term rate, any tenor for such Benchmark (or component thereof) that is or may be used for determining the length of an interest period pursuant to this Agreement as of such date. **Bail-In Action** means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution. **Bail-In Legislation** means (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings). **Bank Secrecy Act** has the meaning specified in the definition of Anti-Terrorism Laws. **Bankruptcy Code** means Title 11 of the United States Code entitled **Bankruptcy**, as now and hereafter in effect, or any successor statute. **Base Rate** means, for any day, a rate per annum equal to the greatest of (a) the Prime Rate in effect on such day, (b) the Federal Funds Effective Rate in effect on such day plus 1/2 of 1%, (c) Term SOFR (which rate shall be calculated based upon an Interest Period of three months and to be determined on a daily basis) plus 1.00%, and (d) 2.00% per annum. Any change in the Prime Rate, the Federal Funds Effective Rate or Term SOFR shall be effective on the effective day of such change in the Prime Rate, the Federal Funds Effective Rate or Term SOFR, respectively. **Base Rate Loan** means a Loan bearing interest at a rate determined by reference to the Base Rate. **Base Rate Term SOFR Determination Day** has the meaning specified in the definition of **Term SOFR**. **Benchmark** means, initially, Term SOFR; provided that if a Benchmark Transition Event has occurred with respect to Term SOFR or the then-current Benchmark, then **Benchmark** means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to Section 2.20(a). **Benchmark Replacement** means, with respect to any Benchmark Transition Event, the sum of: (a) the alternate benchmark rate that has been selected by the Administrative Agent and the Borrower giving due consideration to (i) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement to the then-current Benchmark for Dollar-denominated syndicated credit facilities at such time and (b) the related Benchmark Replacement Adjustment; provided that, if such Benchmark Replacement as so determined would be less than the Floor, such Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents. **Benchmark Replacement Adjustment** means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement, the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by the Administrative Agent and the Borrower giving due consideration to (a) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (b) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for Dollar-denominated syndicated credit facilities at such time. **Benchmark Replacement Date** means the earliest to occur of the following events with respect to the then-current Benchmark: (a) in the case of clause (a) or (b) of the definition of **Benchmark Transition Event**, the later of (i) the date of the public statement or publication of information referenced therein and (ii) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof); or (b) in the case of clause (c) of the definition of **Benchmark Transition Event**, the first date on which all Available Tenors of such Benchmark (or the published component used in the calculation thereof) has been or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof) have been determined and announced by the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be non-representative; provided that such non-representativeness will be determined by reference to the most recent statement or publication referenced in such clause (c) and even if such Benchmark (or such component thereof) or, if such Benchmark is a term rate, any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date. **BSA** For the avoidance of doubt, if such Benchmark is a term rate, the **Benchmark Replacement Date** will be deemed to have occurred in the case of clause (a) or (b) with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof). **Benchmark Transition Event** means the occurrence of one or more of the following events with respect to the then-current Benchmark: (a) a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, any Available Tenor of such Benchmark (or such component thereof); (b) a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New York, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, any Available Tenor of such Benchmark (or such component thereof); or (c) a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative. For the avoidance of doubt, if such Benchmark is a term rate, a **Benchmark Transition Event** will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof). **Benchmark Transition Start Date** means, in the case of a Benchmark Transition Event, the earlier of (a) the applicable Benchmark Replacement Date and (b) if such Benchmark Transition Event is a public statement or publication of information of a prospective event, the 90th day prior to the expected date of such event as of such public statement or publication of information (or if the expected date of such prospective event is fewer than 90 days after such statement or publication, the date of such statement or publication). **Benchmark Unavailability Period** means the period (if any) (a) beginning at the time that a Benchmark Replacement Date has occurred if, at such time, no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with **Section 2.19** and (b) ending at the time that a Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with **Section 2.19**. **Beneficiary** means Administrative Agent and each Lender. **Benefit Plan** means any of (a) an employee benefit plan (as defined in Section 3(3) of ERISA) that is subject to Title I of ERISA, (b) a plan as defined in Section 4975 of the Internal Revenue Code to which Section 4975 of the Internal Revenue Code applies, and (c) any Person whose assets include (for purposes of the Plan Asset Regulations or otherwise for purposes of Title I of ERISA or Section 4975 of the Internal Revenue Code) the assets of any such employee benefit plan or **benefit plan**. **Blocked Account** means a Deposit Account subject to Control Agreement pursuant to which, among other things, Administrative Agent has sole dominion and control (within the meaning of Section 9-104 of the UCC) over such Deposit Account. **Blocked Person** means any Person: (a) that is publicly identified (i) on the most current list of **Specially Designated Nationals and Blocked Persons** published by OFAC or resides, is organized or chartered, or has a place of business in a country or territory subject to OFAC sanctions or embargo program or (ii) as prohibited from doing business with the United States under the International Emergency Economic Powers Act, the Trading With the Enemy Act, or any other Anti-Terrorism Law; (b) that is owned or controlled by, or that owns or controls, or that is acting for or on behalf of, any Person described in clause (a) above; (c) which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law; and (d) that is affiliated or associated with a Person described in clauses (a), (b), or (c) above. **Blue Owl** has the meaning specified in the preamble hereto. **Board of Directors** means, (a) with respect to any corporation or company, the board of directors of the corporation, company or any committee thereof duly authorized to act on behalf of such board, (b) with respect to a partnership, the board of directors of the general partner of the partnership, (c) with respect to a limited liability company, the managing member or members or any controlling committee or board of directors of such company or the sole member or the managing member thereof, and (d) with respect to any other Person, the board or committee of such Person serving a similar function. **Borrower** has the meaning specified in the preamble hereto. **Boxed Warning** means labeling requirements, as may be required by the FDA as set forth in 21 C.F.R. **Business Day** means (a) any day excluding Saturday, Sunday and any day which is a legal holiday under the laws of the State of New York or is a day on which banking institutions located in such jurisdiction are authorized or required by law or other governmental action to close, and (b) with respect to all notices, determinations, fundings and payments in connection with Term SOFR or any SOFR Loans, the term **Business Day** shall mean any day which is a Business Day described in clause (a) and which is also a U.S. Government Securities Business Day. **Capital Lease** means, as applied to any Person, and subject to Section 1.2(a), any lease of any property (whether real, personal or mixed) by that Person (a) as lessee that, in conformity with GAAP, is or should be accounted for as a capital lease on the balance sheet of that Person or (b) as lessee which is a transaction of a type commonly known as a **synthetic lease** (i.e., a transaction that is treated as an operating lease for accounting purposes but with respect to which payments of rent are intended to be treated as payments of principal and interest on a loan for income tax purposes). **Capital Stock** means any and all shares, interests, participations or other equivalents (however designated) of capital stock of a company or a corporation, any and all equivalent ownership interests in a Person (other than a corporation), including, without limitation, shares, partnership interests and membership interests, and any and all warrants, rights or options to purchase or other arrangements or rights to acquire any of the foregoing; provided that Capital Stock shall exclude debt securities and other Indebtedness convertible into or exchangeable for any of the foregoing (including without limitation, Permitted Convertible Indebtedness). **Cash** means money, currency or a credit balance in any demand or Deposit Account. **Cash Equivalents** means, as at any date of determination, (a) marketable securities (i) issued or directly and unconditionally guaranteed as to interest and principal by the United States Government, or (ii) issued by any agency of the United States the obligations of which are backed by the full faith and credit of the United States, in each case maturing within one year after such date, (b) marketable direct obligations issued by any state of the United States of America or any political subdivision of any such state or any public instrumentality thereof, in each case maturing within one year after such date and having, at the time of the acquisition thereof, a rating of at least A-1 from S&P or at least P-1 from Moody's, (c) commercial paper maturing no more than one year from the date of creation thereof and having, at the time of the acquisition thereof, a rating of at least A-1 from S&P or at least P-1 from Moody's, (d) certificates of deposit or bankers' acceptances maturing within one year after such date and issued or accepted by any Lender or by any commercial bank organized under the laws of the United States of America or any state thereof or the District of Columbia that (i) is at least **adequately capitalized** (as defined in the regulations of its primary Federal banking regulator), and (ii) has Tier 1 capital (as defined in such regulations) of not less than \$100,000,000, (e) shares of any money market mutual fund that (i) has substantially all of its assets invested continuously in the types of investments referred to in clauses (a) and (b) above, (ii) has net assets of not less than \$500,000,000, and (iii) has the highest rating obtainable from either S&P or Moody's, and (f) other investments made in accordance with Borrower's cash management policy delivered to the Administrative Agent on or prior to the Closing Date (as such policy may be updated from time to time with the consent of the Administrative Agent (such consent not to be unreasonably withheld, delayed or conditioned)). **Request** means a **Request** substantially in the form of Exhibit D. **Change in Law** has the meaning specified in Section 2.14(a). **Change of Control** means, at any time, the occurrence of any of the following events: (a) any Person or **group** (within the meaning of Rules 13d 3 and

from time to time. **Collateral Documents** means a Dutch law governed security agreement over bank accounts, any present or future intellectual property rights, movable assets and receivables (the **Dutch Security Agreement**), a Dutch law deed of pledge of shares over shares, dividends and related assets (the **Dutch Share Pledge**), and all other instruments, documents and agreements governed by the laws of the Netherlands and delivered by any Loan Party pursuant to this Agreement or any of the other Loan Documents in order to grant to Administrative Agent, for the benefit of Secured Parties, a Lien on any real, **A - 17A - A | A** personal or mixed property of such Loan Party as security for the Obligations, in each case, as such Collateral Documents (Dutch) may be amended or otherwise modified from time to time. **Collateral Documents** (Swiss) means (i) the quota pledge agreement by and among BridgeBio Europe B.V., the Intercreditor Agent (Swiss) and the other Secured Parties, (ii) the bank account pledge agreement by and among Swiss Guarantor, Intercreditor Agent (Swiss) and the other Secured Parties (and any related Control Agreement), (iii) the intellectual property rights pledge agreement by and among Swiss Guarantor, Intercreditor Agent (Swiss) and the other Secured Parties, (iv) the receivables security assignment agreement by and among Swiss Guarantor and Intercreditor Agent (Swiss) (acting also for the benefit of the Secured Parties) and (v) all other instruments, documents and agreements governed by the laws of Switzerland and delivered by any Loan Party pursuant to this Agreement or any of the other Loan Documents in order to grant to Intercreditor Agent (Swiss) (or the Administrative Agent, as applicable), for the benefit of Secured Parties (and/or, if so required by Swiss law, to the Secured Parties directly) a Lien on any real, personal or mixed property, other than movable assets (Fahrnis), of such Loan Party as security for the Obligations, in each case, as such Collateral Documents (Swiss) may be amended or otherwise modified from time to time. **Commercialize** means to market, offer for sale, distribute, sell, import, export or otherwise commercialize a Product. **Common Stock** means the Borrower's common stock. **Compliance Certificate** means a Compliance Certificate substantially in the form of Exhibit B. **Conforming Changes** means, with respect to either the use or administration of Term SOFR or the use, administration, adoption or implementation of any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of **Base Rate**, the definition of **Business Day**, the definition of **U.S. Government Securities Business Day**, the definition of **Interest Period** or any similar or analogous definition (or the addition of a concept of **interest period**), timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, the applicability and length of lookback periods, the applicability of breakage and other technical, administrative or operational matters) that the Administrative Agent, in consultation with the Borrower, decides may be appropriate to reflect the adoption and implementation of any such rate or to permit the use and administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Administrative Agent determines that no market practice for the administration of any such rate exists, in such other manner of administration as the Administrative Agent, in consultation with the Borrower, decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents). **Connection Income Taxes** means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes. **Contractual Obligation** means, as applied to any Person, any provision of any security issued by that Person or of any indenture, mortgage, deed of trust, contract (including, but not limited to, any Material Contract), undertaking, agreement, license or other instrument to which that Person is a party or by which it or any of its properties is bound or to which it or any of its properties is subject. **Control Agreement** means a control agreement, in form and substance reasonably satisfactory to Administrative Agent (or the Intercreditor Agent (Swiss) as applicable), executed and delivered by the applicable Loan Party, Administrative Agent (or the Intercreditor Agent (Swiss) as applicable), and the **A - 18A - A | A** applicable securities intermediary (with respect to a Securities Account) or bank (with respect to a Deposit Account). **Conversion/Continuation Date** means the effective date of a continuation or conversion, as the case may be, as set forth in the applicable Conversion/Continuation Notice. **Conversion/Continuation Notice** means a Conversion/Continuation Notice substantially in the form of Exhibit A-2. **Core Product** means, for purposes of Section 8.01(o), **[***]**. **Counterparty Agreement** means a Counterparty Agreement substantially in the form of Exhibit G delivered by a Loan Party pursuant to Section 5.10. **CPPIB** means CPPIB Credit Investments Inc., together with its Affiliates and Related Funds. **Credit Date** means the date of a Credit Extension. **Credit Extension** means the making of a Loan. **Cross-Default Reference Obligation** has the meaning assigned to such term in the definition of Permitted Convertible Indebtedness. **Currency Agreement** means any foreign exchange contract, currency swap agreement, futures contract, option contract, synthetic or other similar agreement or arrangement, each of which is for the purpose of hedging the foreign currency risk associated with the Borrower and its Subsidiaries' operations and not for speculative purposes. **Data Protection Laws** means applicable Requirements of Law concerning the protection, privacy or security of Personal Information (including any applicable laws of jurisdictions where the Personal Information was collected or otherwise processed) and other applicable consumer protection laws, and all regulations promulgated thereunder, including but not limited to, and to the extent applicable, HIPAA, the EU and UK General Data Protection Regulation (and all laws implementing or supplementing it), the California Consumer Privacy Act (as amended), and Section 5 of the Federal Trade Commission Act. **DCC** means the Dutch Civil Code (Burgerlijk Wetboek). **Debtor Relief Law** means the Bankruptcy Code and any other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief law of the United States, the Netherlands, Switzerland or other applicable jurisdiction from time to time in effect. **Default** means a condition or event that, after notice or lapse of time or both, would constitute an Event of Default. **Default Excess** means, with respect to any Defaulting Lender, the excess, if any, of such Defaulting Lender's Pro Rata Share of the aggregate outstanding principal amount of Term Loans of all Lenders (calculated as if all Defaulting Lenders (other than such Defaulting Lender) had funded all of their respective Defaulted Loans) over the aggregate outstanding principal amount of all Term Loans of such Defaulting Lender. **A - 19A - A | A** **Default Period** means, with respect to any Defaulting Lender, the period commencing on the date of the applicable Funding Default, as applicable, and ending on the earliest of the following dates: (a) the date on which all Term Loan Commitments are cancelled or terminated and/or the Obligations are declared or become immediately due and payable, (b) the date on which (i) the Default Excess with respect to such Defaulting Lender shall have been reduced to zero (whether by the funding by such Defaulting Lender of any Defaulted Loans of such Defaulting Lender or by the non pro rata application of any voluntary or mandatory prepayments of the Loans in accordance with the terms of Section 2.9 or Section 2.10 or by a combination thereof), and (ii) such Defaulting Lender shall have delivered to Borrower and Administrative Agent a written reaffirmation of its intention to honor its obligations hereunder with respect to its Term Loan Commitments and (c) the date on which Borrower, Administrative Agent and Required Lenders waive all Funding Defaults of such Defaulting Lender in writing. **Default Rate** means any interest payable pursuant to Section 2.6. **Defaulted Loan** has the meaning specified in Section 2.17. **Defaulting Lender** has the meaning specified in Section 2.17. **Deposit Account** means a demand, time, savings, passbook or like account with a bank, savings and loan association, credit union or like organization, other than an account evidenced by a negotiable certificate of deposit. **Designated Securities Account** means the Initial Designated Securities Account or the Replacement Designated Securities Account, as applicable. **Designated Assets** means, collectively, (a) each of the investigational small molecules set forth on Schedule 1.2 hereof; (b) all Product Intellectual Property Rights and all regulatory materials with respect to the foregoing clause (a) and (c) all other tangible and intangible assets necessary for, or material to, the exploitation of the foregoing clause (a), and **Designated Asset** means any asset identified in the foregoing clause (a), clause (b) or clause (c); provided, that, Designated Assets (and Designated Asset) shall not include (i) any Product Intellectual Property Rights relating to any other Product of the Borrower and its Subsidiaries or (ii) any other tangible or intangible assets used in the exploitation of any other Product of the Borrower and its Subsidiaries; provided further that (x) any Designated Asset shall cease to be a Designated Asset upon the delivery by the Borrower to the Administrative Agent of an irrevocable written notice (such notice, the **Designated Asset Notice**) electing for such Designated Asset to no longer be designated as a Designated Asset and (y) each of the foregoing shall cease to be a Designated Asset upon consummation of the third Designated Disposition. **Designated Disposition** means an Asset Sale pursuant to Section 6.9(b)(xvii) or 6.9(b)(xviii). **[***] Subsidiaries** means, collectively, each of the Subsidiaries set forth on Schedule 1.3 hereof, and **[***] Subsidiary** means any of the foregoing; provided, however, (x) any of the foregoing shall cease to be a **[***] Subsidiary** upon the delivery by the Borrower to the Administrative Agent of an irrevocable written notice (such notice, the **[***] Subsidiary Notice**) electing for such **[***] Subsidiary** to no longer be designated as a **[***] Subsidiary** and (y) each of the foregoing shall cease to be a **[***] Subsidiary** upon consummation of the third Designated Disposition. **Disputes** has the meaning set forth in Section 4.23(d). **Disqualified Capital Stock** means any Capital Stock that, by its terms (or by the terms of any security or other Capital Stock into which it is convertible or for which it is exchangeable), or upon the **A - 20A - A | A** happening of any event or condition, (a) matures or is mandatorily redeemable (other than solely for Qualified Capital Stock), pursuant to a sinking fund obligation or otherwise (except as a result of a change of control or asset sale so long as any rights of the holders thereof upon the occurrence of a change of control or asset sale event shall be subject to the prior payment in full of the Obligations and the termination of the Term Loan Commitments), (b) is redeemable at the option of the holder thereof (other than solely for Qualified Capital Stock), in whole or in part (except as a result of a change of control or asset sale so long as any rights of the holders thereof upon the occurrence of a change of control or asset sale event shall be subject to the prior payment in full of the Obligations and the termination of the Term Loan Commitments), (c) provides for the scheduled payments of dividends or distributions in cash, or (d) is convertible into or exchangeable for (i) Indebtedness or (ii) any other Capital Stock that would constitute Disqualified Capital Stock, in each case of clauses (a) through (d), prior to the date that is **[***]** after the Stated Term Loan Maturity Date; provided that if such Capital Stock is issued pursuant to a plan for the benefit of current or former employees, directors, independent contractors or other service providers of the Loan Parties or by any such plan to such current or former employees, directors, independent contractors or other service providers, such Capital Stock shall not constitute Disqualified Capital Stock solely because they may be required to be repurchased by a Loan Party in order to satisfy applicable statutory or regulatory obligations, including tax withholding, or as a result of such current or former employee's, director's, independent contractor's or other service provider's termination, death or disability; provided further that Disqualified Capital Stock shall exclude Permitted Equity Derivatives. **Disqualified Institution** means (a) any of those Persons who are bona fide competitors of the Borrower that are identified by the Borrower in writing prior to the First Amendment Effective Date, which list of bona fide competitors of the Borrower may be updated by the Borrower on a quarterly basis by sending such updated list to the Administrative Agent and the Lenders, provided that any such updates shall not take effect until **[***]** after the updated Disqualified Institution list is made available to the Administrative Agent, or (b) any of those banks, financial institutions and other Persons separately identified by the Borrower in writing prior to the First Amendment Effective Date (and, in each case, such specified entities' Affiliates that are reasonably identifiable as Affiliates solely on the basis of their name, provided that the Administrative Agent shall have no obligation to carry out due diligence in order to identify such Affiliates). A list of the Disqualified Institutions shall be provided by the Administrative Agent to a Lender upon its request, including in connection with an assignment or participation hereunder; provided that, any Person that is a Lender and subsequently becomes a Disqualified Institution (but was not a Disqualified Institution at the time it became a Lender) will not be deemed to be a Disqualified Institution hereunder. **Dollars** and the sign **\$** mean the lawful money of the United States of America. **Dutch Guarantor** means a Guarantor formed or incorporated under the laws of the Netherlands, which as of the Closing Date is BridgeBio Europe B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under Dutch law, having its corporate seat (statutaire zetel) in Amsterdam, the Netherlands, with office address Weerdestein 97, 1083 GG Amsterdam, the Netherlands, registered with the Commercial Register (Handelsregister) of the Dutch Chamber of Commerce (Kamer van Koophandel) under number 82337527. **EEA Financial Institution** means (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent. **A - 21A - A | A** **EEA Member Country** means any of the member states of the European Union, Iceland, Liechtenstein, and Norway. **EEA Resolution Authority** means any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including any delegatee) having responsibility for the resolution of any EEA Financial Institution. **Eligible Assignee** means (a) any Lender, any Affiliate of any Lender and any Related Fund (any two or more Related Funds being treated as a single Eligible Assignee for all purposes hereof), (b) any commercial bank, insurance company, investment or mutual fund or other entity that is an **accredited investor** (as defined in Regulation D under the Securities Act) and which extends credit or buys loans as one of its businesses, (c) CPPIB and (d) any other Person (other than a natural Person); provided, in each case, neither Borrower nor any Affiliate of Borrower shall, in any event, be an Eligible Assignee; provided, further, in the case of clause (d) only, no Person owning or controlling any Capital Stock of any Loan Party (unless approved by Administrative Agent) shall, in any event, be an Eligible Assignee under clause (d). **Employee Benefit Plan** means any **employee benefit plan** as defined in Section 3(3) of ERISA which is or was, within the past five plan years, sponsored, maintained or contributed to by the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates. **Encalceret** means any product that contains the pharmaceutical compound known by the name encalceret (and any salt, free acid/base, solvate, hydrate, stereoisomer, crystalline or polymorphic form, prodrug, conjugate or complex of encalceret) in all forms, presentations, doses and formulations (including any improvements and modifications to, metabolites or analogs of and any derivatives therefrom), whether used as a single agent or in combination with other therapeutically active agents. **Environmental Claim** means any complaint, summons, citation, investigation, notice, directive, notice of violation, order, claim, demand, action, litigation, judicial or administrative proceeding, judgment, letter or other communication from any Governmental Authority or any other Person, involving (a) any actual or alleged violation of any Environmental Law, (b) any Hazardous Material or any actual or alleged Hazardous Materials Activity, (c) injury to the environment, natural resource, any Person (including wrongful death) or property (real or personal) in connection with Hazardous Materials or actual or alleged violations of Environmental Laws, or (d) actual or alleged Releases or threatened Releases of Hazardous Materials either (i) on, at or migrating from any assets, properties or businesses currently or formerly owned or operated by any Loan Party or any of its Subsidiaries or any predecessor in interest, (ii) from adjoining properties or businesses, or (iii) onto any facilities which received Hazardous Materials generated by any Loan Party or any of its Subsidiaries or any predecessor in interest. **Environmental Laws** means any and all current or future foreign or domestic, federal or state (or any subdivision of either of them), statutes, ordinances, orders, rules, regulations, judgments, decrees, permits, licenses or binding determinations of any Governmental Authorizations, or any other requirements of Governmental Authorities relating to (a) the manufacture, generation, use, storage, transportation, treatment, disposal or Release of Hazardous Materials, or (b) occupational safety and health, industrial hygiene, or the protection of the environment, human, plant or animal health or welfare. **Environmental Liabilities and Costs** means all liabilities, monetary obligations, losses (including monies paid in settlement), damages, punitive damages, natural resources damages, consequential damages, treble damages, costs and expenses (including all reasonable fees, disbursements and expenses of counsel, experts and consultants and costs of investigations and feasibility studies), fines, penalties, sanctions and interest incurred in connection with any Remedial Action, any Environmental Claim, or any other claim or demand by any Governmental Authority or any Person that relates to any actual or alleged violation of **A - 22A - A | A** Environmental Laws, actual or alleged exposure or threatened exposure to Hazardous Materials, or any actual or alleged Release or threatened Release of Hazardous Materials. **Environmental Lien** means any Lien in favor of any Governmental Authority for Environmental Liabilities and Costs. **ERISA** means the Employee Retirement Income Security Act of 1974. **ERISA Affiliate** means, as applied to any Person, (a) any corporation which is a member of a controlled group of corporations within the meaning of Section 414(b) of the Internal Revenue Code of which that Person is a member; any trade or business (whether or not incorporated) which is a member of a group of trades or businesses under common control within the meaning of Section 414(c) of the Internal Revenue Code of which that Person is a member; and (c) solely for purposes of provisions relating to Section 412 of the Internal Revenue Code, any member of an affiliated service group within the meaning of Section 414(m) or (o) of the Internal Revenue Code of which that Person, any corporation described in clause (a) above or any trade or business described in clause (b) above is a member. Any former ERISA Affiliate of the Borrower or any of its Subsidiaries shall continue to be considered an ERISA Affiliate of the Borrower or any such Subsidiary within the meaning of this definition with respect to the period such entity was an ERISA Affiliate of the Borrower or such Subsidiary and with respect to liabilities arising after such period for which the Borrower or such Subsidiary could be liable under the Internal Revenue Code or ERISA. **ERISA Event** means (a) a **reoperable event** within the meaning of Section 4043 of ERISA and the regulations issued thereunder with respect to any Pension Plan (excluding those for which the provision for thirty day notice to the PBGC has been waived by regulation), (b) the failure to meet the minimum funding standard of Section 412 of the Internal Revenue Code with respect to any Pension Plan

(whether or not waived in accordance with Section 412(c) of the Internal Revenue Code) or the failure to make by its due date a required installment under Section 430(j) of the Internal Revenue Code with respect to any Pension Plan or the failure to make any required contribution to a Multiemployer Plan, (c) the provision by the administrator of any Pension Plan pursuant to Section 4041(a)(2) of ERISA of a notice of intent to terminate such plan in a distress termination described in Section 4041(c) of ERISA, (d) the withdrawal by the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates from any Pension Plan with two or more contributing sponsors or the termination of any such Pension Plan resulting in liability to the Borrower, any of its Subsidiaries or any of their respective Affiliates pursuant to Section 4063 or 4064 of ERISA, (e) the institution by the PBGC of proceedings to terminate any Pension Plan, or the occurrence of any event or condition which constitutes grounds under ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan, (f) the imposition of liability on the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates pursuant to Section 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA, (g) the withdrawal of the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates in a complete or partial withdrawal (within the meaning of Sections 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefor, or the receipt by the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates of notice from any Multiemployer Plan that it is in reorganization or insolvency pursuant to Section 4241 or 4245 of ERISA, or that it intends to terminate or has terminated under Section 4041A or 4042 of ERISA, (h) the imposition on the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates of fines, penalties, taxes or related charges under Chapter 43 of the Internal Revenue Code or under Section 409, Section 502(c), (i) or (l), or Section 4071 of ERISA in respect of any Employee Benefit Plan, or (i) the imposition of a Lien pursuant to Section 430(k) of the Internal Revenue Code or pursuant to ERISA with respect to any Pension Plan, (j) the imposition on Borrower or any of its Subsidiaries of material fines, penalties, taxes or related charges under Chapter 43 of the Internal Revenue Code or under Section 502(c), (i) or (l), of ERISA in respect of any Employee Benefit Plan, (k) the imposition on Borrower - 23A - A | A or any of its Subsidiaries of material liability arising out of a material claim (other than routine claims for benefits) against any Employee Benefit Plan other than a Multiemployer Plan or the assets thereof, or against Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates in connection with any Employee Benefit Plan. **Erroneous Payment** has the meaning specified in Section 9.11(a). **Erroneous Payment Subrogation Rights** has the meaning specified in Section 9.11(d). **EU Bail-In Legislation Schedule** means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time to time. **Event of Default** means each of the conditions or events set forth in Section 8.1. **Exchange Act** means the Securities Exchange Act of 1934. **Excluded Account** means Deposit Accounts (a) the balance of which consists exclusively of withheld income taxes and foreign, federal, state or local employment taxes in such amounts as are required to be paid to the IRS or any other government agencies within the following two months with respect to employees of the Borrower or any of its Subsidiaries, (b) used exclusively for payroll to or for the benefit of employees of the Borrower or any of its Subsidiaries in such amounts as are required to be paid to such employees within the immediately succeeding two payroll cycles, (c) used exclusively for health care reimbursement accounts or employee benefits accounts, including any accounts exclusively containing amounts required to be paid over to an employee benefit plan pursuant to DOL Reg. Sec. 2510.3-102 on behalf of or for the benefit of employees of the Borrower or any of its Subsidiaries, (d) which are segregated Deposit Accounts constituting (and the balance of which consists solely of funds set aside in connection with) fiduciary accounts, escrow accounts or trust accounts, (e) having amounts on deposit or otherwise maintained therein that do not exceed \$[***] individually or \$[***] in the aggregate at any one time, (f) which are Deposit Accounts that are zero balance accounts, or (g) exclusively used to hold cash collateral or other deposits constituting Liens permitted by clauses (d), (k), (o), (w), (x) or (z) of the definition of Permitted Liens, in each case, only to the extent that granting of a security interest in, or Lien on, such Deposit Account would violate the express terms of the agreement giving rise to such Lien. **Excluded Subsidiary** means (a) any not-for-profit Subsidiary, (b) any captive insurance entity, (c) any merger Subsidiary formed in connection with a Permitted Acquisition so long as such merger Subsidiary is merged out of existence pursuant to such Permitted Acquisition or dissolved within [***] of its formation thereof or such later date as permitted by Administrative Agent in its reasonable discretion, (d) [reserved], (e) any Subsidiary that is an Immaterial Subsidiary, (f) any Subsidiary that is prohibited or restricted by any Requirement of Law or by contractual obligations existing on the Closing Date (or, in the case of any newly acquired Subsidiary, in existence at the time of acquisition but not entered into in contemplation thereof) from guaranteeing the Obligations or if guaranteeing the Obligations would require governmental (including regulatory) consent, approval, license or authorization, unless such consent, approval, license or authorization has been obtained, or (g) a Subsidiary with respect to which (i) the burden or cost of providing a guarantee shall outweigh the benefits to be obtained by the Lenders therefrom or (ii) the provision of a guarantee by such Subsidiary would result in material adverse tax consequences to the Borrower and its Subsidiaries, taken as a whole, in each case, as determined by the Borrower and the Administrative Agent. Notwithstanding the foregoing, no Subsidiary that (i) owns any Products or any Intellectual Property Rights material to the business of the Borrower and its Subsidiaries, (ii) is party to any Royalty Monetization Transaction, or (iii) is a Loan Party as of, or at any time after, the Closing Date, shall be an Excluded Subsidiary. **A 24A - A | A** **Excluded Taxes** means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient, (i) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (A) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (B) that are Other Connection Taxes, (ii) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Term Loan Commitment pursuant to a law in effect on the date on which (A) such Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment request by the Borrower under Section 2.18) or (B) such Lender changes its lending office, except in each case to the extent that, pursuant to Section 2.15, amounts with respect to such Taxes were payable either to such Lender's assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii) Taxes attributable to such Recipient's failure to comply with Section 2.15(e), and (iv) any withholding Taxes imposed under FATCA. **Existing Notes** means, collectively, the 2027 Notes and 2029 Notes. **Fair Share** has the meaning specified in Section 7.2. **FASB ASC** means the Accounting Standards Codification of the Financial Accounting Standards Board. **FATCA** means Sections 1471 through 1474 of the Internal Revenue Code, in effect as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Internal Revenue Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Internal Revenue Code. **FDA** means the U.S. Food and Drug Administration or any successor thereto. **FDA Laws** means all applicable statutes, rules, regulations, policies and orders and Requirements of Law administered, implemented, enforced or issued by FDA or any comparable Governmental Authority. **Federal Funds Effective Rate** means for any day, the rate per annum (expressed, as a decimal, rounded upwards, if necessary, to the next higher 1/100 of 1%) equal to the weighted average of the rates on overnight Federal funds transactions with members of the Federal Reserve System, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day; provided, if such day is not a Business Day, the Federal Funds Rate for such day shall be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business Day. **Federal Health Care Program Laws** means collectively, federal Medicare or federal or state Medicaid statutes, Sections 1128, 1128A, or 1128B of the Social Security Act (42 U.S.C. **SS** 1320a-7, 1320a-7a, 1320a-7b and 1320a-7h), the federal TRICARE statute (10 U.S.C. **SS** 1071 et seq.), the civil False Claims Act of 1863 (31 U.S.C. **SS** 3729 et seq.), criminal false claims statutes (e.g., 18 U.S.C. **SS** 287 and 1001), the Program Fraud Civil Remedies Act of 1986 (31 U.S.C. **SS** 3801 et seq.), HIPAA, or related regulations or other Requirements of Law that directly or indirectly govern the distribution, sale and promotion of any drug, biologic or other product subject to regulation under Public Health Laws, including the collection and reporting requirements, and the processing of any applicable rebate, chargeback or **A - 25A - A | A** adjustment, under applicable rules and regulations relating to the Medicaid Drug Rebate Program (42 U.S.C. **SS** 1396f-8) and any state supplemental rebate program, Medicare average sales price reporting (42 U.S.C. **SS** 1395w-3a), the Public Health Service Act (42 U.S.C. **SS** 256b), the VA Federal Supply Schedule (38 U.S.C. **SS** 8126) or under any state pharmaceutical assistance program or U.S. Department of Veterans Affairs agreement, and any successor government programs. **Federal Health Care Programs** shall mean the Medicare, Medicaid and TRICARE programs and any other state or federal health care program, as defined in 42 U.S.C. **SS** 1320a-7b(f). **Federal Reserve Board** means the Board of Governors of the Federal Reserve System of the United States. **Fee Letters** means, collectively, (i) the fee letter agreement, dated the Closing Date, between the Borrower and Administrative Agent and (ii) the arranger fee letter agreement, dated as of the Closing Date, between the Borrower and ORCA I LLC, and **Fee Letter** means either of the foregoing. **Financial Officer Certification** means, with respect to the financial statements or calculations for which such certification is required, the certification of the chief financial officer of the Borrower that such financial statements fairly present, in all material respects, the financial condition of the Borrower and its Subsidiaries as at the dates indicated and the results of their operations and their cash flows for the periods indicated, subject to changes resulting from audit and normal year-end adjustments. **First Amendment** means that certain First Amendment to Financing Agreement, dated as of February 12, 2024, by and among the Borrower, the Guarantors party thereto, the Lenders party thereto and the Administrative Agent. **First Amendment Effective Date** has the meaning assigned to such term in the First Amendment. **First Priority** means, with respect to any Lien purported to be created in any Collateral pursuant to any Collateral Document, that such Lien is the only Lien to which such Collateral is subject, other than any Permitted Lien. **Fiscal Quarter** means a fiscal quarter of any Fiscal Year. **Fiscal Year** means the fiscal year of the Borrower and its Subsidiaries ending on December 31 of each calendar year. **Flood Hazard Property** means any Real Estate Asset encumbered by a mortgage in favor of Administrative Agent, for the benefit of the Secured Parties, and located in an area designated by the Federal Emergency Management Agency as having special flood or mud slide hazards. **Floor** means a rate of interest equal to 1.00% per annum. **Foreign Lender** means any Lender that is not a U.S. Person. **Foreign Official** means any officer or employee of a non-U.S. government or any department, agency, or instrumentality thereof, or of a public international organization, or any person acting in an official capacity for or on behalf of any such government or department, agency, or instrumentality, or for or on behalf of any such public international organization. **A - 26A - A | A** **Foreign Sovereign Immunities Act** means the US Foreign Sovereign Immunities Act of 1976 (28 U.S.C. Sections 1602-1611). **Fosfodenoparin** means any product that contains the pharmaceutical compound known by the name fodenoparin (and any salt, free acid/base, solvate, hydrate, stereoisomer, crystalline or polymorphic form, prodrug, conjugate or complex of fodenoparin) in all forms, presentations, doses and formulations (including any improvements and modifications to, metabolites or analogs of and any derivatives therefrom), whether used as a single agent or in combination with other therapeutically active agents. **Funding Default** has the meaning specified in Section 2.17. **Funding Notice** means a written notice substantially in the form of Exhibit A-1. **GAAP** means, subject to the limitations on the application thereof set forth in Section 1.2, United States generally accepted accounting principles in effect as of the date of determination thereof. **Governmental Authority** means any federal, state, municipal, national or other government, governmental department, commission, board, bureau, court, agency or instrumentality or political subdivision thereof or any entity or officer exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to any government or any court, including any patent office, in each case where associated with a state of the United States, the United States, the Netherlands, Switzerland or a foreign entity or government. **Governmental Authorization** means any permit, license, authorization, clearance, approval, Registration, plan, directive, consent order or consent decree of or from any Governmental Authority. **Grantor** has the meaning specified in the Pledge and Security Agreement. **Guaranteed Obligations** has the meaning specified in Section 7.1. **Guarantor** means each Subsidiary of the Borrower (other than Excluded Subsidiaries) and each other Person which guarantees, pursuant to Article VII or otherwise, all or any part of the Obligations. **Guarantor Subsidiary** means each Guarantor. **Guaranty** means (a) the guaranty of each Guarantor set forth in Article VII and (b) each other guaranty, in form and substance satisfactory to Administrative Agent, made by any other Guarantor for the benefit of the Secured Parties guaranteeing all or part of the Obligations. **Hazardous Materials** means, regardless of amount or quantity, (a) any element, compound or chemical that is defined, listed or otherwise classified as a contaminant, pollutant, toxic pollutant, toxic or hazardous substance, extremely hazardous substance or chemical, hazardous waste, special waste, or solid waste under Environmental Laws or that is likely to cause immediately, or at some future time, harm to or have an adverse effect on, the environment or risk to human health or safety, including, without limitation, any pollutant, contaminant, waste, hazardous waste, toxic substance or dangerous good which is defined or identified in any Environmental Law and which is present in the environment in such quantity or state that it contravenes any Environmental Law, (b) petroleum and its refined products, (c) polychlorinated biphenyls, (d) any substance exhibiting a hazardous waste characteristic, including, without limitation, corrosivity, ignitability, toxicity or reactivity as well as any radioactive or explosive materials, (e) any raw materials, building components (including, without limitation, asbestos-containing materials) and **A - 27A - A | A** manufactured products containing hazardous substances listed or classified as such under Environmental Laws, and (f) any substance or materials that are otherwise regulated under Environmental Law. **Hazardous Materials Activity** means any past, current, proposed or threatened activity, event or occurrence involving any Hazardous Materials, including the use, manufacture, possession, storage, holding, presence, existence, location, Release, threatened Release, discharge, placement, generation, transportation, processing, construction, treatment, abatement, removal, remediation, disposal, disposition or handling of any Hazardous Materials, and any corrective action or response action with respect to any of the foregoing. **Highest Lawful Rate** means the maximum lawful interest rate, if any, that at any time or from time to time may be contracted for, charged, or received under the laws applicable to any Lender which are presently in effect or, to the extent allowed by law, under such applicable laws which may hereafter be in effect and which allow a higher maximum non-usurious interest rate than applicable laws now allow. **HIPAA** means the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (Title XIII of the American Recovery and Reinvestment Act of 2009), and all regulations promulgated thereunder, and other Requirements of Law regulating the privacy and/or security of patient-identifying health care information, including with respect to notification of breach of privacy or security of such information. **Historical Financial Statements** means as of the Closing Date, (a) the audited consolidated financial statements of the Borrower and its Subsidiaries, for the Fiscal Year ended December 31, 2022, consisting of consolidated balance sheets and the related consolidated statements of income, stockholders' equity and cash flows for such Fiscal Year, and (b) the financial statements of the Borrower and its Subsidiaries for each of the Fiscal Quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, consisting of consolidated balance sheets and the related consolidated statements of income and cash flows for each such Fiscal Quarter. **Immaterial Subsidiary** means, as of any date of determination, any Subsidiary of a Loan Party that (i) has assets representing [***]% or less of the total assets of Borrower and its Subsidiaries, determined on a consolidated basis in accordance with GAAP, as of the last day of the most recent Fiscal Quarter for which financial statements have been, or were required to have been, delivered pursuant to Sections 3.1(f), 5.1(b) or 5.1(c), as applicable (the **Test Date**) and (ii) contributes [***]% or less of the total revenues of the Borrower and its Subsidiaries, for the Fiscal Quarter ended on the Test Date; provided, however, that if at any time and from time to time on or after the Closing Date, the Subsidiaries that would otherwise be Immaterial Subsidiaries hereunder (x) comprise more than [***]% of the total assets of Borrower and its Subsidiaries as of the Test Date, (y) contribute more than [***]% of the total revenues of Borrower and its Subsidiaries for the Fiscal Quarter ended on the Test Date or (z) hold Cash and Cash Equivalents in an amount exceeding \$[***], then the Borrower shall, (i) not later than [***] after the date by which financial statements for such period are required to be delivered (or such longer period as the Administrative Agent may agree in its sole discretion), designate in writing to Administrative Agent that one or more of such Subsidiaries is no longer an Immaterial Subsidiary for purposes of this Agreement and (ii) comply with the requirements set forth in Section 5.10. As of the Closing Date, the Subsidiaries listed on Schedule 1.1 are Immaterial Subsidiaries. **Increased Cost Lenders** has the meaning specified in Section 2.18. **Incremental Amendment** has the meaning specified in Section 2.21. **Incremental Term Loan** has the meaning specified in Section 2.21. **A - 28A - A | A** **Incremental Term Loan Commitment** has the meaning specified in Section 2.21. **Indebtedness** means, as applied to any Person, without duplication, (a) all indebtedness for borrowed money, (b) that portion of obligations with respect to Capital Leases that is properly classified as a liability on a balance sheet in conformity with GAAP, (c) all obligations of such Person evidenced by notes, bonds or similar instruments or upon which interest payments are customarily paid and all obligations in respect of notes payable and drafts accepted representing extensions of credit whether or not representing obligations for borrowed money, (d) any obligation owed for all or any part of the deferred purchase price of property or services, including any earn-outs or other deferred payment obligations in connection with an acquisition (excluding (i) any such obligations incurred under ERISA, (ii) trade payables incurred

in the ordinary course of business and repayable in accordance with customary trade terms, (iii) deferred compensation obligations and (iv) earn-outs, milestone obligations or other deferred payment obligations in connection with any Permitted Acquisition or other Investment that are not fixed or subject to any contingency (it being understood that the satisfaction of such contingency shall not result in such obligation ceasing to be ~~an~~contingent~~an~~ for purposes of the foregoing and that the making of any such payment shall constitute an Investment and must be permitted by clause (e) of the definition of Permitted Investments)), (e) all obligations created or arising under any conditional sale or other title retention agreement with respect to property acquired by such Person, (f) all indebtedness secured by any Lien on any property or asset owned or held by that Person regardless of whether the indebtedness secured thereby shall have been assumed by that Person or is non-recourse to the credit of that Person, (g) the face amount of any letter of credit or letter of guaranty issued, bankers~~an~~ acceptances facilities, surety bonds and similar credit transactions issued for the account of that Person or as to which that Person is otherwise liable for reimbursement of drawings, (h) the direct or indirect guaranty, endorsement (otherwise than for collection or deposit in the ordinary course of business), co-making, discounting with recourse or sale with recourse by such Person of the Indebtedness of another, (i) any obligation of such Person the primary purpose or intent of which is to provide assurance to an obligee that the Indebtedness of the obligor thereof will be paid or discharged, (j) any liability of such Person for Indebtedness of another through any agreement (contingent or otherwise) (i) to purchase, repurchase or otherwise acquire such obligation or any security therefor, or to provide funds for the payment or discharge of such obligation (whether in the form of loans, advances, stock purchases, capital contributions or otherwise) or (ii) to maintain the solvency or any balance sheet item, level of income or financial condition of another if, in the case of any agreement described under subclauses (i) or (ii) of this clause (j), the primary purpose or intent thereof is as described in clause (i) above, (k) all net obligations of such Person in respect of any exchange traded or over the counter derivative transaction, including, without limitation, any Interest Rate Agreement, whether entered into for hedging or speculative purposes, (l) Disqualified Capital Stock, and (m) all obligations in respect of Royalty Monetization Transactions. The Indebtedness of any Person shall include the Indebtedness of any partnership or Joint Venture in which such Person is a general partner or joint venturer, unless such Indebtedness is non-recourse to such Person. No Permitted Equity Derivatives shall constitute Indebtedness under the foregoing clause (k). ~~an~~Indemnified Liabilities~~an~~ means, collectively, any and all liabilities (including Environmental Liabilities and Costs), obligations, losses, damages (including natural resource damages), penalties, claims (including Environmental Claims), costs (including the costs of any investigation, study, sampling, testing, abatement, cleanup, removal, remediation or other response action necessary to remove, remediate, clean up or abate any Hazardous Materials Activity), expenses and disbursements of any kind or nature whatsoever (including the reasonable and documented out-of-pocket fees and disbursements of counsel for Indemnitees in connection with any investigative, administrative or judicial proceeding commenced or threatened by any Person, whether or not any such Indemnitee shall be designated as a party or a potential party thereto, and any fees or expenses incurred by Indemnitees in enforcing this indemnity), whether direct, indirect or consequential and whether based on any federal, state or foreign laws, statutes, rules or regulations (including securities and commercial laws, statutes, rules or regulations and Environmental ~~A~~ - 29A - ~~A~~ | ~~A~~ Laws), on common law or equitable cause or on contract or otherwise, that may be imposed on, incurred by, or asserted in writing against any such Indemnitee, in any manner relating to or arising out of (a) this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby (including the Lenders~~an~~ agreement to make Credit Extensions or the use or intended use of the proceeds thereof, or any enforcement of any of the Loan Documents (including any sale of, collection from, or other realization upon any of the Collateral or the enforcement of the Guaranty)), (b) the statements contained in the proposal letter delivered by any Lender to Borrower prior to the Closing Date with respect to the transactions contemplated by this Agreement, or (c) any Environmental Claim or any Hazardous Materials Activity relating to or arising from, directly or indirectly, any past or present activity, operation, land ownership, or practice of the Borrower or any of its Subsidiaries. ~~an~~Indemnified Taxes~~an~~ means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Loan Party under any Loan Document and (b) to the extent not otherwise described in clause (a), Other Taxes. ~~an~~Indemnitee~~an~~ has the meaning specified in Section 10.3. ~~an~~Indemnitee Agent Party~~an~~ has the meaning specified in Section 9.6. ~~an~~Infringatinib~~an~~ means any product that contains the pharmaceutical compound known by the name infratinib (and any salt, free acid/base, solvate, hydrate, stereoisomer, crystalline or polymorphic form, prodrug, conjugate or complex of infratinib) in all forms, presentations, doses and formulations (including any improvements and modifications to, metabolites or analogs of or any derivatives therefrom), whether used as a single agent or in combination with other therapeutically active agents. [***] ~~an~~Initial Term Loan~~an~~ means the Term Loan funded on the Closing Date pursuant to Section 2.1(a)(i). ~~an~~Initial Term Loan Commitment~~an~~ means the commitment of a Lender to make or otherwise fund the Initial Term Loan and ~~an~~Initial Term Loan Commitments~~an~~ means such commitments of all such Lenders in the aggregate. The amount of each Lender~~an~~'s Initial Term Loan Commitment, if any, is set forth on Appendix A or in the applicable Assignment Agreement, subject to any adjustment or reduction pursuant to the terms and conditions hereof. The aggregate amount of the Initial Term Loan Commitments as of the Closing Date is \$450,000,000. ~~an~~Insolvency Proceeding~~an~~ means any proceeding commenced by or against any Person under any provision of any Debtor Relief Law. ~~an~~Installment~~an~~ has the meaning specified in Section 2.8. ~~an~~Installment Payment Date~~an~~ means the last Business Day of each Fiscal Quarter, commencing with the earlier of (x) the Fiscal Quarter ending June 30, 2027 and (y) the first Fiscal Quarter after the Closing Date during which the Borrower~~an~~'s Market Capitalization is less than \$1,500,000,000. ~~an~~Intellectual Property~~an~~ has the meaning specified in the Pledge and Security Agreement. ~~an~~Intellectual Property Rights~~an~~ means any and all rights, title and interests in and to all intellectual property rights of every kind and nature however denominated, as they exist throughout the world, including: ~~A~~ - 30A - ~~A~~ | ~~A~~ (a) any Patent; (b) trademarks, trade names, service marks, brands, trade dress and logos, packaging design, slogans, domain names and the goodwill and activities associated therewith; (c) copyrights, mask work rights, confidential information, trade secrets, database rights, including all compilations, databases and computer programs, manuals and other documentation, and all derivatives, translations, adaptations, and combinations of the above; (d) Know-How; (e) rights of privacy and publicity, and moral rights; and (f) any and all other intellectual property rights or proprietary rights, whether or not patentable, including any and all registrations, applications, recordings, licenses, common-law rights, statutory rights, administrative rights, and contractual rights relating to any of the foregoing, claims of infringement and misappropriation against third parties, and regulatory filings, submissions and approvals. ~~an~~Intercompany Subordination Agreement~~an~~ means that certain Intercompany Subordination Agreement, dated as of the Closing Date, made by the Loan Parties and their Subsidiaries in favor of Administrative Agent for the benefit of the Secured Parties. ~~an~~Intercreditor Agent (Swiss)~~an~~ has the meaning assigned to such term in the Acoramidis Intercreditor Agreement. ~~an~~Intercreditor Agreement~~an~~ means (a) the Acoramidis Intercreditor Agreement or (b) any Acceptable Intercreditor Agreement, and ~~an~~Intercreditor Agreements~~an~~ means, collectively, each of the foregoing. ~~an~~Interest Payment Date~~an~~ means (a) the last Business Day of each Fiscal Quarter, commencing on the first such date to occur after the Closing Date, and (b) the final maturity date of the Loans (whether by scheduled maturity, acceleration or otherwise). ~~an~~Interest Period~~an~~ means, in connection with a SOFR Loan, an interest period of three months (a) initially, commencing on the Credit Date or Conversion/Continuation Date thereof, as the case may be and ending on the Interest Payment Date to occur after such Credit Date or Conversion/Continuation Date, and (b) thereafter, commencing on the day on which the immediately preceding Interest Period expires; provided, (i) if an Interest Period would otherwise expire on a day that is not a Business Day, such Interest Period shall expire on the next succeeding Business Day unless no further Business Day occurs in such month, in which case such Interest Period shall expire on the immediately preceding Business Day, (ii) any Interest Period that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall, subject to clause (b)(iii) of this definition, end on the last Business Day of a calendar month, and (iii) no Interest Period with respect to any portion of any Term Loan shall extend beyond the Stated Term Loan Maturity Date. ~~an~~Interest Rate Agreement~~an~~ means any interest rate swap agreement, interest rate cap agreement, interest rate collar agreement, interest rate hedging agreement or other similar agreement or arrangement, which in each case is (a) for the purpose of hedging the interest rate exposure associated with the Borrower~~an~~'s and its Subsidiaries~~an~~ operations and (b) not for speculative purposes. ~~A~~ - 31A - ~~A~~ | ~~A~~ ~~an~~Interest Rate Determination Date~~an~~ means, the Periodic Term SOFR Determination Day or the Base Rate Term SOFR Determination Day, as the context may require. ~~an~~Internal Revenue Code~~an~~ means the United States Internal Revenue Code of 1986, as amended. ~~an~~Investment~~an~~ means (a) any direct or indirect purchase or other acquisition by the Borrower or any of its Subsidiaries of, or of a beneficial interest in, any of the securities or Capital Stock or all or substantially all of the assets of any other Person (or of any division or business line of such other Person), (b) any direct or indirect redemption, retirement, purchase or other acquisition for value, by any Subsidiary of the Borrower from any Person, of any Capital Stock of such Person, (c) any direct or indirect loan, advance, or capital contributions (or transfer or similar payment made from one entity to its Subsidiary in lieu of any capital contributions that would otherwise be required) by the Borrower or any of its Subsidiaries to any other Person, including all indebtedness (including, without limitation, any intercompany indebtedness) and accounts receivable from that other Person that are not current assets or did not arise from sales to that other Person in the ordinary course of business, and (d) any direct or indirect guarantee of any obligations of any other Person. The amount of any Investment shall be the original cost of such Investment, plus the cost of all additions thereto, without any adjustments for increases or decreases in value, or write ups, write downs or write offs with respect to such Investment, less the amount of cash actually indefeasibly received or returned and not subject to any claw-back or similar rights. ~~an~~IRS~~an~~ means the U.S. Internal Revenue Service. ~~an~~Joint Venture~~an~~ means a joint venture, partnership or other similar arrangement, whether in corporate, partnership or other legal form, in which the Borrower or any of its Subsidiaries holds any Capital Stock or other equity interest; provided, in no event shall any Subsidiary of any Person be considered to be a Joint Venture to which such Person is a party. ~~an~~Know-How~~an~~ means all information and materials, including but not limited to discoveries, improvements, processes, methods, protocols, formulations formulas, data (including pharmacological, toxicological, non-clinical data, clinical data, analytical and quality control data, manufacturing data and descriptions, market data, financial data or descriptions), inventions, devices, assays, chemical formulations, specifications, product samples and other samples, physical, practices, procedures, technology, techniques, designs, drawings, correspondence, computer programs, documents, apparatus, results, strategies, regulatory documentation, information and submissions pertaining to, or made in association with, filings with any Governmental Authority, research in progress, algorithms, data, databases, data collections, chemical and biological materials (including any compounds, DNA, RNA, clones, vectors, cells and any expression product, progeny, derivatives or improvements thereto), and the results of experimentation and testing, including samples in each case, knowledge, know-how, trade secrets and the like, in written, electronic, oral or other tangible or intangible form, patentable or otherwise, which are not generally known. ~~an~~Latest Maturity Date~~an~~ means, as of any date of determination, the latest maturity date applicable to any Term Loan hereunder as of such date. ~~an~~Lender~~an~~ means each lender listed on the signature pages hereto as a Lender, and any other Person that becomes a party hereto pursuant to an Assignment Agreement other than any Person that ceases to be a party hereto pursuant to any Assignment Agreement. ~~an~~Liabilities~~an~~ means all claims, actions, suits, judgments, damages, losses, liability, obligations, responsibilities, fines, penalties, sanctions, costs, fees, taxes, commissions, charges, disbursements and expenses, in each case of any kind or nature (including interest accrued thereon or as a result thereto and ~~A~~ - 32A - ~~A~~ | ~~A~~ fees, charges and disbursements of financial, legal and other advisors and consultants), whether joint or several, whether or not indirect, contingent, consequential, actual, punitive, treble or otherwise. ~~an~~License~~an~~ means any third party to which Borrower or any of its Subsidiaries, directly or indirectly through multiple tiers, grants a license, a sublicense, or other right to Commercialize a Product in any jurisdiction. ~~an~~Lien~~an~~ means (a) any lien, mortgage, pledge, assignment, hypothec, deed of trust, security interest, license or sublicense, charge or encumbrance of any kind (including any agreement to give any of the foregoing, any conditional sale or other title retention agreement, and any lease in the nature thereof) and any option, trust or other preferential arrangement having the practical effect of any of the foregoing, and (b) in the case of securities or Capital Stock, any purchase option, call or similar right of a third party with respect to such securities or Capital Stock. ~~an~~Loan~~an~~ means any Term Loan. ~~an~~Loan Account~~an~~ means an account maintained hereunder by Administrative Agent on its books of account at the Payment Office, and with respect to Borrower, in which it will be charged with the Term Loan made to, and all other Obligations incurred by the Loan Parties. ~~an~~Loan Document~~an~~ means any of this Agreement, the Notes, if any, the Collateral Documents, the Fee Letters, the Flow of Funds Agreement, any Guaranty, the Intercompany Subordination Agreement, the Perfection Certificate, any Intercreditor Agreement, any amendment or supplement to, or any waiver or consent under, any of the foregoing, and any other document executed and delivered by a Loan Party for the benefit of the Administrative Agent in connection herewith. ~~an~~Loan Party~~an~~ means the Borrower or any Guarantor. ~~an~~Loan Party Partner~~an~~ has the meaning set forth in Section 4.33(a). ~~an~~Margin Stock~~an~~ has the meaning specified in Regulation U of the Federal Reserve Board as in effect from time to time. ~~an~~Market Capitalization~~an~~ means, as of any date of determination, an amount equal to (a) the average of the daily volume weighted average price of Borrower~~an~~'s Common Stock as reported for each of the five (5) trading days preceding such date of determination (it being understood that a ~~an~~trading day~~an~~ shall mean a day on which shares of Borrower~~an~~'s Common Stock trade on the NASDAQ (or, if the primary listing of such Common Stock is on the New York Stock Exchange, on the New York Stock Exchange) in an ordinary trading session) multiplied by (b) the total number of issued and outstanding shares of Borrower~~an~~'s Common Stock that are issued and outstanding on the date of the determination and listed on the NASDAQ (or the New York Stock Exchange, as applicable), subject to appropriate adjustment for any stock dividend, stock split, stock combination, reclassification or other similar transaction during the applicable calculation period. ~~an~~Material Adverse Effect~~an~~ means a material adverse effect on (a) the business operations, properties, assets, financial condition, or liabilities of the Borrower and its Subsidiaries taken as a whole, (b) the ability of the Loan Parties (taken as a whole) to fully and timely perform their obligations under the Loan Documents, (c) the legality, validity, binding effect, or enforceability against a Loan Party of a Loan Document to which it is a party, (d) the Collateral or the validity, perfection or priority of Administrative Agent~~an~~'s Liens on the Collateral, or (e) the rights, remedies and benefits available to, or conferred upon, Administrative Agent and any Lender or any other Secured Party under the Loan Documents. ~~A~~ - 33A - ~~A~~ | ~~A~~ ~~an~~Material Contract~~an~~ means any contract or other arrangement to which the Borrower or any of its Subsidiaries is a party (other than the Loan Documents) for which breach, non-performance, cancellation or failure to renew would reasonably be expected to have a Material Adverse Effect, which, as of the Closing Date, are those contracts and arrangements listed on Schedule 4.15. ~~an~~Material Regulatory Liabilities~~an~~ means (i) any Liabilities arising from the violation of FDA Laws, Public Health Laws, Federal Health Care Program Laws, and other applicable comparable Requirements of Law, or the terms, conditions of or requirements applicable to any Registrations (including costs of actions required under applicable Requirements of Law, including FDA Laws and Federal Health Care Program Laws, or necessary to remedy any violation of any terms or conditions applicable to any Registrations), including, but not limited to, withdrawal of approval, recall, revocation, suspension, import detention and seizure of any Product, and (ii) any loss of recurring annual revenues as a result of any loss, suspension or limitation of any Registrations, which, in the case of the foregoing clauses (i) and (ii), (a) exceed \$[***] individually or in the aggregate, or (b) results in a Material Adverse Effect. ~~an~~Measurement Period~~an~~ means, at any date of determination, the most recently completed [***] consecutive Fiscal Quarters of the Borrower and its Subsidiaries for which financial statements have been (or were required to have been) delivered in accordance with Section 5.1(b) or 5.1(c) (or, prior to the first delivery of any such financial statements, the period of [***] consecutive Fiscal Quarters of the Borrower and its Subsidiaries ended September 30, 2023). ~~an~~Moody~~an~~'s~~an~~ means Moody~~an~~'s Investor Services, Inc. ~~an~~Mortgage~~an~~ means a mortgage, deed of trust or deed to secure debt that encumbers Real Property, in form and substance reasonably satisfactory to Administrative Agent, made by a Loan Party in favor (or for the benefit) of Administrative Agent for the benefit of the Secured Parties, to secure the Obligations and is delivered to Administrative Agent as provided in Section 5.11. ~~an~~Multiemployer Plan~~an~~ means any Employee Benefit Plan which is a ~~an~~multiemployer plan~~an~~ as defined in Section 3(37) of ERISA. ~~an~~NDAA~~an~~ means a new drug application submitted to the FDA pursuant to 21 C.F.R. Part 314 to obtain regulatory approval for a product in the United States. ~~an~~Net Income~~an~~ shall mean, for any period, the consolidated net income (or loss) of the Borrower and its Subsidiaries for such period, determined on a consolidated basis in accordance with GAAP. ~~an~~Net Outstanding Amount~~an~~ means, as of any date of determination with respect to any Existing Notes, the sum of (x) the aggregate principal amount thereof outstanding at such time minus (y) up to \$[***] of Additional Equity Proceeds that are held in a Blocked Account (which proceeds shall not, for the avoidance of doubt, constitute Qualified Cash). ~~an~~Net Proceeds~~an~~ means (a) with respect to any Asset Sale, an amount equal to: (i) Cash payments received by the Borrower or any of its Subsidiaries from such Asset Sale, minus (ii) any bona fide costs or expenses incurred in connection with such Asset Sale that are properly attributable to such Asset Sale and to the extent paid or payable to non-Affiliates, including (A) income or gains taxes payable by the seller as a result of any gain recognized in connection with such Asset Sale during the tax period the sale occurs, (B) payment of the outstanding principal amount of, premium or penalty, if any, and interest on any Indebtedness (other than the Loans) that is secured by a Lien on the stock or assets in question and that is required to be repaid under the terms thereof as a result of such Asset Sale, (C) a reasonable reserve for any indemnification payments (fixed or contingent) attributable to seller~~an~~'s indemnities and representations and ~~A~~ - 34A - ~~A~~ | ~~A~~ warranties to

purchaser in respect of such Asset Sale undertaken by the Borrower or any of its Subsidiaries in connection with such Asset Sale, and (D) any reasonable and documented out-of-pocket fees or expenses incurred in connection therewith; provided that upon release of any such reserve, the amount released shall be considered Net Proceeds, (b) with respect to any insurance, condemnation, taking or other casualty proceeds, an amount equal to: (i) any Cash payments or proceeds received by the Borrower or any of its Subsidiaries (A) under any casualty, business interruption or Æœkey manÆ insurance policies in respect of any covered loss thereunder, or (B) as a result of the condemnation or taking of any assets of the Borrower or any of its Subsidiaries by any Person pursuant to the power of eminent domain, condemnation or otherwise, or pursuant to a sale of any such assets to a purchaser with such power under threat of such a taking, minus (ii) (A) any actual costs or expenses incurred by the Borrower or any of its Subsidiaries in connection with the adjustment or settlement of any claims of the Borrower or such Subsidiary in respect thereof, and (B) any bona fide costs and expenses incurred in connection with any sale of such assets as referred to in clause (b)(i)(B) of this definition to the extent paid or payable to non-Affiliates, including income taxes payable as a result of any gain recognized in connection therewith, and (c) with respect to any sale or issuance of Capital Stock, the cash proceeds thereof, net of all Taxes and customary fees, commissions, costs, underwriting discounts and other fees and expenses incurred by Borrower or any Subsidiary in connection therewith. ÆœNIHÆ has the meaning specified in the definition of Public Health Laws. ÆœNon-Loan PartyÆ means a Subsidiary of the Borrower that is not a Loan Party. ÆœNoteÆ means a promissory note evidencing the Initial Term Loan or an Incremental Term Loan, as applicable. ÆœNoticeÆ means a Funding Notice or a Conversion/Continuation Notice. ÆœObligationsÆ means all obligations of every nature of each Loan Party and its Subsidiaries from time to time owed to Administrative Agent (including former Administrative Agents), the Lenders or any of them, under any Loan Document, whether for principal, interest (including interest which, but for the filing of a petition in bankruptcy with respect to such Loan Party, would have accrued on any Obligation, whether or not a claim is allowed against such Loan Party for such interest in the related bankruptcy proceeding), the Applicable Premium, the Prepayment Premium (if any), Erroneous Payment Subrogation Rights, fees, expenses, indemnification or otherwise and whether primary, secondary, direct, indirect, contingent, fixed or otherwise (including obligations of performance). ÆœOFACÆ has the meaning specified in the definition of Anti-Terrorism Laws. ÆœOFAC Sanctions ProgramsÆ means (a) the Requirements of Law and Executive Orders administered by OFAC, including but not limited to, Executive Order No. 13224, and (b) the list of Specially Designated Nationals and Blocked Persons administered by OFAC, in each case, as renewed, extended, amended, or replaced. ÆœOrange Book PatentÆ means any Product Patents listed in the FDAÆ™s Orange Book pursuant to 21 U.S.C. Section 355(b)(1), as such patent listing may be amended from time to time, together with all foreign counterpart patents. ÆœOrganizational DocumentsÆ means (a) with respect to any corporation or company, its certificate of incorporation, its articles or memorandum of incorporation, organization or association, its constitution and its by-laws, and any certificate of change of name, (b) with respect to any limited partnership, its certificate of limited partnership, and its partnership agreement, (c) with respect to any general partnership, A - 35A - A | A its partnership agreement, and (d) with respect to any limited liability company, its trade register excerpt (as applicable), its articles of organization, and its operating agreement (or, in each case of (a) through (d), the equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction). In the event any term or condition of this Agreement or any other Loan Document requires any Organizational Document to be certified by a secretary of state or similar governmental official or authority, the reference to any such ÆœOrganizational DocumentÆ shall only be to a document of a type customarily certified by such governmental official or authority. ÆœOther Connection TaxesÆ means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document). ÆœOther TaxesÆ means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 2.18). ÆœParticipant RegisterÆ has the meaning specified in Section 10.6(h)(ii). ÆœPartyÆ means a party to this agreement. ÆœPatentÆ means any United States issued patent or patent application, including any continuation, continuation-in-part, division, provisional or any substitute applications, any patent issued with respect to any of the foregoing patent applications, any certificate, reissue, reexamination, renewal or patent term extension or adjustment (including any supplementary protection certificate) of any such patent or other governmental actions which extend the duration or any of the subject matter of a patent, and any substitution patent, confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing. ÆœPATRIOT ActÆ has the meaning specified in Section 4.29. ÆœPayment OfficeÆ means Administrative AgentÆ™s office located at 399 Park Avenue, 37th Floor, New York, NY 10022 or such other office or offices of Administrative Agent as may be designated in writing from time to time by Administrative Agent and the Borrower. ÆœPBGCAÆ means the Pension Benefit Guaranty Corporation or any successor thereto. ÆœPension PlanÆ means any Employee Benefit Plan, other than a Multiemployer Plan, which is subject to Section 412 of the Internal Revenue Code, Section 302 of ERISA or Title IV of ERISA. ÆœPerfection CertificateÆ means (a) that certain Perfection Certificate and Diligence Request dated as of the Closing Date and/or (b) a certificate in form reasonably satisfactory to Administrative Agent that provides information with respect to the assets of one or more Loan Parties. ÆœPeriodic Term SOFR Determination DayÆ has the meaning specified in the definition of ÆœTerm SOFRÆ. A - 36A - A | A ÆœPermitted AcquisitionÆ means any acquisition by the Borrower or its Subsidiaries, whether by purchase, merger, in-licensing or otherwise, of all or substantially all of the assets of, all of the Capital Stock of, or a business line or unit or a division of, or Patents or similar or related Intellectual Property Rights of, any Person; provided, that: (a) immediately prior to, and immediately after giving effect thereto, no Event of Default shall have occurred and be continuing or would result therefrom; (b) all transactions in connection therewith shall be consummated, in all material respects, in accordance with all applicable laws and in conformity with all applicable Governmental Authorizations; (c) in the case of the acquisition of Capital Stock, all of the Capital Stock (except for any such securities in the nature of directorsÆ™ qualifying shares required pursuant to applicable law) acquired or otherwise issued by such Person or any newly formed Guarantor Subsidiary in connection with such acquisition, shall be owned [***] by a Loan Party, and the Borrower shall have taken, or caused to be taken, as of the date such Person becomes a Subsidiary, any actions required to be taken as of such date as set forth in Section 5.10, Section 5.11 and/or Section 5.12, as applicable; (d) the Borrower and its Subsidiaries shall be in compliance, on a pro forma basis, with the Permitted Transaction Qualified Cash Requirement after giving effect to such acquisition; (e) Borrower shall have delivered to Administrative Agent at least [***] (or such shorter period as agreed to by Administrative Agent in writing) prior to such proposed acquisition, such information and documents that Administrative Agent may reasonably request, including, without limitation, financial information with respect to such acquired assets, to the extent such financial information is available, and drafts of the respective acquisition agreements related thereto; (f) any Person or assets or division as acquired in such Permitted Acquisition shall be in the same business or lines of business in which the Borrower and/or its Subsidiaries are engaged as of the Closing Date (or in lines of business reasonably related or incidental thereto, or such other lines of business as may be consented to by Administrative Agent (such consent not to be unreasonably withheld or delayed)); (g) such acquisition shall have been approved by the Board of Directors or other governing body or controlling Person of the Person acquired or the Person from whom such assets or division is acquired; and (h) (x) prior to the Sales Milestone Date, the total cash consideration paid (including any deferred purchase price, earnouts, milestone payments based on FDA approval or other similar contingent acquisition consideration, but excluding milestone payments based on annual sales or annual net sale) in connection with all such acquisitions since the Closing Date shall not exceed [***]; and (y) on and after the Sales Milestone Date, total cash consideration paid with respect to milestone payments based on FDA approval shall not exceed [***]; provided, that, in each case, the payment in cash of any deferred purchase price, earnouts or other contingent acquisition consideration shall be subject to compliance with the requirement set forth in clause (d) above. ÆœPermitted Convertible IndebtednessÆ means (x) Indebtedness of the Borrower in respect of the Existing Notes and (y) other Indebtedness of the Borrower that is convertible based on a fixed conversion rate (subject to customary anti-dilution adjustments, Æœmake-wholeÆ increases and other customary changes thereto) into shares of Common Stock of the Borrower or other securities or property following a merger A - 37A - A | A event or other change of the Common Stock of the Borrower, cash or any combination thereof (with the amount of such cash or such combination determined by reference to the market price of such Common Stock or such other securities); provided that (a) at the time such Indebtedness is incurred, no Default or Event of Default has occurred and is continuing or would occur as a result of such incurrence, (b) all necessary corporate, company, shareholder or similar actions shall be taken and consents obtained in connection with the issuance of such Indebtedness, (c) the issuance of such Indebtedness shall be consummated in compliance with all applicable Requirements of Law, and (d) the documentation evidencing such Indebtedness shall have been delivered to Administrative Agent and shall be subject to customary terms for similar convertible transactions in the public markets (as determined by the Borrower in good faith), including all of the following terms: (i) it shall be (and shall remain at all times) unsecured, (ii) it shall not have a maturity (and shall not have any scheduled amortization or other scheduled payments of principal) prior to the date that is [***] after the Stated Term Loan Maturity Date, (iii) it shall not have any negative covenants (other than customary covenants limiting dispositions, mergers and consolidations), (iv) it shall have no restrictions on the BorrowerÆ™s ability to grant liens securing the Obligations, (v) it shall not prohibit the incurrence of the Obligations, (vi) it is not guaranteed by any Subsidiary of the Borrower, and (vii) any cross-default or cross-acceleration event of default (each however defined) provision contained therein that relates to indebtedness or other payment obligations of Borrower (or any of its Subsidiaries) (such indebtedness or other payment obligations, a ÆœCross-Default Reference ObligationÆ) contains a cure period of at least [***] (after written notice to the issuer of such Indebtedness by the trustee or to such issuer and such trustee by holders of at least [***] in aggregate principal amount of such Indebtedness then outstanding) before a default, event of default, acceleration or other event or condition under such Cross-Default Reference Obligation results in an event of default under such cross-default or cross-acceleration provision. ÆœPermitted Equity DerivativesÆ means any forward purchase, accelerated share repurchase, call option, warrant or other derivative transactions in respect of the BorrowerÆ™s Capital Stock; provided, that (x) such transaction shall be classified in the BorrowerÆ™s stockholdersÆ™ equity under ASC 815-40 or any successor provision and (y) the terms, conditions and covenants of each such transaction shall be customary for transactions of such type, as determined by the Borrower in good faith. ÆœPermitted IndebtednessÆ means: (a) the Obligations; (b) to the extent constituting Indebtedness, Permitted Intercompany Investments; provided, that such Indebtedness shall be unsecured and the parties thereto are party to an Intercompany Subordination Agreement; (c) Indebtedness incurred by the Borrower or any of its Subsidiaries arising from agreements providing for indemnification or from guaranties or letters of credit, surety bonds or performance bonds securing the performance of Borrower or any such Subsidiary pursuant to such agreements, in connection with Permitted Acquisitions or Asset Sales permitted hereunder; (d) Indebtedness which may be deemed to exist pursuant to any guaranties, performance, surety, statutory, appeal or similar obligations incurred in the ordinary course of business and Indebtedness constituting guaranties in the ordinary course of business of the obligations of suppliers, customers, franchisees and licensees of the Borrower and its Subsidiaries; (e) Indebtedness incurred in the ordinary course of business in connection with workersÆ™ compensation, unemployment insurance and other types of social security, or to secure the performance of A - 38A - A | A tenders, statutory obligations, surety and appeal bonds, bids, leases, government contracts, trade contracts, performance and return of money bonds and other similar obligations; (f) Indebtedness arising from the honoring by a bank or other financial institution of a check, draft or similar instrument inadvertently (except in the case of daylight overdrafts) drawn against insufficient funds in the ordinary course of business; provided, however, that such Indebtedness is extinguished within [***] of incurrence; (g) Indebtedness outstanding on the Closing Date and described on Schedule 6.1, and any Permitted Refinancing Indebtedness in respect of such Indebtedness; (h) Indebtedness with respect to (i) Capital Leases and (ii) purchase money Indebtedness (including any Indebtedness acquired in connection with a Permitted Acquisition) in an aggregate amount outstanding not to exceed \$[***] at any time, and together with the aggregate outstanding amount of Indebtedness described in clause (l) below, \$[***]; provided that any such Indebtedness shall be secured only by the asset subject to such Capital Lease or by the asset acquired in connection with the incurrence of such Indebtedness; (i) guaranties with respect to Indebtedness of the Borrower or any of its Subsidiaries, to the extent that the Person that is obligated under such guaranty could have incurred such underlying Indebtedness to the extent such guaranties are not prohibited by Section 6.7; provided that, if the Indebtedness being guaranteed is subordinated to the Obligations, such guaranty shall be subordinated to the Obligations on terms at least as favorable to the Secured Parties as those contained in the subordination of such Indebtedness; (j) Indebtedness owed to any Person providing property, casualty, liability, or other insurance to the Loan Parties, so long as the amount of such Indebtedness is not in excess of the amount of the unpaid cost of, and shall be incurred only to defer the cost of, such insurance for the period in which such Indebtedness is incurred and such Indebtedness is outstanding only during such period; (k) contingent liabilities in respect of any indemnification obligation, adjustment of purchase price, non-compete, or similar obligation of any Loan Party incurred in connection with the consummation of one or more Permitted Acquisitions; (l) Indebtedness of a Person whose assets or Capital Stock are acquired by the Borrower or any of its Subsidiaries in a Permitted Acquisition in an aggregate amount outstanding not to exceed, together with the aggregate outstanding amount of Indebtedness described in clause (h) above, \$[***]; provided, that such Indebtedness (i) is either purchase money Indebtedness or a Capital Lease with respect to equipment or mortgage financing with respect to a facility, (ii) was in existence prior to the date of such Permitted Acquisition, and (iii) was not incurred in connection with, or in contemplation of, such Permitted Acquisition; (m) (i) Permitted Convertible Indebtedness in respect thereof in an aggregate outstanding principal amount not to exceed at any time, the greater of (x) \$[***] and (y) [***] of the BorrowerÆ™s Market Capitalization (determined as of the date of pricing of any such Permitted Convertible Indebtedness) and (ii) any Permitted Refinancing Indebtedness in respect thereof; (n) [reserved]; A - 39A - A | A (o) earnouts, holdbacks, seller notes, deferred purchase price or other similar obligations incurred in connection with Permitted Acquisitions or similar Permitted Investments in an aggregate outstanding amount not to exceed \$[***] at any time; (p) any Permitted Royalty Monetization Transaction; (q) Indebtedness of the Borrower or any of its Subsidiaries in respect of treasury, depository, credit or debit card, purchasing cards, or cash management services or any automated clearing house transfers of funds, netting services, overdraft protections and otherwise in connection with deposit, securities, and commodities accounts arising in the ordinary course of business; (r) reimbursement obligations in connection with letters of credit, bank guarantees or similar extensions of credit, in an aggregate outstanding amount not to exceed \$[***] at any time; (s) obligations (contingent or otherwise) existing or arising under any Interest Rate Agreement and any Currency Agreement; (t) Subordinated Indebtedness in an aggregate outstanding amount not to exceed \$[***]; (u) Indebtedness of Joint Ventures or Non-Loan Parties, in an aggregate outstanding amount not to exceed at any time \$[***]; (v) [reserved]; (w) other Indebtedness of the Borrower and its Subsidiaries, in an aggregate outstanding amount not to exceed at any time \$[***]; provided that no Indebtedness between a Loan Party that is not a [***] Subsidiary and not a [***] Subsidiary, on the one hand, and a [***] Subsidiary or [***] Subsidiary, on the other hand, shall be permitted under this clause (w); (x) to the extent constituting Indebtedness, any liability arising as a result of the (establishment) of a fiscal unity (fiscale eenheid) for corporate income tax (vennootschapsbelasting) and/or value added tax (omzetbelasting) purposes between Dutch Guarantors; and (y) any guarantee or indemnity pursuant to section 2:403 DCC in respect of any Dutch Guarantor and any residual liability with respect to such guarantees or indemnity arising under Section 2:404 DCC. For purposes of determining compliance with any Dollar-denominated restriction on the incurrence of Indebtedness, the Dollar equivalent principal amount of Indebtedness denominated in a foreign currency shall be calculated based on the relevant currency exchange rate in effect on the date such Indebtedness was incurred, in the case of term debt, or first committed, in the case of revolving credit debt. ÆœPermitted Intercompany InvestmentsÆ means Investments by (a) a Loan Party to or in another Loan Party; provided that, the aggregate amount of Investments in [***] made on or after [***] pursuant to this clause (a), the proceeds of which are used, directly or indirectly, for the further development or commercialization of any Designated Asset, shall be subject to the limits set forth in clauses (1) and (2) in the third to last proviso of this definition; (b) a Non-Loan Party to or in another Non-Loan Party; (c) a Non-Loan Party to or in a Loan Party, so long as, in the case of a loan or an advance, the parties thereto are party to an Intercompany Subordination Agreement, and (d) a Loan Party to a Subsidiary that is a Non-Loan Party; provided that, with respect to the making of any Investment pursuant to this clause (d), as of the date of such Investment, (i) no Default or Event of Default shall have occurred and be continuing or would result A - 40A - A | A therefrom, (ii) the aggregate outstanding amount of all such Investments as of such date shall not exceed the Available Investment Amount, and (iii) the Borrower and its Subsidiaries shall be in compliance, on a pro forma basis, with the Permitted Transaction Qualified Cash Requirement after giving effect to such Investment; provided further that, no Product, Product Patent or Registration shall be assigned, transferred, contributed, licensed, sublicensed, or otherwise disposed by any Loan Party pursuant to this clause (d) other than Permitted Product Agreements; provided further that, notwithstanding anything to the contrary, the aggregate amount of Investments

made in the [***] Subsidiaries by the [***] Subsidiary Loan Parties on or after the Closing Date shall (1) be limited to investments consisting solely of Cash and Cash Equivalents and (2) not exceed [***] in the aggregate during the [***] after the Closing Date, which cap shall be increased by an additional \$[***] in the aggregate during the [***] (in each case, plus up to an amount equal to [***]% of Additional Equity Proceeds to the extent included in the Available Investment Amount); provided no Investments shall be permitted in any [***] Subsidiary from and after the [***] of the Closing Date; provided further that, notwithstanding anything to the contrary, the aggregate amount of Investments made in the [***] Subsidiaries by the [***] Loan Parties on or after [***] shall (1) be limited to investments consisting solely of Cash and Cash Equivalents and (2) not exceed the amount necessary to maintain such [***] Subsidiaryâ€™s existence and good standing (after giving effect to the Cash and Cash Equivalents then held by such [***] Subsidiary). â€œPermitted Investmentsâ€ means: (a) Investments in Cash and Cash Equivalents; (b) Investments consisting of notes receivable of the Loan Parties, or prepaid royalties and other credit extensions made by the Loan Parties in the ordinary course of business, in an aggregate amount not to exceed \$[***] at any one time outstanding; (c) Permitted Intercompany Investments; (d) loans and advances to employees of the Borrower and its Subsidiaries made in the ordinary course of business in an aggregate outstanding amount not to exceed \$[***]; (e) Permitted Acquisitions; (f) Investments existing on the Closing Date and described on Schedule 6.7; provided, that, as of the First Amendment Effective Date, the Investments listed in clauses (9) through (22) of Schedule 6.7 shall cease to be permitted under this clause (f); (g) any Investments consisting of extensions of credit in the nature of accounts receivable or notes receivable arising from the grant of trade credit in the ordinary course of business or received in compromise or resolution of (i) obligations of trade creditors or customers that were incurred in the ordinary course of business of the Borrower or any of its Subsidiaries, including pursuant to any plan of reorganization or similar arrangement upon the bankruptcy or insolvency of any trade creditor or customer or (ii) litigation, arbitration or other disputes; (h) Investments in negotiable instruments deposited or to be deposited for collection in the ordinary course of business; (i) Investments in the ordinary course of business consisting of customary trade arrangements with customers; â - 41A - â | â (j) advances made in connection with purchases of goods or services in the ordinary course of business; (k) Investments held by a Person acquired in a Permitted Acquisition to the extent that such Investments were not made in contemplation of or in connection with such Permitted Acquisition and were in existence on the date of such Permitted Acquisition; (l) Investments in Joint Ventures using the Available Investment Amount so long as (i) no Default or Event of Default shall have occurred and be continuing or would result therefrom and (ii) the Borrower and its Subsidiaries shall be in compliance, on a pro forma basis, with the Permitted Transaction Qualified Cash Requirement after giving effect to such Investment; (m) Investments in Interest Rate Agreements and Currency Agreements permitted by clause (s) of the definition of Permitted Indebtedness; (n) Permitted Equity Derivatives purchased with the proceeds of Permitted Convertible Indebtedness permitted pursuant to Section 6.5(g); (o) to the extent constituting Investments, advances in respect of transfer pricing and cost-sharing arrangements (i.e., â€œcost-plusâ€ arrangements) that are in the ordinary course of business and permitted pursuant to Section 6.12; (p) Investments accepted by a Loan Party in connection with an Asset Sale permitted hereunder; (q) Investments received in connection with the bankruptcy or reorganization of a customer or supplier in the ordinary course of business; (r) guarantees of operating leases or of other obligations of any Loan Party permitted under this Agreement that do not constitute Indebtedness, in each case, entered into by any Loan Party in the ordinary course of business; (s) so long as no Event of Default has occurred and is continuing or would result therefrom, other Investments in an aggregate amount not to exceed \$[***] per Fiscal Year (with any unused amounts for any Fiscal Year ended after the Closing Date permitted to be carried over to the next Fiscal Year but not any subsequent Fiscal Year) plus the amount of Net Proceeds received by Borrower from the issuance of Qualified Capital Stock of Borrower substantially contemporaneously with the making of such Investment to the extent included in the Available Investment Amount; provided that, with respect to any Investments made using Additional Equity Proceeds, such Investments must, substantially contemporaneously with the making of such Investment, become Collateral hereunder; and (t) (x) purchases of securities under the Designated Securities Account occurring after the Closing Date and prior to the First Amendment Effective Date to the extent purchased with proceeds of the Investments held in the Designated Securities Account as of the Closing Date and (y) subject to compliance with Section 4 of the First Amendment, Investments held in the Designated Securities Account, which shall be limited to (i) the Investments held therein as of the First Amendment Effective Date and (ii) any proceeds of such Investments described in the foregoing subclause (i) in the form of cash or Cash Equivalents. â€œPermitted Liensâ€ means: A - 42A - â | â (a) Liens in favor of Administrative Agent for the benefit of Secured Parties granted pursuant to any Loan Document; (b) Liens for Taxes (i) not yet due and payable or (ii) if obligations with respect to such Taxes are being contested in good faith by appropriate proceedings promptly instituted and diligently conducted and reserves required by GAAP have been made; (c) statutory Liens of landlords, banks (and rights of set off), of carriers, warehousemen, mechanics, repairmen, workmen and materialmen, and other Liens imposed by law (other than any such Lien imposed pursuant to Section 430(k) of the Internal Revenue Code or by ERISA), in each case incurred in the ordinary course of business for amounts not yet overdue; (d) Liens incurred in the ordinary course of business in connection with workersâ€™ compensation, unemployment insurance and other types of social security, or to secure the performance of tenders, statutory obligations, surety and appeal bonds, bids, leases, government contracts, trade contracts, performance and return of money bonds and other similar obligations (exclusive of obligations for the payment of borrowed money or other Indebtedness), so long as no foreclosure, sale or similar proceedings have been commenced with respect to any portion of the Collateral on account thereof; (e) easements, rights of way, restrictions, encroachments, and other minor defects or irregularities in title, in each case which do not and will not interfere in any material respect with the ordinary conduct of the business of the Borrower or any of its Subsidiaries; (f) any interest or title of a lessor or sublessor under any lease of real estate permitted hereunder; (g) Liens solely on any cash earned money deposits made by the Borrower or any of its Subsidiaries in connection with any letter of intent or purchase agreement permitted hereunder; (h) purported Liens evidenced by the filing of precatory UCC financing statements relating solely to operating leases of personal property entered into in the ordinary course of business; (i) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods; (j) any zoning or similar law or right reserved to or vested in any governmental office or agency to control or regulate the use of any Real Property; (k) Liens existing on the Closing Date and described on Schedule 6.2; provided that any such Lien shall only secure the Indebtedness that it secures on the Closing Date and any Permitted Refinancing Indebtedness in respect thereof; (l) Liens securing Capital Leases or purchase money Indebtedness permitted pursuant to clause (h) of the definition of Permitted Indebtedness; provided, any such Lien shall encumber only the asset subject to such Capital Lease or the asset acquired with the proceeds of such Indebtedness; (m) Liens granted in the ordinary course of business on the unearned portion of insurance premiums securing the financing of insurance premiums to the extent the financing is permitted under the definition of Permitted Indebtedness; â - 43A - â | â (n) Liens assumed by the Borrower and its Subsidiaries in connection with a Permitted Acquisition that secure Indebtedness permitted by clause (l) of the definition of Permitted Indebtedness; (o) Liens solely on any cash securing Indebtedness permitted pursuant to clause (r) of the definition of Permitted Indebtedness; (p) Liens securing any judgments, writs or warrants of attachment or similar process not constituting an Event of Default under Section 8.1(h); (q) Liens that are contractual rights of setoff relating to purchase orders entered into with customers, vendors or suppliers of such Person in the ordinary course of business; (r) leases, subleases, licenses or sublicenses that are (i) permitted by Section 6.9(b) or (ii) excluded from the definition of Asset Sale; (s) bankersâ€™ Liens, rights of setoff and other similar Liens existing solely with respect to cash and Cash Equivalents on deposit in one or more accounts maintained by the Borrower or its Subsidiaries, in each case granted in the ordinary course of business in favor of the bank or banks with which such accounts are maintained, securing amounts owing to such bank with respect to cash management and operating account arrangements, including those involving pooled accounts and netting arrangements, as part of a bankâ€™s standard term and conditions, including Liens arising under the general terms and conditions (Algemene Bankvoorwaarden) of any member of the Dutch Bankersâ€™ Association (Nederlandse Vereniging van Banken) or any similar term applied by financial institutions in the Netherlands pursuant to its general terms and conditions and Liens arising under the general terms and conditions (Allgemeine Geschâftsbedingungen) of any Swiss bank with which such accounts are maintained in Switzerland; provided, that, unless such Liens are nonâ€™consensual and arise by operation of law, in no case shall any such Liens secure (either directly or indirectly) the repayment of any Indebtedness; (t) Liens of a collecting bank arising in the ordinary course of business under Section 4â€™208 of the UCC in effect in the relevant jurisdiction covering only the items being collected upon; (u) Liens securing Indebtedness of Joint Ventures or Non-Loan Parties permitted pursuant to clause (u) of the definition of Indebtedness so long as such Liens do not encumber any assets of the Loan Parties; (v) (i) subject to the Acoramidis Intercreditor Agreement, Liens granted under the Acoramidis Revenue Transaction Documents; (ii) subject to any Acceptable Intercreditor Agreement, Liens granted under the definitive documents governing any other Permitted Royalty Monetization Transaction (including the [***]); and (iii) customary back-up security interests granted under any Permitted Royalty Monetization Transaction; (w) Liens on cash collateral in an aggregate amount not to exceed \$[***] securing Indebtedness permitted pursuant to clause (q) of the definition of Permitted Indebtedness; (x) Liens on cash collateral in an aggregate amount not to exceed \$[***] securing Indebtedness permitted pursuant to clause (s) of the definition of Permitted Indebtedness; (y) in respect of a Dutch Guarantor or in connection with any security in the Netherlands, a retention of title arrangement (eigendomsvoorbehoud), privilege (voorrecht), a right of retention (recht van retentie) or a right to reclaim goods (recht van reclame) in the ordinary course of business; and A - 44A - â | â (z) other Liens on assets of the Borrower or any Subsidiary of the Borrower with respect to obligations that do not exceed \$[***] at any one time outstanding. Notwithstanding the foregoing, no Liens on any Product, Product Patent or Registrations shall be permitted (other than non-consensual Liens constituting â€œPermitted Liensâ€ and Liens described in clauses (a), (r) and (v) above). â€œPermitted Product Agreementâ€ means, with respect to any Product, (x) each of the Product Agreements existing on the Closing Date and set forth on Schedule 4.23(b) and (y) each other Product Agreement that grants a license or sublicense of any rights under any Product Intellectual Property Rights or Registrations that allows such Person to develop, manufacture or Commercialize such Product, but, solely with respect to any exclusive license or exclusive sublicense, only outside of the United States and its territories; provided, that, in the case of this clause (y), any such Product Agreement (i) shall not provide for the legal transfer of title to any Product Intellectual Property Rights or Registrations relating to a Product, other than the legal transfer of Registrations to licensees or sublicensees pursuant to such Product Agreement for such counterparty to hold in order to develop or Commercialize the Product that is the subject of such Registration in the applicable foreign jurisdiction other than the United States and its territories, (ii) does not restrict or penalize the disclosure of royalty and similar reports to the Administrative Agent and the Lenders in accordance with Section 5.1(e)(i) hereof and (iii) shall not constitute a Restricted License. For the avoidance of doubt, if a Product Agreement grants [***] such Product Agreement shall not be a â€œPermitted Product Agreement.â€ For clarity, unless otherwise set forth under clauses (i), (ii) or (iii) above, if a Product Agreement grants [***], such Product Agreement shall be a â€œPermitted Product Agreementâ€. â€œPermitted Product Agreement Transactionâ€ means a license or sublicense transaction pursuant to a Permitted Product Agreement; provided that (i) the consideration received for any such transaction shall be in an amount at least equal to the fair market value thereof (as reasonably determined by the Borrowerâ€™s Board of Directors), (ii) no Event of Default shall have occurred and be continuing at the time of such transaction or result therefrom and (iii) no proceeds thereof shall be used to finance the repurchase of Capital Stock of the Borrower or pay dividends on any Capital Stock of the Borrower. â€œPermitted Refinancing Indebtednessâ€ means any Indebtedness of the Borrower or any of its Subsidiaries issued in exchange for, or the Net Proceeds of which are used to renew, refund, refinance, replace, defease or discharge other Indebtedness of the Borrower or any of its Subsidiaries; provided that: (a) the principal amount (or accreted value, if applicable) of such Permitted Refinancing Indebtedness does not exceed the principal amount (or accreted value, if applicable) of the Indebtedness renewed, refunded, refinanced, replaced, defeased or discharged (plus all accrued interest on the Indebtedness and the amount of all fees and expenses, including premiums, incurred in connection therewith); (b) such Permitted Refinancing Indebtedness has a final maturity date later than the final maturity date of, and has a Weighted Average Life to Maturity equal to or greater than the Weighted Average Life to Maturity of, the Indebtedness being renewed, refunded, refinanced, replaced, defeased or discharged; (c) if the Indebtedness being renewed, refunded, refinanced, replaced, defeased or discharged is subordinated in right of payment to the Obligations, such Permitted Refinancing Indebtedness is subordinated in right of payment to, the Obligations on terms at least as favorable to Administrative Agent and the Lenders as those contained in the documentation governing the Indebtedness being renewed, refunded, refinanced, replaced, defeased or discharged; â - 45A - â | â (d) the obligors under, and assets encumbered by the Liens securing, such Permitted Refinancing Indebtedness shall be limited to the obligors under, and assets securing, the Indebtedness being renewed, refunded, refinanced, replaced, defeased or discharged; and (e) in the case of Permitted Convertible Indebtedness, such Indebtedness complies with the terms set forth in the proviso of the definition of Permitted Convertible Indebtedness. â€œPermitted Royalty Monetization Transactionâ€ means, collectively, (a) the Acoramidis Revenue Transaction, (b) the [***] and (c) any other Royalty Monetization Transaction in respect of any Product that consists of the sale or disposition of either (x) revenues or rights to revenues with respect to such Product (any such Royalty Monetization Transaction, a â€œRevenue RMTâ€) or (y) any monetary payments (contingent or otherwise) payable to the Borrower or its Subsidiaries by a counterparty under a Permitted Product Agreement (any such Royalty Monetization Transaction, a â€œPayment RMTâ€), so long as, in each case of this clause (c): (i) solely in the case of any Revenue RMT, the aggregate amount of revenues or rights to revenues sold or otherwise disposed pursuant to such Revenue RMT, together with all other Revenue RMTs with respect to such Product (including any revenue participation interests sold or disposed of under the Acoramidis Revenue Transaction (solely with respect to Acoramidis) or the [***] (solely with respect to [***])), shall not to exceed [***]% of net sales of such Product, (ii) solely in the case of any Payment RMT, the aggregate amount of monetary payments sold or otherwise disposed pursuant to such Payment RMT, together with all other Payment RMTs with respect to such Product, shall not to exceed \$[***], (iii) the consideration received for such transaction shall be in an amount at least equal to the fair market value thereof (as reasonably determined by the Borrowerâ€™s Board of Directors), (iv) the terms of such transaction shall be (A) substantially consistent with the Acoramidis Revenue Transaction or (B) otherwise reasonably acceptable to the Administrative Agent, (v) such transaction is subject to an Acceptable Intercreditor Agreement to the extent secured by any assets of the Borrower or its Subsidiaries (except where such security interest consists solely of a customary back-up security interest, in which case, such transaction shall not be required to be subject to an Acceptable Intercreditor Agreement unless the counterparty to such transaction has required that the Administrative Agent release its Liens on the monetary payments sold or otherwise disposed pursuant to such transaction), (vi) the economic terms of such transaction shall be reasonable and customary for similar transactions, (vii) such transaction shall not (x) require the payment of any milestones, true-ups or other payments that are capable of resulting in aggregate payments in respect of such transaction becoming due and payable prior to the earlier of (i) the payment in full of the Obligations (other than such contingent obligations or liabilities hereunder that by the express terms thereof survive such payment in full of all Obligations) and (ii) the date that is [***] after the Stated Term Loan Maturity Date, when taken together with all royalty and other similar payments made to the counterparty to such transaction during any Fiscal Year and any payments under any other Royalty Monetization Transaction in respect of the same Product or Products during such Fiscal Year, in excess of [***]% of such net sales of such Product or Products for such Fiscal Year or (y) include any financial maintenance covenants, including, without limitation, any minimum cash requirement and (viii) unless the Acoramidis Revenue Transaction shall have terminated or except to the extent permitted under the Acoramidis Revenue Transaction Agreement, any Permitted Royalty Monetization Transaction in respect of Acoramidis shall be (1) unsecured (and shall not include any back-up security interests) and (2) structured as a Payment RMT (and not a Revenue RMT). â€œPermitted Transaction Qualified Cash Requirementâ€ means, with respect to any applicable transaction, the Loan Parties have, on a pro forma basis after giving effect to such transaction, Qualified Cash in amount not less than the greater of (x) \$[***] and (y) [***]. â€œPersonâ€ means and includes natural persons, corporations, companies, limited partnerships, general partnerships, limited liability companies, limited liability partnerships, joint stock companies, Joint A - 46A - â | â Ventures, associations, companies, trusts, banks, trust companies, land trusts, business trusts or other organizations, whether or not legal entities, and Governmental Authorities. â€œPersonal Informationâ€ means any information (i) that identifies or can be reasonably used to identify a natural person, or (ii) defined as â€œpersonal data,â€ â€œpersonal information,â€ â€œprotected health information,â€ â€œpersonal data,â€ or similar term under applicable Data Protection Laws. â€œPledge and Security Agreementâ€ means the Pledge and Security Agreement executed by Grantors in favor of Administrative Agent for the benefit of the Secured Parties. â€œPrepayment Premiumâ€ has the meaning specified in the Fee Letter. â€œPrime Rateâ€ means the rate of interest quoted in The Wall Street Journal, Money Rates Section as the Prime Rate (currently defined as the base rate on corporate loans posted by at least 75% of the nationâ€™s thirty (30) largest banks), as in effect from time to time. The Prime Rate is a reference rate and does not necessarily represent the lowest or best rate actually charged to any customer. The Administrative Agent or any other Lender may make commercial loans or other loans at rates of interest at, above or below the Prime Rate. â€œPrincipal Officeâ€ means Administrative Agentâ€™s â€œPrincipal Officeâ€ as set forth on Appendix B, or such other office as such Person may from time to time designate in writing to Borrower and each Lender. â€œPriority Review Voucherâ€ means a voucher issued by the FDA to the sponsor of a rare pediatric disease product

application, as such term is defined in 21 U.S.C. Â§ 360ff, which entitles the holder of such voucher to priority review of an NDA after the date of approval of the rare pediatric disease product application. â€œPrivacy Policiesâ€ means the meaning specified in Section 4.36. â€œPro Rata Shareâ€ means, with respect to: (a) a Lenderâ€™s obligation to make the Initial Term Loan, the percentage obtained by dividing (i) such Lenderâ€™s Initial Term Loan Commitment by (ii) the Total Initial Term Loan Commitment; (b) a Lenderâ€™s right to receive payments of interest, fees and principal with respect to a Term Loan, the percentage obtained by dividing (i) the aggregate unpaid principal amount of such Lenderâ€™s portion of the Term Loan, by (ii) the aggregate unpaid principal amount of the Term Loan; and (c) all other matters, the percentage obtained by dividing (i) the aggregate unpaid principal amount of such Lenderâ€™s portion of the Term Loan, by (ii) the aggregate unpaid principal amount of the Term Loan. â€œProductâ€ means Acoramidis, Infigratinib, Encaleret, Fosdenopterin, and any other product/product candidate being developed or Commercialized by the Borrower or any of its Subsidiaries from time to time, including but not limited to any acquired Product that is acquired or in-licensed pursuant to a Permitted Acquisition. â€œProduct Agreementâ€ means any agreement entered into between Borrower or any of its Subsidiaries with another Person that includes the granting of a license or sublicense of any rights under any Product Intellectual Property Rights or Registrations that allows such Person to develop, manufacture or Commercialize a Product. Â - 47A - A | Â â€œProduct Intellectual Property Rightsâ€ means (a) the Product Patents and (b) any and all Intellectual Property Rights owned by or exclusively licensed to, or purported to be owned by or exclusively licensed to, the Borrower or its Affiliates relating to any Product. â€œProduct Milestoneâ€ means the date on which the FDA approves a first NDA for Acoramidis; provided (i) that the approved labeling for such Product does not include a Boxed Warning and (ii) the FDA has not required a REMS for such Product in the United States. â€œProduct Milestone Dateâ€ means the date on which the Borrower shall have delivered a certificate representing and warranting, and otherwise demonstrating to the reasonable satisfaction of Administrative Agent, as confirmed in writing by Administrative Agent (such confirmation not to be unreasonably delayed, withheld or conditioned), that the Product Milestone has been achieved. â€œProduct Patentsâ€ means the U.S. and foreign Patents and pending Patent applications owned or in-licensed by Borrower or any of its Subsidiaries, now or in the future, that relate to, or otherwise may be useful in connection with, the research, development, manufacture, use, or sale of one or more of the Products. â€œProduct Revenueâ€ means, for any period, [***], all, in respect of clauses (a) and (b), as determined in accordance with GAAP and calculated on a basis consistent with the Historical Financial Statements delivered to Administrative Agent prior to the Closing Date. â€œProjectionsâ€ has the meaning specified in Section 5.1(u). â€œProtective Advancesâ€ has the meaning specified in Section 9.11. â€œPublic Health Lawsâ€ means all Requirements of Law governing the procurement, development, clinical and non-clinical evaluation, product approval or licensure, manufacture, production, analysis, distribution, dispensing, importation, exportation, use, handling, quality, sale, labeling, promotion, clinical trial registration or post market requirements of any drug, biologic or other product subject to regulation under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Â§ 301 et seq.) and the Public Health Service Act (42 U.S.C. Â§ 201 et seq.), including without limitation the regulations promulgated by the FDA at Title 21 of the Code of Federal Regulations. â€œQualified Capital Stockâ€ means, with respect to any Person, all Capital Stock of such Person that is not Disqualified Capital Stock. â€œQualified Cashâ€ means, as of any date of determination, the sum of (i) unrestricted Cash and Cash Equivalents (other than restrictions created by the Collateral Documents) of the Loan Parties held in Deposit Accounts or in Securities Accounts, or any combination thereof, which such Deposit Accounts or Securities Accounts are subject to a Control Agreement or an Account Charge, less (ii) the Aged Payables Amount; provided, that during the applicable period specified in paragraph 1 of Schedule 5.15, all Cash and Cash Equivalents of the Loan Parties maintained in Deposit Accounts or Securities Accounts that will be subject to a Control Agreement or any Account Charge by the end of such period shall be deemed to be Qualified Cash, notwithstanding the fact that such account may not be subject to a Control Agreement or any Account Charge, as applicable, at such time. â€œQualifying Productâ€ means, for purposes of Section 8.1(o), any of [***]. Â - 48A - A | Â â€œReal Estate Assetâ€ means, at any time of determination, any Real Property owned by a Loan Party, but only to the extent such Real Property constitutes Collateral and is encumbered by a Mortgage pursuant to the terms of this Agreement. â€œReal Propertyâ€ means any real property (including all buildings, fixtures or other improvements located thereon) now, hereafter or heretofore owned, leased, operated or used by Borrower or any of its Subsidiaries. â€œRecipientâ€ means (a) the Administrative Agent or (b) any Lender. â€œRefinancing Convertible Indebtednessâ€ has the meaning specified in Section 6.17. â€œRegistrarâ€ has the meaning specified in Section 2.3(b). â€œRegistrationsâ€ shall mean authorizations, approvals, licenses, permits, certificates, registrations, listings, certificates, or exemptions of or issued by any Governmental Authority that are required for the research, development, manufacture, commercialization, distribution, marketing, storage, transportation, pricing, Governmental Authority reimbursement, use and sale of Products. â€œRegulation Dâ€ means Regulation D of the Federal Reserve Board, as in effect from time to time. â€œRegulatory Actionâ€ means an administrative or regulatory enforcement action, proceeding or investigation, warning letter, untitled letter, Form 483 or similar inspectional observations, other notice of violation letter, recall, seizure, Section 305 notice or other similar written communication, or consent decree, issued or required by the FDA or under the Public Health Laws, or a comparable Governmental Authority in any other regulatory jurisdiction. â€œRegulatory Withdrawal Noticeâ€ has the meaning specified in Section 8.1(o). â€œReinvestment Amountsâ€ has the meaning specified in Section 2.10(a)(i). â€œRelated Fundâ€ means, with respect to any Lender that is an investment fund, any other investment fund that invests in commercial loans and that is managed or advised by the same investment advisor as such Lender or by an Affiliate of such investment advisor. â€œ[***] Cash Amountâ€ means, as of any date of determination, the product of (i) [***], multiplied by (ii) [***]%. â€œReleaseâ€ means any release, spill, emission, leaking, pumping, pouring, injection, escaping, deposit, disposal, discharge, dispersal, dumping, leaching or migration of any Hazardous Material into the indoor or outdoor environment (including the abandonment or disposal of any barrels, containers or other closed receptacles containing any Hazardous Material), including the movement of any Hazardous Material through the air, soil, surface water or groundwater. â€œRelevant Governmental Bodyâ€ means the Federal Reserve Board or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Federal Reserve Board or the Federal Reserve Bank of New York, or any successor thereto. â€œRemedial Actionâ€ means all actions taken to (a) correct or address any actual or threatened non-compliance with Environmental Law, (b) clean up, remove, remediate, contain, treat, monitor, assess, evaluate or in any other way address Hazardous Materials in the indoor or outdoor environment, (c) prevent Â - 49A - A | Â or minimize a Release or threatened Release of Hazardous Materials so they do not migrate or endanger or threaten to endanger public health or welfare or the indoor or outdoor environment, (d) perform pre-remedial studies and investigations and post-remedial operation and maintenance activities; or (e) perform any other actions authorized or required by Environmental Law or Governmental Authority. â€œREMSâ€ means a risk evaluation and mitigation strategy, to the extent required by the FDA pursuant to 21 U.S.C. Â§ 355-1. â€œReplacement Designated Securities Accountâ€ has the meaning assigned to such term in the First Amendment. â€œReplacement Lenderâ€ has the meaning specified in Section 2.18. â€œRequired Lendersâ€ means, as of any date of determination, Lenders whose Pro Rata Share (calculated in accordance with clause (c) of the definition thereof) aggregate at least [***]% as of such date; provided, that, Required Lenders shall include (x) Blue Owl if, as of such date, Blue Owl and its Affiliates and Related Funds collectively hold at least the lesser of (i) [***]% and (ii) [***] of the outstanding principal amount of the Term Loans and (y) CPPIB if, as of such date, CPPIB holds at least the lesser of (i) [***]% and (ii) [***] of the outstanding principal amount of the Term Loans. â€œRequired Prepayment Dateâ€ has the meaning specified in Section 2.11(b). â€œRequirements of Lawâ€ means, with respect to any Person, collectively, the common law and all federal, state, provincial, local, foreign, multinational or international laws, statutes, codes, treaties, standards, rules and regulations, guidelines, ordinances, orders, judgments, writs, injunctions, decrees (including administrative or judicial precedents or authorities) and the interpretation or administration thereof by, and other determinations, directives or requirements of, any Governmental Authority, in each case that are binding upon such Person or any of its property or to which such Person or any of its property is subject. â€œResolution Authorityâ€ means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority. â€œRestricted Junior Paymentâ€ means (a) any dividend or other distribution, direct or indirect, on account of any shares of any class of Capital Stock of the Borrower now or hereafter outstanding, except a dividend payable solely in shares of Capital Stock to the holders of that class, together with any payment or distribution pursuant to a â€œplan of divisionâ€ under the Delaware Limited Liability Act or any comparable transaction under any similar law, (b) any redemption, retirement, sinking fund or similar payment, purchase or other acquisition for value, direct or indirect, of any shares of any class of Capital Stock of the Borrower or any Non-Loan Party now or hereafter outstanding, (c) any payment made to retire, or to obtain the surrender of, any outstanding warrants, options or other rights to acquire shares of any class of Capital Stock of the Borrower or any Non-Loan Party now or hereafter outstanding, (d) any payment made with respect to any Royalty Monetization Transaction, and (e) any payment or prepayment of principal of, premium, if any, or interest on, or redemption, purchase, retirement, defeasance (including in substance or legal defeasance), sinking fund or similar payment with respect to, any Indebtedness that is contractually subordinated to the Obligations. â€œRestricted Licenseâ€ means any Product Agreement entered into on or after the Closing Date that (i) includes provisions restricting or penalizing the granting of a security interest in, or Lien on, such Product Agreement or the related Product Intellectual Property Rights (other than customary non-assignment provisions that are rendered ineffective under the UCC), (ii) restricts the assignment of such Product Â - 50A - A | Â Agreement upon the sale or other disposition of all or substantially all of the assets to which such Product Agreement relates (other than customary provisions requiring the assumption by the applicable purchaser of all obligations under such Product Agreement), or (iii) does not permit the disclosure of information to be provided thereunder to Administrative Agent and the Lenders, any purchaser or prospective purchaser in a foreclosure or other Asset Sale of all or any portion of the Collateral (subject to customary confidentiality obligations); provided a Product Agreement shall not be a â€œRestricted Licenseâ€ by virtue of clause (iii) if Borrower and/or the applicable Subsidiary has used commercially reasonable efforts to permit, or other obtain permission for, such disclosure. â€œRoyalty Monetization Transactionâ€ means any monetization or financing transaction involving (a) the sale, transfer, option or collateralization of (i) any monetary payments (contingent or otherwise) payable to the Borrower or its Subsidiaries by a counterparty under a Product Agreement, or (ii) any Product Revenues, or (b) the provision of financing for the development, manufacture and/or Commercialization of any Product in exchange for the future payment of royalties, milestones and other amounts (whether or not contingent), including but not limited to sales of royalty streams, royalty bonds and other royalty financings, synthetic royalty, development financings and revenue interest transactions (including but not limited to clinical trial funding arrangements), and hybrid monetization transactions. â€œS&Pâ€ means Standard & Poorâ€™s Ratings Group, a division of The McGraw Hill Corporation. â€œSafety Noticesâ€ has the meaning specified in Section 4.33(e). â€œSales Milestoneâ€ means the achievement by the Borrower and its Subsidiaries of Product Revenue (calculated on a trailing twelve-month basis) of at least [***] from the sale of Acoramidis. â€œSales Milestone Dateâ€ means the date on which the Borrower shall have delivered a certificate representing and warranting, and otherwise demonstrating to the reasonable satisfaction of Administrative Agent, as confirmed in writing by Administrative Agent (such confirmation not to be unreasonably delayed, withheld or conditioned), that the Sales Milestone has been achieved, which may be measured as of any month end based on monthly financial statements; provided, that, in the case of financial statements for any month which is not the final month for any Fiscal Quarter, such financial statements shall be prepared in accordance with GAAP and be accompanied by a Financial Officer Certification. â€œSanctioned Entityâ€ means (a) a country or territory or a government of a country or territory, (b) an agency of the government of a country or territory, (c) an organization directly or indirectly controlled by a country or territory or its government, or (d) a Person resident in or determined to be resident in a country or territory, in each case of clauses (a) through (d) that is a target of Sanctions, including a target of any country or territory sanctions program administered and enforced by OFAC. â€œSanctioned Personâ€ means, at any time (a) any Person named on the list of Specially Designated Nationals and Blocked Persons maintained by OFAC, OFACâ€™s consolidated Non-SDN list or any other Sanctions-related list maintained by any Governmental Authority, (b) a Person or legal entity that is a target of Sanctions, (c) any Person operating, organized or resident in a Sanctioned Entity, or (d) any Person directly or indirectly owned or controlled (individually or in the aggregate) by or acting on behalf of any such Person or Persons described in clauses (a) through (c) above. â€œSanctionsâ€ means individually and collectively, respectively, any and all economic sanctions, trade sanctions, financial sanctions, sectoral sanctions, secondary sanctions, trade embargoes anti-terrorism laws and other sanctions laws, regulations or embargoes, including those imposed, administered or enforced from time to time by: (a) the United States of America, including those administered by OFAC, the U.S. Department of State, the U.S. Department of Commerce, or through any existing or future executive order, Â - 51A - A | Â (b) the United Nations Security Council, (c) the European Union or any European Union member state, (d) His Majestyâ€™s Treasury of the United Kingdom, or (e) any other Governmental Authority with jurisdiction over any Lender or any Loan Party or any of their respective Subsidiaries or Affiliates. â€œSecond Amendmentâ€ means that certain Second Amendment to Financing Agreement, dated as of June 20, 2024, by and among the Borrower, the Guarantors party thereto, the Lenders party thereto and the Administrative Agent. â€œSecond Amendment Effective Dateâ€ has the meaning assigned to such term in the Second Amendment. â€œSecured Partiesâ€ has the meaning assigned to that term in the Pledge and Security Agreement. â€œSecurities Accountâ€ means a securities account (as defined in the UCC). â€œSecurities Actâ€ means the Securities Act of 1933. â€œSenior Total Debtâ€ means, as of any date of determination, the aggregate outstanding principal amount of third party Indebtedness of the Borrower and its Subsidiaries consisting of Indebtedness of the type described in clause (a), (b), (c) or (g) of the definition thereof, in each case, to the extent not subordinated on terms and conditions reasonably satisfactory to Administrative Agent in right of payment to the Obligations; provided, that Senior Total Debt shall not include Indebtedness in respect of any letter of credit except to the extent of any unreimbursed obligations in respect of any such drawn letter of credit that is not paid when due. â€œSenior Total Net Leverage Ratioâ€ means, as of any date of determination, the ratio of (x) the sum of (i) Senior Total Debt as of such date minus (ii) the lesser of (a) Qualified Cash as of such date and (b) \$[***], to (y) Adjusted EBITDA for the most recently ended Measurement Period. â€œSOFRâ€ means a rate equal to the secured overnight financing rate as administered by the SOFR Administrator. â€œSOFR Administratorâ€ means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate). â€œSOFR Loanâ€ means a Loan that bears interest at a rate based on Term SOFR, other than pursuant to clause (c) of the definition of â€œBase Rateâ€. â€œSolvency Certificateâ€ means a solvency certificate substantially in the form of Exhibit F. â€œSolventâ€ means, (a) for purposes of Section 4.20(a), with respect to the Borrower, that as of the date of determination, (i) the sum of the Borrowerâ€™s debt (including contingent liabilities) does not exceed the present fair saleable value of the Borrowerâ€™s present assets, (ii) the Borrowerâ€™s capital is not unreasonably small in relation to its business as contemplated on the Closing Date and reflected in the Initial Projections or with respect to any transaction contemplated or undertaken after the Closing Date, (iii) the Borrower has not incurred and does not intend to incur, or believe (nor should it reasonably believe) that it will incur, debts beyond its ability to pay such debts as they become due (whether at maturity or otherwise) and (iv) the Borrower is â€œsolventâ€ within the meaning given that term and similar terms under applicable laws relating to fraudulent transfers and conveyances; and (b) for purposes of Section 4.20(b), with respect to the Loan Parties (taken as a whole), that as of the date of determination, (i) the sum of the Loan Partiesâ€™ debt (including contingent liabilities) does not exceed the present fair saleable value of such Â - 52A - A | Â Loan Partiesâ€™ present assets, (ii) the Loan Partiesâ€™ capital is not unreasonably small in relation to their business (taken as a whole) as contemplated on the Closing Date and reflected in the Initial Projections or with respect to any transaction contemplated or undertaken after the Closing Date, (iii) the Loan Parties have not incurred and do not intend to incur, or believe (nor should they reasonably believe) that they will incur, debts beyond their ability (taken as a whole) to pay such debts as they become due (whether at maturity or otherwise) and (iv) the Loan Parties (taken as a whole) are â€œsolventâ€ within the meaning given that term and similar terms under applicable laws relating to fraudulent transfers and conveyances. â€œSpecial Installmentâ€ has the meaning specified in Section 2.8. â€œSpecified Productsâ€ means, collectively, [***], and â€œSpecified Productâ€ means any of the foregoing. â€œSpecified Subsidiariesâ€ means, collectively, [***], and â€œSpecified Subsidiaryâ€ means any of the foregoing; provided, however, that each of the foregoing shall cease to be a Specified Subsidiary upon the twenty-first month anniversary of the Closing Date to the extent that such Specified Subsidiary remains a Subsidiary of the Borrower at such time. â€œ[***] Subsidiariesâ€ means, collectively, (a) the Specified Subsidiaries and (b) [***], and â€œ[***] Subsidiaryâ€ means any of the foregoing; provided, however, that [***] shall cease to be a [***] Subsidiary upon delivery by the Borrower to the Administrative Agent of an irrevocable written notice (such notice, the â€œ[***] Noticeâ€) electing for [***] to no longer be designated as a [***] Subsidiary. â€œSpringing Term Loan Maturity Date Iâ€ means the date that is ninety-one (91) days prior to the stated maturity of the 2027 Notes. â€œSpringing Term Loan Maturity Date IIâ€ means the date that is ninety-one (91) days prior to the stated maturity of the 2029 Notes. â€œStated Term Loan Maturity Dateâ€ means January 17, 2029. [***]. â€œ[***] Noticeâ€ has the meaning specified in the definition of [***] Subsidiary. â€œSubordinated Indebtednessâ€ means Indebtedness that is subordinated in right of payment to the Obligations pursuant to a subordination agreement satisfactory to the Administrative Agent in its reasonable discretion. â€œSubsidiaryâ€ means, with respect to any Person, any corporation, company, partnership, limited liability company, association, joint venture or other business entity of which more than [***]% of the total voting power of shares of stock, shares, or other

ownership interests entitled (without regard to the occurrence of any contingency) to vote in the election of the Person or Persons (whether directors, managers, trustees or other Persons performing similar functions) having the power to direct or cause the direction of the management and policies thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof; provided, in determining the percentage of ownership interests of any Person controlled by another Person, no ownership interest in the nature of a "qualifying share" of the former Person shall be deemed to be outstanding. A - 53A - A | A "Swiss Federal Tax Administration" means the tax authorities referred to in art. 34 of the Swiss Withholding Tax Act. "Swiss Guarantor" means any Guarantor formed or incorporated under the laws of Switzerland, which as of the Closing Date is BridgeBio International GmbH, a Swiss limited liability company. "Swiss Withholding Tax" means taxes imposed under the Swiss Withholding Tax Act. "Swiss Withholding Tax Act" means the Swiss Federal Act on the Withholding Tax of October 13, 1965 (Bundesgesetz "über die Verrechnungssteuer"), together with the related ordinances, regulations and guidelines, all as amended and applicable from time to time. "Taxes" means any present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholdings), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. "Term Loan" means, collectively, the Initial Term Loan and each Incremental Term Loan (if any). "Term Loan Commitment" means, collectively, the Initial Term Loan Commitment and the Incremental Term Loan Commitments (if any). "Term Loan Maturity Date" means the earliest of (a) the Stated Term Loan Maturity Date, (b) the Springing Term Loan Maturity Date I, solely to the extent that as of such date, (i) the 2027 Notes remain outstanding and (ii) the Net Outstanding Amount in respect of the 2027 Notes is greater than \$50,000,000, (c) the Springing Term Loan Maturity Date II, solely to the extent that as of such date, (i) the 2029 Notes remain outstanding and (ii) the Net Outstanding Amount in respect of the 2029 Notes is greater than \$50,000,000 and (d) the date that the Term Loan shall become due and payable in full hereunder, whether by acceleration or otherwise. "Term SOFR" means, (a) for any calculation with respect to a SOFR Loan, the Term SOFR Reference Rate for a tenor comparable to the applicable Interest Period on the day (such day, the "Periodic Term SOFR Determination Day") that is "[*]" prior to the first day of such Interest Period, as such rate is published by the Term SOFR Administrator; provided, however, that if as of 5:00 p.m. (New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U. Business Day is not more than "[*]" prior to such Periodic Term SOFR Determination Day, and (b) for any calculation with respect to an Base Rate Loan on any day, the Term SOFR Reference Rate for a tenor of one month on the day (such day, the "Base Rate Term SOFR Determination Day") that is "[*]" prior to such day, as such rate is published by the Term SOFR Administrator; provided, however, that if as of 5:00 p.m. (New York City time) on any Base Rate Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding Business Day for which such Term SOFR Reference Rate for A - 54A - A | A such tenor was published by the Term SOFR Administrator so long as such first preceding Business Day is not more than "[*]" prior to such Base Rate Term SOFR Determination Day; provided, further, that if Term SOFR determined as provided above (including pursuant to the proviso under clause (a) or clause (b) above) shall ever be less than the Floor, then Term SOFR shall be deemed to be the Floor. "Term SOFR Administrator" means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the Administrative Agent in its reasonable discretion). "Term SOFR Reference Rate" means the forward-looking term rate based on SOFR. "Terminated Lender" has the meaning specified in Section 2.18. "Test Date" has the meaning specified in the Definition of Excluded Subsidiary. "Title Policy" has the meaning specified in Section 5.11. "Total Initial Term Loan Commitment" means the sum of the amounts of the "Lenders' Initial Term Loan Commitments. "Transaction Costs" means the reasonable and documented fees, costs and expenses payable by the Borrower or any of its Subsidiaries on or before the Closing Date in connection with the transactions contemplated by the Loan Documents (including the Closing Date Refinancing). "[*]" "Assets" means, collectively, (a) investigational small molecules for the treatment of "[*]", (b) all Product Intellectual Property Rights and all regulatory materials with respect to the foregoing clause (a), (c) all other tangible and intangible assets necessary for, or material to, the exploitation of the foregoing clause (a); provided, that, "[*]" Assets shall not include (i) any Product Intellectual Property Rights relating to any other Product of the Borrower and its Subsidiaries or (ii) any other tangible or intangible assets used in the exploitation of any other Product of the Borrower and its Subsidiaries. "Type of Loan" means with respect to any Term Loan, a Base Rate Loan or a SOFR Loan. "UCC" means the Uniform Commercial Code (or any similar or equivalent legislation) as in effect in any applicable jurisdiction. "UK Financial Institution" means any BRD Undertaking (as such term is defined under the PRA Rulebook (as amended from time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms. "UK Resolution Authority" means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution. "Unadjusted Benchmark Replacement" means the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment. A - 55A - A | A "U.S." or "United States" or "United States" means the United States of America. "U.S. Government Securities Business Day" means any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities. "U.S. Person" means any Person that is a "United States person" as defined in Section 7701(a)(30) of the Internal Revenue Code. "Waivable Mandatory Prepayment" has the meaning specified in Section 2.11(b). "Weighted Average Life to Maturity" means, when applied to any Indebtedness at any date, the number of years obtained by dividing: (a) the sum of the products obtained by multiplying (i) the amount of each then remaining installment, sinking fund, serial maturity or other required payments of principal, including payment at final maturity, in respect of the Indebtedness, by (ii) the number of years (calculated to the nearest one-twelfth) that will elapse between such date and the making of such payment; by (b) the then outstanding principal amount of such Indebtedness. "Withholding Agent" means Loan Parties and the Administrative Agent. "Write-Down and Conversion Powers" means, (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers. Section 1.2 Accounting and Other Terms. (a) Except as otherwise expressly provided herein, all accounting terms not otherwise defined herein shall have the meanings assigned to them in conformity with GAAP. Financial statements and other information required to be delivered by the Borrower to Lenders pursuant to Sections 5.1(b) and 5.1(c) shall be prepared in accordance with GAAP as in effect at the time of such preparation (and delivered together with the reconciliation statements provided for in Section 5.1(f), if applicable). Subject to the foregoing, calculations in connection with the definitions, covenants and other provisions hereof shall utilize accounting principles and policies in conformity with those used to prepare the Historical Financial Statements. Notwithstanding the foregoing, for purposes of determining compliance with any covenant (including the computation of any financial covenant) contained herein, (i) Indebtedness of the Borrower and its Subsidiaries shall be deemed to be carried at 100% of the outstanding principal amount thereof, and the effects of FASB ASC 825 and FASB ASC 470 20 on financial liabilities shall be disregarded, (ii) with respect to the accounting for leases as either operating leases or capital leases and the impact of such accounting in accordance with FASB ASC 840 on the definitions and covenants herein, GAAP as in effect on December 31, 2018 shall be applied and (iii) with respect to revenue recognition and the impact of such A - 56A - A | A accounting in accordance with FASB ASC 606 on the definitions and covenants herein, GAAP as in effect on December 31, 2017 shall be applied. (b) All terms used in this Agreement which are defined in Article 8 or Article 9 of the UCC as in effect from time to time in the State of New York and which are not otherwise defined herein shall have the same meanings herein as set forth therein, provided that terms used herein which are defined in the UCC as in effect in the State of New York on the date hereof shall continue to have the same meaning notwithstanding any replacement or amendment of such statute except as Administrative Agent may otherwise determine. (c) For purposes of determining compliance with any incurrence or expenditure tests set forth in this Agreement, any amounts so incurred or expended (to the extent incurred or expended in a currency other than Dollars (\$)) shall be converted into Dollars on the basis of the exchange rates (as shown on the Bloomberg currency page for such currency or, if the same does not provide such exchange rate, by reference to such other recognized and publicly available service for displaying exchange rates as may be reasonably selected by Administrative Agent or, in the event no such service is available, on such other basis as is reasonably satisfactory to Administrative Agent) as in effect on the date of such incurrence or expenditure under any provision of any such Section that has an aggregate Dollar limitation provided for therein (and to the extent the respective incurrence or expenditure test regulates the aggregate amount outstanding at any time and it is expressed in terms of Dollars, all outstanding amounts originally incurred or spent in currencies other than Dollars shall be converted into Dollars on the basis of the exchange rates (as shown on the Bloomberg currency page for such currency or, if the same does not provide such exchange rate, by reference to such other recognized and publicly available service for displaying exchange rates as may be reasonably selected by Administrative Agent or, in the event no such service is available, on such other basis as is reasonably satisfactory to Administrative Agent) as in effect on the date of any new incurrence or expenditures made under any provision of any such Section that regulates the Dollar amount outstanding at any time). Section 1.3 Interpretation, Etc. Any of the terms defined herein may, unless the context otherwise requires, be used in the singular or the plural, depending on the reference. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine, and neuter forms. The word "will" shall be construed to have the same meaning and effect as the word "shall." References herein to any Section, Appendix, Schedule or Exhibit shall be to a Section, an Appendix, a Schedule or an Exhibit, as the case may be, hereof unless otherwise specifically provided. The use herein of the word "including" or "including," when following any general statement, term or matter, shall not be construed to limit such statement, term or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not no limiting language (such as "without limitation" or "but not limited to" or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that fall within the broadest possible scope of such general statement, term or matter. The words "asset" and "property" shall be construed to have the same meaning and effect and to refer to any right or interest in or to assets and properties of any kind whatsoever, whether real, personal or mixed and whether tangible or intangible. Any reference herein or in any other Loan Document to the satisfaction, repayment, or payment in full of the Obligations or Guaranteed Obligations shall mean (a) the payment or repayment in full in immediately available funds of (i) the principal amount of, and interest accrued and unpaid with respect to, all outstanding Loans, together with the payment of any premium applicable to the repayment of the Loans, including any Applicable Premium and any Prepayment Premium, (ii) all costs, expenses, or indemnities payable pursuant to Section 10.2 or Section 10.3 of this Agreement that have accrued and are unpaid regardless of whether demand has been made therefor, and (iii) all fees, charges (including loan fees, service fees, professional fees, and expense reimbursement) and other Obligations that have accrued hereunder or under any other Loan Document and are unpaid, (b) the receipt by Administrative Agent of cash collateral in order to secure any other contingent Obligations for A - 57A - A | A which a claim or demand for payment has been made on or prior to such time or in respect of matters or circumstances known to the Administrative Agent or a Lender at such time that are reasonably expected to result in any loss, cost, damage, or expense (including attorneys' fees and legal expenses), such cash collateral to be in such amount as Administrative Agent reasonably determines is appropriate to secure such contingent Obligations, and (c) the termination of all of the Term Loan Commitments. Notwithstanding anything in this Agreement to the contrary, (A) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (B) all requests, rules, guidelines or directives concerning capital adequacy promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities shall, in each case, be deemed to be enacted, adopted, issued, phased in or effective after the date of this Agreement regardless of the date enacted, adopted, issued, phased in or effective. Unless the context requires otherwise (a) any definition of or reference to any Loan Document, agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth in any Loan Document), (b) any reference to any law or regulation shall (i) include all statutory and regulatory provisions consolidating, amending, replacing or interpreting or supplementing such law or regulation, and (ii) unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time, and (c) any reference herein to any Person shall be construed to include such Person's successors and permitted assigns. This Section 1.3 shall apply, mutatis mutandis, to all Loan Documents. Section 1.4 Time References. Unless otherwise indicated herein, all references to time of day refer to Eastern Standard Time or Eastern daylight saving time, as in effect in New York City on such date. For purposes of the computation of a period of time from a specified date to a later specified date, the word "from" means "from" and including" and the words "to" and "until" each means "to" but excluding"; provided, however, that with respect to a computation of fees or interest payable to Administrative Agent or any Lender, such period shall in any event consist of at least one full day. Section 1.5 Certain Matters of Construction. References in this Agreement to "determination" by Administrative Agent include good faith estimates by Administrative Agent (in the case of quantitative determinations) and good faith beliefs by Administrative Agent (in the case of qualitative determinations). A Default or Event of Default shall be deemed to exist at all times during the period commencing on the date that such Default or Event of Default occurs to the date on which such Default or Event of Default is waived in writing pursuant to this Agreement or, in the case of a Default, is cured within any period of cure expressly provided for in this Agreement; and an Event of Default shall "continue" or be "continuing" until such Event of Default has been waived in writing by the Required Lenders. Any Lien referred to in this Agreement or any other Loan Document as having been created in favor of Administrative Agent, any agreement entered into by Administrative Agent pursuant to this Agreement or any other Loan Document, any payment made by or to or funds received by Administrative Agent pursuant to or as contemplated by this Agreement or any other Loan Document, or any act taken or omitted to be taken by Administrative Agent, shall, unless otherwise expressly provided, be created, entered into, made or received, or taken or omitted, for the benefit or account of Administrative Agent and the Lenders. Wherever the phrase "to the knowledge of any Loan Party" or words of similar import relating to the knowledge or the awareness of any Loan Party are used in this Agreement or any other Loan Document, such phrase shall mean and refer to (i) the actual knowledge of a senior officer of any Loan Party or (ii) the knowledge that a senior officer would have obtained if such officer had engaged in good faith and diligent performance of such officer's duties, including the making of such reasonably specific inquiries as may be necessary of the employees or agents of such Loan Party and a good faith attempt to ascertain the existence or accuracy of the matter to which such phrase relates. All covenants hereunder shall be given independent effect so that if a particular action or condition is not permitted by any of such covenants, the fact that it would be permitted by an A - 58A - A | A exception to, or otherwise within the limitations of, another covenant shall not avoid the occurrence of a default if such action is taken or condition exists. In addition, all representations and warranties hereunder shall be given independent effect so that if a particular representation or warranty proves to be incorrect or is breached, the fact that another representation or warranty concerning the same or similar subject matter is correct or is not breached will not affect the incorrectness of a breach of a representation or warranty hereunder. Section 1.6 Dutch Terms. In this Agreement, where it relates to a Dutch Guarantor, other Dutch person or the context so requires, a reference to: (a) "the Netherlands" means the European part of the Kingdom of the Netherlands and "Dutch" means in or of the Netherlands; (b) "constitutional documents" or "organizational documents" means the articles of association (statuten) and deed of incorporation (akte van oprichting) and an up-to-date extract of registration of the Trade Register of the Dutch Chamber of Commerce; (c) a "security interest", "lien" or "security" includes any mortgage (hypotheek), pledge (pandrecht), retention of title arrangement (eigendomsvoorbehoud), right of retention (recht van retentie), right to reclaim goods (recht van reclame) and any right in rem (beperkt recht) created for the purpose of granting security (goederenrechtelijke zekerheid); (d) a "covenanting-up", "administration" or "dissolution" includes declared bankrupt (failliet

(a) a *coobligator* includes a curator or a beoogd curator; (b) an *afgevaardigde* includes a bewindvoerder or a beoogd bewindvoerder; (c) a *afgevaardigde* includes surseance van betaling and a moratorium is declared includes surseance verleend; (h) any *afgevaardigde* or *afgevaardigde* taken in connection with insolvency proceedings includes that person having filed a notice under Section 36 of the Dutch Tax Collection Act of The Netherlands (Invoeringswet 1990), but not (for the avoidance of doubt) where such notice is (deemed) filed by reason of a request by that person for the postponement of its tax liability payments made - and the authorities *afgevaardigde* consent to and actual postponement of such payments - in accordance with the Decree of the Dutch State Secretary of Finance dated 13 September 2022, Decree no. 2022 - 219271 (Besluit noodmaatregelen coronacrisis) (as preceded, amended or replaced from time to time); (i) *afgevaardigde* means schuld; (j) *afgevaardigde* means grove schuld; (k) *afgevaardigde* means opzet; (l) an *afgevaardigde* includes a conservator beslag or executore beslag; (m) a *afgevaardigde* or an *afgevaardigde* receiver *afgevaardigde* does not include a curator or bewindvoerder; *afgevaardigde* - 59A - *afgevaardigde* (n) *afgevaardigde* failliet means kwade trouw; (o) a *afgevaardigde*, trustee, custodian, sequestrator, conservator or similar official *afgevaardigde* includes a herstructureringsdeskundige or an observator; and (p) a *afgevaardigde* necessary action to authorize *afgevaardigde* where applicable, includes without limitation: (i) any action required to comply with the Dutch Works Councils Act (Wet op de ondernemingsraden); and (ii) obtaining an unconditional positive advice (advies) from the competent works council(s). Article II LOANS Section 2.1 Term Loans. (a) Loan Commitment. Subject to the terms and conditions hereof, each Lender severally agrees to make, on the Closing Date, an Initial Term Loan to the Borrower in an amount equal to such Lender's Initial Term Loan Commitment. The Borrower may request only one borrowing under the Initial Term Loan Commitment which shall be on the Closing Date. Any amount borrowed under this Section 2.1(a) and subsequently repaid or prepaid may not be reborrowed. Subject to Section 2.9, all amounts owed hereunder with respect to the Term Loan shall be paid in full no later than the Term Loan Maturity Date. Each Lender's Initial Term Loan Commitment shall terminate immediately and without further action on the Closing Date after giving effect to the funding of such Lender's Initial Term Loan Commitment on such date. (b) Borrowing Mechanics for Term Loans. (i) Borrower shall deliver to Administrative Agent a fully executed Funding Notice no later than three Business Days prior to the Closing Date (or such shorter period permitted by Administrative Agent), with respect to Term Loans made on the Closing Date. Following the Closing Date (and subject to the conditions set forth in Section 3.2), whenever Borrower desires that Lenders make a Loan, Borrower shall deliver to Administrative Agent a fully executed and delivered Funding Notice no later than 12:00 p.m. (New York City time) at least one (1) Business Day prior to the proposed Credit Date for any Base Rate Loan and at least three (3) Business Days prior to the proposed Credit Date for any SOFR Loan (or in the case of any Incremental Term Loan, at such other times as may be set forth in the applicable Incremental Amendment). Except as otherwise provided herein, a Funding Notice for a Term Loan that is a SOFR Loan shall be irrevocable on and after the related Interest Rate Determination Date, and Borrower shall be bound to make a borrowing in accordance therewith. Promptly upon receipt by Administrative Agent of any such Funding Notice, Administrative Agent shall notify each Lender of the proposed borrowing. Administrative Agent and Lenders (A) may act without liability upon the basis of written or facsimile notice believed by Administrative Agent in good faith to be from Borrower (or from any Authorized Officer thereof designated in writing purportedly from Borrower to Administrative Agent), (B) shall be entitled to rely conclusively on any Authorized Officer's authority to request a Term Loan on behalf of Borrower until Administrative Agent receives written notice to the contrary, and (C) shall have no duty to verify the authenticity of the signature appearing on any written Funding Notice. *afgevaardigde* - 60A - *afgevaardigde* (ii) Each Lender shall make its applicable Term Loan available to Administrative Agent not later than 12:00 p.m. on the applicable Credit Date, by wire transfer of same day funds in Dollars, at Administrative Agent's Principal Office. Upon satisfaction or waiver of the conditions precedent specified herein, Administrative Agent shall make the proceeds of the applicable Term Loans available to Borrower on the applicable Credit Date by causing an amount of same day funds in Dollars equal to the proceeds of all such Loans received by Administrative Agent from Lenders to be credited to the account of Borrower at Administrative Agent's Principal Office or to such other account as may be designated in writing to Administrative Agent by Borrower. (c) Pro Rata Shares; Availability of Funds. (i) Pro Rata Shares. All Loans shall be made by Lenders simultaneously and proportionately to their respective Pro Rata Shares, it being understood that no Lender shall be responsible for any default by any other Lender in such other Lender's obligation to make a Loan requested hereunder nor shall any Term Loan Commitment of any Lender be increased or decreased as a result of a default by any other Lender in such other Lender's obligation to make a Loan requested hereunder or purchase a participation required hereby. (ii) Availability of Funds. Unless Administrative Agent shall have been notified by any Lender prior to the applicable Credit Date that such Lender does not intend to make available to Administrative Agent the amount of such Lender's Loan requested on such Credit Date, Administrative Agent may assume that such Lender has made such amount available to Administrative Agent on such Credit Date and Administrative Agent may, in its sole discretion, but shall not be obligated to, make available to Borrower a corresponding amount on such Credit Date. If such corresponding amount is not in fact made available to Administrative Agent by such Lender, Administrative Agent shall be entitled to recover such corresponding amount on demand from such Lender together with interest thereon, for each day from such Credit Date until the date such amount is paid to Administrative Agent, at the customary rate set by Administrative Agent for the correction of errors among banks for three (3) Business Days and thereafter at the Base Rate. If such Lender does not pay such corresponding amount forthwith upon Administrative Agent's demand therefor, Administrative Agent shall promptly notify Borrower, and Borrower shall immediately pay such corresponding amount to Administrative Agent together with interest thereon, for each day from such Credit Date until the date such amount is paid to Administrative Agent, at the rate payable hereunder for Base Rate Loans for such Class of Loans. Nothing in this Section 2.1(d)(ii) shall be deemed to relieve any Lender from its obligation to fulfill its Term Loan Commitments hereunder or to prejudice any rights that Borrower may have against any Lender as a result of any default by such Lender hereunder. Section 2.2 Use of Proceeds. (a) The proceeds of the Initial Term Loans shall be applied by Borrower (A) to finance the Closing Date Refinancing and to pay the Transaction Costs and (b) for working capital, pipeline development and general corporate purposes of the Borrower and its Subsidiaries. No portion of the proceeds of the Term Loans shall be used in any manner that causes or might cause such Credit Extension or the application of such proceeds to violate Regulation T, Regulation U or Regulation X of the Federal Reserve Board or any other regulation thereof or to violate the Exchange Act. (b) Borrower acknowledges and agrees that no amounts borrowed under the Term Loans shall be used in a manner which would constitute a *afgevaardigde* of proceeds in Switzerland as interpreted by the Swiss Federal Tax Administration for purposes of Swiss Withholding Tax, except and to the extent that a written confirmation or tax ruling countersigned by the Swiss Federal Tax Administration has been obtained (in a form satisfactory to Administrative Agent, as directed by the Required Lenders) confirming *afgevaardigde* - 61A - *afgevaardigde* that the intended *afgevaardigde* of proceeds in Switzerland *afgevaardigde* does not result in interest payments in respect of any Term Loan becoming subject to withholding or deduction for Swiss Withholding Tax. Section 2.3 Evidence of Debt; Register; Lenders' Books and Records; Notes. (a) Lenders' Evidence of Debt. Each Lender shall maintain on its internal records an account or accounts evidencing the Obligations of Borrower to such Lender, including the amounts of the Term Loans made by it and each repayment and prepayment in respect thereof. Any such recordation shall be conclusive and binding on Borrower, absent manifest error; provided, that the failure to make any such recordation, or any error in such recordation, shall not affect Borrower's Obligations in respect of any Term Loans; and provided further, in the event of any inconsistency between the Register and any Lender's records, the recordations in the Register shall govern. (b) Register. Administrative Agent shall maintain at one of its offices a register for the recordation of the names and addresses of Lenders and the principal amount of the Term Loans (and stated interest therein) of each Lender from time to time (the *afgevaardigde*). The Register shall be available for inspection by Borrower and any Lender at any reasonable time and from time to time upon reasonable prior written notice. Administrative Agent shall record in the Register the Term Loans, and each repayment or prepayment in respect of the principal amount of the Term Loans, and any such recordation shall be conclusive and binding on Borrower and each Lender, absent manifest error; provided, failure to make any such recordation, or any error in such recordation, shall not affect Borrower's Obligations in respect of any Term Loan. Borrower hereby designates the entity serving as Administrative Agent to serve as Borrower's non-fiduciary agent solely for purposes of maintaining the Register as provided in this Section 2.3, and Borrower hereby agree that, to the extent such entity serves in such capacity, the entity serving as Administrative Agent and its officers, directors, employees, agents and affiliates shall constitute *afgevaardigde*. (c) Notes. If so requested by any Lender by written notice to Borrower at least two (2) Business Days prior to the Closing Date, or at any time thereafter, Borrower shall execute and deliver to such Lender (and/or, if applicable and if so specified in such notice, to any Person who is an assignee of such Lender pursuant to Section 10.6) on the Closing Date (or, if such notice is delivered after the Closing Date, promptly after Borrower's receipt of such notice) a Note or Notes. Section 2.4 Interest. (a) Except as otherwise set forth herein, each Loan shall bear interest on the unpaid principal amount thereof from the date made to repayment (whether by acceleration or otherwise) thereof as follows: (i) if a Base Rate Loan, at the Base Rate plus the Applicable Margin; or (ii) if a SOFR Loan, at the Term SOFR plus the Applicable Margin. (b) The basis for determining the rate of interest with respect to any Loan, and the Interest Period with respect to any SOFR Loan, shall be selected by Borrower and notified to Administrative Agent and Lenders pursuant to the applicable Funding Notice or Conversion/Continuation Notice, as the case may be. If on any day a Loan is outstanding with respect to which a Funding Notice or Conversion/Continuation Notice has not been delivered to Administrative Agent in accordance with the terms hereof specifying the applicable basis for determining the rate of interest, then for that day such Loan shall be a SOFR Loan. *afgevaardigde* - 62A - *afgevaardigde* (c) In connection with SOFR Loans there shall be no more than six (6) Interest Periods outstanding at any time. In the event Borrower fails to specify between a Base Rate Loan or a SOFR Loan in the applicable Funding Notice or Conversion/Continuation Notice, the Borrower shall automatically be deemed to have selected a SOFR Loan. As soon as practicable on each Interest Rate Determination Date, Administrative Agent shall determine (which determination shall, absent manifest error, be final, conclusive and binding upon all parties) the interest rate that shall apply to the SOFR Loans for which an interest rate is then being determined for the applicable Interest Period (or the Base Rate Loan for which an interest rate is then being determined to the extent the Base Rate is determined pursuant to clause (c) of the definition thereof) and shall promptly give notice thereof (in writing) to Borrower and each Lender. (d) Interest payable hereunder shall be computed on the basis of a 360-day year, in each case for the actual number of days elapsed in the period during which it accrues. In computing interest on any Loan, the date of the making of such Loan or the first day of an Interest Period applicable to such Loan or, with respect to a Base Rate Loan being converted from a SOFR Loan, the date of conversion of such SOFR Loan to such Base Rate Loan, as the case may be, shall be included, and the date of payment of such Loan or the expiration date of an Interest Period applicable to such Loan or, with respect to a Base Rate Loan being converted to a SOFR Loan, the date of conversion of such Base Rate Loan to SOFR Loan, as the case may be, shall be excluded; provided, if a Loan is repaid on the same day on which it is made, one day's interest shall be paid on that Loan. (e) Except as otherwise set forth herein, interest on each Term Loan shall be payable in cash and in arrears (i) on each Interest Payment Date and (ii) upon any prepayment of that Term Loan, whether voluntary or mandatory, to the extent accrued on the amount being prepaid. (f) In connection with the use or administration of Term SOFR (including as contemplated by the last sentence of Section 2.19), the Administrative Agent will have the right, in consultation with the Borrower, to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document. The Administrative Agent will promptly notify Borrower and the Lenders of the effectiveness of any Conforming Changes in connection with the use or administration of Term SOFR. (g) Minimum Interest. When entering into this Agreement, Loan Parties have assumed in bona fide that any amounts, including interests and fees, payable under a Loan Document by a Loan Party are not and will not become subject to any tax deduction on account of Swiss Withholding Tax. Notwithstanding the foregoing, if a tax deduction is required by law in respect of any amount payable by a Loan Party under a Loan Document and should it be unlawful for such Loan Party to comply with Section 2.15(a) for any reason, where this would otherwise be required by the terms of Section 2.15(a), then: (i) the applicable interest rate in relation to that payment shall be the interest rate which would have applied to that payment as provided for by Section 2.4(a) or any other relevant provision in any Loan Document divided by 1 minus the rate at which the relevant tax deduction is required to be made under Swiss domestic tax law and/or applicable double taxation treaties (where the rate at which the relevant tax deduction is required to be made is for this purpose expressed as a fraction of 1); and (ii) the Loan Party shall: (A) pay the relevant amount at the adjusted rate in accordance with Section 2.4(g)(i); *afgevaardigde* - 63A - *afgevaardigde* (B) make the tax deduction on the interest so recalculated; and (C) all references to a rate of interest under a Loan Document shall be construed accordingly; and (iii) to the extent that any amount payable by a Loan Party under any Loan Document becomes subject to Swiss Withholding Tax, the relevant Lender and the relevant Loan Party shall promptly cooperate in completing any procedural formalities (including submitting forms and documents required by the appropriate tax authority) to the extent possible and necessary (A) for such Loan Party to obtain authorisation to make interest payments without them being subject to Swiss Withholding Tax and (B) to ensure that any person which is entitled to a full or partial refund under any applicable double taxation treaty is so refunded. Section 2.5 Conversion/Continuation. (a) Subject to Section 2.19(b), Borrower shall have the option: (i) to convert at any time all or any part of any Term Loan equal to \$5,000,000 and integral multiples of \$1,000,000 in excess of that amount from one Type of Loan to another Type of Loan; provided, a SOFR Loan may only be converted on the expiration of the Interest Period applicable to such SOFR Loan unless Borrower shall pay all amounts due under Section 2.19(b) in connection with any such conversion; or (ii) upon the expiration of any Interest Period applicable to any SOFR Loan, to continue all or any portion of such Loan equal to \$5,000,000 and integral multiples of \$1,000,000 in excess of that amount as a SOFR Loan. (b) Borrower shall deliver a Conversion/Continuation Notice to Administrative Agent no later than 12:00 p.m. (New York City time) at least one (1) Business Day in advance of the proposed conversion date (in the case of a conversion to a Base Rate Loan) and at least three

Voluntary Prepayments. (a) Voluntary Prepayments. $\text{\AA}$ - 65 $\text{\AA}$ - $\text{\AA}$ | $\text{\AA}$ (i) Subject to the terms of the Fee Letter, Borrower may prepay at any time the Term Loan on any Business Day in whole or in part (together with any amounts due pursuant to Section 2.19), in an aggregate minimum amount of \\$5,000,000 and integral multiples of \\$1,000,000 in excess of that amount. (ii) All such prepayments shall be made (A) upon not less than one (1) Business Day $\text{\AA}$ ™s prior written notice in the case of Base Rate Loans and (B) upon not less than three (3) Business Days $\text{\AA}$ ™ prior written notice in the case of SOFR Loans, in each case given to Administrative Agent by 10:00 a.m. on the date required (and Administrative Agent will promptly notify each Lender). Upon the giving of any such notice, the principal amount of the Term Loans specified in such notice shall become due and payable on the prepayment date specified therein. Any such voluntary prepayment shall be applied as specified in Section 2.11(a) with respect to the Term Loans. Section 2.10 Mandatory Prepayments. (a) Asset Sales. (i) No later than the [***] following the date of receipt by any Loan Party of any Net Proceeds from Asset Sales (other than any Asset Sale described in clauses (i), (ii) (unless the Product Milestone Date has not occurred [***]), (iii), (v), (vi), (vii), (viii), (x), (xi), (xii), (xv), (xvi), (xvii) (but only with respect to Net Proceeds received prior to the Product Milestone Date (unless the Product Milestone Date has not occurred on or prior to [***])), or (xviii) (but only with respect to Net Proceeds received prior to the Product Milestone Date (unless the Product Milestone Date has not occurred on or prior to [***])) of Section 6.9(b)) in excess of [***] in the aggregate in any Fiscal Year, Borrower shall, subject to Section 2.11(b), prepay the Term Loans in the manner set forth in Section 2.11(a) in an aggregate amount equal to such Net Proceeds in excess of [***] in the aggregate for such Fiscal Year; provided, such prepayment shall not be required so long as (i) no Default or Event of Default shall have occurred and be continuing, (ii) Borrower has delivered Administrative Agent prior written notice of Borrower $\text{\AA}$ ™s intention to apply such monies (the $\text{\AA}$ Reinvestment Amounts $\text{\AA}$) to the costs of purchase of other assets useful in the business of the Loan Parties including capital expenditures (other than, for the avoidance doubt, working capital, short-term investments and research and development expenses), (iii) the monies are held in a Deposit Account in which Administrative Agent has a perfected first-priority security interest, and (iv) the Loan Parties complete such reinvestment or purchase within [***] after the initial receipt of such monies, the Loan Parties shall have the option to apply the Reinvestment Amounts to reinvest in or to the costs of purchase of other assets used or useful in the business of the Loan Parties; provided, that if any such Net Proceeds cease to be intended to be or cannot be so reinvested during the applicable [***] period, subject to Section 2.11(b), Borrower shall prepay the Loans in an amount equal to any such Net Proceeds within [***] after the Borrower reasonably determines that such Net Proceeds are no longer intended to be or cannot be so reinvested to the prepayment of the Term Loans as set forth in Section 2.11(a); provided, further, that prior to the Product Milestone Date, Reinvestments Amounts under this Section 2.10(a)(i) shall not exceed [***] in any given Fiscal Year and [***] in the aggregate. For the avoidance of doubt, it is understood and agreed that (A) Net Proceeds received by any Loan Party on or after the Product Milestone Date (and, if the Product Milestone Date has not occurred on or prior to [***], Net Proceeds received by any Loan Party on or [***]) from any Asset Sale described in clause (xvii) or (xviii) of Section 6.9(b) shall be subject to this Section 2.10(a)(i) and (B) if the Product Milestone Date has not occurred on or prior to [***], Net Proceeds received by any Loan Party on or after [***] from any Asset Sale described in clause (ii) of Section 6.9(b) shall be subject to this Section 2.10(a)(i). (ii) To the extent that any Loan Party receives any Net Proceeds from Asset Sales permitted under clause (ii), (xvii) or (xviii) of Section 6.9(b) at any time prior to the Product Milestone Date, [***]. $\text{\AA}$ - 66 $\text{\AA}$ - $\text{\AA}$ | $\text{\AA}$ (iii) Nothing contained in this Section 2.10(a) shall permit the Borrower or any of its Subsidiaries to sell or otherwise dispose of any assets other than in accordance with Section 6.9. (b) Insurance/Condemnation Proceeds. No later than the [***] following the date of receipt by any Loan Party, or Administrative Agent as loss payee, of any Net Proceeds from insurance or any condemnation, taking or other casualty in excess of [***] in the aggregate in any Fiscal Year, Borrower shall, subject to Section 2.11(b), prepay the Term Loan in the manner set forth in Section 2.11(a) in an aggregate amount equal to such Net Proceeds in excess of [***] in the aggregate for such Fiscal Year; provided, such prepayment shall not be required so long as (i) no Default or Event of Default shall have occurred and be continuing, (ii) Borrower has delivered Administrative Agent prior written notice of Borrower $\text{\AA}$ ™s intention to apply the Reinvestment Amounts to the costs of purchase of other assets used or useful in the business of the Loan Parties (including capital expenditures) (other than, for the avoidance doubt, working capital, short-term investments and research and development expenses), (iii) the monies are held in a Deposit Account in which Administrative Agent has a perfected first-priority security interest, and (iv) the Loan Parties complete such purchase within 365 days after the initial receipt of such monies; provided, that if any such Net Proceeds are no longer intended to be or cannot be so reinvested during the applicable 365 day period, and subject to Section 2.11(b), an amount equal to any such Net Proceeds shall be applied [***] after the Borrower reasonably determines that such Net Proceeds are no longer intended to be or cannot be so reinvested to the prepayment of the Term Loans as set forth in Section 2.11(a). (c) Issuance of Debt. On the date of receipt by the Borrower or any of its Subsidiaries of any Cash proceeds from the incurrence of any Indebtedness of the Borrower or any of its Subsidiaries (other than with respect to any Indebtedness permitted to be incurred pursuant to Section 6.1), Borrower shall prepay the Loans in an aggregate amount equal to [***]% of such proceeds, net of underwriting discounts and commissions and other reasonable costs and expenses associated therewith, in each case, paid to non-Affiliates, including reasonable legal fees and expenses. (d) [Reserved]. (e) Prepayment Certificate. Concurrently with any prepayment of the Term Loan pursuant to Section 2.10(a) through Section 2.10(c), Borrower shall deliver to Administrative Agent a certificate of an Authorized Officer demonstrating the calculation of the amount of the applicable net proceeds and compensation owing to Lenders pursuant to the Fee Letter, if any, as the case may be. In the event that Borrower shall subsequently determine that the actual amount received exceeded the amount set forth in such certificate, Borrower shall promptly make an additional prepayment of the Loans, and Borrower shall concurrently therewith deliver to Administrative Agent a certificate of an Authorized Officer demonstrating the derivation of such excess. Section 2.11 Application of Prepayments. (a) Application of Prepayments of Term Loans. (i) Any prepayment of the Term Loan pursuant to Section 2.9 shall be applied as specified by Borrower pursuant to a written notice to Administrative Agent; provided that in the event Borrower fails to specify how such prepayment shall be applied, such prepayment shall be applied to prepay the Term Loans first, to reduce the scheduled remaining Installments in direct order of maturity. (ii) Except in connection with any Waivable Mandatory Prepayment provided for in Section 2.11(b), so long as no Application Event has occurred and is continuing, any mandatory prepayment of any Loan pursuant to Section 2.10 shall be applied first, to accrued interest and fees with respect to the Term Loans being prepaid and second, to reduce the scheduled remaining Installments on a $\text{\AA}$ - 67 $\text{\AA}$ - $\text{\AA}$ | $\text{\AA}$ pro rata basis. After application of mandatory prepayments of Term Loans described in this clause (ii) and to the extent there are mandatory prepayment amounts remaining after such application, such amounts shall be applied to the remaining principal of the Term Loans until paid in full. (b) Waivable Mandatory Prepayment. Anything contained herein to the contrary notwithstanding, in the event Borrower is required to make any mandatory prepayment (a $\text{\AA}$ Waivable Mandatory Prepayment $\text{\AA}$) of the Term Loans pursuant to Section 2.10 (other than Section 2.11(c)), not less than [***] prior to the date (the $\text{\AA}$ Required Prepayment Date $\text{\AA}$) on which Borrower is required to make such Waivable Mandatory Prepayment, Borrower shall notify Administrative Agent of the amount of such prepayment, and Administrative Agent will promptly thereafter notify each Lender holding an outstanding Term Loan of the amount of such Lender $\text{\AA}$ ™s Pro Rata Share of such Waivable Mandatory Prepayment and such Lender $\text{\AA}$ ™s option to refuse such amount. Each such Lender may exercise such option by giving written notice to Borrower and Administrative Agent of its election to do so on or before 10:00 a.m. on the [***] prior to the Required Prepayment Date (it being understood that any Lender which does not notify Borrower and Administrative Agent of its election to exercise such option on or before 10:00 a.m. on the [***] prior to the Required Prepayment Date shall be deemed to have elected, as of such date, not to exercise such option). On the Required Prepayment Date, Borrower shall pay to Administrative Agent the amount of the Waivable Mandatory Prepayment, which amount shall be applied (i) in an amount equal to that portion of the Waivable Mandatory Prepayment payable to those Lenders that have elected not to exercise such option, to prepay the Term Loans of such Lenders (which prepayment shall be applied in accordance with Section 2.11(a)), and (ii) to the extent of any excess, to Borrower for working capital and general corporate purposes. (c) At any time an Application Event has occurred and is continuing, all payments shall be applied pursuant to Section 2.12(f). Nothing contained herein shall modify the provisions of Section 2.12(b) regarding the requirement that all prepayments be accompanied by accrued interest and fees on the principal amount being prepaid to the date of such prepayment and the applicable Applicable Premium, Prepayment Premium, or any requirement otherwise contained herein to pay all other amounts as the same become due and payable. Section 2.12 General Provisions Regarding Payments. (a) All payments by Borrower of principal, interest, fees and other Obligations shall be made in Dollars in immediately available funds, without defense, recoupment, setoff or counterclaim, free of any restriction or condition, and delivered to Administrative Agent, for the account of Lenders, not later than 10:00 a.m. on the date such payment is due and payable to Administrative Agent $\text{\AA}$ ™s Account. Funds received by Administrative Agent after that time on such due date may be deemed to have been paid by Borrower on the next Business Day. (b) All payments in respect of the principal amount of any Term Loan shall be accompanied by payment of accrued but unpaid interest on the principal amount being repaid or prepaid, any Prepayment Premium, any Applicable Premium, and all other amounts due and payable hereunder with respect to the principal amount being repaid or prepaid. (c) Administrative Agent shall promptly distribute to each Lender at such address as such Lender shall indicate in writing, such Lender $\text{\AA}$ ™s applicable Pro Rata Share of all payments and prepayments of principal and interest due hereunder, together with all other amounts due with respect thereto, including, without limitation, all fees payable with respect thereto, to the extent received by Administrative Agent. $\text{\AA}$ - 68 $\text{\AA}$ - $\text{\AA}$ | $\text{\AA}$ (d) Subject to the provisos set forth in the definition of $\text{\AA}$ Interest Period $\text{\AA}$, whenever any payment to be made hereunder shall be stated to be due on a day that is not a Business Day, such payment shall be made on the next succeeding Business Day and such extension of time shall be included in the computation of the payment of interest hereunder or of the commitment fees hereunder. (e) Administrative Agent may deem any payment by or on behalf of Borrower hereunder that is not made in same day funds prior to 10:00 a.m. to be a non-conforming payment. Any such payment shall not be deemed to have been received by Administrative Agent until the later of (i) the time such funds become available funds, and (ii) the applicable next Business Day. Administrative Agent shall give prompt notice to Borrower and each applicable Lender if any payment is non-conforming. Any non-conforming payment may constitute or become a Default or Event of Default in accordance with the terms of Section 8.1(a). Interest shall continue to accrue on any principal as to which a non $\text{\AA}$ conforming payment is made until such funds become available funds (but in no event less than the period from the date of such payment to the next succeeding applicable Business Day) at the Default Rate determined pursuant to Section 2.6 from the date such amount was due and payable until the date such amount is paid in full. (f) At any time an Application Event has occurred and is continuing, or the maturity of the Obligations shall have been accelerated pursuant to Section 8.2, all payments or proceeds received by Administrative Agent hereunder or under any Collateral Document in respect of any of the Obligations, including, but not limited to all proceeds received by Administrative Agent in respect of any sale, any collection from, or other realization upon all or any part of the Collateral, shall be applied in full or in part as follows: first, ratably to pay the Obligations in respect of any fees (other than any Prepayment Premium and Applicable Premium), expense reimbursements, indemnities and other amounts then due and payable to Administrative Agent until paid in full; second, ratably to pay interest then due and payable in respect of Protective Advances until paid in full; third, ratably to pay principal of Protective Advances then due and payable until paid in full; fourth, ratably to pay the Obligations in respect of any fees (other than any Prepayment Premium and Applicable Premium) and indemnities then due and payable to the Lenders until paid in full; fifth, ratably to pay interest then due and payable in respect of the Term Loan until paid in full; sixth, ratably to pay the principal of the Initial Term Loan until paid in full; seventh, ratably to pay the Obligations in respect of any Prepayment Premium and Applicable Premium then due and payable to the Lenders until paid in full; and eighth, to the ratable payment of all other Obligations then due and payable until paid in full. (g) For purposes of Section 2.12(f) (other than clause eighth of Section 2.12(f)), $\text{\AA}$ repaid in full $\text{\AA}$ means payment in cash of all amounts due and payable under the Loan Documents according to the terms thereof, including loan fees, service fees, professional fees, interest (and specifically including $\text{\AA}$ - 69 $\text{\AA}$ - $\text{\AA}$ | $\text{\AA}$ interest accrued after the commencement of any Insolvency Proceeding), default interest, interest on interest, and expense reimbursements, whether or not same would be or is allowed or disallowed in whole or in part in any Insolvency Proceeding, except to the extent that default or overdue interest (but not any other interest) and loan fees, each arising from or related to a default, are disallowed in any Insolvency Proceeding; provided, however, that for purposes of clause eighth of Section 2.12(f), $\text{\AA}$ repaid in full $\text{\AA}$ means payment in cash of all amounts due and payable under the Loan Documents according to the terms thereof, including loan fees, service fees, professional fees, interest (and specifically including interest accrued after the commencement of any Insolvency Proceeding), default interest, interest on interest, and expense reimbursements, whether or not the same would be or is allowed or disallowed in whole or in part in any Insolvency Proceeding. (h) Except as set forth in Section 10.26, (x) in the event of a direct conflict between the priority provisions of Section 2.12(f) and other provisions contained in any other Loan Document, it is the intention of the parties hereto that both such priority provisions in such documents shall be read together and construed, to the fullest extent possible, to be in concert with each other; and (y) in the event of any actual, irreconcilable conflict that cannot be resolved as aforesaid, the terms and provisions of Section 2.12(f) shall control and govern. (i) The Lenders and Borrower hereby authorize Administrative Agent to, and Administrative Agent may, from time to time, charge the Loan Account with any amount due and payable by Borrower under any Loan Document. Each of the Lenders and Borrower agree that Administrative Agent shall have the right to make such charges whether or not any Default or Event of Default shall have occurred and be continuing or whether any of the conditions precedent in Section 3.2 have been satisfied. Any amount charged to the Loan Account shall be deemed a Loan hereunder made by the Lenders to Borrower, funded by Administrative Agent on behalf of the Lenders and subject to Section 2.2. The Lenders and Borrower confirm that any charges which Administrative Agent may so make to the Loan Account as herein provided will be made as an accommodation to Borrower and solely at Administrative Agent $\text{\AA}$ ™s discretion, provided that Administrative Agent shall from time to time charge the Loan Account of Borrower with any amount due and payable under any Loan Document. (j) Notwithstanding the foregoing provisions hereof, if any Conversion/Continuation Notice is withdrawn as to any Affected Lender or if any Affected Lender makes Base Rate Loans in lieu of its Pro Rata Share of any SOFR Loans, Administrative Agent shall give effect thereto in apportioning payments received thereafter. Section 2.13 Ratable Sharing. Lenders hereby agree among themselves that, except as otherwise provided in the Collateral Documents with respect to amounts realized from the exercise of rights with respect to Liens on the Collateral, if any of them shall, whether by voluntary payment (other than a voluntary prepayment of Term Loans made and applied in accordance with the terms hereof), through the exercise of any right of set off or banker $\text{\AA}$ ™s lien, by counterclaim or cross action or by the enforcement of any right under the Loan Documents or otherwise, or as adequate protection of a deposit treated as cash collateral under the Bankruptcy Code, receive payment or reduction of a proportion of the aggregate amount of principal, interest, fees and other amounts then due and owing to such Lender hereunder or under the other Loan Documents (collectively, the $\text{\AA}$ Aggregate Amounts Due $\text{\AA}$) to such Lender) which is greater than the proportion received by any other Lender in respect of the Aggregate Amounts Due to such other Lender having Term Loans, then the Lender receiving such proportionately greater payment shall (a) notify Administrative Agent and each other Lender of the receipt of such payment and (b) apply a portion of such payment to purchase participations (which it shall be deemed to have purchased from each seller of a participation simultaneously upon the receipt by such seller of its portion of such payment) in the Aggregate Amounts Due to the other Lenders so that all such recoveries of Aggregate Amounts Due shall be shared by all Lenders having Term Loans in proportion to the Aggregate Amounts Due to them; provided, if all or $\text{\AA}$ - 70 $\text{\AA}$ - $\text{\AA}$ | $\text{\AA}$ part of such proportionately greater payment received by such purchasing Lender is thereafter recovered from such Lender upon the bankruptcy or reorganization of Borrower or otherwise, those purchases shall be rescinded and the purchase prices paid for such participations shall be returned to such purchasing Lender ratably to the extent of such recovery, but without interest. Borrower expressly consent to the foregoing arrangement and agrees that any holder of a participation so purchased may exercise any and all rights of banker $\text{\AA}$ ™s lien, set off or counterclaim with respect to any and all monies owing by Borrower to that holder with respect thereto as fully as if that holder were owed the amount of the participation held by that holder. Section 2.14 Increased Costs; Capital Adequacy. (a) Compensation For Increased Costs and Taxes. In the event that Administrative Agent or any Lender shall determine (which determination shall, absent manifest error, be final and conclusive and binding upon all parties hereto) that any law, treaty or governmental rule, regulation or order, or any change therein or in the interpretation, administration or application thereof (including the introduction of any new law, treaty or governmental rule, regulation or order), or any determination of a court or Governmental Authority, in each case that becomes effective after the date hereof, or compliance by Administrative Agent or such Lender with any guideline, request or directive issued or made after the date hereof by any central bank or other governmental or quasi-Governmental Authority (whether or not having the force of law) (a $\text{\AA}$ Change in Law $\text{\AA}$): (i) subjects Administrative Agent or such Lender (or its applicable lending office) to any additional Tax (other than any (A) Indemnified Taxes, (B) Taxes described in clauses (ii) through (iv) of the definition of Excluded Taxes and (C) Connection Income Taxes) with respect to this Agreement or any of the other Loan Documents or any of its obligations hereunder or thereunder or any payments to Administrative Agent or such Lender (or its applicable lending office) of principal, interest, fees or any other amount payable hereunder; (ii) [reserved]; or (iii) imposes any other condition (other than with respect to a Tax matter) on or affecting Administrative agent or such Lender (or its applicable lending office) or its obligations hereunder or the London interbank market; and

the result of any of the foregoing is to increase the cost to Administrative Agent or such Lender of agreeing to make, making or maintaining Loans hereunder or to reduce any amount received or receivable by Administrative Agent or such Lender (or its applicable lending office) with respect thereto; then, in any such case, Borrower shall promptly pay to Administrative Agent or such Lender, upon receipt of the statement referred to in the next sentence, such additional amount or amounts (in the form of an increased rate of, or a different method of calculating, interest or otherwise as Administrative Agent or such Lender in its sole discretion shall determine) as may be necessary to compensate Administrative Agent or such Lender for any such increased cost or reduction in amounts received or receivable hereunder. Administrative Agent or such Lender shall deliver to Borrower (with a copy to Administrative Agent, if applicable) a written statement, setting forth in reasonable detail the basis for calculating the additional amounts owed to Administrative Agent or such Lender under this Section 2.14(a), which statement shall be conclusive and binding upon all parties hereto absent manifest error. (b) Capital Adequacy Adjustment. In the event that any Lender shall have determined that the adoption, effectiveness, phase in or applicability after the Closing Date of any law, rule or regulation (or any provision thereof) regarding capital adequacy, or any change therein or in the interpretation or administration thereof by any Governmental Authority, central bank or comparable agency charged with the interpretation or administration thereof, or compliance by any Lender (or its applicable lending office) with any guideline, request or directive regarding capital adequacy (whether or not having the force of law) of any such Governmental Authority, central bank or comparable agency, has or would have the effect of reducing the rate of return on the capital of such Lender or any corporation controlling such Lender as a consequence of, or with reference to, such Lender's Term Loans or other obligations hereunder with respect to the Term Loan to a level below that which such Lender or such controlling corporation could have achieved but for such adoption, effectiveness, phase in, applicability, change or compliance (taking into consideration the policies of such Lender or such controlling corporation with regard to capital adequacy), A - 71A - A | then from time to time, within [***] after receipt by Borrower from such Lender of the statement referred to in the next sentence, Borrower shall pay to such Lender such additional amount or amounts as will compensate such Lender or such controlling corporation on an after tax basis for such reduction. Such Lender shall deliver to Borrower (with a copy to Administrative Agent) a written statement, setting forth in reasonable detail the basis for calculating the additional amounts owed to Lender under this Section 2.14(b), which statement shall be conclusive and binding upon all parties hereto absent manifest error. A certificate of a Lender setting forth the amount or amounts necessary to compensate such Lender or its holding company, as the case may be, as specified in paragraph (a) or (b) of this Section 2.14(c) and delivered to Borrower, shall be conclusive absent manifest error. The Borrower shall pay such Lender the amount shown as due on any such certificate within [***] after receipt thereof. Failure or delay on the part of any Lender to demand compensation pursuant to this Section 2.14(c) shall not constitute a waiver of such Lender's right to demand such compensation; provided that the Borrower shall not be required to compensate a Lender pursuant to this Section 2.14(c) for any increased costs incurred or reductions suffered more than [***] prior to the date that such Lender notifies Borrower of the Change in Law giving rise to such increased costs or reductions, and of such Lender's intention to claim compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the nine-month period referred to above shall be extended to include the period of retroactive effect thereof). Section 2.15 Taxes; Withholding, Etc. (a) Withholding of Taxes. Any and all payments by or on account of any obligation of the Borrower under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable law. If any applicable law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by the Borrower shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made. (b) Other Taxes. The Borrower shall timely pay to the relevant Governmental Authorities in accordance with applicable law or, at the option of Administrative Agent, timely reimburse it for the payment of, any Other Taxes. (c) Tax Indemnification. (i) The Borrower shall indemnify each Recipient, within [***] after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error. (ii) Each Lender shall severally indemnify Administrative Agent, within [***] after demand therefor, for (x) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified Administrative Agent for such Indemnified Taxes and without A - 72A - A | A limiting the obligation of the Borrower to do so), (y) any Taxes attributable to such Lender's failure to comply with the provisions of Section 10.6(h)(ii) relating to the maintenance of a Participant Register and (z) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by Administrative Agent to the Lender from any other source against any amount due to Administrative Agent under this paragraph. (d) Evidence of Payments. As soon as practicable after any payment of Taxes by the Borrower to a Governmental Authority pursuant to this Section, the Borrower shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent. (e) Evidence of Exemption From Withholding Tax. (i) Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall, deliver to Borrower and Administrative Agent, at the time or times reasonably requested by Borrower or Administrative Agent, such properly completed and executed documentation reasonably requested by Borrower or Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by Borrower or Administrative Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by Borrower or Administrative Agent as will enable Borrower or Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in paragraphs (e)(ii)(A), (ii)(B) and (ii)(D) of this Section 2.15) shall not be required if in the Lender's reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender. (ii) Without limiting the generality of the foregoing: (A) any Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax; (B) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is applicable: A - 73A - A | A (1) in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the applicable article of such tax treaty; (2) executed copies of IRS Form W-8ECI; (3) in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Internal Revenue Code, (x) a certificate in form and substance reasonably acceptable to the Borrower and the Administrative Agent to the effect that such Foreign Lender is not a bank within the meaning of Section 881(c)(3)(A) of the Internal Revenue Code, a 10 percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Internal Revenue Code, or a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Internal Revenue Code (a U.S. Tax Compliance Certificate) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E; or (4) to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate in form and substance reasonably acceptable to the Borrower and the Administrative Agent, IRS Form W-9, or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate in form and substance reasonably acceptable to the Borrower and the Administrative Agent on behalf of each such direct and indirect partner; (C) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and (D) if a payment made to a Lender under any Loan Document would be subject to United States federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of A - 74A - A | A FATCA (including those contained in Section 1471(b) or 1472(b) of the Internal Revenue Code, as applicable), such Lender shall deliver to Borrower and Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by Borrower or Administrative Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Internal Revenue Code) and such additional documentation reasonably requested by Borrower or Administrative Agent as may be necessary for Borrower and Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender's obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (D), FATCA shall include any amendments made to FATCA after the date of this Agreement. (iii) Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify Borrower and Administrative Agent in writing of its legal inability to do so. (f) If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section (including by the payment of additional amounts pursuant to this Section), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this paragraph (f) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this paragraph (f), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this paragraph (f) the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This paragraph shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person. (g) For the avoidance of doubt, for purposes of this Section 2.15, the term "applicable law" includes FATCA. (h) Each party's obligations under this Section 2.15 shall survive the resignation or replacement of Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Term Loan Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document. Section 2.16 Obligation to Mitigate. Each Lender agrees that, as promptly as practicable after the officer of such Lender responsible for administering its Term Loans becomes aware of the occurrence of an event or the existence of a condition that would cause such Lender to become an Affected Lender or that would entitle such Lender to receive payments under Section 2.13, 2.14, 2.15 or 2.19, it will, to the extent not inconsistent with the internal policies of such Lender and any applicable legal or regulatory restrictions, use reasonable efforts to (a) make, issue, fund or maintain its Credit Extensions, including any Affected Loans, through another office of such Lender, or (b) take such other measures as such Lender may A - 75A - A | A deem reasonable, if as a result thereof the circumstances which would cause such Lender to be an Affected Lender would cease to exist or the additional amounts which would otherwise be required to be paid to such Lender pursuant to Section 2.13, 2.14, 2.15 or 2.19 would be materially reduced and if, as determined by such Lender in its sole discretion, the making, issuing, funding or maintaining of such Term Loans through such other office or in accordance with such other measures, as the case may be, would not otherwise adversely affect such Term Loans or the interests of such Lender; provided, such Lender will not be obligated to utilize such other office pursuant to this Section 2.16 unless Borrower agree to pay all incremental expenses incurred by such Lender as a result of utilizing such other office as described above. A certificate as to the amount of any such expenses payable by Borrower pursuant to this Section 2.16 (setting forth in reasonable detail the basis for requesting such amount) submitted by such Lender to Borrower (with a copy to Administrative Agent) shall be conclusive absent manifest error. Section 2.17 Defaulting Lenders. Anything contained herein to the contrary notwithstanding, in the event that (x) [reserved], (y) becomes the subject of a Bail-in Action, or (z) other than at the direction or request of any regulatory agency or authority, defaults (in each case, a Defaulting Lender) in its obligation to fund (a Funding Default) a Term Loan (in each case, a Defaulted Loan), then (a) during any Default Period with respect to such Defaulting Lender, such Defaulting Lender shall be deemed not to be a Lender for purposes of voting on any matters (including the granting of any consents or waivers) with respect to any of the Loan Documents; and (b) to the extent permitted by applicable law, until such time as the Default Excess, if any, with respect to such Defaulting Lender shall have been reduced to zero, (i) any voluntary prepayment of the Term Loans shall, if Administrative Agent so directs at the time of making such voluntary prepayment, be applied to Term Loans of other Lenders as if such Defaulting Lender had no Term Loans outstanding and the outstanding Term Loans of such Defaulting Lender were zero, and (ii) any mandatory prepayment of the Term Loans shall, if Administrative Agent so directs at the time of making such mandatory prepayment, be applied to the Term Loans of other Lenders (but not to the Term Loans of such Defaulting Lender) as if such Defaulting Lender had funded all Defaulted Loans of such Defaulting Lender, it being understood and agreed that Borrower shall be entitled to retain any portion of any mandatory prepayment of the Term Loans that is not paid to such Defaulting Lender solely as a result of the operation of the provisions of this clause (b). No Term Loan Commitment of any Lender shall be increased or otherwise affected, and, except as otherwise expressly provided in this Section 2.17, performance by Borrower of their obligations hereunder and the other Loan Documents shall not be excused or otherwise modified as a result of any Funding Default or the operation of this Section 2.17. The rights and remedies against a Defaulting Lender under this Section 2.17 are in addition to other rights and remedies which Borrower may have against such Defaulting Lender with respect to any Funding Default and which Administrative Agent or any Lender may have against such Defaulting Lender with respect to any Funding Default. Section 2.18 Removal or Replacement of a Lender. Anything contained herein to the contrary notwithstanding, in the event that: (a) (i) any Lender (an Increased Cost Lender) shall give notice to Borrower that such Lender is an Affected Lender or that such Lender is entitled to receive payments under Section 2.14, 2.15 or 2.16, (ii) the circumstances which have caused such Lender to be an Affected Lender or which entitle such Lender to receive such payments shall remain in effect, and (iii) such Lender shall fail to withdraw such notice within five Business Days after Borrower's request for such withdrawal; or (b) (i) any Lender shall become a Defaulting Lender, (ii) the Default Period for such Defaulting Lender shall remain in effect, and (iii) such Defaulting Lender shall fail to cure the default as a result of which it has become a Defaulting Lender within five Business Days after Borrower's request that it cure such default; or (c) in connection with any proposed amendment, modification, termination, waiver or consent with respect to any of the provisions hereof as contemplated by Section 10.5(b), the consent of Administrative Agent and Required Lenders shall have been obtained but the consent of one or more of such other Lenders (each a Non-Consenting Lender) whose consent

is required shall not have been obtained; then, with respect to each such Increased Cost Lender, Defaulting Lender or Non-Consenting Lender (the "Terminated A - 76A - A | A Lender"), Administrative Agent may (which, in the case of an Increased-Cost Lender, only after receiving written request from Borrower to remove such Increased-Cost Lender), by giving written notice to Borrower and any Terminated Lender of its election to do so, elect to cause such Terminated Lender (and such Terminated Lender hereby irrevocably agrees) to assign its outstanding Term Loans in full to one or more Eligible Assignees (each a "Replacement Lender") in accordance with the provisions of Section 10.6 and Terminated Lender shall pay any fees payable thereunder in connection with such assignment; provided, (1) on the date of such assignment, the Replacement Lender shall pay to Terminated Lender an amount equal to the sum of (A) an amount equal to the principal of, and all accrued interest on, all outstanding Loans of the Terminated Lender and (B) an amount equal to all accrued, but theretofore unpaid fees owing to such Terminated Lender pursuant to Section 2.7; (2) on the date of such assignment, Borrower shall pay any amounts payable to such Terminated Lender pursuant to Section 2.14 or 2.15; and (3) in the event such Terminated Lender is a Non-Consenting Lender, each Replacement Lender shall consent, at the time of such assignment, to each matter in respect of which such Terminated Lender was a Non-Consenting Lender. Upon the prepayment of all amounts owing to any Terminated Lender, such Terminated Lender shall no longer constitute a "Lender" for purposes hereof; provided, any rights of such Terminated Lender to indemnification hereunder shall survive as to such Terminated Lender. For the avoidance of doubt, all fees that would otherwise be due and payable to any Non-Consenting Lender, including, without limitation, any Prepayment Premium and any Applicable Premium, shall continue to be due and payable to such Non-Consenting Lender. Section 2.19 Making or Maintaining SOFR Loans. (a) Illegality or Impracticability of SOFR Loans. In the event that on any date any Lender shall have determined (which determination shall be final and conclusive and binding upon all parties hereto but shall be made only after consultation with Borrower and Administrative Agent) that the making, maintaining or continuation of its SOFR Loans (i) has become unlawful as a result of compliance by such Lender in good faith with any law, treaty, governmental rule, regulation, guideline or order (or would conflict with any such treaty, governmental rule, regulation, guideline or order not having the force of law even though the failure to comply therewith would not be unlawful), or (ii) has become impracticable, as a result of contingencies occurring after the date hereof which materially and adversely affect the banking market, then, and in any such event, such Lender shall be an "Affected Lender" and it shall on that day give notice (by facsimile or by telephone confirmed in writing) to Borrower and Administrative Agent of such determination (which notice Administrative Agent shall promptly transmit to each other Lender). Thereafter (A) the obligation of the Affected Lender to make Loans as, or to convert Loans to, SOFR Loans shall be suspended until such notice shall be withdrawn by the Affected Lender, (B) to the extent such determination by the Affected Lender relates to a SOFR Loan then being requested by Borrower pursuant to a Funding Notice or a Conversion/Continuation Notice, the Affected Lender shall make such Loan as (or continue such Loan as or convert such Loan to, as the case may be) a Base Rate Loan, (C) the Affected Lender's obligation to maintain its outstanding SOFR Loans (the "Affected Loans") shall be terminated at the earlier to occur of the expiration of the Interest Period then in effect with respect to the Affected Loans or when required by law, and (D) the Affected Loans shall automatically convert into Base Rate Loans on the date of such termination. Notwithstanding the foregoing, to the extent a determination by an Affected Lender as described above relates to a SOFR then being requested by Borrower pursuant to a Funding Notice or a Conversion/Continuation Notice, Borrower shall have the option, to rescind such Funding Notice or Conversion/Continuation Notice as to all Lenders by giving notice (by facsimile or by telephone confirmed in writing) to Administrative Agent of such rescission on the date on which the Affected Lender gives notice of its determination as described above (which notice of rescission Administrative Agent shall promptly transmit to each other Lender). Except as provided in the immediately preceding sentence, nothing in this Section 2.19(a) shall affect the obligation of any Lender other than an Affected Lender to make or maintain Loans as, or to convert Loans to, SOFR Loans in accordance with the terms hereof. A - 77A - A | A (b) Compensation for Breakage or Non-Commencement of Interest Periods. Borrower shall compensate each Lender, upon written request by such Lender (which request shall set forth the basis for requesting such amounts), for all reasonable losses, expenses and liabilities (including any interest paid or calculated to be due and payable by such Lender to lenders of funds borrowed by it to make or carry its SOFR Loans and any loss, expense or liability sustained by such Lender in connection with the liquidation or re-employment of such funds but excluding loss of anticipated profits) which such Lender may sustain: (i) if for any reason (other than a default by such Lender) a borrowing of any SOFR Loan does not occur on a date specified therefor in a Funding Notice, or a conversion to or continuation of any SOFR Loan does not occur on a date specified therefor in a Conversion/Continuation Notice for conversion or continuation; (ii) if any prepayment or other principal payment of, or any conversion of, any of its SOFR Loans occurs on any day other than the last day of an Interest Period applicable to that Loan (whether voluntary, mandatory, automatic, by reason of acceleration, or otherwise); or (iii) if any prepayment of any of its SOFR Loans is not made on any date specified in a notice of prepayment given by Borrower. (c) Provisions with Respect to Term SOFR. Subject to Section 2.20, if prior to the commencement of any Interest Period for any SOFR Loan, (i) Administrative Agent shall have determined that adequate and reasonable means do not exist for ascertaining Term SOFR for such Interest Period, including, without limitation, because the use of "Term SOFR" has been discontinued (any determination of Administrative Agent to be conclusive and binding absent manifest error), or (ii) Administrative Agent shall have received notice from the Required Lenders that Term SOFR does not adequately and fairly reflect the cost to such Lenders of making, funding or maintaining their SOFR Loans for such Interest Period, then Administrative Agent shall give written notice to Borrower and to the Lenders as soon as practicable thereafter. Until Administrative Agent shall notify Borrower and the Lenders that the circumstances giving rise to such notice no longer exist, (A) the obligations of the Lenders to make SOFR Loans, or to continue or convert outstanding Loans as or into SOFR Loans, shall be suspended and (B) all such affected Loans shall be converted into Base Rate Loans on the last day of the then current Interest Period applicable thereto. Notwithstanding anything to the contrary herein, but subject to Section 2.20, to the extent that (x) adequate and reasonable means do not exist for ascertaining Term SOFR with a three-month tenor, including, without limitation because Term SOFR for such tenor has been discontinued or is no longer published and (y) other Available Tenors for Term SOFR are still available and generally used in the banking market, then the Administrative Agent shall, in consultation with the Borrower, replace three-month Term SOFR with Term SOFR of such other Available Tenor. Section 2.20 Benchmark Replacement Setting. (a) Benchmark Replacement. Notwithstanding anything to the contrary herein or in any other Loan Document, upon the occurrence of a Benchmark Transition Event, the Administrative Agent and the Borrower may amend this Agreement to replace the then-current Benchmark with a Benchmark Replacement. Any such amendment with respect to a Benchmark Transition Event will become effective at 5:00 p.m. (New York City time) on [***] after the Administrative Agent has posted such proposed amendment to all affected Lenders and the Borrower so long as the Administrative Agent has not received, by such time, written notice of objection to such amendment from Lenders comprising the Required Lenders. No replacement of a Benchmark with a Benchmark Replacement pursuant to this Section 2.20(a) will occur prior to the applicable Benchmark Transition Start Date. A - 78A - A | A (b) Benchmark Replacement Conforming Changes. In connection with the use, administration, adoption or implementation of a Benchmark Replacement, the Administrative Agent will have the right, in consultation with the Borrower, to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document. (c) Notices; Standards for Decisions and Determinations. The Administrative Agent will promptly notify the Borrower and the Lenders of (i) the implementation of any Benchmark Replacement and (ii) the effectiveness of any Conforming Changes in connection with the use, administration, adoption or implementation of a Benchmark Replacement. The Administrative Agent will notify the Borrower of (x) the removal or reinstatement of any tenor of a Benchmark pursuant to Section 2.20(d) and (v) the commencement of any Benchmark Unavailability Period. Any determination, decision or election that may be made by the Administrative Agent or, if applicable, any Lender (or group of Lenders) pursuant to this Section 2.20, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action or any selection, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this Section 2.20. (d) Unavailability of Tenor of Benchmark. Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (i) if the then-current Benchmark is a term rate (including Term SOFR Reference Rate) and either (A) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion or (B) the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative, then the Administrative Agent may modify the definition of "Interest Period" (or any similar or analogous definition) for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and (ii) if a tenor that was removed pursuant to clause (i) above either (A) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (B) is not, or is no longer, subject to an announcement that it is not or will not be representative for a Benchmark (including a Benchmark Replacement), then the Administrative Agent may modify the definition of "Interest Period" (or any similar or analogous definition) for all Benchmark settings at or after such time to reinstate such previously removed tenor. (e) Benchmark Unavailability Period. Upon the Borrower's receipt of notice of the commencement of a Benchmark Unavailability Period, (i) the Borrower may revoke any pending request for a Borrowing of, conversion to or continuation of SOFR Loans to be made, converted or continued during any Benchmark Unavailability Period and, failing that, the Borrower will be deemed to have converted any such request into a request for a Borrowing of or conversion to Base Rate Loans and (ii) any outstanding affected SOFR Loans will be deemed to have been converted to Base Rate Loans at the end of the applicable Interest Period. During a Benchmark Unavailability Period or at any time that a tenor for the then-current Benchmark is not an Available Tenor, the component of the Base Rate based upon the then-current Benchmark or such tenor for such Benchmark, as applicable, will not be used in any determination of the Base Rate. Section 2.21 Incremental Term Loans. The Borrower may, from time to time after the Closing Date, with the prior written consent of the Administrative Agent, on one or more occasions request additional term loans ("Incremental Term Loans") by delivering notice to the Administrative Agent at [***] A - 79A - A | A prior to the requested Credit Date identifying the amount of Incremental Term Loans so requested; provided, however, that: (a) the aggregate amount of all such Incremental Term Loans shall not exceed \$300,000,000; (b) the Lenders making such Incremental Term Loans have received investment committee approval (in such investment committee's sole discretion) with respect thereto, and no Lender shall be obligated to provide any Incremental Term Loan Commitments or fund any Incremental Term Loan without its consent; (c) any such Incremental Term Loan shall be in an amount not less than \$[***] (or such lesser amount then agreed to by the Administrative Agent); (d) the conditions precedent set forth in clauses (i) & (iii) of Section 3.2(a) of this Agreement shall have been satisfied as of the date such Incremental Term Loans are incurred (it being understood and agreed that the incurrence of such Incremental Term Loans shall not be subject to any other conditions precedent set forth in Section 3.2(a) of this Agreement, except to the extent agreed to by the Borrower and the Lenders providing such Incremental Term Loans); (e) the terms and conditions with respect to any such Incremental Term Loans (including any fees payable in connection therewith) shall be set forth in the applicable Incremental Amendment with respect thereto; provided, however, that: (i) the final maturity date of such Incremental Term Loans shall be no earlier than the Latest Maturity Date of the then outstanding Term Loans; (ii) the Weighted Average Life to Maturity of such Incremental Term Loans shall be no shorter than the remaining Weighted Average Life to Maturity of the then outstanding Term Loans (determined without giving effect to any prepayments that reduce amortization or that would otherwise modify the Weighted Average Life to Maturity); (iii) such Incremental Term Loans may participate on a pro rata basis or a less than pro rata basis (but not greater than a pro rata basis) in any voluntary or mandatory repayments or prepayments of the Term Loans; (iv) such Incremental Term Loans (A) shall rank pari passu in right of payment and with respect to security with the Obligations, (B) may not be secured by any assets other than the Collateral and (C) may not be guaranteed by any Person that is not a Loan Party; (v) except as otherwise expressly permitted in this Section 2.21 (and except for any terms and conditions with respect to any Incremental Term Loans that are applicable only after the Latest Maturity Date of the then outstanding Term Loans), the terms and conditions with respect to any Incremental Term Loans shall not be (A) materially more favorable to the Lenders of such Incremental Term Loans than the existing terms and conditions contained in the Loan Documents that apply to the Lenders of the then outstanding Term Loans (unless such existing terms and conditions contained in the Loan Documents are amended so as to conform to the materially more favorable terms and conditions that apply to the Lenders of the Incremental Term Loans) or (B) materially adverse to the Lenders of the then outstanding Term Loans (in their capacity as such Lenders); and A - 80A - A | A (f) the commitments in respect of such Incremental Term Loans (the "Incremental Term Loan Commitments") shall become Term Loan Commitments hereunder pursuant to an amendment (an "Incremental Amendment") to this Agreement and, as appropriate, the other Loan Documents, executed by the Borrower, each existing Lender agreeing to provide such Term Loan Commitment, if any, each additional Lender agreeing to provide such Term Loan Commitment, if any, and the Administrative Agent. Except as otherwise required by this Section 2.21, any such Incremental Amendment may, without the consent of any other Lenders, effect such amendments to this Agreement and the other Loan Documents as may be necessary or appropriate, in the reasonable opinion of the Administrative Agent and the Borrower, to effect the provisions of this Section 2.21. Article II CONDITIONS PRECEDENT Section 3.1 Closing Date. The obligation of each Lender to make a Credit Extension on the Closing Date is subject to the satisfaction, or waiver in accordance with Section 10.5, of the following conditions on or before the Closing Date: (a) Loan Documents. Administrative Agent shall have received copies of each Loan Document duly executed and delivered by each applicable Loan Party for each Lender. (b) Organizational Documents; Incumbency. Administrative Agent shall have received a Secretary's or Director's Certificate for each Loan Party attaching (i) copies of each Organizational Document of such Loan Party and, to the extent applicable, certified as of a recent date by the appropriate governmental official or authority or registered agent, each dated the Closing Date or a recent date prior thereto; (ii) signature and incumbency certificates (or a commercial register excerpt evidencing the signatory power) of the officers or (managing) directors of such Person executing the Loan Documents to which it is a party; (iii) resolutions of the Board of Directors or similar governing body of such Loan Party (and, in respect of Swiss Guarantor, resolutions of the quotaholders such Swiss Guarantor) approving and authorizing the execution, delivery and performance of this Agreement and the other Loan Documents to which it is a party or by which it or its assets may be bound as of the Closing Date, certified as of the Closing Date by its secretary, assistant secretary or a director as being in full force and effect without modification or amendment; and (iv) a good standing certificate (to the extent such concept exists) from the applicable Governmental Authority of such Loan Party's jurisdiction of incorporation, organization or formation, each dated a recent date prior to the Closing Date. (c) Organizational and Capital Structure. The organizational structure and capital structure of the Borrower and its Subsidiaries shall be as set forth on Schedule 4.2. (d) Governmental Authorizations and Consents. Each Loan Party shall have obtained all Governmental Authorizations and all consents of other Persons, in each case that are necessary or advisable in connection with the transactions contemplated by the Loan Documents and each of the foregoing shall be in full force and effect and in form and substance reasonably satisfactory to Administrative Agent. All applicable waiting periods shall have expired without any action being taken or threatened by any competent authority which would restrain, prevent or otherwise impose adverse conditions on the transactions contemplated by the Loan Documents or the financing thereof and no action, request for stay, petition for review or rehearing, reconsideration, or appeal with respect to any of the foregoing shall be pending, and the time for any applicable agency to take action to set aside its consent on its own motion shall have expired. A - 81A - A | A (e) Personal Property Collateral. In order to create in favor of Administrative Agent, for the benefit of Secured Parties, a valid, perfected First Priority security interest (subject to any exceptions permitted in the Collateral Documents) in the personal property Collateral, Administrative Agent shall have received (subject to Section 5.15): (i) evidence reasonably satisfactory to Administrative Agent of the compliance by each Loan Party of their obligations under the Pledge and Security Agreement and the other Collateral Documents (including, without limitation, their obligations to authorize or execute, as the case may be, and deliver UCC financing statements, originals of Capital Stock (including stock certificates, if any, representing pledged Capital Stock along with appropriate endorsements), instruments and chattel paper, and any agreements governing deposit and/or securities accounts as provided therein), together with (A) appropriate financing statements on Form UCC-1 in form for filing in such office or offices as may be necessary or, in the opinion of Administrative Agent, desirable to perfect the security interests purported to be created by each Pledge and Security Agreement and each other Collateral Document and (B) evidence reasonably satisfactory to Administrative Agent of the filing of such UCC-1 financing statements; (ii) a completed Perfection Certificate dated the Closing Date and executed by an Authorized Officer of the Borrower, together with all attachments contemplated hereby, including (A) the results of a recent search, by a Person satisfactory to Administrative Agent, of all effective UCC financing statements (or equivalent filings) made with respect to any assets or property of any Loan Party in the jurisdictions specified in the Perfection Certificate, together with copies of all such filings disclosed by such search, and (B) UCC termination statements (or similar documents) duly

executed (if applicable) by all applicable Persons for filing in all applicable jurisdictions as may be necessary to terminate any effective UCC financing statements (or equivalent filings) disclosed in such search (other than any such financing statements in respect of Permitted Liens); and (iii) evidence that each Loan Party shall have taken or caused to be taken any other action, executed and delivered or caused to be executed and delivered any other agreement, document and instrument (including without limitation, Control Agreements for all Deposit Accounts and Security Accounts held by a Loan Party) and made or caused to be made any other filing and recording reasonably required by Administrative Agent. (f) Financial Statements; Initial Projections. Lenders shall have received from the Borrower (i) the Historical Financial Statements and (ii) the Initial Projections. (g) Evidence of Insurance. Subject to Section 5.15, the Administrative Agent shall have received a certificate from Borrower's insurance broker or other evidence reasonably satisfactory to it that all insurance required to be maintained pursuant to Section 5.5 is in full force and effect, together with endorsements naming Administrative Agent, for the benefit of Secured Parties, as additional insured and loss payee thereunder to the extent required under Section 5.5, in each case, in form and substance reasonably satisfactory to Administrative Agent. (h) Opinions of Counsel. Lenders and their respective counsel shall have received an executed copy of the favorable written opinion of (i) Latham & Watkins LLP, counsel for Loan Parties (and each Loan Party hereby instructs such counsel to deliver such opinions to Administrative Agent and Lenders), (ii) Loyens & Loeff, Dutch counsel to the Administrative Agent and the Lenders and (iii) Homburger AG, Swiss counsel to the Administrative Agent and the Lenders, in case as to such matters as Administrative Agent may reasonably request, dated the Closing Date and otherwise in form and substance reasonably satisfactory to Administrative Agent. A - 82A - A | A (i) Fees. Borrower shall have paid to Administrative Agent, the fees and expenses then due and payable pursuant to Section 2.7 and Section 10.2. (j) Solvency Certificate. On the Closing Date, Administrative Agent shall have received a duly executed Solvency Certificate of a director or the chief financial officer of the Borrower substantially in the form of Exhibit F, dated as of the Closing Date and addressed to Administrative Agent and Lenders. (k) Closing Date Certificate. Borrower shall have delivered to Administrative Agent a duly executed Closing Date Certificate, together with all attachments thereto. (l) No Litigation. There shall not exist any action, suit, investigation, litigation or proceeding or other legal or regulatory developments, pending or threatened in any court or before any arbitrator or Governmental Authority that singly or in the aggregate, materially impairs the transactions contemplated by the Loan Documents or that would have a Material Adverse Effect. (m) Minimum Qualified Cash. Administrative Agent shall have received evidence reasonably satisfactory to it that the Loan Parties shall have Qualified Cash of at least \$70,000,000 (on a pro forma basis immediately after giving effect to any Credit Extensions made on the Closing Date, the Closing Date Refinancing, and the payment of all Transaction Costs required to be paid in Cash). (n) No Material Adverse Effect/Material Regulatory Liability. Since [***], no event, circumstance or change shall have occurred that has caused or evidences, either in any case or in the aggregate, a Material Adverse Effect or a Material Regulatory Liability. (o) Completion of Proceedings. All partnership, corporate and other proceedings taken or to be taken in connection with the transactions contemplated hereby and all documents incidental thereto not previously found reasonably acceptable by Administrative Agent and its counsel shall be reasonably satisfactory in form and substance to Administrative Agent and such counsel. (p) Bank Regulations. Administrative Agent shall have received all documentation and other information reasonably requested that is required by bank regulatory authorities under applicable know-your-customer and anti-money laundering rules and regulations, including the PATRIOT Act, and all such documentation and other information shall be in form and substance reasonably satisfactory to Administrative Agent. (q) Funding Notice. Administrative Agent shall have received a fully executed and delivered Funding Notice. (r) Representations and Warranties. The representations and warranties contained herein and in each other Loan Document, certificate or other writing delivered to Administrative Agent or any Lender pursuant hereto or thereto on or prior to the date hereof shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified as to materiality or to Material Adverse Effect in the text thereof, which representations and warranties shall be true and correct in all respects subject to such qualification) on and as the date hereof to the same extent as though made on and as of that date, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified as to materiality or to Material Adverse Effect in the text thereof, which representations and warranties shall be true and correct in all respects subject to such qualification) on and as of such earlier date. A - 83A - A | A (s) No Default or Event of Default. No event shall have occurred and be continuing or would result from the consummation of the transactions contemplated herein that would constitute an Event of Default or a Default. (t) Agent of Service of Process Letter. Each Loan Party organized outside of the United States shall have delivered to Administrative Agent a letter appointing an agent for service of process as required under Section 10.22. (u) Registrations. All Registrations from the FDA and EMA in respect of the Products shall be valid and subsisting and in full force and effect. (v) Works Council. If applicable, a positive or neutral advice from each relevant works council of each Dutch Guarantor which, if conditional, contains conditions which can reasonably be complied with, including the request for advice or, a confirmation of the board of directors of each relevant Loan Party included in the board resolutions that no works council has jurisdiction in respect of any of the transactions contemplated by the Loan Documents. Each Lender, by delivering its signature page to this Agreement and funding the Initial Term Loan on the Closing Date, shall be deemed to have acknowledged receipt of, and consented to and approved, each Loan Document and each other document required to be approved by Administrative Agent, Required Lenders or Lenders, as applicable, on the Closing Date. Section 3.2 Conditions to Each Subsequent Credit Extension. (a) Conditions Precedent. The obligation of each Lender to make any Loan on any date following the Closing Date is subject to the satisfaction, or waiver in accordance with Section 10.5, of the following conditions precedent: (i) Administrative Agent shall have received a fully executed and delivered Funding Notice; (ii) as of such Credit Date, the representations and warranties contained herein and in each other Loan Document, certificate or other writing delivered to the Administrative Agent or any Lender pursuant hereto or thereto on or prior to the Credit Date shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified as to materiality or to Material Adverse Effect in the text thereof, which representations and warranties shall be true and correct in all respects subject to such qualification) on and as of that Credit Date to the same extent as though made on and as of that date, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified as to materiality or to Material Adverse Effect in the text thereof, which representations and warranties shall be true and correct in all respects subject to such qualification) on and as of such earlier date; (iii) as of such Credit Date, no event shall have occurred and be continuing or would result from the consummation of the applicable Credit Extension that would constitute an Event of Default or a Default; (iv) the Administrative Agent shall have received evidence reasonably satisfactory to it that the Loan Parties shall have Qualified Cash of at least \$70,000,000 (on a pro forma basis immediately after giving effect to the Credit Extension made on such Credit Date); A - 84A - A | A (v) the Loan Parties shall have paid all fees, costs and expenses then due and payable by the Loan Parties pursuant to this Agreement and the other Loan Documents, including, without limitation, Section 2.7, and Section 10.2 hereof; and (b) Notices. Any Notice shall be executed by an Authorized Officer of Borrower in a writing delivered to Administrative Agent. Article IV REPRESENTATIONS AND WARRANTIES In order to induce the Administrative Agent and Lenders to enter into this Agreement and to make each Credit Extension to be made thereby, each Loan Party represents and warrants to the Administrative Agent and Lender, on the Closing Date and on each Credit Date, that the following statements are true and correct: Section 4.1 Organization; Requisite Power and Authority; Qualification. Each of the Borrower and its Subsidiaries (a) is duly organized or incorporated, validly existing and in good standing (to the extent such concept exists) under the laws of its jurisdiction of organization or incorporation as identified in Schedule 4.1, (b) has all requisite power and authority to own and operate its properties, to carry on its business as now conducted and as proposed to be conducted, to enter into the Loan Documents to which it is a party and to carry out the transactions contemplated thereby and, in the case of Borrower, to make the borrowings hereunder, and (c) is qualified to do business and in good standing (to the extent such concept exists) in every jurisdiction where its assets are located and wherever necessary to carry out its business and operations, except in jurisdictions where the failure to be so qualified or in good standing (to the extent such concept exists) has not had, and would not be reasonably expected to have, a Material Adverse Effect. Section 4.2 Capital Stock and Ownership. The Capital Stock of each of the Borrower and its Subsidiaries has been duly authorized and validly issued and is fully paid and non-assessable. Except as set forth on Schedule 4.2, as of the date hereof, there is no existing option, warrant, call, right, commitment or other agreement to which the Borrower or any of its Subsidiaries is a party requiring, and there is no membership interest or other Capital Stock of the Borrower or any of its Subsidiaries outstanding which upon conversion or exchange would require, the issuance by the Borrower or any of its Subsidiaries of any additional membership interests or other Capital Stock of the Borrower or any of its Subsidiaries or other securities convertible into, exchangeable for or evidencing the right to subscribe for or purchase, a membership interest or other Capital Stock of the Borrower or any of its Subsidiaries. Schedule 4.2 correctly sets forth the ownership interest of the Borrower and each of its Subsidiaries in their respective Subsidiaries. Section 4.3 Due Authorization. The execution, delivery and performance of the Loan Documents and the consummation by each Loan Party of the transactions contemplated hereby and by the other Loan Documents have been duly authorized by all necessary action on the part of each Loan Party that is a party thereto. Section 4.4 No Conflict. The execution, delivery and performance by Loan Parties of the Loan Documents to which they are parties and the consummation of the transactions contemplated by the Loan Documents do not and will not (a) (i) violate any provision of any law or any governmental rule or regulation applicable to the Borrower or any of its Subsidiaries, (ii) any of the Organizational Documents of the Borrower or any of its Subsidiaries, or (iii) any order, judgment or decree of any court or other agency of government binding on the Borrower or any of its Subsidiaries, except, in the cases of clauses (a)(i) and (a)(iii), as would not reasonably be expected to result in a Material Adverse Effect; (b) conflict with, result A - 85A - A | A in a breach of or constitute (with due notice or lapse of time or both) a default under any Material Contract; (c) result in or require the creation or imposition of any Lien upon any of the properties or assets of the Borrower or any of its Subsidiaries (other than any Liens created under any of the Loan Documents in favor of Administrative Agent, on behalf of Secured Parties); (d) result in any default, non-compliance, suspension revocation, impairment, forfeiture or non-renewal of any permit, license, authorization or approval applicable to its operations or any of its properties except as would not reasonably be expected to result in a Material Adverse Effect; or (e) require any approval of stockholders, members or partners or any approval or consent of any Person under any Material Contract, except for such approvals or consents which will be obtained on or before the Closing Date and disclosed in writing to Lenders. Section 4.5 Governmental Consents. The execution, delivery and performance by Loan Parties of the Loan Documents to which they are parties and the consummation of the transactions contemplated by the Loan Documents do not and will not require any registration with, consent or approval of, or notice to, or other action to, with or by, any Governmental Authority except for filings and recordings with respect to the Collateral to be made, or otherwise delivered to Administrative Agent for filing and/or recordation, as of the Closing Date. Section 4.6 Binding Obligation. Each Loan Document has been duly executed and delivered by each Loan Party that is a party thereto and is the legally valid and binding obligation of such Loan Party, enforceable against such Loan Party in accordance with its respective terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors' rights generally or by equitable principles relating to enforceability. Section 4.7 Historical Financial Statements. The Historical Financial Statements were prepared in conformity with GAAP and fairly present, in all material respects, the financial position, on a consolidated basis, of the Persons described in such financial statements as at the respective dates thereof and the results of operations and cash flows, on a consolidated basis, of the entities described therein for each of the periods then ended, subject, in the case of any such unaudited financial statements, to changes resulting from audit and normal year end adjustments and the absence of footnotes. As of the Closing Date, neither the Borrower nor any of its Subsidiaries has any contingent liability or liability for taxes, long term lease or unusual forward or long term commitment that is not reflected in the Historical Financial Statements or the notes thereto and which in any such case is material in relation to the business, operations, properties, assets and condition (financial or otherwise) of the Borrower and its Subsidiaries taken as a whole. Section 4.8 Initial Projections. On and as of the Closing Date, the projections of the Borrower and its Subsidiaries for the Fiscal Years [***] through [***] including quarterly projections for each quarter during the Fiscal Years [***] through [***] and annual projections for each of the Fiscal Years [***] through [***] (the Initial Projections) are based on good faith estimates and assumptions made by the management of the Borrower; provided, the Initial Projections are not to be viewed as facts and that actual results during the period or periods covered by the Initial Projections may differ from such Initial Projections and that the differences may be material; provided, further, as of the Closing Date, management of the Borrower believed that the Initial Projections were reasonable. Section 4.9 No Material Adverse Effect. Since [***], no event, circumstance or change has occurred that has caused or evidences, either in any case or in the aggregate, a Material Adverse Effect. Section 4.10 Adverse Proceedings. Etc. There are no Adverse Proceedings that (a) relate to any Loan Document or the transactions contemplated hereby or thereby or (b) individually or in the aggregate, would materially impair Administrative Agent's security interest in the Collateral, the Borrower's and its Subsidiaries' respective rights, powers or remedies with respect to applicable Products or could otherwise A - 86A - A | A reasonably be expected to have a Material Adverse Effect. Neither the Borrower nor any of its Subsidiaries is in violation of or in default with respect to any final judgments, writs, injunctions, decrees, rules, laws or regulations of any court or any federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign except to the extent such violation or default would not reasonably be expected to result in a Material Adverse Effect. Section 4.11 Payment of Taxes. All material Tax returns and reports of the Borrower and its Subsidiaries required to be filed by or with respect to any of them have been timely filed, and all material Taxes due and payable and all material assessments, fees and other governmental charges upon or with respect to the Borrower and its Subsidiaries and upon or with respect to their respective properties, assets, income, businesses and franchises which are due and payable have been paid when due and payable, except Taxes that are being contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves are being maintained in accordance with GAAP. There is no pending or, to the knowledge of the Borrower, proposed material Tax assessment, deficiency, audit or other proceeding against the Borrower or any of its Subsidiaries, except for such assessment, deficiency, audit or other proceeding that is being contested by the Borrower or such Subsidiary in good faith and by appropriate proceedings and for which adequate reserves are being maintained in accordance with GAAP. Notwithstanding the foregoing, in the case of any Credit Date, matters occurring after the Closing Date that are permitted under Section 5.3 shall not violate this Section 4.11 with respect to such Credit Date. Section 4.12 Properties, Title. Each of the Borrower and its Subsidiaries has (a) good, sufficient, marketable and legal title to (in the case of fee interests in Real Property), (b) valid leasehold interests in (in the case of leasehold interests in real or personal property), and (c) good and valid title to (in the case of all other personal property), all of their respective properties and assets reflected in their respective Historical Financial Statements referred to in Section 4.7 and in the most recent financial statements delivered pursuant to Section 5.1, in each case except for (i) assets disposed of since the date of such financial statements in the ordinary course of business or as otherwise permitted under Section 6.9, or (ii) defects in title or interests which would not, individually or in the aggregate, reasonably be expected to interfere with the Borrower or its applicable Subsidiary's ability to conduct its business as currently conducted or utilize such property for its intended purpose. All such properties and assets are in working order and condition, ordinary wear and tear excepted, and all such properties and assets are free and clear of Liens (other than Permitted Liens). As of the Closing Date, Schedule 4.12 contains a true, accurate and complete list of all Real Property of the Borrower and its Subsidiaries or where Collateral having an aggregate fair market value in excess of \$[***] or a substantial portion of the books and records of the Borrower and its Subsidiaries are located. Section 4.13 Environmental Matters. Except as any such failure could not reasonably be expected to result in a Material Adverse Effect: (a) No Environmental Claim has been asserted against any Loan Party or any predecessor in interest nor has any Loan Party received written notice of any threatened or pending Environmental Claim against Loan Party or any predecessor in interest. (b) There has been no Release of Hazardous Materials and there are no Hazardous Materials present in violation of Environmental Law at any of the properties currently owned or leased by any Loan Party. (c) The operation of the business of, and all of the Real Property owned or leased by, each Loan Party are in compliance with all Environmental Laws. A - 87A - A | A (d) Each Loan Party holds and is in compliance Governmental Authorizations required under any Environmental Laws in connection with the operations carried on by it and the Real Property owned or leased by it. Section 4.14 No Defaults. Neither the Borrower nor any of its Subsidiaries is in default in the performance, observance or fulfillment of any of the obligations, covenants or conditions contained in any of its Contractual Obligations, and no condition exists which, with the giving of notice or the lapse of time or both, could constitute such a default, except, in each case, where the consequences, direct or indirect, of such default or defaults, if any, could not reasonably be expected to have a Material Adverse Effect. Section 4.15 Material Contracts. (a) Schedule 4.15 contains a true, correct and complete list of all the Material Contracts in effect on the Closing Date, which, together with any updates provided pursuant to

Section 5.1(n) all such Material Contracts are in full force and effect and no defaults currently exist thereunder (other than as described in Schedule 4.15 or in such updates). (b) Except as described in Schedule 4.15, each Material Contract is a legal, valid and binding obligation of the Borrower, its Subsidiaries and, to the knowledge of the Loan Parties, each other party thereto, is enforceable in accordance with its terms and is in full force and effect, subject bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors' rights and to general equity principles. Neither the Borrower nor its Subsidiaries, nor to the knowledge of the Borrower or its Subsidiaries, any other party to any Material Contract, is in material breach or default, under the terms of any Material Contract, and no condition exists which, with the giving of notice or the lapse of time or both, could constitute a material breach or default by the Borrower or any of its Subsidiaries thereunder. Section 4.16 Governmental Regulation. Neither the Borrower nor any of its Subsidiaries is subject to regulation under the Public Utility Holding Company Act of 2005, the Federal Power Act or the Investment Company Act of 1940 or under any other federal or state statute or regulation which may limit its ability to incur Indebtedness or which may otherwise render all or any portion of the Obligations unenforceable. Neither the Borrower nor any of its Subsidiaries is a "registered investment company" or a company "controlled by a registered investment company" or a "principal underwriter" of a "registered investment company" as such terms are defined in the Investment Company Act of 1940. Section 4.17 Margin Stock. Neither the Borrower nor any of its Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying any Margin Stock. No part of the proceeds of the Term Loans made to such Loan Party will be used to purchase or carry any such Margin Stock or to extend credit to others for the purpose of purchasing or carrying any such Margin Stock or for any purpose that violates, or is inconsistent with, the provisions of Regulation T, U or X of the Federal Reserve Board or any similar regulation in any other jurisdiction. Section 4.18 Employee Benefit Plans. No ERISA Event has occurred or is reasonably expected to occur that has resulted or could reasonably be expected to result in a Material Adverse Effect. Section 4.19 Certain Fees. No broker's fee or finder's fee or commission will be payable with respect hereto or any of the transactions contemplated hereby. Section 4.20 Solvency. (a) - 88A - (A) (a) Borrower is, both immediately before and immediately upon the incurrence of the Credit Extension by Borrower on the Closing Date and on each date on which this representation and warranty is made, will be, Solvent. (b) The Loan Parties are, on a consolidated basis, both immediately before and immediately upon the incurrence of the Credit Extension by the Borrower on the Closing Date and on each date on which this representation and warranty is made, will be, Solvent. Section 4.21 ERISA. The underlying assets of the Borrower and its Subsidiaries do not constitute "plan assets" (within the meaning of 29 CFR 2510.3-101 et seq., as modified by Section 3(42) of ERISA (the "Plan Asset Regulations") or any similar applicable law) of one or more Benefit Plans and the execution, delivery and performance of this Agreement and the other Loan Documents by Borrower and its Subsidiaries do not and will not constitute a non-exempt prohibited transaction under Section 406 of ERISA or Section 4975 of the Internal Revenue Code. Section 4.22 Compliance with Statutes, Etc. Each of the Borrower and its Subsidiaries is in compliance with (i) its Organizational Documents and (ii) all applicable laws, statutes, regulations and orders of, and all applicable restrictions imposed by, all Governmental Authorities, in respect of the conduct of its business and the ownership of its property, except such non-compliance that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. Section 4.23 Intellectual Property. (a) To the knowledge of the Borrower and its Subsidiaries, each of the Borrower and its Subsidiaries own, or control, all Intellectual Property Rights that are necessary or material to the conduct of its business as currently conducted and proposed to be conducted, including the discovery, development, manufacture, use and Commercialization of the Products. (b) Schedule 4.23(b) sets forth a true, correct and complete listing, under separate headings, of all (i) exclusive in-license agreements pursuant to which the Borrower or its Subsidiaries in-licenses any Product Intellectual Property Rights, and (ii) exclusive out-license agreements pursuant to which the Borrower or its Subsidiaries have granted any Person any right or interest under any Product Intellectual Property Rights, and (iii) any other in-license agreement or out-license agreements, in each case, are otherwise necessary or materially for the use of or rights in the Intellectual Property Rights (including co-existence agreements, settlement agreements, and covenants not to sue) (collectively, "License Agreements"). Each License Agreement identified on Schedule 4.23(b) is a valid and binding obligation of the applicable Loan Party and, to the knowledge of Borrower or the applicable Subsidiary that is party to a License Agreement, the counterpart(ies) thereto and is enforceable against each counterparty thereto in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law). Neither Borrower nor any of its Subsidiaries has received any written notice in connection with any such License Agreement challenging the validity, enforceability or interpretation of any provision of such agreement. Neither Borrower nor any of its Subsidiaries has (A) given written notice to a counterparty of the termination of any such License Agreement (whether in whole or in part) or any written notice to a counterparty expressing any intention to terminate any such License Agreement or (B) received from a counterparty thereto any written notice of termination of any such License Agreement (whether in whole or in part) or any written notice from a counterparty stating its intention to terminate any such License Agreement. Neither Borrower nor any of its Subsidiaries has consented to any assignment by the counterparty to any License Agreement of any of its rights or obligations under any such License Agreement, and, to the knowledge of Borrower or the applicable Subsidiary that is party to a License Agreement, the counterparty has not assigned any of its rights or obligations under any such License Agreement to any Person. Neither Borrower nor any of its Subsidiaries has notified in writing the respective counterparty to any License Agreement or any other Person of any claims for indemnification under any License Agreement nor has Borrower or any Subsidiary received any written claims for indemnification under any License Agreement. Neither Borrower nor any Subsidiary has received any written notice from, or given any written notice to, any counterparty to any License Agreement alleging any infringement of any of the Patent Rights licensed thereunder. (c) Schedule 4.23(c) sets forth a true, correct and complete listing, including the owner and registration or application number, of all the Product Intellectual Property Rights that are U.S. (federal or state) and foreign (i) Product Patents, and identifies the owner of each such patent/application, (ii) registered trademarks and trademark applications, (iii) registered copyrights and copyright applications, (iv) domain names, and (v) any other form of registered Product Intellectual Property Rights. Except as identified in Schedule 4.23(c), (i) the owner listed on Schedule 4.23(c) is the exclusive owner of such registration or application; (ii) to Borrower's and its Subsidiaries' knowledge, such registrations are valid, subsisting and enforceable; (iii) none of those registrations or applications have lapsed or been abandoned, cancelled or expired; (iv) the applicable Loan Party has taken all reasonable steps to maintain such registrations or applications, including by timely filing fees and responses; and (v) each individual associated with the filing and prosecution of such registrations or applications, including the named inventors in the case of the Product Patents, has complied in all material respects with all applicable duties of candor and good faith in dealing with any patent office, including the USPTO, in those jurisdictions where such duties exist. Borrower may update this list to add additional registrations or applications, so long as such amendment occurs by written notice to Administrative Agent, subject to the Loan Party's obligations and restrictions under this Agreement. (d) There is no opposition, interference, reexamination, inter partes review, post-grant review, derivation or other post-grant proceeding, injunction, claim, suit, action, subpoena, hearing, inquiry, investigation (by the International Trade Commission or otherwise), complaint, arbitration, mediation, demand, decree or other dispute, disagreement, proceeding or claim (collectively, "Disputes") that is pending or currently threatened in writing, that challenges the legality, scope, validity, enforceability, infringement, ownership, inventorship or other rights with respect to any of the Product Intellectual Property Rights that are owned by Borrower or its Subsidiaries and to the knowledge of Borrower and its Subsidiaries, that are licensed by Borrower or its Subsidiaries. Neither the Borrower nor its Subsidiaries is aware of any facts that could provide a reasonable basis for such a claim challenging the legality, scope, validity, enforceability, infringement, ownership, inventorship or other rights with respect to any of the Product Intellectual Property Rights that are owned by Borrower or its Subsidiaries and to the knowledge of Borrower and its Subsidiaries, that are licensed by Borrower or its Subsidiaries. The Borrower and its Subsidiaries have not received any written notice that there is any, and to their knowledge there is no Person who is or claims to be an inventor under any of the Product Patents who is not a named inventor thereof. (e) There is no past, pending or threatened (in writing), and to the knowledge of Borrower and its Subsidiaries, no event has occurred or circumstance exists that (with or without notice or lapse of time, or both) could reasonably be expected to give rise to or serve as a basis for any, action, suit, or proceeding, or any investigation or claim by any Person that claims or alleges that the discovery, development, manufacture, use or Commercialization of any Product, once marketed, does or could infringe on any Patent or other Intellectual Property Rights of any other Person or constitute misappropriation of any other Person's trade secrets or other Intellectual Property Rights and neither the Borrower nor its Subsidiaries is aware of any facts that could provide a reasonable basis for such a claim. (f) To the knowledge of the Borrower, there is no product that infringes or, once marketed, could infringe on any issued Patents included in the Product Intellectual Property Rights that are that are owned by Borrower or its Subsidiaries and to the knowledge of Borrower and its Subsidiaries, that are licensed by Borrower or its Subsidiaries. (g) Except as disclosed in Schedule 4.23(f), neither the Borrower nor its Subsidiaries has entered into any Contractual Obligation, commitment or undertaking (i) creating a lien, charge, security interest or other encumbrance on, or relating to or affecting the Product Intellectual Property Rights or any of its royalties on, or proceeds from, sales of the Product, (ii) pursuant to which the Borrower or its Subsidiaries has sold, transferred, assigned or pledged to any Person royalties on, or proceeds from, sales of the Product, or (iii) providing for milestone payments or similar development-, commercialization- or intellectual property-related payments to any Person applicable (or that with further development and commercialization may become applicable) to the Product. Section 4.24 Insurance. Each of the Borrower and its Subsidiaries keeps its property adequately insured and maintains (a) insurance to such extent and against such risks, as is customary with companies in the same or similar businesses, (b) workmen's compensation insurance in the amount required by applicable law, (c) public liability insurance, which shall include product liability insurance, in the amount customary with companies in the same or similar business against claims for personal injury or death on properties owned, occupied or controlled by it, and (d) such other insurance as may be required by law or as may be required under Section 5.5 hereof. Schedule 4.24 sets forth a list of all insurance maintained by each Loan Party on the Closing Date. Section 4.25 Common Enterprise. The successful operation and condition of each of the Loan Parties is dependent on the continued successful performance of the functions of the group of the Loan Parties as a whole and the successful operation of each of the Loan Parties is dependent on the successful performance and operation of each other Loan Party. Each Loan Party expects to derive benefit (and its Board of Directors or other governing body has determined that it may reasonably be expected to derive benefit), directly and indirectly, from (a) successful operations of each of the other Loan Parties and (b) the credit extended by the Lenders to the Loan Parties hereunder, both in their separate capacities and as members of the group of companies. Each Loan Party has determined that execution, delivery, and performance of this Agreement and any other Loan Documents to be executed by such Loan Party is within its purpose, will be of direct and indirect benefit to such Loan Party, and is in its best interest. Section 4.26 Permits, Etc. Each Loan Party has, and is in compliance with, all permits, licenses, authorizations, approvals, entitlements and accreditations required for such Person lawfully to own, lease, manage or operate, or to acquire, each business currently owned, leased, managed or operated, or to be acquired, by such Person, which, if not obtained, could not reasonably be expected to have a Material Adverse Effect. No condition exists or event has occurred which, in itself or with the giving of notice or lapse of time or both, would result in the suspension, revocation, impairment, forfeiture or non-renewal of any such permit, license, authorization, approval, entitlement or accreditation, and there is no claim that any thereof is not in full force and effect, except, in each case, to the extent any such condition, event or claim could not be reasonably be expected to have a Material Adverse Effect. Section 4.27 Bank Accounts and Securities Accounts. Schedule 4.27 sets forth a complete and accurate list as of the Closing Date of all deposit, checking and other bank accounts, all securities and other accounts maintained with any broker dealer and all other similar accounts maintained by each Loan Party, together with a description thereof (i.e., the bank or broker dealer at which such deposit or other account is maintained and the account number and the purpose thereof). Section 4.28 Security Interests. (a) With respect to the Collateral Documents governed by New York law, such Collateral Documents, upon execution and delivery thereof by the parties thereto, will create in favor of Administrative Agent, for the benefit of the Secured Parties, a legal, valid and enforceable security interest in the Collateral described therein and (i) when the Pledged Equity Interests (as defined in the Pledge and Security Agreement) constituting certificated securities (as defined in the UCC) required to be delivered to the Administrative Agent under the Pledge and Security Agreement is delivered to the Administrative Agent, together with appropriate instruments of transfer, the Lien created under such Collateral Documents will constitute a fully perfected First Priority Lien on, and security interest in, all right, title and interest of the Loan Parties in such Pledged Equity Interests, in each case prior and superior in right to any other Person, and (ii) when financing statements in appropriate form are filed and maintained in the applicable filing offices, the Lien created under such Collateral Documents will constitute a fully perfected First Priority Lien on, and security interest in, all right, title and interest of the Loan Parties in the Collateral described in such Collateral Documents to the extent that a security interest in such Collateral may be perfected by the filings of such financing statements, in each case prior and superior in right to any other Person. (b) Upon the filing and recordation of the Pledge and Security Agreement (or a short form thereof), or an agreed upon filing or "short form" instrument referenced therein with the United States Patent and Trademark Office or the United States Copyright Office, as applicable, together with financing statements in appropriate form filed and maintained in the applicable filing offices, the Liens created by the Pledge and Security Agreement shall constitute fully perfected First Priority Liens on, and security interests in, all right, title and interests of the Loan Parties in the Intellectual Property in which a security interest may be perfected by filing in the United States and its territories and possessions, in each case prior and superior in right to any other Person (it being understood that subsequent recordings in the United States Patent and Trademark Office and the United States Copyright Office may be necessary to perfect a Lien on United States Patents, Patent applications, registered trademarks, trademark applications, including the goodwill associated with the trademarks, registered United States copyrights and copyright applications and exclusive licenses of registered United States copyrights acquired by the Loan Parties after the date hereof). Section 4.29 PATRIOT ACT and FCPA. To the extent applicable, each Loan Party is in compliance with (a) the laws, regulations and Executive Orders administered by OFAC, and (b) the Bank Secrecy Act, as amended by the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (USA PATRIOT Act) of 2001 (the "PATRIOT Act"). Neither the Loan Parties nor any of their officers, directors, employees, agents or shareholders acting on the Loan Parties' behalf shall use the proceeds of the Loans to make any payments, directly or indirectly (including through any third party intermediary), to any Foreign Official in violation of the United States Foreign Corrupt Practices Act of 1977 (the "FCPA"). None of the Loan Parties, nor any of their Affiliates, is in violation of any Anti-Terrorism Law or engages in or conspires to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the Anti-Terrorism Laws. None of the Loan Parties, nor any of their Affiliates, or their respective agents acting or benefiting in any capacity in connection with the Loans or other transactions hereunder, is a Blocked Person. None of the Loan Parties, nor any of their agents acting in any capacity in connection with the Loans or other transactions hereunder (A) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (

where such invalidity would not reasonably be expected to, individually or in the aggregate, result in Material Regulatory Liabilities. To the knowledge of the Borrower and its Subsidiaries, neither the FDA nor any comparable Governmental Authority is has threatened limiting, suspending, or revoking such Registrations or changing the scope of the marketing authorization or the labeling of any Products under such Registrations, except where such limitations, suspensions, revocations or changes would not, whether individually or in the aggregate, reasonably be expected to result in Material Regulatory Liabilities. To the knowledge of the Borrower and its Subsidiaries, except as would not, whether individually or in the aggregate, reasonably be expected to result in Material Regulatory Liabilities, there is no false or materially misleading information or significant omission in any Product application or other notification, submission or report to the FDA or any comparable Governmental Authority that was not corrected by subsequent submission, and all such applications, notifications, submissions and reports provided the Borrower and its Subsidiaries were true, complete, and correct in as of the date of submission to FDA or any comparable Governmental Authority. The Borrower and its Subsidiaries have not failed to fulfill and perform their material obligations which are due under each such Registration, and to the knowledge of the Borrower, no event has occurred which would reasonably be expected constitute a breach or default under any such Registration, in each case that would reasonably be expected to result in Material Regulatory Liabilities,. To the knowledge of the Borrower and its Subsidiaries, any third party that develops, researches, manufactures, commercializes, distributes, sells or markets Products pursuant to an agreement with the Borrower or its Subsidiaries (a “Loan Party Partner”) is in compliance with all Registrations from the FDA and any comparable Governmental Authority insofar as they pertain to Products, and each such Loan Party Partner is, and since [***] has been, in compliance with applicable Public Health Laws, except in each case where the failure to so be in compliance would not reasonably be expected to, individually or in the aggregate, result in Material Regulatory Liabilities. (b) Each of the Borrower and its Subsidiaries is in compliance, and since [***] has been in compliance, with all applicable Public Health Laws, except to the extent that any such “non-compliance, individually or in the aggregate, would not reasonably be expected to result in Material Regulatory Liabilities. (c) To the extent applicable, all products designed, developed, investigated, manufactured, prepared, assembled, packaged, tested, labeled, distributed, sold, marketed or delivered by or on behalf of the Borrower or any of its Subsidiaries, that are subject to the jurisdiction of the FDA or any comparable Governmental Authority have been since [***] and are being designed, developed, investigated, manufactured, prepared, assembled, packaged, tested, labeled, distributed, sold, marketed or delivered in compliance with all applicable Public Health Laws, except for such noncompliance that would not reasonably be expected to, individually or in the aggregate, result in a Material Regulatory Liabilities. None of the Products has been the subject of any products liability or warranty action against the Borrower or its Subsidiaries or any non-legal claim for clinical trial compensation by trial participants, except as would not reasonably be expected to, individually or in the aggregate, result in Material Regulatory Liabilities. (d) Neither the Borrower nor any of its Subsidiaries is currently subject to any material obligation arising pursuant to a Regulatory Action and, to the knowledge of the Borrower and its Subsidiaries, no such material obligation or Regulatory Action has been threatened by a Governmental Authority in writing. (e) Since [***], there have been no material recalls, field notifications, field corrections, market withdrawals or replacements, detentions, warnings, “adverse doctor letters”, investigator notices, safety alerts or other written notice of action relating to an actual or potential lack of safety, efficacy, or regulatory compliance of any Products (“adverse Safety Notices”), and to the knowledge of the Borrower and its Subsidiaries, there are no facts or circumstances that are reasonably likely to result in (x) a material Safety Notice, (y) a material change in labeling of any Product, (z) a material termination or suspension of research, testing, manufacturing, distribution, or commercialization of any Product. Section 4.34 Governmental Contracts. Except as set forth on Schedule 4.34 as of the Closing Date hereof, neither the Borrower nor any of its Subsidiaries is a party to any contract or agreement with any Governmental Authority and none of the Borrower’s or such Subsidiary’s accounts receivables or other rights to receive payment are subject to the Federal Assignment of Claims Act (31 U.S.C. Section 3727) or any similar state, county or municipal law. Section 4.35 Healthcare Regulatory Laws. (a) None of the Borrower and its Subsidiaries, nor, to their knowledge, any officer, director, managing employee or agent (as those terms are defined in 42 C.F.R. “1001.1001) thereof, is a party to, or bound by, any written order, individual integrity agreement, corporate integrity agreement, deferred or non-prosecution agreement or other written agreement with any Governmental Authority concerning their compliance with Federal Health Care Program Laws in any material respect. (b) None of the Borrower, its Subsidiaries, or any officer, director, managing employee or, to the knowledge of the Borrower, agent (as those terms are defined in 42 C.F.R. “1001.1001) thereof, or any Loan Party Partner: (i) has been, since [***], convicted of any criminal offense relating to the delivery of an item or service under any Federal Health Care Program; (ii) has had, since [***], a civil monetary penalty assessed against it, him or her under Section 1128A of the Social Security Act; (iii) has been listed on the U.S. General Services Administration published list of parties excluded from federal procurement programs and non-procurement programs; or (iv) to the knowledge of the Borrower and its Subsidiaries, is the target or subject of any current or potential suit, claim, action, proceeding, arbitration, mediation, inquiry, subpoena or investigation relating to any of the foregoing or any Federal Health Care “94A “A “A Program-related offense, or which could result in the imposition of material penalties or the debarment, suspension or exclusion from participation in any Federal Health Care Program. Since [***], none of the Borrower, its Subsidiaries, or any officer, director, managing employee or, to the knowledge of the Borrower, agent (as those terms are defined in 42 C.F.R. “1001.1001) thereof has been debarred, excluded, disqualified or suspended from participation in any Federal Health Care Program or under any FDA Laws (including 21 U.S.C. “335a). (c) None of the Borrower and its Subsidiaries, nor to the knowledge of the Borrower, any officer, director, managing employee or agent (as those terms are defined in 42 C.F.R. “1001.1001) thereof, nor to the knowledge of the Borrower and its Subsidiaries, any Loan Party Partner, has, since [***], violated any Federal Health Care Program Laws, except where the violation would not reasonably be expected to result, either individually or in the aggregate, in Material Regulatory Liabilities. (d) To the knowledge of the Borrower and its Subsidiaries, since [***], no person has filed or has threatened to file in writing against the Borrower or any of its Subsidiaries, an action relating to any FDA Law, Public Health Law or Federal Health Care Program Law under any whistleblower statute, including without limitation, the False Claims Act of 1863 (31 U.S.C. “3729 et seq.). Section 4.36 Data Protection. Each of the Borrower and its Subsidiaries is operating, and since [***] has been operating in material compliance with: (i) applicable Data Protection Laws; (ii) applicable industry standards with which Borrower and its Subsidiaries have agreed to comply; and (iii) all of the Borrower and each of its Subsidiaries’ internal privacy policies, in each case relating to privacy, data protection, consumer protection, consent or the collection, retention, protection, and use of Personal Information collected, used or maintained by the Loan Parties or by third parties provided with access to the records of the Borrower and each of its Subsidiaries that contain any Personal Information. To the extent required by applicable Data Protection Laws, each of the Borrower and its Subsidiaries has adopted and published privacy notices and policies, that comply in all material respects with applicable Data Protection Laws and accurately describe the privacy practices of the Borrower or any Subsidiary (as applicable), to any website, mobile application or other electronic platform and complied in all material respects with those notices and policies (collectively, with each of the Borrower and each of its Subsidiaries’ internal privacy policies, the “Privacy Policies”). The execution, delivery and performance of this Agreement complies in all material respects with (i) all Data Protection Laws and (ii) the Borrower’s and each Subsidiary’s Privacy Policies. During [***], neither the Borrower nor any Subsidiary, nor to the knowledge of the Borrower and its Subsidiaries any third party acting on behalf of the Borrower or any Subsidiary, has experienced any incidences in which Personal Information of the Borrower or any Subsidiary was stolen or improperly accessed, including any breach of security or other loss, unauthorized access, use or disclosure of such Personal Information, except for those that have been remedied without material cost or liability or the duty to notify any other person. During [***], neither the Borrower nor any Subsidiary, nor, to the knowledge of the Borrower and its Subsidiaries any third party acting on behalf of the Borrower or any Subsidiary, has received any: (i) written, or to the knowledge of the Borrower or its Subsidiaries, oral inquiry or complaint alleging material noncompliance with Data Protection Laws; or (ii) written or, to the knowledge of the Borrower or its Subsidiaries, oral claim for compensation for loss or unauthorized collection, processing or disclosure of Personal Information, except as would not reasonably be expected to be material to the Borrower and its Subsidiaries, taken as a whole. Section 4.37 Centre of Main Interests. For the purposes of Regulation (EU) 2015/848 on insolvency proceedings (recast) (the Regulation), each Dutch Guarantor’s center of main interest (as that term is used in Article 3(1) of the Regulation) is situated in the Netherlands and no Dutch Guarantor has an establishment (as that term is used in Article 2(10) of the Regulation) in any other jurisdiction. “95A “A “A Article AFFIRMATIVE COVENANTS Each Loan Party covenants and agrees that, so long as any Term Loan Commitment is in effect and until payment in full of all Obligations (other than any such contingent obligations or liabilities hereunder that by the express terms thereof survive such payment in full of all Obligations), each Loan Party shall perform, and shall cause each of its Subsidiaries to perform, all covenants in this Article V. Section 5.1 Financial Statements and Other Reports. Unless otherwise provided below, Borrower will deliver to Administrative Agent and Lenders: (a) Cash Reports. Promptly, but in any event within [***] after the end of each fiscal month of the Borrower, a report of the current Cash and Cash Equivalent balances of the Loan Parties, which report shall identify Qualified Cash and other Cash and Cash Equivalents of the Loan Parties not constituting Qualified Cash; provided, that at any time the current Cash and Cash Equivalent balances of the Loan Parties is less than \$[***], Administrative Agent may request at any time (but not more frequently than once every two weeks), and the Borrower shall promptly provide, a report of at least [***]% of the current Cash and Cash Equivalent balances of the Loan Parties, which report shall identify unrestricted and restricted Cash and Cash Equivalents (or, if greater, all Cash and Cash Equivalent balances required to satisfy the covenant set forth in Section 6.8) all in reasonable detail, together with a Financial Officer Certification; (b) Quarterly Financial Statements. As soon as available, and in any event within 45 days after the end of each of the first three Fiscal Quarters of each Fiscal Year, the consolidated balance sheets of the Borrower and its Subsidiaries as at the end of such Fiscal Quarter and the related consolidated statements of operations and cash flows of the Borrower and its Subsidiaries for such Fiscal Quarter (including a description of (i) all development costs, salary, and expenses paid or payable by Borrower or its Subsidiaries in connection with all Products or non-ordinary course Investments made by Borrower or such Subsidiary during the applicable period and (ii) all costs, royalty, milestone payments and licensing payments, dividends, and distributions, paid or received by Borrower or its Subsidiaries in connection with any Product on a Product by Product basis during the applicable period, in each case, which shall be in form and detail reasonably satisfactory to Administrative Agent), setting forth in each case in comparative form the corresponding figures for the corresponding periods of the previous Fiscal Year, all in reasonable detail, prepared in accordance with GAAP, and delivered together with a Financial Officer Certification; (c) Annual Financial Statements. As soon as available, and in any event within 90 days after the end of each Fiscal Year, (i) the consolidated balance sheets of the Borrower and its Subsidiaries as at the end of such Fiscal Year and the related consolidated statements of operations, stockholders’ equity and cash flows of the Borrower and its Subsidiaries for such Fiscal Year (including a description of (x) all development costs, salary, and expenses paid or payable by Borrower or its Subsidiaries in connection with all Products or non-ordinary course Investments made by Borrower or such Subsidiary during the applicable period and (y) all costs, royalty, milestone payments and licensing payments, dividends, and distributions, paid or received by Borrower or its Subsidiaries in connection with any Product on a Product by Product basis during the applicable period, in each case, which shall be in form and detail reasonably satisfactory to Administrative Agent), setting forth in each case in comparative form the corresponding figures for the previous Fiscal Year, in reasonable detail, together with a Financial Officer Certification with respect thereto; and (ii) with respect to such consolidated financial statements a report thereon of Deloitte & Touche LLP or other such independent certified public accountants of recognized national standing selected by the Borrower, and reasonably satisfactory to Administrative Agent (it being understood and agreed that any “Big-4” accounting firm shall satisfactory to the Administrative “96A “A “A (A) Agent) (which financial statements, report and opinion shall be prepared in accordance with GAAP and shall not be subject to any qualification, emphasis of matter or statement as to “going concern” or scope of audit (other than with respect to or resulting from an upcoming maturity of Indebtedness or any default thereunder), and shall state that such consolidated financial statements fairly present, in all material respects, the consolidated financial position of the Borrower and its Subsidiaries as at the dates indicated and the results of their operations and their cash flows for the periods indicated in conformity with GAAP); (d) Compliance Certificate. Together with each delivery of financial statements of the Borrower and its Subsidiaries pursuant to Section 5.1(b) or Section 5.1(c), a duly executed and completed Compliance Certificate attaching evidence of the Cash and Cash Equivalent balances contained in each Deposit Account and Securities Account of the Loan Parties as of the last day of the period then ended; (e) Royalty Reports; Notice of Disputes. Promptly (but in any event within [***]) after (i) receipt by the Borrower or any of its Subsidiaries, a copy of any royalty reports or similar reports outlining fees to be paid or payable with respect to any Product from any Licensee or any notices of any disputes from such Licensee or any other counterparty to any Material Contract or Permitted Product Agreement or (ii) production or delivery by the Borrower or any of its Subsidiaries to a third party, any royalty or similar reports in connection with any Royalty Monetization Transaction to which such entity is a party with respect to royalties or other fees paid or payable with respect to any Product. (f) Statements of Reconciliation after Change in Accounting Principles. If, as a result of any change in accounting principles and policies from those used in the preparation of the Historical Financial Statements, the consolidated financial statements of the Borrower and its Subsidiaries delivered pursuant to Section 5.1(b) or Section 5.1(c) will differ in any material respect from the consolidated financial statements that would have been delivered pursuant to such subdivisions had no such change in accounting principles and policies been made, then, together with the first delivery of such financial statements after such change, one or more statements of reconciliation for all such prior financial statements in form and substance satisfactory to Administrative Agent; (g) Notice of Default. Promptly (but in any event within [***]) upon any officer of the Borrower obtaining knowledge (i) of any condition or event that constitutes a Default or an Event of Default or that notice has been given to such Borrower with respect thereto; (ii) that any Person has given any written notice to the Borrower or any of its Subsidiaries or taken any other action with respect to any event or condition set forth in Section 8.1(b); or (iii) of the occurrence of any event or change that has caused or evidences or results in, in any case or in the aggregate, a Material Adverse Effect or Material Regulatory Liabilities, a certificate of its Authorized Officer specifying the nature and period of existence of such condition, event or change, or specifying the notice given and action taken by any such Person and the nature of such claimed Event of Default, Default, default, event or condition, and what action the Borrower has taken, is taking and proposes to take with respect thereto; (h) Notice of Litigation. Promptly (but in any event within [***]) upon any officer of the Borrower obtaining knowledge of (i) the institution of, or non-frivolous written threat of, any Adverse Proceeding or (ii) any material development in any Adverse Proceeding that, in the case of either clause (i) or (ii) which relates to the Products, the Collateral or the Material Contracts or which could result in Material Regulatory Liabilities, or which seeks to enjoin or otherwise prevent the consummation of, or to recover any damages or obtain relief as a result of, the transactions contemplated hereby, written notice thereof together with such other information as may be reasonably available to Borrower to enable Lenders and their counsel to evaluate such matters; (i) ERISA. Promptly (but in any event within [***]) upon becoming aware of the occurrence of or forthcoming occurrence of any ERISA Event that could reasonably be expected to result “97A “A “A in a material Liability to a Loan Party, a written notice specifying the nature thereof, what action (if any) a Loan Party or any ERISA Affiliate has taken, is taking or proposes to take with respect thereto and, when known, any action taken or threatened by the IRS, the Department of Labor or the PBGC with respect thereto; (j) Insurance Report. As soon as practicable and in any event [***] prior to end of such Fiscal Year, a report in form and substance reasonably satisfactory to Administrative Agent outlining all material insurance coverage maintained as of the date of such report by the Borrower and its Subsidiaries and all material insurance coverage planned to be maintained by the Borrower and its Subsidiaries in the immediately succeeding Fiscal Year; (k) Regulatory and Product Notices. Each Loan Party shall promptly (but in any event within [***]) after the receipt or occurrence thereof notify Administrative Agent of: (i) any written notice received by the Borrower or its Subsidiaries alleging potential or actual material violations of any Public Health Law by the Borrower or its Subsidiaries, (ii) any written notice that the FDA (or international equivalent) is limiting, suspending or revoking any Registration (including, but not limited to, by the issuance of a clinical hold), (iii) any written notice that the Borrower or its Subsidiaries has become subject to any Regulatory Action (other than any inspection or investigation in the ordinary course of business), (iv) the exclusion or debarment from any governmental healthcare program or debarment or disqualification by FDA (or international equivalent) of the Borrower or its Subsidiaries or its or their Authorized Officers, (v) any written notice that the Borrower or any Subsidiary, or any of their licensees or sublicensees (including licensees or sublicensees under the Product Agreements or Material Contracts), is being investigated or is the subject of any allegation of potential or actual violations of any Federal Health Care Program Laws in any material respect, (vi) any written notice that any material product of the Borrower or its Subsidiaries has been seized, withdrawn, recalled, detained, or subject to a suspension of manufacturing, or the commencement of any proceedings in the United States or any other jurisdiction seeking the withdrawal, recall, suspension, import detention, or seizure of any Product are pending or threatened in writing against the Borrower or its Subsidiaries, or (vii) limiting or adversely changing the scope of marketing authorization or the labeling of the products of the Borrower and its Subsidiaries under any such Registration, except, in each case of (i) through (vii) above, where such action would not reasonably be expected to have, either individually or in the aggregate, Material Regulatory Liabilities; provided, however, that with respect to any occurrence in clauses (i) through (vii)

above that could, with notice or the passage of time, or both, lead to a Default or an Event of Default under Section 8.1(o) of this Agreement, each Loan Party shall promptly (but in any event within [***] of Administrative Agentâ€™s request) provide to Administrative Agent copies of all communications with FDA and all other documentation and information in such Loan Partyâ€™s possession, custody or control reasonably requested by Administrative Agent relating to such notice or change and the events that led up to it (subject to suitable confidentiality restrictions); Â - 98A - Â | Â (l) Notice Regarding Material Contracts. Promptly (but in any event within [***) (i) after a Loan Party or a Subsidiary of a Loan Party receives any notice (written or oral) of default or event of default under any Material Contract, (ii) after a Loan Party or a Subsidiary of a Loan Party receives or otherwise becomes aware of any dispute, litigation, purchase price adjustment (other than in accordance with the terms of such Material Contract), indemnity claim, exercise of rights of set-off or deduction, in each case, reasonably expected to be in excess of \$[***] (including any of the foregoing threatened in writing) under or with respect any Material Contract, or (iii) after any new Material Contract is entered into, in each case of clauses (i) through (iii), furnish a written statement describing such event or Material Contract, with copies of such notices or new Material Contracts together with all pertinent detail and information relating thereto in such Loan Party or Subsidiary of Loan Partyâ€™s possession, custody or control, delivered to Administrative Agent, and an explanation of any actions being taken with respect thereto, if applicable (subject to customary confidentiality restrictions). Each Loan Party or Subsidiary of a Loan Party shall provide Administrative Agent with written notice upon becoming aware of a counterpartyâ€™s material breach of its obligations under any Material Contract; (m) Information Regarding Collateral. Borrower will furnish to Administrative Agent prior written notice of any change (a) in any Loan Partyâ€™s legal name or jurisdiction of organization, (b) in any Loan Partyâ€™s identity or corporate structure, or (c) in any Loan Partyâ€™s U.S. federal or other taxpayer identification number (if any) or chief executive office. The Borrower agrees not to effect or permit any change referred to in the preceding sentence unless all filings have been made under the UCC or otherwise that are required in order for Administrative Agent to continue at all times following such change to have a valid, legal and perfected security interest in all the Collateral and for the Collateral at all times following such change to have a valid, legal and perfected security interest as contemplated in the Collateral Documents. The Borrower also agrees promptly to notify Administrative Agent if any material portion of the Collateral is damaged or destroyed; (n) Annual Collateral Verification. Each year, at the time of delivery of annual financial statements with respect to the preceding Fiscal Year pursuant to Section 5.1(c), Borrower shall deliver to Administrative Agent an Officerâ€™s Certificate (a) either confirming that there has been no change in such information since the date of the Perfection Certificate delivered on the Closing Date or the date of the most recent certificate delivered pursuant to this Section 5.1(n) and/or identifying such changes, or (b) certifying that all UCC financing statements (including fixtures filings, as applicable) or other appropriate filings, recordings or registrations, have been filed of record in each governmental, municipal or other appropriate office in each jurisdiction identified in the Perfection Certificate or pursuant to clause (a) above to the extent necessary to protect and perfect the security interests under the Collateral Documents for a period of not less than [***] after the date of such certificate (except as noted therein with respect to any continuation statements to be filed within such period); (o) Products. Promptly, but in any event within [***] after the receipt by the Borrower or any of its Subsidiaries or the occurrence thereof, as applicable, notify Administrative Agent of: (i) granting of any licenses or sublicenses by the Borrower or any of its Subsidiaries under any Permitted Product Agreement; (ii) amending an existing, or entering into any, new Permitted Product Agreement; (iii) amending an existing, or entering into any new, agreement governing any Royalty Monetization Transaction; Â - 99A - Â | Â (iv) any material communications with the FDA that could reasonably be expected to result in a Material Adverse Effect; and (v) copies of all royalty reports relating to any Product (x) provided to a third party by Borrower or its Subsidiaries, or (y) received by Borrower or its Subsidiaries from a third party; (p) Notices Re Intellectual Property. Promptly (but in any event within [***) deliver notice of material infringements of any material Intellectual Property Rights owned or licensed by such Loan Party or any of its Subsidiaries that are known to the Borrower; (q) Regulatory Documentation. The Borrower shall be responsible for, and shall maintain, with respect to each Product, all submissions to Governmental Authorities relating to the Products, including clinical studies, tests and biostudies, including all Product non-disclosure agreements, and the drug master files, as well as all correspondence with Governmental Authorities with respect thereto (including Registrations and licenses and regulatory drug lists, and any amendments or supplements thereto). Concurrent with the delivery of a Compliance Certificate following the end of each Fiscal Quarter in accordance with Section 5.1(d) and promptly following Administrative Agentâ€™s reasonable request from time to time, Borrower shall promptly provide to Administrative Agent copies of any and all material regulatory filings submitted to any such Governmental Authorities with respect to the Products; (r) Maintenance, Defense and Enforcement of Product Patents. Borrower shall take all commercially reasonable steps to maintain, defend and enforce the Product Patents, including by timely filing fees and responses with the United States Patent and Trademark Office or any applicable foreign counterpart. Borrower shall provide prompt written notice to Administrative Agent of any material occurrences with respect to any Product Patents, and, upon Administrative Agentâ€™s request from time to time, shall promptly provide Administrative Agent with complete and correct copies of (i) any certification received by Borrower, its Subsidiaries, or any of their respective licensors or licensees pursuant to 21 U.S.C. Â§ 355(j)(2)(A)(vii)(I), (II), (III) or (IV) relating to any of the Orange Book Patents, and (ii) any pleadings, briefs, declarations, correspondence and other documents relating to any Dispute involving any of the Orange Book Patents; (s) Other Information. (A) Promptly upon their becoming available and in any event within [***] of the Borrowerâ€™s receipt thereof, copies of (i) all material reports and all registration statements and prospectuses, if any, filed by the Borrower or any of its Subsidiaries with any securities exchange or with the Securities and Exchange Commission or any governmental or private regulatory authority, (ii) all amendments, waivers, consents, notices of defaults and reservations of rights with respect to and received by the Borrower or its Subsidiaries from any holder of its Indebtedness having a principal amount greater than \$[***], and (iii) all press releases and other statements made available generally by the Borrower or any of its Subsidiaries to the public concerning material developments in the business of the Borrower or any of its Subsidiaries, (B) promptly after submission to any Governmental Authority, all documents and information furnished to such Governmental Authority in connection with any investigation of any Loan Party (other than a routine inquiry), and (C) such other information and data with respect to the Borrower or any of its Subsidiaries as from time to time may be reasonably requested by Administrative Agent; provided that in no event shall the Borrower or its Subsidiaries be required to disclose or provide any information or data (i) in respect to which disclosure to the Administrative Agent or any Lender (or their respective representatives or contractors) is prohibited by law or any binding agreement with any third party (it being understood and agreed that the foregoing shall not limit any obligations of the Borrower and its Subsidiaries set forth in clause (iii) of the definition of â€œRestricted Licenseâ€ with respect to any Product Agreements) or (ii) that, if disclosed to the Administrative Agent, would result in forfeiture of attorney-client privilege; provided, further, that in each case of clauses (i) and (ii), Borrower shall promptly notify Â - 100A - Â | Â Administrative Agent that it is withholding information in reliance on this proviso, unless such notice is not permitted by applicable law, rule or regulation; (t) Environmental Reports. Upon request of Administrative Agent, deliver true and complete copies of all environmental reports, audits and investigations within the possession or control of a Loan Party or any of its Subsidiaries that is related to the Real Estate Assets; and (u) Projections. (i) Within [***] of approval by the Borrowerâ€™s Board of Directors, and in any event within [***] after the end of each Fiscal Year, a detailed consolidated budget covering the then current and immediately following Fiscal Year (including a projected consolidated balance sheet of the Borrower and its Subsidiaries as of the end of each Fiscal Quarter of such Fiscal Year and the related projected consolidated statements of cash flow (including projected Product revenue broken down by Product) and income for each such Fiscal Quarter) (the â€œProjectionsâ€), (ii) [***], and (iii) [***]. Each Projection delivered under this Section 5.1(u) shall be accompanied by a certificate of a Authorized Officer stating that such Projections are based on reasonable estimates, information and assumptions and that such Authorized Officer has no reason to believe that such Projections are incorrect or misleading in any material respect, it being recognized by the Administrative Agent and the Lenders that such financial information as it relates to future events is not to be viewed as fact and that actual results during the period or periods covered by such financial information may differ from the projected results set forth therein by a material amount. Notwithstanding the foregoing, the obligations in paragraphs (b) and (c) of this Section 5.1 may be satisfied with respect to financial information of Borrower and its Subsidiaries by furnishing Borrowerâ€™s Form 10-K or 10-Q, as applicable, filed with the SEC; provided that, to the extent such information is in lieu of information required to be provided under Section 5.1(c), such materials and opinion meet the standards set forth in Section 5.1(c). Â Section 5.2 Existence. Except as otherwise permitted under Section 6.9(a), each Loan Party will, and will cause each of the Borrowerâ€™s Subsidiaries to, at all times preserve and keep in full force and effect its existence and all rights and Governmental Authorizations, qualifications, franchises, licenses and permits material to its business and to conduct its business in each jurisdiction in which its business is conducted; provided, no Loan Party or any of the Borrowerâ€™s Subsidiaries shall be required to preserve any such existence, right or Governmental Authorizations, qualifications, franchise, licenses and permits if such Personâ€™s Board of Directors (or similar governing body) shall determine that the preservation thereof is no longer desirable in the conduct of the business of such Person, and that the loss thereof is not disadvantageous in any material respect to such Person or to Lenders. Section 5.3 Payment of Taxes and Claims. Each Loan Party will, and will cause each of the Borrowerâ€™s Subsidiaries to, file all material Tax returns required to be filed by or with respect to the Borrower or any of its Subsidiaries and pay all material Taxes imposed upon or with respect to it or any of its properties, assets, income, businesses or franchises before any penalty or fine accrues thereon, and all material claims (including claims for labor, services, materials and supplies) for sums that have become due and payable and that by law have or may become a Lien upon any of its properties or assets, prior to the time when any penalty or fine shall be incurred with respect thereto; provided, no such Tax or claim need be paid if it is being contested in good faith by appropriate proceedings promptly instituted and diligently conducted, so long as (a) adequate reserve or other appropriate provision, as shall be required in conformity with GAAP shall have been made therefor, and (b) in the case of a Tax or claim which has or may become a Lien against any of the Collateral, such contest proceedings conclusively operate to stay imposition of any penalty, fine or Lien resulting from the non-payment thereof. No Loan Party will, nor will it permit any of the Borrowerâ€™s Subsidiaries to, file or consent to the filing of any consolidated income tax return with any Person (other than the Borrower or its Subsidiaries). Â - 101A - Â | Â Section 5.4 Maintenance of Properties. Each Loan Party will, and will cause each of its Subsidiaries to (a) maintain or cause to be maintained in good repair, working order and condition, ordinary wear and tear excepted, all properties used or useful in the business of the Borrower and its Subsidiaries and from time to time will make or cause to be made all appropriate repairs, renewals and replacements thereof, except to the extent any such failure to maintain could not reasonably be expected to have a Material Adverse Effect, and (b) comply at all times with the provisions of all material leases to which it is a party as lessee or under which it occupies property, so as to prevent any loss or forfeiture thereof or thereunder, except to the extent any such failure to comply could not reasonably be expected to have a Material Adverse Effect. Section 5.5 Insurance. (a) The Loan Parties will maintain or cause to be maintained, with financially sound and reputable insurers, (i) business interruption insurance reasonably satisfactory to Administrative Agent, and (ii) casualty insurance, such public liability insurance, third party property damage insurance or such other insurance with respect to liabilities, losses or damage in respect of the assets, properties and businesses of the Loan Parties as may customarily be carried or maintained under similar circumstances by Persons of established reputation engaged in similar businesses, in each case in such amounts (giving effect to self-insurance), with such deductibles, covering such risks and otherwise on such terms and conditions as shall be customary for such Persons. Each such policy of insurance shall (1) name Administrative Agent, on behalf of Lenders as an additional insured thereunder as its interests may appear, and (2) in the case of each casualty insurance policy, contain a loss payable clause or endorsement, satisfactory in form and substance to Administrative Agent, that names Administrative Agent, on behalf of Secured Parties as the loss payee thereunder. If any Loan Party or any of its Subsidiaries fails to maintain such insurance, Administrative Agent may, upon prior written notice to the Borrower, arrange for such insurance, but at the Borrowerâ€™s expense and without any responsibility on Administrative Agentâ€™s part for obtaining the insurance, the solvency of the insurance companies, the adequacy of the coverage, or the collection of claims. Upon the occurrence and during the continuance of an Event of Default, Administrative Agent shall have the sole right, in the name of the Lenders, any Loan Party and its Subsidiaries, to file claims under any insurance policies, to receive, receipt and give acquittance for any payments that may be payable thereunder, and to execute any and all endorsements, receipts, releases, assignments, reassignments or other documents that may be necessary to effect the collection, compromise or settlement of any claims under any such insurance policies. (b) Each of the insurance policies required to be maintained under this Section 5.5 shall provide for at [***] (or [***] in the case of non-payment) prior written notice to Administrative Agent of the cancellation or material modification thereof. Receipt of such notice shall entitle Administrative Agent (but Administrative Agent shall not be obligated), upon prior written notice to Loan Parties, to renew any such policies, cause the coverages and amounts thereof to be maintained at levels required pursuant to this Section 5.5 or otherwise to obtain similar insurance (including with respect to coverage types, limits and premiums) in place of such policies, in each case at the expense of the Loan Parties. Section 5.6 Books and Records; Inspections. Each Loan Party will, and will cause each of its Subsidiaries to, (a) maintain at all times at the chief executive office of the Borrower copies of all books and records of Borrower and its Subsidiaries, (b) keep adequate books of record and account in which full, true and correct entries in all material respects are made of all dealings and transactions in relation to its business and activities, and (c) permit any representatives designated by Administrative Agent or any Lender (including employees of Administrative Agent, any Lender or any consultants, auditors, accountants, lawyers and appraisers retained by Administrative Agent) to visit any of the properties of any Loan Party and any of the Borrowerâ€™s Subsidiaries to inspect, copy and take extracts from its and their financial and accounting records, and to discuss its and their affairs, finances and accounts with its and their Â - 102A - Â | Â officers and independent accountants and auditors, all upon reasonable notice and at such reasonable times during normal business hours (so long as no Default or Event of Default has occurred and is continuing) and as often as may reasonably be requested; provided that, absent the occurrence and continuance of an Event of Default, Administrative Agent and Lenders (collectively) shall not exercise such rights more often than one time during any Fiscal Year. The Loan Parties agree to pay the reasonable and documented out-of-pocket costs and expenses incurred by the examiner in connection therewith. Section 5.7 Lenders Meetings and Conference Calls. (a) The Borrower will, upon the reasonable request of Administrative Agent or Required Lenders, participate in a meeting of Administrative Agent and Lenders once during each Fiscal Year to be held at Borrowerâ€™s corporate offices (or at such other location as may be agreed to by Borrower and Administrative Agent) at such time as may be agreed to by the Borrower and Administrative Agent. (b) Within [***] after delivery of financial statements and other information required to be delivered pursuant to Section 5.1(b), the Borrower shall, upon [***], cause its chief financial officer or other Authorized Officers to participate in a conference call with Administrative Agent and all Lenders who choose to participate in such conference call, during which conference call the chief financial officer or such Authorized Officer shall review the financial condition of the Borrower and its Subsidiaries and such other matters as Administrative Agent or any Lender may reasonably request. Section 5.8 Compliance with Laws. (a) Each Loan Party will comply, and shall cause each of the Borrowerâ€™s Subsidiaries and all other Persons, if any, on or occupying any Real Property, to comply, with the requirements of all applicable laws, rules, regulations and orders of any Governmental Authority (including all Environmental Laws), non-compliance with which could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. (b) Without limiting the generality of the foregoing, each Loan Party shall, and shall cause each of its Subsidiaries to, comply with all FDA Laws and Public Health Laws, and with all applicable Federal Health Care Program Laws, except where the failure to comply would not reasonably be expected to result, either individually or in the aggregate, in Material Regulatory Liabilities. All products developed, manufactured, tested, investigated, distributed or marketed by or on behalf of the Loan Parties and their Subsidiaries that are subject to the jurisdiction of the FDA or any comparable Governmental Authority shall be developed, tested, manufactured, investigated, distributed, sold and marketed in compliance with the FDA Laws and any other Requirement of Law, including, without limitation, good manufacturing practices, labeling, advertising, record-keeping, and adverse event reporting, except where the failure to comply with such FDA Laws or other Requirements of Law would not reasonably be expected to result, either individually or in the aggregate, in Material Regulatory Liabilities. Section 5.9 Environmental. (a) Each Loan Party shall (i) keep its Real Property free of any Environmental Liens; (ii) maintain and comply in all material respects with all Governmental Authorizations issued to it or required to be maintained by it under applicable Environmental Laws, except as any such failure could not reasonably be expected to result in a Material Adverse Effect; (iii) take all steps to prevent any Release of Hazardous Materials from any Real Property, except as any such failure could not reasonably be expected to result in a Material Adverse Effect; and (iv) ensure that there are no Hazardous Materials on, at or migrating from any Real Property, except as any such failure could not reasonably be expected to result in a Material Adverse Effect. Â - 103A - Â | Â (b) The Loan Parties shall promptly (but in any event within [***) (i) notify Administrative Agent in writing (A) of any material Environmental Claims asserted in writing against or material Environmental Liabilities and Costs of any Loan Party, and (B) any notice of Environmental Lien recorded against any Real Property, and (ii) provide such other documents and information as reasonably requested by Administrative Agent in relation to any matter pursuant to this Section 5.9(b). Section 5.10 Subsidiaries. In the event that (x) any Subsidiary of a Loan Party ceases to be an Excluded Subsidiary or (y) any

Person becomes a Subsidiary of a Loan Party and such Person is not an Excluded Subsidiary, Borrower, in each case, shall (a) within [***] of such Person (organized under the laws of the United States, any state thereof or the District of Columbia) becoming a Subsidiary or ceasing to be an Excluded Subsidiary and within [***] of such Person (organized/ incorporated under the laws of any jurisdiction other than the laws of the United States, any state thereof or the District of Columbia) becoming a Subsidiary or ceasing to be an Excluded Subsidiary, as applicable, cause such Subsidiary to become a Guarantor hereunder and a Grantor under the Pledge and Security Agreement by executing and delivering to Administrative Agent a Counterpart Agreement, and (b) take all such actions and execute and deliver, or cause to be executed and delivered, all such documents, instruments, agreements, and certificates as are similar to those described in Sections 3.1(b), 3.1(e) and 3.1(h). With respect to each such Subsidiary, the Borrower shall promptly send to Administrative Agent written notice setting forth with respect to such Person (i) the date on which such Person became a Subsidiary of Borrower or ceased to be an Excluded Subsidiary, which such notice, in the case of any Subsidiary which has ceased to be an Immaterial Subsidiary, shall be provided within [***] of delivery of the financial statements for the Fiscal Quarter in which such Subsidiary ceased to be an Immaterial Subsidiary, and (ii) all of the data required to be set forth in Schedules 4.1 and 4.2 with respect to all Subsidiaries of the Borrower; provided, such written notice shall be deemed to supplement Schedules 4.1 and 4.2 for all purposes hereof.

Section 5.11 Real Estate Assets. In the event that any Loan Party acquires fee title to a Real Property during the term of this Agreement, the Borrower shall promptly provide the Administrative Agent with written notice of the same. Within [***] after the acquisition of any such Real Property (or such later time as agreed to by Administrative Agent in its sole discretion), such Loan Party shall deliver to Administrative Agent: (a) a fully executed and notarized Mortgage, in proper form for creating a valid and enforceable lien on the Real Property described therein once recorded in the appropriate real estate records and in proper form for recording in such real estate records; (b) an opinion of counsel in the jurisdiction in which such Real Property is located with respect to the enforceability of such Mortgage and such other matters as Administrative Agent may reasonably request, in each case in form and substance reasonably satisfactory to Administrative Agent; (c)(i) an ALTA extended mortgagee title insurance policy or an unconditional commitment therefor with respect to such Mortgage (each, a "Title Policy") from a title company reasonably satisfactory to Administrative Agent (the "Title Company"), in an amount not less than the fair market value of such Real Estate Asset, together with a title report issued by the Title Company with respect thereto, dated not more than [***] prior to the date such Real Property was acquired, and copies of all recorded documents listed as exceptions to title or otherwise referred to therein, which Title Policy shall be effective as of the date of the Mortgage and otherwise be in form and substance reasonably satisfactory to Administrative Agent and (ii) evidence satisfactory to Administrative Agent that such Loan Party has paid to or deposited with the Title Company all expenses and premiums of the Title Company and all other sums required in connection with the issuance of such Title Policy and all recording and stamp taxes (including mortgage recording and intangible taxes) payable in connection with recording the Mortgage for such Real Property in the appropriate real estate records; (d) to the extent required by law, evidence of flood insurance with respect to such Real Property in compliance with any applicable regulations of the Federal Reserve Board, and in form and substance reasonably satisfactory to Administrative Agent; and (e) an ALTA/NSPS survey of such Real Property in form sufficient to permit the Title Company to issue the Title Policy in the form required by Administrative Agent and otherwise in form and substance satisfactory to Administrative Agent, which shall be either (1) certified to "1044 - A" Administrative Agent and dated not more than [***] prior to the date such Real Property was acquired (or such earlier time as agreed to by Administrative Agent in its sole discretion), or (2) accompanied by a survey or "change of ownership" affidavit executed by the owner of such Real Property and acceptable to the Title Company to issue the Title Policy in the form required by Administrative Agent, as applicable. In addition to the foregoing, the Borrower shall, at the request of Required Lenders, deliver to Administrative Agent an appraisal of such Real Property to verify the amount of the Mortgage and/or Title Policy, but only if required by applicable law or regulation. Section 5.12 Further Assurances. At any time or from time to time upon the request of Administrative Agent, each Loan Party will, at its expense, promptly execute, acknowledge and deliver such further documents and do such other acts and things as Administrative Agent may reasonably request in order to effect fully the purposes of the Loan Documents, including providing Lenders with any information reasonably requested pursuant to Section 10.21. In furtherance and not in limitation of the foregoing, each Loan Party shall take such actions as Administrative Agent may reasonably request from time to time to ensure that the Obligations are guaranteed by the Guarantors and are secured by substantially all of the assets of the Loan Parties and all of the outstanding Capital Stock of the Borrower and its Subsidiaries, in each case, to the extent constituting Collateral. Section 5.13 Control Agreements, Blocked Accounts, Etc. (a) Subject to Section 5.15, each Loan Party shall hold all of its cash and Cash Equivalents in a Deposit Account or Securities Account that is, except for Excluded Accounts, subject to a Control Agreement or Account Charge, as applicable. All such Control Agreements governed under the laws of a state or territory of the United States shall provide for "cash dominion" with respect to each such account, including each disbursement account that is not an Excluded Account other than with respect to any Blocked Account, which shall at all times be subject to the sole dominion and control of the Administrative Agent. With respect to each Control Agreement providing for "cash dominion", Administrative Agent will not deliver to the relevant depository institution a notice or other instruction which provides for exclusive control over such account by Administrative Agent unless an Event of Default has occurred and is continuing. (b) If the Borrower elects to deposit Additional Equity Proceeds into any Blocked Account for purposes of satisfying the Net Outstanding Amount requirements in connection with the Springing Term Loan Maturity Date I or the Springing Term Loan Maturity Date II, (i) the Borrower shall maintain such Blocked Account at all times subject to the sole dominion and control of the Administrative Agent and (ii) the Administrative Agent shall not release the Additional Equity Proceeds held in such account to the Borrower except (x) to the extent that such proceeds are, concurrently or substantially concurrently therewith, applied either to repay the applicable Existing Notes at maturity or to repurchase or redeem the applicable Existing Notes prior to the stated maturity thereof in a transaction permitted by Section 6.17 or (y) upon the conversion, repayment, refinancing or other satisfaction and discharge in full of the applicable Existing Notes in a transaction permitted by Section 6.17. In the case of clause (x) of the immediately preceding sentence, the Administrative Agent shall release to the Borrower an amount of Additional Equity Proceeds equal to the lesser of (1) the amount equal to the principal amount of the applicable Existing Notes being repaid, repurchased or redeemed and (2) the remaining balance of Additional Equity Proceeds maintained in such Blocked Account; and in the case of clause (y) of the immediately preceding sentence, the Administrative Agent shall release to the Borrower the remaining balance of Additional Equity Proceeds maintained in such Blocked Account. Section 5.14 DAC6. "A - 105A - A" (a) In this Section 5.14, "DAC6" means the Council Directive of 25 May 2018 (2018/822/EU) amending Directive 2011/16/EU. (b) The Borrower shall supply to the Administrative Agent (in sufficient copies for all the Lenders, if the Administrative Agent so requests): (i) promptly upon the making of such analysis or the obtaining of such advice, any analysis made or advice obtained on whether any transaction contemplated by the Loan Documents or any transaction carried out (or to be carried out) in connection with any transaction contemplated by the Loan Documents contains a hallmark as set out in Annex IV of DAC6; and (ii) promptly upon the making of such reporting and to the extent permitted by applicable law and regulation, any reporting made to any governmental or taxation authority by or on behalf of any Loan Party or by any adviser to such Loan Party in relation to DAC6 or any law or regulation which implements DAC6 and any unique identification number issued by any governmental or taxation authority to which any such report has been made (if available). Section 5.15 Post-Closing Matters. Borrower shall, and shall cause each of the Loan Parties to, satisfy the requirements set forth on Schedule 5.15 on or before the date specified for such requirement or such later date to be determined by Administrative Agent in its sole discretion. Article VINEGATIVE COVENANTS Each Loan Party covenants and agrees that, so long as any Term Loan Commitment is in effect and until payment in full of all Obligations (other than any such contingent obligations or liabilities hereunder that by the express terms thereof survive such payment in full of all Obligations), such Loan Party shall perform, and shall cause each of its Subsidiaries to perform, all covenants in this Article VI. Section 6.1 Indebtedness. No Loan Party shall, nor shall it permit any of the Borrower's Subsidiaries to, directly or indirectly, create, incur, assume or guaranty, or otherwise become or remain directly or indirectly liable with respect to any Indebtedness, except Permitted Indebtedness. Section 6.2 Liens. No Loan Party shall, nor shall it permit any of its Subsidiaries to, directly or indirectly, create, incur, assume or permit to exist any Lien on or with respect to any property or asset of any kind (including any document or instrument in respect of goods or accounts receivable) of the Borrower or any of its Subsidiaries, whether now owned or hereafter acquired, or any income or profits therefrom, except Permitted Liens. Section 6.3 Material Contracts. No Loan Party shall, nor shall it permit any of its Subsidiaries to, (i) amend or permit the amendment of any provision of any Material Contract, or to waive any of their respective rights under any Material Contract, in each case, in a manner (x) materially adverse to the interests of the Administrative Agent and the Lenders (in their respective capacities as such) or (y) that would result in the occurrence of the events described in clause (ii) below, or (ii) terminate or permit the termination of any Material Contract. Section 6.4 No Further Negative Pledges. Except with respect to restrictions (a) under this Agreement and the other Loan Documents, (b) that are binding on a Subsidiary at the time such Subsidiary becomes a Subsidiary, so long as such restrictions were not entered into in contemplation of such Person becoming a Subsidiary, (c) on specific property encumbered to secure payment of particular Indebtedness "A - 106A - A" or to be sold pursuant to an executed agreement with respect to an Asset Sale permitted under Section 6.9(b), (d) under any Permitted Royalty Monetization Transaction (provided that such restrictions apply solely to the assets securing such Permitted Royalty Monetization Transaction and are not more restrictive than the provisions of this Agreement), (e) by reason of customary provisions restricting assignments, subletting or other transfers contained in leases, licenses and similar agreements entered into in the ordinary course of business (provided that such restrictions are limited to the property or assets secured by such Liens or the property or assets subject to such leases, licenses or similar agreements, as the case may be), and (f) that are customary provisions restricting assignment or transfer of any agreement entered into in the ordinary course of business (other than Restricted Licenses), no Loan Party nor any of the Borrower's Subsidiaries shall enter into any agreement prohibiting the creation or assumption of any Lien upon any of its properties or assets, whether now owned or hereafter acquired. Section 6.5 Restricted Junior Payments. No Loan Party shall, nor shall it permit any of its Subsidiaries through any manner or means or through any other Person to, directly or indirectly, pay or make any Restricted Junior Payment, in each case, except for: (a) the payment of dividends to Borrower's equityholders in the form of Common Stock; (b) (x) the issuance of Capital Stock of Borrower upon the exercise of any warrants, options or rights to acquire such Capital Stock, including upon conversion of any Indebtedness that is convertible into or exchangeable for Capital Stock of Borrower, and (y) cash payments in lieu of issuing fractional shares in connection with the exercise of warrants, options or other securities convertible or exchangeable into Capital Stock of Borrower; (c) the payment of dividends or other Restricted Junior Payments by a Subsidiary of the Borrower to the Borrower or such Subsidiary "direct parent company"; (d) [***]; (e) (x) subject to the terms of any Acceptable Intercreditor Agreement applicable thereto, payments with respect to Permitted Royalty Monetization Transactions constituting (i) regularly scheduled payments, (ii) underpayment, indemnification and tax withholding obligations, (iii) reimbursable expenses or (iv) reasonable and customary fees paid in connection with any amendment, consent or waiver in connection with, any Permitted Royalty Monetization Transaction documents, in each case of the foregoing clauses (i), (ii) and (iii), in accordance with the Permitted Royalty Monetization Transaction documents applicable thereto and (y) payments permitted by Section 4.01(a) and (b) of the Acoramidis Intercreditor Agreement (other than voluntary prepayment of the Buy-Out Payment (as defined in the Acoramidis Revenue Transaction Agreement) in connection with the exercise of the Buy Out Right (as defined in the Acoramidis Intercreditor Agreement)); (f) the issuance of Capital Stock of any Subsidiary of the Borrower to the extent permitted by Section 6.10; (g) the purchase by the Borrower of Capital Stock (other than Disqualified Capital Stock, but including pursuant to Permitted Equity Derivatives) of the Borrower substantially contemporaneously with the incurrence of and otherwise in connection with, Permitted Convertible Indebtedness; provided that the aggregate consideration for such Capital Stock (including Permitted Equity Derivatives) shall not exceed [***]% of the Net Proceeds received by the Borrower from the incurrence of such Permitted Convertible Indebtedness (it being understood that the "aggregate consideration" paid for "A - 107A - A" Any Permitted Equity Derivatives shall be net of any proceeds paid to the Borrower in respect of any related Permitted Equity Derivatives); (h) other Restricted Junior Payments not to exceed the Available Investment Amount so long as (x) No Default or Event of Default shall have occurred and be continuing or would result therefrom and (y)(i) prior to the Product Milestone Date, on a pro forma basis after giving effect to such Restricted Junior Payment, the Loan Parties shall have Qualified Cash of not less than, \$[***] and (ii) on and after the Product Milestone Date, the Borrower shall have delivered a Financial Officer Certification (together with such other evidence as is reasonably requested by Administrative Agent) representing and warranting, and otherwise demonstrating to the reasonable satisfaction of Administrative Agent, that as of the date of such Restricted Junior Payment, Product Revenue (calculated on trailing twelve month basis) from the sale of Acoramidis is at least \$[***], which may be measured as of any month end based on monthly financials; provided, that, in the case of financial statements for any month which is not the final month for any Fiscal Quarter, such financial statements shall be prepared in accordance with GAAP and be accompanied by a Financial Officer Certification; and (i) the Loan Parties may purchase, redeem, retire or otherwise acquire for value Capital Stock (and any related stock appreciation rights, plans, equity incentive or achievement plans or any similar plans) of a Person being acquired in any Permitted Acquisition or other Investment permitted by Section 6.7 in connection with such Permitted Acquisition or other Investment; provided that such purchase, redemption, retirement or acquisition shall be a part of the consideration or purchase price paid for such Permitted Acquisition (i.e. subject to any applicable caps with respect to the purchase price of such Permitted Acquisition). Section 6.6 Restrictions on Subsidiary Distributions. Except as provided herein, no Loan Party shall, nor shall it permit any of its Subsidiaries to, create or otherwise cause or suffer to exist or become effective any consensual encumbrance or restriction of any kind on the ability of any Subsidiary of the Borrower to (a) pay dividends or make any other distributions on any of such Subsidiary's Capital Stock owned by Borrower or any other Subsidiary of Borrower, (b) repay or prepay any Indebtedness owed by such Subsidiary to Borrower or any other Subsidiary of Borrower, (c) make loans or advances to Borrower or any other Subsidiary of Borrower, or (d) transfer any of its property or assets to Borrower or any other Subsidiary of Borrower, in each case, other than restrictions (i) in agreements evidencing purchase money Indebtedness permitted by clause (h) or (l) of the definition of Permitted Indebtedness that impose restrictions on the property so acquired, (ii) by reason of customary provisions restricting assignments, change of control, subletting or other transfers contained in leases, licenses, joint venture agreements and other agreements (including, without limitation, Permitted Product Agreements, but solely to the extent that such customary provisions are not broader than the scope of the Royalty Monetization Transactions or Permitted Product Agreements expressly permitted under this Agreement) entered into in the ordinary course of business, (iii) that are or were created by virtue of any transfer of, agreement to transfer or option or right with respect to any property, assets or Capital Stock not otherwise prohibited under this Agreement and (iv) that are set forth herein and in the other Loan Documents. No Loan Party shall, nor shall it permit its Subsidiaries to, enter into any Contractual Obligations which would prohibit a Subsidiary of the Borrower from being a Loan Party (other than Excluded Subsidiaries). Section 6.7 Investments. The Borrower shall not, nor shall it permit any of its Subsidiaries to, directly or indirectly, make or own any Investment in any Person, including without limitation any Joint Venture, except Permitted Investments. Notwithstanding the foregoing, in no event shall any Loan Party make any Investment which results in or facilitates in any manner any Restricted Junior Payment not otherwise permitted under the terms of Section 6.5. "A - 108A - A" Section 6.8 Minimum Qualified Cash. The Loan Parties shall not permit Qualified Cash at any time to be less than the sum of (i) \$70,000,000, plus (ii) the Released Cash Amount at such time. Section 6.9 Fundamental Changes; Disposition of Assets. No Loan Party shall, nor shall it permit any of its Subsidiaries to: (a) enter into any transaction of merger or consolidation, or liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution), including by means of a "plan of division" under the Delaware Limited Liability Company Act or any comparable transaction under any similar law, except: (i) (x) any Subsidiary of the Borrower that is a Loan Party may be merged with or into the Borrower or any Guarantor Subsidiary (other than a [***] Subsidiary or [***] Subsidiary), or be liquidated, wound up or dissolved, or all or any part of its business, property or assets may be conveyed, sold, leased, transferred or otherwise disposed of, in one transaction or a series of transactions, to the Borrower or any Guarantor Subsidiary (other than a [***] Subsidiary or [***] Subsidiary); and (y) any Non-Loan Party may be merged with or into the Borrower or any other Subsidiary (other than a [***] Subsidiary or [***] Subsidiary), or be liquidated, wound up or dissolved, or all or any part of its business, property or assets may be conveyed, sold, leased, transferred or otherwise disposed of, in one transaction or a series of transactions, to the Borrower or any other Subsidiary (other than a [***] Subsidiary or [***] Subsidiary); provided, that in each case of clauses (x) and (y), in the case of such merger involving the Borrower, the Borrower shall be the continuing or surviving Person and in the case of such merger not involving the Borrower but involving a Guarantor Subsidiary, such Guarantor Subsidiary shall be the continuing or surviving person; (ii) Permitted Acquisitions, other Permitted Investments, and Asset Sales permitted by Section 6.9(b); or (iii) any Subsidiary may liquidate or dissolve or change its legal form if the Borrower determine in good faith that such action is in the best interests of the Borrower and the Subsidiaries and is not materially disadvantageous to the Lenders; provided that if such Subsidiary is a Loan Party any assets held by such Loan Party shall be transferred to another Loan Party (other than a [***] Subsidiary or [***] Subsidiary) or otherwise transferred in accordance with Section 6.9(b); or (b) enter into or consummate any Asset Sale, in one transaction or a series of transactions, of all or any part of its

business, assets or property of any kind whatsoever (including, without limitation, any Product (including, without limitation, any Intellectual Property Rights related thereto), any Product Agreement (including, without limitation, any Loan Partyâ€™s rights thereunder), and any Registration), whether real, personal or mixed and whether tangible or intangible, whether now owned or hereafter acquired, or, except for (and in each case pursuant to armsâ€™ length transactions on market terms and for fair market value (in each case, as reasonably determined by the Borrower or the applicable Subsidiary); provided that any such Asset Sales with any Affiliate of the Borrower shall be subject to Section 6.12): (i) Permitted Royalty Monetization Transactions; (ii) Permitted Product Agreement Transactions; (iii) to the extent constituting Asset Sales, (x) Permitted Acquisitions and other Permitted Investments, (y) Permitted Liens (other than pursuant to clause (r) of the definition thereof) and (z) Restricted Junior Payments permitted under Section 6.5 (other than Section 6.5(e)); Â - 109Â - Â | Â (iv) Asset Sales of any Priority Review Voucher; (v) Asset Sales of inventory and immaterial assets in the ordinary course of business; (vi) Asset Sales of obsolete or worn out, retired or surplus property, whether now owned or hereafter acquired, in the ordinary course of business; (vii) surrender or waiver of contractual rights and settlement or waiver of contractual or litigation claims in the ordinary course of business; (viii) Asset Sales to the Borrower or any Guarantor Subsidiary (other than a [***] Subsidiary or [***] Subsidiary); (ix) Asset Sales by any Non-Loan Party; (x) [***]; (xi) Asset Sales of marketing rights outside of the United States among the Borrower and its Subsidiaries; (xii) Asset Sales of Real Property, including in connection with any sale-leaseback transaction; (xiii) the disposition, unwinding or other termination of any Interest Rate Agreement, any Currency Agreement or any Permitted Equity Derivative or the entry into any Permitted Equity Derivatives; (xiv) Asset Sales of capital assets to the extent that (x) such property is exchanged for credit against the purchase price of similar replacement property or (y) the proceeds of such Asset Sale are promptly applied to the purchase price of such replacement property; (xv) [***]; (xvi) [***]; (xvii) [***]; (xviii) [***]; and (xiv) other Asset Sales in an aggregate amount not to exceed \$[***] for any Fiscal Year (with any unused amounts for any Fiscal Year ended after the Closing Date permitted to be carried over to the next Fiscal Year but not any subsequent Fiscal Year). Notwithstanding anything to the contrary contained herein, (i) no assignment, transfer, contribution, license, sublicense or other disposition of any Product, Product Patent or Registration is permitted hereunder except as specifically permitted under this Agreement and (ii) no assignment, transfer, contribution, license, sublicense or other disposition shall be made by a Loan Party or any Subsidiary of a Loan Party to a [***] Subsidiary or a [***] Subsidiary (it being understood and agreed that the foregoing shall not restrict or prohibit any Permitted Intercompany Investments). Â - 110Â - Â | Â Section 6.10 Disposal of Subsidiary Interests. Except for (i) any sale of all or a portion of its interests in the Capital Stock of any of its Subsidiaries in compliance with the provisions of Section 6.9(b), (ii) Liens permitted by Section 6.2, (iii) any issuance of Capital Stock by a Subsidiary of the Borrower to the Borrower or to another Loan Party (other than a [***] Subsidiary or a [***] Subsidiary), (iv) [***], (v) [***], (vi) [***], and (vii) [***], no Loan Party shall, nor shall it permit any of its Subsidiaries to, (a) directly or indirectly sell, assign, pledge or otherwise encumber or dispose of any Capital Stock of any of its Subsidiaries, except to qualify directors if required by applicable law; or (b) permit any of its Subsidiaries directly or indirectly to sell, assign, pledge or otherwise encumber or dispose of any Capital Stock of any of its Subsidiaries, except to another Loan Party (other than a [***] or a [***] Subsidiary) (subject to the restrictions on such disposition otherwise imposed hereunder), or to qualify directors if required by applicable law. Notwithstanding anything to the contrary, unless the Acoramidis Revenue Transaction shall have terminated or except to the extent permitted under the Acoramidis Revenue Transaction Agreement, in no event shall any Subsidiary Seller Party (as defined in the Acoramidis Revenue Transaction Agreement) cease to be wholly-owned, directly or indirectly, by the Borrower. Section 6.11 Sales and Lease Backs. Except as permitted by Section 6.9(b)(xii), no Loan Party shall, nor shall it permit any of its Subsidiaries to, directly or indirectly, become or remain liable as lessee or as a guarantor or other surety with respect to any lease of any property (whether real, personal or mixed), whether now owned or hereafter acquired, which such Loan Party (a) has sold or transferred or is to sell or to transfer to any other Person (other than the Borrower or any of its Subsidiaries) or (b) intends to use for substantially the same purpose as any other property which has been or is to be sold or transferred by such Loan Party to any Person (other than the Borrower or any of its Subsidiaries) in connection with such lease. Section 6.12 Transactions with Shareholders and Affiliates. No Loan Party shall, nor shall it permit any of its Subsidiaries to, directly or indirectly, enter into or permit to exist any transaction (including the purchase, sale, lease or exchange of any property or the rendering of any service) with any Affiliate of the Borrower or of any such holder; provided, that the Loan Parties and their Subsidiaries may enter into or permit to exist any such transaction if the terms of such transaction are not less favorable to the Borrower or that Subsidiary, as the case may be, than those that might be obtained at the time from a Person who is not such a holder or Affiliate; further, provided, further, that the foregoing restrictions shall not apply to any of the following: (a) any transaction among the Borrower and its Subsidiaries expressly permitted hereunder; (b) reasonable and customary fees paid to members of the Board of Directors (or similar governing body) of the Borrower and its Subsidiaries; (c) Restricted Junior Payments of the type described in clause (a), (b) or (c) of the definition thereof and permitted under Section 6.5; (d) compensation arrangements for officers and other employees of the Borrower and its Subsidiaries entered into in the ordinary course of business; and (e) transactions described in Schedule 6.12 (including without limitation, any intercompany licenses or other arrangements existing on the Closing Date). Section 6.13 Conduct of Business. From and after the Closing Date, no Loan Party shall, nor shall it permit any of its Subsidiaries to, engage in any business other than the businesses engaged in by such Loan Party on the Closing Date (or any other business reasonably related thereto). Â - 111Â - Â | Â Section 6.14 Changes to Organizational Documents. No Loan Party shall amend or permit any amendments to any Loan Partyâ€™s Organizational Documents in a manner materially adverse to the Administrative Agent of the Lenders, including, without limitation, any amendment, modification or change to any of Loan Partyâ€™s Organizational Documents to effect a division or plan of division pursuant to Section 18-217 of the Delaware Limited Liability Company Act (or any similar statute or provision under applicable law). Section 6.15 Accounting Methods. The Loan Parties will not and will not permit any of their Subsidiaries to modify or change its fiscal year or its method of accounting (other than as may be required to conform to GAAP). Section 6.16 Deposit Accounts and Securities Accounts. Subject to Section 5.15, no Loan Party shall establish or maintain a Deposit Account or a Securities Account that is not subject to a Control Agreement or Account Charge, except for Excluded Accounts. The Designated Securities Account shall not hold any assets other than the Permitted Investments described in clause (t) of the definition thereof. Investments in equity securities issued by public companies shall be limited to Investments held in the Designated Securities Account. Section 6.17 Prepayments of Certain Indebtedness. No Loan Party shall, directly or indirectly, voluntarily purchase, redeem, defease or prepay any principal of, premium, if any, interest or other amount payable in respect of any Indebtedness prior to its scheduled maturity, other than (a) the Obligations, (b) [reserved], (c) Indebtedness secured by a Permitted Lien if the asset securing such Indebtedness has been sold or otherwise disposed of in accordance with Section 6.9(b), (d) converting (or exchanging) any Indebtedness to (or for) Qualified Capital Stock of the Borrower, (e) Indebtedness permitted by clauses (b), (c), (d), (e), (h), (j), (l), (q), (r) and (s) of the definition of Permitted Indebtedness, (f) in an amount not to exceed the Available Investment Amount, so long as (x) no Default or Event of Default shall have occurred and be continuing or would result therefrom and (y) the Borrower and its Subsidiaries shall be in compliance, on a pro forma basis, with the Permitted Transaction Qualified Cash Requirement after giving effect thereto, (g) Restricted Junior Payments permitted under Section 6.5, (h) the payment of customary fees, regularly scheduled interest and reimbursement of fees and expenses in accordance with the documentation for any Permitted Indebtedness, and (i) solely with the proceeds of any Permitted Refinancing Indebtedness of such specific Indebtedness being prepaid as permitted hereunder. Notwithstanding the foregoing, and for the avoidance of doubt, this Section 6.17 shall not prohibit the conversion by holders of (excluding any cash payment upon conversion, except to the extent expressly permitted pursuant to the immediately succeeding paragraph), or required payment of any interest with respect to, any Permitted Convertible Indebtedness, in each case, in accordance with the terms of the indenture governing such Permitted Convertible Indebtedness. Notwithstanding the foregoing, the Borrower may (i) repurchase, exchange or induce the conversion of Permitted Convertible Indebtedness by delivery of shares of the Borrowerâ€™s Common Stock and/or other Qualified Capital Stock and/or a different series of Permitted Convertible Indebtedness (which series matures no earlier than, and does not require any scheduled amortization or other scheduled payments of principal prior to, the analogous date under the indenture governing the Permitted Convertible Indebtedness that are so repurchased, exchanged or converted) (any such series of Permitted Convertible Indebtedness, â€œRefinancing Convertible Indebtednessâ€) and/or by payment of cash (x) in lieu of any fractional shares, (y) in respect of accrued and unpaid interest of such Permitted Convertible Indebtedness and (z) in an amount that does not exceed the Net Proceeds received by the Borrower from the substantially concurrent issuance of shares of the Borrowerâ€™s Common Stock (to the extent included in the Available Investment Amount) and/or a Refinancing Convertible Indebtedness and (ii) redeem or repurchase (in part or in full) in cash any Permitted Convertible Indebtedness prior to the stated maturity thereof (including via Â - 112Â - Â | Â open-market repurchases) or upon the conversion thereof, so long as (x) such purchases are at a cash purchase price not in excess of the principal amount of such Permitted Convertible Indebtedness plus accrued and unpaid interest or, in the case of conversion, settlement consideration consisting of cash does not exceed the principal amount of Permitted Convertible Indebtedness so converted, (y) no Default or Event of Default shall have occurred and be continuing or would result therefrom and (z) on a pro forma basis after giving effect to such Restricted Junior Payment, the Loan Parties shall have Qualified Cash not less than an amount equal to [***]% of the outstanding principal amount of the Term Loans at such time. Section 6.18 Anti-Terrorism Laws. None of the Loan Parties, nor any of their Affiliates or agents shall: (a) conduct any business or engage in any transaction or dealing with any Blocked Person, including the making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, (b) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to the OFAC Sanctions Programs or (c) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in the OFAC Sanctions Programs, the PATRIOT Act or any other Anti-Terrorism Law. The Borrower shall deliver to the Lenders any certification or other evidence requested from time to time by any Lender in its sole discretion, confirming the Loan Partiesâ€™ compliance with this Section 6.18. Section 6.19 Anti-Corruption Laws. No Loan Party shall use, or permit any of its Subsidiaries to use, directly or indirectly, any of the proceeds of any Loan for the purpose of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any Anti-Corruption Law. Section 6.20 Use of Proceeds. The Loan Parties will not and will not permit any of their Subsidiaries to use the proceeds of any Loan to directly, or to any Loan Partyâ€™s knowledge after due care and inquiry, indirectly, to make any payments to a Sanctioned Entity or a Sanctioned Person, to fund any investments, loans or contributions in, or otherwise make such proceeds available to, a Sanctioned Entity or a Sanctioned Person, to fund any operations, activities or business of a Sanctioned Entity or a Sanctioned Person or in any other manner that would result in a violation of Sanctions by any Person and no part of the proceeds of any Loan will be used directly or, to any Loan Partyâ€™s knowledge after due care and inquiry, indirectly in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any Sanctions, Anti-Corruption Laws or Anti-Terrorism Laws. Article VIIGUARANTY Section 7.1 Guaranty of the Obligations. Subject to the provisions of Section 7.2, Guarantors jointly and severally hereby irrevocably and unconditionally guaranty for the ratable benefit of the Beneficiaries the due and punctual payment in full of all Obligations when the same shall become due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise (including amounts that would become due but for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code, 11 U.S.C. Â§ 362(a)) (collectively, the â€œGuaranteed Obligationsâ€). Â - 113Â - Â | Â Section 7.2 Contribution by Guarantors. All Guarantors desire to allocate among themselves, in a fair and equitable manner, their obligations arising under this Guaranty. Accordingly, in the event any payment or distribution is made on any date by a Guarantor under this Guaranty such that its Aggregate Payments exceeds its Fair Share as of such date, such Guarantor shall be entitled to a contribution from each of the other Guarantors in an amount sufficient to cause each Guarantorâ€™s Aggregate Payments to equal its Fair Share as of such date. â€œFair Shareâ€ means, with respect to any Guarantor as of any date of determination, an amount equal to (a) the ratio of (i) the Fair Share Contribution Amount with respect to such Guarantor, to (ii) the aggregate of the Fair Share Contribution Amounts with respect to all Guarantors multiplied by, (b) the aggregate amount paid or distributed on or before such date by all Guarantors under this Guaranty in respect of the Guaranteed Obligations. â€œFair Share Contribution Amountâ€ means, with respect to any Guarantor as of any date of determination, the maximum aggregate amount of the obligations of such Guarantor under this Guaranty that would not render its obligations hereunder subject to avoidance as a fraudulent transfer or conveyance under Section 548 of Title 11 of the United States Code or any comparable applicable provisions of state law; provided, solely for purposes of calculating the â€œFair Share Contribution Amountâ€ with respect to any Guarantor for purposes of this Section 7.2, any assets or liabilities of such Guarantor arising by virtue of any rights to subrogation, reimbursement or indemnification or any rights to or obligations of contribution hereunder shall not be considered as assets or liabilities of such Guarantor. â€œAggregate Paymentsâ€ means, with respect to any Guarantor as of any date of determination, an amount equal to (A) the aggregate amount of all payments and distributions made on or before such date by such Guarantor in respect of this Guaranty (including, without limitation, in respect of this Section 7.2), minus (B) the aggregate amount of all payments received on or before such date by such Guarantor from the other Guarantors as contributions under this Section 7.2. The amounts payable as contributions hereunder shall be determined as of the date on which the related payment or distribution is made by the applicable Guarantor. The allocation among Guarantors of their obligations as set forth in this Section 7.2 shall not be construed in any way to limit the liability of any Guarantor hereunder. Each Guarantor is a third party beneficiary to the contribution agreement set forth in this Section 7.2. Section 7.3 Payment by Guarantors. Subject to Section 7.2, Guarantors hereby jointly and severally agree, in furtherance of the foregoing and not in limitation of any other right which any Beneficiary may have at law or in equity against any Guarantor by virtue hereof, that upon the failure of the Borrower to pay any of the Guaranteed Obligations when and as the same shall become due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise (including amounts that would become due but for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code, 11 U.S.C. Â§ 362(a)), Guarantors will upon demand pay, or cause to be paid, in Cash, to Administrative Agent for the ratable benefit of Beneficiaries, an amount equal to the sum of the unpaid principal amount of all Guaranteed Obligations then due as aforesaid, accrued and unpaid interest on such Guaranteed Obligations (including interest which, but for the Borrowerâ€™s becoming the subject of a case under the Bankruptcy Code, would have accrued on such Guaranteed Obligations, whether or not a claim is allowed against such Borrower for such interest in the related bankruptcy case) and all other Guaranteed Obligations then owed to Beneficiaries as aforesaid. Section 7.4 Liability of Guarantors Absolute. Each Guarantor agrees that its obligations hereunder are irrevocable, absolute, independent and unconditional and shall not be affected by any circumstance which constitutes a legal or equitable discharge of a guarantor or surety other than payment in full of the Guaranteed Obligations. In furtherance of the foregoing and without limiting the generality thereof, each Guarantor agrees as follows: (a) this Guaranty is a guaranty of payment when due and not of collectability. This Guaranty is a primary obligation of each Guarantor and not merely a contract of surety; Â - 114Â - Â | Â (b) Administrative Agent may enforce this Guaranty upon the occurrence of an Event of Default notwithstanding the existence of any dispute between the Borrower and any Beneficiary with respect to the existence of such Event of Default; (c) the obligations of each Guarantor hereunder are independent of the obligations of Borrower and the obligations of any other guarantor (including any other Guarantor) of the obligations of Borrower, and a separate action or actions may be brought and prosecuted against such Guarantor whether or not any action is brought against the Borrower or any of such other guarantors and whether or not the Borrower is joined in any such action or actions; (d) payment by any Guarantor of a portion, but not all, of the Guaranteed Obligations shall in no way limit, affect, modify or abridge any Guarantorâ€™s liability for any portion of the Guaranteed Obligations which has not been paid. Without limiting the generality of the foregoing, if Administrative Agent is awarded a judgment in any suit brought to enforce any Guarantorâ€™s covenant to pay a portion of the Guaranteed Obligations, such judgment shall not be deemed to release such Guarantor from its covenant to pay the portion of the Guaranteed Obligations that is not the subject of such suit, and such judgment shall not, except to the extent satisfied by such Guarantor, limit, affect, modify or abridge any other Guarantorâ€™s liability hereunder in respect of the Guaranteed Obligations; (e) any Beneficiary, upon such terms as it deems appropriate, without notice or demand and without affecting the validity or enforceability hereof or giving rise to any reduction, limitation, impairment, discharge or termination of any Guarantorâ€™s liability hereunder, from time to time may (i) renew, extend, accelerate, increase the rate of interest on, or otherwise change the time, place, manner or terms of payment of the Guaranteed Obligations; (ii) settle, compromise, release or discharge, or accept or refuse any offer of performance with respect to, or substitutions for, the Guaranteed Obligations or any agreement relating thereto and/or subordinate the payment of the same to the payment of any other obligations; (iii) request and accept other guaranties of the Guaranteed Obligations and take and hold security for the payment hereof or the Guaranteed Obligations; (iv) release, surrender, exchange, substitute, compromise, settle, rescind, waive, alter, subordinate or modify, with or without consideration, any security for payment of the Guaranteed Obligations, any other guaranties of the Guaranteed Obligations, or any other obligation of any Person (including any other Guarantor) with respect to the Guaranteed Obligations; (v) enforce and apply any security now or hereafter held by or for the benefit of such Beneficiary in respect hereof or the Guaranteed Obligations and direct the order or manner of

sale thereof, or exercise any other right or remedy that such Beneficiary may have against any such security, in each case as such Beneficiary in its discretion may determine consistent herewith and any applicable security agreement, including foreclosure on any such security pursuant to one or more judicial or non-judicial sales, whether or not every aspect of any such sale is commercially reasonable, and even though such action operates to impair or extinguish any right of reimbursement or subrogation or other right or remedy of any Guarantor against the Borrower or any security for the Guaranteed Obligations; and (vi) exercise any other rights available to it under the Loan Documents; and (f) this Guaranty and the obligations of Guarantors hereunder shall be valid and enforceable and shall not be subject to any reduction, limitation, impairment, discharge or termination for any reason (other than payment in full in cash of the Guaranteed Obligations), including the occurrence of any of the following, whether or not any Guarantor shall have had notice or knowledge of any of them: (i) any failure or omission to assert or enforce or agreement or election not to assert or enforce, or the stay or enjoining, by order of court, by operation of law or otherwise, of the exercise or enforcement of, any claim or demand or any right, power or remedy (whether arising under the Loan Documents, at law, in equity or otherwise) with respect to the Guaranteed Obligations or any agreement relating thereto, or with respect to any other guaranty of or security for the payment of the Guaranteed Obligations; (ii) any rescission, waiver, amendment or modification of, or any consent to departure from, any of the terms or provisions (including $\text{\AA}$ - 115A - $\text{\AA}$ | $\text{\AA}$ provisions relating to events of default) hereof, any of the other Loan Documents or any agreement or instrument executed pursuant thereto, or of any other guaranty or security for the Guaranteed Obligations, in each case whether or not in accordance with the terms hereof or such Loan Document or any agreement relating to such other guaranty or security; (iii) the Guaranteed Obligations, or any agreement relating thereto, at any time being found to be illegal, invalid or unenforceable in any respect; (iv) the application of payments received from any source (other than payments received pursuant to the other Loan Documents or from the proceeds of any security for the Guaranteed Obligations, except to the extent such security also serves as collateral for indebtedness other than the Guaranteed Obligations) to the payment of indebtedness other than the Guaranteed Obligations, even though any Beneficiary might have elected to apply such payment to any part or all of the Guaranteed Obligations; (v) any Beneficiary $\text{\AA}$ ™s consent to the change, reorganization or termination of the corporate structure or existence of the Borrower or any of their Subsidiaries and to any corresponding restructuring of the Guaranteed Obligations; (vi) any failure to perfect or continue perfection of a security interest in any collateral which secures any of the Guaranteed Obligations; (vii) any defenses, set offs or counterclaims which the Borrower may allege or assert against any Beneficiary in respect of the Guaranteed Obligations, including failure of consideration, breach of warranty, payment, statute of frauds, statute of limitations, accord and satisfaction and usury; and (viii) any other act or thing or omission, or delay to do any other act or thing, which may or might in any manner or to any extent vary the risk of any Guarantor as an obligor in respect of the Guaranteed Obligations. Section 7.5 Waivers by Guarantors. Each Guarantor hereby waives, for the benefit of Beneficiaries: (a) any right to require any Beneficiary, as a condition of payment or performance by such Guarantor, to (i) proceed against the Borrower, any other guarantor (including any other Guarantor) of the Guaranteed Obligations or any other Person, (ii) proceed against or exhaust any security held from the Borrower, any such other guarantor or any other Person, (iii) proceed against or have resort to any balance of any Deposit Account or credit on the books of any Beneficiary in favor of the Borrower or any other Person, or (iv) pursue any other remedy in the power of any Beneficiary whatsoever; (b) any defense arising by reason of the incapacity, lack of authority or any disability or other defense of the Borrower or any other Guarantor including any defense based on or arising out of the lack of validity or the unenforceability of the Guaranteed Obligations or any agreement or instrument relating thereto or by reason of the cessation of the liability of the Borrower or any other Guarantor from any cause other than payment in full in cash of the Guaranteed Obligations; (c) any defense based upon any statute or rule of law which provides that the obligation of a surety must be neither larger in amount nor in other respects more burdensome than that of the principal; (d) any defense based upon any Beneficiary $\text{\AA}$ ™s errors or omissions in the administration of the Guaranteed Obligations, except behavior which amounts to bad faith; (e) (i) any principles or provisions of law, statutory or otherwise, which are or might be in conflict with the terms hereof and any legal or equitable discharge of such Guarantor $\text{\AA}$ ™s obligations hereunder, (ii) the benefit of any statute of limitations affecting such Guarantor $\text{\AA}$ ™s liability hereunder or the enforcement thereof, (iii) any rights to set offs, recoupments and counterclaims, and (iv) promptness, diligence and any requirement that any Beneficiary protect, secure, perfect or insure any security interest or lien or any property subject thereto; (f) notices, demands, presentments, protests, notices of protest, notices of dishonor and notices of any action or inaction, including acceptance hereof, notices of default hereunder or any agreement or instrument related thereto, notices of any renewal, extension or modification of the Guaranteed Obligations or any agreement related thereto, notices of any extension of credit to the Borrower and notices of any of the matters referred to in Section 7.4 and any right to consent to any thereof; and (g) any defenses or benefits that may be derived from or afforded by law which limit the liability of or exonerate guarantors or sureties, or which may conflict with the terms hereof. Section 7.6 Guarantors $\text{\AA}$ ™ Rights of Subrogation, Contribution, Etc. Until the Guaranteed Obligations shall have been indefeasibly paid in cash in full and the Term Loan Commitments have been terminated, each Guarantor hereby waives any claim, right or remedy, direct or indirect, that such Guarantor now has or may hereafter have against the Borrower or any other Guarantor or any of its assets in connection $\text{\AA}$ - 116A - $\text{\AA}$ | $\text{\AA}$ with this Guaranty or the performance by such Guarantor of its obligations hereunder, in each case whether such claim, right or remedy arises in equity, under contract, by statute, under common law or otherwise and including without limitation (a) any right of subrogation, reimbursement or indemnification that such Guarantor now has or may hereafter have against the Borrower with respect to the Guaranteed Obligations, (b) any right to enforce, or to participate in, any claim, right or remedy that any Beneficiary now has or may hereafter have against the Borrower, and (c) any benefit of, and any right to participate in, any collateral or security now or hereafter held by any Beneficiary. In addition, until the Guaranteed Obligations shall have been indefeasibly paid in full and the Term Loan Commitments have been terminated, each Guarantor shall withhold exercise of any right of contribution such Guarantor may have against any other guarantor (including any other Guarantor) of the Guaranteed Obligations, including, without limitation, any such right of contribution as contemplated by Section 7.2. Each Guarantor further agrees that, to the extent the waiver or agreement to withhold the exercise of its rights of subrogation, reimbursement, indemnification and contribution as set forth herein is found by a court of competent jurisdiction to be void or voidable for any reason, any rights of subrogation, reimbursement or indemnification such Guarantor may have against the Borrower or against any collateral or security, and any rights of contribution such Guarantor may have against any such other guarantor, shall be junior and subordinate to any rights any Beneficiary may have against the Borrower, to all right, title and interest any Beneficiary may have in any such collateral or security, and to any right any Beneficiary may have against such other guarantor. If any amount shall be paid to any Guarantor on account of any such subrogation, reimbursement, indemnification or contribution rights at any time when all Guaranteed Obligations shall not have been finally and indefeasibly paid in full, such amount shall be held in trust for Administrative Agent on behalf of Beneficiaries and shall forthwith be paid over to Administrative Agent for the benefit of Beneficiaries to be credited and applied against the Guaranteed Obligations, whether matured or unmatured, in accordance with the terms hereof. Section 7.7 Subordination of Other Obligations. Any Indebtedness of the Borrower or any Guarantor now or hereafter held by any Guarantor is hereby subordinated in right of payment to the Guaranteed Obligations, and any such indebtedness collected or received by such Guarantor after an Event of Default has occurred and is continuing shall be held in trust for Administrative Agent on behalf of Beneficiaries and shall forthwith be paid over to Administrative Agent for the benefit of Beneficiaries to be credited and applied against the Guaranteed Obligations but without affecting, impairing or limiting in any manner the liability of such Guarantor under any other provision hereof. Section 7.8 Continuing Guaranty. This Guaranty is a continuing guaranty and shall remain in effect until all of the Guaranteed Obligations shall have been paid in full and the Term Loan Commitments have been terminated. Each Guarantor hereby irrevocably waives any right to revoke this Guaranty as to future transactions giving rise to any Guaranteed Obligations. Section 7.9 Authority of Guarantors or Borrower. It is not necessary for any Beneficiary to inquire into the capacity or powers of any Guarantor or the Borrower or the officers, directors or agents acting or purporting to act on behalf of any of them. Section 7.10 Financial Condition of Borrower. Any Credit Extension may be made to Borrower or continued from time to time without notice to or authorization from any Guarantor regardless of the financial or other condition of Borrower at the time of any such grant or continuation is entered into, as the case may be. No Beneficiary shall have any obligation to disclose or discuss with any Guarantor its assessment, or any Guarantor $\text{\AA}$ ™s assessment, of the financial condition of a Borrower. Each Guarantor has adequate means to obtain information from Borrower on a continuing basis concerning the financial condition of such Borrower and its ability to perform its obligations under the Loan Documents, and each Guarantor assumes the responsibility for being and keeping informed of the financial condition of Borrower and of all circumstances bearing upon the risk of non-payment of the Guaranteed Obligations. Each Guarantor hereby waives and relinquishes any duty on the part of any Beneficiary to disclose any matter. $\text{\AA}$ - 117A - $\text{\AA}$ | $\text{\AA}$ fact or thing relating to the business, operations or conditions of Borrower now known or hereafter known by any Beneficiary. Section 7.11 Bankruptcy, Etc. (a) So long as any Guaranteed Obligations remain outstanding, no Guarantor shall, without the prior written consent of Administrative Agent acting pursuant to the instructions of Required Lenders, commence or join with any other Person in commencing any bankruptcy, reorganization or insolvency case or proceeding of or against the Borrower or any other Guarantor. The obligations of Guarantors hereunder shall not be reduced, limited, impaired, discharged, deferred, suspended or terminated by any case or proceeding, voluntary or involuntary, involving the bankruptcy, insolvency, receivership, administration, reorganization, liquidation, examinership or arrangement of the Borrower or any other Guarantor or by any defense which the Borrower or any other Guarantor may have by reason of the order, decree or decision of any court or administrative body resulting from any such proceeding. (b) Each Guarantor acknowledges and agrees that any interest on any portion of the Guaranteed Obligations which accrues after the commencement of any case or proceeding referred to in clause (a) above (or, if interest on any portion of the Guaranteed Obligations ceases to accrue by operation of law by reason of the commencement of such case or proceeding, such interest as would have accrued on such portion of the Guaranteed Obligations if such case or proceeding had not been commenced) shall be included in the Guaranteed Obligations because it is the intention of Guarantors and Beneficiaries that the Guaranteed Obligations which are guaranteed by Guarantors pursuant hereto should be determined without regard to any rule of law or order which may relieve a Borrower of any portion of such Guaranteed Obligations. Guarantors will permit any trustee in bankruptcy, receiver, examiner, administrator, debtor in possession, assignee for the benefit of creditors or similar person to pay Administrative Agent, or allow the claim of Administrative Agent in respect of, any such interest accruing after the date on which such case or proceeding is commenced. (c) In the event that all or any portion of the Guaranteed Obligations are paid by a Borrower, the obligations of Guarantors hereunder shall continue and remain in full force and effect or be reinstated, as the case may be, in the event that all or any part of such payment(s) are rescinded or recovered directly or indirectly from any Beneficiary as a preference, fraudulent transfer or otherwise, and any such payments which are so rescinded or recovered shall constitute Guaranteed Obligations for all purposes hereunder. Section 7.12 Discharge of Guaranty Upon Sale of Guarantor. If any Guarantor (or any of its successors in interest hereunder) ceases to be a Subsidiary of the Borrower as a result of a sale or other disposition of the Capital Stock of such Guarantor (or successor in interest, as applicable) (including by merger or consolidation) permitted under, and in accordance with the terms and conditions of, this Agreement, the Guaranty of such Guarantor or such successor in interest, as the case may be, hereunder shall automatically be discharged and released without any further action by any Beneficiary or any other Person effective as of the time of such Asset Sale. Section 7.13 Swiss Guaranty Limitations. Notwithstanding anything to the contrary in this Article VII, any other provision of this Agreement and any other Loan Document to which Swiss Guarantor is or will be a party, the obligations of, and any Lien granted by, Swiss Guarantor (and the respective rights of Administrative Agent, Lenders and/or Secured Parties, respectively) under this Article VII, any such other provision of this Agreement and any such other Loan Document are subject to the following limitations and procedures: (a) If and to the extent: $\text{\AA}$ - 118A - $\text{\AA}$ | $\text{\AA}$ (i) Swiss Guarantor becomes directly or indirectly liable (in particular, by a joint obligation, guarantee or indemnity) and/or grants a Lien under this Article VII, any such other provision of this Agreement and any such other Loan Document for, and/or to secure, obligations of any of its (direct or indirect) parent companies (upstream liability/Lien) or sister companies (cross-stream liability/Lien) (the $\text{\AA}$ Restricted Obligations $\text{\AA}$); and (ii) Swiss Guarantor $\text{\AA}$ ™s payment under such liability and/or the application of any proceeds from enforcing such Lien to discharge the Restricted Obligations would constitute a repayment of capital (Einlagen $\text{\AA}$ ckgew $\text{\AA}$ hr/Kapital $\text{\AA}$ ckzahlung), a violation of the legally protected reserves (gesetzlich gesch $\text{\AA}$ tzte Reserven) or the payment of a (constructive) dividend (Gewinnaussch $\text{\AA}$ ttung) under Swiss corporate law or would otherwise not be permitted under applicable law, Swiss Guarantor $\text{\AA}$ ™s payment obligation under such liability and/or the application of any proceeds from enforcing such Lien to be used to discharge the Restricted Obligations shall be limited to the maximum amount permitted under applicable law and practice at the time of payment and/or enforcement (the $\text{\AA}$ Maximum Amount $\text{\AA}$); provided that: (A) the Maximum Amount shall not be less than the profits and reserves of Swiss Guarantor available for distribution as dividends determined in accordance with Swiss law and applicable Swiss accounting principles at the time of payment and/or enforcement; (B) such limitation is required under the applicable law at that time; and (C) such limitation shall not free Swiss Guarantor from its respective payment obligations (and/or affect the respective Lien granted by Swiss Guarantor) in excess of the Maximum Amount, but merely postpone the performance date of such payment obligations and/or the time of using proceeds from enforcing such Lien towards discharging the Restricted Obligations until such time or times as performance and/or using enforcement proceeds is again permitted under then applicable law. (b) In case Swiss Guarantor $\text{\AA}$ ™s payments made and/or the proceeds from enforcing a Lien granted by Swiss Guarantor and used to discharge the Restricted Obligations are by law subject to Swiss Withholding Tax: (i) if and to the extent legally possible, Swiss Guarantor shall use reasonable efforts to procure that such payment can be made and/or enforcement proceeds can be used without a Swiss Withholding Tax deduction, by way of discharging Swiss Guarantor $\text{\AA}$ ™s obligations in respect of Swiss Withholding Tax by notification pursuant to applicable law (including tax treaties), rather than by way of payment of Swiss Withholding Tax; (ii) if and to the extent the notification procedure pursuant to sub-paragraph (b)(i) of this Section 7.13 is not legally available: (A) in the event of Swiss Guarantor $\text{\AA}$ ™s payments: Swiss Guarantor shall deduct Swiss Withholding Tax at such rate (currently 35% at the date of this Agreement, subject to applicable tax treaties) as is in force from time to time from any such payment and promptly pay the amount of such Swiss Withholding Tax $\text{\AA}$ - 119A - $\text{\AA}$ | $\text{\AA}$ to the Tax Swiss Federal Tax Administration and provide evidence of such payment to Administrative Agent and Lenders; and/or (B) in the event of application of proceeds from enforcing Liens: Administrative Agent (computed as directed by the Required Lenders) shall deduct Swiss Withholding Tax at such rate (currently 35% at the date of this Agreement, subject to applicable tax treaties) as is in force from time to time from any such enforcement proceeds and pay (in the name and for account of Swiss Guarantor) the amount of such Swiss Withholding Tax to the Tax Swiss Federal Tax Administration within thirty (30) days after presentation by Swiss Guarantor to Administrative Agent and Lenders of the relevant form of the Swiss Federal Tax Administration, it being agreed that Swiss Guarantor shall promptly complete the relevant form of the Swiss Federal Tax Administration and submit it to Administrative Agent and Lenders for approval (in case of Administrative Agent, as directed by the Required Lenders), such approval not to be unreasonably withheld; (iii) Swiss Guarantor shall promptly notify Administrative Agent and Lenders upon, as applicable, making the notification pursuant to sub-paragraph (b)(i) of this Section 7.13 and/or the Swiss Withholding Tax payment pursuant to sub-paragraph (b)(ii)(A) of this Section 7.13, in each case accompanied with appropriate documentary evidence; and (iv) in case of a deduction of Swiss Withholding Tax, Swiss Guarantor shall use reasonable efforts to ensure that any person (other than Administrative Agent and Lenders and/or Secured Parties, respectively) who is entitled to a full or partial refund of Swiss Withholding Tax deducted from such payment or enforcement proceeds will, as soon as possible after such deduction: (A) request a refund of Swiss Withholding Tax under applicable law (including tax treaties); and (B) pay to Administrative Agent upon receipt any amount so refunded, and, if Administrative Agent or a Lender and/or a Secured Party, respectively, is entitled to a full or partial refund of Swiss Withholding Tax deducted from such payment or enforcement proceeds, Swiss Guarantor shall promptly upon request provide Administrative Agent or the relevant Lender and/or Secured Party, respectively, with the documents required by law (including tax treaties) to be provided by the payer of Swiss Withholding Tax in order to enable Administrative Agent (as directed by the Required Lenders) or the relevant Lender and/or Secured Party, respectively, to prepare a claim for refund of Swiss Withholding Tax. (c) If Swiss Withholding Tax is to be deducted in accordance with paragraph (b) of this Section 7.13, Administrative Agent (as directed and calculated by the Required Lenders) shall be entitled to request, until the Maximum Amount is reached, further payments from Swiss Guarantor and/or apply further proceeds from the enforcement of a Lien to discharge Restricted Obligations up to an amount which is equal to that amount which would have been obtained if no deduction of Swiss Withholding Tax were required. (d) Upon written request by Administrative Agent (as directed by the Required Lenders) at the time when Swiss Guarantor $\text{\AA}$ ™s payment is required and/or a Lien granted by Swiss Guarantor $\text{\AA}$ - 120A - $\text{\AA}$ | $\text{\AA}$ is enforced to discharge the Restricted Obligations, Swiss Guarantor shall promptly take and/or cause to be taken the following: (i) preparation of an up-to-date (interim) audited balance sheet of Swiss Guarantor; (ii) confirmation of the auditors of Swiss Guarantor that the relevant amount represents the Maximum Amount (to the extent required by applicable Swiss law); (iii) passing of quotaholders $\text{\AA}$ ™ resolutions to approve the (resulting) distribution; (iv) conversion of restricted reserves into profits and reserves freely available for the distribution as dividends (to the extent permitted by mandatory Swiss law); (v) revaluation of Swiss Guarantor $\text{\AA}$ ™s hidden

reserves (to the extent permitted by mandatory Swiss law); (vi) write-up or realization any of Swiss Guarantorâ€™s assets that are shown in its balance sheet with a book value that is significantly lower than the market value of the assets, in case of realization, however, only if such assets are not necessary for Swiss Guarantorâ€™s business (nicht betriebsnotwendig) (in each case, to the extent permitted by applicable law and Swiss accounting standards); and (vii) all other measures that are necessary or useful to allow Swiss Guarantorâ€™s payments and/or the application of enforcement proceeds with a minimum of limitations. (e) The limitations and procedures of this Section 7.13 shall also apply to any other obligation of Swiss Guarantor under any Loan Document to grant economic benefits to or of any of its (direct or indirect) parent companies (upstream) or sister companies (cross-stream), including, for the avoidance of doubt, any waiver of set-off or subrogation rights or any subordination or waiver of intra-group claims Article VIIIEVENTS OF DEFAULT Section 8.1 Events of Default. If any one or more of the following conditions or events shall occur: (a) Failure to Make Payments When Due. Failure by a Borrower to pay (i) the principal of and premium, if any, on any Term Loan whether at stated maturity, by acceleration or otherwise; (ii) when due any installment of principal of any Term Loan, by notice of voluntary prepayment, by mandatory prepayment or otherwise; or (iii) within [***] when due any interest on any Term Loan or any fee or any other amount due hereunder; or (b) Default in Other Agreements. (i) Failure of any Loan Party or any Loan Partyâ€™s Subsidiaries to pay when due any principal of or interest on or any other amount payable in respect of one or more items of Indebtedness (other than Indebtedness referred to in Section 8.1(a) in an individual principal amount, put price or other accelerated amount of \$[***] or more or with an aggregate principal amount, put price or other accelerated amount of \$[***] or more, in each case beyond the grace period, if any, provided therefor, or (ii) breach or default by any Loan Party with respect to any other material term Â - 121Â - Â | Â of (A) one or more items of Indebtedness in the individual or aggregate principal amounts referred to in clause (i) above, or (B) any loan agreement, mortgage, indenture or other agreement relating to such item(s) of Indebtedness, in each case beyond the grace or cure period, if any, provided therefor, if the effect of such breach or default is to cause, or to permit the holder or holders of that Indebtedness (or a trustee on behalf of such holder or holders), to cause, that Indebtedness to become or be declared due and payable (or subject to a compulsory repurchase or redeemable) or to require the prepayment, redemption, repurchase or defeasance of, or to cause the Borrower or any of the Borrowerâ€™s Subsidiaries to make any offer to prepay, redeem, repurchase or defease such Indebtedness, prior to its stated maturity or the stated maturity of any underlying obligation, as the case may be; or (c) Breach of Certain Covenants. Failure of any Loan Party to perform or comply with any term or condition contained in Section 2.2, Section 5.1, Section 5.2, Section 5.3, Section 5.5, Section 5.7, Section 5.8, Section 5.10, Section 5.13, Section 5.15, or Article VI; or (d) Breach of Representations, Etc. Any representation, warranty, certification or other statement made or deemed made by any Loan Party in any Loan Document or in any statement or certificate at any time given by any Loan Party or any of the Borrowerâ€™s Subsidiaries in writing pursuant hereto or thereto or in connection herewith or therewith shall be false in any material respect (except that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified as to âœœmaterialityâœ or âœœMaterial Adverse Effectâœ in the text thereof, which representations and warranties shall be true and correct in all respects subject to such qualification) as of the date made or deemed made; or (e) Other Defaults Under Loan Documents. Any Loan Party shall default in the performance of or compliance with any term contained herein or any of the other Loan Documents, other than any such term referred to in any other Section of this Section 8.1, and such default shall not have been remedied or waived within [***] after the earlier of (i) an officer of such Loan Party becoming aware of such default, or (ii) receipt by Borrower of written notice from Administrative Agent or any Lender of such default; or (f) Involuntary Bankruptcy; Appointment of Receiver, Etc. (i) A court of competent jurisdiction shall enter a decree or order for relief in respect of the Borrower or any of its Subsidiaries in an involuntary case under the Bankruptcy Code or under any other applicable bankruptcy, insolvency or similar law now or hereafter in effect, which decree or order is not stayed; or any other similar relief shall be granted under any applicable federal or state law; or (ii) an involuntary case shall be commenced against the Borrower or any of its Subsidiaries under the Bankruptcy Code or under any other applicable bankruptcy, insolvency or similar law now or hereafter in effect; or a decree or order of a court having jurisdiction in the premises for the appointment of a receiver, administrator, examiner, liquidator, sequester, trustee, custodian or other officer having similar powers over the Borrower or any of its Subsidiaries, or over all or a substantial part of its property, shall have been entered; or there shall have occurred the involuntary appointment of an interim receiver, receiver, examiner, administrator, trustee or other custodian of the Borrower or any of its Subsidiaries for all or a substantial part of its property; or a warrant of attachment, execution or similar process shall have been issued against any substantial part of the property of the Borrower or any of its Subsidiaries, and any such event described in the foregoing clause (i) or (ii) shall continue for [***] without having been dismissed, bonded or discharged; or (g) Voluntary Bankruptcy; Appointment of Receiver, Etc. (i) The Borrower or any of its Subsidiaries shall have an order for relief entered with respect to it or shall commence a voluntary case under the Bankruptcy Code or under any other applicable bankruptcy, insolvency or similar law now or hereafter in effect, or shall consent to the entry of an order for relief in an involuntary case, or to the conversion of an involuntary case to a voluntary case, under any such law, or shall consent to the Â - 122Â - Â | Â appointment of or taking possession by a receiver, examiner, administrator, trustee or other custodian for all or a substantial part of its property; or the Borrower or any of its Subsidiaries shall make any assignment for the benefit of creditors; or (ii) the Borrower or any of its Subsidiaries shall be unable, or shall fail generally, or shall admit in writing its inability, to pay its debts as such debts become due; or the Board of Directors (or similar governing body) of the Borrower or any of its Subsidiaries shall adopt any resolution or otherwise authorize any action to approve any of the actions referred to herein or in Section 8.1(f); or (h) Judgments and Attachments. Any money judgment, writ or warrant of attachment or similar process involving (i) in any individual case an amount in excess of \$[***] or (ii) in the aggregate at any time an amount in excess of \$[***] (in either case to the extent not adequately covered by insurance as to which a solvent and unaffiliated insurance company has not denied coverage) shall be entered or filed against the Borrower or any of its Subsidiaries or any of their respective assets and shall remain undischarged, unvacated, unbonded or unstayed for a period of [***] (or in any event later than [***] prior to the date of any proposed sale thereunder); or (i) Dissolution. Any order, judgment or decree shall be entered against any Loan Party or any of its Subsidiaries decreeing the dissolution or split up of such Loan Party or any of its Subsidiaries and such order shall remain undischarged or unstayed for a period in excess of [***]; or (j) Change of Control. A Change of Control shall occur; or (k) Guaranties, Collateral Documents and other Loan Documents. At any time after the execution and delivery thereof, (i) the Guaranty for any reason, other than the satisfaction in full in cash of all Obligations, shall cease to be in full force and effect (other than in accordance with its terms) or shall be declared to be null and void or any Guarantor shall repudiate its obligations thereunder, (ii) this Agreement or any Collateral Document [***] ceases to be in full force and effect (other than by reason of a release of Collateral in accordance with the terms hereof or thereof or the satisfaction in full in cash of the Obligations in accordance with the terms hereof) or shall be declared null and void, or Administrative Agent shall not have or shall cease to have a valid and perfected Lien in any portion of the Collateral [***] purported to be covered by the Collateral Documents with the priority required by the relevant Collateral Documents, in each case for any reason other than the failure of Administrative Agent or any Secured Party to take any action within its control, or (iii) any Loan Party shall contest the validity or enforceability of any Loan Document in writing or deny in writing that it has any further liability, including with respect to future advances by Lenders, under any Loan Document to which it is a party; or (l) Proceedings. The indictment of any Loan Party or any of its Subsidiaries under any criminal statute, or commencement of criminal or civil proceedings against any Loan Party or any of its Subsidiaries pursuant to which statute or proceedings the penalties or remedies sought or available include forfeiture to any Governmental Authority of any material portion of the property of such Person; or (m) ERISA. The occurrence of any ERISA Event which, individually or in the aggregate, has resulted or could reasonably be expected to result in a Material Adverse Effect; or (n) Material Contracts. The occurrence of a default, event of default, termination event or an event identified in any Material Contract, in each case, that could give rise to a termination of such Material Contract occurs; provided that if such default, event of default, termination event or similar event can be cured, or if any grace period applies with respect thereto (regardless of whether such event can be cured), then no Event of Default shall occur pursuant to this clause (n), unless such default, event of default, termination event or similar event remains uncured on the date that is [***] prior to the end of any specified cure period or the applicable grace period provided under such Material Contract, and provided Â - 123Â - Â | Â further, that if the applicable Loan Party is contesting such default, event of default, termination event or similar event and as a result of such contest, as evidenced by such Loan Partyâ€™s written certification to Administrative Agent, such Loan Party believes that such Material Contract cannot be validly terminated as a result of such purported default, event of default, or event, Administrative Agent will give due regard to any such evidence and analysis in exercising its good faith judgment in determining, in its sole discretion, whether or not an Event of Default shall have occurred pursuant to this clause (n); provided, further, that in the case of any Permitted Equity Derivative a Loan Party is the âœœDefaulting Partyâœ or âœœAffected Partyâœ (each howsoever defined); or (o) Regulatory Event. At any time, either (i) U.S. marketing approval of the Core Product at such time is suspended pursuant to Section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Â§ 355(e)) on a finding that there is an imminent hazard to the public health, or (ii) the Borrower or any of its Affiliates receives a notification from FDA under Section 505(e) and 21 C.F.R. Â§ 314.150 that FDA intends to withdraw U.S. marketing approval of the Core Product or such notification is published in the Federal Register (each, a âœœRegulatory Withdrawal Noticeâœ) and that, notwithstanding the Borrowerâ€™s opportunity to request a hearing or otherwise oppose FDAâ€™s actions, such Regulatory Withdrawal Notice is reasonably likely to result in the FDAâ€™s withdrawal of U.S. marketing approval for such Core Product (as determined by an independent third party regulatory expert selected by Administrative Agent and reasonably acceptable to Borrower pursuant to the procedure set forth below) (upon the occurrence of the events described in either clause (i) or (ii) above, such Core Product shall be an âœœAffected Productâœ); [***]. [***]. Section 8.2 Remedies. Upon the occurrence and during the continuance of any Event of Default, Administrative Agent may, and shall at the request of the Required Lenders: (a) declare that all or any portion of the Term Loan Commitments (if any) shall immediately terminate and the unpaid principal amount of all outstanding Term Loans, all interest accrued and unpaid thereon, and all other amounts owing or payable hereunder or under any other Loan Document to be immediately due and payable; without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived by each Loan Party; and/or (b) exercise on behalf of itself and the Lenders all rights and remedies available to it and the Lenders under the Loan Documents or applicable law or in equity or under any other instrument, document or agreement now existing or hereafter arising; provided, that upon the occurrence of any event specified in Section 8.1(f) or (g) above, the unpaid principal amount of all outstanding Term Loans and all interest and other amounts as aforesaid shall automatically become due and payable without further act of Administrative Agent or any Lender. Section 8.3 Rights Not Exclusive. The rights provided for in this Agreement and the other Loan Documents are cumulative and are not exclusive of any other rights, powers, privileges or remedies provided by law or in equity, or under any other instrument, document or agreement now existing or hereafter arising. Â - 124Â - Â | Â Article IXADMINISTRATIVE AGENT Section 9.1 Appointment of Administrative Agent. (a) Blue Owl is hereby appointed Administrative Agent hereunder and under the other Loan Documents and each Lender hereby authorizes Blue Owl, in such capacity, to act as its agent in accordance with the terms hereof and the other Loan Documents to perform, exercise and enforce any and all other rights and remedies of the Lenders with respect to the Loan Parties, the Obligations or otherwise related to any of same to the extent reasonably incidental to the exercise by Administrative Agent of the rights and remedies specifically authorized to be exercised by Administrative Agent by the terms of this Agreement or any other Loan Parties. (b) In relation to any Liens over Collateral granted under the Collateral Documents (Swiss): (i) Administrative Agent shall hold: (A) any Lien created or expressed to be created under or pursuant to a Collateral Document (Swiss) by way of a security assignment (Sicherungsabtretung) or transfer for security purposes (SicherungsÂ/bereingung) or any other non-accessory (nicht akzessorische) Lien; (B) the benefit of this paragraph; and (C) any proceeds and other benefits of such Lien, in its own name and for the benefit of all Secured Parties which have the benefit of such Lien in accordance with this Agreement and the respective Collateral Document (Swiss); (ii) each Secured Party (other than Administrative Agent) hereby directs and authorizes Administrative Agent: (A) to (I) accept and execute as its direct representative (direkter Stellvertreter) any Swiss law pledge or any other Swiss law accessory (akzessorische) security created or expressed to be created under or pursuant to a Collateral Document (Swiss) for the benefit and/or in the name and for the account of such Secured Party and (II) hold, administer and, if necessary, enforce any such Lien in the name and for the account of each relevant Secured Party which has the benefit of such Lien; (B) to agree as its direct representative (direkter Stellvertreter) to amendments and alterations to any Collateral Document (Swiss) which creates a pledge or any other Swiss law accessory (akzessorische) Lien; (C) to effect as its direct representative (direkter Stellvertreter) any release of Lien created under a Collateral Document (Swiss) in accordance with this Agreement; and Â - 125Â - Â | Â (D) to exercise as its direct representative (direkter Stellvertreter) such other rights granted to Administrative Agent under this Agreement or under the relevant Collateral Document (Swiss); and (iii) each Secured Party (other than Administrative Agent) hereby directs and authorizes Administrative Agent to hold: (A) any Swiss law pledge or any other Swiss law accessory (akzessorische) Lien; (B) the benefit of this paragraph; and (C) any proceeds of such Lien, as creditor in its own right but in the name and for the account of such Secured Parties in accordance with this Agreement and the respective Collateral Document (Swiss). (iv) Each of the Loan Parties and the Secured Parties shall release and hereby releases Administrative Agent from the restrictions of representing several parties (Doppel-/Mehrfachvertretung) or engaging in self-dealing (InsichgeschÂft) and similar restrictions under any applicable law, in each case to the extent legally possible for such Loan Party or Secured Party. Any Loan Party or Secured Party prevented by applicable law or its constitutional documents to grant the release from the restrictions of representing several parties (Doppel-/Mehrfachvertretung) or engaging in self-dealing (Selbstkontrahieren) shall notify Administrative Agent without undue delay. (c) Administrative Agent hereby agrees to act upon the express conditions contained herein and the other Loan Documents, as applicable. The provisions of this Article IX are solely for the benefit of Administrative Agent and Lenders and no Loan Party shall have any rights as a third party beneficiary of any of the provisions thereof. In performing its functions and duties hereunder, Administrative Agent shall act solely as an agent of Lenders and does not assume and shall not be deemed to have assumed any obligation towards or relationship of agency or trust with or for the Borrower or any of its Subsidiaries. Section 9.2 Powers and Duties. Each Lender irrevocably authorizes Administrative Agent to take such action on such Lenderâ€™s behalf and to exercise such powers, rights and remedies hereunder and under the other Loan Documents as are specifically delegated or granted to Administrative Agent by the terms hereof and thereof, together with such powers, rights and remedies as are reasonably incidental thereto. Administrative Agent shall have only those duties and responsibilities that are expressly specified herein and the other Loan Documents. Administrative Agent may exercise such powers, rights and remedies and perform such duties by or through its agents or employees Administrative Agent shall not have, by reason hereof or any of the other Loan Documents, a fiduciary relationship in respect of any Lender; and nothing herein or any of the other Loan Documents, expressed or implied, is intended to or shall be so construed as to impose upon Administrative Agent any obligations in respect hereof or any of the other Loan Documents except as expressly set forth herein or therein. Section 9.3 General Immunity. (a) No Responsibility for Certain Matters. Administrative Agent shall not be responsible to any Lender for the execution, effectiveness, genuineness, validity, enforceability, collectability or sufficiency hereof or any other Loan Document or for any representations, warranties, recitals or statements made herein or therein or made in any written or oral statements or in any financial Â - 126Â - Â | Â or other statements, instruments, reports or certificates or any other documents furnished or made by Administrative Agent to Lenders or by or on behalf of any Loan Party to Administrative Agent or any Lender in connection with the Loan Documents and the transactions contemplated thereby or for the financial condition or business affairs of any Loan Party or any other Person liable for the payment of any Obligations, nor shall Administrative Agent be required to ascertain or inquire as to the performance or observance of any of the terms, conditions, provisions, covenants or agreements contained in any of the Loan Documents or as to the use of the proceeds of the Loans or as to the existence or possible existence of any Event of Default or Default or to make any disclosures with respect to the foregoing. Anything contained herein to the contrary notwithstanding, Administrative Agent shall not have any liability arising from confirmations of the amount of outstanding Term Loans or the component amounts thereof. (b) Exculpatory Provisions. Neither Administrative Agent nor any of its officers, partners, directors, employees or agents shall be liable to Lenders for any action taken or omitted by Administrative Agent under or in connection with any of the Loan Documents except to the extent caused by Administrative Agentâ€™s gross negligence or willful misconduct, as determined by a court of competent jurisdiction in a final, non-applicable order. Administrative Agent shall be entitled to refrain from any act or the taking of any action (including the failure to take an action) in connection herewith or any of the other Loan Documents or from the exercise of any power, discretion or authority vested in it hereunder or thereunder unless and until Administrative Agent shall have received instructions in respect thereof from Required Lenders (or such other Lenders as may be required to give such instructions under Section 10.5) and, upon receipt of such instructions from Required Lenders (or such other Lenders, as the case may be), Administrative Agent shall be entitled to act or (where so instructed) refrain from acting, or to exercise such power, discretion or authority, in accordance with such instructions. Without prejudice to the generality of the foregoing, (i) Administrative Agent shall be entitled to rely, and shall be fully protected in relying, upon any communication, instrument or document believed by it to be genuine and correct and to have been signed or sent

by the proper Person or Persons, and shall be entitled to rely and shall be protected in relying on opinions and judgments of attorneys (who may be attorneys for the Borrower and its Subsidiaries), accountants, experts and other professional advisors selected by it; and (ii) no Lender shall have any right of action whatsoever against Administrative Agent as a result of Administrative Agent acting or (where so instructed) refraining from acting hereunder or any of the other Loan Documents in accordance with the instructions of Required Lenders (or such other Lenders as may be required to give such instructions under Section 10.5). (c) Notice of Default. Administrative Agent shall not be deemed to have knowledge or notice of the occurrence of any Default or Event of Default, except with respect to Events of Default in the payment of principal, interest and fees required to be paid to Administrative Agent for the account of the Lenders, unless Administrative Agent shall have received written notice from a Lender or the Loan Party referring to this Agreement, describing such Default or Event of Default and stating that such notice is a "notice of default." Administrative Agent will notify the Lenders of its receipt of any such notice. Administrative Agent shall take such action with respect to any such Default or Event of Default as may be directed by the Required Lenders in accordance with Article VII; provided, however, that unless and until Administrative Agent has received any such direction, Administrative Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Default or Event of Default as it shall deem advisable or in the best interest of the Lenders. Section 9.4 Administrative Agent Entitled to Act as Lender. The agency hereby created shall in no way impair or affect any of the rights and powers of, or impose any duties or obligations upon, Administrative Agent in its individual capacity as a Lender hereunder. With respect to its participation in the Term Loans, Administrative Agent shall have the same rights and powers hereunder as any other Lender and may exercise the same as if it were not performing the duties and functions delegated to it hereunder, and the term "Lender" shall, unless the context clearly otherwise indicates, include Administrative Agent - 127A - A | A in its individual capacity. Administrative Agent and its Affiliates may accept deposits from, lend money to, own securities of, and generally engage in any kind of banking, trust, financial advisory or other business with the Borrower or any of its Affiliates as if it were not performing the duties specified herein, and may accept fees and other consideration from Borrower for services in connection herewith and otherwise without having to account for the same to Lenders. Section 9.5 Lenders' Representations, Warranties and Acknowledgment. (a) Each Lender represents and warrants that it has made its own independent investigation of the financial condition and affairs of the Borrower and its Subsidiaries in connection with Credit Extensions hereunder and that it has made and shall continue to make its own appraisal of the creditworthiness of the Borrower and its Subsidiaries. Administrative Agent shall not have any duty or responsibility, either initially or on a continuing basis, to make any such investigation or any such appraisal on behalf of Lenders or to provide any Lender with any credit or other information with respect thereto, whether coming into its possession before the making of the Term Loans or at any time or times thereafter, and Administrative Agent shall not have any responsibility with respect to the accuracy of or the completeness of any information provided to Lenders. (b) Each Lender, by delivering its signature page to this Agreement and funding its Term Loan on the Closing Date, shall be deemed to have acknowledged receipt of, and consented to and approved, each Loan Document and each other document required to be approved by Administrative Agent, Required Lenders or Lenders, as applicable on the Closing Date. Section 9.6 Right to Indemnify. EACH LENDER, IN PROPORTION TO ITS PRO RATA SHARE, SEVERALLY AGREES TO INDEMNIFY ADMINISTRATIVE AGENT, ITS AFFILIATES AND ITS RESPECTIVE OFFICERS, PARTNERS, DIRECTORS, TRUSTEES, EMPLOYEES AND AGENTS OF ADMINISTRATIVE AGENT (EACH, AN "INDEMNITEE AGENT PARTY"), TO THE EXTENT THAT SUCH INDEMNITEE AGENT PARTY SHALL NOT HAVE BEEN REIMBURSED BY ANY LOAN PARTY, FOR AND AGAINST ANY AND ALL LIABILITIES, OBLIGATIONS, LOSSES, DAMAGES, PENALTIES, ACTIONS, JUDGMENTS, SUITS, COSTS, EXPENSES (INCLUDING COUNSEL FEES AND DISBURSEMENTS) OR DISBURSEMENTS OF ANY KIND OR NATURE WHATSOEVER WHICH MAY BE IMPOSED ON, INCURRED BY OR ASSERTED AGAINST SUCH INDEMNITEE AGENT PARTY IN EXERCISING ITS POWERS, RIGHTS AND REMEDIES OR PERFORMING ITS DUTIES HEREUNDER OR UNDER THE OTHER LOAN DOCUMENTS OR OTHERWISE IN ITS CAPACITY AS SUCH INDEMNITEE AGENT PARTY IN ANY WAY RELATING TO OR ARISING OUT OF THIS AGREEMENT OR THE OTHER LOAN DOCUMENTS, IN ALL CASES, WHETHER OR NOT CAUSED BY OR ARISING, IN WHOLE OR IN PART, OUT OF THE COMPARATIVE, CONTRIBUTORY, OR SOLE NEGLIGENCE OF SUCH INDEMNITEE AGENT PARTY; PROVIDED, NO LENDER SHALL BE LIABLE FOR ANY PORTION OF SUCH LIABILITIES, OBLIGATIONS, LOSSES, DAMAGES, PENALTIES, ACTIONS, JUDGMENTS, SUITS, COSTS, EXPENSES OR DISBURSEMENTS RESULTING FROM SUCH INDEMNITEE AGENT PARTY'S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, AS DETERMINED BY A COURT OF COMPETENT JURISDICTION IN A FINAL, NON-APPEALABLE ORDER. IF ANY INDEMNITY FURNISHED TO ANY INDEMNITEE AGENT PARTY FOR ANY PURPOSE SHALL, IN THE OPINION OF SUCH INDEMNITEE AGENT PARTY, BE INSUFFICIENT OR BECOME IMPAIRED, SUCH INDEMNITEE AGENT PARTY MAY CALL FOR ADDITIONAL INDEMNITY AND CEASE, OR NOT COMMENCE, TO DO THE ACTS INDEMNIFIED AGAINST UNTIL SUCH ADDITIONAL INDEMNITY IS FURNISHED; PROVIDED, IN NO EVENT SHALL THIS SENTENCE REQUIRE ANY LENDER TO INDEMNIFY ANY INDEMNITEE AGENT PARTY AGAINST ANY LIABILITY, OBLIGATION, LOSS, DAMAGE, PENALTY, ACTION, JUDGMENT, SUIT, COST, EXPENSE OR DISBURSEMENT IN EXCESS OF SUCH LENDER'S PRO RATA SHARE - 128A - A | A THEREOF; AND PROVIDED FURTHER, THIS SENTENCE SHALL NOT BE DEEMED TO REQUIRE ANY LENDER TO INDEMNIFY ANY INDEMNITEE AGENT PARTY AGAINST ANY LIABILITY, OBLIGATION, LOSS, DAMAGE, PENALTY, ACTION, JUDGMENT, SUIT, COST, EXPENSE OR DISBURSEMENT DESCRIBED IN THE PROVISIO IN THE IMMEDIATELY PRECEDING SENTENCE. Section 9.7 Successor Administrative Agent. (a) Administrative Agent may resign at any time by giving thirty days' (or such shorter period as shall be agreed by the Required Lenders) prior written notice thereof to Lenders and Borrower. Upon any such notice of resignation, Required Lenders shall have the right, upon five Business Days' notice to Borrower, to appoint a successor Administrative Agent. If no successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may, on behalf of the Lenders appoint a successor Administrative Agent from among the Lenders. Upon the acceptance of any appointment as Administrative Agent hereunder by a successor Administrative Agent that successor Administrative Agent shall thereupon succeed to and become vested with all the rights, powers, privileges and duties of the retiring Administrative Agent, and the retiring Administrative Agent shall promptly (i) transfer to such successor Administrative Agent all sums, securities or Capital Stock and other items of Collateral held under the Collateral Documents, together with all records and other documents necessary or appropriate in connection with the performance of the duties of the successor Administrative Agent under the Loan Documents, and (ii) execute and deliver to such successor Administrative Agent such amendments to financing statements, and take such other actions, as may be necessary or appropriate in connection with the assignment to such successor Administrative Agent of the security interests created under the Collateral Documents, whereupon such retiring Administrative Agent shall be discharged from its duties and obligations hereunder. After any retiring Administrative Agent's resignation hereunder as Administrative Agent, the provisions of this Article IX shall inure to its benefit as to any actions taken or omitted to be taken by it while it was Administrative Agent hereunder. (b) Notwithstanding anything herein to the contrary, Administrative Agent may assign its rights and duties as Administrative Agent, as applicable, hereunder to an Affiliate of Blue Owl without the prior written consent of, or prior written notice to, Borrower or the Lenders; provided that Borrower and the Lenders may deem and treat such assigning Administrative Agent as Administrative Agent for all purposes hereof, unless and until such assigning Administrative Agent provides written notice to Borrower and the Lenders of such assignment. Upon such assignment such Affiliate shall succeed to and become vested with all rights, powers, privileges and duties as Administrative Agent hereunder and under the other Loan Documents. (c) Administrative Agent may perform any and all of its duties and exercise its rights and powers under this Agreement or under any other Loan Document by or through any one or more sub-agents appointed by Administrative Agent. Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Affiliates. The exculpatory, indemnification and other provisions of Section 9.3, Section 9.6 and of this Section 9.7 shall apply to any of the Affiliates of Administrative Agent and shall apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent. All of the rights, benefits and privileges (including the exculpatory and indemnification provisions) of Section 9.3, Section 9.6 and of this Section 9.7 shall apply to any such sub-agent and to the Affiliates of any such sub-agent, and shall apply to their respective activities as sub-agent as if such sub-agent and Affiliates were named herein. Notwithstanding anything herein to the contrary, with respect to each sub-agent appointed by Administrative Agent, (i) such sub-agent shall be a third party beneficiary under this Agreement with respect to all such rights, benefits and privileges (including - 129A - A | A exculpatory and rights to indemnification) and shall have all of the rights, benefits and privileges of a third party beneficiary, including an independent right of action to enforce such rights, benefits and privileges (including exculpatory rights and rights to indemnification) directly, without the consent or joinder of any other Person, against any or all of the Loan Parties and the Lenders, (ii) such rights, benefits and privileges (including exculpatory rights and rights to indemnification) shall not be modified or amended without the consent of such sub-agent, and (iii) such sub-agent shall only have obligations to Administrative Agent and not to any Loan Party, Lender or any other Person and no Loan Party, Lender or any other Person shall have the rights, directly or indirectly, as a third party beneficiary or otherwise, against such sub-agent. Section 9.8 Collateral Documents and Guaranty. (a) Administrative Agent under Collateral Documents and Guaranty. Each Lender hereby further authorizes Administrative Agent on behalf of and for the benefit of Lenders, to be the agent for and representative of Lenders with respect to the Guaranty, the Collateral and the Collateral Documents. Subject to Section 10.5, without further written consent or authorization from Lenders, Administrative Agent may execute any documents or instruments necessary to (i) release any Lien encumbering any item of Collateral that is the subject of a sale or other disposition of assets permitted hereby or to which Required Lenders (or such other Lenders as may be required to give such consent under Section 10.5) have otherwise consented, (ii) enter into customary non-disturbance or similar agreements in connection with the licensing of Intellectual Property expressly permitted pursuant to this Agreement to the extent reasonably requested by any Loan Party, subject to documentation to be reasonably acceptable to Administrative Agent, or (iii) release any Guarantor from the Guaranty pursuant to Section 7.12 or with respect to which Required Lenders (or such other Lenders as may be required to give such consent under Section 10.5) have otherwise consented. (b) Right to Realize on Collateral and Enforce Guaranty. Anything contained in any of the Loan Documents to the contrary notwithstanding, Borrower, Administrative Agent and each Lender hereby agree that (i) no Lender shall have any right individually to realize upon any of the Collateral or to enforce the Guaranty, it being understood and agreed that all powers, rights and remedies hereunder may be exercised solely by Administrative Agent, on behalf of Lenders in accordance with the terms hereof and all powers, rights and remedies under the Collateral Documents may be exercised solely by Administrative Agent, and (ii) in the event of a foreclosure by Administrative Agent on any of the Collateral pursuant to a public or private sale or any sale of the Collateral in a case under the Bankruptcy Code, Administrative Agent or any Lender may be the purchaser of any or all of such Collateral at any such sale and Administrative Agent, as agent for and representative of Secured Parties (but not any Lender or Lenders in its or their respective individual capacities unless Required Lenders shall otherwise agree in writing) shall be entitled, for the purpose of bidding and making settlement or payment of the purchase price for all or any portion of the Collateral sold at any such public sale, to use and apply any of the Obligations as a credit on account of the purchase price for any collateral payable by Administrative Agent at such sale. Section 9.9 Agency for Perfection. Administrative Agent and each Lender hereby appoints each other Lender as agent and bailee for the purpose of perfection the security interests in and liens upon the Collateral in assets which, in accordance with Article 9 of the UCC, can be perfected only by possession or control (or where the security interest of a secured party with possession or control has priority over the security interest of another secured party) and Administrative Agent and each Lender hereby acknowledges that it holds possession of or otherwise controls any such Collateral for the benefit of the Lenders as secured party. Should any Lender obtain possession or control of any such Collateral, such Lender shall notify Administrative Agent thereof, and, promptly upon Administrative Agent's request therefore shall deliver such Collateral to Administrative Agent or in accordance with Administrative Agent's instructions. In addition, Administrative Agent shall also have the power and authority hereunder to appoint such other sub-agents as may be necessary or required under applicable state law or otherwise to perform its duties - 130A - A | A and enforce its rights with respect to the Collateral and under the Loan Documents. Each Loan Party by its execution and delivery of this Agreement hereby consents to the foregoing. Section 9.10 Reports and Other Information; Confidentiality; Disclaimers. By becoming a party to this Agreement, each Lender: (a) is deemed to have requested that Administrative Agent furnish such Lender or Administrative Agent, promptly after it becomes available, a copy of each field audit or examination report with respect to the Borrower or its Subsidiaries (each a "Report" and collectively, "Reports") prepared by or at the request of Administrative Agent, and Administrative Agent shall so furnish each Lender with such Reports, (b) expressly agrees and acknowledges that Administrative Agent does not (i) make any representation or warranty as to the accuracy of any Report, and (ii) shall not be liable for any information contained in any Report, (c) expressly agrees and acknowledges that the Reports are not comprehensive audits or examinations, that Administrative Agent or other party performing any audit or examination will inspect only specific information regarding the Borrower and its Subsidiaries and will rely significantly upon the Borrower's and its Subsidiaries' books and records, as well as on representations of such Person's personnel, (d) agrees to keep all Reports and other material, non-public information regarding the Borrower and its Subsidiaries and their operations, assets, and existing and contemplated business plans in a confidential manner in accordance with Section 10.17, and (e) without limiting the generality of any other indemnification provision contained in this Agreement, agrees: (i) to hold Administrative Agent and any other Lender preparing a Report harmless from any action the indemnifying Lender may take or fail to take or any conclusion the indemnifying Lender may reach or draw from any Report in connection with any loans or other credit accommodations that the indemnifying Lender has made or may make to Borrower, or the indemnifying Lender's participation in, or the indemnifying Lender's purchase of, a loan or loans of a Borrower, and (ii) to pay and protect, and indemnify, defend and hold Administrative Agent, and any such other Lender preparing a Report harmless from and against, the claims, actions, proceedings, damages, costs, expenses, and other amounts (including, attorneys' fees and costs) incurred by Administrative Agent and any such other Lender or agent preparing a Report as the direct or indirect result of any third parties who might obtain all or part of any Report through the indemnifying Lender or Administrative Agent. In addition to the foregoing: (x) any Lender may from time to time request of Administrative Agent in writing that Administrative Agent provide to such Lender a copy of any report or document provided by the Borrower or its Subsidiaries to Administrative Agent that has not been contemporaneously provided by the Borrower or such Subsidiary to such Lender, and, upon receipt of such request, Administrative Agent promptly shall provide a copy of same to such Lender, (y) to the extent that Administrative Agent is entitled, under any provision of the Loan Documents, to request additional reports or information from the Borrower or its Subsidiaries, any Lender may, from time to time, reasonably request Administrative Agent to exercise such right as specified in such Lender's notice to Administrative Agent, whereupon Administrative Agent promptly shall request of Borrower the additional reports or information reasonably specified by such Lender, and, upon receipt thereof from Borrower or such Subsidiary, Administrative Agent promptly shall provide a copy of same to such Lender, and (z) any time that Administrative Agent renders to Borrower a statement regarding the Loan Account, Administrative Agent shall send a copy of such statement to each Lender. - 131A - A | A Section 9.11 Protective Advances. Subject to the limitations set forth below, upon the occurrence and during the continuance of Event of Default, Administrative Agent is authorized by Borrower and the Lenders, from time to time in Administrative Agent's sole discretion (but Administrative Agent shall have absolutely no obligation to), to make disbursements or advances to Borrower, which the Administrative Agent, in its sole discretion, deems necessary or desirable (i) to preserve or protect the Collateral, or any portion thereof, (ii) to enhance the likelihood of, or maximize the amount of, repayment of the Loans and other Obligations, or (iii) to pay any other amount chargeable to or required to be paid by Borrower pursuant to the terms of this Agreement and the other Loan Documents, including, without limitation, payments of principal, interest, fees and reimbursable expenses (any of such Loans are in this clause (c) referred to as "Protective Advances"). Protective Advances may be made even if the conditions precedent set forth in Article III have not been satisfied. The interest rate on all Protective Advances shall be at the Base Rate plus the Applicable Margin. Each Protective Advance shall be secured by the Liens in favor of the Administrative Agent in and to the Collateral and shall constitute Obligations hereunder. The Protective Advances shall constitute Obligations hereunder which may be charged to the Loan Account in accordance with Section 2.12(i). Borrower shall pay the unpaid principal amount and all unpaid and accrued interest of each Protective Advance on the earlier of the Term Loan Maturity Date and the date on which demand for payment is made by Administrative Agent. Administrative Agent shall notify each Lender and Borrower in writing in advance of each such Protective Advance, which notice shall include a description of the purpose of such Protective Advance. Without limitation to its obligations pursuant to Section 9.6, each Lender agrees that it shall make available to Administrative Agent, upon the Administrative Agent's demand, in Dollars in immediately available funds, the amount equal to such Lender's Pro Rata Share of each such Protective Advance. If such funds are not made available to Administrative Agent by such Lender, Administrative Agent shall be entitled to recover such funds on demand from such Lender, together with interest thereon for each day from the date such payment was due until the date such amount is paid to Administrative Agent, at the Federal Funds Rate for three (3)

Business Days and thereafter at the Base Rate. Section 9.12 Erroneous Payments. (a) If Administrative Agent (x) notifies a Lender or any Person who has received funds on behalf of a Lender (any such Lender or other recipient (and each of their respective successors and assigns), a "Payment Recipient") that Administrative Agent has determined in its sole discretion (whether or not after receipt of any notice under immediately succeeding clause (b)) that any funds (as set forth in such notice from Administrative Agent) received by such Payment Recipient from Administrative Agent or any of its Affiliates were erroneously or mistakenly transmitted to, or otherwise erroneously or mistakenly received by, such Payment Recipient (whether or not known to such Lender or other Payment Recipient on its behalf) (any such funds, whether transmitted or received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise, individually and collectively, an "Erroneous Payment") and (y) demands in writing the return of such Erroneous Payment (or a portion thereof), such Erroneous Payment shall at all times remain the property of Administrative Agent pending its return or repayment as contemplated below in this Section 9.12 and held in trust for the benefit of Administrative Agent, and such Lender shall (or, with respect to any Payment Recipient who received such funds on its behalf, shall cause such Payment Recipient to) promptly, but in no event later than [***] thereafter (or such later date as Administrative Agent may, in its sole discretion, specify in writing), return to Administrative Agent the amount of any such Erroneous Payment (or portion thereof) as to which such a demand was made, in same day funds (in the currency so received), together with interest thereon (except to the extent waived in writing by the Administrative Agent) in respect of each day from and including the date such Erroneous Payment (or portion thereof) was received by such Payment Recipient to the date such amount is repaid to the Administrative Agent in same day funds at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank - 132A - A | A compensation from time to time in effect. A notice of Administrative Agent to any Payment Recipient under this clause (a) shall be conclusive, absent manifest error. (b) Without limiting immediately preceding clause (a), each Lender or any Person who has received funds on behalf of a Lender (and each of their respective successors and assigns), agrees that if it receives a payment, prepayment or repayment (whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise) from the Administrative Agent (or any of its Affiliates) (x) that is in a different amount than, or on a different date from, that specified in this Agreement or in a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates) with respect to such payment, prepayment or repayment, (y) that was not preceded or accompanied by a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates), or (z) that such Lender or other such recipient, otherwise becomes aware was transmitted, or received, in error or by mistake (in whole or in part), then in each such case: (i) it acknowledges and agrees that (A) in the case of immediately preceding clauses (x) or (y), an error and mistake shall be presumed to have been made (absent written confirmation from Administrative Agent to the contrary) or (B) an error and mistake has been made (in the case of immediately preceding clause (z)), in each case, with respect to such payment, prepayment or repayment; and (ii) such Lender shall (and shall use commercially reasonable efforts to cause any other recipient that receives funds on its respective behalf to) promptly (and, in all events, within [***] of its knowledge of the occurrence of any of the circumstances described in immediately preceding clauses (x), (y) and (z)) notify Administrative Agent of its receipt of such payment, prepayment or repayment, the details thereof (in reasonable detail) and that it is so notifying Administrative Agent pursuant to this Section 9.12(b). For the avoidance of doubt, the failure to deliver a notice to Administrative Agent pursuant to this Section 9.12(b) shall not have any effect on a Payment Recipient's obligations pursuant to Section 9.12(a) or on whether or not an Erroneous Payment has been made. (c) Each Lender hereby authorizes Administrative Agent to set off, net and apply any and all amounts at any time owing to such Lender under any Loan Document, or otherwise payable or distributable by Administrative Agent to such Lender under any Loan Document with respect to any payment of principal, interest, fees or other amounts, against any amount that Administrative Agent has demanded to be returned under immediately preceding clause (a). (d) The parties hereto agree that (x) irrespective of whether Administrative Agent may be equitably subrogated, in the event that an Erroneous Payment (or portion thereof) is not recovered from any Payment Recipient that has received such Erroneous Payment (or portion thereof) for any reason, the Administrative Agent shall be subrogated to all the rights and interests of such Payment Recipient (and, in the case of any Payment Recipient who has received funds on behalf of a Lender, to the rights and interests of such Lender, as the case may be) under the Loan Documents with respect to such amount (the "Erroneous Payment Subrogation Rights") and (y) an Erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any Obligations owed by the Borrower; provided that this Section 9.12 shall not be interpreted to increase (or accelerate the due date for), or have the effect of increasing (or accelerating the due date for), the Obligations of the Borrower relative to the amount (or timing for payment) of the Obligations that would have been payable had such Erroneous Payment not been made by Administrative Agent; provided, further, that for the avoidance of doubt, immediately preceding clauses (x) and (y) shall not apply to the extent any such Erroneous Payment is, and solely with respect to the amount of such Erroneous Payment that is, comprised of funds received by Administrative Agent from, or on behalf of A - 133A - A | A (including through the exercise of remedies under any Loan Document), the Borrower for the purpose of a payment on the Obligations. (e) To the extent permitted by applicable law, no Payment Recipient shall assert any right or claim to an Erroneous Payment, and hereby waives, and is deemed to waive, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by Administrative Agent for the return of any Erroneous Payment received, including, without limitation, any defense based on "discharge for value" or any similar doctrine. Each party's obligations, agreements and waivers under this Section 9.12 shall survive the resignation or replacement of Administrative Agent, any transfer of rights or obligations by, or the replacement of, a Lender, or the repayment, satisfaction or discharge of all Obligations (or any portion thereof) under any Loan Document Section 9.13 Parallel Liability. In this Section 9.13, "Corresponding Liabilities" means all present and future liabilities and contractual and non-contractual obligations of Loan Party under or in connection with this Agreement and the other Loan Documents, but excluding its Parallel Liability. "Parallel Liability" means a Loan Party's undertaking pursuant to this Section 9.13. (a) Each Loan Party irrevocably and unconditionally undertakes to pay to Administrative Agent an amount equal to the aggregate amount of its Corresponding Liabilities (as these may exist from time to time). (b) The Parties agree that: (i) a Loan Party's Parallel Liability is due and payable at the same time as, for the same amount of and in the same currency as its Corresponding Liabilities; (ii) a Loan Party's Parallel Liability is decreased to the extent that its Corresponding Liabilities have been irrevocably paid or discharged and its Corresponding Liabilities are decreased to the extent that its Parallel Liability has been irrevocably paid or discharged; (iii) a Loan Party's Parallel Liability is independent and separate from, and without prejudice to, its Corresponding Liabilities, and constitutes a single obligation of that Loan Party to the Administrative Agent (even though that Loan Party may owe more than one Corresponding Liability to the Secured Parties under the Loan Documents) and an independent and separate claim of the Administrative Agent to receive payment of that Parallel Liability (in its capacity as the independent and separate creditor of that Parallel Liability and not as a co-creditor in respect of the Corresponding Liabilities); and (iv) for purposes of this Section 9.13, Administrative Agent acts in its own name and not as agent, representative or trustee of the Secured Parties and accordingly holds neither its claim resulting from a Parallel Liability nor any Lien securing a Parallel Liability on trust. This Section 9.13 has been included solely for Dutch law purposes and shall be governed by, and construed in accordance with, the laws of The Netherlands. A - 134A - A | A Article XMISCELLANEOUS Section 10.1 Notices. (a) Notices Generally. Unless otherwise specifically provided herein, any notice or other communication herein required or permitted to be given to a Loan Party, Administrative Agent, shall be sent to such Person's address as set forth on Appendix B or in the other relevant Loan Document, and in the case of any Lender, the address as indicated on Appendix B or otherwise indicated to Administrative Agent in writing. Each notice hereunder shall be in writing and may be personally served, telexed or sent by facsimile or United States mail or courier service and shall be deemed to have been given when delivered in person or by courier service and signed for against receipt thereof, upon receipt of facsimile, or [***] after depositing it in the United States mail with postage prepaid and properly addressed; provided, no notice to Administrative Agent shall be effective until received by Administrative Agent. (b) Electronic Communications. (i) Administrative Agent and the Loan Parties may, in their discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it; provided that approval of such procedures may be limited to particular notices or communications. Notices and other communications to the Lenders hereunder may be delivered or furnished by electronic communication (including e-mail and Internet or intranet websites) pursuant to procedures approved by Administrative Agent, provided that the foregoing shall not apply to notices to any Lender pursuant to Article II if such Lender has notified Administrative Agent that it is incapable of receiving notices under such Article by electronic communication. (ii) Unless Administrative Agent otherwise prescribes, (A) notices and other communications sent to an e-mail address shall be deemed received upon the sender's receipt of an acknowledgement from the intended recipient (such as by the "return receipt requested" function, as available, return e-mail or other written acknowledgement), and (B) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient, at its e-mail address as described in the foregoing clause (A), of notification that such notice or communication is available and identifying the website address thereof; provided that, for both clauses (A) and (B) above, if such notice, email or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next Business Day for the recipient. Section 10.2 Expenses. Whether or not the transactions contemplated hereby shall be consummated, Borrower agree to pay promptly (a) all of Administrative Agent's actual and reasonable out-of-pocket costs and expenses of preparation, negotiation, execution and administration of the Loan Documents and any consents, amendments, waivers or other modifications thereto; (b) all the reasonable fees, expenses and disbursements of counsel to Administrative Agent in connection with the negotiation, preparation, execution and administration of the Loan Documents and any consents, amendments, waivers or other modifications thereto and any other documents or matters requested by Borrower; (c) all the actual documented costs and reasonable expenses of creating and perfecting Liens in favor of Administrative Agent, for the benefit of Secured Parties, including filing and recording fees, expenses and taxes, stamp or documentary taxes, search fees, title insurance premiums and reasonable fees, expenses and disbursements of counsel to Administrative Agent and of counsel providing any opinions that Administrative Agent or Required Lenders may request in respect of the Collateral or the Liens created pursuant to the Collateral Documents; (d) all of Administrative Agent's actual documented costs and reasonable and documented A - 135A - A | A out-of-pocket fees, expenses for, and disbursements of any of Administrative Agent's auditors, accountants, consultants or appraisers whether internal or external, and all reasonable and documented out-of-pocket attorneys' fees (including expenses and disbursements of outside counsel) incurred by Administrative Agent; (e) all the actual documented costs and reasonable and documented expenses (including the reasonable and documented out-of-pocket fees, expenses and disbursements of any appraisers, consultants, advisors and agents employed or retained by Administrative Agent and its counsel) in connection with the custody or preservation of any of the Collateral; (f) all the actual documented costs and reasonable and documented out-of-pocket expenses of Administrative Agent and Lenders in connection with the attendance at any meetings in connection with this Agreement and the other Loan Documents (including the meetings referred to in Section 5.7); (g) all other actual and reasonable costs and expenses incurred by Administrative Agent in connection with the syndication of the Loans and Term Loan Commitments and the negotiation, preparation and execution of the Loan Documents and any consents, amendments, waivers or other modifications thereto and the transactions contemplated thereby; and (h) after the occurrence and during the continuance of an Event of Default, all costs and expenses, including reasonable attorneys' fees (including expenses and disbursements of outside counsel) and costs of settlement, incurred by Administrative Agent and Lenders in enforcing any Obligations of or in collecting any payments due from any Loan Party hereunder or under the other Loan Documents by reason of such Default or Event of Default (including in connection with the sale of, collection from, or other realization upon any of the Collateral or the enforcement of the Guaranty) or in connection with any refinancing or restructuring of the credit arrangements provided hereunder in the nature of a "work out" or pursuant to any insolvency or bankruptcy cases or proceedings. Section 10.3 Indemnity. (a) IN ADDITION TO THE PAYMENT OF EXPENSES PURSUANT TO SECTION 10.2, WHETHER OR NOT THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE CONSUMMATED, EACH LOAN PARTY AGREES TO DEFEND (SUBJECT TO INDEMNITEES' SELECTION OF COUNSEL), INDEMNIFY, PAY AND HOLD HARMLESS, ADMINISTRATIVE AGENT AND LENDER, THEIR AFFILIATES AND THEIR RESPECTIVE OFFICERS, PARTNERS, DIRECTORS, TRUSTEES, EMPLOYEES AND AGENTS OF ADMINISTRATIVE AGENT AND EACH LENDER (EACH, AN "INDEMNITEE"), FROM AND AGAINST ANY AND ALL INDEMNIFIED LIABILITIES, IN ALL CASES, WHETHER OR NOT CAUSED BY OR ARISING, IN WHOLE OR IN PART, OUT OF THE COMPARATIVE, CONTRIBUTORY, OR SOLE NEGLIGENCE OF SUCH INDEMNITEE; PROVIDED, NO LOAN PARTY SHALL HAVE ANY OBLIGATION TO ANY INDEMNITEE HEREUNDER WITH RESPECT TO ANY INDEMNIFIED LIABILITIES TO THE EXTENT SUCH INDEMNIFIED LIABILITIES ARISE FROM THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, AS DETERMINED BY A COURT OF COMPETENT JURISDICTION IN A FINAL, NON-APPEALABLE ORDER, OF THAT INDEMNITEE OR ANY OF ITS AFFILIATES. TO THE EXTENT THAT THE UNDERTAKINGS TO DEFEND, INDEMNIFY, PAY AND HOLD HARMLESS SET FORTH IN THIS SECTION 10.3 MAY BE UNENFORCEABLE IN WHOLE OR IN PART BECAUSE THEY ARE VIOLATIVE OF ANY LAW OR PUBLIC POLICY, THE APPLICABLE LOAN PARTY SHALL CONTRIBUTE THE MAXIMUM PORTION THAT IT IS PERMITTED TO PAY AND SATISFY UNDER APPLICABLE LAW TO THE PAYMENT AND SATISFACTION OF ALL INDEMNIFIED LIABILITIES INCURRED BY INDEMNITEES OR ANY OF THEM. (b) To the extent permitted by applicable law, no party hereto shall assert, and each party hereto hereby waives, any claim against each other party hereto and their respective Affiliates, directors, employees, attorneys or agents, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) (whether or not the claim therefor is based on contract, tort or duty imposed by any applicable legal requirement) arising out of, in connection with, as a A - 136A - A | A result of, or in any way related to, this Agreement or any Loan Document or any agreement or instrument contemplated hereby or thereby or referred to herein or therein, the transactions contemplated hereby or thereby, any Loan or the use of the proceeds thereof or any act or omission or event occurring in connection therewith, and each party hereto hereby waives, releases and agrees not to sue upon any such claim or any such damages, whether or not accrued and whether or not known or suspected to exist in its favor. (c) This Section 10.3 shall not apply with respect to Taxes other than any Taxes that represent Indemnified Liabilities arising from any non-Tax claim. Section 10.4 Set-Off. In addition to any rights now or hereafter granted under applicable law and not by way of limitation of any such rights, upon the occurrence of any Event of Default each Lender, and their respective Affiliates is hereby authorized by each Loan Party at any time or from time to time subject to the consent of Administrative Agent (such consent not to be unreasonably withheld or delayed), without notice to any Loan Party or to any other Person (other than Administrative Agent), any such notice being hereby expressly waived, to set off and to appropriate and to apply any and all deposits (general or special, including Indebtedness evidenced by certificates of deposit, whether matured or unmatured, but not including trust accounts (in whatever currency)) and any other Indebtedness at any time held or owing by such Lender to or for the credit or the account of any Loan Party (in whatever currency) against and on account of the obligations and liabilities of any Loan Party to such Lender hereunder, the participations under the other Loan Documents, including all claims of any nature or description arising out of or connected hereto, or with any other Loan Document, irrespective of whether or not (a) such Lender shall have made any demand hereunder, (b) the principal of or the interest on the Term Loans or any other amounts due hereunder shall have become due and payable pursuant to Article II and although such obligations and liabilities, or any of them, may be contingent or unmatured or (c) such obligation or liability is owed to a branch or office of such Lender different from the branch or office holding such deposit or obligation or such Indebtedness. Section 10.5 Amendments and Waivers. (a) Required Lenders' Consent. Subject to Section 10.5(b) and 10.5(c), no amendment, modification, termination or waiver of any provision of the Loan Documents, or consent to any departure by any Loan Party therefrom, shall in any event be effective without the written consent of Administrative Agent and the Required Lenders. (b) Affected Lenders' Consent. Without the written consent of each Lender (other than a Defaulting Lender) that would be affected thereby, no amendment, modification, termination, or consent shall be effective if the effect thereof would: (i) extend the scheduled final maturity of any Loan or Note; (ii) waive, reduce or postpone any scheduled repayment; (iii) reduce the rate of interest on any Loan (other than any waiver of any increase in the interest rate applicable to any Loan pursuant to Section 2.6) or any fee payable hereunder; (iv) extend the time for payment of any such interest or fees; (v) reduce the principal amount of any Loan; (vi) amend, modify, terminate or waive any provision of this Section 10.5(b) or Section 10.5(c); A - 137A - A | A (vii) amend the definition of "Required Lenders" or "Pro Rata Share"; (viii) release all or substantially all of the Collateral or all or substantially all of the Guarantors from the Guaranty except as expressly provided in the Loan Documents; (ix) subordinate any of the Obligations or any Lien created by this Agreement or any other Loan Document; or (x) consent to the assignment or transfer by any Loan Party of any of its rights and obligations under any Loan Document. (c) Other Consents. No amendment, modification, termination or waiver of any provision of the Loan Documents, or consent to any departure by any Loan Party therefrom, shall amend, modify, terminate or waive any provision of Article IX as the same applies to Administrative Agent, or any other provision hereof as the same applies to the rights or obligations of Administrative Agent, in each case without the consent of Administrative Agent. (d) Execution of Amendments, Etc. Administrative Agent may, but

shall have no obligation to, with the consent of any Lender, execute amendments, modifications, waivers or consents on behalf of such Lender. Any waiver or consent shall be effective only in the specific instance and for the specific purpose for which it was given. No notice to or demand on any Loan Party in any case shall entitle any Loan Party to any other or further notice or demand in similar or other circumstances. Any amendment, modification, termination, waiver or consent effected in accordance with this Section 10.5 shall be binding upon each Lender at the time outstanding, each future Lender and, if signed by a Loan Party, on such Loan Party. Section 10.6 Successors and Assigns; Participations. (a) Generally. This Agreement shall be binding upon the parties hereto and their respective successors and assigns and shall inure to the benefit of the parties hereto and the successors and assigns of Lenders. No Loan Partyâ€™s rights or obligations hereunder nor any interest therein may be assigned or delegated by any Loan Party without the prior written consent of all Lenders. Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, Indemnatee Agent Parties under Section 9.6, Indemnitees under Section 10.3, their respective successors and assigns permitted hereby and, to the extent expressly contemplated hereby, Affiliates of each of Administrative Agent and Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement. (b) Register. Borrower, Administrative Agent and Lenders shall deem and treat the Persons listed as Lenders in the Register as the holders and owners of the corresponding Term Loan Commitments and Loans listed therein for all purposes hereof, and no assignment or transfer of any such Term Loan Commitment or Loan shall be effective, in each case, unless and until an Assignment Agreement effecting the assignment or transfer thereof shall have been delivered to and accepted by Administrative Agent and recorded in the Register as provided in Section 10.6(e). Prior to such recordation, all amounts owed with respect to the applicable Term Loan Commitment or Loan shall be owed to the Lender listed in the Register as the owner thereof, and any request, authority or consent of any Person who, at the time of making such request or giving such authority or consent, is listed in the Register as a Lender shall be conclusive and binding on any subsequent holder, assignee or transferee of the corresponding Term Loan Commitments or Loans. Â - 138Â - Â | Â (c) Right to Assign. Each Lender shall have the right at any time to sell, assign or transfer all or a portion of its rights and obligations under this Agreement, including, without limitation, all or a portion of its Term Loan Commitment or Loans owing to it or other Obligations (provided, however, that each such assignment shall be of a uniform, and not varying, percentage of all rights and obligations under and in respect of any Loan and any related Term Loan Commitments): (i) to any Person (other than a Disqualified Institution) meeting the criteria of clause (a) or clause (c) of the definition of the term â€œEligible Assigneeâ€ upon the giving of notice to Borrower and Administrative Agent; (ii) to any Person (other than a Disqualified Institution) otherwise constituting an Eligible Assignee, so long as [***], with the consent of Administrative Agent and upon giving notice to the Borrower; (iii) to any Person otherwise constituting an Eligible Assignee, [***], with the consent of the Borrower (which shall not be unreasonably withheld, delayed or conditioned and if Borrower shall not have responded in writing within [***] after receipt of written notice of the proposed assignment, Borrower shall be deemed to have approved such assignment) and Administrative Agent; and (iv) if an Event of Default as occurred and is continuing, to any other Person constituting an Eligible Assignee, with the consent of Administrative Agent; provided, that each assignment pursuant to Section 10.6(c)(ii) and (iii) shall be in an aggregate amount of not less than \$[***] (or such lesser amount as may be agreed to by Borrower and Administrative Agent). (d) Mechanics. The assigning Lender and the assignee thereof shall execute and deliver to Administrative Agent an Assignment Agreement, together with such forms or certificates or with respect to Tax withholding matters as the assignee under such Assignment Agreement may be required to deliver to Administrative Agent pursuant to Section 2.15(d). (e) Notice of Assignment. Upon its receipt and acceptance of a duly executed and completed Assignment Agreement, any forms or certificates required by this Agreement in connection therewith, Administrative Agent shall record the information contained in such Assignment Agreement in the Register, shall give prompt notice thereof to Borrower and shall maintain a copy of such Assignment Agreement. (f) Representations and Warranties of Assignee. Each Lender, upon execution and delivery hereof or upon executing and delivering an Assignment Agreement, as the case may be, represents and warrants as of the Closing Date or as of the applicable Effective Date (as defined in the applicable Assignment Agreement) that (i) it is an Eligible Assignee; (ii) it has experience and expertise in the making of or investing in commitments or loans such as the applicable Term Loan Commitments or Loans, as the case may be; and (iii) it will make or invest in, as the case may be, its Term Loan Commitments or Loans for its own account in the ordinary course of its business and without a view to distribution of such Term Loan Commitments or Loans within the meaning of the Securities Act or the Exchange Act or other federal securities laws. (g) Effect of Assignment. Subject to the terms and conditions of this Section 10.6, as of the later (i) of the â€œEffective Dateâ€ specified in the applicable Assignment Agreement or (ii) the date such assignment is recorded in the Register: (A) the assignee thereunder shall have the rights and obligations of a â€œLenderâ€ hereunder to the extent such rights and obligations hereunder have been assigned to it pursuant to such Assignment Agreement and shall thereafter be a party hereto and a â€œLenderâ€ for all Â - 139Â - Â | Â purposes hereof; (B) the assigning Lender thereunder shall, to the extent that rights and obligations hereunder have been assigned thereby pursuant to such Assignment Agreement, relinquish its rights (other than any rights which survive the termination hereof under Section 10.8) and be released from its obligations hereunder (and, in the case of an Assignment Agreement covering all or the remaining portion of an assigning Lenderâ€™s rights and obligations hereunder, such Lender shall cease to be a party hereto; provided, anything contained in any of the Loan Documents to the contrary notwithstanding, such assigning Lender shall continue to be entitled to the benefit of all indemnities hereunder as specified herein with respect to matters arising out of the prior involvement of such assigning Lender as a Lender hereunder); (C) the Term Loan Commitments shall be modified to reflect the Term Loan Commitment of such assignee and any Term Loan Commitment of such assigning Lender, if any; and (D) if any such assignment occurs after the issuance of any Note hereunder, the assigning Lender shall, upon the effectiveness of such assignment or as promptly thereafter as practicable, surrender its applicable Notes to Administrative Agent for cancellation, and thereupon Borrower shall issue and deliver new Notes, if so requested by the assignee and/or assigning Lender, to such assignee and/or to such assigning Lender, with appropriate insertions, to reflect the new Term Loan Commitments and/or outstanding Loans of the assignee and/or the assigning Lender. (h) Participations. (i) Each Lender shall have the right at any time to sell one or more participations to any Person (other than the Borrower, any of its Subsidiaries or any of its Affiliates) in all or any part of its Term Loan Commitments, Loans or in any other Obligation. The holder of any such participation, other than an Affiliate of the Lender granting such participation, shall not be entitled to require such Lender to take or omit to take any action hereunder except with respect to any amendment, modification or waiver that would (i) extend the final scheduled maturity of any Term Loan or Note in which such participant is participating, or reduce the rate or extend the time of payment of interest or fees thereon (except in connection with a waiver of applicability of any post default increase in interest rates) or reduce the principal amount thereof, or increase the amount of the participantâ€™s participation over the amount thereof then in effect (it being understood that a waiver of any Default or Event of Default or of a mandatory reduction in the Term Loan Commitment shall not constitute a change in the terms of such participation, and that an increase in any Term Loan Commitment or Loan shall be permitted without the consent of any participant if the participantâ€™s participation is not increased as a result thereof), (ii) consent to the assignment or transfer by any Loan Party of any of its rights and obligations under this Agreement, or (iii) release all or substantially all of the Collateral under the Collateral Documents or all or substantially all of the Guarantors from the Guaranty (in each case, except as expressly provided in the Loan Documents) supporting the Loans hereunder in which such participant is participating. Borrower agree that each participant shall be entitled to the benefits of Sections 2.14, 2.15 and 2.19(c) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section 10.6(c); provided, a participant shall not be entitled to the benefits of Section 2.15 unless, at the time such participant is claiming such benefits, Borrower is notified of the participation sold to such participant and such participant agrees, for the benefit of Borrower, to comply with Section 2.15 as though it were a Lender. To the extent permitted by law, each participant also shall be entitled to the benefits of Section 10.4 as though it were a Lender, provided such participant agrees to be subject to Section 2.13 as though it were a Lender. (ii) In the event that any Lender sells participations in its Term Loan Commitments, Loans or in any other Obligation hereunder, such Lender shall, acting solely for this purpose as a non-fiduciary agent of Borrower, maintain a register on which it enters the name and address of all participants in the Term Loan Commitments, Loans or Obligations held by it and the principal amount (and stated interest thereon) of the portion of such Term Loan Commitments, Loans or Obligations which are the subject of the participation (the â€œParticipant Registerâ€); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any participant Â - 140Â - Â | Â or any information relating to a participantâ€™s interest in any commitments, loans or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. A Term Loan Commitment, Loan or Obligation hereunder may be participated in whole or in part only by registration of such participation on the Participant Register (and each Note shall expressly so provide). The Participant Register shall be available for inspection by Borrower at any reasonable time and from time to time upon reasonable prior notice. For the avoidance of doubt, Administrative Agent (in its capacity as administrative agent) shall not have any responsibility for maintaining a Participant Register. (i) Certain Other Assignments. In addition to any other assignment permitted pursuant to this Section 10.6, any Lender or the Administrative Agent may assign, pledge and/or grant a security interest in, all or any portion of its Loans, the other Obligations owed by or to such Lender, and its Notes, if any, to secure obligations of such Lender or the Administrative Agent or any of their Affiliates to any Person providing any loan, letter of credit or other extension of credit or financial arrangement to or for the account of such Lender or the Administrative Agent or any of their Affiliates and any agent, trustee or representative of such Person (without the consent of, or notice to, or any other action by, any other party hereto), including, without limitation, any Federal Reserve Bank as collateral security pursuant to Regulation A of the Federal Reserve Board and any operating circular issued by such Federal Reserve Bank; provided, no Lender or the Administrative Agent, as between Borrower and such Lender or the Administrative Agent, shall be relieved of any of its obligations hereunder as a result of any such assignment and pledge; provided further, in no event shall such Person, agent, trustee or representative of such Person or the applicable Federal Reserve Bank be considered to be a â€œLenderâ€ or â€œAgentâ€ or be entitled to require the assigning Lender or the Administrative Agent to take or omit to take any action hereunder. Section 10.7 Independence of Covenants. All covenants hereunder shall be given independent effect so that if a particular action or condition is not permitted by any of such covenants, the fact that it would be permitted by an exception to, or would otherwise be within the limitations of, another covenant shall not avoid the occurrence of a Default or an Event of Default if such action is taken or condition exists. Section 10.8 Survival of Representations, Warranties and Agreements. All representations, warranties and agreements made herein shall survive the execution and delivery hereof and the making of any Credit Extension. Notwithstanding anything herein or implied by law to the contrary, the agreements of each Loan Party set forth in Sections 2.14, 2.15, 2.19(c), 10.2, 10.3, 10.4, and 10.10 and the agreements of Lenders set forth in Sections 2.13, 9.3(b) and 9.6 shall survive the payment of the Term Loans and the termination hereof. Section 10.9 No Waiver; Remedies Cumulative. No failure or delay on the part of Administrative Agent or any Lender in the exercise of any power, right or privilege hereunder or under any other Loan Document shall impair such power, right or privilege or be construed to be a waiver of any default or acquiescence therein, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other power, right or privilege. The rights, powers and remedies given to Administrative Agent and each Lender hereby are cumulative and shall be in addition to and independent of all rights, powers and remedies existing by virtue of any statute or rule of law or in any of the other Loan Documents. Any forbearance or failure to exercise, and any delay in exercising, any right, power or remedy hereunder shall not impair any such right, power or remedy or be construed to be a waiver thereof, nor shall it preclude the further exercise of any such right, power or remedy. Â - 141Â - Â | Â Section 10.10 Marshalling; Payments Set Aside. Neither Administrative Agent nor any Lender shall be under any obligation to marshal any assets in favor of any Loan Party or any other Person or against or in payment of any or all of the Obligations. To the extent that any Loan Party makes a payment or payments to Administrative Agent or Lenders (or to Administrative Agent, on behalf of Lenders), or Administrative Agent or Lenders enforce any security interests or exercise their rights of setoff, and such payment or payments or the proceeds of such enforcement or setoff or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside and/or required to be repaid to a trustee, receiver or any other party under any bankruptcy law, any other state or federal law, common law or any equitable cause, then, to the extent of such recovery, the obligation or part thereof originally intended to be satisfied, and all Liens, rights and remedies therefor or related thereto, shall be revived and continued in full force and effect as if such payment or payments had not been made or such enforcement or setoff had not occurred. Section 10.11 Severability. In case any provision in or obligation hereunder or any Note or other Loan Document shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby. Section 10.12 Obligations Several; Independent Nature of Lendersâ€™ Rights. The obligations of Lenders hereunder are several and no Lender shall be responsible for the obligations or Term Loan Commitment of any other Lender hereunder. Nothing contained herein or in any other Loan Document, and no action taken by Lenders pursuant hereto or thereto, shall be deemed to constitute Lenders as a partnership, an association, a joint venture or any other kind of entity. The amounts payable at any time hereunder to each Lender shall be a separate and independent debt, and, subject to Section 9.8, each Lender shall be entitled to protect and enforce its rights arising under this Agreement and the other Loan Documents and it shall not be necessary for any other Lender to be joined as an additional party in any proceeding for such purpose. Section 10.13 Headings. Section headings herein are included herein for convenience of reference only and shall not constitute a part hereof for any other purpose or be given any substantive effect. Section 10.14 APPLICABLE LAW. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN THE STATE OF NEW YORK. Section 10.15 CONSENT TO JURISDICTION. (a) ALL JUDICIAL PROCEEDINGS BROUGHT AGAINST ANY LOAN PARTY ARISING OUT OF OR RELATING HERETO OR ANY OTHER LOAN DOCUMENT, OR ANY OF THE OBLIGATIONS, MAY BE BROUGHT IN ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN THE STATE, COUNTY AND CITY OF NEW YORK. BY EXECUTING AND DELIVERING THIS AGREEMENT, EACH LOAN PARTY, FOR ITSELF AND IN CONNECTION WITH ITS PROPERTIES, IRREVOCABLY (I) ACCEPTS GENERALLY AND UNCONDITIONALLY THE NON-EXCLUSIVE JURISDICTION AND VENUE OF SUCH COURTS; (II) WAIVES ANY DEFENSE OF FORUM NON CONVENIENS; (III) AGREES THAT SERVICE OF ALL PROCESS IN ANY SUCH PROCEEDING IN ANY SUCH COURT MAY BE MADE BY REGISTERED OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO THE APPLICABLE LOAN PARTY AT ITS ADDRESS PROVIDED IN ACCORDANCE WITH SECTION 10.1 OR TO ANY PROCESS AGENT SELECTED FOR SUCH LOAN PARTY IN ACCORDANCE WITH SECTION 3.1(U) OR SECTION Â - 142Â - Â | Â 5.10 IS SUFFICIENT TO CONFER PERSONAL JURISDICTION OVER THE APPLICABLE LOAN PARTY IN ANY SUCH PROCEEDING IN ANY SUCH COURT, AND OTHERWISE CONSTITUTES EFFECTIVE AND BINDING SERVICE IN EVERY RESPECT; AND (IV) AGREES THAT ADMINISTRATIVE AGENT AND LENDERS RETAIN THE RIGHT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW OR TO BRING PROCEEDINGS AGAINST ANY LOAN PARTY IN THE COURTS OF ANY OTHER JURISDICTION. (b) EACH LOAN PARTY HEREBY AGREES THAT PROCESS MAY BE SERVED ON IT BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO THE ADDRESSES PERTAINING TO IT AS SPECIFIED IN SECTION 10.1 OR WITH RESPECT TO ANY LOAN PARTY NOT ORGANIZED IN THE UNITED STATES OR ANY STATE THEREOF, TO COGENCY GLOBAL INC., LOCATED AT 122 EAST 42ND STREET, 18TH FLOOR, NEW YORK, NY 10168, AND HEREBY APPOINTS COGENCY GLOBAL INC. (OR ANOTHER AGENT APPOINTED PURSUANT TO SECTION 10.22) AS ITS AGENT TO RECEIVE SUCH SERVICE OF PROCESS. ANY AND ALL SERVICE OF PROCESS AND ANY OTHER NOTICE IN ANY SUCH ACTION, SUIT OR PROCEEDING SHALL BE EFFECTIVE AGAINST ANY LOAN PARTY IF GIVEN BY REGISTERED OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED, OR BY ANY OTHER MEANS OR MAIL WHICH REQUIRES A SIGNED RECEIPT, POSTAGE PREPAID, MAILED AS PROVIDED ABOVE. Section 10.16 WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY AGREES TO WAIVE ITS RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING HEREUNDER OR UNDER ANY OF THE OTHER LOAN DOCUMENTS OR ANY DEALINGS BETWEEN THEM RELATING TO THE SUBJECT MATTER OF THIS LOAN TRANSACTION OR THE LENDER/BORROWER RELATIONSHIP THAT IS BEING ESTABLISHED. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. EACH PARTY HERETO ACKNOWLEDGES THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THIS WAIVER IN ENTERING INTO THIS AGREEMENT, AND THAT EACH WILL CONTINUE TO RELY ON THIS WAIVER IN ITS RELATED FUTURE DEALINGS. EACH PARTY HERETO FURTHER WARRANTS AND REPRESENTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT IT

KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING (OTHER THAN BY A MUTUAL WRITTEN WAIVER SPECIFICALLY REFERRING TO THIS SECTION 10.15(b) AND EXECUTED BY EACH OF THE PARTIES HERETO), AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS HERETO OR ANY OF THE OTHER LOAN DOCUMENTS OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE LOANS MADE HEREUNDER. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT. Section 10.17 Confidentiality. Administrative Agent and Lender shall hold all non-public information regarding Borrower and its Subsidiaries and their businesses identified as such by Borrower and obtained by such Lender from Borrower or its Subsidiaries pursuant to the requirements hereof in accordance with such Lender’s customary procedures for handling confidential information of such nature, it being understood and agreed by the Loan Parties that, in any event, Administrative Agent or Lender may make (i) disclosures of such information to Affiliates of Administrative Agent or Lender and to their agents, advisors, directors, officers, and shareholders (and to other persons authorized by a Lender or Agent to - 143A - A | A organize, present or disseminate such information in connection with disclosures otherwise made in accordance with this Section 10.17), (ii) disclosures of such information reasonably required by any bona fide or potential assignee, transferee or participant in connection with the contemplated assignment, transfer or participation by any such Lender of any Loans or any participations therein, (iii) disclosure to any rating agency when required by it, (iv) disclosure to any Lender’s financing sources, provided that prior to any disclosure, such financing source is informed of the confidential nature of the information, (v) disclosures of such information to any actual or potential investors, members, and partners of Administrative Agent any Lender or their Affiliates, provided that prior to any disclosure, such investor or partner is informed of the confidential nature of the information, and (vi) disclosure required or requested in connection with any public filings, whether pursuant to any securities laws or regulations or rules promulgated therefor (including the Investment Company Act of 1940 or otherwise) or representative thereof or by the National Association of Insurance Commissioners (and any successor thereto) or pursuant to legal or judicial process; provided, unless specifically prohibited by applicable law or court order, Administrative Agent and Lender shall make reasonable efforts to notify Borrower of any request by any Governmental Authority or representative thereof (other than any such request in connection with any examination of the financial condition or other routine examination of such Lender by such Governmental Authority) for disclosure of any such non-public information prior to disclosure of such information. Notwithstanding anything to the contrary set forth herein, each party (and each of their respective employees, representatives or other agents) may disclose to any and all persons, without limitations of any kind, the tax treatment and tax structure of the transactions contemplated by this Agreement and all materials of any kind (including opinions and other tax analyses) that are provided to any such party relating to such tax treatment and tax structure. However, any information relating to the tax treatment or tax structure shall remain subject to the confidentiality provisions hereof (and the foregoing sentence shall not apply) to the extent reasonably necessary to enable the parties hereto, their respective Affiliates, and their and their respective Affiliates’ directors and employees to comply with applicable securities laws. For this purpose, “tax structure” means any facts relevant to the federal income tax treatment of the transactions contemplated by this Agreement but does not include information relating to the identity of any of the parties hereto or any of their respective Affiliates. Notwithstanding the foregoing, on or after the Closing Date, Administrative Agent and any Lender may, at its own expense, issue news releases and publish “tombstoned” advertisements and other announcements relating to this transaction in newspapers, trade journals and other appropriate media (which may include use of logos of one or more of the Loan Parties) (collectively, “Trade Announcements”). No Loan Party shall issue any Trade Announcement or disclose the name of any Administrative Agent or any Lender except (A) disclosures required by applicable law, regulation, legal process or the rules of the Securities and Exchange Commission, so long as Administrative Agent has received a copy of such disclosure at least three (3) Business Days prior to such disclosure and if Administrative Agent provides comments on such disclosure, Borrower will incorporate any such reasonable comments in good faith, to the extent not prohibited by law, or (B) with the prior approval of Administrative Agent and such Lender. Section 10.18 Usury Savings Clause. Notwithstanding any other provision herein, the aggregate interest rate charged or agreed to be paid with respect to any of the Obligations, including all charges or fees in connection therewith deemed in the nature of interest under applicable law shall not exceed the Highest Lawful Rate. If the rate of interest (determined without regard to the preceding sentence) under this Agreement at any time exceeds the Highest Lawful Rate, the outstanding amount of the Loans made hereunder shall bear interest at the Highest Lawful Rate until the total amount of interest due hereunder equals the amount of interest which would have been due hereunder if the stated rates of interest set forth in this Agreement had at all times been in effect. In addition, if when the Loans made hereunder are repaid in full the total interest due hereunder (taking into account the increase provided for above) is less than the total amount of interest which would have been due hereunder if the stated rates of interest set forth in this Agreement had at all times been in effect, then to the extent permitted by law, Borrower shall pay to Administrative Agent an amount equal to the difference between the amount of interest paid and the amount of interest which would have been paid if the Highest Lawful Rate had at all times been in effect. A - 144A - A | A Notwithstanding the foregoing, it is the intention of Lenders and Borrower to conform strictly to any applicable usury laws. Accordingly, if any Lender contracts for, charges, or receives any consideration which constitutes interest in excess of the Highest Lawful Rate, then any such excess shall be cancelled automatically and, if previously paid, shall at such Lender’s option be applied to the outstanding amount of the Loans made hereunder or be refunded to Borrower. In determining whether the interest contracted for, charged, or received by Administrative Agent or a Lender exceeds the Highest Lawful Rate, such Person may, to the extent permitted by applicable law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest, throughout the contemplated term of the Obligations hereunder. Section 10.19 Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. This Agreement shall become effective upon the execution of a counterpart hereof by each of the parties hereto. Delivery of an executed counterpart of a signature page of this Agreement by facsimile or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Agreement. The words “execution,” “executed,” “assigned,” “signature,” and words of like import in or related to any document to be signed in connection with this Agreement and the other Loan Documents and the transactions contemplated hereby and thereby (including without limitation Assignment Agreement, amendments, Notices, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act. For the purposes of this Section 10.19, “electronic signature” shall be construed so as to include the electronic signature of each witness, if any, of an electronic signature used to execute this Agreement. Section 10.20 Effectiveness. This Agreement shall become effective upon the execution of a counterpart hereof by each of the parties hereto and receipt by Borrower and Administrative Agent of written notification of such execution and authorization of delivery thereof. Section 10.21 PATRIOT Act Notice. Each Lender and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Loan Parties that pursuant to the requirements of the PATRIOT Act, it may be required to obtain, verify and record information that identifies each Loan Party, which information includes the name and address of the Loan Parties and other information that will allow such Lender or Agent, as applicable, to identify the Loan Parties in accordance with the PATRIOT Act or other Anti-Terrorism Laws of the Loan Parties and other information that will allow such Lender or Agent, as applicable, to identify the Loan Parties in connection with the PATRIOT Act. Section 10.22 Service of Process. Each Loan Party that is organized outside of the United States shall appoint Cogency Global Inc., or other agent for service of process reasonably acceptable to Administrative Agent, as its agent for the purpose of accepting service of any process in the United States with respect to any Loan Document and the transactions contemplated thereby. Section 10.23 Waiver of Immunity. To the extent that any Loan Party has or hereafter may acquire (or may be attributed, whether or not claimed) any immunity (sovereign or otherwise) from any legal action, suit or proceeding, from jurisdiction of any court or from set-off or any legal process (whether service of process or notice, attachment prior to judgment, attachment in aid of execution of judgment, A - 145A - A | A execution of judgment or otherwise) with respect to itself or any of its property, such Loan Party hereby irrevocably waives and agrees not to plead or claim, to the fullest extent permitted by law, such immunity in respect of (a) its obligations under the Loan Documents, (b) any legal proceedings to enforce such obligations and (c) any legal proceedings to enforce any judgment rendered in any proceedings to enforce such obligations. Each Loan Party hereby agrees that the waivers set forth in this Section 10.23 shall be to the fullest extent permitted under the Foreign Sovereign Immunities Act and are intended to be irrevocable for purposes of the Foreign Sovereign Immunities Act. Section 10.24 Acknowledgement and Consent to Bail-In of Affected Financial Institutions. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the write-down and conversion powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by: (a) the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and (b) the effects of any Bail-In Action on any such liability, including, if applicable: (i) a reduction in full or in part or cancellation of any such liability; (ii) a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or (iii) the variation of the terms of such liability in connection with the exercise of the write-down and conversion powers of the applicable Resolution Authority. Section 10.25 Representation of Dutch Guarantors. If any party to this Agreement incorporated under the laws of the Netherlands is represented by an attorney in connection with the signing and/or execution of this Agreement, it is hereby expressly acknowledged and accepted by the other parties to this Agreement that the existence and extent of that attorney’s authority and effects of that attorney’s exercise, or purported exercise, of his or her authority shall be governed by the laws of the Netherlands. Section 10.26 Intercreditor Agreements. Notwithstanding anything to the contrary in this Agreement or in any other Loan Document: (x) the Liens granted to the Administrative Agent in favor of the Secured Parties pursuant to the Loan Documents and the exercise of any right related to any Collateral shall be subject, in each case, to the terms of any applicable Intercreditor Agreement and (y) in the event of any conflict between the express terms and provisions of this Agreement or any other Loan Document, on the one hand, and of any applicable Intercreditor Agreement, on the other hand, the terms and provisions of such Intercreditor Agreement shall control. [Remainder of page intentionally left blank] A - 146A - A | EX-10.2 3 bbio-ex10_2.htm EX-10.2 EX-10.2 A Exhibit 10.2 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. A STOCK OPTION AND INCENTIVE PLAN A SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS A The name of the plan is the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of BridgeBio Pharma, Inc. (the “Company”) and its Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company or one of its Affiliates. A The following terms shall be defined as set forth below: A “Act” means the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. A “Administrator” means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two Non-Employee Directors who are independent. A “Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 of the Act. The Board will have the authority to determine the time or times at which “parent” or “subsidiary” status is determined within the foregoing definition. A “Award” or “Awards,” except where referring to a particular category of grant under the Plan, shall include Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights. A “Award Certificate” means a written or electronic document setting forth the terms and provisions applicable to an Award granted under the Plan. Each Award Certificate is subject to the terms and conditions of the Plan. A “Board” means the Board of Directors of the Company. A “Cash-Based Award” means an Award entitling the recipient to receive a cash-denominated payment. A “Code” means the U.S. Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations. A “Consultant” means a consultant or adviser who provides bona fide services to the Company or an Affiliate as an independent contractor and who qualifies as a consultant or adviser under Instruction A.1.(a)(1) of Form S-8 under the Act. A “Dividend Equivalent Right” means an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee; provided, however, that no such credits shall be received or paid in respect of any Stock Option or Stock Appreciation Right. A “Effective Date” means the date on which the Plan becomes effective as set forth in Section 19. A “Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. A “Fair Market Value” of the Stock on any given date means the fair market value of the Stock determined in good faith by the Administrator; provided, however, that if the Stock is listed on the National Association of Securities Dealers Automated Quotation System (“NASDAQ”), NASDAQ Global Market, The New York Stock Exchange or another national securities exchange or traded on any established market, the determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination shall be made by reference to the last date 1 A preceding such date for which there are market quotations; provided further, however, that if the date for which Fair Market Value is determined is the Registration Date, the Fair Market Value shall be the “Price to the Public” (or equivalent) set forth on the cover page for the final prospectus relating to the Company’s initial public offering. A “Incentive Stock Option” means any Stock Option designated and qualified as an “incentive stock option” as defined in Section 422 of the Code. A “Non-Employee Director” means a member of the Board who is not also an employee of the Company or any Subsidiary. A “Non-Qualified Stock Option” means any Stock Option that is not an Incentive Stock Option. A “Option” or “Stock Option” means any option to purchase shares of Stock granted pursuant to Section 5. A “Registration Date” means the date upon which the registration statement on Form S-1 that is filed by the Company with respect to the initial public offering is declared effective by the U.S. Securities and Exchange Commission. A “Restricted Shares” means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture or the Company’s right of repurchase. A “Restricted Stock Award” means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. A “Restricted Stock Unit” means an Award of stock units subject to such restrictions and conditions as the Administrator may determine at the time of grant. A “Sale Event” means (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company’s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii) the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv) any other transaction in which the owners of the Company’s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company. A “Sale Price” means the value as determined by the Administrator of the consideration payable, or otherwise to be received by stockholders, per share of Stock pursuant to a Sale Event. A “Section 409A” means Section 409A of the Code and the regulations and other guidance promulgated thereunder. A “Service Relationship” means any relationship as an employee, Non-Employee Director or Consultant of the Company or any Affiliate. Unless as otherwise set forth in the Award Certificate, a Service Relationship shall be deemed to continue without interruption in the event a grantee’s status changes from full-time employee to part-time employee or a grantee’s status changes from employee to Consultant or Non-Employee Director or vice versa; provided, that there is no interruption or other termination of Service Relationship in connection with the grantee’s change in capacity. A “Stock” means the Common Stock, par value \$0.001 per share, of the Company, subject to

entireties pursuant to Section 3. A "Stock Appreciation Right" means an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. A "Subsidiary" means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly. A "Ten Percent Owner" means an employee who owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than 10 percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation. A "Unrestricted Stock Award" means an Award of shares of Stock free of any restrictions. SECTION 2. ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEE AND DETERMINE AWARDS (a) Administration of Plan. The Plan shall be administered by the Administrator. (b) Powers of Administrator. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority: (i) to select the individuals to whom Awards may from time to time be granted; (ii) to determine the time or times of grant, and the extent, if any, of Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees; (iii) to determine the number of shares of Stock to be covered by any Award; (iv) to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Certificates; (v) to accelerate at any time the exercisability or vesting of all or any portion of any Award; (vi) subject to the provisions of Section 5(c), to extend at any time the period in which Stock Options may be exercised; and (vii) at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan. All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees. (c) Delegation of Authority to Grant Awards. Subject to applicable law, the Administrator, in its discretion, may delegate to a committee consisting of one or more officers of the Company including the Chief Executive Officer of the Company all or part of the Administrator's authority and duties with respect to the granting of Awards to individuals who are (i) not subject to the reporting and other provisions of Section 16 of the Exchange Act and (ii) not members of the delegated committee. Any such delegation by the Administrator shall include a limitation as to the amount of Stock underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator's delegate or delegates that were consistent with the terms of the Plan. (d) Award Certificate. Awards under the Plan shall be evidenced by Award Certificates that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event the employment (or other Service Relationship) terminates. (e) Indemnification. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys' fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company's articles or bylaws or any directors' and officers' liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company. (f) Non-U.S. Award Recipients. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Affiliates operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i) determine which Affiliates shall be covered by the Plan; (ii) determine which individuals outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable laws; (iv) establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall be incorporated into and made part of this Plan); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section 3(a) hereof; and (v) take any action, before or after an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law. (g) Prohibition on Repricing. The exercise price per share for the Stock subject to a Stock Option or Stock Appreciation Right shall be determined by the Committee and set forth in the applicable Award Certificate, and shall not be less than the Fair Market Value on the applicable date of grant of the applicable Award. In no event may any Stock Option or Stock Appreciation Right granted under this Plan be amended, other than subject to adjustment pursuant to Section 3(c) and/or Section 3(d), as applicable, to decrease the exercise price thereof, be cancelled in exchange for cash or other Awards or in conjunction with the grant of any new Stock Option or Stock Appreciation Right with a lower exercise price, or otherwise be subject to any action that would be treated, under the applicable national securities exchange listing standards or for accounting purposes, as a "repurchase" of such Stock Option or Stock Appreciation Right, unless such amendment, cancellation, or action is approved by the Company's stockholders. SECTION 3. STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION (a) Stock Issuable. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 47,723,827 shares, subject to adjustment as provided in this Section 3. For purposes of this limitation, the shares of Stock underlying any Awards under the Plan (which, for the avoidance of doubt, includes any predecessor plan thereto prior to any amendment and/or restatement), that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan and, to the extent permitted under Section 422 of the Code and the regulations promulgated thereunder, the shares of Stock that may be issued as Incentive Stock Options. In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of Award; provided, however, that no more than 47,723,827 shares of the Stock may be issued in the form of Incentive Stock Options, subject to adjustment as provided in this Section 3. A The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company. (b) Maximum Awards to Non-Employee Directors. Notwithstanding anything to the contrary in this Plan, the value of all Awards awarded under this Plan and all other cash compensation paid by the Company to any Non-Employee Director (i) in any calendar year shall not exceed \$1,250,000 and (ii) in any calendar year subsequent to the calendar year in which such Non-Employee Director is first elected to the Board shall not exceed \$600,000. For the purpose of this limitation, the value of any Award shall be its grant date fair value, as determined in accordance with Financial Accounting 4 Standards Board Accounting Standard Codification ("ASC") Topic 718 or successor provision but excluding the impact of estimated forfeitures related to service-based vesting provisions. (c) Changes in Stock. Subject to Section 3(d) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company's capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for issuance under the Plan, including the maximum number of shares that may be issued in the form of Incentive Stock Options, (ii) the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii) the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (iv) the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of shares subject to Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares. (d) Mergers and Other Transactions. In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree. To the extent the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards, upon the effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate. In such case, except as may be otherwise provided in the relevant Award Certificate, all Options and Stock Appreciation Rights with time-based vesting conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become fully vested and exercisable as of the effective time of the Sale Event, all other Awards with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a Sale Event in the Administrator's discretion or to the extent specified in the relevant Award Certificate. In the event of such termination, (i) the Company shall have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the Sale Price multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or less than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no consideration); or (ii) each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the extent then exercisable) held by such grantee. The Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied by the number of vested shares of Stock under such Awards. A 5 A SECTION 4. ELIGIBILITY A Grantees under the Plan will be such employees, Non-Employee Directors or Consultants of the Company and its Affiliates as are selected from time to time by the Administrator in its sole discretion; provided that Awards may not be granted to employees, Directors or Consultants who are providing services only to any parent of the Company, as such term is defined in Rule 405 of the Act, unless (i) the stock underlying the Awards is treated as a "service recipient stock" under Section 409A or (ii) the Company has determined that such Awards are exempt from or otherwise comply with Section 409A. SECTION 5. STOCK OPTIONS (a) Award of Stock Options. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be in such form as the Administrator may from time to time approve. A Stock Options granted under the Plan may be either Incentive Stock Options or Non-Qualified Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a "subsidiary corporation" within the meaning of Section 424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock Option. A Stock Options granted pursuant to this Section 5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so determines, Stock Options may be granted in lieu of cash compensation at the optionee's election, subject to such terms and conditions as the Administrator may establish. (b) Exercise Price. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section 5 shall be determined by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the exercise price of such Incentive Stock Option shall be not less than 110 percent of the Fair Market Value on the grant date. Notwithstanding the foregoing, Stock Options may be granted with an exercise price per share that is less than 100 percent of the Fair Market Value on the date of grant (i) pursuant to a transaction described in, and in a manner consistent with, Section 424(a) of the Code, (ii) to individuals who are not subject to U.S. income tax on the date of grant or (iii) the Stock Option is otherwise compliant with Section 409A. (c) Option Term. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the date of grant. (d) Exercisability; Rights of a Stockholder. Stock Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. For the avoidance of doubt, Stock Options granted under this Plan may not provide for any dividends or Dividend Equivalent Rights thereon. (e) Method of Exercise. Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods except to the extent otherwise provided in the Option Award Certificate: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of shares of Stock that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date; (iii) by the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or (iv) with respect to Stock Options that are not Incentive Stock Options, by a "net exercise" arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. A Payment instruments will be received subject to collection. The transfer to the optionee on the records

exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. A (b) Exercise Price of Stock Appreciation Rights. The exercise price of a Stock Appreciation Right shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant. A (c) Grant and Exercise of Stock Appreciation Rights. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section 5 of the Plan. A (d) Terms and Conditions of Stock Appreciation Rights. Stock Appreciation Rights shall be subject to such terms and conditions as shall be determined on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. For the avoidance of doubt, Stock Appreciation Rights granted under this Plan may not provide for any dividends or Dividend Equivalent Rights thereon. A SECTION 7. RESTRICTED STOCK AWARDS A (a) Nature of Restricted Stock Awards. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. Conditions may be based on 7 A continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives. A (b) Rights as a Stockholder. Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that if the lapse of restrictions with respect to the Restricted Stock Award is tied to the attainment of performance goals, any dividends paid by the Company during the performance period shall accrue and shall not be paid to the grantee until and to the extent the performance goals are met with respect to the Restricted Stock Award. Any such grant or sale of Restricted Stock Awards shall require that any and all dividends, Dividend Equivalent Rights or other distributions paid thereon during the period of such restrictions be automatically deferred and/or reinvested in additional Restricted Stock, which shall be subject to the same restrictions as the underlying Award. For the avoidance of doubt, any such dividends, Dividend Equivalent Rights or other distributions on Restricted Stock shall be deferred until, and paid contingent upon, the vesting of such Restricted Shares. Unless the Administrator shall otherwise determine, (i) uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture until such Restricted Shares are vested as provided in Section 7(d) below, and (ii) certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as provided in Section 7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe. (c) Restrictions. Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Stock Award Certificate. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 15 below, in writing after the Award is issued, if a grantee's employment (or other Service Relationship) with the Company and its Affiliates terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee's legal representative simultaneously with such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration. A (d) Vesting of Restricted Shares. The Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Shares and the Company's right of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed to be vested. A SECTION 8. RESTRICTED STOCK UNITS A (a) Nature of Restricted Stock Units. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Certificate) upon the satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Except in the case of Restricted Stock Units with a deferred settlement date that complies with Section 409A, at the end of the vesting period, the Restricted Stock Units, to the extent vested, shall be settled in the form of shares of Stock. Restricted Stock Units with deferred settlement dates are subject to Section 409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section 409A. A (b) Election to Receive Restricted Stock Units in Lieu of Compensation. The Administrator may, in its sole discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise 8 A due to such grantee in the form of an award of Restricted Stock Units. Any such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with Section 409A and such other rules and procedures established by the Administrator. Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number of Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if such payment had not been deferred as provided herein. The Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems appropriate. Any Restricted Stock Units that are elected to be received in lieu of cash compensation shall be fully vested, unless otherwise provided in the Award Certificate. A (c) Rights as a Stockholder. A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his or her Restricted Stock Units, subject to the provisions of Section 11 and such additional terms and conditions as the Administrator may determine. A (d) Termination. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 15 below, in writing after the Award is issued, a grantee's right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee's termination of employment (or cessation of Service Relationship) with the Company and its Affiliates for any reason. A SECTION 9. UNRESTRICTED STOCK AWARDS A Grant or Sale of Unrestricted Stock. The Administrator may grant (or sell at par value or such higher purchase price determined by the Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee. A SECTION 10. CASH-BASED AWARDS A Grant of Cash-Based Awards. The Administrator may grant Cash-Based Awards under the Plan. A Cash-Based Award is an Award that entitles the grantee to a payment in cash upon the attainment of specified performance goals, including continued employment (or other Service Relationship). The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains, the conditions upon which the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated payment amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be made in cash. A SECTION 11. DIVIDEND EQUIVALENT RIGHTS A (a) Dividend Equivalent Rights. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee. A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Certificate. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such 9 A other Award. For the avoidance of doubt, as determined by the Administrator, dividends and Dividend Equivalent Rights may accrue with respect to Awards granted hereunder, but no dividends or Dividend Equivalent Rights shall be paid out or settled unless and until, and then only to the extent that, the applicable securities underlying an Award have been earned or vest. A (b) Termination. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 15 below, in writing after the Award is issued, a grantee's rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee's termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason. A SECTION 12. TRANSFERABILITY OF AWARDS A (a) Transferability. Except as provided in Section 12(b) below, during a grantee's lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee's legal representative or guardian in the event of the grantee's incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void. A (b) Administrator Action. Notwithstanding Section 12(a), the Administrator, in its discretion, may provide either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her Non-Qualified Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award. In no event may an Award be transferred by a grantee for value. A (c) Family Member. For purposes of Section 12(b), a family member shall mean a grantee's child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee's household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests. A (d) Designation of Beneficiary. To the extent permitted by the Company and valid under applicable law, each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee's death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee's estate or legal heirs. A SECTION 13. TAX WITHHOLDING A (a) Payment by Grantee. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for tax purposes, pay to the Company or any applicable Affiliate, or make arrangements satisfactory to the Administrator regarding payment of, any U.S. and non-U.S. federal, state, or local taxes of any kind required by law to be withheld by the Company or any applicable Affiliate with respect to such income. The Company and its Affiliates shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee or to satisfy any applicable withholding obligations by any other method of withholding that the Company and its Affiliates deem appropriate. The Company's obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee. A (b) Payment in Stock. The Administrator may cause any tax withholding obligation of the Company or any applicable Affiliate to be satisfied, in whole or in part, by the Company withholding from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory rate or such 10 A lesser amount as is necessary to avoid liability accounting treatment. For purposes of share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of Stock includable in income of the Participants. The Administrator may also require any tax withholding obligation of the Company or any applicable Affiliate to be satisfied, in whole or in part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company or any applicable Affiliate in an amount that would satisfy the withholding amount due. A SECTION 14. SECTION 409A AWARDS A Awards are intended to be exempt from Section 409A to the greatest extent possible and to otherwise comply with Section 409A. The Plan and all Awards shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute a nonqualified deferred compensation within the meaning of Section 409A (a 409A Award), the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section 409A. In this regard, if any amount under a 409A Award is payable upon a separation from service (within the meaning of Section 409A) to a grantee who is then considered a specified employee (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the grantee's separation from service, or (ii) the grantee's death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. Further, the settlement of any 409A Award may not be accelerated except to the extent permitted by Section 409A. SECTION 15. TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC. A (a) Termination of Service Relationship. If the grantee's Service Relationship is with an Affiliate and such Affiliate ceases to be an Affiliate, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan. A (b) For purposes of the Plan, the following events shall not be deemed a termination of a Service Relationship: A (i) a transfer to the employment of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another; or A (ii) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee's right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing. A SECTION 16. AMENDMENTS AND TERMINATION A The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall adversely affect rights under any outstanding Award without the holder's consent. To the extent required under the rules of any securities exchange or market system on which the Stock is listed, to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section 422 of the Code, Plan amendments shall be subject to approval by Company stockholders. Nothing in this Section 16 shall limit the Administrator's authority to take any action permitted pursuant to Section 3(c) or 3(d). A SECTION 17. STATUS OF PLAN A With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company's obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence. A 11 A SECTION 18. GENERAL PROVISIONS A (a) No Distribution. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof. A (b) Issuance of Stock. To the extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee's last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee's last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic book entry records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of any Award, unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan

[illegible]

company of any agreement, statement or other evidence that the Company may require to satisfy itself as to the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. (b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee's name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock. (c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. (d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof. 3. Termination of Service Relationship. If the Optionee's Service Relationship with the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. (a) Termination Due to Death. If the Optionee's Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee's death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee's legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. (b) Termination Due to Disability. If the Optionee's Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee's disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination, may thereafter be exercised by the Optionee for a period of 12 months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect. 2A (c) Termination for Cause. If the Optionee's Service Relationship with the Company or a Subsidiary terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, Cause shall mean, unless otherwise provided in an employment or other service agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee's duties to the Company. (d) Other Termination. If the Optionee's Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee's death, the Optionee's disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect. The Administrator's determination of the reason for termination of the Optionee's Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. 4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee's lifetime, only by the Optionee, and thereafter, only by the Optionee's legal representative or legatee. 6. Tax Withholding. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. 7. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee's Service Relationship with the Company or a Subsidiary at any time. 8. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supercedes all prior agreements and discussions between the parties concerning such subject matter. 9. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the Relevant Companies) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the Relevant Information). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 3A 10. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. BridgeBio Pharma, Inc. By: Title: The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company's instructions to the Optionee (including through an online acceptance process) is acceptable. Dated: 2021 Optionee's Signature 2021 Optionee's name and address: 2021 4A NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: \$ [FMV on Grant Date] Grant Date: Expiration Date: [No more than 10 years] Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan as amended through the date hereof (the Plan), BridgeBio Pharma, Inc. (the Company) hereby grants to the Optionee named above, who is a Director of the Company but is not an employee of the Company, an option (the Stock Option) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value \$0.001 per share (the Stock), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended. 1. Exercisability Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated so long as the Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates: Incremental Number of Option Shares Exercisable* Exercisability Date (%) (%) (%) (%) (%) (%) [Notwithstanding the foregoing, in the event of a Sale Event, 100% of the then-outstanding and unvested Option Shares shall immediately be deemed vested and exercisable on the date of such Sale Event]; provided, that the Optionee continues to have a Service Relationship with the Company or a Subsidiary until the date of such Sale Event. Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. 2. Manner of Exercise. (a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased. Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; (iv) by a net exercise arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection. The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company's receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. (b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee's name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock. (c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. (d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof. 3. Termination of Service Relationship. If the Optionee's Service Relationship with the Company or a Subsidiary ceases, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. (a) Termination Due to Death. If the Optionee's Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee's death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee's legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. (b) Other Termination. If the Optionee's Service Relationship with the Company or a Subsidiary ceases for any reason other than the Optionee's death, any portion of this Stock Option outstanding on such date may be 2A exercised, to the extent exercisable on the date the Optionee ceased to have a Service Relationship with the Company or a Subsidiary, for a period of six months from the date the Optionee ceased to have a Service Relationship with the Company or a Subsidiary or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date the Optionee ceases to have a Service Relationship with the Company or a Subsidiary shall terminate immediately and be of no further force or effect. 4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee's lifetime, only by the Optionee, and thereafter, only by the Optionee's legal representative or legatee. 6. No Obligation to Continue Service Relationship. Neither the Plan nor this Stock Option confers upon the Optionee any rights with respect to continuance of a Service Relationship with the Company or a Subsidiary. 7. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supercedes all prior agreements and discussions between the parties concerning such subject matter. 8. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the Relevant Companies) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the Relevant Information). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 9. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. BridgeBio Pharma, Inc. By: Title: The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company's instructions to the

of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased. Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; (iv) by a "net exercise" arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest 1 A whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection. The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company's receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. (b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee's name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock. (c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. (d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof. 3. Termination of Service Relationship. Except as may otherwise be provided by the Administrator, if the Optionee's Service Relationship with the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. (a) Termination Due to Death. If the Optionee's Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee's death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee's legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. (b) Termination Due to Disability. If the Optionee's Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee's disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination, may thereafter be exercised by the Optionee for a period of 12 months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect. (c) Termination for Cause. If the Optionee's Service Relationship with the Company or a Subsidiary terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, "Cause" shall mean, unless otherwise provided in a consulting or other service agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee's duties to the Company. 2A A (d) Other Termination. If the Optionee's Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee's death, the Optionee's disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect. The Administrator's determination of the reason for termination of the Optionee's Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. 4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee's lifetime, only by the Optionee, and thereafter, only by the Optionee's legal representative or legatee. 6. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee's Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee's Service Relationship with the Company or a Subsidiary at any time. 7. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. 8. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the "Relevant Companies") may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the "Relevant Information"). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 9. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. BridgeBio Pharma, Inc. A By: A A Title: A The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company's instructions to the Optionee (including through an online acceptance process) is acceptable. Dated: A A A 3A A A Optionee's Signature A A A Optionee's name and address: A A A A A A A 4A A RESTRICTED STOCK AWARD AGREEMENT UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Grantee: A No. of Shares: A Grant Date: A A Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (the "Plan") as amended through the date hereof, BridgeBio Pharma, Inc. (the "Company") hereby grants a Restricted Stock Award (an "Award") to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the number of shares of Common Stock, par value \$0.001 per share (the "Stock") of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the Grantee of consideration with respect to the par value of the Stock in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator. 1. Award. The shares of Restricted Stock awarded hereunder shall be issued and held by the Company's transfer agent in book entry form, and the Grantee's name shall be entered as the stockholder of record on the books of the Company. Thereupon, the Grantee shall have all the rights of a stockholder with respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in Paragraph 2 below. The Grantee shall (i) sign and deliver to the Company a copy of this Award Agreement and (ii) deliver to the Company a stock power endorsed in blank. 2. Restrictions and Conditions. (a) Any book entries for the shares of Restricted Stock granted herein shall bear an appropriate legend, as determined by the Administrator in its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan. (b) Shares of Restricted Stock granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by the Grantee prior to vesting. (c) If the Grantee's Service Relationship with the Company or a Subsidiary is voluntarily or involuntarily terminated for any reason (including death) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted Stock shall immediately and automatically be forfeited and returned to the Company. 3. Vesting of Restricted Stock. The restrictions and conditions in Paragraph 2 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee continues to have a Service Relationship with the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 2 shall lapse only with respect to the number of shares of Restricted Stock specified as vested on such date. Incremental Number of Shares Vested Vesting Date () A () A () A () A 1A A () A A Subsequent to such Vesting Date or Dates, the shares of Stock on which all restrictions and conditions have lapsed shall no longer be deemed Restricted Stock. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 3. 4. Dividends. Dividends on shares of Restricted Stock shall be paid currently to the Grantee. 5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Award shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 6. Transferability. This Agreement is personal to the Grantee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. 7. Tax Withholding. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. Except in the case where an election is made pursuant to Paragraph 8 below, the Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued or released by the transfer agent a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. 8. Election Under Section 83(b). The Grantee and the Company hereby agree that the Grantee may, within 30 days following the Grant Date of this Award, file with the Internal Revenue Service and the Company an election under Section 83(b) of the Internal Revenue Code. In the event the Grantee makes such an election, he or she agrees to provide a copy of the election to the Company. The Grantee acknowledges that he or she is responsible for obtaining the advice of his or her tax advisors with regard to the Section 83(b) election and that he or she is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with regard to such election. 9. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee's Service Relationship with the Company or a Subsidiary at any time. 10. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. 11. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the "Relevant Companies") may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the "Relevant Information"). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 12. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. 2A A BridgeBio Pharma, Inc. A By: A A Title: A The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company's instructions to the Grantee (including through an online acceptance process) is acceptable. Dated: A A A Grantee's Signature A A A Grantee's name and address: A A A A A A A 3A A RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Grantee: A No. of Restricted Stock Units: A Grant Date: A A Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan as amended through the date hereof (the "Plan"), BridgeBio Pharma, Inc. (the "Company") hereby grants an award of the number of Restricted Stock Units listed above (an "Award") to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value \$0.001 per share (the "Stock") of the Company. 1. Restrictions on Transfer of Award. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement. 2. Vesting of Restricted Stock Units. The restrictions and conditions of Paragraph 1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee continues to have a Service Relationship with the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date. Incremental Number of Restricted Stock Units Vested Vesting Date () A () A () A () A 1A A () A () A () A A The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. 3. Termination of Service Relationship. If the Grantee's Service Relationship with the Company or a Subsidiary terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. 4. Issuance of Shares of Stock. As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. 1A A 5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 6. Tax Withholding. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part,

withholding from shares of Stock to be issued to the Grantee a number of shares of Stock to aggregate Fair Market Value at the time of issuance due to Section 409A of the Code. This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as "short-term deferrals" as described in Section 409A of the Code. 8. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee's Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee's Service Relationship with the Company or a Subsidiary at any time. 9. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. 10. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the "Relevant Companies") may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the "Relevant Information"). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 11. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. BridgeBio Pharma, Inc. A B: A Title: A The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company's instructions to the Grantee (including through an online acceptance process) is acceptable. Dated: A A A Grantee's Signature A A A Grantee's name and address: A A A A A A A A A A A A RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Grantee: A No. of Restricted Stock Units: A Grant Date: A Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan as amended through the date hereof (the "Plan"), BridgeBio Pharma, Inc. (the "Company") hereby grants an award of the number of Restricted Stock Units listed above (an "Award") to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value \$0.001 per share (the "Stock") of the Company. 1. Restrictions on Transfer of Award. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement. 2. Vesting of Restricted Stock Units. The restrictions and conditions of Paragraph 1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee continues to have a Service Relationship with the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date. Incremental Number of Restricted Stock Units Vested Vesting Date (%) A (%) A [Notwithstanding the foregoing, in the event of a Sale Event, 100% of the then-outstanding and unvested Restricted Stock Units shall immediately be deemed vested on the date of such Sale Event]; provided, that the Grantee continues to have a Service Relationship with the Company or a Subsidiary until the date of such Sale Event. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. 3. Termination of Service Relationship. If the Grantee's Service Relationship with the Company or a Subsidiary terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. 4. Issuance of Shares of Stock. As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested 1A Pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. 5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 6. Section 409A of the Code. This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as "short-term deferrals" as described in Section 409A of the Code. 7. No Obligation to Continue as a Director. Neither the Plan nor this Award confers upon the Grantee any rights with respect to continuance as a Director. 8. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. 9. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the "Relevant Companies") may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the "Relevant Information"). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 10. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. BridgeBio Pharma, Inc. A B: A Title: A The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company's instructions to the Grantee (including through an online acceptance process) is acceptable. Dated: A A A Grantee's Signature A A A Grantee's name and address: A A A A A A A A A A A A RESTRICTED STOCK UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Grantee: A No. of Restricted Stock Units: A Grant Date: A Vesting Commencement Date: A Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan as amended through the date hereof (the "Plan"), BridgeBio Pharma, Inc. (the "Company") hereby grants an award of the number of Restricted Stock Units listed above (an "Award") to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Class A Common Stock, par value \$0.001 per share (the "Stock") of the Company. 1. Restrictions on Transfer of Award. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement. 2. Vesting of Restricted Stock Units. The restrictions and conditions of Paragraph 1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee continues to have a Service Relationship with the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date. Incremental Number of Restricted Stock Units Vested Vesting Date (%) A (%) A [Notwithstanding the foregoing, in the event of a Sale Event, 100% of the then-outstanding and unvested Restricted Stock Units shall immediately be deemed vested on the date of such Sale Event]; provided, that the Grantee continues to have a Service Relationship with the Company or a Subsidiary until the date of such Sale Event. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. 3. Termination of Service Relationship. If the Grantee's Service Relationship with the Company or a Subsidiary terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. 4. Issuance of Shares of Stock. As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. 1A 5 Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 6. Section 409A of the Code. This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as "short-term deferrals" as described in Section 409A of the Code. 7. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Service Relationship of the Grantee at any time. 8. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. 9. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the "Relevant Companies") may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the "Relevant Information"). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 10. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. BridgeBio Pharma, Inc. A B: A Title: A The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company's instructions to the Grantee (including through an online acceptance process) is acceptable. Dated: A A A Grantee's Signature A A A Grantee's name and address: A A A A A A A A A A A A EARLY EXERCISE NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES AND CONSULTANTS UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Optionee: A No. of Option Shares: A Option Exercise Price per Share: \$ [FMV on Grant Date] Grant Date: A Vesting Commencement Date: A Expiration Date: A Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan as amended through the date hereof (the "Plan"), BridgeBio Pharma, Inc. (the "Company") hereby grants to the Optionee named above an option (the "Option") to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value \$0.001 per share (the "Stock") of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended. 1. Vesting Schedule. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the vesting schedule hereunder, this Stock Option shall vest as follows: [], so long as Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates. This Stock Option shall be immediately exercisable, regardless of whether the Option Shares are vested. This Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. 2. Manner of Exercise. (a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased. To the extent this Stock Option is only partially exercised, such exercise shall first be with respect to the Option Shares, if any, that have previously vested, and then with respect to the Option Shares that will next vest, with the Option Shares that vest at the latest date being exercised last. Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as 1A A The Administrator shall prescribe as a condition of such payment procedure; (iv) by a "net exercise" arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection. The transfer to the Optionee on the records of the Company or of

the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. (a) Termination Due to Death. If the Optionee's Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee's death, any portion of this Stock Option outstanding on such date, to the extent vested on the date of death, may thereafter be exercised by the Optionee's legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not vested on the date of death shall terminate immediately and be of no further force or effect. (b) Termination Due to Disability. If the Optionee's Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee's disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent vested on the date of such termination, may thereafter be exercised by the Optionee for a period of 12 months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not vested on the date of disability shall terminate immediately and be of no further force or effect. 2A (c) Termination for Cause. If the Optionee's Service Relationship with the Company or a Subsidiary terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, Cause shall mean, unless otherwise provided in an employment, consulting or other service agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of no contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee's duties to the Company. (d) Other Termination. If the Optionee's Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee's death, the Optionee's disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent vested on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not vested on the date of termination shall terminate immediately and be of no further force or effect. The Administrator's determination of the reason for termination of the Optionee's Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. 4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee's lifetime, only by the Optionee, and thereafter, only by the Optionee's legal representative or legatee. 6. Tax Withholding. If applicable, the Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause any such required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. 7. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee's Service Relationship with the Company or a Subsidiary at any time. 8. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. 9. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the Relevant Companies) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the Relevant Information). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 3A 10. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. BridgeBio Pharma, Inc. A By: A Title: A The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company's instructions to the Optionee (including through an online acceptance process) is acceptable. Dated: A A A Optionee's Signature A A A Optionee's name and address: A A A A A A A A A A Appendix A RESTRICTED STOCK AWARD AGREEMENT UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Grantee: A No. of Shares: A Purchase Date: A BridgeBio Pharma, Inc. (the Company) hereby sells to the Grantee, and the Grantee hereby purchases from the Company, on [], 20[], the number of shares of Stock set forth above, pursuant to the exercise of the Stock Option under the Early Exercise Non-Qualified Stock Option Agreement for Company Employees and Consultants Under the Company's 2021 Amended and Restated Stock Option and Incentive Plan (as amended from time to time, the Plan) and such agreement, the Option Agreement, for the aggregate Option Exercise Price for the shares so purchased. 1. Award. The shares of Restricted Stock awarded hereunder shall be issued and held by the Company's transfer agent in book entry form, and the Grantee's name shall be entered as the stockholder of record on the books of the Company. Thereupon, the Grantee shall have all the rights of a stockholder with respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in Paragraph 2 below. The Grantee shall (i) sign and deliver to the Company a copy of this Award Agreement and (ii) deliver to the Company a stock power endorsed in blank. 2. Restrictions and Conditions. (a) Any book entries for the shares of Restricted Stock granted herein shall bear an appropriate legend, as determined by the Administrator in its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan. (b) Shares of Restricted Stock granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by the Grantee prior to vesting. (c) If the Grantee's Service Relationship with the Company or a Subsidiary is voluntarily or involuntarily terminated for any reason (including death) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted Stock shall immediately and automatically be repurchased by the Company at a repurchase price per share equal to the lower of the Option Exercise Price per share paid by the Grantee (subject to adjustment under Section 3(c) of the Plan) for the Restricted Stock or the current Fair Market Value per share as of the date the Company elects to exercise its repurchase right. 3. Vesting of Restricted Stock. The restrictions and conditions in Paragraph 2 of this Agreement shall lapse and become vested on the respective dates indicated under the Vesting Schedule set forth in the Option Agreement. 4. Dividends. Dividends on shares of Restricted Stock shall be paid currently to the Grantee. 5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 6. Transferability. This Agreement is personal to the Grantee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. 1A 7. Tax Withholding. The Grantee shall, not later than the date as of which the receipt of the Restricted Stock becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. Except in the case where an election is made pursuant to Paragraph 8 below, the Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued or released by the transfer agent a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. 8. Election Under Section 83(b). The Grantee and the Company hereby agree that the Grantee may, within 30 days following the purchase of the Restricted Stock, file with the Internal Revenue Service and the Company an election under Section 83(b) of the Internal Revenue Code. In the event the Grantee makes such an election, he or she agrees to provide a copy of the election to the Company. The Grantee acknowledges that he or she is responsible for obtaining the advice of his or her tax advisors with regard to the Section 83(b) election and that he or she is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with regard to such election. 9. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee's Service Relationship with the Company or a Subsidiary at any time. 10. Integration. This Agreement constitutes the entire agreement between the parties with respect to the Restricted Stock and supersedes all prior agreements and discussions between the parties concerning such subject matter. 11. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the Relevant Companies) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the Relevant Information). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 12. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. BridgeBio Pharma, Inc. A By: A Title: A The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company's instructions to the Grantee (including through an online acceptance process) is acceptable. Dated: A A A Grantee's Signature A 2A A A Grantee's name and address: A A A A A A A A A A EARLY EXERCISE INCENTIVE STOCK OPTION AGREEMENT UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Optionee: A No. of Option Shares: A Option Exercise Price per Share: \$ [FMV on Grant Date (110% of FMV if a 10% owner)] Grant Date: A Vesting Commencement Date: A Expiration Date: [up to 10 years (5 if a 10% owner)] A Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan as amended through the date hereof (the Plan), BridgeBio Pharma, Inc. (the Company) hereby grants to the Optionee named above an option (the Stock Option) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value \$0.001 per share (the Stock), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. 1. Vesting Schedule. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the vesting schedule hereunder, this Stock Option shall vest as follows: [], so long as Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates. This Stock Option shall be immediately exercisable, regardless of whether the Option Shares are vested. This Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. Further, to the extent this Stock Option and any other incentive stock options of the Optionee having an aggregate Fair Market Value in excess of \$100,000 (determined as of the Grant Date) first become exercisable in any year, such options will not qualify as incentive stock options. 2. Manner of Exercise. (a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased. To the extent this Stock Option is only partially exercised, such exercise shall first be with respect to the Option Shares, if any, that have previously vested, and then with respect to the Option Shares that will next vest, with the Option Shares that vest at the latest date being exercised last. Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; or (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as 1A the Administrator shall prescribe as a condition of such payment procedure; or (iv) a combination of (i), (ii) and (iii) above. Payment instruments will be received subject to collection. The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company's receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. (b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee's name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock. (c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. (d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof. (e) In the event the Optionee exercises a portion of this Stock Option with respect to Option Shares that have not vested, the Optionee shall also deliver a Restricted Stock Award Agreement covering such unvested Option Shares in the form of Appendix A hereto (the Restricted Stock Agreement) with the same vesting schedule for such Option Shares as set forth for such Option Shares herein. 3. Termination of Service Relationship. If the Optionee's Service Relationship with the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. (a) Termination Due to Death. If the Optionee's Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee's death, any portion of this Stock Option outstanding on such date, to the extent vested on the date of death, may thereafter be exercised by the Optionee's legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not vested on the date of death shall terminate immediately and be of no further force or effect. (b) Termination Due to Disability. If the Optionee's Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee's disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent vested on the date of such termination, may thereafter be exercised by the Optionee for a period of 12 months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not vested on the date of disability shall terminate immediately and be of no further force or effect. (c) Termination for Cause.

If the Optionee's Service Relationship with the Company or a Subsidiary terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, Cause shall mean, unless otherwise provided in an 2A A employment or other service agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee's duties to the Company. (d) Other Termination. If the Optionee's Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee's death, the Optionee's disability, or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent vested on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not vested on the date of termination shall terminate immediately and be of no further force or effect. The Administrator's determination of the reason for termination of the Optionee's Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. 4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee's lifetime, only by the Optionee, and thereafter, only by the Optionee's legal representative or legatee. 6. Status of the Stock Option. This Stock Option is intended to qualify as an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended (the Code), but the Company does not represent or warrant that this Stock Option qualifies as such. The Optionee should consult with his or her own tax advisors regarding the tax effects of this Stock Option and the requirements necessary to obtain favorable income tax treatment under Section 422 of the Code, including, but not limited to, holding period requirements. To the extent any portion of this Stock Option does not so qualify as an incentive stock option, such portion shall be deemed to be a non-qualified stock option. If the Optionee intends to dispose or does dispose (whether by sale, gift, transfer or otherwise) of any Option Shares within the one-year period beginning on the date after the transfer of such shares to him or her, or within the two-year period beginning on the day after the grant of this Stock Option, he or she will so notify the Company within 30 days after such disposition. 7. Tax Withholding. If applicable, the Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause any such required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. 8. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee's Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee's Service Relationship with the Company or a Subsidiary at any time. 9. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. 10. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the Relevant 3A A Companies) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the Relevant Information). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 11. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. BridgeBio Pharma, Inc. A By: A A Title: A The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company's instructions to the Optionee (including through an online acceptance process) is acceptable. Dated: A A A Optionee's Signature A A A Optionee's name and address: A A A A A A A A A Appendix A RESTRICTED STOCK AWARD AGREEMENT UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Grantee: A No. of Shares: A Purchase Date: A A BridgeBio Pharma, Inc. (the Company) hereby sells to the Grantee, and the Grantee hereby purchases from the Company, on [], 20[], the number of shares of Stock set forth above, pursuant to the exercise of the Stock Option under the Early Exercise Incentive Stock Option Agreement Under the Company's 2021 Amended and Restated Stock Option and Incentive Plan (as amended from time to time, the Plan) and such agreement, the Option Agreement), for the aggregate Option Exercise Price for the shares so purchased. 1. Award. The shares of Restricted Stock awarded hereunder shall be issued and held by the Company's transfer agent in book entry form, and the Grantee's name shall be entered as the stockholder of record on the books of the Company. Thereupon, the Grantee shall have all the rights of a stockholder with respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in Paragraph 2 below. The Grantee shall (i) sign and deliver to the Company a copy of this Award Agreement and (ii) deliver to the Company a stock power endorsed in blank. 2. Restrictions and Conditions. (a) Any book entries for the shares of Restricted Stock granted herein shall bear an appropriate legend, as determined by the Administrator in its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan. (b) Shares of Restricted Stock granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by the Grantee prior to vesting. (c) If the Grantee's Service Relationship with the Company or a Subsidiary is voluntarily or involuntarily terminated for any reason (including death) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted Stock shall immediately and automatically be repurchased by the Company at a repurchase price per share equal to the lower of the Option Exercise Price per share paid by the Grantee (subject to adjustment under Section 3(c) of the Plan) for the Restricted Stock or the current Fair Market Value per share as of the date the Company elects to exercise its repurchase right. 3. Vesting of Restricted Stock. The restrictions and conditions in Paragraph 2 of this Agreement shall lapse and become vested on the respective dates indicated under the Vesting Schedule set forth in the Option Agreement. 4. Dividends. Dividends on shares of Restricted Stock shall be paid currently to the Grantee. 5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 6. Transferability. This Agreement is personal to the Grantee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. 1A A 7. Tax Withholding. The Grantee shall, not later than the date as of which the receipt of the Restricted Stock becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. 8. Election Under Section 83(b). The Grantee and the Company hereby agree that the Grantee may, within 30 days following the purchase of the Restricted Stock, file with the Internal Revenue Service and the Company an election under Section 83(b) of the Internal Revenue Code. In the event the Grantee makes such an election, he or she agrees to provide a copy of the election to the Company. The Grantee acknowledges that he or she is responsible for obtaining the advice of his or her tax advisors with regard to the Section 83(b) election and that he or she is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with regard to such election. 9. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee's Service Relationship with the Company or a Subsidiary at any time. 10. Integration. This Agreement constitutes the entire agreement between the parties with respect to the Restricted Stock and supersedes all prior agreements and discussions between the parties concerning such subject matter. 11. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the Relevant Companies) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the Relevant Information). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 12. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. BridgeBio Pharma, Inc. A By: A A Title: A The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company's instructions to the Grantee (including through an online acceptance process) is acceptable. Dated: A A A Grantee's Signature A A A Grantee's name and address: A A A 2A A NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES AND CONSULTANTS UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Optionee: A No. of Option Shares: A Option Exercise Price per Share: \$ [FMV on Grant Date] Grant Date: A Vesting Commencement Date: A Expiration Date: A Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan as amended through the date hereof (the Plan), BridgeBio Pharma, Inc. (the Company) hereby grants to the Optionee named above an option (the Stock Option) of the Company specified above to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value \$0.001 per share (the Stock) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended. 1. Exercisability Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable as follows: [], so long as Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates. Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. 2. Manner of Exercise. (a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased. Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; (iv) by a net exercise arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest 1A A whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection. The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company's receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. (b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee's name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock. (c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. (d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof. 3. Termination of Service Relationship. If the Optionee's Service Relationship with the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. (a) Termination Due to Death. If the Optionee's Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee's death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee's legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. (b) Termination Due to Disability. If the Optionee's Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee's disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination, may thereafter be exercised by the Optionee for a period of 12 months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect. (c) Termination for Cause. If the Optionee's Service Relationship with the Company or a Subsidiary terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, Cause shall mean, unless otherwise provided in an employment, consulting or other service agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee's duties to the Company. 2A A (d) Other Termination. If the Optionee's Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee's death, the Optionee's disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable

on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect. The Administrator’s determination of the reason for termination of the Optionee’s Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. 4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee’s lifetime, only by the Optionee, and thereafter, only by the Optionee’s legal representative or legatee. 6. Tax Withholding. If applicable, the Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause any such required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. 7. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee’s Service Relationship with the Company or a Subsidiary at any time. 8. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. 9. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 10. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. BridgeBio Pharma, Inc. A A By: A A Title: A 3A A The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Optionee (including through an online acceptance process) is acceptable. Dated: A A A A Optionee’s Signature A A A A Optionee’s name and address: A A A A A 4A A RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), BridgeBio Pharma, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value \$0.001 per share (the “Stock”) of the Company. 1. Restrictions on Transfer of Award. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement. 2. Vesting of Restricted Stock Units. The restrictions and conditions of Paragraph 1 of this Agreement shall lapse on the dates specified in the following schedule; provided, that the Grantee continues to have a Service Relationship with the Company or a Subsidiary on each applicable vesting date: []. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. 3. Termination of Service Relationship. If the Grantee’s Service Relationship with the Company or a Subsidiary terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. 4. Issuance of Shares of Stock. As soon as practicable following each vesting date (but in no event later than two and one-half months after the end of the year in which the vesting date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. 5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 6. Tax Withholding. As applicable and in accordance with applicable tax laws, the Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes and/or social insurance contribution required by law to be withheld on account of such taxable event. In such event, (a) if the Grantee is then a member of the Board of Directors of the Company and/or an “officer” (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of the Company, the Company shall, on a mandatory basis, cause the required tax withholding and/or social insurance contribution obligation to be satisfied in whole by withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due and (b) if the A A Grantee is not then a member of the Board of Directors of the Company or an “officer” (as defined in the Exchange Act), the Company shall, on a mandatory basis, cause the required tax withholding and/or social insurance contribution obligation to be satisfied in whole by an irrevocable “sell-to-cover” arrangement whereby a brokerage firm designated by the Company that is a member of the Financial Industry Regulatory Authority (i) sells on behalf of the Grantee a number of shares of Stock to be delivered in connection with the settlement of this Award in an amount sufficient to satisfy the required tax withholding and/or social insurance contribution obligation and (ii) irrevocably commits to forward the proceeds from such sale directly to the Company. The mandatory “sell-to-cover” arrangement described in clause (b) is imposed by the Company on Grantee in connection with the receipt of this Award and is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and to be interpreted to meet the requirements of Rule 10b5-1(c). In addition, the Grantee hereby certifies that Grantee is adopting this Agreement, including this Section 6, in good faith and not as part of a plan or scheme to evade the prohibitions of Section 10(b) and Rule 10b-5 of the Exchange Act. 7. Section 409A of the Code. This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as “eshort-term deferrals” as described in Section 409A of the Code. 8. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee’s Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee’s Service Relationship with the Company or a Subsidiary at any time. 9. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. 10. Data Privacy Consent. In order to administer the Plan and this Agreement, to implement, manage and administer the Grantee’s participation in the Plan, and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth, salary, nationality, job title, any shares of Common Stock or directorships held in the Company, details of all equity awards or any other entitlement to stock awarded, canceled, exercised, vested, unvested or outstanding and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Grantee (i) voluntarily consents to and authorizes the Company to hold, collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; (iv) understands that the Relevant Information may be transferred to one or more stock plan service provider(s) selected by the Company, which may assist the Company with the implementation, administration, and management of the Plan; (v) understands that the recipients of the Relevant Information may be located in the United States or elsewhere, and that the recipient’s country (e.g., the United States) may have different, including less stringent, data privacy laws and protections than the Grantee’s country of residence; and (vi) authorizes the transfer of the Relevant Information to any jurisdiction which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 11. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. BridgeBio Pharma, Inc. A A By: A A Name: Title: A 2A A The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Grantee (including through an online acceptance process) is acceptable. Dated: A A A A Grantee’s Signature A A A A Grantee’s name and address: A A A A A 3A A RESTRICTED STOCK AWARD AGREEMENT UNDER THE 2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Shares: Grant Date: Pursuant to the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (the “Plan”) as amended through the date hereof, BridgeBio Pharma, Inc. (the “Company”) hereby grants a Restricted Stock Award (an “Award”) to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the number of shares of Common Stock, par value \$0.001 per share (the “Stock”) of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the Grantee of consideration with respect to at least the par value of the Stock in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator. 1. Award. The shares of Restricted Stock awarded hereunder shall be issued and held by the Company’s transfer agent in book entry form, and the Grantee’s name shall be entered as the stockholder of record on the books of the Company. Thereupon, the Grantee shall have all the rights of a stockholder with respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in Paragraph 2 below. The Grantee shall (i) sign and deliver to the Company a copy of this Award Agreement and (ii) deliver to the Company a stock power endorsed in blank. 2. Restrictions and Conditions. (a) Any book entries for the shares of Restricted Stock granted herein shall bear an appropriate legend, as determined by the Administrator in its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan. (b) Shares of Restricted Stock granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by the Grantee prior to vesting. (c) If the Grantee’s Service Relationship with the Company or a Subsidiary is voluntarily or involuntarily terminated for any reason (including death) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted Stock shall immediately and automatically be forfeited and returned to the Company. 3. Vesting of Restricted Stock. The restrictions and conditions in Paragraph 2 of this Agreement shall lapse on the dates specified in the following schedule; provided, that the Grantee continues to have a Service Relationship with the Company or a Subsidiary on each applicable vesting date: []. Subsequent to such Vesting Date or Dates, the shares of Stock on which all restrictions and conditions have lapsed shall no longer be deemed Restricted Stock. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 3. 4. Dividends. Dividends on shares of Restricted Stock shall be paid currently to the Grantee. 5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Award shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 1A A 6. Transferability. This Agreement is personal to the Grantee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. 7. Tax Withholding. As applicable and in accordance with applicable tax laws, the Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes and/or social insurance contribution required by law to be withheld on account of such taxable event. In such event, except in the case where an election is made pursuant to Paragraph 8 below, (a) if the Grantee is then a member of the Board of Directors of the Company and/or an “officer” (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of the Company, the Company shall, on a mandatory basis, cause the required tax withholding and/or social insurance contribution obligation to be satisfied in whole by withholding from shares of Stock to be issued or released by the transfer agent a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due and (b) if the Grantee is not then a member of the Board of Directors of the Company or an “officer” (as defined in the Exchange Act), the Company shall, on a mandatory basis, cause the required tax withholding and/or social insurance contribution obligation to be satisfied in whole by an irrevocable “sell-to-cover” arrangement whereby a brokerage firm designated by the Company that is a member of the Financial Industry Regulatory Authority (i) sells on behalf of the Grantee a number of shares of Stock to be delivered in connection with the settlement of this Award in an amount sufficient to satisfy the required tax withholding and/or social insurance contribution obligation and (ii) irrevocably commits to forward the proceeds from such sale directly to the Company. The mandatory “sell-to-cover” arrangement described in clause (b) is imposed by the Company on Grantee in connection with the receipt of this Award and is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and to be interpreted to meet the requirements of Rule 10b5-1(c). In addition, the Grantee hereby certifies that Grantee is adopting this Agreement, including this Section 7, in good faith and not as part of a plan or scheme to evade the prohibitions of Section 10(b) and Rule 10b-5 of the Exchange Act. 8. Election Under Section 83(b). The Grantee and the Company hereby agree that the Grantee may, within 30 days following the Grant Date of this Award, file with the Internal Revenue Service and the Company an election under Section 83(b) of the Internal Revenue Code. In the event the Grantee makes such an election, he or she agrees to provide a copy of the election to the Company. The Grantee acknowledges that he or she is responsible for obtaining the advice of his or her tax advisors with regard to the Section 83(b) election and that he or she is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with regard to such election. 9. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee’s Service Relationship with the Company or a Subsidiary at any time. 10. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. 11. Data Privacy Consent. In order to administer the Plan and this Agreement, to implement, manage and administer the Grantee’s participation in the Plan, and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth, salary, nationality, job title, any shares of Common Stock or directorships held in the Company, details of all equity awards or any other entitlement to stock awarded, canceled, exercised, vested, unvested or outstanding and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Grantee (i) voluntarily consents to and authorizes the Company to hold, collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; (iv) understands that the Relevant Information may be transferred to one or more stock plan service provider(s) selected by the Company, which may assist the Company with

[illegible]

Disclosure - Debt - Schedule of Total Interest Expense Recognized Related to Notes (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Debt - Schedule of Future Minimum Payments under Notes (Details) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Debt - Schedule of Balances of Borrowing under Loan Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Debt - Schedule of Balances of Borrowing under Financing Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Debt - Schedule of Future Minimum Payments Under Term Loan Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Funding Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - License and Collaboration Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - License and Collaboration Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - In-licensing and Other Research and Development Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - Sale of Nonfinancial Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - Leases - Components of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 996075 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 996085 - Disclosure - Leases - Schedule of Supplemental Information Related to Remaining Lease Term and Discount Rate (Details) link:presentationLink link:calculationLink link:definitionLink 996095 - Disclosure - Leases - Schedule of Future Minimum Lease Payments for Noncancelable Leases (Details) link:presentationLink link:calculationLink link:definitionLink 996105 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996115 - Disclosure - Public Offerings - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996125 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation for Employees and Non Employees (Details) link:presentationLink link:calculationLink link:definitionLink 996135 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996145 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity under Plans (Details) link:presentationLink link:calculationLink link:definitionLink 996155 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 996165 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Award Activity under Plans (Details) link:presentationLink link:calculationLink link:definitionLink 996175 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-based Compensation Expense Related to Restricted Stock Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 996185 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Stock Options and Stock Purchase Rights under ESPP (Details) link:presentationLink link:calculationLink link:definitionLink 996195 - Disclosure - Restructuring, Impairment and Related Charges - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996205 - Disclosure - Restructuring, Impairment and Related Charges - Summary of Restructuring, Impairment and Related Charges (Details) link:presentationLink link:calculationLink link:definitionLink 996215 - Disclosure - Restructuring, Impairment and Related Charges - Schedule of Activity Related to Restructuring Liabilities Associated to Restructuring Initiatives (Details) link:presentationLink link:calculationLink link:definitionLink 996225 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996235 - Disclosure - Income Taxes - Summary of Components of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 996245 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes and Effective Tax Rates (Details) link:presentationLink link:calculationLink link:definitionLink 996255 - Disclosure - Net Loss Per Share - Schedule of Common Stock Equivalents were Anti-dilutive (Details) link:presentationLink link:calculationLink link:definitionLink 996265 - Disclosure - Subsequent Event - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Other Nonoperating Income (Expense) [Member] Other income (expense), net Merger transactions completion date. Merger Transactions Completion Date Merger transactions completion date Statement [Line Items] Statement [Line Items] Percentage of corporate alternative minimum tax rate. Percentage of Corporate Alternative Minimum Tax Rate Percentage of corporate alternative minimum tax rate Liabilities, Fair Value Disclosure [Abstract] Liability Commissions paid Payments for Commissions Debt Instrument [Axis] Debt Instrument Plan Name [Domain] Plan Name Proceeds from issuance of term loans after deducting debt discount and issuance costs. Proceeds from Issuance of Term Loans After Deducting Debt Discount and Issuance Costs Proceeds from issuance of Term Loans after deducting debt discount and issuance costs Number of performance-based stock options issued in exchange of subsidiary equity. Number Of Performance Based Stock Options Issued In Exchange Of Subsidiary Equity Number of Performance-Based stock options issued in exchange of subsidiary equity Principal value and interest on two point five zero percentage convertible senior notes due two thousand and twenty seven. Principal Value And Interest On Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven [Member] 2027 Notes and Interest on 2027 Notes Frank McCormick [Member] Frank McCormick member. Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Repurchase of RSU shares to satisfy tax withholding Entity Address, Postal Zip Code Entity Address, Postal Zip Code Dr. Charles J. Homcy [Member] Dr Charles J Homcy [Member] Dr. Charles J. Homcy, Disposal Group Name [Axis] Aspa Therapeutics, Inc. and Adrenas Therapeutics Inc. Aspa Therapeutics, Inc. And Adrenas Therapeutics Inc. [Member] Aspa and Adrenas Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Restructuring Charges, Total Restructuring expenses Restructuring expenses incurred Restructuring, impairment and related charges Costs and Expenses [Abstract] Operating costs and expenses: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Number of equal monthly installments. Number Of Equal Monthly Installments Number of equal monthly installments LianBio, Lian Bio [Member] LianBio Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized compensation cost Potential milestone fixed monetary amount settlement in stock. Potential Milestone Fixed Monetary Amount Settlement In Stock Potential Fixed Monetary Amount Settlement in Stock Reimbursable research and development Reimbursable Research And Development Reimbursable research and development. Placement agent commission. Placement Agent Commission Placement agent commission LEO call option liability current. L E O Call Option Liability Current LEO call option liability Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-Average Exercise Price per Option, Exercisable Transaction costs incurred in merger transactions. Transaction Costs Incurred In Merger Transactions Transaction costs incurred Debt Instrument Option to Purchase Additional Notes Exercised. Debt Instrument Option To Purchase Additional Notes Exercised Proceeds from exercise of option to purchase additional notes Cash, Cash Equivalents, and Marketable Securities [Text Block] Cash Equivalents and Marketable Securities Two thousand nineteen stock option and incentive plan. Two Thousand Nineteen Stock Option And Incentive Plan [Member] A&R 2019 Plan BridgeBio Services, Inc. Bridge Bio Services Inc [Member] BridgeBio Equity Plan Shares, Outstanding Ending balance, shares Beginning balance, shares Other Noncash Income (Expense) Other noncash adjustments Other Noncash Income (Expense), Total Potential milestone payments. Potential Milestone Payments Milestone payments Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Investment in nonconsolidated entity Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total Regular equity program member. Regular Equity Program Member Regular Equity Program Fair Value, Inputs, Level 2 [Member] Level 2 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Performance-based milestone awards. Performance Based Milestone Awards Performance-based milestone awards Notes Payable, Fair Value Disclosure Estimated fair value of notes payable Debt instrument tranche one. Debt Instrument Tranche One [Member] Tranche I Long-Term Debt, Type [Domain] Maximum required future payment upon achievement of certain development and milestone events net sales metrics. Maximum Required Future Payment Upon Achievement Of Certain Development And Milestone Events Net Sales Metrics Maximum required future payment upon achievement of certain development and milestone events net sales metrics Schedule of interest expense recognized and effective interest rates related to notes. Schedule Of Interest Expense Recognized And Effective Interest Rates Related To Notes [Table Text Block] Schedule of Total Interest Expense Recognized and Effective Interest Related to Notes Business Combination, Consideration Transferred Aggregate consideration Business Combination, Consideration Transferred, Total Schedule of supplemental cash flow information related to leases. Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block] Schedule of Supplemental Cash Flow Information Related to Leases 2023 at the market agreement. Two Thousand Twenty Three At The Market Agreement [Member] 2023 ATM Agreement Payment for private equity financing with external investors Payment for Private Equity Financing with External Investors Payment for equity private financing with external investors. Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Operating leases. Remainder of 2024 Recognized intangible asset recorded in "Accrued research and development liabilities" Recognized Intangible Asset Recorded In Accrued Research And Development Liabilities Recognized intangible asset recorded in Accrued research and development liabilities. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Restructuring Cost [Table] AccruedExitFeesForResearchAndDevelopment Restructuring liabilities Accrued Exit Fees For Research And Development. Principle amount paid to lenders Principle Amount Paid To Lenders Principle amount paid to lenders. Product and Service [Axis] Product and Service Agreement to pay remaining payable amount. Agreement to Pay Remaining Payable Amount Agreement to pay remaining payable amount Lender Name [Axis] Lender Name Investment, Name [Domain] Investment, Name Performance based milestone awards compensation expense. Performance Based Milestone Awards Compensation Expense Performance-based milestone awards compensation expense Depreciation, Depletion and Amortization Depreciation and amortization Depreciation, Depletion and Amortization, Total Cost sharing credit of the lesser of fixed percentage of certain agreed upon service costs. Cost Sharing Credit Of The Lesser Of Fixed Percentage Of Certain Agreed Upon Service Costs Cost sharing credit of the lesser of a fixed percentage of certain agreed upon service costs Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Close-out plan costs subject to reimbursement Close-Out Plan Costs Subject To Reimbursement Close-out plan costs subject to reimbursement. Stock Repurchased During Period, Shares Stock repurchased during period, shares Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption Noncash Investing and Financing Items [Abstract] Supplemental Disclosures of Noncash Investing and Financing Information: Employee Stock [Member] Employee Stock Purchase Plan Unvested market-based restricted stock unit. Unvested Market Based Restricted Stock Unit [Member] Unvested Market-Based RSUs Equity [Text Block] Public Offerings Interest two thousand and twenty seven and two thousand and twenty nine. Interest Two Thousand and Twenty Seven and Two Thousand and Twenty Nine [Member] Interest on 2027 and 2029 Notes Cash equivalents and marketable securities. Cash Equivalents And Marketable Securities [Abstract] Deposit percentage of proceeds net of certain permitted costs received from asset sale transactions into escrow accounts Deposit Percentage of Proceeds Net of Certain Permitted Costs Received from Asset Sale Transactions into Escrow Accounts Deposit percentage of proceeds net of certain permitted costs received from asset sale transactions into escrow accounts. Alexion Pharmaceuticals Alexion Agreements Alexion Agreements [Member] Alexion agreements. Sale of Stock [Domain] Sale of Stock Cash and Cash Equivalents [Domain] Long-Term Debt, Gross Principal Principal value of term loans Lease agreement expiration. Lease Agreement Expiration Lease agreement expiration Debt instrument tranche four. Debt Instrument Tranche Four [Member] Tranche IV Debt instrument potential payment extended amortization date. Debt Instrument Potential Payment Extended Amortization Date Debt instrument potential payment extended amortization date Entity Central Index Key Entity Central Index Key Cash Equivalents, at Carrying Value Amortized Cost Basis Cash Equivalents Amortized Cost Basis Cash Equivalents Potential milestone fixed monetary amount settlement in cash or stock at sole discretion. Potential Milestone Fixed Monetary Amount Settlement In Cash Or Stock At Sole Discretion Potential Fixed Monetary Amount Settlement in Cash or stock at our sole discretion Upfront nonrefundable payment received Upfront Nonrefundable Payment Received Upfront nonrefundable payment received. Issuance (repurchase) of noncontrolling interest. Issuance Repurchase Of Noncontrolling Interest Issuance of noncontrolling interests Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Options Outstanding, Cancelled Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Gain on deconsolidation of a subsidiary Gain from diconsolidation Deconsolidation, Gain (Loss), Amount Realized losses recognized on investment in equity securities Realized losses recognized on investment in equity securities Equity Securities, FV-NI, Realized Gain (Loss), Total Equity Securities, FV-NI, Realized Gain (Loss) Net realized gains recognized on investments in equity securities sold Aggregate offering price of common stock that may issued and sold. Aggregate Offering Price Of Common Stock That May Issued And Sold Aggregate offering price of common stock that may issued and sold Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Aggregate carrying amount of equity method investment Equity Method Investment, Aggregate Cost Sales milestone payments yet to be received. Sales Milestone Payments Yet To Be Received Sales milestone payments yet to be received Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, Minimum Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Principal value interest on term loans of financing agreement. Principal Value Interest On Term Loans Of Financing Agreement [Member] Term Loans, Interest on Term Loans of Financing Agreement Net payable position. Net Payable Position Net payable position Aggregate offering issuance and sale price of common stock to be issued. Aggregate Offering Issuance And Sale Price Of Common Stock To Be Issued Aggregate offering, issuance and sale price of common stock to be issued Potential sales milestone payments. Potential Sales Milestone Payments Potential sales milestone payments Income Statement [Abstract] Entity Address, State or Province Entity Address, State or Province Warrants to purchase common stock Warrant to purchase shares of common stock Warrant to Purchase shares of common stock Loss before income taxes Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Parent [Member] Parent License agreement. License Agreement [Member] License Agreement Restricted Cash Restricted Cash [Member] Restricted cash. Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Debt instrument, convertible, threshold percentage of stock price trigger Exit cost. Exit cost Development and regulatory milestone payments yet to be received. Development and regulatory milestone payments yet to be received License fees License Fees License fees. Eidos Therapeutics, Inc Eidos Therapeutics, Inc. Eidos Therapeutics Inc [Member] Eidos Private placement offering. Private Placement Offering Member Private Placement Offering Dr. Neil Kumar [Member] Dr Neil Kumar [Member] Dr. Neil Kumar. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable Loss (gain) on deconsolidation of PellePharm Gain Loss On Deconsolidation Of Entities Gain loss on deconsolidation of entities. Liability Class [Axis] Equity Method Investment, Nonconsolidated Investee [Domain] Payments of Debt Issuance Costs Issuance costs and discounts associated with issuance of term loan Issuance costs and discounts associated with term loan under Financing Agreement Treasury stock, shares Treasury Stock, Common, Shares Cover [Abstract] Cover Subsequent Event [Line Items] Development and Manufacturing Services Agreement, Development And Manufacturing Services Agreement [Member] Resilience DMSAs Two thousand twenty four follow on offering. Two Thousand Twenty Four Follow On Offering [Member] 2024 Follow-on Offering Assets acquisition required milestone payments. Assets Acquisition Required Milestone Payments Assets acquisition required milestone payments Net loss per share attributable to common stockholders of BridgeBio, basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gains Transfers (to) from noncontrolling interests (Note 5) Noncash or part noncash investing transfer (from) to noncontrolling interest. Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest Finance Lease, Principal Payments Financing cash flows for finance lease - cash paid for principal Debt instrument interest only extension date. Debt Instrument Interest Only Extension Date Debt instrument interest only extension date License and Collaboration Agreements License and collaboration agreement. License And Collaboration Agreement [Text Block] Concentration of Credit Risk and Other Risks and Uncertainties Concentration Of Credit Risk And Other Risks And Uncertainties Policy [Text Block] Concentration of credit risk and other risks and uncertainties. Variable Interest Entity, Primary Beneficiary [Member] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary License and Services Revenue License [Member] Number of employees for replacement awards. Number Of Employees For Replacement Awards Number of employees for replacement awards Debt Instrument, Unused Borrowing Capacity, Amount Debt instrument, amount available to be drawn Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four Amortization expenses, 2025 Amortization expenses, 2028 Share-Based Payment Arrangement, Expense Total stock-based compensation Stock-based compensation Cash released from escrow accounts Percentage of Cash Released from Escrow Accounts Percentage of cash released from escrow accounts. Finance Lease, Weighted Average Discount Rate, Percent Finance lease Long-Term Debt Debt instrument drawn amount Term Loan, net BMS Bristol Myers Squibb Company [Member] Bristol-Myers Squibb Company. Debt instrument, option to purchase additional notes remaining portion exercised. Debt Instrument Option To Purchase Additional Notes Remaining Portion Exercised Proceeds from exercise of remaining portion of option to purchase

additional notes Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance 2023 Follow-on Offering 2023 Follow-on Offering [Member] 2023 follow-on offering. Plan Name [Axis] Plan Name US Treasury Bill Securities [Member] Treasury Bills Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Options Outstanding, Outstanding, Ending balance Options Outstanding, Outstanding, Beginning balance Debt Instrument tranche two. Debt Instrument Tranche Two [Member] Tranche II Assets, Current [Abstract] Current assets: Common Stock, Capital Shares Reserved for Future Issuance Common shares reserved for future issuance Future potential development and sales milestone payments yet to be received. Future Potential Development And Sales Milestone Payments Yet To Be Received Future potential development and sales milestone payments yet to receive Fair value liabilities transfers between level one level two or level three amount. Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount Fair value liabilities, transfers between Level 1, Level 2 or Level 3 Navire BMS Navire BMS [Member] Navire BMS Short term marketable securities contractual maturities. Short Term Marketable Securities Contractual Maturities Short-term marketable securities contractual maturities Number of options issued in exchange of subsidiary equity. Number Of Options Issued In Exchange Of Subsidiary Equity Number of options issued in exchange of subsidiary equity Temporary equity transfer to (from) noncontrolling interest. Temporary Equity Transfer To From Noncontrolling Interest Temporary Equity, transfers from (to) noncontrolling interest Performance based milestone awards compensation expense settled with equity. Performance Based Milestone Awards Compensation Expense Settled With Equity Performance based milestone awards compensation expense settled with equity Investment Type [Axis] Investment Type Deferred Tax Liabilities, Net Deferred tax liability, net Deferred Tax Liabilities, Net, Total Share-based payment arrangement, consecutive trading days. Share-Based Payment Arrangement, Consecutive Trading Days Share-based payment arrangement, consecutive trading days Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Cancelled Other RSAs Other R S As [Member] Other RSAs Lessee operating and financing leases disclosure. Lessee Operating And Financing Leases Disclosure [Text Block] Leases Temporary equity issuance (repurchase) of noncontrolling interest, value. Temporary Equity Issuance Repurchase Of Noncontrolling Interest Value Temporary Equity, issuance (repurchase) of noncontrolling interest Issuance of noncontrolling interests Product and Service [Domain] Product and Service Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive income Contractual obligation interest portion. Contractual Obligation Interest Portion Less amounts representing interest Debt Instrument [Line Items] Debt Instrument [Line Items] Sales [Member] Revenue Debt Instrument, Term Expected life of notes Property, Plant and Equipment, Net Property and equipment, net Property, Plant and Equipment, Net, Total Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Lessee, Operating Lease, Liability, to be Paid, Year Four Operating leases, 2028 Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities: Net Gains (Losses) Included in Other Income (Expense), Net Net gains (losses) included in Other income (expense), net. Total net gains included in "Other income (expense), net" Fair Value, Recurring [Member] Recurring Seller parties. Seller Parties [Member] Seller Parties Reimbursable remaining due in eleven equal monthly commencing installments Reimbursable Remaining Due In Eleven Equal Monthly Commencing Installments Reimbursable remaining due in eleven equal monthly commencing installments. Restructuring and Related Activities [Abstract] Net proceeds received from escrow account. Net Proceeds Received From Escrow Account Net proceeds received from escrow account percentage Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Common Stock, Par or Stated Value Per Share Common stock, par value Employee Stock Options Unrealized gain (losses) on available-for-sale securities Unrealized gains (losses) on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Cash, Cash Equivalents and Marketable Securities Cash, Cash Equivalents And Marketable Securities [Policy Text Block] Cash, Cash Equivalents And Marketable Securities [Policy Text Block] Intangible Assets Disclosure [Text Block] Intangible Assets Statement of Cash Flows [Abstract] Counterparty Name [Axis] Counterparty Name Share-based compensation arrangement by share-based payment award, equity instruments other than options, grant date fair value. Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grant Date Fair Value Grant-date fair value of RSUs Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Equity investment Equity Method Investments Percentage of outstanding securities Percentage of Outstanding Securities Percentage of outstanding securities Gain recognized, net of transactions costs Net gain recognized transaction costs Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Deposit percentage of proceeds net of certain permitted costs received from asset sale transactions into escrow accounts Debt instrument mandatory prepayments percentage of net cash proceeds from prepayment event transaction. Debt Instrument Mandatory Prepayments Percentage of Net Cash Proceeds from Prepayment Event Transaction Debt instrument mandatory prepayments percentage of net cash proceeds from prepayment event transaction Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses Entity Entity [Domain] Eidos Award Exchange Plan. Eidos Award Exchange Plan [Member] Eidos Award Exchange Plan Restricted Stock [Member] Restricted Stock Awards Acquired Finite-Lived Intangible Assets [Line Items] Equity Components [Axis] Equity Components Entity Address, Address Line One Entity Address, Address Line One Employee-related Liabilities, Current Accrued compensation and benefits Employee-related Liabilities, Current, Total Receivable from Licensing and Collaboration Agreements [Member] Receivable from licensing and collaboration agreements. Receivable from Licensing and Collaboration Agreements Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Unvested Shares of Restricted Stock Outstanding, Granted Accrued compensation and benefits. Accrued Compensation and Benefits [Member] Accrued Compensation and Benefits Intangible Asset, Finite-Lived [Table] Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Summary of intangible assets Summary of Recognized Intangible Assets Nonrefundable upfront license fees. Nonrefundable Upfront License Fees Nonrefundable upfront license fee Property, Plant and Equipment [Line Items] Interest Adjust on two point five zero percentage convertible senior notes due two thousand and twenty seven. Interest Adjust On Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven [Member] Interest on 2027 Notes Subsequent Event Type [Axis] License and collaboration agreement. License And Collaboration Agreement [Abstract] Total other income (expense), net Nonoperating Income (Expense) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Common Stock Equivalents were Anti-dilutive Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Voting shares Number of restricted stock units issued in exchange of subsidiary equity. Number Of Restricted Stock Units Issued In Exchange Of Subsidiary Equity Number of RSUs issued in exchange of subsidiary equity Lessee operating lease liability payments due after year four. Lessee Operating Lease Liability Payments Due After Year Four Operating leases, Thereafter Number of restricted stock awards issued in exchange of subsidiary equity. Number Of Restricted Stock Awards Issued In Exchange Of Subsidiary Equity Number of RSAs issued in exchange of subsidiary equity Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Unvested Shares of Restricted Stock Outstanding, Ending balance Unvested Shares of Restricted Stock Outstanding, Beginning balance Unvested shares of restricted stock outstanding Gain from sale of Priority Review Voucher, excluding transaction costs. Gain from Sale of Priority Review Voucher, Excluding Transaction Costs Gain from sale of priority review voucher, excluding transaction costs Equity Method and Other Equity Investments Equity Method and Other Equity Investments [Policy Text Block] Equity method and other equity investments. Amendment Flag Amendment Flag Amendment Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest, Total Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests Increase (Decrease) in Operating Lease Liability Operating lease liabilities Accrued professional and other accrued liabilities. Accrued Professional And Other Accrued Liabilities [Member] Accrued Professional and Other Accrued Liabilities Reimbursable payment outstanding. Reimbursable Payment Outstanding Reimbursable payment outstanding Notes, net Convertible Senior Notes Convertible senior notes. Potential regulatory milestone payments. Potential Regulatory Milestone Payments Potential regulatory milestone payments Operating Lease, Liability, Noncurrent Operating lease liabilities, net of current portion Term loan agreement. Term Loan Agreement [Member] Term Loan Agreement Helsinki. Helsinki [Member] Helsinki Corporate Debt Securities [Member] Corporate Debt Securities Debt Instrument, Name [Domain] Debt Instrument, Name Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Fair value of shares issued under license agreements. Fair Value Of Shares Issued Under License Agreements Fair value of shares issued under license agreements Embedded Derivative, Fair Value of Embedded Derivative Liability Embedded derivative Reimbursable remaining commencing installments Reimbursable Remaining Commencing Installments Reimbursable remaining commencing installments. Common stock price Sale of stock, public offering price per share Sale of Stock, Price Per Share Payment from escrow accounts Payment from Escrow Accounts Payment from escrow accounts. Funding agreements. Funding Agreements [Line Items] Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] SOFR Lessee, Lease, Description [Table] Lessee Lease Description [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Options Outstanding, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Options Outstanding, Exercisable Variable Rate [Domain] Variable Rate Aggregate purchase price Stock Issued With Premium Stock Issued With Premium Research and Development Services Performance Obligation Research and Development Expense [Member] Research and Development Expense Contractual Obligation, to be Paid, Year Two 2026 Equity Component [Domain] Equity Component Statistical Measurement [Domain] Statistical Measurement Debt Instrument Payment Amortization Date Debt Instrument Payment Amortization Date Debt instrument payment amortization date Unpaid issuance cost on Private Placement offering. Unpaid Issuance Cost On Private Placement offering Unpaid issuance cost on Private Placement offering Interest Expense, Debt Interest expense Total interest and amortization expense Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Other income (expense), net Net loss Net income (loss) excluding redeemable noncontrolling interests net income (loss). Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss Net income (loss) Treasury Stock Treasury Stock, Common [Member] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Reconciliation of Cash, Cash Equivalents and Restricted Cash: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net loss Share-based payment arrangement, performance period from date of grant. Share-based Payment Arrangement, Performance Period From Date Of Grant Share-based payment arrangement, performance period from date of grant Deferred revenue, current portion Deferred Revenue, Current Deferred Revenue, Current, Total Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Operating Lease, Payments Operating cash flows for operating leases Proceeds from Stock Options Exercised Proceeds from stock option exercises, net of repurchases Loan Agreement [Member] Loan Agreement [Member] Loan Agreement Stanford License Agreement Stanford License Agreement [Member] Stanford license agreement. Percentage of sales agents commissions on gross proceeds of sales of common stock. Percentage Of Sales Agents Commissions On Gross Proceeds Of Sales Of Common Stock Percentage of sales agents commission Restricted cash - Included in "Prepaid expenses and other current assets" Restricted cash Restricted Cash, Current Two thousand sixteen equity incentive plan and two thousand eighteen stock option and incentive plan. Two Thousand Sixteen Equity Incentive Plan And Two Thousand Eighteen Stock Option And Incentive Plan [Member] Eidos 2016 and 2018 Plans Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extendible Enumeration] Business acquisition cash per share. Business Acquisition Cash Per Share Cash per share in transaction Randal W. Scott [Member] Randal W. Scott. Debt instruments maturity year. Debt Instruments Maturity Year Maturity year Business acquisition equity interests issued or issuable fair value. Business Acquisition Equity Interests Issued Or Issuable Fair Value Total fair value Sales Commissions and Fees Sales agent fees and commissions Deferred Revenue Noncurrent Deferred Revenue, Noncurrent, Total Deferred revenue, noncurrent Deferred revenue, net of current portion Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, Maximum Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted-Average Exercise Price per Option, Cancelled Alexion License Agreements Alexion License Agreements [Member] Alexion license agreements. Restricted cash, non-current - included in "Other assets" Restricted Cash, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Class of Stock [Domain] Class of Stock Severance Costs Severance and employee-related costs Accrued regulatory-based milestone payment. Accrued Regulatory Based Milestone Payment Accrued regulatory-based milestone payment Equity, Fair Value Adjustment Cumulative unrealized loss on ongoing mark-to-market adjustments of investment in equity security Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss attributable to common stockholders of BridgeBio Temporary Equity, deconsolidation of a subsidiary Temporary Equity Deconsolidation Of Entities Temporary equity deconsolidation of entities. Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Contingent Consideration by Type [Axis] Contingent Consideration by Type Commitments and Contingencies. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Summary of Components of Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Close-out plan costs Close-Out Plan Costs Close-out plan costs. Sale of Nonfinancial Assets [Abstract] Sale of Nonfinancial Assets. Percentage of cash commission on gross proceeds of sales of common stock. Percentage Of Cash Commission On Gross Proceeds Of Sales Of Common Stock Percentage of cash commission Deposited of escrow account receipt Deposited Of Escrow Account Receipt Deposited of escrow account receipt. Weighted-average Estimated Useful Lives Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Debt instrument accrued interest convertible into principal. Debt Instrument Accrued Interest Convertible into Principal Accrued interest convertible into principal Hercules Capital, Inc. Hercules Capital Inc [Member] Hercules Capital, Inc Aspa Therapeutics Inc. Aspa Therapeutics Inc [Member] Aspa Reduction of obligation. Reduction Of Obligation Reduction of obligation Antidilutive Securities [Axis] Antidilutive Securities Sale of Nonfinancial Assets Sale of Nonfinancial Assets [Text Block] Sale of Nonfinancial Assets. Agency Discount Notes Agency Discount Notes [Member] Agency discount notes. Net proceeds received permitted costs. Net Proceeds Received Permitted Costs Net proceeds received permitted costs percentage Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Summary of Restricted Stock Award Activity Performance based stock options. Performance Based Stock Options [Member] Performance-Based Stock Options Finite-Lived Intangible Assets [Line Items] Entity Interactive Data Current Entity Interactive Data Current Employee and non-employee service share based compensation. Employee And Non Employee Service Share Based Compensation [Line Items] Employee And Non Employee Service Share Based Compensation [Line Items] Short-term liability Short-term Liability Fair Value Disclosure Short-term liability fair value disclosure. Restricted cash - Included in "Prepaid expenses and other current assets" Restricted Cash and Cash Equivalents Included in Prepaid Expenses and Other Current Assets Restricted cash and cash equivalents included in prepaid expenses and other current assets. Accounting Standards Update [Domain] Accounting Standards Update Document Quarterly Report Document Quarterly Report Tranche one advance. Tranche One Advance [Member] Tranche 1 Advance Consolidated Entities [Axis] Consolidated Entities Sale of existing inventory. Sale Of Existing Inventory Sale of certain existing inventory Public offerings and share repurchase program and securities purchase agreement. Public Offerings And Share Repurchase Program And Securities Purchase Agreement [Abstract] Public Offerings, Share Repurchase Program and Securities Purchase Agreement [Abstract] Direct offering expense. Direct Offering Expense Direct offering expense Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Vested Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Total cash, cash equivalents and restricted cash at end of periods shown in the condensed consolidated statements of cash flows Statement of Financial Position Location, Balance [Axis] Balance Sheet Location Receivables, Long-term Contracts or Programs, Total Receivables, Long-Term Contracts or Programs Total receivables Receivables from licensing and collaboration agreements Statistical Measurement [Axis] Statistical Measurement Two point five zero percentage convertible senior notes due two thousand and twenty seven. Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven [Member] 2027 Notes Debt instrument minimum unrestricted cash. Debt Instrument Minimum Unrestricted Cash Minimum unrestricted cash balance Equity Method Investment [Table] Schedule Of Equity Method Investments [Table] Debt instrument prepayment premium percentage. Debt Instrument Prepayment Premium Percentage Debt instrument prepayment premium percentage Operating Lease, Cost Straight line operating lease costs Debt Instrument, Periodic

Payment, Principal Additional quarterly principal payments ASC 808 Accounting Standard Update 201818 [Member] Accounting Standard Update 2018-18. Debt Instrument, Payment Terms Description of payment terms of notes Assets, Fair Value Disclosure Total financial assets Related and Nonrelated Parties [Domain] Related Party Lease, Cost Total lease cost Equal monthly installments amount. Equal Monthly Installments Amount Equal monthly installments amount Warrants exercised Warrants exercised Proceeds from issuance of common stock issuance cost Proceeds From Issuance Of Common Stock Issuance Cost Proceeds from issuance of common stock issuance cost Finance Lease, Interest Payment on Liability Operating cash flows for finance lease Commercial Paper [Member] Commercial Paper Agreement for convenience day Agreement For Convenience Day Agreement convenience least days Finite-Lived Intangible Assets, Gross, Total Intangible assets gross amount Gross amount Capitalization of finite-lived intangible asset Interest Payable Interest payable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Granted Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized compensation cost, period for recognition Wholly owned subsidiary disclosure. Wholly Owned Subsidiary Disclosure [Abstract] Exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd. Exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd. [Member] Exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd. U.S. Federal Federal Income Tax Expense (Benefit), Continuing Operations Federal Income Tax Expense (Benefit), Continuing Operations, Total Schedule of funding agreements. Schedule Of Funding Agreements [Table] Regulatory milestone payment receivable subject to achievement of regulator milestones Regulatory Milestone Payment Receivable Subject To Achievement Of Regulator Milestones Regulatory milestone payment receivable subject to achievement of regulator milestones. Agreement and Plan of Merger. Agreement And Plan Of Merger [Member] Merger Agreement Accretion Expense Accretion of debt Ownership [Domain] Ownership Stock-based compensation cost associated with performance-based milestone awards Share-Based Payment Arrangement, Expensed and Capitalized, Amount Share-based Payment Arrangement, Expensed and Capitalized, Amount, Total Debt Instrument, Convertible, Threshold Consecutive Trading Days Debt instrument, convertible, threshold consecutive trading days Statement of Income Location, Balance [Axis] Income Statement Location Cash and Cash Equivalents [Axis] Assets Total assets Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] Cost related to manufacturing suite and additional equipment. Cost Related to Manufacturing Suite and Additional Equipment Cost related to manufacturing suite and additional equipment Payments to Acquire Equity Securities, FV-NI Purchases of investments in equity securities Equity Method Investment, Nonconsolidated Investee, Other [Member] Other investment Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Unvested Shares of Restricted Stock Outstanding, Vested Restricted Cash and Cash Equivalents, Noncurrent, Total Restricted Cash and Cash Equivalents, Noncurrent Restricted cash - Included in "Other assets" Restructuring Reserve, Current Restructuring liabilities Restructuring liabilities, balance Restructuring liabilities, balance Entity Address, City or Town Entity Address, City or Town AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Gain from recognition of receivable from licensing and collaboration agreements. Gain From Recognition Of Receivable From Licensing And Collaboration Agreements Gain from recognition of receivable from licensing and collaboration agreement Net loss from equity method investment Net loss from equity method investment Loss from equity method investment Income (Loss) from Equity Method Investments Difference of between fair value of equity investment and underlying equity in net assets Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Maximum amount of stock remaining eligible to be sold Sale of Stock, Maximum Amount Of Stock Remaining Eligible To Be Sold Sale of Stock, maximum amount of stock remaining eligible to be sold. Assets, Fair Value Disclosure [Abstract] Assets Upfront payment yet to be received Upfront Payment Yet To Be Received Upfront payment yet to be received. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unvested Shares of Restricted Stock Outstanding, Cancelled Payments for Restructuring Cash payments Debt Instrument, Face Amount Debt Instrument face amount Principal value Debt instrument convertible threshold consecutive trading day period. Debt Instrument Convertible Threshold Consecutive Trading Day Period Number of consecutive trading day period (Measurement period) for conversion of notes Proceeds from Sale of Productive Assets, Total Proceeds from Sale of Productive Assets Proceeds from sale of certain assets Restructuring Cost and Reserve [Line Items] Accounting Standards Update 2020-06 [Member] (ASU 2020-06) Share Price Repurchase of common stock price per share Purchase price per share Debt instrument option to purchase additional notes. Debt Instrument Option To Purchase Additional Notes Debt instrument option to purchase additional notes Private Placement [Member] Private Placement Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Construction in Progress [Member] Construction-in-Progress Number of common shares authorized to issue for issuance of awards Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Other Consolidated Entities. Other Consolidated Entities [Member] Other Subsidiaries Equity Plan Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Issuance of shares, shares Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total Leland Stanford Junior University Leland Stanford Junior University [Member] Leland Stanford Junior University. Restructuring Reserve, Settled without Cash Noncash activities Operating Lease, Weighted Average Discount Rate, Percent Operating leases Percentage of net vested shares of common stock to be issued Percentage Of Net Vested Shares Of Common Stock To Be Issued Percentage of net vested shares of common stock to be issued Fair Value Disclosures [Abstract] Amount paid to lenders Amount paid to Lenders Amount paid to lenders. Debt instrument convertible threshold business days. Debt Instrument Convertible Threshold Business Days Number of business days in consideration of conversion of notes Prepayment fee. Prepayment fee Prepayment fee Recognize license revenue. Recognize License Revenue Recognized license revenue Commissions on gross proceeds of sales of common stock. Commissions On Gross Proceeds Of Sales Of Common Stock Commissions on gross proceeds of sales of common stock Equity Securities, FV-NI, Unrealized Gain (Loss), Total Equity Securities, FV-NI, Unrealized Gain (Loss) Net unrealized losses recognized on investments in equity securities held as of the end of the period Unrealized gain on ongoing mark-to-market adjustments of investment in equity security Shares issued Stock Issued During Period, Value, New Issues Issuance of common stock under public offerings, net Regulatory milestone payments term. Regulatory Milestone Payments Term Regulatory milestone payments term Two thousand nineteen stock option and incentive plan and inducement equity plan. Two Thousand Nineteen Stock Option And Incentive Plan And Inducement Equity Plan [Member] A&R 2019 Plan and 2019 Inducement Plan Lessee, Lease, Description [Line Items] Lessee Lease Description [Line Items] Liabilities, Current [Abstract] Current liabilities: Loan security agreement. Loan Security Agreement [Member] Loan Security Agreement Unvested performance-based restricted stock unit. Unvested Performance Based Restricted Stock Unit [Member] Unvested Performance-Based RSUs Document Type Document Type Document Type Accrued Professional and Other Accrued Liabilities Accrued Professional and Other Accrued Liabilities, Policy [Policy Text Block] Accrued professional and other accrued liabilities, policy. Accounting Standards Update [Axis] Accounting Standards Update Cumulative Effect, Period of Adoption, Adjusted Balance [Member] Cumulative Effect, Period of Adoption, Adjusted Balance Exit fee Exit Fees Exit fees. Schedule of Provision for Income Taxes and the Effective Tax Rates Schedule of Provision for Income Taxes and the Effective Tax Rates [Table Text Block] Schedule of provision for income taxes and the effective tax rates. Foundation Medicine Diagnostics Agreement Foundation Medicine Diagnostics Agreement [Member] Foundation medicine diagnostics agreement. Debt instrument maturity date extension. Debt Instrument Maturity Date Extension Debt instrument maturity date extension Title of 12(b) Security Title of 12(b) Security Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Restructuring, impairment and related charges. Restructuring, Impairment and Related Charges [Member] Restructuring, Impairment and Related Charges Statement of Financial Position Location, Balance [Domain] Balance Sheet Location Lease, Cost [Table Text Block] Components of Lease Cost Performance-based milestone awards. Performance-Based Milestone Awards [Member] Performance-Based Milestone Awards Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Total intrinsic value of options exercised Research and development liabilities Research and development expense Research and development Research and Development Expense, Total Payment, Tax Withholding, Share-Based Payment Arrangement Repurchase of RSU shares to satisfy tax withholding Term loan, net Long-Term Debt, Excluding Current Maturities Long-Term Debt, Excluding Current Maturities, Total Percentage of close-out plan costs, subject to reimbursement Percentage Of Close-Out Plan Costs Subject To Reimbursement Percentage of close-out plan costs subject to reimbursement. Debt instrument, convertible, increase in conversion rate, number of common stock issuable. Debt Instrument Convertible Increase In Conversion Rate Number Of Common Stock Issuable Debt instrument, increase in conversion rate, number of shares issuable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Options Outstanding, Granted Incremental term loan. Incremental Term Loan [Member] Incremental Term Loan Asset Class [Domain] Asset Class Construction-in-progress asset Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Principal value of two point five zero percentage convertible senior notes due two thousand and twenty seven. Principal Value Of Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven [Member] 2027 Notes Subsequent Event Type [Domain] Maximum potential performance based milestone awards to be settled in shares. Maximum Potential Performance Based Milestone Awards To Be Settled In Shares Maximum potential milestone performance-based awards to be settled in fully-vested RSA Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Assumptions Used to Determine Fair Value of Stock Purchase Rights Debt instrument amortization payment date. Debt Instrument Amortization Payment Date Amortization payment date Assumed conversion of two thousand twenty nine notes. Assumed Conversion Of Two Thousand Twenty Nine Notes [Member] Assumed Conversion of 2029 Notes Two thousand twenty one capped call transactions. Two Thousand Twenty One Capped Call Transactions [Member] 2021 Capped Call Transactions Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Schedule of Activity Related to Restructuring Liabilities Associated to Restructuring Initiatives Agreement additional extension period option. Agreement Additional Extension Period Option Agreement additional extension period Loan and Security Agreement Loan and Security Agreement [Member] Loan and security agreement. Development milestone payments yet to be received. Development Milestone Payments Yet To Be Received Development milestone payments yet to be received Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Available-for-sale securities, continuous unrealized loss position, more than 12 months Supranational debt securities. Supranational Debt Securities [Member] Supranational Debt Securities Financial Instruments [Domain] Financial Instruments Percentage of ownership reduced for private equity financing Percentage of Ownership Reduced For Private Equity Financing Percentage of ownership reduced for private equity financing. Sale of Stock [Axis] Sale of Stock Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities: Investments [Domain] Investments Payments for Repurchase of Common Stock Repurchase of common stock Repurchases of common stock Unvested restricted stock award. Unvested Restricted Stock Award [Member] Unvested RSAs Debt Instrument, Repaid, Principal Principal payments Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Summary of Restricted Stock Units Activity Allocation of transaction price to licenses. Allocation Of Transaction Price To Licenses Allocation of transaction price to licenses Marketable Securities, Current Marketable Securities, Current, Total Marketable securities Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax, Total Revenue Statement of Comprehensive Income [Abstract] Share repurchase transactions. Share Repurchase Transactions [Member] Share Repurchase Transactions Reclassification of final payment obligation related to a manufacturing agreement that was recognized in the prior period (see Note 13) Reclassification of final payment obligation related to manufacturing agreement recognized in prior period. Reclassification Of Final Payment Obligation Related To Manufacturing Agreement Recognized In Prior Period Income Tax Disclosure [Text Block] Income Taxes Payable Related To Manufacturing Suite Payable related to manufacturing suite, Remaining payable related to dedicated manufacturing suite A&R 2019 Inducement Plan Two thousand nineteen inducement equity plan. Two Thousand Nineteen Inducement Equity Plans [Member] Ownership [Axis] Ownership Unpaid issuance costs. Unpaid Issuance Costs Unpaid issuance costs Consolidated Entities [Domain] Consolidated Entities TheRas, Inc The Ras Inc [Member] TheRas, Inc. Priority Review Voucher Priority Review Voucher [Member] Priority Review Voucher. Deferred and unpaid issuance cost for funding agreement. Deferred And Unpaid Issuance Cost For Funding Agreement Deferred and unpaid issuance cost for Funding Agreement Selling, General and Administrative Expense Selling, general and administrative Selling, General and Administrative Expense, Total Common Stock Held Common Stock Held Common stock held Stock Repurchased During Period, Value Stock repurchased, value In-licensing and other research and development agreements. In-Licensing And Other Research And Development Agreements [Abstract] In-Licensing and Other Research and Development Agreements [Abstract] Funding agreement. Funding Agreement [Abstract] Increase (decrease) in common shares reserved for future issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Total Transition Service Agreement Transition Service Agreement [Member] Transition service agreement. Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Net, Beginning Balance Finite-Lived Intangible Assets, Net, Ending Balance Finite-lived intangible asset Capitalization of finite-lived intangible asset Total Fair value of equity investment amount Fair Value of Equity Investment Amount Fair value of equity investment amount. Upfront payment received. Upfront Payment Received Upfront payment received Percentage of royalty interest payments on net sales. Percentage of Royalty Interest Payments on Net Sales Percentage of royalty interest payments on net sales Debt Instrument, Frequency of Periodic Payment Debt instrument, frequency of interest payment Other Accrued Liabilities, Current Other accrued liabilities Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Proceeds from (Payments for) Other Financing Activities Other financing activities Entity Address, Address Line Two Entity Address, Address Line Two Liabilities and Equity [Abstract] Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders' Deficit Gain (Loss) on Securities [Table Text Block] Summary of Total Realized and Unrealized Gains and Losses Associated with Investments in Equity Securities Document Period End Date Document Period End Date Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Reimbursable commercial contracted activities Reimbursable Commercial Contracted Activities Reimbursable commercial contracted activities. Origin Biosciences, Inc. Origin Biosciences Inc [Member] Origin Biosciences, Inc. Contractual Obligation, to be Paid, Year Four 2028 Effective Tax Rate Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent, Total Accounts Payable [Member] Accounts Payable Cash and cash equivalents fair value disclosure. Cash And Cash Equivalents Fair Value Disclosure [Abstract] Cash equivalents: Entities affiliated with Perceptive Life Sciences Master Fund Ltd. Entities Affiliated With Perceptive Life Sciences Master Fund Ltd [Member] Entities Affiliated With Perceptive Life Sciences Master Fund Ltd Debt Instrument, Convertible, Threshold Trading Days Debt instrument, convertible, threshold trading days Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of diluted net loss per share License and collaboration agreement. License And Collaboration Agreement [Member] License and Collaboration Agreement Base rate plus interest. Base Rate plus Interest [Member] Base Rate plus Interest Percentage of Underwriters Commissions Percentage of Underwriters Commissions on Gross Proceeds of Sales of Common Stock Percentage of underwriters commissions on gross proceeds of sales of common stock Two point five zero percentage convertible senior notes due two thousand and twenty seven and two thousand and twenty nine. Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven And Two Thousand And Twenty Nine [Member] 2027 and 2029 Notes Hannah A. Valentine [Member] Hannah A. Valentine. APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Deferred Revenue Deferred Revenue Deferred Revenue, Total Deferred revenue QED Therapeutics, Inc. Q E D Therapeutics Inc [Member] QED Therapeutics, Inc Income tax expense Income tax expense Total income tax expense Income Tax Expense (Benefit) Provision for income tax Debt Securities, Available-for-Sale [Abstract] Marketable securities: One time fees receivable noncurrent. One Time Fees Receivable Noncurrent One time fees asset non-current Trading Symbol Trading Symbol Weighted-average remaining lease term. Weighted Average Remaining Lease Term [Abstract] Weighted-average remaining lease term (in years) Cash Flow, Operating Activities, Lessee [Abstract] Cash paid for amounts included in the measurement of lease liabilities: Variable Rate [Axis] Variable Rate Equity, Attributable to Parent Stockholders' Equity Attributable to Parent, Beginning Balance Stockholders' Equity Attributable to Parent, Ending Balance Total BridgeBio stockholders' deficit Debt Instrument, Description of Variable Rate Basis Interest rate description The Nasdaq Global Select Market NASDAQ/NGS (GLOBAL SELECT MARKET) [Member] Unvested restricted stock unit. Unvested Restricted Stock Unit [Member] Unvested RSUs Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Other Liabilities, Noncurrent Other liabilities Other Liabilities, Noncurrent, Total Other long-term liabilities Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Debt Instrument, Convertible, Conversion Price Initial conversion price per share State State and Local Income Tax Expense (Benefit), Continuing Operations State and Local Income Tax Expense

(Benefit), Continuing Operations, Total Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) Sale of stock, number of shares issued and sold Sale of Stock, Number of Shares Issued in Transaction Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member] Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member] 2029 Notes Deferred revenue Deferred revenue Increase (Decrease) in Deferred Revenue Variable Lease, Cost Variable lease costs Property, Plant and Equipment [Table] Debt instrument market capitalization amount. Debt Instrument Market Capitalization Amount Market capitalization amount Equity Securities, FV-NI, Gain (Loss) Total net gains (losses) included in "Other income (expense), net" Loss from investment in equity securities, net Gain from investment in equity securities, net Percentage of aggregate amount not to exceed the original net cash proceeds received from asset sale transactions Percentage of Aggregate Amount not Exceed the Original Net Cash Proceeds Received from Asset Sale Transactions Percentage of aggregate amount not exceed the original net cash proceeds received from asset sale transactions. Share Repurchase Program [Axis] Share Repurchase Program Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock Based Compensation for Employees and Non Employees Nature of Operations [Text Block] Organization and Description of Business Maximum percentage of employee payroll deduction for stock purchase Maximum Percentage Of Employee Payroll Deduction For Stock Purchase Maximum percentage of employee payroll deduction for stock purchase. Receipt of escrow account Receipt Of Escrow Account Receipt of escrow account Future potential regulatory milestones Future Potential Regulatory Milestones Future potential regulatory milestones. Number of performance-based restricted stock awards issued in exchange of subsidiary equity. Number Of Performance Based Restricted Stock Awards Issued In Exchange Of Subsidiary Equity Number of Performance-Based RSAs issued in exchange of subsidiary equity Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized Losses Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized compensation cost Leases [Abstract] At-the-market offerings. At The Market Offering [Member] At-the-Market Offerings Restructuring and Related Costs [Table Text Block] Summary of Restructuring, Impairment and Related Charges Termination agreement. Termination Agreement [Member] Termination Agreement Use of Estimates, Policy [Policy Text Block] Use of Estimates Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block] Schedule of cash, cash equivalents and restricted cash. Proceeds from Issuance of Long-Term Debt, Total Proceeds from Issuance of Long-Term Debt Proceeds from term loan under Financing Agreement Percentage of automatic annual increase in number of shares reserved for future issuance Percentage Of Automatic Annual Increase In Number Of Shares Reserved For Future Issuance Percentage of automatic annual increase in number of shares reserved for future issuance. Underwriting fees and commissions Underwriting Fees and Commissions Underwriting fees and commissions. Purchase Agreement. Purchase Agreement [Member] Purchase Agreement Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, Minimum Schedule of future minimum lease payments for noncancelable operating and finance leases. Schedule Of Future Minimum Lease Payments For Noncancelable Operating And Finance Leases Table [Text Block] Schedule of Future Minimum Lease Payments for Noncancelable Leases Scenario [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Excess of purchase price over the value of common stock shares Excess Of Purchase Price Over Value Of Common Stock Shares Excess of purchase price over the value of common stock shares. Finite lived intangible assets amortization expense rolling after year four. Finite Lived Intangible Assets Amortization Expense Rolling After Year Four Amortization expenses, thereafter Security Exchange Name Security Exchange Name Business acquisition common share. Business Acquisition Common Share Right to receive of common stock Counterparty Name [Domain] Counterparty Name Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Fair Value by Liability Class [Domain] Equity Method And Cost Method Investment Abstract Equity Method And Cost Method Investment [Abstract] Contractual Obligation, to be Paid, Year Three 2027 Call option expense (income). Call Option Expense Income LEO call option income Gain on remeasurement of LEO call option liability Debt Instrument, Convertible, Number of Equity Instruments Debt instrument, conversion, equivalent shares of common stock Unbilled Receivables, Current Unbilled receivables Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Class of Stock [Axis] Class of Stock Legal Entity [Axis] Legal Entity Fair Value Disclosures [Text Block] Fair Value Measurements Lessee, Operating Lease, Liability, to be Paid, Year Three Operating leases, 2027 Weighted-average fair value of stock-based awards granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant date fair value of options granted Percentage share of global development costs. Percentage Share Of Global Development Costs Percentage share of global development costs Warrant to purchase percentage. Warrant To Purchase Percentage Warrant to purchase percentage Subsequent Event Subsequent Event [Member] Maximum [Member] Maximum Restructuring and Related Activities Disclosure [Text Block] Restructuring, Impairment and Related Charges Liabilities and Equity Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit Increase (decrease) in accrued research and development liabilities. Increase Decrease In Accrued Research And Development Liabilities Accrued research and development liabilities Maximum number of shares eligible to purchase during offering period Maximum Number Of Shares Eligible To Purchase During Offering Period Maximum number of shares eligible to purchase during offering period. Gain (Loss) on Extinguishment of Debt, Total Gain (Loss) on Extinguishment of Debt Loss on extinguishment of debt Loss on extinguishment of debt Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Royalty interest payments may adjust to maximum rate. Royalty Interest Payments May Adjust to Maximum Rate Royalty interest payments may adjust to maximum rate Supplemental Cash Flow Information [Abstract] Supplemental Disclosure of Cash Flow Information: Prime Rate [Member] Prime Rate Equity Method Investment and Other Equity Investments Investment [Text Block] Net loss per share attributable to common stockholders of BridgeBio, diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Asset Acquisition [Line Items] Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries Decrease In Cash And Cash Equivalents Resulting From Deconsolidation Of Entities Decrease in cash and cash equivalents resulting from deconsolidation of entities. Liabilities Total liabilities Market-Based Restricted Stock Units (RSUs). Market-Based Restricted Stock Units (RSUs) [Member] Restructuring and Related Cost, Expected Cost, Total Restructuring and Related Cost, Expected Cost Estimated charges to be incurred Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Assets, Current Total current assets Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Contractual obligation due after fourth year. Contractual Obligation Due After Fourth Year Thereafter Reimbursement percentage of research and development costs incurred. Reimbursement Percentage of Research and Development Costs Incurred Reimbursement percentage of research and development costs incurred Forecast Forecast [Member] Scenario Forecast Shares issued Stock Issued During Period, Shares, New Issues Issuance of common stock under public offerings, net, shares Cash Cash [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Proceeds from issuance of common stock net of issuance cost. Proceeds from Issuance of Common Stock Net of Issuance Cost Proceeds from issuance of common stock, net of issuance cost Satisfy tax withholding. Satisfy Tax Withholding [Member] Satisfy Tax Withholding Payment following FDA approval of Truseltiq. Payment Following F D A Approval Of Truseltiq [Member] Payment Following FDA Approval of Truseltiq Entity Filer Category Entity Filer Category Two thousand twenty stock and equity award exchange program. Two Thousand Twenty Stock And Equity Award Exchange Program [Member] 2020 Stock and Equity Award Exchange Program 2020 Stock and Equity Award Exchange Program Schedule of potential milestone amounts and accruals. Schedule Of Potential Milestone Amounts And Accruals Table [Text Block] Schedule of Potential Milestone Amounts and Accruals Estimated fair value of outstanding term loan. Estimated Fair Value of Outstanding Term Loan Estimated fair value of outstanding term loan Launch milestone payment. Launch Milestone Payment Launch milestone payment Equity, Including Portion Attributable to Noncontrolling Interest Ending balance Beginning balance Total stockholders' deficit Number of shares issued in exchange of subsidiary equity. Number Of Shares Issued In Exchange Of Subsidiary Equity Number of shares issued in exchange of subsidiary equity Payments to Acquire Marketable Securities Purchases of marketable securities Payments to Acquire Marketable Securities, Total Other income (expense), net: Nonoperating Income (Expense) [Abstract] Financing Agreement. Financing Agreement [Member] Financing Agreement Deconsolidation of a subsidiary Noncontrolling Interest, Decrease from Deconsolidation Current Fiscal Year End Date Current Fiscal Year End Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured on Recurring And Nonrecurring Basis [Line Items] Noncontrolling Interest [Member] Non-controlling Interests Operating leases, Imputed interest Operating leases, Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Capped call transactions. Capped Call Transactions [Member] 2020 Capped Call Transactions Restricted Stock Units (RSUs) 2029 Contractual Obligation, to be Paid, Year Five Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Share-based Payment Arrangement, Noncash Expense, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding, Ending balance Related and Nonrelated Parties [Axis] Related Party Interest Expense, Debt, Excluding Amortization Contractual interest expense Accrued unpaid interest Debt Instrument, Fee Amount Transaction-related fees Assumed conversion of two thousand twenty seven notes. Assumed Conversion Of Two Thousand Twenty Seven Notes [Member] Assumed Conversion of 2027 Notes Fair value assets transfers between level one level two or level three amount. Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount Fair value assets, transfers between Level 1, Level 2 or Level 3 PellePharm, Inc Pelle Pharm Inc [Member] PellePharm, Inc. Entity Registrant Name Entity Registrant Name Other income Other Income Finance Lease, Weighted Average Remaining Lease Term Finance lease Cost of Revenue, Total Cost of Revenue Cost of revenue Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Earnings Per Share [Text Block] Net Loss Per Share Debt Instrument, Maturity Date Maturity date Entity Emerging Growth Company Entity Emerging Growth Company Cost sharing credits received. Cost Sharing Credits Received Cost sharing credits received Potential milestone fixed monetary settlement amount. Potential Milestone Fixed Monetary Settlement Amount Total Potential Fixed Monetary Settlement Amount Accrued research and development expenses Accrued Research and Development Accrued research and development. Two thousand nineteen employee stock purchase plan. Two Thousand Nineteen Employee Stock Purchase Plan [Member] 2019 Employee Stock Purchase Plan Equity Method Investments and Joint Ventures [Abstract] Money Market Funds [Member] Money Market Funds Payment for an intangible asset Payments to Acquire Intangible Assets Potential milestone accrued settlement amount. Potential Milestone Accrued Settlement Amount Total Accrued Settlement Amount Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Leidos Biomedical Research, Inc Leidos Biomedical Research Inc [Member] Leidos Biomedical Research, Inc. Net of certain transaction expenses. Net of Certain Transaction Expenses Net of certain transaction expenses Noncontrolling Interest Disclosure [Text Block] Noncontrolling Interests Warrants Not Settled in Cash, Fair Value Disclosure Fair value of warrants Schedule of Equity Method Investments [Line Items] Schedule Of Equity Method Investments [Line Items] Supplemental agreement. Supplemental Agreement [Member] Supplemental Agreement Public Offerings, Share Repurchase Program And Securities Purchase Agreement. Public Offerings, Share Repurchase Program And Securities Purchase Agreement [Line Items] Bayer Consumer Care AG and Kyowa Kirin Co., Ltd Bayer Consumer Care AG and Kyowa Kirin Co., Ltd [Member] Bayer consumer care AG and kyowa kirin co., ltd. Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, Maximum Common stock options issued and outstanding. Common Stock Options Issued And Outstanding [Member] Common Stock Options Issued and Outstanding Common Stock, Shares Authorized Common stock, shares authorized Share Repurchase Program [Domain] Share Repurchase Program Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Repurchase of RSU shares to satisfy tax withholding, shares Accrued interest Interest Payable, Current Interest payable Schedule of Long-Term Debt Instruments [Table Text Block] Schedule of Loans Balances Proceeds from issuance of common stock through Follow-on offering, net Net proceeds issued from offerings Proceeds from issuance of common stock through public offerings, net Proceeds from Sale and Maturity of Marketable Securities Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities, Total Noncontrolling Interest, Period Increase (Decrease) Transfers from (to) noncontrolling interests Noncontrolling Interest, Period Increase (Decrease), Total Cash and Cash Equivalents [Abstract] Finance Lease, Interest Expense Interest on finance lease liability Finance lease costs Equity Method Investment, Nonconsolidated Investee [Axis] Fair Value, Inputs, Level 1 [Member] Level 1 Debt Disclosure [Abstract] Proceeds from issuance of notes after deducting discount and offering expenses. Proceeds From Issuance Of Notes After Deducting Discount And Offering Expenses Proceeds from issuance of notes after deducting discount and offering expenses Onetime payment amount paid to purchasers. Onetime Payment Amount Paid to Purchasers Onetime payment amount paid to purchasers Entity Listings, Exchange [Axis] Schedule of cash equivalents and marketable securities. Schedule Of Cash Equivalents And Marketable Securities Table [Text Block] Schedule of Cash Equivalent and Marketable Securities Classified as Available-for-Sale Debt discount, issuance costs and exit fee accretion Debt Instrument Unamortized Discount Premium Debt Issuance Costs And Exit Fees Accretion Debt instrument unamortized discount premium debt issuance costs and exit fees accretion. Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-Average Exercise Price per Option, Granted Amortization of Intangible Assets Amortization of Intangible Assets, Total Amortization expenses Financial Instrument [Axis] Financial Instrument Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Unpaid issuance costs Unpaid issuance costs associated with term loan under Financing Agreement Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Life (years), Outstanding, Ending balance Funding Agreement. Funding Agreement [Member] Payment in Kind (PIK) Note [Member] Payment in Kind Accrual for milestones not probable. Accrual for Milestones Not Probable Accrual for milestones not probable Impairment, Long-Lived Asset, Held-for-Use, Total Impairment of long-lived assets Impairment loss Long-lived assets impairments and write-offs Unpaid public offering issuance costs. Unpaid Public Offering Issuance Costs Unpaid public offering issuance costs Share-Based Payment Arrangement [Abstract] Accrued professional and other accrued liabilities Accrued professional and other accrued liabilities Accrued Professional And Other Accrued Liabilities Current Accrued professional and other accrued liabilities current. Potential milestone accrued amount settlement in cash. Potential Milestone Accrued Amount Settlement In Cash Accrued Amount Settlement in Cash Financing activity transactions with noncontrolling interests. Financing Activity Transactions With Noncontrolling Interests Transactions with noncontrolling interests Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Issuance of shares Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total Other Liabilities [Member] Other liabilities Equity Securities, FV-NI, Current Equity security investment Investments in equity securities Schedule of employees and non-employees service share-based compensation. Schedule Of Employees And Non Employees Service Share Based Compensation [Table] Schedule Of Employees And Non Employees Service Share Based Compensation [Table] Weighted-average discount rate. Weighted Average Discount Rate [Abstract] Weighted-average discount rate Proceeds from Issuance of Warrants Net proceeds received as special cash dividends Remaining balance in escrow accounts Remaining Balance in Escrow Accounts Remaining balance in escrow accounts. Debt instrument prepayment percentage. Debt Instrument Prepayment Percentage Prepayment percentage Debt Securities, Available-for-Sale Estimated Fair Value Debt Securities, Available-for-sale, Total Accounting Policies [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activity Regulatory and sales-based milestone payments yet to be received. Regulatory and Sales-based Milestone Payments Yet to be Received Regulatory and sales-based milestone payments yet to be received Cash and Cash Equivalents [Line Items] Cash And Cash Equivalents [Line Items] Income Tax Disclosure [Abstract] Equity Method Investee's IPO Equity Method Investee's IPO [Member] Equity Method Investee's IPO. Equity, Attributable to Parent [Abstract] Stockholders' equity (deficit): Project Agreement. Project Agreement [Member] Resilience PAs SOFR plus interest. SOFR plus Interest [Member] SOFR plus Interest Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Disposal Group Name [Domain] Statement [Table] Statement [Table] Redeemable convertible noncontrolling interests. Redeemable Convertible Noncontrolling Interests [Member] Redeemable Convertible Noncontrolling Interests Purchase of capped calls. Purchase Of Capped Calls Purchase of capped calls Purchase of capped calls Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total Comprehensive loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests Comprehensive loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests Comprehensive loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests Subsequent Event [Table] Accrued Liabilities and Other Liabilities [Abstract] Upfront, regulatory and launch milestone payments yet to be received. Upfront Regulatory And Launch Milestone Payments Yet To Be Received Upfront, regulatory and launch milestone payments yet to be received Manufacturing agreement. Manufacturing Agreement [Member] Manufacturing Agreement Preferred

Stock, Shares Authorized Preferred stock, shares authorized Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Accrued research and development liabilities current. Accrued Research And Development Liabilities Current Accrued research and development liabilities Fair Value Adjustment of Warrants Fair value adjustment of warrants Securities Act File Number Entity File Number Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Performance based restricted stock awards. Performance Based Restricted Stock Awards [Member] Performance-Based RSAs Earnings Per Share [Abstract] Milestone liability. Milestone Liability Milestone liability Service agreement term. Service Agreement Term Agreement term Gain (Loss) on Sale of Investments, Total Gain (Loss) on Sale of Investments Realized net gains from investment Summary of Accrued Professional and Other Accrued Liabilities Schedule Of Accrued Professional and Other Accrued Liabilities Table [Text Block] Schedule of accrued professional and other accrued liabilities. Contractual Obligation, Fiscal Year Maturity [Table Text Block] Schedule of Future Minimum Payments Statement of Financial Position [Abstract] Interest Expense, Operating and Nonoperating Interest expense Interest Expense, Total Trading arrangement securities sold Trading Arrangement Securities Sold Trading arrangement securities sold. Kyowa kirin exclusive license. Kyowa Kirin Exclusive License [Member] Kyowa Kirin Exclusive License Loss from operations Operating Income (Loss) Securities Sold, Not yet Purchased [Member] Securities Sold Not Yet Purchased Shares issued, price per share Public offering price per share Shares Issued, Price Per Share Entity Shell Company Entity Shell Company Increase (decrease) receivable from licensing and collaboration agreements. Increase Decrease Receivable From Licensing And Collaboration Agreements Licensing and collaboration agreements Receivables from licensing and collaboration agreements Accrued termination charges. Accrued Termination Charges Accrued termination charges Accrued Professional Fees, Current Accrued professional services Debt Instrument, Interest Rate, Effective Percentage Effective interest rate Entity Tax Identification Number Entity Tax Identification Number Potential milestone accrued amount settlement in cash or stock at sole discretion. Potential Milestone Accrued Amount Settlement In Cash Or Stock At Sole Discretion Accrued Amount Settlement in Cash or stock at our sole discretion Assets [Abstract] Assets Entity Current Reporting Status Entity Current Reporting Status Threshold percentage of stock price trigger in measurement period. Threshold Percentage Of Stock Price Trigger In Measurement Period Threshold percentage of stock price trigger in measurement period Restricted cash Restricted Cash and Cash Equivalents, Current, Total Restricted Cash and Cash Equivalents, Current Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common stockholders of BridgeBio Adjustments of carrying value of noncontrolling interest additional paid-in capital. Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital Adjustments of carrying value of noncontrolling interest additional paid-in capital Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Life (years), Exercisable Debt Securities, Available-for-sale, Realized Gain (Loss), Total Debt Securities, Available-for-Sale, Realized Gain (Loss) Realized gains or losses on available-for-sale securities Rule 10b5-1 Trading Plan [Member] Rule 10b5-1 Trading Plan. Percentage of additional minimum qualified balance on cash released from escrow accounts Percentage of Additional Minimum Qualified Balance on Cash Released from Escrow Accounts Percentage of additional minimum qualified balance on cash released from escrow accounts. Navire Navire Pharma, Inc Navire Pharma Inc [Member] Navire Pharma, Inc. Long-Term Debt, Type [Axis] Leidos Biomedical Research License and Cooperative Research and Development Agreements Leidos Biomedical Research License And Cooperative Research And Development Agreements [Member] Leidos biomedical research license and cooperative research and development agreements. Subsequent Events [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus First installment due amount, paid Payments of First Installment Due Amount Related to Regulatory Milestone Payments Payments of first installment due amount related to regulatory milestone payments. Business combination potential cash consideration. Business Combination Potential Cash Consideration Cash consideration Payment-in-kind interest added to principal of term loan Payment-in-kind Interest Added to Principal of Term Loan Payment-in-kind interest added to principal of term loan. Proceeds from Equity Method Investment, Distribution, Return of Capital Proceeds from special cash dividends received from investments in equity securities Other accrued liabilities. Other Accrued Liabilities [Member] Other Accrued Liabilities Preferred Stock, Value, Issued Undesignated preferred stock, \$0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Derecognition of capitalized finite lived Intangible asset net. Derecognition of Capitalized Finite Lived Intangible Asset Net Derecognition of capitalized intangible asset net. Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two Amortization expenses, 2023 Amortization expenses, 2026 Debt instrument prepaid includes final payment charge and prepayment fee Repayments of Long-Term Debt Repayments of Long-Term Debt, Total Repayment of term loan under Loan and Security Agreement Repayment of term loan under Loan and Security Agreement Two thousand twenty one share repurchase program. Two Thousand Twenty One Share Repurchase Program [Member] 2021 Share Repurchase Program Unpaid property and equipment Capital Expenditures Incurred but Not yet Paid Finite-Lived Intangible Assets, Accumulated Amortization Intangible assets less accumulated amortization Less: accumulated amortization Interest adjust on two point two five percentage convertible senior notes due two thousand and twenty nine. Interest Adjust On Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member] Interest on 2029 Notes Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows Adjustments to additional paid in capital related to premium payments. Adjustments To Additional Paid In Capital Related To Premium Payments Adjustments to additional paid in capital related to premium payments City Area Code City Area Code Definitive agreement to sell Disposal Group, Including Discontinued Operation, Consideration Contractual Obligation, to be Paid, Year One 2025 Liabilities, Current Total current liabilities Proceeds from Dividends Received Net proceeds received as special cash dividends Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender Pre-tax impairment gain (loss) on asset. Pre-tax Impairment Gain (Loss) on Asset Pre-tax impairment loss on asset Commercial Product Supply Commercial Product Supply [Member] Commercial product supply. Proceeds from Debt, Net of Issuance Costs Proceeds from term loan Payments to Acquire Additional Interest in Subsidiaries Cash consideration paid Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration] Restricted Cash, Noncurrent, Asset, Statement of Financial Position [Extensible List] Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Impairment loss Operating Lease, Impairment Loss Summary of significant accounting policies. Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Public Offerings, Share Repurchase Program and Securities Purchase Agreement. Public Offerings, Share Repurchase Program And Securities Purchase Agreement [Table] Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Business Exit Costs Winding down, exit and other related costs Performance based milestone awards period for recognition. Performance Based Milestone Awards Period For Recognition Performance-based milestone awards period for recognition Tranche two advance Tranche Two Advance [Member] Tranche 2 Advance License agreement percentage share of profits and losses. License Agreement Percentage Share Of Profits And Losses License agreement percentage share of profits and losses Voting interest entity investment threshold, percentage. Voting Interest Entity Investment Threshold Percentage Percentage of voting shares Commitments and Contingencies Disclosure [Abstract] Principal value and interest on two thousand and twenty seven and two thousand and twenty nine. Principal Value and Interest on Two Thousand And Twenty Seven and Two Thousand And Twenty Nine [Member] 2027 Notes and Interest on 2027 Notes and 2029 Notes and Interest on 2029 Notes Treasury stock, at cost; 6,191,761 shares as of June 30, 2024 and December 31, 2023 Treasury Stock, Value Treasury Stock, Value, Total Treasury Stock, Value, Beginning Balance Treasury Stock, Value, Ending Balance Shares Acquired, Average Cost Per Share Stock repurchased, average price per share Payable termination fees for other existing services. Payable Termination Fees for Other Existing Services Payable related to termination fees for other existing services Debt Issuance Costs, Net Debt issuance costs including initial purchasers discounts, legal and other professional fees Unamortized debt issuance costs Debt Issuance Costs, Net, Total Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Basis Reimbursement percentage of commercial activity costs incurred. Reimbursement Percentage of Commercial Activity Costs Incurred Reimbursement percentage of commercial activity costs incurred Scheduled amortization payments. Scheduled Amortization Payments [Member] Scheduled Amortization Payments Debt instrument net leverage ratio. Debt Instrument Net Leverage Ratio Net leverage ratio Operating Lease, Liability, Current Operating lease liabilities, current portion Underwriting discounts and commissions Underwriting Discounts and Commissions underwriting discounts and commissions. Debt Instrument, Interest Rate, Stated Percentage Stated interest rate Retained Earnings [Member] Accumulated Deficit Amortization of Debt Issuance Costs and Discounts Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts, Total Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Initial transaction price for license and collaboration agreement. Initial Transaction Price For License And Collaboration Agreement Initial transaction price for the license and collaboration agreement Increase in initial transaction price for license and collaboration agreement. Increase in Initial Transaction Price for License and Collaboration Agreement Increase in initial transaction price for license and collaboration agreement BridgeBio Oncology Therapeutics. Bridge Bio Oncology Therapeutics [Member] BridgeBio Oncology Therapeutics Document Transition Report Document Transition Report Temporary equity, ending balance Temporary equity, beginning balance Redeemable convertible noncontrolling interests Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests Temporary equity carrying amount net including portion attributable to noncontrolling interests Debt Instrument, Date of First Required Payment Interest payable beginning date Share Repurchase Program, Authorized, Amount Share repurchase program, authorized amount Increase (Decrease) in Other Operating Assets other assets Increase (Decrease) in Other Operating Assets, Total Purchase price as percentage of lower of fair market value as of beginning or end of offering period Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Lessee, Operating Lease, Liability, to be Paid, Year Two Operating leases, 2026 Contractual Obligation, to be Paid, Remainder of Fiscal Year 2022 Remainder of 2024 Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Temporary Equity, Net Income Temporary Equity, net income (loss) Reimbursable payment received Reimbursable Payment Received Reimbursable Payment Received Proceeds from Stock Plans Proceeds from BridgeBio common stock issuances under ESPSP Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-Average Exercise Price per Option, Exercised Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Unamortized debt discount and issuance costs Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Amortization expenses, remainder period Amortization expenses, remainder of 2022 Minimum [Member] Minimum Minimum Common Stock [Member] Common Stock Net proceeds deposited to escrow accounts Net Proceeds Deposited to Escrow Accounts Net proceeds deposited to escrow accounts. Warrants, fair value disclosure. Warrants Fair Value Disclosure LianBio Warrant Investment, Name [Axis] Investment, Name Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Ending balance Weighted-Average Grant Date Fair Value, Beginning balance Weighted average grant date fair value Additional Paid-in Capital [Member] Additional Paid-in Capital Debt Securities, Available-for-sale, Current, Total Debt Securities, Available-for-Sale, Current Total marketable securities Potential milestone fixed monetary amount settlement in cash. Potential Milestone Fixed Monetary Amount Settlement In Cash Potential Fixed Monetary Amount Settlement in Cash Sale of stock premium over last reported sale price percentage. Sale Of Stock Premium Over Last Reported Sale Price Percentage Premium over last reported sale price percentage Variable Interest Entity [Table] Schedule Of Variable Interest Entities [Table] Estimated shares issuable performance based milestone compensation arrangement. Estimated Shares Issuable Performance Based Milestone Compensation Arrangement [Member] Estimated Shares Issuable Performance Based Milestone Compensation Arrangement Estimated Shares Issuable Under Performance-Based Milestone Compensation Arrangements Percentage of principal amount to be repurchased in fundamental change. Percentage Of Principal Amount To Be Repurchased In Fundamental Change Percentage of principal amount to be repurchased in fundamental change Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Short-term Marketable Securities Short-Term Investments [Member] Property, Plant and Equipment [Member] Property and Equipment Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss: Statement of Income Location, Balance [Domain] Income Statement Location Lessee, Operating Lease, Liability, to be Paid, Year One Operating leases, 2025 Other Assets, Noncurrent Other assets Other Assets, Noncurrent, Total Payment for disposition fee Payment for Disposition Fee Payment for disposition fee. Proceeds from term loan, net of issuance costs Payments of Financing Costs, Total Payments of Financing Costs Payment of debt discount and issuance costs Issuance costs associated with term loan Commitments and Contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Helsinn Therapeutics. Helsinn Therapeutics [Member] Helsinn Therapeutics Goodwill and Intangible Assets Disclosure [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Noncash lease expense Noncash Lease Expense Noncash Lease Expense Share-Based Payment Arrangement, Plan Modification, Number of Grantees Affected Number of grantees Debt Instrument, Convertible, Conversion Ratio Conversion rate Accrued professional and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued exit fees. Accrued Exit Fees Accrued exit fees Cash Equivalents Unrealized Losses Cash Equivalents Unrealized Losses Unrealized Losses Unrealized Losses Equity, Attributable to Noncontrolling Interest Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance Stockholders' Equity Attributable to Noncontrolling Interest, Total Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance Exchange [Domain] Principal value and interest on two point two five percentage convertible senior notes due two thousand and twenty nine. Principal Value And Interest On Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member] 2029 Notes and Interest on 2029 Notes Basis of Accounting, Policy [Policy Text Block] Basis of Presentation and Principles of Consolidation Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Scenario [Domain] Debt Issuance Costs, Noncurrent, Net Debt issuance costs allocated to liability component Debt Issuance Costs, Noncurrent, Net, Total Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Debt issuance costs allocated to equity component Proceeds received from asset sale transactions Proceeds Received from Asset Sale Transactions Proceeds received from asset sale transactions. Common stock, \$0.001 par value; 500,000,000 shares authorized; 194,224,499 shares issued and 188,032,738 shares outstanding as of June 30, 2024, 181,274,712 shares issued and 175,082,951 shares outstanding as of December 31, 2023 Common Stock, Value, Issued Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Asset Acquisition [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Increase (Decrease) in Employee Related Liabilities Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities, Total Children intended for treatment with canavan disease maximum age. Children Intended For Treatment With Canavan Disease Maximum Age Children intended for treatment with Canavan Disease, under the age. Investment Income, Interest Interest income Gain (Loss) on Disposition of Assets, Total Gain (Loss) on Disposition of Assets Loss on sale of certain assets Restructuring, Settlement and Impairment Provisions Total Restructuring, impairment and related charges Cash and Cash Equivalents, Fair Value Disclosure Cash Equivalents, Estimated Fair Value Total cash equivalents Cash Equivalents, Estimated Fair Value Debt instrument principal amount denomination for conversion into common stock. Debt Instrument Principal Amount Denomination For Conversion Into Common Stock Denomination of the principal amount of debt in consideration conversion of the notes Cash and Cash Equivalent [Table] Schedule Of Cash And Cash Equivalents [Table] Proceeds from Sale of Equity Securities, FV-NI Proceeds from sales of investments in equity securities License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses. License Agreements Share Of Co Commercialization Loss As Reduction To Selling General And Administrative Expenses License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses Percentage of excise tax benefit on corporate stock buy-back. Percentage of Excise Tax Benefit on Corporate Stock Buy-Back Percentage of excise tax on corporate stock buy-back Debt Instrument, Offering Date Debt instrument issuance date Cash, cash equivalents and restricted cash maturity period Cash Cash Equivalents And Restricted Cash Maturity Period Cash cash equivalents and restricted cash maturity period. Dr. Brian Stephenson [Member] Dr Brian Stephenson [Member] Dr. Brian Stephenson. Contingent Consideration Type [Domain] Contingent Consideration Type Operating lease liabilities Operating Lease, Liability Operating lease liabilities Total operating lease liabilities Measurement Frequency [Axis] Measurement Frequency Percentage of total unbilled receivables Percentage of Unbilled Receivables Percentage of unbilled receivables. Commitments

and contingencies (Note 8) Commitments and Contingencies Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months Amortization expenses, 2022 Amortization expenses, 2025 Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Tranche A loan. Tranche A Loan [Member] Tranche A Loan number of shares covered by capped calls. Number Of Shares Covered By Capped Calls Number of shares covered by capped calls Schedule of supplemental information related to remaining lease term and discount rate. Schedule Of Supplemental Information Related To Remaining Lease Term And Discount Rate Table [Text Block] Schedule of Supplemental Information Related to Remaining Lease Term and Discount Rate Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted. Total Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Gain on deconsolidation carrying values of net assets held Gain on Deconsolidation Carrying Values of Net Assets Held Gain on deconsolidation carrying values of net assets held. Cumulative accrued interest convertible into principal Debt Instrument Cumulative Accrued Interest Convertible Into Principal Debt instrument cumulative accrued interest convertible into principal. Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Repurchase of Eidos noncontrolling interests for cash and shares, including transaction costs of \$70,734 Difference recognized in equity Debt instrument capped call transaction cap price per share. Debt Instrument Capped Call Transaction Cap Price Per Share Capped call transaction, cap price per share Lessee, Operating Lease, Liability, to be Paid Operating leases, Total future minimum lease payments Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three Amortization expenses, 2024 Amortization expenses, 2027 Origin and sentynl therapeutics, inc. Origin and Sentynl Therapeutics, Inc. [Member] Origin-Sentynl APA In-licensing and other research and development agreements disclosure. In-Licensing And Other Research And Development Agreements Disclosure [Text Block] In-licensing and Other Research and Development Agreements Deferred and unpaid issuance cost recorded to accrued professional and other accrued liabilities. Deferred And Unpaid Issuance Cost Recorded To Accrued Professional And Other Accrued Liabilities Deferred and unpaid issuance costs recorded to "Accrued professional and other accrued liabilities" Funding agreement. Funding Agreement [Text Block] Funding Agreement Estimated shares issuable employee stock purchase plan. Estimated Shares Issuable Employee Stock Purchase Plan [Member] Estimated Shares Issuable Under the ESPP Foreign Foreign Income Tax Expense (Benefit), Continuing Operations Foreign Income Tax Expense (Benefit), Continuing Operations, Total Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss Entity Small Business Entity Small Business Incremental compensation cost for awards modification. Incremental Compensation Cost For Awards Modification Incremental compensation cost for awards modification Adrenas Therapeutics Inc. Adrenas Therapeutics Inc [Member] Adrenas Therapeutics, Inc Adrenas Debt Instrument, Basis Spread on Variable Rate Interest rate Potential milestone accrued amount settlement in stock. Potential Milestone Accrued Amount Settlement In Stock Accrued Amount Settlement in Stock Debt Disclosure [Text Block] Debt Foundation Medicine, Inc Foundation Medicine Inc [Member] Foundation Medicine, Inc. Accrued research and development liabilities. Accrued Research and Development Liabilities [Member] Accrued Research and Development Liabilities Unrealized Gains Cash Equivalents Unrealized Gains Cash equivalents unrealized gains. Accrual of payment-in-kind interest on term loan Accrual Of Payment In Kind Interest On Term Loan Accrual of payment-in-kind interest on term loan. Revenue Revenues Revenues, Total Nonrefundable upfront payment receivable. Nonrefundable Upfront Payment Receivable Nonrefundable upfront payment receivable US Treasury Securities [Member] U.S. Treasury Notes U.S. Treasury Notes Royalty interest payments equal to cap amount. Royalty Interest Payments Equal to Cap Amount Royalty interest payments equal to cap amount BridgeBio pharma limited liability company. Bridge Bio Pharma Limited Liability Company [Member] Bridge Bio Pharma Limited Liability Company Proceeds from sale of priority review voucher Proceeds From Sale Of Priority Review Voucher Proceeds from sale of priority review voucher. Gross proceeds from sale of priority review voucher Allocation of transaction price for research and development Allocation Of Transaction Price For Research and Development Allocation Of Transaction Price for Research and Development. Initial term loan. Initial Term Loan [Member] Initial Term Loan Allocation of transaction price to transfer of existing inventory. Allocation Of Transaction Price To Transfer Of Existing Inventory Allocation of transaction price to transfer of certain existing inventory Two thousand twenty one stock option and incentive plan. Two Thousand Twenty One Stock Option And Incentive Plan [Member] 2021 A&R Plan Contractual Obligation Total future payments Resilience Agreements Resilience Agreements [Member] Resilience Agreements Silicon valley bank and Hercules loan. Silicon Valley Bank And Hercules Loan [Member] Silicon Valley Bank and Hercules Loan Agreement Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities: Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price per Option, Outstanding, Ending balance Weighted-Average Exercise Price per Option, Outstanding, Beginning balance Net carrying amount Notes, net Convertible Notes Payable, Noncurrent Asset Class [Axis] Asset Class Principal value on two point two five percentage convertible senior notes due two thousand and twenty nine. Principal Value On Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member] 2029 Notes Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill), Total Intangible assets, net Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating lease right-of-use assets obtained in exchange for operating lease obligations ATM Offering. ATM Offering Member ATM Offering Measurement Frequency [Domain] Measurement Frequency Noncontrolling Interest [Abstract] Regulatory and sales milestones. Regulatory and sales milestones Fair Value, Inputs, Level 3 [Member] Level 3 Operating Lease, Weighted Average Remaining Lease Term Operating leases Term loan after January seventeen two thousand twenty four. Term Loan After January Seventeen Two Thousand Twenty Four [Member] Term Loan After January 17, 2024 Bayer Exclusive License Agreement. Bayer Exclusive License Agreement [Member] Bayer Exclusive License Agreement Subsequent Events [Text Block] Subsequent Events Minimum threshold percentage of aggregate principal by trustee or holders. Minimum Threshold Percentage Of Aggregate Principal By Trustee Or Holders Minimum threshold percentage of aggregate principal by trustee or holders Share-Based Payment Arrangement [Member] Equity Compensation Plans Principal value of convertible senior notes due two thousand and twenty nine and two thousand and twenty seven. Principal Value Of Convertible Senior Notes Due Two Thousand And Twenty Nine And Two Thousand And Twenty Seven [Member] 2029 Notes and 2027 Notes Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Debt instrument tranche three. Debt Instrument Tranche Three [Member] Tranche III Wholly Owned Subsidiary Disclosure. Wholly Owned Subsidiary Disclosure [Text Block] Eidos Deferred Offering Costs Deferred issuance costs Deferred offering costs Costs and Expenses Total operating costs and expenses Total financial liabilities Liabilities, Fair Value Disclosure Lease Agreements and Letters of Credit Lease Agreements and Letters of Credit [Member] Lease agreements and letters of credit. Regulatory-based milestone payment Regulatory Based Milestone Payment Regulatory based milestone payment. Debt instrument deposit percentage of proceeds net of certain permitted costs upon receipt of upfront payments from license agreements Debt instrument deposit percentage of proceeds net of certain permitted costs upon receipt of upfront payments from license agreements Accounts Receivable, Allowance for Credit Loss, Beginning Balance Accounts Receivable, Allowance for Credit Loss, Ending Balance Accounts Receivable, Allowance for Credit Loss Allowance for credit losses XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Jul. 25, 2024 Cover [Abstract] A A Document Type 10-Q A Amendment Flag false A Document Period End Date Jun. 30, 2024 A Document Fiscal Year Focus 2024 A Document Fiscal Period Focus Q2 A Trading Symbol BBIO A Entity Registrant Name BridgeBio Pharma, Inc. A Entity Central Index Key 0001743881 A Current Fiscal Year End Date -12-31 A Entity Filer Category Large Accelerated Filer A Entity Current Reporting Status Yes A Entity Small Business false A Entity Emerging Growth Company false A Entity Shell Company false A Entity File Number 001-38959 A Entity Incorporation, State or Country Code DE A Entity Tax Identification Number 84-1850815 A Entity Address, Address Line One 3160 Porter Drive A Entity Address, Address Line Two Suite 250 A Entity Address, City or Town Palo Alto A Entity Address, State or Province CA A Entity Address, Postal Zip Code 94304 A City Area Code 650 A Local Phone Number 391-9740 A Entity Common Stock, Shares Outstanding A 188,032,738 Document Quarterly Report true A Document Transition Report false A Entity Interactive Data Current Yes A Title of 12(b) Security Common Stock, par value \$0.001 per share A Security Exchange Name NASDAQ A X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + References No definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Area code of city + References No definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Cover page. + References No definition available. + Details Name: dei CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition End date of current fiscal year in the format --MM-DD. + References No definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:MonthDayItemType Balance Type: na Period Type: duration X - Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + References No definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + References No definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:YearItemType Balance Type: na Period Type: duration X - Definition For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + References No definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateTimeItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as an quarterly report. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as a transition report. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + References No definition available. + Details Name: dei DocumentType Namespace Prefix: dei_ Data Type: dei:submissionItemType Balance Type: na Period Type: duration X - Definition Address Line 1 such as Attn, Building Name, Street Name + References No definition available. + Details Name: dei EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Address Line 2 such as Street or Suite number + References No definition available. + Details Name: dei EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the City or Town + References No definition available. + Details Name: dei EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Code for the postal or zip code + References No definition available. + Details Name: dei EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the state or province. + References No definition available. + Details Name: dei EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + References No definition available. + Details Name: dei EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition Indicate if registrant meets the emerging growth company criteria. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - Definition Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - Definition Two-character EDGAR code representing the state or country of incorporation. + References No definition available. + Details Name: dei EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Indicates that the company is a Smaller Reporting Company (SRC). + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - Definition Local phone number for entity. + References No definition available. + Details Name: dei LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Title of a 12(b) registered security. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - Definition Name of the Exchange on which a security is registered. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - Definition Trading symbol of an instrument as listed on an exchange. + References No definition available. + Details Name: dei TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 11 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets: A A Cash and cash

equivalents \$ 407,958 \$ 375,935 [1] Marketable securities 39,813 0 Investments in equity securities 0 58,949 [1] Receivables from licensing and collaboration agreements 660 1,751 [1] Restricted cash 139,409 16,653 [1] Prepaid expenses and other current assets 28,396 24,305 [1] Total current assets 616,236 477,593 [1] Investment in nonconsolidated entity 117,006 0 Property and equipment, net 9,840 11,816 [1] Operating lease right-of-use assets 7,267 8,027 [1] Intangible assets, net 55,123 26,319 [1] Other assets 18,903 22,625 [1] Total assets 794,375 546,380 [1] Current liabilities: $\hat{A}$ $\hat{A}$ Accounts payable 18,126 10,655 [1] Accrued compensation and benefits 29,056 57,370 [1] Accrued research and development liabilities 33,178 29,765 [1] Operating lease liabilities, current portion 4,623 4,128 [1] Deferred revenue, current portion 15,098 6,096 [1] Accrued professional and other accrued liabilities 34,283 35,830 [1] Total current liabilities 134,364 143,844 [1] Term loan, net 435,447 446,445 [1] Operating lease liabilities, net of current portion 7,059 8,981 [1] Deferred revenue, net of current portion 16,961 3,727 [1] Other long-term liabilities 485 5,634 [1] Total liabilities 1,876,468 1,888,915 [1] Commitments and contingencies (Note 8) Redeemable convertible noncontrolling interests (223) 478 Stockholders' equity (deficit): $\hat{A}$ $\hat{A}$ Undesignated preferred stock, \$0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding common stock, \$0.001 par value; 500,000,000 shares authorized; 194,224,499 shares issued and 188,032,738 shares outstanding as of June 30, 2024, 181,274,712 shares issued and 175,082,951 shares outstanding as of December 31, 2023 194 181 [1] Treasury stock, at cost; 6,191,761 shares as of June 30, 2024 and December 31, 2023 (275,000) (275,000) [1] Additional paid-in capital 1,851,058 1,481,032 [1] Accumulated other comprehensive income (4) 31 [1] Accumulated deficit (2,669,173) (2,560,501) [1] Total BridgeBio stockholders' deficit (1,092,925) (1,354,257) [1] Noncontrolling interests 11,055 11,244 [1] Total stockholders' deficit (1,081,870) (1,343,013) [1][2] Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit 794,375 546,380 [1] 2029 Notes $\hat{A}$ $\hat{A}$ Current liabilities: $\hat{A}$ $\hat{A}$ Notes, net 737,882 736,905 [1] 2027 Notes $\hat{A}$ $\hat{A}$ Current liabilities: $\hat{A}$ $\hat{A}$ Notes, net \$ 544,270 \$ 543,379 [1] [1] The condensed consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements as of that date. [2] The consolidated balances as of December 31, 2023 and 2022 are derived from the audited consolidated financial statements as of those dates. X - DefinitionAccrued professional and other accrued liabilities current. + ReferencesNo definition available. + Details Name: bbio_AccruedProfessionalAndOtherAccruedLiabilitiesCurrentNamespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued research and development liabilities current. + ReferencesNo definition available. + Details Name: bbio_AccruedResearchAndDevelopmentLiabilitiesCurrentNamespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionConvertible senior notes. + ReferencesNo definition available. + Details Name: bbio_ConvertibleSeniorNotesNamespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTemporary equity carrying amount net including portion attributable to noncontrolling interests + ReferencesNo definition available. + Details Name: bbio_TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterestsNamespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://www.xbrli.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap_AccountsPayableCurrentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-11>Reference 3: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference> 4: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference> 5: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 6: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference> 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14> + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_AdditionalPaidInCapitalCommonStockNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrli.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrli.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 4: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 8: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 9: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 10: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 11: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 12: <http://www.xbrli.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrli.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 15: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 16: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 17: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 21: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 22: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 28: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 29: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 30: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap_AssetsNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 3: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: <http://www.xbrli.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 9: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 10: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 11: <http://www.xbrli.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 12: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 13: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 14: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 15: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 16: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 17: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20:

<https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap DeferredRevenueCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap DeferredRevenueNonCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482736/825-10-45-1A> + Details Name: us-gaap EquitySecuritiesFvNI Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482686/350-30-45-1> + Details Name: us-gaap IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in equity method investee and investment in and advance to affiliate. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 15: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 29: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30> + Details Name: us-gaap Liabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 8: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-5>Reference 10:

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15:

FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-41Reference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap TreasuryStockValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: us-gaap DebtInstrumentAxis=bbio TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=bbio TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 12 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Parenthetical) - \$ / shares Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] A - A Preferred stock, par value \$ 0.001 \$ 0.001 Preferred stock, shares authorized 25,000,000 25,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value \$ 0.001 \$ 0.001 Common stock, shares authorized 500,000,000 500,000,000 Common stock, shares issued 194,224,499 181,274,712 Common stock, shares outstanding 188,032,738 175,082,951 Treasury stock, shares 6,191,761 6,191,761 X - Definition Face amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Definition The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3:

[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4): [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5):

graph 22-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 6: http://www.fasb.org/us-gaap/role/ref/legacyRef -Topic 220-SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncomeStatementAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22-Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap InterestExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22-Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap InvestmentIncomeInterest Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap NonoperatingIncomeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB

Reference 34: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1)Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A) + Details Name: us-gaap ProfitLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1> + Details Name: us-gaap ResearchAndDevelopmentExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 5.P.4.b.1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-599-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-599-2)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 5.P.3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-599-1) + Details Name: us-gaap RestructuringCharges Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 11.L\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5)

[illegible]

- DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1:

<https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 42: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1>Reference 43: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 44: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 45: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 46: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-15>Reference 47: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-16>Reference 48: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 41 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481175/810-10-55-41>Reference 49: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476166/350-60-65-1> + Details Name: us-gaap StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of net income or loss attributable to temporary equity interest. + ReferencesNo definition available. + Details Name: us-gaap TemporaryEquityNetIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 16 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD (\$) in Thousands 6 Months Ended Jun 30, 2024 Jun 30, 2023 Operating activities: $\dot{A}$ $\dot{A}$ Net loss \$ (111,704) \$ (303,435) Adjustments to reconcile net loss to net cash used in operating activities: $\dot{A}$ $\dot{A}$ Stock-based compensation 38,511 49,085 Loss on extinguishment of debt 26,590 0 Accretion of debt 3,683 4,580 Depreciation and amortization 3,170 3,270 Noncash lease expense 2,093 2,024 Accrual of payment-in-kind interest on term loan 0 6,742 Net loss from equity method investment 7,925 0 Loss (gain) on deconsolidation of PellePharm (126,294) 1,241 Gain from investment in equity securities, net (8,136) (2,399) Fair value adjustment of warrants 0 (222) Other noncash adjustments (1,911) (328) Changes in operating assets and liabilities: $\dot{A}$ $\dot{A}$ Receivables from licensing and collaboration agreements 1,091 8,466 Prepaid expenses and other current assets (6,506) 1,057 Other assets 942 32 Accounts payable 8,858 (4,098) Accrued compensation and benefits (8,378) (11,071) Accrued research and development liabilities 7,067 (11,322) Operating lease liabilities (2,981) (2,443) Deferred revenue 22,236 (3,184) Accrued professional and other liabilities (1,090) 4,330 Net cash used in operating activities (144,834) (257,675) Investing activities: $\dot{A}$ $\dot{A}$ Purchases of marketable securities (93,811) (19,754) Maturities of marketable securities 55,000 41,550 Purchases of investments in equity securities (20,671) (71,504) Proceeds from sales of investments in equity securities 63,229 67,068 Proceeds from special cash dividends received from investments in equity securities 25,682 0 Payment for an intangible asset (3,190) 0 Purchases of property and equipment (749) (440) Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries (98) (503) Net cash provided by investing activities 25,792 16,417 Financing activities: $\dot{A}$ $\dot{A}$ Proceeds from term loan under Financing Agreement 450,000 0 Issuance costs and discounts associated with term loan under Financing Agreement (15,986) 0 Repayment of term loan under Loan and Security Agreement (473,417) 0 Proceeds from issuance of common stock through public offerings, net 314,759 144,049 Proceeds from BridgeBio common stock issuances under ESPP 2,364 1,809 Proceeds from stock option exercises, net of repurchases 778 312 Repurchase of RSU shares to satisfy tax withholding (4,679) (1,715) Other financing activities 0 4,563 Net cash provided by financing activities 273,819 149,018 Net increase (decrease) in cash, cash equivalents and restricted cash 154,777 (92,240) Cash, cash equivalents and restricted cash at beginning of period 394,732 416,884 Cash, cash equivalents and restricted cash at end of period 549,509 324,644 Supplemental Disclosure of Cash Flow Information: $\dot{A}$ $\dot{A}$ Cash paid for interest 49,046 28,738 Supplemental Disclosures of Noncash Investing and Financing Information: $\dot{A}$ $\dot{A}$ Unpaid public offering issuance costs 18 0 Unpaid property and equipment 70 131 Deferred and unpaid issuance costs recorded to "Accrued professional and other accrued liabilities" 74 0 Transfers (to) from noncontrolling interests (Note 5) (1,929) (5,940) Reconciliation of Cash, Cash Equivalents and Restricted Cash: $\dot{A}$ $\dot{A}$ Cash and cash equivalents 407,958 302,438 Restricted cash 139,409 19,930 Restricted cash - Included in "Other assets" 2,142 2,276 Total cash, cash equivalents and restricted cash at end of periods shown in the condensed consolidated statements of cash flows \$ 549,509 \$ 324,644 X - DefinitionAccrual of payment-in-kind interest on term loan. + ReferencesNo definition available. + Details Name: bbio AccrualOfPaymentInKindInterestOnTermLoan Namespace Prefix: bbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDecrease in cash and cash equivalents resulting from deconsolidation of entities. + ReferencesNo definition available. + Details Name: bbio DecreaseInCashAndCashEquivalentsResultingFromDeconsolidationOfEntities Namespace Prefix: bbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDeferred and unpaid issuance cost recorded to accrued professional and other accrued liabilities. + ReferencesNo definition available. + Details Name: bbio DeferredAndUnpaidIssuanceCostRecordedToAccruedProfessionalAndOtherAccruedLiabilities Namespace Prefix: bbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGain loss on deconsolidation of entities. + ReferencesNo definition available. + Details Name: bbio GainLossOnDeconsolidationOfEntities Namespace Prefix: bbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) in accrued research and development liabilities. + ReferencesNo definition available. + Details Name: bbio IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities Namespace Prefix: bbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (decrease) receivable from licensing and collaboration agreements. + ReferencesNo definition available. + Details Name: bbio IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements Namespace Prefix: bbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNoncash Lease Expense + ReferencesNo definition available. + Details Name: bbio NoncashLeaseExpense Namespace Prefix: bbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash or part noncash investing transfer (from) to noncontrolling interest. + ReferencesNo definition available. + Details Name: bbio NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest Namespace Prefix: bbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUnpaid public offering issuance costs. + ReferencesNo definition available. + Details Name: bbio UnpaidPublicOfferingIssuanceCosts Namespace Prefix: bbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481639/420-10-35-4>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482017/420-10-50-1> + Details Name: us-gaap AccretionExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-4>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-3>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-5> + Details Name: us-gaap CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22> + Details Name: us-gaap DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479536/321-10-50-4> + Details Name: us-gaap EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481766/480-10-25-13> + Details Name: us-gaap FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481303/470-50-40-2>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481303/470-50-40-4> + Details Name: us-gaap GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -

Accounting Standards Codification - Section 50 - Paragraph 32 - Subparagraph (ee) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4:

-Paragraph 1 - Subparagraph (SX 210.4-08(g)(1)(iii)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap ProfitLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap RepaymentsOfLongTermDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5 + Details Name: us-gaap RestrictedCashAndCashEquivalentsNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap ShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 17 R8.htm IDEA: XBRL DOCUMENT v3.24.2.1 Organization and Description of Business 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Organization and Description of Business 1.Organization and Description of Business BridgeBio Pharma, Inc. (â€œBridgeBioâ€ or the â€œCompanyâ€) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBioâ€™s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. Since inception, BridgeBio has either created wholly-owned subsidiaries or has made investments in certain controlled entities, including partially-owned subsidiaries for which BridgeBio has a majority voting interest, and variable interest entities (â€œVIEsâ€) for which BridgeBio is the primary beneficiary (collectively, â€œweâ€, â€œourâ€, or â€œusâ€). BridgeBio is headquartered in Palo Alto, California. X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap NatureOfOperations Namespace Prefix: us-gaap Data Type: dt-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 18 R9.htm IDEA: XBRL DOCUMENT v3.24.2.1 Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies 2.Summary of Significant Accounting Policies Basis of Presentation and Principles of ConsolidationThe condensed consolidated financial statements include the accounts of BridgeBio Pharma, Inc. and its wholly-owned subsidiaries and controlled entities, substantially all of which are denominated in U.S. dollars. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record â€œNet loss attributable to redeemable convertible noncontrolling interests and noncontrolling interestsâ€ in our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties.In determining whether an entity is considered a controlled entity, we applied the VIE and Voting Interest Entity (â€œVOEâ€) models. We assess whether we are the primary beneficiary of a VIE based on our power to direct the activities of the VIE that most significantly impact the VIEâ€™s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Entities that do not qualify as a VIE are assessed for consolidation under the VOE model. Under the VOE model, BridgeBio consolidates the entity if it determines that it has a controlling financial interest in the entity through its ownership of greater than 50% of the outstanding voting shares of the entity and that other equity holders do not have substantive voting, participating or liquidation rights. We assess whether we are the primary beneficiary of a VIE or whether we have a majority voting interest for entities consolidated under the VOE model at the inception of the arrangement and at each reporting date. The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles (â€œGAAPâ€) in the United States and applicable rules and regulations of the U.S. Securities and Exchange Commission (the â€œSECâ€) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC.The condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of our financial position, our results of operations and comprehensive loss, stockholdersâ€™ deficit and our cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim periods. Cash, Cash Equivalents and Marketable SecuritiesWe consider all highly liquid investments purchased with original maturities of 90 days or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market instruments, such as money market funds and U.S. treasury bills.Our marketable securities consist of high investment grade fixed income securities that are primarily invested in U.S. treasury bills. We classify our marketable securities as available-for-sale securities and report them at fair value in â€œCash and cash equivalentsâ€ or â€œMarketable securitiesâ€ on the condensed consolidated balance sheets with related unrealized gains and losses included as a component of stockholdersâ€™ deficit. We classify our marketable securities as either short-term or long-term based on each instrumentâ€™s underlying contractual maturity date. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity which is included in â€œInterest incomeâ€ on the condensed consolidated statements of operations. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in â€œOther income (expense), net.â€ The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.Our cash, cash equivalents and marketable securities are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as commercial paper, U.S. government obligations, treasury bills, and money market funds, and places restrictions on maturities and concentrations by type and issuer.The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown on the condensed consolidated statements of cash flows: Â Â Â Â Â June 30, 2024 Â Â December 31, 2023 Â Â Â (in thousands) Â Â Cash and cash equivalents Â \$ 407,958 Â Â \$ 375,935 Â Â Restricted cash Â Â 139,409 Â Â Â 16,653 Â Â Restricted cash, non-current â€ included in â€œOther assetsâ€ Â Â 2,142 Â Â Â 2,144 Â Â Total cash, cash equivalents and restricted cashÂ Â Â shown on the condensed consolidated statements of cash flows Â \$ 549,509 Â Â Â \$ 394,732 Â Â Restricted CashÂ Restricted cash primarily represents funds in a controlled account that was established in connection with the Companyâ€™s Term Loans described in Note 9. Under the terms of the Financing Agreement (as defined in Note 9), the Company is required to deposit 75% of proceeds, net of certain permitted costs, received from certain asset sale transactions into escrow accounts to be controlled by the Administrative Agent. During the three months ended June 30, 2024, we received \$235.0 million in aggregate from Bayer Consumer Care AG and Kyowa Kirin Co., Ltd, and deposited net proceeds of \$159.3 million into the

escrow accounts, which was classified as restricted cash^(c) on the condensed consolidated balance sheet as of June 30, 2024. Pursuant to the terms of the Amended Financing Agreement (as defined in Note 9), between June 20, 2024 and through the earlier of the FDA approval date of a first NDA for acoramidis and November 30, 2024, the Company is able to request a release of funds in an aggregate amount not to exceed 50% of the original net cash proceeds received from asset sale transactions. As of June 30, 2024, \$20.0 million was released from the escrow accounts and classified as cash, with a remaining balance of \$139.3 million in the escrow accounts classified as restricted cash^(c) on the condensed consolidated balance sheet. Refer to Note 9 and Note 11 for further details regarding the Financing Agreement and the exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd. As of December 31, 2023, the use of such non-interest-bearing cash was restricted per the terms of the underlying amended Loan and Security Agreement and was to be used solely for certain research and development expenses directly attributable to the performance of obligations associated with the Navire-BMS License Agreement, which is further described in Note 11. As of December 31, 2023, restricted cash related to this agreement was \$16.5 million, which is presented as part of Restricted cash^(c) on the condensed consolidated balance sheet. Upon the termination of the Loan and Security Agreement and full repayment of the term loan in January 2024 (refer to Note 9 for details), the non-interest-bearing cash was no longer restricted as of June 30, 2024. Additionally, under certain lease agreements and letters of credit, we have pledged cash and cash equivalents as collateral. As of June 30, 2024, restricted cash related to such agreements was \$0.1 million and \$2.1 million, which is presented as part of Restricted cash^(c) and Other assets^(c), respectively, on the condensed consolidated balance sheets. As of December 31, 2023, restricted cash related to such agreements was \$0.1 million and \$2.1 million, which is presented as part of Restricted cash^(c) and Other assets^(c), respectively, on the condensed consolidated balance sheets. Equity Method and Other Equity Investments We use the equity method to account for any of our investments under the scope of ASC 323 Investments in Equity Method and Joint Ventures, where we may not be the primary beneficiary, but may still exercise significant influence over operating activities of the investee. Our consolidated net loss includes our Company's proportionate share of the net income or loss from equity method investment and amortization of any in-process research and development (acquired intangible). Our judgment regarding the level of influence over each equity method investee includes considering key factors such as our ownership interest, representation on the board of directors, participation in policy-making decisions, and other material transactions. Since inception through April 29, 2024, TheRas, Inc. (the "TheRas") has been a majority-owned subsidiary of the Company that had been consolidated. On April 30, 2024, the Company completed a \$200.0 million private equity financing with external investors of TheRas, Inc., to accelerate the development of its oncology portfolio. Upon completion of the private equity financing, Company ownership was reduced to approximately 37.9% of TheRas' equity. As part of the private equity financing transaction, TheRas' Certificate of Incorporation and Investors' Rights Agreement were amended and restated to reflect a change in TheRas' governance structure and composition of the board of directors, which was determined to be a VIE reconsideration event. Based on the VIE reconsideration assessment, TheRas was deemed a VIE. As a result of the change in governance structure and composition of the board of directors, BridgeBio is no longer the primary beneficiary, as it no longer has the power over key decisions that significantly impact TheRas' economic performance. Accordingly, BridgeBio deconsolidated TheRas, Inc. and accounted for BridgeBio's retained investment in TheRas, Inc., for which it has significant influence through its ownership interest, using the equity method of accounting as of April 30, 2024. As of December 31, 2020, we had an equity method and equity security investments in PellePharm. The equity security investments in PellePharm were without a readily determinable fair value and were carried at cost less impairment plus or minus observable price changes. PellePharm became a consolidated VIE in April 2021 under ASC 810, Consolidation. On January 16, 2023, PellePharm's board of directors authorized the assignment of all PellePharm's assets to PellePharm ABC, LLC for liquidation and distribution under the General Assignment for the Benefit of Creditors (ABC). As part of the ABC proceedings, PellePharm's board of directors resigned effective March 6, 2023. The date the board of directors resigned was determined to be a VIE reconsideration event. Based on the changes to PellePharm's governance structure and composition of the board of directors as a result of the ABC, BridgeBio was no longer the primary beneficiary, as it no longer had the power over key decisions that significantly impact PellePharm's economic performance. Accordingly, BridgeBio deconsolidated PellePharm effective during the three months ended March 31, 2023. Refer to Note 6 for further discussion on the TheRas and PellePharm investments. Accrued Professional and Other Accrued Liabilities Accrued professional and other accrued liabilities consisted of the following balances: As of June 30, 2024, As of December 31, 2023, (in thousands) Accrued professional services \$ 7,503 \$ 7,412 Accrued interest \$ 11,352 \$ 11,761 Milestone liability \$ 6,380 \$ 6,000 Other accrued liabilities \$ 9,048 \$ 4,657 Accrued professional and other accrued liabilities \$ 34,283 \$ 35,830 Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, receivables from license and collaboration agreements, and restricted cash. Substantially all of our cash, cash equivalents, marketable securities and restricted cash are held in financial institutions in the United States. Amounts on deposit may at times exceed federally insured limits. Although management currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced or recorded any credit losses associated with its balances as of June 30, 2024 and December 31, 2023, and for the three and six months ended June 30, 2024 and 2023. We are subject to credit risk from receivables from license and collaboration agreements. We have not experienced any material losses related to receivables from individual customers or groups of customers. We also do not require any collateral. Receivables from license and collaboration agreements are recorded net of allowance for credit losses, if any. We are subject to certain risks and uncertainties and we believe that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing, regulatory approval and market acceptance of, and reimbursement for, product candidates, performance of third-party contract research organizations and manufacturers upon which we rely, development of sales channels, protection of our intellectual property, litigation or claims against us based on intellectual property, patent, product, regulatory, clinical or other factors, and our ability to attract and retain employees necessary to support our growth. We are dependent on third-party manufacturers to supply products for research and development activities in our programs. In particular, we rely and expect to continue to rely on a small number of manufacturers to supply us with our requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to: allowance for credit losses, accruals for research and development activities, such as clinical, development, regulatory, and sales-based milestone payments in our in-licensing agreements and asset acquisitions, accruals for performance-based milestone compensation arrangements, determining and allocating the transaction price to performance obligations for transactions accounted for under ASC 606, Revenue from Contracts with Customers, the expected recoverability and estimated useful lives of our long-lived assets, and additional charges as a result of, or that are associated with, any restructuring initiative as well as impairment and related charges. We base our estimates on historical experience and on various other assumptions that we believe are reasonable. Actual results may differ from those estimates or assumptions. X - References No definition available. + Details Name: us-gaap Accounting Policies Abstract Namespace Prefix: us-gaap_ Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for all significant accounting policies of the reporting entity. + Reference Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483246/235-10-10-Reference 2: http://fasb.org/us-gaap/roic/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap Significant Accounting Policies TextBlock Namespace Prefix: us-gaap_ Data Type: dt-types:textBlockItem Type Balance Type: na Period Type: duration XML R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] A Fair Value Measurements 3.Fair Value Measurements The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation: As of June 30, 2024, Total Level 1 Assets Level 2 Assets Level 3 Assets (in thousands) Assets Cash equivalents: \$ 85,605 \$ 85,605 Agency discount notes \$ 98,504 \$ 98,504 Treasury bills \$ 139,282 \$ 139,282 Total cash equivalents \$ 323,391 \$ 323,391 Marketable securities: \$ 39,813 \$ 39,813 Treasury bills \$ 39,813 \$ 39,813 Total marketable securities \$ 39,813 \$ 39,813 Total financial assets \$ 363,204 \$ 363,204 December 31, 2023, Total Level 1 Assets Level 2 Assets Level 3 Assets (in thousands) Assets Cash equivalents: \$ 1,707 \$ 1,707 Money market funds \$ 13,530 \$ 13,530 Treasury bills \$ 256,067 \$ 256,067 Total cash equivalents \$ 269,597 \$ 269,597 Investments in equity securities: \$ 58,949 \$ 58,949 Embedded derivative \$ 1,554 \$ 1,554 Total financial assets \$ 330,100 \$ 330,100 There are no transfers between Level 1, Level 2 or Level 3 during the periods presented. There are uncertainties on the fair value measurement of the instrument classified under Level 3 due to the use of unobservable inputs and interrelationships between these unobservable inputs, which could result in higher or lower fair value measurements. Marketable Securities The fair value of our marketable securities classified within Level 2 is based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. Investments in Equity Securities We have investments in equity securities of publicly held companies and we do not have restrictions on our ability to sell these securities. We have classified our investments in equity securities within Level 1, as the fair value of these equity securities are derived from observable inputs such as quoted prices in active markets. Our investments in equity securities, which only consisted of an investment in LianBio, had an aggregate fair value of nil as of June 30, 2024 (refer to Note 6). Our investments in equity securities had an aggregate fair value of \$58.9 million as of December 31, 2023, which included an investment in LianBio with a fair value of \$22.4 million. Total realized and unrealized gains and losses associated with investments in equity securities during the periods presented consisted of the following: Three Months Ended June 30, Six Months Ended June 30, 2024, 2024 Net realized gains recognized on investments in equity securities sold \$ 1,638 \$ 8,136 Net unrealized losses recognized on investments in equity securities held as of the end of the period \$ (203) \$ (6,397) Total net gains included in Other income (expense), net \$ 1,435 \$ 8,136 LianBio WarrantAs of December 31, 2023 our subsidiary, QED Therapeutics, Inc. (the "QED"), held a warrant which entitles QED to purchase shares of LianBio (the "LianBio Warrant", refer to Note 6). We had classified the LianBio Warrant, which pertains to an equity security of a publicly held company, within Level 1 as the fair value of this equity security is derived from observable inputs such as quoted prices in an active market. In February 2024, we fully exercised the LianBio Warrant and purchased 347,569 shares of LianBio common stock for an immaterial amount. Notes The fair values of our 2.25% convertible senior notes due 2029 (the "2029 Notes") and our 2.50% convertible senior notes due 2027 (the "2027 Notes") (collectively, the "Notes", refer to Note 9), which differ from their respective carrying values, are determined by prices for the Notes observed in market trading. The market for trading of the Notes is not considered to be an active market and therefore the estimate of fair value is based on Level 2 inputs. As of June 30, 2024, the estimated fair value of our 2029 Notes and 2027 Notes, which have aggregate face values of \$747.5 million and \$550.0 million, respectively, were \$604.1 million and \$553.7 million, respectively, based on their market prices on the last trading day for the period. As of December 31, 2023, the estimated fair value of our 2029 Notes and 2027 Notes was \$638.7 million and \$695.8 million, respectively, based on their market prices on the last trading day for the period. Term Loan The fair value of our outstanding term loan (refer to Note 9) is estimated using the net present value of the payments, discounted at an interest rate that is consistent with a market interest rate, which is a Level 2 input. The estimated fair value of our outstanding term loan under the Financing Agreement (as defined in Note 9 below) as of June 30, 2024 was \$464.9 million and under the Loan Agreement (as defined in Note 9 below) as of December 31, 2023 was \$389.1 million. X - References No definition available. + Details Name: us-gaap FairValueDisclosures Abstract Namespace Prefix: us-gaap_ Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (

equivalents consist primarily of amounts invested in equity market instruments, such as money market funds and U.S. treasury bills. Cash equivalents and marketable securities classified as available-for-sale consisted of the following:

	June 30, 2024	December 31, 2023
Amortized Cost Basis	\$ 139,282.4	\$ 139,282.4
Unrealized Gains	\$ 85,605.4	\$ 85,605.4
Unrealized Losses	\$ 85,605.4	\$ 85,605.4
Estimated Fair Value	\$ 139,282.4	\$ 139,282.4
Cash equivalents	\$ 98,509.4	\$ 98,509.4
Money market funds	\$ 98,509.4	\$ 98,509.4
Treasury bills	\$ 98,509.4	\$ 98,509.4
Marketable securities	\$ 98,509.4	\$ 98,509.4
Total cash equivalents	\$ 323,396.4	\$ 323,396.4
Total marketable securities	\$ 323,396.4	\$ 323,396.4
Total cash equivalents and marketable securities	\$ 646,792.8	\$ 646,792.8

	June 30, 2024	December 31, 2023
Amortized Cost Basis	\$ 13,530.0	\$ 13,530.0
Unrealized Gains	\$ 256,036.4	\$ 256,036.4
Unrealized Losses	\$ 256,036.4	\$ 256,036.4
Estimated Fair Value	\$ 13,530.0	\$ 13,530.0
Cash equivalents	\$ 269,597.4	\$ 269,597.4
Money market funds	\$ 269,597.4	\$ 269,597.4
Treasury bills	\$ 269,597.4	\$ 269,597.4
Marketable securities	\$ 269,597.4	\$ 269,597.4
Total cash equivalents	\$ 269,597.4	\$ 269,597.4
Total marketable securities	\$ 269,597.4	\$ 269,597.4
Total cash equivalents and marketable securities	\$ 539,194.8	\$ 539,194.8

 There have been no significant realized gains or losses on available-for-sale securities for the periods presented. There were no available-for-sale securities that have been in a continuous unrealized loss position for more than 12 months. We believe that we have the ability to realize the full value of all of these investments upon their respective maturities. X - DefinitionCash equivalents and marketable securities. + ReferencesNo definition available. + Details Name: bbio CashEquivalentsAndMarketableSecuritiesAbstract Namespace Prefix: bbio Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/320/tableOfContent> + Details Name: us-gaap CashEquivalentsAndMarketableSecuritiesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 21 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Noncontrolling Interests 6 Months Ended Jun. 30, 2024 Noncontrolling Interest [Abstract] A Noncontrolling Interests 5.Noncontrolling InterestsAs of June 30, 2024 and December 31, 2023, we had both redeemable convertible noncontrolling interests and noncontrolling interests in consolidated partially-owned entities, for which BridgeBio is the primary beneficiary under the VIE model. These balances are reported as separate components outside stockholders' deficit in Redeemable convertible noncontrolling interests and as part of stockholders' deficit in Noncontrolling interests on the condensed consolidated balance sheets. We adjust the carrying value of noncontrolling interests to reflect the book value attributable to noncontrolling stockholders of consolidated partially-owned entities when there is a change in the ownership during the respective reporting period and such adjustments are recorded to Additional paid-in capital. For the three and six months ended June 30, 2024, the adjustments in the aggregate amounted to \$(0.1) million and \$(1.9) million, respectively. For the three and six months ended June 30, 2023, the adjustments in the aggregate amounted to \$(3.1) million and \$(5.9) million, respectively. All such adjustments are disclosed within the X-Transfers from (to) noncontrolling interests line item on the condensed consolidated statements of redeemable convertible noncontrolling interests and stockholders' deficit. X - DefinitionThe entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net income or loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/810/tableOfContent> + Details Name: us-gaap MinorityInterestDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NoncontrollingInterestAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 22 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Method Investment and Other Equity Investments 6 Months Ended Jun. 30, 2024 Equity Method And Cost Method Investment [Abstract] A Equity Method Investment and Other Equity Investments 6.Equity Method Investment and Other Equity Investments TheRasOn April 30, 2024, TheRas, Inc., doing business as BridgeBio Oncology Therapeutics (BBOT), a majority-owned subsidiary of the Company, completed a \$200.0 million private equity financing with external investors to accelerate the development of its oncology portfolio. Upon completion of the private equity financing, the Company's ownership of BBOT's equity was reduced to approximately 37.9%. As part of the private equity financing transaction, BBOT's Certificate of Incorporation and Investors' Rights Agreement were amended and restated to reflect a change to BBOT's governance structure and composition of the board of directors, which was determined to be a VIE reconsideration event. Based on the VIE reconsideration assessment, BBOT was deemed a VIE. As a result of the change in governance structure and composition of the board of directors, BridgeBio is no longer the primary beneficiary of BBOT, as it no longer has the power over key decisions that significantly impact BBOT's economic performance. Accordingly, BridgeBio deconsolidated BBOT on April 30, 2024. During the three months ended June 30, 2024, we recognized a \$126.3 million net gain from deconsolidation of a subsidiary, which is presented on the condensed consolidated statements of operations for the three and six months ended June 30, 2024. The gain on deconsolidation represents the difference between BridgeBio's equity investment in BBOT, valued at \$124.9 million upon deconsolidation and the carrying value of the net assets held by BBOT on April 30, 2024. Upon the deconsolidation of BBOT, BridgeBio accounted for its retained investment in BBOT, for which it has significant influence through its ownership interest, using the equity method of accounting under ASC 323 - Investments. Equity Method and Joint Ventures. BBOT was also deemed a related party. BridgeBio's equity investment in BBOT, valued at \$124.9 million upon deconsolidation, was compared to BridgeBio's percentage of underlying equity in net assets of BBOT, which includes an implied difference of \$49.6 million between the fair value of the equity investment and the underlying equity in the net assets of BBOT (referred to as basis difference). The basis difference was attributed to BBOT's in-process research and development (IP&D asset), and is amortized as a component of net loss from equity method investment over the estimated useful life of the IP&D asset. The amortization of the IP&D asset for the period from May 1, 2024 through June 30, 2024 was immaterial. For the period from May 1, 2024 through June 30, 2024, we recognized a net loss from equity method investment of \$7.9 million. As of June 30, 2024, the aggregate carrying amount of our equity method investment in BBOT is \$117.0 million and is presented as investment in nonconsolidated entity on our condensed consolidated balance sheets. In addition, on April 30, 2024, the Company and BBOT entered into an 18-month transition service agreement (the Transition Service Agreement) for the provision of certain transitional consulting services to be provided by the Company and BBOT. Under the Transition Service Agreement, the Company recognized \$0.8 million in other income during the three and six months ended June 30, 2024, and \$0.1 million in prepaid expenses and other current assets as of June 30, 2024 for transitional consulting services provided by BridgeBio to BBOT. The Company also recognized \$0.3 million in research and development liabilities during the three and six months ended June 30, 2024, and \$0.3 million in accrued research and development liabilities for transitional consulting services provided by BBOT to BridgeBio as of June 30, 2024. LianBio In October 2019, our subsidiary, BridgeBio Pharma LLC (BBP LLC), entered into an exclusivity agreement with LianBio, an exempt company organized under the laws of the Cayman Islands (together with its subsidiaries, LianBio), pursuant to which BBP LLC received equity in LianBio (the LianBio Exclusivity Agreement). We account for BBP LLC's equity interest in LianBio under ASC 321 Investments - Equity Securities as an investment in equity securities. For the three months ended June 30, 2024 and 2023, we recorded an unrealized gain of nil and \$1.6 million, respectively, for the ongoing mark-to-market adjustments of the investment. For the six months ended June 30, 2024 and 2023, we recorded an unrealized gain of nil and \$3.6 million, respectively, for the ongoing mark-to-market adjustments of the investment (refer to Note 3). As of December 31, 2023, QED also held warrants which entitled QED to purchase 347,569 shares of LianBio. The LianBio Warrant was measured at fair value on a recurring basis, with changes in fair value recognized in our condensed consolidated statements of operations as part of Other income (expense), net. The LianBio Warrant, which is presented as part of Other assets on our condensed consolidated balance sheets, had a fair value of \$1.6 million as of December 31, 2023. In February 2024, QED exercised the 347,569 shares of LianBio warrants it held for an immaterial amount. In March 2024, we received net proceeds of \$25.7 million as special cash dividends and recognized net realized gains of \$1.8 million from our investment in LianBio equity securities. As of June 30, 2024, the Company held 5,350,361 shares of LianBio common stock. PellePharmAs of April 15, 2021, BridgeBio had been the primary beneficiary of PellePharm as it had power over key decisions that significantly impact PellePharm's economic performance. BridgeBio also had the obligation to absorb losses or the right to receive benefits from PellePharm that could potentially be significant to PellePharm through its common and preferred stock interest in PellePharm. Accordingly, BridgeBio had consolidated PellePharm during the period April 15, 2021 through December 31, 2022. On January 16, 2023, PellePharm's board of directors authorized the assignment of all PellePharm's assets to PellePharm ABC, LLC for liquidation and distribution under the General Assignment for the Benefit of Creditors (ABC Proceeding). As part of the ABC Proceeding, PellePharm's board of directors resigned effective March 6, 2023. The date the board of directors resigned was determined to be a VIE reconsideration event. Based on the changes to PellePharm's governance structure and composition of the board of directors as a result of the ABC, BridgeBio was no longer the primary beneficiary, as it no longer had the power over key decisions that significantly impact PellePharm's economic performance. Accordingly, during the three months ended March 31, 2023, BridgeBio deconsolidated PellePharm and recognized a loss of \$1.2 million which is presented as part of Other income (expense), net on the condensed consolidated statements of operations for the six months ended June 30, 2023. X - DefinitionEquity Method And Cost Method Investment Abstract + ReferencesNo definition available. + Details Name: bbio EquityMethodAndCostMethodInvestmentAbstract Namespace Prefix: bbio Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investment. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/320/tableOfContent> Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Name Accounting Standards Codification-Topic 321-Publisher](http://www.xbrl.org/2009/role/commonPracticeRef-Name Accounting Standards Codification-Topic 321-Publisher FASB-URI https://asc.fasb.org/321/tableOfContent)

Balance Type: na Period Type: duration XML 24 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] A Commitments and Contingencies 8.Commitments and Contingencies Milestone Compensation Arrangements We have performance-based milestone compensation arrangements with certain employees and consultants, whose vesting is contingent upon meeting various milestones, with fixed monetary amounts known at inception that can be settled in the form of cash or equity at our sole discretion. We also have performance-based milestone compensation arrangements with certain employees and consultants as part of the 2020 Stock and Equity Award Exchange Program (the "Exchange Program" (the "Exchange Program", refer to Note 15). The compensation arrangements under the Exchange Program are to be settled in the form of equity only. Performance-based milestone awards that are settled in the form of equity are satisfied in the form of fully-vested restricted stock awards (the "RSAs"). We accrue for such contingent compensation when the related milestone is probable of achievement and is recorded in "Accrued compensation and benefits" for the current portion and in "Other long-term liabilities" for the noncurrent portion on the condensed consolidated balance sheets. There is no accrued compensation expense for performance-based milestone awards that are assessed to be not probable of achievement. The table below shows our commitment for the potential milestone amounts and the accruals for milestones deemed probable of achievement as of June 30, 2024.

	Potential Fixed Monetary Amount	Accrued Amount (1)	Settlement Type	(in thousands)	Cash	\$	9,073	\$	26	Stock	(2)	\$	31,147	\$	26	Cash or stock at our sole discretion	\$	66,980	\$	1,727	Total	\$	107,200	\$	1,753	(1)
(1) Amount recorded for performance-based milestone awards that are probable of achievement.																										
(2) Includes the performance-based milestone awards that were granted as part of the Exchange Program further discussed in Note 15.																										

Other Research and Development and Commercial Agreements We may also enter into contracts in the normal course of business with contract research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for preclinical studies, supplies, and other services and products for commercial and operating purposes. These contracts generally provide for termination on notice with potential termination charges. As of June 30, 2024 and December 31, 2023, there were no material amounts accrued related to termination charges (refer to Note 16).

Indemnification In the ordinary course of business, we may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by us, our negligence or willful misconduct, violations of law, or intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with directors and certain officers and employees that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No material demands have been made upon us to provide indemnification under such agreements, and thus, there are no claims that we are aware of that could have a material effect on our condensed consolidated financial statements. We also maintain director and officer insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. To date, we have not incurred any material costs and have not accrued any material liabilities on the condensed consolidated financial statements as a result of these provisions.

Contingencies From time to time, we may become involved in legal proceedings arising in the ordinary course of business. We are not currently a party to any material legal proceedings. X - References No definition available. + Details Name: us-gaap-CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap- Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for commitments and contingencies. + References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 405-SubTopic 3-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/405-30/tableOfContentReference> 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3): <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/450/tableOfContentReference> 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 440-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/954-440-50-1Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 440-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/954-440-50-1Reference 5): [http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6](http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6): [| | June 30, 2024 | December 31, 2023 | June 30, 2024 | December 31, 2023 | June 30, 2024 | December 31, 2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|----------------------------------|--------------------------------|------------------------------|-------------------|---------------|-------------------|------------|------------|------------|--|------------|------------|-------------|------------|---------------------|---|------------|------------|------------|----------|----------|-----------|-----------|-----------|-----------|-----------|-------------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| Notes | \\$ 2029 Notes | \\$ 2027 Notes | \\$ \(in thousands\) | \\$ \(in thousands\) | Principal | \\$ 747,500 | \\$ 550,000 | \\$ 747,500 | \\$ 550,000 | Unamortized debt discount and issuance costs | \\$ \(9,618\) | \\$ \(5,730\) | \\$ \(10,595\) | \\$ \(6,621\) | Net carrying amount | \\$ 737,882 | \\$ 544,270 | \\$ 736,905 | \\$ 543,379 | | | | | | | | | | | | | | | | | | | | | | | | |
| The following table sets forth the total interest expense recognized and effective interest rates related to the Notes for the periods presented: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | Contractual interest expense | \\$ 4,204 | \\$ 3,437 | \\$ 7,641 | \\$ 8,409 | \\$ 6,875 | \\$ 15,284 | Amortization of debt discount and issuance costs | \\$ 490 | \\$ 447 | \\$ 937 | \\$ 891 | \\$ 1,868 | Total interest and amortization expense | \\$ 4,694 | \\$ 3,884 | \\$ 8,584 | \\$ 9,386 | \\$ 7,766 | \\$ 17,152 | \\$ 17,152 | \\$ 17,152 | \\$ 17,152 | \\$ 17,152 | Effective interest rate | 2.6% | 2.8% | 2.6% | 2.8% | 2.6% | 2.8% | 2.6% | 2.8% | 2.6% | 2.8% | 2.6% | 2.8% | 2.6% | 2.8% | 2.6% | 2.8% |
| | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2023 | Contractual interest expense | \\$ 4,204 | \\$ 3,437 | \\$ 7,641 | \\$ 8,409 | \\$ 6,875 | \\$ 15,284 | Amortization of debt discount and issuance costs | \\$ 477 | \\$ 436 | \\$ 913 | \\$ 867 | \\$ 1,819 | Total interest and amortization expense | \\$ 4,681 | \\$ 3,873 | \\$ 8,554 | \\$ 9,361 | \\$ 7,742 | \\$ 17,103 | \\$ 17,103 | \\$ 17,103 | \\$ 17,103 | \\$ 17,103 | Effective interest rate | 2.6% | 2.8% | 2.6% | 2.8% | 2.6% | 2.8% | 2.6% | 2.8% | 2.6% | 2.8% | 2.6% | 2.8% | 2.6% | 2.8% | | |
| As of June 30, 2024, interest payable on the 2029 and 2027 Notes amounted to \\$7.0 million and \\$4.0 million, respectively. As of December 31, 2023, interest payable on the 2029 and 2027 Notes amounted to \\$7.0 million and \\$4.0 million, respectively. Future minimum payments under the Notes as of June 30, 2024 are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

	June 30, 2024	December 31, 2023
Notes	\\$ 2029 Notes	\\$ 2027 Notes	](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 440-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/440/tableOfContent+Details Name: us-gaap-CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap-Data Type: dtr-type:textBlockItemType Balance Type: na Period Type: duration XML 25 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] A Debt 9.Debt Notes 2029 Notes, net On January 28, 2021, we issued an aggregate of $717.5 million principal amount of our 2029 Notes pursuant to an Indenture dated January 28, 2021 (the)

A A 2027 Notes A A Total A A (in thousands) A Remainder of 2024 A \$ 8,409 A A \$ 6,875 A A \$ 15,284 A Year ended December 31; A A A A A A 2025 A A 16,819 A A 13,750 A A 30,569 A 2026 A 16,819 A A 13,750 A A 30,569 A 2027 A 16,819 A A A 556,875 A A 573,694 A 2028 A 16,819 A A A A 16,819 A Thereafter A 755,909 A A A A 755,909 A Total future payments A 231,594 A A 591,250 A A 1,422,844 A Less amounts representing interest A (84,094) A A (41,250) A A (125,344) Total principal amount A \$ 747,500 A A \$ 550,000 A A \$ 1,297,500 A A Capped Call and Share Repurchase Transactions with Respect to the Notes On each of January 25, 2021 and March 4, 2020, concurrently with the pricing of the 2029 Notes and 2027 Notes, respectively, we entered into separate privately negotiated capped call transactions (the A 2021 Capped Call TransactionsA and the A 2020 Capped Call TransactionsA, respectively), or, together, the Capped Call Transactions, with certain financial institutions, or the Capped Call Counterparties. We used approximately \$61.3 million and \$49.3 million of the net proceeds from the 2021 Note Offering and 2020 Note Offering, respectively, to pay for the cost of the respective Capped Call Transactions. The Capped Call Transactions are expected generally to reduce the potential dilution to BridgeBioA s common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap initially equal to \$131.58 for the 2021 Capped Call Transactions and \$62.12 for the 2020 Capped Call Transactions (both of which represented a premium of 100% over the last reported sale price of BridgeBioA s common stock on the date of the Capped Call Transactions) and are subject to certain adjustments under the terms of the Capped Call Transactions. The 2021 Capped Calls and 2020 Capped Calls cover 7,702,988 shares and 12,878,305 shares, respectively, of our common stock (subject to anti-dilution and certain other adjustments), which are the same number of shares of common stock that initially underlie the Notes. The 2021 Capped Calls have an initial strike price of approximately \$97.04 per share, which corresponds to the initial conversion price of the 2029 Notes. The 2020 Capped Calls have an initial strike price of approximately \$42.71 per share, which corresponds to the initial conversion price of the 2027 Notes. The Capped Call Transactions are separate transactions, entered into by us with the Capped Call Counterparties, and are not part of the terms of the Notes. These Capped Call instruments meet the conditions outlined in ASC 815-40, Derivatives and Hedging, to be classified in stockholdersA equity and are not subsequently remeasured as long as the conditions for equity classification continue to be met. We recorded a reduction to additional paid-in capital of approximately \$61.3 million and \$49.3 million for the years ended December 31, 2021 and 2020, respectively, related to the premium payments for the Capped Call Transactions. Additionally, we used approximately \$50.0 million and \$75.0 million of the net proceeds from the 2021 Note Offering and 2020 Note Offering to repurchase 759,993 shares and 2,414,681 shares, respectively, of our common stock concurrently with the closing of the Note Offerings from certain of the NotesA Initial Purchasers in privately negotiated transactions. The agreed purchase price per share of common stock in the repurchases were \$65.79 and \$31.06, which were the last reported sale prices per share of our common stock on The Nasdaq Global Select Market, or Nasdaq, on January 25, 2021 and March 4, 2020, respectively. The shares repurchased were recorded as A Treasury stock.A Term Loan, net Loan and Security Agreement In November 2021, we entered into a Loan and Security Agreement (the A Loan AgreementA, and as amended by the First Amendment (as defined below) and the Second Amendment (as defined below), the A Amended Loan AgreementA), by and among (i) U.S. Bank National Association, in its capacity as administrative agent (in such capacity, the A Administrative AgentA) and collateral agent (in such capacity, the A Collateral AgentA), (ii) certain lenders (the A LendersA), (iii) BridgeBio, as a borrower, and (iv) certain subsidiaries of BridgeBio, as guarantors (the A GuarantorsA). In May 2022, we entered into the First Amendment to the Loan Agreement (the A First AmendmentA) and in November 2022, we entered into the Second Amendment to the Loan Agreement (the A Second AmendmentA), as further described below. In January 2024, we fully repaid the term loan under the Loan Agreement as further described below. Pursuant to the original terms and conditions of the Loan Agreement, the Lenders agreed to extend term loans to us in an aggregate principal amount of up to \$750.0 million, comprised of (i) a tranche 1 advance of \$450.0 million (the A Tranche 1 AdvanceA), and (ii) a tranche 2 advance of \$300.0 million (the A Tranche 2 AdvanceA) (collectively, the A Term Loan AdvancesA). The Tranche 1 Advance under the Loan Agreement was funded on November 17, 2021. The Tranche 2 Advance remained available for funding until December 31, 2022, which was available at our election after the occurrence of certain milestone events relating to data from our clinical trials. The terms related to the Tranche 2 Advance were modified in the First Amendment and Second Amendment as further discussed below. The First AmendmentA s term included the reduction of the aggregate amount of the Tranche 2 Advance from \$300.0 million to \$100.0 million. The Second Amendment eliminated the \$100.0 million Tranche 2 Advance. As a result of the Second Amendment, the total aggregate principal amount of the loan is \$450.0 million before any mandatory prepayment. As security for our obligations under the Loan Agreement, each of BridgeBio and the Guarantors granted the Collateral Agent, for the benefit of the Lenders, a continuing security interest in substantially all of the assets of BridgeBio and the Guarantors (including all equity interests owned or hereafter acquired by BridgeBio and the Guarantors), subject to certain customary exceptions. Upon exceeding certain investment and disposition thresholds, additional subsidiaries of BridgeBio will be required to join as guarantors. Any outstanding principal on the Term Loan Advances will accrue interest at a fixed rate equal to 9.0% per annum. 3.0% of which can be a payment-in-kind (A PIKA) until January 1, 2025. Interest payments are payable quarterly following the funding of a Term Loan Advance. We would be required to make principal payments on the outstanding balance of the Term Loan Advances commencing on January 2, 2025 (the A Term Loan Amortization DateA) in nine quarterly installments, plus interest. If we have achieved certain milestone events relating to data from the clinical trial of acoramidis (the A Acoramidis MilestoneA) on or prior to January 1, 2025, then the Term Loan Amortization Date would be automatically extended to January 2, 2026. Any amounts outstanding under the Term Loan Advances are due and payable on November 17, 2026 (the A Maturity DateA). We may prepay the outstanding principal amount of the Term Loan Advances at any time (in whole, but not in part), plus accrued and unpaid interest and a prepayment premium ranging from 1.0% to 3.0% of the principal amount outstanding depending on the timing of payment (plus a customary make-whole amount if prepaid on or prior to November 17, 2022). At the LendersA election, we were also required to make mandatory prepayments upon the occurrence of certain prepayment events related to the repurchase or redemption of pledged collateral, entry into certain royalty transactions, disposition of other assets or subsidiaries, and entry into licensing and other monetization transactions (all such events are referred to as prepayment events), which could be 50.0% or 75.0% of net cash proceeds from such transaction depending on achievement of the Acoramidis Milestone. Subject to the mandatory prepayment requirements for certain prepayment events, the Loan Agreement contains customary affirmative and limited negative covenants which, among other things, limit our ability to (i) incur additional indebtedness, (ii) pay dividends or make certain distributions, (iii) dispose of our assets, grant liens, license or encumber our assets or (iv) fundamentally alter the nature of our business. BridgeBio and the Guarantors have broad ability to license our intellectual property, dispose of other assets and enter into monetization and royalty transactions, subject in each case to the requirement to make a mandatory prepayment described above. The Loan Agreement provides that BridgeBio and the Guarantors may, subject to certain limitations, (x) repurchase BridgeBioA s equity interest and the equity interest of any of its subsidiaries, (y) enter into any joint ventures or similar investments, and (z) make other investments and acquisitions. Subject to the mandatory prepayment requirement described above, portfolio companies owned by BridgeBio that are not parties to the Loan Agreement are, subject to certain exceptions, not subject to any covenants or limitations under the Loan Agreement. The Loan Agreement also contains customary events of default, including among other things, our failure to make any principal or interest payments when due, the occurrence of certain bankruptcy or insolvency events or the breach of the covenants under the Loan Agreement. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate our obligations under the Loan Agreement. We received net proceeds from the Tranche 1 Advance of \$431.3 million, after deducting debt discount and issuance costs of \$18.7 million, of which approximately \$1.1 million of debt issuance costs were incurred for professional services provided by KKR Capital Markets LLC. KKR Capital Markets LLC is an affiliate of KKR Genetic Disorder L.P., a related party being a principal stockholder of BridgeBio. In May 2022, we entered into the First Amendment, which, among other things, A permitted the sale of our priority review voucher (A PRVA, refer to Note 12) and, generally, future dispositions of other PRVs; A reduced the aggregate amount of the Tranche 2 Advance from \$300.0 million to \$100.0 million and modified certain conditions to the availability thereof, as mentioned above; A amended the principal payments such that the entire outstanding principal balance of the Term Loan Advances is due and payable at the Maturity Date or upon early termination; and A modified the terms and conditions governing when certain entities into which we have made investments will be required to become guarantors under the Amended Loan Agreement. In June 2022, the receipt of an upfront payment under the license development and commercialization agreement that our subsidiary, Navire Pharma, Inc. (A NavireA), entered into with Bristol-Myers Squibb Company (A BMSA), which is further described in Note 11, triggered certain mandatory prepayment provisions of the Amended Loan Agreement. As a result, we paid \$20.5 million to the Lenders in June 2022, of which \$20.1 million and \$0.4 million were applied to principal and exit fee, respectively. Pursuant to the terms of the Loan Agreement, we exercised our option to convert \$3.4 million and \$6.7 million of accrued interest into principal via PIK for the three and six months ended June 30, 2023, respectively. In November 2022, we entered into the Second Amendment, which, among other things, A acknowledged that our prior prepayment made with certain cash proceeds received in connection the receipt of an upfront payment under the Navire-BMS License Agreement, which is further described in Note 11, satisfied the mandatory prepayment requirement under the Amended Loan Agreement, on the terms and conditions specified in the Amended Loan Agreement; A permitted certain budgeted expenses to be excluded from the definition of cash proceeds subject to the CompanyA s mandatory prepayment obligations, on the terms and conditions specified in the Amended Loan Agreement, refer to Note 2 under Restricted Cash section for further discussion; A removed certain threshold amounts applicable to certain prepayment events; and A terminated the LendersA s \$100.0 million Tranche 2 Advance. The balances of our borrowing under the Amended Loan Agreement consisted of the following: A A December 31, 2023 A A (in thousands) A Principal value of term loan A \$ 429,916 A PIK added to principal A A 25,531 A Debt discount, issuance costs and exit fee accretion A A (9,002) A Term loan, net A \$ 446,445 A For the three and six months ended June 30, 2024, we recognized interest expense related to the Amended Loan Agreement of nil and \$3.0 million, respectively, of which nil and \$0.4 million, respectively, relates to amortization of debt discount and issuance costs. For the three and six months ended June 30, 2023, we recognized interest expense related to the Amended Loan Agreement of \$11.6 million and \$23.0 million, respectively, of which \$1.4 million and \$2.8 million, respectively, relates to amortization of debt discount and issuance costs. As of December 31, 2023, interest payable under the Amended Loan Agreement included in A Accrued professional and other accrued liabilitiesA in our condensed consolidated balance sheet amounted to \$6.7 million. On January 17, 2024, the Company fully repaid the Amended Loan Agreement for \$475.8 million, which consisted of \$455.4 million for the outstanding principal, \$9.1 million for the prepayment fee, \$8.6 million for the exit cost, \$2.4 million in accrued interest and \$0.3 million for transaction-related fees using the proceeds from the Financing Agreement and cash on hand, and recognized a loss on extinguishment of debt of \$26.6 million. Financing Agreement On January 17, 2024, the Company and each of the guarantors entered into a Financing Agreement, which was amended on February 12, 2024 (the A Financing AgreementA), with the lenders party thereto (the A LendersA) and Blue Owl Capital Corporation, as administrative agent for the Lenders (the A Administrative AgentA). Pursuant to the terms and conditions of the Financing Agreement, the Lenders have agreed to extend a senior secured credit facility to the Company in an aggregate principal amount of up to \$750.0 million, comprised of (i) an initial term loan in an aggregate principal amount of \$450.0 million (the A Initial Term LoanA) and (ii) one or more incremental term loans in an aggregate amount not to exceed \$300.0 million (collectively, the A Incremental Term LoanA, and together with the Initial Term Loan, collectively, the A Term LoansA), subject to the satisfaction of certain terms and conditions set forth in the Financing Agreement. The Initial Term Loan was funded on January 17, 2024. Incremental Term Loans are available at the CompanyA s and the LendersA mutual consent from time to time after January 17, 2024. The obligations of the Company under the Financing Agreement are and will be guaranteed by certain of the CompanyA s existing and future direct and indirect subsidiaries, subject to certain exceptions (such subsidiaries, collectively, the A GuarantorsA). As security for the obligations of the Company and the Guarantors, each of the Company and the Guarantors are required to grant to the Administrative Agent, for the benefit of the Lenders and secured parties, a continuing first priority security interest in substantially all of the assets of the Company and the Guarantors (including all equity interests owned or hereafter acquired by the Company and the Guarantors), subject to certain customary exceptions. Any outstanding principal on the Term Loans will initially bear interest at a rate per annum equal to (A) in the case of Term Loans bearing interest based on the base rate defined in the Financing Agreement (and which base rate will not be less than 2.00%), the sum of (i) the base rate plus (ii) 5.75% and (B) in the case of Term Loans bearing interest based on the three-month forward-looking term secured overnight financing rate administered by the Federal Reserve Bank of New York (A Term SOFRA), the sum of (i) three-month Term SOFRA (subject to 1.00% per annum floor), plus (ii) 6.75%. Accrued interest is payable quarterly following the funding of the Initial Term Loan on the Closing Date, on any date of prepayment or repayment of the Term Loans and at maturity. The Company will be required to make principal payments of \$22.5 million on the outstanding balance of the Initial Term Loan commencing on June 30, 2027 in quarterly installments (the A Scheduled Amortization PaymentsA); provided that if the Company achieves a senior total net leverage ratio of less than or equal to 5.00:1.00, up to four (4) Scheduled Amortization Payments may be deferred for a period of one fiscal quarter each. Such Scheduled Amortization Payments would be reduced in connection with voluntary or mandatory prepayments, if any, of the Initial Term Loans. Incremental Term Loans, if any, will be payable in accordance with their respective amortization schedules. Additionally, if the CompanyA s market capitalization is less than \$1.5 billion at any time after January 17, 2024, the Company shall also be required to make additional quarterly principal payments of \$10.0 million on the outstanding balance of the Initial Term Loan (the A Special Amortization PaymentsA) commencing with the first quarterly installment payment date occurring thereafter. The outstanding balance of the Term Loans, if not repaid sooner, shall be due and payable in full on the maturity date thereof. The stated maturity date of the Term Loans is January 17, 2029, with two springing earlier maturity dates at 91 days prior to the stated maturity dates of the CompanyA s outstanding convertible senior notes, in each case to the extent there is an aggregate outstanding amount of such notes of more than \$50.0 million on such dates. The Company may prepay the Term Loans at any time (in whole or in part) or be required to make mandatory prepayments upon the occurrence of certain customary prepayment events. The mandatory prepayment events include certain permitted asset sales transactions (which include certain sales, leases, assignments, conveyances, transfers, licenses or exchanges of property) that occur prior to the date the FDA approves a first NDA for acoramidis, which would require the Company to deposit 75% of net cash received from such transactions into an escrow account controlled by the Administrative Agent, and the Company may also be subject to a specified disposition fee per transaction for certain asset sale transactions. In certain instances and during certain time periods, prepayments will be subject to customary prepayment fees. The amount of any prepayment fee may vary, but the maximum amount that may be due with any such prepayment would be an amount equal to 3.00% of the Term Loans being prepaid at such time, plus a customary make whole amount. We have entered into asset sales transactions that occurred during the three months ended March 31, 2024 for the exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd, for which the Company is required to deposit 75% of the proceeds, net of certain permitted costs, upon receipt of the upfront payments from Bayer Consumer Care AG and Kyowa Kirin Co., Ltd, into the escrow accounts. During the three months ended June 30, 2024, we received \$235.0 million in aggregate from Bayer Consumer Care AG and Kyowa Kirin Co., Ltd, and deposited net proceeds of \$159.3 million into the escrow accounts. Refer to Note 11 for further details regarding the exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd. The completion of the \$200.0 million private equity financing with external investors of BBOT was considered an asset sale transaction that was subject to a disposition fee under the Financing Agreement. Accordingly, we paid a disposition fee of \$1.1 million to the Administrative Agent during the three months ended June 30, 2024. Refer to Note 6 for further details regarding the BBOT private equity financing transaction. The Financing Agreement contains affirmative covenants and negative covenants applicable to the Company and its subsidiaries that are customary for financings of this type. Such covenants, among other items, limit the CompanyA s and its subsidiariesA ability to (i) incur additional permitted indebtedness, (ii) pay dividends or make certain distributions, (iii) dispose of its and their assets, grant liens and license or permit other encumbrances on its and their assets, (iv) fundamentally alter the nature of their businesses and (v) enter into certain transactions with affiliates. The Company and the Guarantors are also required to maintain a minimum qualified cash balance of \$70.0 million, at all times. The Company and its subsidiaries are permitted to license their intellectual property, dispose of other assets and enter into monetization and royalty transactions, in each case, subject to satisfaction of certain terms and conditions. The Financing Agreement also includes representations, warranties, indemnities and events of default that are customary for financings of this type, including an event of default relating to a change of control of the Company. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate the CompanyA s obligations under the Financing Agreement. On June 20, 2024, the Company and each of the guarantors entered into the Second Amendment to the Financing Agreement (the Financing Agreement, as amended by the Second Amendment, the A Amended Financing AgreementA). Under the Amended Financing Agreement, between June 20, 2024 and through the earlier of the date the FDA approves a first NDA for acoramidis and November 30,

As of June 30, 2024, the Company is able to request a release or ruds in an aggregate amount not to exceed 50% of the original net cash proceeds received from asset sales transactions. As of June 30, 2024, \$20.0 million was released from the escrow accounts and classified as cash, with a remaining balance of \$139.3 million in the escrow accounts classified as restricted cash on the condensed consolidated balance sheet. Furthermore, under the Amended Financing Agreement, the minimum qualified cash balance was amended from \$70.0 million to \$70.0 million plus 40% of any cash released by the Company from the escrow accounts, at all times. As of June 30, 2024, the minimum unrestricted qualified cash balance was \$78.0 million. We received net proceeds from the Initial Term Loan of \$434.0 million, after deducting debt discount and issuance costs of \$16.0 million. The balances of our borrowing under the Amended Financing Agreement consisted of the following: As of June 30, 2024, (in thousands) A Principal value of term loan A \$ 450,000 A Debt discount, issuance costs and exit fee accretion A (14,553) Term loan, net A \$ 435,447 A For the three and six months ended June 30, 2024, we recognized interest expense related to the Amended Financing Agreement of \$14.3 million and \$26.2 million, respectively, of which \$0.7 million and \$1.4 million, respectively, relates to amortization of debt discount and issuance costs. As of June 30, 2024, interest payable under the Amended Financing Agreement included in Accrued professional and other accrued liabilities in our condensed consolidated balance sheet amounted to \$0.3 million. Future minimum payments under the Amended Financing Agreement as of June 30, 2024 are as follows: Amount A (in thousands) A Remainder of 2024 A \$ 27,515 A Year Ending December 31: A 2025 A \$ 53,995 A 2026 A \$ 53,995 A 2027 A \$ 119,454 A 2028 A \$ 131,732 A 2029 A \$ 294,327 A Total future payments A \$ 681,018 A Less amounts representing interest A (231,018) Total principal amount of term loan payments A \$ 450,000 A The amounts in the table above do not take into account any changes due to mandatory payments under the terms of the Amended Financing Agreement. X - ReferencesNo definition available. + Details Name: us-gaap DebtDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1:

commercialize infigratinib for achondroplasia, hypochondroplasia and other skeletal dysplasias in Japan and the related know-how; andâ€¢research and development services to conduct ongoing clinical trials. We determined that the performance obligations outlined above are capable of being distinct and distinct with the context of the contract given such rights and activities are independent of each other. The license can be used by Kyowa Kirin without any development activities. Similarly, those services provide a distinct benefit to Kyowa Kirin within the context of the contract, separate from the license, as the services could be provided by Kyowa Kirin or another third party without our assistance. We determined the initial transaction price at inception of the KKC Agreement to be \$100.0 million, which is comprised of the fixed and non-refundable upfront payment. No additional development or sales milestone payments are included in the transaction price, as all such payments are variable consideration that are fully constrained as of June 30, 2024. We include variable consideration in our transaction price to the extent that it is probable that it will not result in a significant revenue reversal when the uncertainty associated with the variable consideration is subsequently resolved. As part of managementâ€™s evaluation of the variable consideration, we considered numerous factors, including the fact that achievement of the milestones is outside of our control, contingent upon the success of our existing and future clinical trials, Kyowa Kirinâ€™s efforts, and receipt of regulatory approval that is subject to scientific risks of success. Royalty arrangements and commercial-based milestones will be recognized when the sales occur or the milestones are achieved pursuant to the sales-based royalty exception under ASC 606 because the license is the predominant item to which the royalties or commercial-based milestones relate. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. We allocated the transaction price of \$100.0 million based on the SSP of each of the performance obligations as follows:â€¢\$69.1 million for the upfront transfer of the license; and â€¢\$30.9 million for research and development services to conduct the ongoing clinical trials. The SSP for the license was determined using an approach that considered discounted, probability-weighted cash flows related to the license transferred. The SSP for the ongoing research and development services were based on estimates of the associated effort and cost of these services, adjusted for a reasonable gross profit margin that would be expected to be realized under similar contracts. We recognize revenue for each of the two performance obligations as follows:â€¢We recognized revenue related to the license at a point in time upon transfer of the rights and control of the license to KKC. The transfer of the rights and control of the license occurred in February 2024, thus we recognized the full amount allocated to the license and related know-how during the three months ended March 31, 2024.â€¢We are recognizing revenue relating to the research and development services for the ongoing clinical trials over time using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. We expect the development services to extend through 2029. We have recognized \$1.3 million and \$2.9 million of revenue relating to this performance obligation during the three and six months ended June 30, 2024, respectively. As of June 30, 2024, there are no outstanding receivables from licensing and collaboration agreements relating to the KKC Agreement within our condensed consolidated balance sheet. During the three and six months ended June 30, 2024, we recognized license revenue of \$1.3 million and \$72.1 million under the KKC Agreement. Our condensed consolidated balance sheet as of June 30, 2024 includes a deferred revenue balance of \$28.0 million (\$13.7 million presented as â€¢Deferred revenue, current portionâ€¢ and \$14.3 million included in â€¢Deferred revenue, net of current portionâ€¢) related to our research and development services obligation. In addition, under the terms of the Financing Agreement, the KKC Agreement represents an asset sale transaction that requires the Company to deposit 75% of proceeds, net of certain permitted costs, received from the transaction into an escrow account to be controlled by the Administrative Agent. In June 2024, we deposited \$74.6 million into the escrow account from the receipt of the \$100.0 million from KKC. Refer to Note 9 for further details regarding the Financing Agreement. License, Development and Commercialization Agreement with BMS On May 12, 2022, BridgeBio and our subsidiary, Navire, entered into an exclusive license, development and commercialization agreement with BMS (the â€¢Navire-BMS License Agreementâ€¢), pursuant to which Navire granted BMS exclusive rights to develop and commercialize Navireâ€™s product candidate, BBP-398, in all indications worldwide, except for the Peopleâ€™s Republic of China, Macau, Hong Kong, Taiwan, Thailand, Singapore, and South Korea (the â€¢Asia Regionâ€¢). The development and commercialization of BBP-398 within the Asia Region is governed under the Navire-LianBio License Agreement (as discussed below). The Navire-BMS License Agreement expands an earlier agreement between Navire and BMS that was executed in July 2021 to study BBP-398 in a combination therapy trial to treat advanced solid tumors with KRAS mutations (the â€¢2021 Navire-BMS Agreementâ€¢). The Navire-BMS License Agreement does not alter the terms of the 2021 Navire-BMS Agreement. Under the terms of the Navire-BMS License Agreement, Navire was entitled to receive a non-refundable, upfront payment of \$90.0 million, which Navire received in full in June 2022. Additionally, Navire is eligible to receive additional payments totaling up to approximately \$815.0 million in the aggregate, subject to the achievement of development, regulatory and commercial milestones, as well as tiered royalties in the low-to-mid teens as a percentage of adjusted net sales by BMS of the licensed products sold worldwide, outside of the Asia Region. Navire will retain the option to acquire higher royalties in the United States in connection with funding a portion of development costs upon the initiation of registrational studies. Based on the terms of the Navire-BMS License Agreement, Navire will continue to lead its ongoing Phase 1 monotherapy and combination therapy trials (collectively, the â€¢Phase 1 Trialsâ€¢), and BMS will lead and fund all other development and commercialization activities. Navire is fully funding the Phase 1 trials with the exception of the combination therapy governed under the 2021 Navire-BMS Agreement. In accordance with the 2021 Navire-BMS Agreement, both parties are sharing all research and development costs equally for this trial. We have recorded all research and development costs for the Phase 1 Trials, as well as the reimbursement for the costs associated with the trial governed by the 2021 Navire-BMS Agreement within â€¢Research and developmentâ€¢ in our condensed consolidated statement of operations. In March 2024, we received written notice from BMS for the termination of the Navire-BMS License Agreement effective June 2024, and all rights and obligations thereunder. In April 2024, Navire and BMS entered into a Clinical Collaboration Termination Agreement which terminated the 2021 Navire-BMS Agreement. Navire and BMS agreed to pursue reasonable efforts to wind down activities under both the Navire-BMS License Agreement and the 2021 Navire-BMS Agreement. As a result of the termination, Navire is no longer entitled to any future unearned development, regulatory or sales-based milestone and royalty payments. However, we may in the future be eligible to receive earned payments for any milestones already achieved prior to termination and for achieving any milestones while closing out the remaining services. We determined that the Navire-BMS License Agreement falls within the scope of ASC 606 as BMS is a customer in this arrangement, and we identified the following performance obligations in the agreement: â€¢an exclusive license to develop and commercialize BBP-398 and the related know-how; and â€¢research and development services to complete the Phase 1 Trials for BBP-398. We determined that the performance obligations outlined above are capable of being distinct and distinct with the context of the contract given such rights and activities are independent of each other. The license can be used by BMS without the research and development services. Similarly, those services provide a distinct benefit to BMS within the context of the contract, separate from the license, as the services could be provided by BMS or another third party without our assistance. We may enter into clinical and commercial supply agreements for the licensed territory. We determined that the optional right to future products under these supply agreements does not represent a material right. In March 2023, Navire and BMS entered into a clinical supply agreement for the supply of clinical quantities of the licensed product. Navire has supplied insignificant amounts to BMS as part of the clinical supply agreement for the three and six months ended June 30, 2024 and 2023. We determined the initial transaction price at inception of the Navire-BMS License Agreement to be \$90.0 million, which is comprised of the fixed and non-refundable upfront payment. No additional development, regulatory, or sales milestone payments are included in the transaction price, as all such payments are variable consideration that are fully constrained as of June 30, 2024. We include variable consideration in our transaction price to the extent that it is probable that it will not result in a significant revenue reversal when the uncertainty associated with the variable consideration is subsequently resolved. As part of managementâ€™s evaluation of the variable consideration, we considered numerous factors, including the fact that achievement of the milestones is outside of our control, contingent upon the success of our existing and future clinical trials, BMSâ€™ efforts, and receipt of regulatory approval that is subject to scientific risks of success. Royalty arrangements and commercial-based milestones will be recognized when the sales occur or the milestones are achieved pursuant to the sales-based royalty exception under ASC 606 because the license is the predominant item to which the royalties or commercial-based milestones relate. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. We allocated the transaction price of \$90.0 million based on the SSP of each of the performance obligations as follows:â€¢\$70.2 million for the upfront transfer of the license; and â€¢\$19.8 million for research and development services to complete the Phase 1 Trials of BBP-398. The SSP for the license was determined using an approach that considered discounted, probability-weighted cash flows related to the license transferred. The SSP for the ongoing research and development services were based on estimates of the associated effort and cost of these services, adjusted for a reasonable gross profit margin that would be expected to be realized under similar contracts. We recognize revenue for each of the two performance obligations as follows:â€¢We recognize revenue related to the license at a point in time upon transfer of the rights and control of the license to BMS. The transfer of the rights and control of the license occurred in June 2022, thus we recognized the full amount allocated to the license and related know-how during the three months ended June 30, 2022.â€¢We are recognizing revenue related to the research and development services to complete the Phase 1 Trials for BBP-398 over time using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. As a result of the Navire-BMS License Agreement termination, the research and development services performance obligation is complete and there are no remaining performance obligations. As such, the remaining revenue allocated to this performance obligation was recognized during the three months ended March 31, 2024. â€¢Revenue recognized related to this performance obligation for the three and six months ended June 30, 2024 was nil and \$9.9 million, respectively. Revenue recognized related to this performance obligation for the three and six months ended June 30, 2023, was \$1.5 million and \$3.2 million, respectively. For the three and six months ended June 30, 2024, we have recognized nil and \$9.9 million, respectively, in revenue relating to the Navire-BMS Agreement. For the three and six months ended June 30, 2023, we have recognized \$1.5 million and \$3.2 million in revenue, respectively, relating to the Navire-BMS Agreement. As of June 30, 2024, there are no remaining balances in deferred revenue within our condensed consolidated balance sheet. Our condensed consolidated balance sheet as of December 31, 2023 includes a deferred revenue balance of \$9.9 million (\$6.1 million presented as â€¢Deferred revenue, current portionâ€¢ and \$3.8 million included in â€¢Deferred revenue, net of current portionâ€¢) related to our research and development services obligation. License and Collaboration Agreement with Helsinn On March 29, 2021, QED entered into a license and collaboration agreement with Helsinn Healthcare S.A. (â€¢HHCâ€¢) and Helsinn Therapeutics (U.S.), Inc. (â€¢HTUâ€¢, and collectively with HHC, â€¢Helsinnâ€¢) (the â€¢QED-Helsinn License and Collaboration Agreementâ€¢), pursuant to which QED granted to HHC exclusive licenses to develop, manufacture and commercialize QEDâ€™s product candidate, infigratinib, in oncology and all other indications except achondroplasia or any other skeletal dysplasias, worldwide, except for the Peopleâ€™s Republic of China, Hong Kong and Macau (â€¢Greater Chinaâ€¢), and under which QED received a co-exclusive license to co-commercialize infigratinib in the United States in the licensed indications. The QED-Helsinn License and Collaboration Agreement became effective on April 16, 2021. Upon approval by the FDA in May 2021, QED and HTU co-commercialized infigratinib in the licensed indications in the United States and shared profits and losses on a 50:50 basis. Additionally, QED and Helsinn shared global, excluding Greater China, research and development costs for infigratinib in the licensed indications at a rate of 40% for QED and 60% for Helsinn. On February 28, 2022, QED and Helsinn amended the QED-Helsinn License and Collaboration Agreement (the â€¢Amended QED-Helsinn License and Collaboration Agreementâ€¢) effective on March 1, 2022. Under the terms of the Amended QED-Helsinn License and Collaboration Agreement, Helsinn had an exclusive license to commercialize infigratinib in the United States and was responsible for solely developing, manufacturing and commercializing infigratinib in oncology indications except for achondroplasia or any other skeletal dysplasias worldwide, outside of Greater China. QED retains all rights to develop, manufacture and commercialize infigratinib in skeletal dysplasia, including achondroplasia. The Amended QED-Helsinn License and Collaboration Agreement also provided for a transitional period, which extended from the effective date through August 31, 2022, for which QED was contracted to assist in research and development and commercialization activities. The costs related to QEDâ€™s contracted activities incurred during the transitional period were fully reimbursable by Helsinn and were due to QED subsequent to the transitional period. Helsinn also agreed to reimburse QEDâ€™s obligation to FMI described in Note 7 as part of the Amended QED-Helsinn License and Collaboration Agreement. In recording this transaction, we recognized a corresponding gain as part of â€¢Other income (expense), netâ€¢ for the three months ended September 30, 2022. Effective December 21, 2022, QED and Helsinn (the â€¢Helsinn Partiesâ€¢), entered into a Mutual Termination Agreement (â€¢MTAâ€¢), which terminates the Amended QED-Helsinn License and Collaboration Agreement and all rights and obligations thereunder. The Helsinn Parties agreed to perform certain close-out services to enable QED to pursue the development, manufacture and commercialization of infigratinib as a potential treatment of non-oncology indications, such as in achondroplasia worldwide, excluding China, Hong Kong, and Macau. As a result of the termination, QED is no longer entitled to any future regulatory or sales-based milestone payments. QED was subject to royalties on net sales of TRUSELTQTMTM through March 31, 2023, at which date Helsinn no longer sold the licensed product. Helsinn permanently discontinued the distribution of TRUSELTQTMTM and the FDA announced the withdrawal of the NDA approval in May 2023, additionally, all clinical investigations under the associated IND are discontinued. Helsinn completed sales of the licensed product during the three months ended March 31, 2023, and the associated revenue recognized was immaterial. The Helsinn Parties developed a Close-Out Plan, as defined within the MTA. Activities within the Close-Out Plan are to be shared equally subsequent to the lower of the first \$11.0 million of costs, or QEDâ€™s obligation to FMI, which are the responsibility of QED. QED reached the threshold of \$11.0 million in January 2023. The activities within the Close-Out Plan were substantially completed in 2023. Upon the effective date of the MTA, outstanding obligations of \$31.3 million (\$18.8 million relating to contracted research and development and commercial activities and \$12.5 million relating to the reimbursement of QEDâ€™s obligation to FMI) under the Amended QED-Helsinn License and Collaboration Agreement related to the contracted services during the transitional period became due, of which all payments have been paid in full. In March 2024, QED reduced its obligation to FMI to \$9.6 million and therefore, pursuant to the MTA, QEDâ€™s responsibility for close-out activities was lowered to this amount and Helsinnâ€™s reimbursement of QEDâ€™s obligation to FMI was reduced from \$11.0 million to \$9.6 million. As a result of the reduced FMI obligation, Helsinn is required to share evenly an additional \$1.4 million of close-out costs and QED is required to reimburse Helsinn \$1.4 million relating to the FMI obligation, resulting in a net payable position to Helsinn from QED of \$0.7 million. For the three and six months ended June 30, 2024, QED has incurred immaterial close out costs and the net costs are subject to 50% reimbursement from Helsinn. For the three and six months ended June 30, 2023, QED has incurred \$2.1 million and \$5.7 million of close-out costs, respectively, of which \$2.1 million and \$4.5 million are subject to 50% reimbursement from Helsinn, respectively. As of June 30, 2024, there is no outstanding receivable balance due from Helsinn. As of December 31, 2023, the outstanding receivable due from Helsinn was \$0.6 million. The outstanding receivables are presented in â€¢Receivables from licensing and collaboration agreementsâ€¢ within our condensed consolidated balance sheets. Close-out costs incurred, including Helsinnâ€™s reimbursements, are recorded in â€¢Restructuring, impairment and related chargesâ€¢ for the three and six months ended June 30, 2024 and 2023, respectively, within our condensed consolidated statement of operations (refer to Note 16). The QED-Helsinn License and Collaboration Agreement, the Amended QED-Helsinn License Collaboration Agreement, and the MTA are considered to be within the scope of ASC 808 as the parties are active participants and are exposed to the significant risks and rewards of the collaborative activity. The QED-Helsinn License and Collaboration Agreement and the Amended QED-Helsinn License and Collaboration Agreement are also partially within the scope of ASC 606 for the units of account where Helsinn is identified as a customer. For the units of account in the collaboration arrangement that do not represent a vendor-customer relationship, including the performance of collaborative research and development and commercialization services, we determined that ASC 606 is not appropriate to apply by analogy and applied a reasonable and rational accounting policy election that faithfully depicts the transfer of services to the collaboration partner over the estimated performance period. Reimbursement payments from Helsinn associated with the collaborative research and development and commercialization services are recognized as the related expense is incurred and classified as an offset to the underlying expense and excluded from the transaction price. We evaluated the terms of the QED-Helsinn License and Collaboration Agreement and identified Helsinn as a customer with the following two distinct performance obligations: (1) exclusive licenses to develop, manufacture, and commercialize the underlying product, and (2) transfer of inventory within the transitional supply period. The Amended QED-Helsinn License and Collaboration Agreement did not give rise to any additional performance obligations. All of the license revenue relating to these units of account accounted for under ASC 606 were recognized in the year ended December 31, 2021. For the unit of account that is within the scope of ASC 808 relating to collaborative research and development services, pursuant to the QED-Helsinn License and Collaboration Agreement, the Amended QED-Helsinn License Collaboration Agreement, and the MTA, we have recognized an immaterial amount of Helsinnâ€™s share of research and development expenses for the three and six months ended June 30, 2024 as a reduction to restructuring, impairment and related charges. We have recognized Helsinnâ€™s share of research and development expenses of \$1.0 million and \$2.2 million for the three and six months ended June 30, 2023, respectively. License Agreement with LianBio Navire In August 2020,

Navire entered into an exclusive license agreement with LianBio (the Navire-LianBio License Agreement). Pursuant to the Navire-LianBio License Agreement, Navire granted to LianBio an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize SHP2 inhibitor BBP-398, or BBP-398, for tumors driven by RAS and receptor tyrosine kinase mutations. Under the terms of the Navire-LianBio License Agreement, LianBio will receive commercial rights in China and selected Asian markets and participate in clinical development activities for BBP-398. In consideration for the rights granted to LianBio, we received a nonrefundable \$8.0 million upfront payment, which we recognized as license revenue in 2020. We will also have the right to receive future development and sales milestone payments of up to \$382.1 million, and tiered royalty payments from single-digit to low-teens on net sales of the product in licensed territories. We recognized \$8.5 million in license revenue, representing a regulatory milestone payment in 2021. We accounted for the Navire-LianBio License Agreement under ASC 606 and identified the exclusive license as a distinct performance obligation since LianBio can benefit from the license on its own by developing and commercializing the underlying product using its own resources. In addition, we may enter into clinical and commercial supply agreements for the licensed territory. We determined that the optional right to future products under these supply agreements does not represent a material right. In July 2022, Navire and LianBio entered into a clinical supply agreement for the manufacture and supply of clinical quantities of the licensed product. During the three and six months ended June 30, 2024 and 2023, Navire has not provided any clinical supply to LianBio. QED In October 2019, QED entered into an exclusive license agreement with LianBio (the QED-LianBio License Agreement). Pursuant to the QED-LianBio License Agreement, QED granted to LianBio an exclusive, sublicensable license under the licensed patent rights and know-how to develop, manufacture and commercialize infigratinib for any and all human prophylactic and therapeutic uses in all cancer indications (including in combination with other therapies) in certain territories outside the United States. Under the QED-LianBio License Agreement, QED received a nonrefundable upfront payment of \$10.0 million and is eligible to receive development and sales milestones payments of up to \$132.5 million and tiered royalties on net sales ranging from the low to mid-teens. In addition, QED also received warrants which entitled QED to purchase 10% of the then-fully diluted shares of one of the subsidiaries of LianBio upon achievement of certain contingent development milestones (refer to Note 6). We accounted for the QED-LianBio License Agreement and the LianBio Exclusivity Agreement as a single transaction under ASC 606 and identified the exclusive license as a distinct performance obligation since LianBio can benefit from the license on its own by developing and commercializing the underlying product using its own resources. In addition, we may enter into clinical and commercial supply agreements for the licensed territory. We determined that LianBio's optional right to future products under these supply agreements is not considered to represent a material right. A clinical supply agreement was entered into in November 2021. QED has not provided any clinical supplies to LianBio during the three and six months ended June 30, 2024. QED provided insignificant amounts of clinical supplies to LianBio during the three and six months ended June 30, 2023 and has recorded such amounts within Revenue in our condensed consolidated statement of operations. License Agreement with Alexion In September 2019, Eidos Therapeutics, Inc. (the EidosAlexion License Agreement), to develop, manufacture, and commercialize in Japan the compound known as acoramidis (previously known as AG10) and any of its various chemical forms and any pharmaceutical products containing acoramidis. Under the Eidos-Alexion License Agreement, Eidos received an upfront nonrefundable payment of \$25.0 million and is eligible to receive \$30.0 million in regulatory milestone payments and royalties in the low-teens based on net sales of acoramidis in Japan. The royalty rate is subject to reduction if Alexion is required to obtain intellectual property rights from third parties to develop, manufacture or commercialize acoramidis in Japan, or upon the introduction of generic competition into market. Eidos also entered into a stock purchase agreement with Alexion, under which Eidos sold to Alexion 556,173 shares of Eidos common stock at a price per share of \$44.95, for an aggregate purchase price of approximately \$25.0 million. The excess of the purchase price over the value of the Eidos shares, determined based on the closing price of a share of Eidos' common stock of \$41.91 as reported on Nasdaq as of the date of execution, was \$1.7 million and recognized in revenue as part of the upfront payment as discussed below. Eidos accounted for the Eidos-Alexion License Agreement under ASC 606 and identified the exclusive license as a distinct performance obligation since Alexion can benefit from the license on its own by developing and commercializing the underlying product using its own resources. Eidos recognized the \$25.0 million upfront fee and \$1.7 million premium paid for Eidos' stock for a total upfront payment of \$26.7 million in license revenue upon the effective date of the license agreement in September 2019. Eidos determined that the license was a right to use its intellectual property and as of the effective date, it had provided all necessary information to Alexion to benefit from the license and the license term had begun. In addition, Eidos entered into a clinical supply agreement in July 2020 and may enter into a commercial supply agreement for the licensed territory. Eidos determined that the optional right to future products under these supply agreements is not considered to represent a material right. Eidos has supplied insignificant amounts to Alexion as part of the clinical supply agreement during the three and six months ended June 30, 2024 and 2023, respectively, and has recorded such amounts within Revenue in our condensed consolidated statements of operations. Receivables from Licensing and Collaboration Agreements Receivables from licensing and collaboration agreements represent valid claims against our partners, customers, biopharmaceutical companies including unbilled receivables and royalty payments due from third parties for licensing the Company's technologies. Unbilled receivables include balances due from our biopharmaceutical customers related to development services and transition-related receivables that are recognized upon incurrence of the costs for the partnered programs but prior to the achievement of contractual billing rights. As of June 30, 2024 and December 31, 2023, the Company had unbilled receivables of \$0.2 million and \$0.9 million, respectively, of which 70.6% and 61.9%, respectively, of total unbilled receivables related to one partner. Total receivables from licensing and collaboration agreements as of June 30, 2024 and December 31, 2023 are \$0.7 million and \$1.8 million, respectively, and are presented as Receivables from licensing and collaboration agreements within our condensed consolidated balance sheets. The Company evaluates the collectability of its receivables from licensing and collaboration agreements based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management's best estimate of the amount of probable credit losses. As of June 30, 2024 and December 31, 2023, the Company did not have an allowance for credit losses. X - Definition License and collaboration agreement. + References No definition available. + Details Name: bbio LicenseAndCollaborationAgreementAbstract Namespace Prefix: bbio Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition License and collaboration agreement. + References No definition available. + Details Name: bbio LicenseAndCollaborationAgreementTextBlock Namespace Prefix: bbio Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 28 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 In-licensing and Other Research and Development Agreements 6 Months Ended Jun. 30, 2024 In-Licensing And Other Research And Development Agreements [Abstract] A In-licensing and Other Research and Development Agreements 12. In-licensing and Other Research and Development Agreements Stanford License Agreement In April 2016, Eidos entered into a license agreement with the Board of Trustees of the Leland Stanford Junior University, (the Stanford University), relating to Eidos' drug discovery and development initiatives. Under this agreement and its amendments, Eidos has been granted certain worldwide exclusive licenses to make, use, and sell products that are covered by licensed patent rights. In March 2017, Eidos paid a license fee of \$10,000, which was recorded as research and development expense during the year ended December 31, 2017, as the acquired assets did not have any alternative future use. Eidos may also be required to make future payments of up to approximately \$1.0 million to Stanford University upon achievement of specific intellectual property, clinical and regulatory milestone events, and pay royalties of up to low single-digit percentages on future net sales, if any. In addition, Eidos is obligated to pay Stanford University a percentage of non-royalty revenue received by Eidos from its sublicensees, with the amount owed decreasing annually for three years based on when the applicable sublicense agreement is executed. Additionally, under the license agreement with Stanford University, we will pay Stanford University a portion of all nonroyalty sublicensing consideration attributable to the sublicense of the licensed compounds. For the six months ended June 30, 2024, we incurred and paid \$8.1 million of licensing fees due to Stanford University related to the Company entering into an exclusive license agreement with Bayer in March 2024. For the three and six months ended June 30, 2023, the licensing fees incurred were not material. Diagnostics Agreement with Foundation Medicine As discussed in Note 7, QED and FMI entered into a diagnostics agreement relating to QED's drug discovery and development initiatives. For the three and six months ended June 30, 2024 and 2023, the research and development expenses QED recognized were not material in connection with this agreement. Resilience Development and Manufacturing Service Agreements In September 2023, Aspa Therapeutics, Inc. (the Aspa) and Adrenas Therapeutics Inc. (the Adrenas), each entered into a Development and Manufacturing Services Agreement (collectively the Resilience DMSAs) and a Project Agreement (collectively the Resilience PASs), (collectively the Resilience Agreements) with Resilience US, Inc. (the Resilience), for Resilience to provide contract development, manufacturing, testing and related services with respect to therapeutic and pharmaceutical products for the clinical development applications of BBP-812 and BBP-631, respectively. BBP-812 is an intravenous AAV9 investigational drug product intended for the treatment of children with Canavan Disease, under the age of five years. BBP-631 is an intravenous AAV5 investigational drug product intended for the treatment of adults and children with congenital adrenal hyperplasia. The Resilience DMSAs have ten-year terms and may each be extended for additional two-year periods. Under the Resilience PASs, Resilience will provide Aspa with a cost sharing credit of the lesser of a fixed percentage of certain agreed upon service costs or \$15.5 million. Under the Resilience PASs, Resilience will provide Adrenas with a cost sharing credit of the lesser of a fixed percentage of certain agreed upon service costs or \$29.3 million. In addition to the payments for their share of services performed by Resilience, Aspa and Adrenas may each be required to make future payments of up to \$10.0 million upon achievement of certain development and approval milestone events, and royalty payments (mid-single digits for BBP-812 and low-single digits for BBP-631) based on achievement of certain net sales metrics. For the three and six months ended June 30, 2024, \$0.4 million and \$0.9 million, respectively, in research and development expenses was incurred, which was net of \$0.5 million and \$1.1 million, respectively, in cost sharing credits received in connection with the Resilience Agreements. Other License and Collaboration Agreements In addition to the agreements described above, we have also entered into other license and collaboration agreements with various institutions and business entities on terms similar to those described above, none of which are material individually or in the aggregate. X - Definition In-licensing and other research and development agreements. + References No definition available. + Details Name: bbio InLicensingAndOtherResearchAndDevelopmentAgreementsAbstract Namespace Prefix: bbio Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition In-licensing and other research and development agreements disclosure. + References No definition available. + Details Name: bbio InLicensingAndOtherResearchAndDevelopmentAgreementsDisclosureTextBlock Namespace Prefix: bbio Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 29 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases 6 Months Ended Jun. 30, 2024 Leases [Abstract] A Leases 13. Leases We have operating leases for our corporate headquarters, office spaces and laboratory facilities. One of our office space leases has a finance lease component representing lessor provided furniture and office equipment. Our finance lease, which is presented as part of Property and equipment, net in our condensed consolidated balance sheets, is not material. Certain leases include renewal options at our election and we include the renewal options when we are reasonably certain that the renewal option will be exercised. The lease liabilities were measured using a weighted-average discount rate based on the most recent borrowing rate as of the calculation of the respective lease liability, adjusted for the remaining lease term and aggregate amount of the lease. The components of lease cost are as follows: A A Three Months Ended June 30, A Six Months Ended June 30, A A 2024 A 2023 A A 2024 A 2023 A A (in thousands) A A (in thousands) A Straight line operating lease costs A \$ 1,024 A A \$ 992 A A \$ 2,093 A A \$ 2,024 A Finance lease costs A A 100 A A 105 A A 201 A A 213 A Variable lease costs A A 1,477 A A 1,700 A A 3,490 A A 3,418 A Total lease cost A \$ 2,601 A A \$ 2,797 A A \$ 5,784 A A \$ 5,655 A Supplemental cash flow information related to leases are as follows: A A Six Months Ended June 30, A A 2024 A A 2023 A A (in thousands) A Cash paid for amounts included in the measurement of lease liabilities: A A A A Operating cash flows for operating leases A \$ 2,981 A A \$ 2,443 A Operating cash flows for finance lease A A 222 A A 217 A Operating lease right-of-use assets obtained in exchange A A A for operating lease obligations A A 1,292 A A A 828 A A Supplemental information related to the remaining lease term and discount rate are as follows: A A June 30, A A 2024 A 2023 A A Weighted-average remaining lease term (in years) A A A A Operating leases A 4.0 A A 5.2 A Finance lease A 1.6 A A 2.6 A Weighted-average discount rate A A A A Operating leases A 6.24 % A 6.34 % Finance lease A 6.62 % A 6.62 % As of June 30, 2024, future minimum lease payments for our noncancelable operating leases are as follows. Future minimum lease payments under our finance lease are not material. A A Amount A A (in thousands) A Remainder of 2024 A \$ 2,509 A Year ending December 31: A A 2025 A 5,103 A 2026 A 2,276 A 2027 A 459 A 2028 A 459 A Thereafter A \$ 2,179 A Total future minimum lease payments A A 12,985 A Imputed interest A A (1,303) Total A \$ 11,682 A A Reported as of June 30, 2024 A A A A Operating lease liabilities, current portion A \$ 4,623 A Operating lease liabilities, net of current portion A A 7,059 A Total operating lease liabilities A \$ 11,682 A The impairment loss recognized was not material for the three and six months ended June 30, 2024. No impairment loss was recognized during the three and six months ended June 30, 2023. X - Definition Lessee operating and financing leases disclosure. + References No definition available. + Details Name: bbio LesseeOperatingAndFinancingLeasesDisclosureTextBlock Namespace Prefix: bbio Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 30 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Public Offerings 6 Months Ended Jun. 30, 2024 Public Offerings And Share Repurchase Program And Securities Purchase Agreement [Abstract] A Public Offerings 14. Public Offerings 2023 Follow-on Offerings In March 2023, we entered into an Underwriting Agreement (the 2023 Follow-on Agreement) with Goldman Sachs & Co. LLC, Evercore Group L.L.C., Morgan Stanley & Co. LLC and KKR Capital Markets LLC (the KCMs), as representatives of several underwriters (collectively, the Underwriters), relating to an underwritten public offering (the 2023 Follow-on offering) of 8,823,530 shares of the Company's common stock, \$0.001 par value per share (the Common Stock), at a public offering price of \$17.00 per share. The Company also granted the Underwriters a 30-day option to purchase, at the public offering price less underwriting discounts and commissions, up to an additional 1,323,529 shares of Common Stock. The Company paid the Underwriters a commission of 4.3% of the aggregate gross proceeds received from all sales of the common stock under the 2023 Follow-on Agreement. The Underwriters included KCM, which is an affiliate of KKR Genetic Disorder L.P., a related party being a stockholder who beneficially owns greater than 5% of our outstanding securities. KCM received a commission of 0.315% of the aggregate gross proceeds received from all sales of the common stock under the 2023 Follow-on Agreement. In March 2023, 8,823,530 shares were issued under the 2023 Follow-on Agreement, for net proceeds of \$143.0 million, after deducting underwriting fees and commissions of \$6.5 million (of which \$0.5 million related to commissions paid to KCM) and offering costs of \$0.5 million. In April 2023, the Underwriters partially exercised their 30-day option to purchase additional shares, for which 63,470 shares were issued for net proceeds of \$1.0 million, after deducting underwriting fees and commissions of less than \$0.1 million. 2023 Shelf Registration Statement and ATM Agreement In May 2023, we filed a shelf registration statement on Form S-3 (the 2023 Shelf) with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and units or any combination thereof. We also concurrently entered into an Equity Distribution Agreement (the ATM Agreement) with Goldman Sachs & Co. LLC and SVB Securities LLC (collectively, the ATM Sales Agents), with respect to an at-the-market offering program under which we may issue and sell, from time to time at our sole discretion and pursuant to a prospectus supplement, shares of our common stock, par value \$0.001 per share, having an aggregate offering price of up to \$450.0 million through the ATM Sales Agents. We will pay the ATM Sales Agents a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. During the year ended December 31, 2023, 2,171,217 shares were issued under the ATM Agreement, for net proceeds of \$65.0 million, after deducting sales agent fees and commissions of \$1.0 million. During the six months ended June 30, 2024, 1,061,991 shares were issued under the ATM Agreement, for net proceeds of \$38.1 million, after deducting sales agent fees and commissions of \$0.6 million. As of June 30, 2024, we are still eligible to sell up to \$345.3 million of our common stock pursuant to the ATM Agreement under the 2023 Shelf. 2024 Follow-on Offering In March 2024, we entered into an Underwriting Agreement (the 2024 Follow-on Agreement) with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of several underwriters (collectively, the 2024 Underwriters), relating to an underwritten public offering (the 2024 Follow-on offering) of 8,620,690 shares of the Company's common stock, \$0.001 par value per share, at a public offering price of \$29.00 per share. The Company also granted the 2024 Underwriters a 30-day option to purchase, at the public offering price less underwriting discounts and commissions, up to an additional 1,293,103 shares of Common Stock, which the 2024 Underwriters exercised in full on the closing of the 2024 Follow-on offering. The Company paid the Underwriters a commission of 3.6% of the aggregate gross proceeds received from all sales of the common stock under the Follow-on Agreement. In March 2024, 9,913,793 shares (including the 1,293,103 shares issued upon

exercise of the 2024 Underwritersâ€™ option to purchase additional shares) were issued under the 2024 Follow-on Agreement, for net proceeds of \$276.6 million, after deducting underwriting fees and commissions of \$10.3 million and offering costs of \$0.6 million. X - DefinitionPublic offerings and share repurchase program and securities purchase agreement. + ReferencesNo definition available. + Details Name: bbio PublicOfferingsAndShareRepurchaseProgramAndSecuritiesPurchaseAgreementAbstract Namespace Prefix: bbio Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 31 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation 6 Months Ended June 30, 2024 Share-Based Payment Arrangement [Abstract] A Stock-Based Compensation 15.Stock-Based Compensation Under each of the legal entityâ€™s equity plans, we recorded stock-based compensation in the following expense categories in our condensed consolidated statements of operations for employees and non-employees: A A Three Months Ended June 30, 2024 A A Six Months Ended June 30, 2024 A A BridgeBioEquity Plan A A OtherSubsidiariesEquity Plan A A Total A A BridgeBioEquity Plan A A OtherSubsidiariesEquity Plan A A Total A A (in thousands) A A A A Research and development A A \$ 4,937 A A \$ â€” A A \$ 4,937 A A \$ 17,679 A A \$ 37 A A \$ 17,716 A A Selling, general and administrative A A 16,471 A A A â€” A A 16,471 A A 32,542 A A A â€” A A 32,542 A A Restructuring, impairment and related charges A A 43 A A A â€” A A 43 A A A â€” A A 43 A A A 43 A A A â€” A A 43 A A Total stock-based compensation A A \$ 21,451 A A \$ â€” A A \$ 21,451 A A \$ 50,264 A A \$ 37 A A \$ 50,301 A A A Three Months Ended June 30, 2023 A A Six Months Ended June 30, 2023 A A BridgeBioEquity Plan A A OtherSubsidiariesEquity Plan A A Total A A BridgeBioEquity Plan A A OtherSubsidiariesEquity Plan A A Total A A (in thousands) A A A A Research and development A A \$ 13,188 A A \$ 41 A A \$ 13,229 A A \$ 24,925 A A \$ 83 A A \$ 25,008 A A Selling, general and administrative A A 13,947 A A A â€” A A 13,947 A A 25,645 A A A â€” A A 25,645 A A Total stock-based compensation A A \$ 27,135 A A \$ 41 A A \$ 27,176 A A \$ 50,570 A A \$ 83 A A \$ 50,653 A A We recorded nil and \$11.8 million of stock-based compensation expense for the three and six months ended June 30, 2024, respectively, for performance-based milestone awards that were achieved during the periods and were settled in cash. We recorded nil and \$1.6 million of stock-based compensation expense for the three and six months ended June 30, 2023, respectively, for performance-based milestone awards that were achieved during the periods and were settled in cash. Equity-Based Awards of BridgeBioIn December 2023, the 2019 Inducement Equity Plan was amended and restated to increase the number of shares authorized for issuance from 2,000,000 shares to 3,750,000 shares. In June 2024, our stockholders approved an amendment and restatement of our 2021 Amended and Restated Stock Option and Incentive Plan (the â€œ2021 A&R Planâ€), to, among other things, increase the number of shares authorized for issuance by 6,500,000 shares. As of June 30, 2024, 9,855,774 shares and 1,486,257 shares were reserved for future issuances under the 2021 A&R Plan and the Amended and Restated 2019 Inducement Equity Plan (the â€œA&R 2019 Inducement Planâ€), respectively. Pursuant to the Merger Transactions, we also reserved 2,802,644 shares in 2021 specifically under the Eidos Award Exchange (the â€œEidos Award Exchange Planâ€), all of which were issued upon execution of the Eidos Award Exchange as discussed below. The 2021 A&R Plan, the A&R 2019 Inducement Plan and the Eidos Award Exchange Plan are collectively referred herein as the â€œPlans.â€ 2020 Stock and Equity Award Exchange Program (Exchange Program) On April 22, 2020, we completed our 2020 Stock and Equity Award Exchange Program (the â€œExchange Programâ€) for certain subsidiaries, which was an opportunity for eligible controlled entitiesâ€™ employees and consultants to exchange their subsidiary equity (including common stock, vested and unvested stock options and RSAs) for BridgeBio equity (including common stock, vested and unvested stock options and RSAs) and/or performance-based milestone awards tied to the achievement of certain development and regulatory milestones. The Exchange Program aligns our incentive compensation structure for employees and consultants across the BridgeBio group of companies to be consistent with the achievement of our overall corporate goals. In connection with the Exchange Program, we issued awards of BridgeBio equity under the then 2019 Amended and Restated Stock Option and Incentive Plan (the â€œ2019 A&R Planâ€), which was amended and restated in December 2021 into the 2021 A&R Plan and further amended and restated in June 2024, as mentioned above, to 149 grantees covering 554,064 shares of common stock, 1,268,110 stock options to purchase common stock, 50,145 shares of RSAs and 22,611 shares of performance-based RSAs. The exchange also included performance-based milestone awards of up to \$183.4 million to be settled in fully-vested RSAs in the future upon achievement of the milestones. In consideration for all the subsidiariesâ€™ shares tendered, BridgeBio increased its ownership in controlled entities included in the Exchange Program and the corresponding noncontrolling interest decreased. On November 18, 2020, we completed a stock and equity award under our Exchange Program for a subsidiary. We issued awards of BridgeBio equity under the then 2019 A&R Plan to 16 grantees covering 24,924 shares of common stock, 70,436 stock options to purchase common stock, and 10,772 shares of performance-based stock options to purchase common stock. The exchange also included performance-based milestone awards of up to \$11.7 million to be settled in fully-vested RSAs in the future upon achievement of the milestones. We evaluated the exchange of the controlled entitiesâ€™ outstanding common stock and equity awards for BridgeBio awards as a modification under ASC 718, Share Based Payments. Under ASC 718, a modification is a change in the terms or conditions of a stock-based compensation award. In assessing the accounting treatment, we consider the fair value, vesting conditions and classification as an equity or liability award of the controlled entity equity before the exchange, compared to the BridgeBio equity received as part of the exchange to determine whether modification accounting must be applied. When applying modification accounting, we considered the type of modification to determine the appropriate stock-based compensation cost to be recognized on April 22 and November 18, 2020, (each the â€œModification Dateâ€), and subsequent to the Modification Date. We considered the total shares of common stock and equity awards, whether vested or unvested, held by each participant in each controlled entity as the unit of account. The controlled entityâ€™s common stock and equity awards in each unit of account was exchanged for a combination of BridgeBioâ€™s common stock, time-based vesting equity awards and/or performance-based milestone awards. Other than the exchange of the controlled entity equity awards for performance-based milestone awards, all other exchanged BridgeBio equity awards retained the original vesting conditions. As a result, there was no incremental stock-based compensation expense resulting from the exchange of time-based equity awards. At the completion of the Exchange Program, we determined \$17.4 million of the performance-based milestone awards were probable of achievement and represented the incremental stock-based compensation cost resulting from the modification of time-based equity awards to performance-based milestone awards. These performance-based milestone awards were to be recognized over a period ranging from 0.7 year to 1.7 years. There was no incremental stock-based compensation cost arising from the completion of the Exchange Program on November 18, 2020. Under ASC 718, we account for such performance-based milestone awards as a liability in â€œAccrued compensation and benefitsâ€ and in â€œOther long-term liabilitiesâ€ on the condensed consolidated balance sheets due to the fixed milestone amount that will be converted into a variable number of shares of BridgeBioâ€™s common stock to be granted upon the achievement date. For the three and six months ended June 30, 2024 we recognized reversals of \$8.9 million and \$8.7 million, respectively, of stock-based compensation cost associated with performance-based milestone awards as of June 30, 2024 as the obligation was no longer determined to be probable. For the three and six months ended June 30, 2023 we recognized \$0.5 million and \$2.2 million, respectively, of stock-based compensation cost associated with performance-based milestone awards whereby the milestones were determined to be probable of achievement as of June 30, 2023. Refer to Note 8 for contingent compensation accrued associated with performance-based milestones that are determined to be probable as of June 30, 2024. Performance-based Milestone Awards Apart from the Exchange Program discussed above, we have performance-based milestone compensation arrangements with certain employees and consultants whose vesting is contingent upon meeting various regulatory and development milestones, with fixed monetary amounts known at inception that can be settled in the form of cash or equity at our sole discretion, upon achievement of each contingent milestone. Upon achievement of a contingent milestone and if such performance-based milestone awards are settled in the form of equity, these are satisfied in the form of fully-vested RSAs. We recognize such contingent stock-based compensation expense when the milestone is probable of achievement. For the three and six months ended June 30, 2024, we recognized \$(1.0) million and \$0.9 million, respectively, of stock-based compensation cost associated with performance-based milestone awards whereby the milestones were determined to be probable of achievement as of June 30, 2024. The \$(1.0) million and \$0.9 million in stock-based compensation associated with performance-based milestone awards during the three and six months ended June 30, 2024, respectively, includes reversals totaling \$1.6 million as the obligation was no longer determined to be probable. For the three and six months ended June 30, 2023, we recognized \$2.0 million and \$3.0 million, respectively, of stock-based compensation cost associated with performance-based milestone awards whereby the milestones were determined to be probable of achievement as of June 30, 2023. Refer to Note 8 for contingent compensation accrued associated with performance-based milestone awards that are determined to be probable as of June 30, 2024. Stock Option Grants of BridgeBioA The following table summarizes BridgeBioâ€™s stock option activity under the Plans for the six months ended June 30, 2024: A A Options Outstanding A A Weighted-Average Exercise Price per Option A A Weighted-Average Remaining Contractual Life (years) A A Aggregate Intrinsic Value (in thousands) A A Outstanding as of December 31, 2023 A A A 12,332,442 A A A A A A Regular equity program A A 10,793,862 A A A A \$ 25.69 A A 7.1 A A \$ 178,594 A Eidos Awards Exchange A A 1,221,942 A A A \$ 14.60 A A A 4.7 A A \$ 31,580 A Exchange Program A A 316,638 A A A A \$ 2.19 A A 5.3 A A \$ 12,105 A Granted A A A 398,764 A A A A A A A Regular equity program A A 398,764 A A A A \$ 27.56 A A A A A Exercised A A A (49,982) A A A A A Regular equity program A A (14,066) A A A \$ 19.04 A A A A Eidos Awards Exchange A A (35,916) A A A A 14.21 A A A A Cancelled A A A (3,867) A A A A A Eidos Awards Exchange A A (3,867) A A A A \$ 63.38 A A A A A Outstanding as of June 30, 2024 A A A 12,677,357 A A A A A Regular equity program A A 11,178,560 A A A A \$ 25.76 A A A 6.8 A A \$ 66,111 A Eidos Awards Exchange A A 1,182,159 A A A A \$ 14.45 A A 4.2 A A \$ 13,513 A Exchange Program A A 316,638 A A A A \$ 2.19 A A 4.8 A A \$ 7,436 A Exercisable as of June 30, 2024 A A A 10,018,943 A A A A A Regular equity program A A 8,525,576 A A A A \$ 26.82 A A 6.2 A A \$ 45,274 A Eidos Awards Exchange A A 1,179,149 A A A A \$ 14.43 A A 4.2 A A \$ 13,508 A Exchange Program A A 314,218 A A A A \$ 2.18 A A 4.8 A A \$ 7,382 A The options granted to employees and non-employees are exercisable at the price of BridgeBioâ€™s common stock at the respective grant dates. The options granted have a service condition and generally vest over a period of three to four years. The weighted-average grant date fair value of options granted during the six months ended June 30, 2024 was \$21.30. The aggregate intrinsic value of options outstanding and exercisable as of June 30, 2024 in the table above are calculated based on the difference between the exercise price and the current fair value of BridgeBioâ€™s common stock. The total intrinsic value of options exercised for the six months ended June 30, 2024 was \$0.9 million. For the three and six months ended June 30, 2024, we recognized stock-based compensation expense of \$5.9 million and \$12.2 million, respectively, related to stock options under the Plans. For the three and six months ended June 30, 2023, we recognized stock-based compensation expense of \$8.1 million and \$15.0 million, respectively, related to stock options under the Plans. As of June 30, 2024, there was \$32.3 million of total unrecognized compensation cost related to stock options under the Plans that is expected to be recognized over a weighted-average period of 1.9 years. Restricted Stock Units (RSUs) of BridgeBioThe following table summarizes BridgeBioâ€™s RSU activity under the Plans for the six months ended June 30, 2024: A A Unvested Shares of RSUs Outstanding A A Weighted-Average Grant Date Fair Value A A Balance as of December 31, 2023 A A A 8,942,813 A A \$ 16.27 A A Granted A A 3,899,497 A A \$ 28.28 A A Vested A A (1,957,694) A A \$ 17.73 A A Cancelled A A (329,776) A A \$ 20.39 A A Balance as of June 30, 2024 A A 10,554,840 A A \$ 20.31 A A For the three and six months ended June 30, 2024, we recognized stock-based compensation expense of \$22.5 million and \$39.3 million, respectively, related to RSUs under the Plans. For the three and six months ended June 30, 2023 we recognized stock-based compensation expense of \$15.1 million and \$27.4 million, respectively, related to RSUs under the Plans. As of June 30, 2024, there was \$197.7 million of total unrecognized compensation cost related to RSUs under the Plans that is expected to be recognized over a weighted-average period of 2.9 years. Market-Based RSUs of BridgeBioIn December 2023, the Company approved and granted performance restricted stock units under the 2021 A&R Plan to certain employees with vesting based on achievement of market capitalization targets (â€œmarket-based RSUsâ€), which are subject to the continued service of the employees through the vest date and are subject to accelerated vesting upon a change in control event. The achievement of the market capitalization targets will be measured based on BridgeBio market capitalization data (available on the Nasdaq.com website) meeting the targets for 20-consecutive trading days during the performance period of up to six years from the date of grant. The respective grant-date fair value of the market-based RSUs, which aggregated to \$10.8 million, was determined using the Monte Carlo valuation model and are recognized as compensation expense over the derived service period of the awards. The assumptions used in the Monte Carlo valuation included expected volatility ranging from 96.8% - 113.7%, risk free rate ranging from 4.22% - 4.35%, no expected dividend yield, expected term of three to six years and possible future market capitalization over the derived service period based on historical stock prices and market capitalization. As of June 30, 2024, 375,000 market-based RSUs were outstanding with a weighted average grant date fair value of \$28.73. For three and six months ended June 30, 2024, we recognized stock-based compensation expense of \$2.4 million and \$4.8 million, respectively, related to market-based RSU awards. As of June 30, 2024, there was \$5.2 million of total unrecognized compensation cost related to market-based RSUs under the Plans that is expected to be recognized over a weighted-average period of 0.8 year. Restricted Stock Awards (RSAs) of BridgeBioA The following table summarizes our RSA activity under the Plans for the six months ended June 30, 2024: A A Unvested Shares of RSAs Outstanding A A Weighted-Average Grant Date Fair Value A A Balance as of December 31, 2023 A A 85,453 A A \$ 7.27 A A Granted â€” Exchange Program A A 8,057 A A \$ 38.74 A A Vested â€” Exchange Program A A

(0,05) \$ A \$ 38.74 \$ Vested æ™ Regular equity program Å (85,453) Å \$ 7.27 Å Balance as of June 30, 2024 Å Å æ™ Å Å æ™ Å Å For the three and six months ended June 30, 2024 and 2023, we recognized stock-based compensation expense related to RSAs under the Plans as follows: Å Å Three Months Ended June 30, Å Å Six Months Ended June 30, Å Å 2024 Å Å 2023 Å Å 2024 Å Å 2023 Å Å (in thousands) Å Exchange Program Å æ™ Å Å æ™ Å Å æ™ Å Å \$ 312 Å Å \$ 3,605 Å Other RSAs Å æ™ Å Å æ™ Å Å 1,023 Å Å 621 Å Å 2,049 Å Total stock-based compensation expense Å æ™ Å Å 1,023 Å Å \$ 933 Å Å \$ 5,654 Å As of June 30, 2024, there was no unrecognized compensation cost related to RSAs under the Plans. The balance of unvested RSAs as of December 31, 2023 is included as outstanding shares disclosed on the condensed consolidated balance sheets as the shares were issued but were subject to forfeiture per the terms of the awards.2019 Employee Stock Purchase Plan (ESPP) of BridgeBioOn June 22, 2019, we adopted the 2019 ESPP, which became effective on June 25, 2019 and was amended and restated effective as of December 12, 2019. The ESPP initially reserves and authorizes the issuance of up to a total of 2,000,000 shares of common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2020, by the lower of: (i) 1% of the outstanding number of shares of common stock on the immediately preceding December 31, (ii) 2,000,000 shares or (iii) such lesser number of shares as determined by the Compensation Committee.Under the ESPP, eligible employees may purchase shares of BridgeBioæ™ s common stock through payroll deductions at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or the end of six-month offering periods. An employeeæ™ s payroll deductions under the ESPP are limited to 15% of the employeeæ™ s compensation and employees may not purchase more than 3,500 of shares of BridgeBioæ™ s common stock during any offering period.For the three and six months ended June 30, 2024, stock-based compensation expense related to our ESPP was \$0.5 million and \$1.1 million, respectively. For the three and six months ended June 30, 2023, stock-based compensation expense related to our ESPP was \$0.4 million and \$0.9 million, respectively. As of June 30, 2024, 3,462,568 shares were reserved for future issuance under the ESPP.Valuation AssumptionsWe used the Black-Scholes model to estimate the fair value of stock options and stock purchase rights under the ESPP. For the six months ended June 30, 2024, we used the following weighted-average assumptions in the Black-Scholes calculations: Å Å Stock Options Å ESPP Å Expected term (in years) Å 6.00Å - 6.03 Å Å 0.50 Å Expected volatility Å 92.0% - 92.3% Å Å 55.8% - 122.1% Å Risk-free interest rate Å 4.2% - 4.3% Å Å 5.3% - 5.5% Å Dividend yield Å æ™ Å Å æ™ Å Å æ™ Å Weighted-average fair value of stock-based awards granted Å \$ 21.30 Å Å \$ 14.14 Å Equity Awards of Eidos Prior to the Eidos Merger Transactions in 2021, Eidos issued its own equity-based awards under the Eidos 2016 Equity Incentive Plan and the Eidos 2018 Stock Option and Incentive Plan (collectively, the æœEidos Plansæ). Upon closing of the Eidos Merger Transactions, we issued 2,776,672 stock options to purchase common stock of BridgeBio and 25,972 shares of BridgeBio RSUs to 88 employees of Eidos under the Eidos Award Exchange in exchange for their then outstanding common stock options and RSUs under the Eidos Plans (the æœReplaced Awardsæ). The awards issued in the Eidos Award Exchange have the same vesting terms and conditions as the Replaced Awards. We evaluated the exchange of the awards as a modification under ASC 718 and recognized no incremental compensation cost from such modification. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X -ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restructuring, Impairment and Related Charges 6 Months Ended Jun. 30, 2024 Restructuring and Related Activities [Abstract] Å Restructuring, Impairment and Related Charges 16.Restricturing, Impairment and Related ChargesIn January 2022, we committed to a restructuring initiative designed to drive operational changes in our business processes, efficiencies and cost savings to advance our corporate strategy and development programs. The restructuring initiative included, among other components, consolidation and rationalization of our facilities, reprioritization of development programs and the reduction in our workforce.In March 2024, upon entering into the Bayer Agreement and termination of the Navire-BMS License Agreement (refer to Note 11 for details regarding these transactions), we have committed to additional restructuring plans to reprioritize and advance our corporate strategy and development programs. We estimate that we will incur a remaining \$12.0 million to \$16.0 million in restructuring charges, consisting primarily of winding down costs, exit and other related costs, and severance and employee-related costs. Our estimate of the costs is subject to certain assumptions and actual results may differ from those estimates or assumptions. We may also incur additional costs that are not currently foreseeable as we continue to evaluate our restructuring alternatives to drive operational changes in business processes, efficiencies and cost savings.æœRestructuring, impairment and related chargesæ included in our condensed consolidated statements of operations for the three and six months ended June 30, 2024 and 2023 consisted of the following: Å Å Three Months Ended June 30, Å Å Six Months Ended June 30, Å Å 2024 Å Å 2023 Å Å 2024 Å Å 2023 Å Å (in thousands) Å Long-lived assets impairments and write-offs Å æ™ Å Å æ™ Å Å \$ 271 Å Å \$ æ™ Å Severance and employee-related costs Å 538 Å Å 572 Å Å 2,503 Å Å 715 Å Winding down, exit and other related costs Å 2,353 Å Å 2,959 Å Å 3,517 Å Å \$ 1,815 Å Total Å \$ 2,891 Å Å \$ 3,531 Å Å \$ 6,291 Å Å \$ 6,900 Å The following table summarizes the activity related to the restructuring liabilities associated with our restructuring initiatives for the six months ended June 30, 2024 and 2023: Å Å Six Months Ended June 30, Å Å 2024 Å Å 2023 Å Å (in thousands) Å Beginning balance Å \$ 55 Å Å \$ 6,826 Å Restructuring, impairment and related charges Å 6,291 Å Å 6,900 Å Cash payments Å Å (3,121) Å Å (11,526) Å Noncash activities Å (318) Å Å æ™ Å Ending balance Å \$ 2,907 Å Å \$ 2,200 Å Å Restructuring liabilities are presented in our condensed consolidated balance sheets as follows: Å Å June 30, 2024 Å Å December 31, 2023 Å Å (in thousands) Å Accounts payable Å \$ 1,314 Å Å \$ 48 Å Accrued compensation and benefits Å 780 Å Å Å æ™ Å Accrued research and development liabilities Å 651 Å Å 7 Å Accrued professional and other accrued liabilities Å 162 Å Å Å æ™ Å Total Å \$ 2,907 Å Å \$ 55 Å X -ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X -DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes 6 Months Ended Jun. 30, 2024 Income Tax Disclosure [Abstract] Å Income Taxes 17.Income Taxes BridgeBio is subject to U.S. federal, state and foreign income taxes as a corporation. BridgeBioæ™ s tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate adjusted for the effect of discrete items arising in that quarter. There was no provision for income tax for the three and six months ended June 30, 2024 and 2023.Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, we have recorded a full valuation allowance against our otherwise recognizable net deferred tax assets. Our policy is to recognize interest and penalties associated with uncertain tax benefits as part of the income tax provision and include accrued interest and penalties with the related income tax liability on the condensed consolidated balance sheets. To date, we have not recognized any interest and penalties in our condensed consolidated statements of operations, nor have we accrued for or made payments for interest and penalties. Our unrecognized gross tax benefits would not reduce the estimated annual effective tax rate if recognized because we have recorded a full valuation allowance on its deferred tax assets. X -ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X -DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic

at each reporting date. The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles (   GAAP  ) in the United States and applicable rules and regulations of the U.S. Securities and Exchange Commission (the    SEC  ) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC. The condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of our financial position, our results of operations and comprehensive loss, stockholders' deficit and our cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim periods. Cash, Cash Equivalents and Marketable Securities Cash, Cash Equivalents and Marketable SecuritiesWe consider all highly liquid investments purchased with original maturities of 90 days or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market instruments, such as money market funds and U.S. treasury bills.Our marketable securities consist of high investment grade fixed income securities that are primarily invested in U.S. treasury bills. We classify our marketable securities as available-for-sale securities and report them at fair value in    Cash and cash equivalents   or    Marketable securities   on the condensed consolidated balance sheets with related unrealized gains and losses included as a component of stockholders' deficit. We classify our marketable securities as either short-term or long-term based on each instrument's underlying contractual maturity date. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity which is included in    Interest income   on the condensed consolidated statements of operations. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in    Other income (expense), net.   The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.Our cash, cash equivalents and marketable securities are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as commercial paper, U.S. government obligations, treasury bills, and money market funds, and places restrictions on maturities and concentrations by type and issuer.The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown on the condensed consolidated statements of cash flows:     June 30, 2024     December 31, 2023     (in thousands)     Cash and cash equivalents     \$ 407,958         \$ 375,935     Restricted cash             139,409             16,653     Restricted cash, non-current     included in    Other assets           2,142         2,144     Total cash, cash equivalents and restricted cash         shown on the condensed consolidated statements of cash flows     \$ 549,509         \$ 394,732     Restricted Cash Restricted Cash     Restricted cash primarily represents funds in a controlled account that was established in connection with the Company's Term Loans described in Note 9. Under the terms of the Financing Agreement (as defined in Note 9), the Company is required to deposit 75% of proceeds, net of certain permitted costs, received from certain asset sale transactions into escrow accounts to be controlled by the Administrative Agent. During the three months ended June 30, 2024, we received \$235.0 million in aggregate from Bayer Consumer Care AG and Kyowa Kirin Co., Ltd. and deposited net proceeds of \$159.3 million into the escrow accounts, which was classified as    restricted cash   on the condensed consolidated balance sheet as of June 30, 2024. Furthermore, under the terms of the Amended Financing Agreement (as defined in Note 9), between June 20, 2024 and through the earlier of the FDA approval date of a first NDA for acoramidis and November 30, 2024, the Company is able to request a release of funds in an aggregate amount not to exceed 50% of the original net cash proceeds received from asset sale transactions. As of June 30, 2024, \$20.0 million was released from the escrow accounts and classified as cash, with a remaining balance of \$139.3 million in the escrow accounts classified as    restricted cash   on the condensed consolidated balance sheet. Refer to Note 9 and Note 11 for further details regarding the Financing Agreement and the exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd.As of December 31, 2023, the use of such non-interest-bearing cash was restricted per the terms of the underlying amended Loan and Security Agreement and was to be used solely for certain research and development expenses directly attributable to the performance of obligations associated with the Navire-BMS License Agreement, which is further described in Note 11. As of December 31, 2023, restricted cash related to this agreement was \$16.5 million, which is presented as part of    Restricted cash   on the condensed consolidated balance sheet. Upon the termination of the Loan and Security Agreement and full repayment of the term loan in January 2024 (refer to Note 9 for details), the non-interest-bearing cash was no longer restricted as of June 30, 2024. Additionally, under certain lease agreements and letters of credit, we have pledged cash and cash equivalents as collateral. As of June 30, 2024, restricted cash related to such agreements was \$0.1 million and \$2.1 million, which is presented as part of    Restricted cash   and    Other assets  , respectively, on the condensed consolidated balance sheets. As of December 31, 2023, restricted cash related to such agreements was \$0.1 million and \$2.1 million, which is presented as part of    Restricted cash   and    Other assets  , respectively, on the condensed consolidated balance sheets. Equity Method and Other Equity Investments Equity Method and Other Equity InvestmentsWe use the equity method to account for any of our investments under the scope of ASC 323 Investments     Equity Method and Joint Ventures, where we may not be the primary beneficiary, but may still exercise significant influence over operating activities of the investee. Our consolidated net loss includes our Company's proportionate share of the net income or loss from equity method investment and amortization of any in-process research and development (   IPR&D asset  ). Our judgment regarding the level of influence over each equity method investee includes considering key factors such as our ownership interest, representation on the board of directors, participation in policy-making decisions, and other material transactions. Since inception through April 29, 2024, TheRas, Inc. (   TheRas  ) has been a majority-owned subsidiary of the Company that had been consolidated. On April 30, 2024, the Company completed a \$200.0 million private equity financing with external investors of TheRas, Inc., to accelerate the development of its oncology portfolio. Upon completion of the private equity financing, Company ownership was reduced to approximately 37.9% of TheRas' equity. As part of the private equity financing transaction, TheRas' Certificate of Incorporation and Investors' Rights Agreement were amended and restated to reflect a change in TheRas' governance structure and composition of the board of directors, which was determined to be a VIE reconsideration event. Based on the VIE reconsideration assessment, TheRas was deemed a VIE. As a result of the change in governance structure and composition of the board of directors, BridgeBio is no longer the primary beneficiary, as it no longer has the power over key decisions that significantly impact TheRas' economic performance. Accordingly, BridgeBio deconsolidated TheRas, Inc. and accounted for BridgeBio's retained investment in TheRas, Inc., for which it has significant influence through its ownership interest, using the equity method of accounting as of April 30, 2024.As of December 31, 2020, we had an equity method and equity security investments in PellePharm. The equity security investments in PellePharm were without a readily determinable fair value and were carried at cost less impairment plus or minus observable price changes. PellePharm became a consolidated VIE in April 2021 under ASC 810, Consolidation. On January 16, 2023, PellePharm's board of directors authorized the assignment of all PellePharm's assets to PellePharm ABC, LLC for liquidation and distribution under the General Assignment for the Benefit of Creditors (   ABC  ). As part of the ABC proceedings, PellePharm's board of directors resigned effective March 6, 2023. The date the board of directors resigned was determined to be a VIE reconsideration event. Based on the changes to PellePharm's governance structure and composition of the board of directors as a result of the ABC, BridgeBio was no longer the primary beneficiary, as it no longer had the power over key decisions that significantly impact PellePharm's economic performance. Accordingly, BridgeBio deconsolidated PellePharm effective during the three months ended March 31, 2023. Refer to Note 6 for further discussion on the TheRas and PellePharm investments. Accrued Professional and Other Accrued Liabilities Accrued Professional and Other Accrued LiabilitiesAccrued professional and other accrued liabilities consisted of the following balances:     June 30, 2024     December 31, 2023     (in thousands)     Accrued professional services     \$ 7,503         \$ 7,412     Accrued interest             11,352             17,761     Milestone liability             6,380             6,000     Other accrued liabilities             9,048             4,657     Accrued professional and other accrued liabilities     \$ 34,283         \$ 35,830     Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, receivables from license and collaboration agreements, and restricted cash. Substantially all of our cash, cash equivalents, marketable securities and restricted cash are held in financial institutions in the United States. Amounts on deposit may at times exceed federally insured limits. Although management currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced or recorded any credit losses associated with its balances as of June 30, 2024 and December 31, 2023, and for the three and six months ended June 30, 2024 and 2023. We are subject to credit risk from receivables from license and collaboration agreements. We have not experienced any material losses related to receivables from individual customers or groups of customers. We also do not require any collateral. Receivables from license and collaboration agreements are recorded net of allowance for credit losses, if any. We are subject to certain risks and uncertainties and we believe that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing, regulatory approval and market acceptance of, and reimbursement for, product candidates, performance of third-party contract research organizations and manufacturers upon which we rely, development of sales channels, protection of our intellectual property, litigation or claims against us based on intellectual property, patent, product, regulatory, clinical or other factors, and our ability to attract and retain employees necessary to support our growth. We are dependent on third-party manufacturers to supply products for research and development activities in our programs. In particular, we rely and expect to continue to rely on a small number of manufacturers to supply us with our requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. Use of Estimates Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to:    allowance for credit losses,    accruals for research and development activities, such as clinical, development, regulatory, and sales-based milestone payments in our in-licensing agreements and asset acquisitions,    accruals for performance-based milestone compensation arrangements,    determining and allocating the transaction price to performance obligations for transactions accounted for under ASC 606, Revenue from Contracts with Customers,    the expected recoverability and estimated useful lives of our long-lived assets, and    additional charges as a result of, or that are associated with, any restructuring initiative as well as impairment and related charges.We base our estimates on historical experience and on various other assumptions that we believe are reasonable. Actual results may differ from those estimates or assumptions. Stock-Based Compensation We evaluated the exchange of the controlled entities' outstanding common stock and equity awards for BridgeBio awards as a modification under ASC 718, Share Based Payments. Under ASC 718, a modification is a change in the terms or conditions of a stock-based compensation award. In assessing the accounting treatment, we consider the fair value, vesting conditions and classification as an equity or liability award of the controlled entity equity before the exchange, compared to the BridgeBio equity received as part of the exchange to determine whether modification accounting must be applied. When applying modification accounting, we considered the type of modification to determine the appropriate stock-based compensation cost to be recognized on April 22 and November 18, 2020, (each the    Modification Date  ), and subsequent to the Modification Date. X - DefinitionAccrued professional and other accrued liabilities, policy. + ReferencesNo definition available. + Details Name: bbio_AccruedProfessionalAndOtherAccruedLiabilitiesPolicyPolicyTextBlock Namespace Prefix: bbio_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionCash, Cash Equivalents And Marketable Securities [Policy Text Block] + ReferencesNo definition available. + Details Name: bbio_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock Namespace Prefix: bbio_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionConcentration of credit risk and other risks and uncertainties. + ReferencesNo definition available. + Details Name: bbio_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock Namespace Prefix: bbio_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEquity method and other equity investments. + ReferencesNo definition available. + Details Name: bbio_EquityMethodAndOtherEquityInvestmentsPolicyTextBlock Namespace Prefix: bbio_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/1718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI

[illegible]

-Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap DebtInstrumentLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of long-bet instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap TypeOfArrangementAxis=bbio FinancingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LineOfCreditFacilityAxis=bbio LoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=bbio TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenAndTwoThousandAndTwentyNineMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Tables) 6 Months Ended June 30, 2024 Leases [Abstract] A Components of Lease Cost The components of lease cost are as follows: A A Three Months Ended June 30, A A Six Months Ended June 30, A A 2024 A A 2023 A A 2024 A A 2023 A A (in thousands) A A Straight line operating lease costs A \$ 1,024 A A \$ 992 A A \$ 2,093 A A \$ 2,024 A Finance lease costs A \$ 100 A A \$ 105 A A \$ 201 A A \$ 213 A Variable lease costs A \$ 1,477 A A \$ 1,700 A A \$ 3,490 A A \$ 3,418 A Total lease cost A \$ 2,601 A A \$ 2,797 A A \$ 5,784 A A \$ 5,655 A Schedule of Supplemental Cash Flow Information Related to Leases Supplemental cash flow information related to leases are as follows: A A Six Months Ended June 30, A A 2024 A A 2023 A A (in thousands) A Cash paid for amounts included in the measurement of lease liabilities: A A A A Operating cash flows for operating leases A \$ 2,981 A A \$ 2,443 A Operating cash flows for finance lease A \$ 222 A A \$ 217 A Operating lease right-of-use assets obtained in exchange A A A A for operating lease obligations A \$ 1,292 A A \$ 828 A Schedule of Supplemental Information Related to Remaining Lease Term and Discount Rate Supplemental information related to the remaining lease term and discount rate are as follows: A A June 30, A A 2024 A A 2023 A A Weighted-average remaining lease term (in years) A A A A Operating leases A 4.0 A A 5.2 A Finance lease A 1.6 A A 2.6 A Weighted-average discount rate A A A A Operating leases A 6.24 % A A 6.34 % Finance lease A 6.62 % A A 6.62 % Schedule of Future Minimum Lease Payments for Noncancelable Leases As of June 30, 2024, future minimum lease payments for our noncancelable operating leases are as follows. Future minimum lease payments under our finance lease are not material. A A Amount A A (in thousands) A Remainder of 2024 A \$ 2,509 A Year ending December 31: A A 2025 A \$ 5,103 A 2026 A \$ 2,276 A 2027 A \$ 459 A 2028 A \$ 459 A Thereafter A \$ 2,179 A Total future minimum lease payments A \$ 12,985 A Imputed interest A \$ (1,303) A Total A \$ 11,682 A A A Reported as of June 30, 2024 A A A Operating lease liabilities, current portion A \$ 4,623 A Operating lease liabilities, net of current portion A \$ 7,059 A Total operating lease liabilities A \$ 11,682 A X - DefinitionSchedule of future minimum lease payments for noncancelable operating and finance leases. + ReferencesNo definition available. + Details Name: bbio ScheduleOffFutureMinimumLeasePaymentsForNoncancelableOperatingAndFinanceLeasesTableTextBlock Namespace Prefix: bbio Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSchedule of supplemental cash flow information related to leases. + ReferencesNo definition available. + Details Name: bbio ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock Namespace Prefix: bbio Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSchedule of supplemental information related to remaining lease term and discount rate. + ReferencesNo definition available. + Details Name: bbio ScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateTableTextBlock Namespace Prefix: bbio Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap LeaseCostTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation (Tables) 6 Months Ended June 30, 2024 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] A Summary of Stock Based Compensation for Employees and Non Employees Under each of the legal entityâ€™s equity plans, we recorded stock-based compensation in the following expense categories in our condensed consolidated statements of operations for employees and non-employees: A A Three Months Ended June 30, 2024 A A Six Months Ended June 30, 2024 A A BridgeBioEquity Plan A A OtherSubsidiariesEquity Plan A A Total A A BridgeBioEquity Plan A A OtherSubsidiariesEquity Plan A A Total A A A A A A (in thousands) A A A A A A Research and development A \$ 4,937 A A \$ â€” A A \$ 4,937 A A \$ 17,679 A A \$ 37 A A \$ 17,716 A Selling, general and administrative A \$ 16,471 A A \$ â€” A A \$ 16,471 A A \$ 32,542 A A \$ â€” A A \$ 32,542 A Restructuring, impairment and related charges A \$ 43 A A \$ â€” A A \$ 43 A A \$ 43 A A \$ 43 A Total stock-based compensation A \$ 21,451 A A \$ â€” A A \$ 21,451 A A \$ 50,264 A A \$ 37 A A \$ 50,301 A A A A Three Months Ended June 30, 2023 A A Six Months Ended June 30, 2023 A A BridgeBioEquity Plan A A OtherSubsidiariesEquity Plan A A Total A A BridgeBioEquity Plan A A OtherSubsidiariesEquity Plan A A Total A A A A A A (in thousands) A A A A A A Research and development A \$ 13,188 A A \$ 41 A A \$ 13,229 A A \$ 24,925 A A \$ 83 A A \$ 25,008 A Selling, general and administrative A \$ 13,947 A A \$ â€” A A \$ 13,947 A A \$ 25,645 A A \$ â€” A A \$ 25,645 A A Total stock-based compensation A \$ 27,135 A A \$ 41 A A \$ 27,176 A A \$ 50,570 A A \$ 83 A A \$ 50,653 A Summary of Stock Option Activity The following table summarizes BridgeBioâ€™s stock option activity under the Plans for the six months ended June 30, 2024: A A OptionsOutstanding A A Weighted-AverageExercisePrice perOption A A Weighted-AverageRemainingContractualLife (years) A A AggregateIntrinsicValue (in thousands) A Outstanding as of December 31, 2023 A A A A A A A A A A Regular equity program A 10,793,862 A A A A \$ 25.69 A A 7.1 A A \$ 178,594 A Eidos Awards Exchange A 1,221,942 A A A A \$ 14.60 A A 4.7 A A \$ 31,580 A Exchange Program A 316,638 A A A A \$ 2.19 A A 5.3 A A \$ 12,105 A Granted A A A A 398,764 A A A A A A A A Regular equity program A 398,764 A A A A \$ 27.56 A A A A A A Exercised A A A A (49,982) A A A A A A A A Regular equity program A (14,066) A A A A 19,04 A A A A A A Eidos Awards Exchange A (35,916) A A A A 14,21 A A A A A Cancelled A A A A (3,867) A A A A A A A A Eidos Awards Exchange A (3,867) A A A A 63.38 A A A A A A Outstanding as of June 30, 2024 A A A A 12,677,357 A A A A A A A A Regular equity program A 11,178,560 A A A A \$ 25.76 A A 6.8 A A \$ 66,111 A Eidos Awards Exchange A 1,182,159 A A A A \$ 14.45 A A 4.2 A A \$ 13,513 A Exchange Program A 316,638 A A A A \$ 2.19 A A 4.8 A A \$ 7,436 A Exercisable as of June 30, 2024 A A A A 10,018,943 A A A A A A A A Regular equity program A 8,525,576 A A A A \$ 26.82 A A 6.2 A A \$ 45,274 A Eidos Awards Exchange A 1,179,149 A A A A \$ 14.43 A A 4.2 A A \$ 13,508 A Exchange Program A 314,218 A A A A \$ 2.18 A A 4.8 A A \$ 7,382 A Summary of Restricted Stock Units Activity The following table summarizes BridgeBioâ€™s RSU activity under the Plans for the six months ended June 30, 2024: A A UnvestedShares ofRSUsOutstanding A A Weighted-AverageGrant DateFair Value A Balance as of December 31, 2023 A 8,942,813 A A \$ 16.27 A Granted A 3,899,497 A A \$ 28.28 A Vested A (1,957,694) A A \$ 17.73 A Cancelled A (329,776) A A \$ 20.39 A Balance as of June 30, 2024 A 10,554,840 A A \$ 20.31 A Summary of Restricted Stock Award Activity The following table summarizes our RSA activity under the Plans for the six months ended June 30, 2024: A A UnvestedShares ofRSAsOutstanding A A Weighted-AverageGrant DateFair Value A Balance as of December 31, 2023 A 85,453 A A \$ 7.27 A Granted â€” A A \$ 7.27 A Exchange Program A 8,057 A A \$ 38.74 A Vested â€” A A \$ 38.74 A Exchange Program A (8,057) A A \$ 38.74 A Vested â€” A A \$ 38.74 A Regular equity program A (85,453) A A \$ 7.27 A Balance as of June 30, 2024 A â€” A A \$ â€” A A 2019 Employee Stock Purchase Plan A Share Based Compensation Arrangement By Share Based Payment Award [Line Items] A Schedule of Assumptions Used to Determine Fair Value of Stock Purchase Rights We used the Black-Scholes model to estimate the fair value of stock options and stock purchase rights under the ESPP. For the six months ended June 30, 2024, we used the following weighted-average assumptions in the Black-Scholes calculations: A A Stock Options A ESPP A Expected term (in years) A 6.00A - 6.03 A A 0.50 A Expected volatility A 92.0% - 92.3% A A 55.8% - 122.1% A Risk-free interest rate A 4.2% - 4.3% A A 5.3% - 5.5% A Dividend yield A â€” A A \$ â€” A A Weighted-average fair value of stock-based awards granted A 21.30 A A \$ 14.14 A Restricted Stock Awards A Share Based Compensation Arrangement By Share Based Payment Award [Line Items] A Summary of Stock Based Compensation for Employees and Non Employees For the three and six months ended June 30, 2024 and 2023, we recognized stock-based compensation expense related to RSAs under the Plans as follows: A A Three Months Ended June 30, A A Six Months Ended June 30, A A 2024 A A 2023 A A (in thousands) A Exchange Program A \$ â€” A A \$ â€” A A \$ 312 A A \$ 3,605 A Other RSAs A \$ â€” A A \$ 1,023 A A \$ 621 A A \$ 2,049 A Total stock-based compensation expense A \$ â€” A A \$ 1,023 A A \$ 933 A A \$ 5,654 A X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock units. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2)-(f) Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap PlanNameAxis=bbio TwoThousandNineteenEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AwardTypeAxis=us-gaap RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restructuring, Impairment and Related Charges (Tables) 6 Months Ended Jun. 30, 2024 Restructuring and Related Activities [Abstract] Å Summary of Restructuring, Impairment and Related Charges Å Å Å Restructuring, impairment and related charges Å Å Å included in our condensed consolidated statements of operations for the three and six months ended June 30, 2024 and 2023 consisted of the following: Å Å Å Three Months Ended June 30, Å Å Å Six Months Ended June 30, Å Å Å 2024 Å Å Å 2023 Å Å Å 2023 Å Å Å (in thousands) Å Long-lived assets impairments and write-offs Å Å Å \$ Å Å Å \$ Å Å Å \$ Å Å Å \$ Å Å Å Severance and employee-related costs Å Å Å 538 Å Å Å 572 Å Å Å 2,503 Å Å Å 715 Å Winding down, exit and other related costs Å Å Å 2,353 Å Å Å 2,959 Å Å Å 3,517 Å Å Å 6,185 Å Total Å Å Å \$ 2,891 Å Å Å \$ 3,531 Å Å Å \$ 6,291 Å Å Å \$ 6,900 Å Schedule of Activity Related to Restructuring Liabilities Associated to Restructuring Initiatives The following table summarizes the activity related to the restructuring liabilities associated with our restructuring initiatives for the six months ended June 30, 2024 and 2023: Å Å Å Six Months Ended June 30, Å Å Å 2024 Å Å Å 2023 Å Å Å (in thousands) Å Beginning balance Å Å \$ 55 Å Å Å \$ 6,826 Å Restructuring, impairment and related charges Å Å 6,291 Å Å 6,900 Å Cash payments Å Å (3,121) Å Å (11,526) Å Noncash activities Å Å (318) Å Å Å Å Å Ending balance Å Å \$ 2,907 Å Å Å \$ 2,200 Å Å Restructuring liabilities are presented in our condensed consolidated balance sheets as follows: Å Å Å June 30, 2024 Å Å December 31, 2023 Å Å Å (in thousands) Å Accounts payable Å Å \$ 1,314 Å Å \$ 48 Å Accrued compensation and benefits Å Å 780 Å Å Å Å Å Accrued research and development liabilities Å Å 651 Å Å 7 Å Accrued professional and other accrued liabilities Å Å 162 Å Å Å Å Å Total Å Å \$ 2,907 Å Å Å \$ 55 Å X - ReferencesNo definition available. + Details Name: us-gaap RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap ScheduleOfRestructuringReserveByTypeOfCostTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 45 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share (Tables) 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Å Schedule of Common Stock Equivalents were Anti-dilutive The following table summarizes the common stock equivalents that were anti-dilutive: Å Å As of June 30, Å Å 2024 Å Å 2023 Å Unvested RSAs Å Å Å Å Å 363,022 Å Unvested RSUs Å 10,554,840 Å Å Å 10,250,071 Å Unvested performance-based RSUs Å 3,326 Å Å 7,875 Å Unvested market-based RSUs Å 375,000 Å Å Å Å Å Common stock options issued and outstanding Å 12,677,357 Å Å 12,850,536 Å Estimated shares issuable under performance-based milestone Å Å compensation arrangements Å 3,811,055 Å Å 11,438,950 Å Estimated shares issuable under the ESPP Å 106,012 Å Å 123,340 Å Assumed conversion of 2027 Notes Å 12,878,305 Å Å 12,878,305 Å Assumed conversion of 2029 Notes Å 7,702,988 Å Å 7,702,988 Å Å 48,108,883 Å Å 55,615,087 Å X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 46 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Additional Information (Details) - USD (\$) in Thousands 3 Months Ended 6 Months Ended Apr. 30, 2024 Jan. 17, 2024 Jun. 30, 2024 Jun. 30, 2024 Jun. 31, 2023 Summary Of Significant Accounting Policies [Line Items] Å Å Å Å Å Cash, cash equivalents and restricted cash maturity period Å Å Å 90 days Å Restricted cash Å Å Å \$ 139,409 Å 139,409 Å 16,653 [1] Restricted cash, non-current - included in "Other assets" Å Å Å \$ 2,142 Å 2,142 Å 2,144 Restricted Cash, Noncurrent, Asset, Statement of Financial Position [Extensible List] Å Å Å Other assets Other assets Other assets BridgeBio Oncology Therapeutics Å Å Å Å Å Summary Of Significant Accounting Policies [Line Items] Å Å Å Å Å Payment for private equity financing with external investors Å Å Å \$ 200,000 Å Å Å BridgeBio Oncology Therapeutics | TheRas, Inc Å Å Å Å Å Summary Of Significant Accounting Policies [Line Items] Å Å Å Å Å Payment for private equity financing with external investors Å 200,000 Å Å Å Å Percentage of ownership reduced for private equity financing 37.90% Å Å Å Å Å Financing Agreement Å Å Å Å Å Summary Of Significant Accounting Policies [Line Items] Å Å Å Å Å Deposit percentage of proceeds net of certain permitted costs received from asset sale transactions into escrow accounts Å 75.00% Å Å Å Percentage of aggregate amount not to exceed the original net cash proceeds received from asset sale transactions Å Å 50.00% Å Payment from escrow accounts Å Å \$ 20,000 Å Remaining balance in escrow accounts Å Å 139,300 139,300 Å Financing Agreement | Cash Å Å Å Å Å Summary Of Significant Accounting Policies [Line Items] Å Å Å Å Å Payment from escrow accounts Å Å 20,000 Å Financing Agreement | Restricted Cash Å Å Å Å Å Summary Of Significant Accounting Policies [Line Items] Å Å Å Å Å Remaining balance in escrow accounts Å Å 139,300 139,300 Å Financing Agreement | Bayer Consumer Care AG and Kyowa Kirin Co., Ltd Å Å Å Å Å Summary Of Significant Accounting Policies [Line Items] Å Å Å Å Å Proceeds received from asset sale transactions Å Å 235,000 Å Å Net proceeds deposited to escrow accounts Å Å 159,300 Å Å Loan and Security Agreement Å Å Å Å Å Summary Of Significant Accounting Policies [Line Items] Å Å Å Å Å Restricted cash Å Å Å Å \$ 16,500 Lease Agreements and Letters of Credit Å Å Å Å Å Summary Of Significant Accounting Policies [Line Items] Å Å Å Å Å Restricted cash Å Å 100 100 100 Restricted cash, non-current - included in "Other assets" Å Å \$ 2,100 Å 2,100 Å 2,100 Restricted Cash, Noncurrent, Asset, Statement of Financial Position [Extensible List] Å Å Å Other assets Other assets Other assets Minimum Å Å Å Å Å Summary Of Significant Accounting Policies [Line Items] Å Å Å Å Å Percentage of voting shares Å Å 50.00% Å [1] The condensed consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements as of that date. X - DefinitionCash cash equivalents and restricted cash maturity period. + ReferencesNo definition available. + Details Name: bbio CashCashEquivalentsAndRestrictedCashMaturityPeriod Namespace Prefix: bbio Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionDebt instrument mandatory prepayments percentage of net cash proceeds from prepayment event transaction. + ReferencesNo definition available. + Details Name: bbio DebtInstrumentMandatoryPrepaymentsPercentageOfNetCashProceedsFromPrepaymentEventTransaction Namespace Prefix: bbio Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionNet proceeds deposited to escrow accounts. + ReferencesNo definition available. + Details Name: bbio NetProceedsDepositedToEscrowAccounts Namespace Prefix: bbio Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionPayment for equity private financing with external investors. + ReferencesNo definition available. + Details Name: bbio PaymentForPrivateEquityFinancingWithExternalInvestors Namespace Prefix: bbio Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionPayment from escrow accounts. + ReferencesNo definition available. + Details Name: bbio PaymentFromEscrowAccounts Namespace Prefix: bbio Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionPercentage of aggregate amount not exceed the original net cash proceeds received from asset sale transactions. + ReferencesNo definition available. + Details Name: bbio PercentageOfAggregateAmountNotExceedTheOriginalNetCashProceedsReceivedFromAssetSaleTransactions Namespace Prefix: bbio Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionPercentage of ownership reduced for private equity financing. + ReferencesNo definition available. + Details Name: bbio PercentageOfOwnershipReducedForPrivateEquityFinancing Namespace Prefix: bbio Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionProceeds received from asset sale transactions. + ReferencesNo definition available. + Details Name: bbio ProceedsReceivedFromAssetSaleTransactions Namespace Prefix: bbio Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionRemaining balance in escrow accounts. + ReferencesNo definition available. + Details Name: bbio RemainingBalanceInEscrowAccounts Namespace Prefix: bbio Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionSummary of significant accounting policies. + ReferencesNo definition available. + Details Name: bbio SummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: bbio Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionVoting interest entity investment threshold, percentage. + ReferencesNo definition available. + Details Name: bbio VotingInterestEntityInvestmentThresholdPercentage Namespace Prefix: bbio Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap RestrictedCashCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not

limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1:

DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1:

[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55-Paragraph 1- Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4:](#)

[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aaa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5:](#)

[http://www.xbrl.org/2009/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8:](#)

[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9:](#)

[http://www.xbrl.org/2009/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10:](#)

[http://www.xbrl.org/2009/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap AvailableForSaleSecuritiesDebtSecuritiesNamespacePrefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1:](#)

[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2:](#)

[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Fair Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap CashAndCashEquivalentsFairValueDisclosure NamespacePrefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reported information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap CashAndCashEquivalentsLineItems NamespacePrefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1:](#)

[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2:](#)

[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CashEquivalentsAtCarryingValue NamespacePrefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap USTreasuryBillSecuritiesMember NamespacePrefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FinancialInstrumentAxis=us-gaap MoneyMarketFundsMember NamespacePrefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ShortTermInvestmentsMember NamespacePrefix: Data Type: na Balance Type: Period Type: XML 53 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cash Equivalents and Marketable Securities - Additional Information \(Details\) - USD \(\\$\)](#)

[6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Cash and Cash Equivalents \[Abstract\] A A Realized gains or losses on available-for-sale securities \\$ 0 \\$ 0 Available-for-sale securities, continuous unrealized loss position, more than 12 months \\$ 0 \\$ 0 X - ReferencesNo definition available. + Details Name: us-gaap CashAndCashEquivalentsAbstract NamespacePrefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income \(available-for-sale\), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1:](#)

[http://www.xbrl.org/2009/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2:](#)

[http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 3:](#)

[http://www.xbrl.org/2009/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger NamespacePrefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of realized gain \(loss\) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income \(available-for-sale\). + ReferencesReference 1:](#)

[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9 + Details Name: us-gaap DebtSecuritiesAvailableForSaleRealizedGainLoss NamespacePrefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 54 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Noncontrolling Interests - Additional Information \(Details\) - USD \(\\$\)](#)

[\\$ In Millions 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2023 Jun. 30, 2023 Noncontrolling Interest \[Abstract\] A A A Adjustments of carrying value of noncontrolling interest additional paid-in capital \\$ \(0.1\) \\$ \(3.1\) \\$ \(1.9\) \\$ \(5.9\) X - DefinitionAdjustments of carrying value of noncontrolling interest additional paid-in capital. + ReferencesNo definition available. + Details Name: bbio AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital NamespacePrefix: bbio Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NoncontrollingInterestAbstract NamespacePrefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 55 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Method Investment and Other Equity Investments - Additional Information \(Details\) - USD \(\\$\)](#)

[\\$ In Thousands 1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended Apr. 30, 2024 Mar. 31, 2024 Feb. 29, 2024 Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2023 Schedule Of Equity Method Investments \[Line Items\] A A A A A Unrealized gain on ongoing mark-to-market adjustments of investment in equity security A A A \\$ 0 \(203\) \\$ 0 \(6,397\) Gain from deconsolidation A A A A 126,294 0 126,294 0 Loss from equity method investment A A A \(7,925\) 0 \(7,925\) 0 Prepaid expenses and other current assets A A A 28,396 28,396 28,396 A 24,305 \[1\] Research and development liabilities A A A 114,695 107,488 255,667 200,349 Fair value of warrants A A A A A \\$ 1,600 Realized losses recognized on investment in equity securities A A A 0 1,638 8,136 8,796 A LianBio | Equity Method Investee's IPO A A A A A A A A A Schedule Of Equity Method Investments \[Line Items\] A A A A A Unrealized gain on ongoing mark-to-market adjustments of investment in equity security A A A \\$ 1,600 \\$ 3,200 A Bridge Bio Pharma Limited Liability Company | LianBio A A A A A A A A A Schedule Of Equity Method Investments \[Line Items\] A A A A A Common stock held A A A A A 5,350,361 A Net proceeds received as special cash dividends A \\$ 25,700 A A A A A Realized net gains from investment A \\$ 1,800 A A A A A Bridge Bio Pharma Limited Liability Company | Entities Affiliated With Perceptive Life Sciences Master Fund Ltd | LianBio A A A A A A A A A Schedule Of Equity Method Investments \[Line Items\] A A A A A Warrants to purchase common stock A A A A A 347,569 Warrants exercised A A 347,569 A A A A BridgeBio Oncology Therapeutics A A A A A A A A A Schedule Of Equity Method Investments \[Line Items\] A A A A A A A A Payment for private equity financing with external investors A A A 200,000 A A A BridgeBio Oncology Therapeutics | TheRas, Inc A A A A A A A A A Schedule Of Equity Method Investments \[Line Items\] A A A A A A A A Payment for private equity financing with external investors \\$ 200,000 A A A A A A A A Percentage of ownership reduced for private equity financing 37.90% A A A A A A A A Gain from deconsolidation A A A 126,300 A \\$ 126,300 A A Equity investment \\$ 124,900 A A 124,900 124,900 A Difference of between fair value of equity investment and underlying equity in net assets A A 49,600 49,600 49,600 A Loss from equity method investment A A 7,900 A A A A Aggregate carrying amount of equity method investment A A 117,000 117,000 A BridgeBio Oncology Therapeutics | TheRas, Inc | Transition Service Agreement A A A A A A A A A Schedule Of Equity Method Investments \[Line Items\] A A A A A A A A Prepaid expenses and other current assets A A A 100 100 A A Other income A A A 800 A 800 A A Research and development liabilities A A A 300 A 300 A A Accrued research and development expenses A A A A 300 A A PellePharm, Inc A A A A A A A A A Schedule Of Equity Method Investments \[Line Items\] A A A A A A A A Realized losses recognized on investment in equity securities A A A A A \\$ 1,200 A \[1\] The condensed consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements as of that date. X - DefinitionAccrued research and development. + ReferencesNo definition available. + Details Name: bbio AccruedResearchAndDevelopment NamespacePrefix: bbio Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommon Stock Held + ReferencesNo definition available. + Details Name: bbio CommonStockHeld NamespacePrefix: bbio Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPayment for equity private financing with external investors. + ReferencesNo definition available. + Details Name: bbio PaymentForPrivateEquityFinancingWithExternalInvestors NamespacePrefix: bbio Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of ownership reduced for private equity financing. + ReferencesNo definition available. + Details Name: bbio WarrantToPurchaseSharesOfCommonStock NamespacePrefix: bbio Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWarrants exercised + ReferencesNo definition available. + Details Name: bbio WarrantsExercised NamespacePrefix: bbio Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain \(loss\) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer. + ReferencesReference 1:](#)

[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1](#)

https://role/ref/legacyRef -Topic 220-SubTopic 20-Name Accounting Standards Codification -Section S99 -Paragraph 2 -SubParagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue and income classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_OtherIncome Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDividends received on equity and other investments during the current period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -SubParagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-16 + Details Name: us-gaap_ProceedsFromDividendsReceived Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionFair value portion of warrants not settleable in cash classified as equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsNotSettleableInCashFairValueDisclosure Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bbio_LianBioMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=bbio_BridgeBioPharmaLimitedLiabilityCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bbio_EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=bbio_BridgeBioOncologyTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-srt_ConsolidatedEntitiesAxis=bbio_TheRasIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_TransitionServiceAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=bbio_PellePharmIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 56 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets - Summary of Recognized Intangible Assets (Details) - USD (\$) in Thousands 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Acquired Finite-Lived Intangible Assets [Line Items] Å Å Weighted-average Estimated Useful Lives 10 years 6 months 11 years Gross amount \$ 32,500 \$ 32,500 Less: accumulated amortization (7,377) (6,181) Total \$ 25,123 \$ 26,319 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionWeighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife Namespace Prefix: us-ga

not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. A noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482686/350-30-45-2> + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480265/350-10-545-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478859/928-340-50-1> + Details Name: us-gaap_FiniteLivedIntangibleAssetsCrossNamespaces Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482686/350-30-45-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-3>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483154/926-20-50-5> + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_FoundationMedicineDiagnosticsAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=bbio_FoundationMedicineIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name

transaction 75.00% Minimum | Financing Agreement | Debt Instrument [Line Items] 70,000,000 Minimum | Loan Agreement | Debt Instrument [Line Items] Debt instrument prepayment premium percentage 1.00% Debt instrument mandatory prepayments percentage of net cash proceeds from prepayment event transaction 50.00% 2029 Notes Debt Instrument [Line Items] Debt Instrument face amount \$ 717,500,000 \$ 747,500,000 \$ 747,500,000 \$ 747,500,000 Proceeds from exercise of option to purchase additional notes 67,500,000 Debt instrument option to purchase additional notes 97,500,000 Proceeds from exercise of remaining portion of option to purchase additional notes \$ 30,000,000 Debt instrument issuance date Jan. 28, 2021 Maturity year 2029 Debt instrument, frequency of interest payment semiannually Interest payable beginning date Aug. 01, 2021 Stated interest rate 2.25% 2.25% 2.25% Maturity date Feb. 01, 2029 Description of payment terms of notes The 2029 Notes are senior, unsecured obligations of BridgeBio and will accrue interest payable semiannually in arrears on February 1 and August 1 of each year, beginning on August 1, 2021, at a rate of 2.25% per year. The 2029 Notes will mature on February 1, 2029, unless earlier converted, redeemed or repurchased. Proceeds from issuance of notes after deducting discount and offering expenses \$ 731,400,000 \$ 731,400,000 \$ 731,400,000 Direct offering expense 0 Purchase of capped calls 61,300,000 Repurchase of common stock 50,000,000 Denomination of the principal amount of debt in consideration conversion of the notes \$ 1,000 Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Threshold percentage of stock price trigger in measurement period 98.00% Conversion rate 10.3050 Initial conversion price per share | \$ / shares \$ 97.04 Debt instrument, conversion, equivalent shares of common stock | shares 7,702,988 Percentage of principal amount to be repurchased in fundamental change 100.00% Minimum threshold percentage of aggregate principal by trustee or holders 25.00% Debt issuance costs including initial purchasers discounts, legal and other professional fees \$ 16,100,000 Expected life of notes 8 years Interest payable 7,000,000 \$ 7,000,000 \$ 7,000,000 Interest expense 4,694,000 4,681,000 9,386,000 9,361,000 Amortization of debt discount and issuance costs 490,000 477,000 977,000 952,000 2029 Notes | Maximum Debt Instrument [Line Items] Debt Instrument increase in conversion rate, number of shares issuable | shares 11,361,851 2027 Notes Debt Instrument [Line Items] Debt Instrument face amount \$ 550,000,000 \$ 550,000,000 \$ 550,000,000 Proceeds from exercise of option to purchase additional notes \$ 75,000,000 Debt instrument issuance date Mar. 09, 2020 Maturity year 2027 Debt instrument, frequency of interest payment semi-annually Interest payable beginning date Sep. 15, 2020 Stated interest rate 2.50% 2.50% 2.50% Maturity date Mar. 15, 2027 Description of payment terms of notes The 2027 Notes will accrue interest payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2020, at a rate of 2.50% per year. The 2027 Notes will mature on March 15, 2027, unless earlier converted or repurchased. Proceeds from issuance of notes after deducting discount and offering expenses \$ 537,000,000 \$ 537,000,000 \$ 537,000,000 Purchase of capped calls 49,300,000 Repurchase of common stock 75,000,000 Denomination of the principal amount of debt in consideration conversion of the notes \$ 1,000 Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 42.71 Debt instrument, conversion, equivalent shares of common stock | shares 12,878,305 Percentage of principal amount to be repurchased in fundamental change 100.00% Minimum threshold percentage of aggregate principal by trustee or holders 25.00% Debt issuance costs including initial purchasers discounts, legal and other professional fees \$ 13,000,000 \$ 13,000,000 \$ 13,000,000 Expected life of notes 7 years Debt issuance costs allocated to equity component \$ 4,100,000 \$ 4,100,000 \$ 4,100,000 Debt issuance costs allocated to liability component \$ 8,900,000 \$ 8,900,000 \$ 8,900,000 Interest payable 4,000,000 \$ 4,000,000 \$ 4,000,000 Interest expense 3,884,000 3,873,000 7,766,000 7,742,000 Amortization of debt discount and issuance costs 447,000 \$ 436,000 891,000 \$ 867,000 2027 Notes | Maximum Debt Instrument [Line Items] Debt instrument, increase in conversion rate, number of shares issuable | shares 17,707,635 2021 Capped Call Transactions Debt Instrument [Line Items] Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 97.04 Capped call transaction, cap price per share | \$ / shares \$ 131.58 Number of shares covered by capped calls | shares 7,702,988 Adjustments to additional paid in capital related to premium payments \$ 61,300,000 2021 Capped Call Transactions | Share Repurchase Transactions Debt Instrument [Line Items] Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 42.71 Capped call transaction, cap price per share | \$ / shares \$ 62.12 Premium over last reported sale price percentage 100.00% Number of shares covered by capped calls | shares 12,878,305 Adjustments to additional paid in capital related to premium payments \$ 49,300,000 2020 Capped Call Transactions | Share Repurchase Transactions Debt Instrument [Line Items] Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 42.71 Capped call transaction, cap price per share | \$ / shares \$ 62.12 Premium over last reported sale price percentage 100.00% Number of shares covered by capped calls | shares 12,878,305 Adjustments to additional paid in capital related to premium payments \$ 49,300,000 2020 Capped Call Transactions | Share Repurchase Transactions Debt Instrument [Line Items] Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 42.71 Capped call transaction, cap price per share | \$ / shares \$ 62.12 Premium over last reported sale price percentage 100.00% Number of shares covered by capped calls | shares 12,878,305 Adjustments to additional paid in capital related to premium payments \$ 49,300,000 2020 Capped Call Transactions | Share Repurchase Transactions Debt Instrument [Line Items] Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 42.71 Capped call transaction, cap price per share | \$ / shares \$ 62.12 Premium over last reported sale price percentage 100.00% Number of shares covered by capped calls | shares 12,878,305 Adjustments to additional paid in capital related to premium payments \$ 49,300,000 2020 Capped Call Transactions | Share Repurchase Transactions Debt Instrument [Line Items] Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 42.71 Capped call transaction, cap price per share | \$ / shares \$ 62.12 Premium over last reported sale price percentage 100.00% Number of shares covered by capped calls | shares 12,878,305 Adjustments to additional paid in capital related to premium payments \$ 49,300,000 2020 Capped Call Transactions | Share Repurchase Transactions Debt Instrument [Line Items] Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 42.71 Capped call transaction, cap price per share | \$ / shares \$ 62.12 Premium over last reported sale price percentage 100.00% Number of shares covered by capped calls | shares 12,878,305 Adjustments to additional paid in capital related to premium payments \$ 49,300,000 2020 Capped Call Transactions | Share Repurchase Transactions Debt Instrument [Line Items] Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 42.71 Capped call transaction, cap price per share | \$ / shares \$ 62.12 Premium over last reported sale price percentage 100.00% Number of shares covered by capped calls | shares 12,878,305 Adjustments to additional paid in capital related to premium payments \$ 49,300,000 2020 Capped Call Transactions | Share Repurchase Transactions Debt Instrument [Line Items] Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 42.71 Capped call transaction, cap price per share | \$ / shares \$ 62.12 Premium over last reported sale price percentage 100.00% Number of shares covered by capped calls | shares 12,878,305 Adjustments to additional paid in capital related to premium payments \$ 49,300,000 2020 Capped Call Transactions | Share Repurchase Transactions Debt Instrument [Line Items] Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 42.71 Capped call transaction, cap price per share | \$ / shares \$ 62.12 Premium over last reported sale price percentage 100.00% Number of shares covered by capped calls | shares 12,878,305 Adjustments to additional paid in capital related to premium payments \$ 49,300,000 2020 Capped Call Transactions | Share Repurchase Transactions Debt Instrument [Line Items] Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 42.71 Capped call transaction, cap price per share | \$ / shares \$ 62.12 Premium over last reported sale price percentage 100.00% Number of shares covered by capped calls | shares 12,878,305 Adjustments to additional paid in capital related to premium payments \$ 49,300,000 2020 Capped Call Transactions | Share Repurchase Transactions Debt Instrument [Line Items] Debt instrument, convertible, threshold trading days | TradingDay 20 Debt instrument, convertible, threshold consecutive trading days | TradingDay 30 Debt instrument, convertible, threshold percentage of stock price trigger 130.00% Number of consecutive trading day period (Measurement period) for conversion of notes 5 days Number of business days in consideration of conversion of notes 5 days Conversion rate 23.4151 Initial conversion price per share | \$ / shares \$ 42.71 Capped call transaction, cap price per share | \$ / shares \$ 62.12 Premium over last reported sale price percentage 100.00% Number of shares covered by capped calls | shares 12,878,305 Adjustments to additional paid

DefinitionPrepayment fee. + ReferencesNo definition available. + Details Name: bbio_PrepaymentFee Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPrinciple amount paid to lenders. + ReferencesNo definition available. + Details Name: bbio_PrincipleAmountPaidToLenders Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of notes after deducting discount and offering expenses. + ReferencesNo definition available. + Details Name: bbio_ProceedsFromIssuanceOfNotesAfterDeductingDiscountAndOfferingExpenses Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of term loans after deducting debt discount and issuance costs. + ReferencesNo definition available. + Details Name: bbio_ProceedsFromIssuanceOfTermLoansAfterDeductingDebtDiscountAndIssuanceCosts Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPurchase of capped calls. + ReferencesNo definition available. + Details Name: bbio_PurchaseOfCappedCalls Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRemaining balance in escrow accounts. + ReferencesNo definition available. + Details Name: bbio_RemainingBalanceInEscrowAccounts Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSale of stock premium over last reported sale price percentage. + ReferencesNo definition available. + Details Name: bbio_SaleOfStockPremiumOverLastReportedSalePricePercentage Namespace Prefix: bbio_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThreshold percentage of stock price trigger in measurement period. + ReferencesNo definition available. + Details Name: bbio_ThresholdPercentageOfStockPriceTriggerInMeasurementPeriod Namespace Prefix: bbio_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-50-2> + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69E>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69F>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1F>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-3> + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-5> + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRatio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-50-5>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-3>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-7>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-6> + Details Name: us-gaap_DebtInstrumentConvertibleConversionRatio1 Namespace Prefix: us-gaap_Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-50-5>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-3>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-7>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-6> + Details Name: us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments Namespace Prefix: us-gaap_Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThreshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 Namespace Prefix: us-gaap_Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionMinimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThreshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays Namespace Prefix: us-gaap_Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionDate the debt agreement requires the first payment to be made, in YYYY-MM-DD format. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 210 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-50-5>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477734/942-470-50-3> + Details Name: us-gaap_DebtInstrumentDateOfFirstRequiredPayment1 Namespace Prefix: us-gaap_Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDescription of reference rate used for variable rate of debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentDescriptionOfVariableRateBasis Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482900/835-30-50-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-2> + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of the fee that accompanies borrowing money under the debt instrument. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-50-5>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-50-5>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482900/835-30-50-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-2> + Details Name: us-gaap_DebtInstrumentFrequencyOfPeriodicPayment Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-50-5>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B> + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-50-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-50-3>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 7: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69E>Reference 8: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69F>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 11: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1D>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1D>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1D>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1E>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1E>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1E>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1F>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1F>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1F>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1F>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1I>Reference 26: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-2>Reference 27: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482900/835-30-50-1> + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period

Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1:

initiationLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(f\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph \(SX 210.12-04\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 6: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 7: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E>Reference 8: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 11: [http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/194](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)

topbtopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 38 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482240/230-10-45-28Reference 5:

[illegible]

[Name Accounting Standards Codification - Section 50 - Paragraph 1D - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16:](#)
[http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1D - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17:](#) [http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1D - Subparagraph \(c\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18:](#) [http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1E - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 19:](#)
[http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1E - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 20:](#) [http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1E - Subparagraph \(d\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 21:](#) [http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1F - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 22:](#)
[http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1F - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 23:](#) [http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1F - Subparagraph \(b\)\(1\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 24:](#) [http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1F - Subparagraph \(b\)\(2\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 25:](#) [http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1F - Subparagraph \(c\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 26:](#) [http://www.xbrl.org/2009/role/commonPracticeRef - Topic 835 - SubTopic 30 - Name Accounting Standards Codification - Section 45 - Paragraph 2 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27:](#) [http://www.xbrl.org/2009/role/commonPracticeRef - Topic 835 - SubTopic 30 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap DebtInstrumentLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium \(discount\) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1:](#) [http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification - Section 599 - Paragraph 1 - Subparagraph \(SX 210.5-02\(22\)\) - SubTopic 10 - Topic 210 - Publisher FASB - URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:](#)
[http://www.xbrl.org/2003/role/exampleRef - Topic 835 - SubTopic 30 - Name Accounting Standards Codification - Section 55 - Paragraph 8 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3:](#) [http://fasb.org/us-gaap/role/ref/legacyRef - Topic 942 - SubTopic 210 - Name Accounting Standards Codification - Section 599 - Paragraph 1 - Subparagraph \(SX 210.9-03\(16\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27:](#) [http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 69B - Publisher FASB - URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5:](#)
[http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 69C - Publisher FASB - URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6:](#) [http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1D - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7:](#) [http://www.xbrl.org/2009/role/commonPracticeRef - Topic 944 - SubTopic 210 - Name Accounting Standards Codification - Section 599 - Paragraph 1 - Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(2\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8:](#) [http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 4 - Subparagraph \(b\)\(3\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap LongTermDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap TypeOfArrangementAxis=bbio FinancingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt - Schedule of Future Minimum Payments Under Term Loan Agreement \(Details\) \\$ in Thousands Jun. 30, 2024 USD \(\\$ \) Term Loans, Interest on Term Loans of Financing Agreement A Debt Instrument \[Line Items\] A Remainder of 2024 \\$ 27,515 2025 53,995 2026 53,995 2027 119,454 2028 131,732 2029 294,327 Total future payments 681,018 Financing Agreement A Debt Instrument \[Line Items\] A Total future payments 450,000 Less amounts representing interest \\$ \(231,018\) X - DefinitionContractual obligation interest portion. + ReferencesNo definition available. + Details Name: bbio ContractualObligationInterestPortion Namespace Prefix: bbio Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + ReferencesReference 1:](#) [http://www.xbrl.org/2009/role/commonPracticeRef - Topic 235 - SubTopic 10 - Name Accounting Standards Codification - Section 599 - Paragraph 3 - Publisher FASB - URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap ContractualObligation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date \(rolling approach\). + ReferencesNo definition available. + Details Name: us-gaap ContractualObligationDueInFifthYear Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date \(rolling approach\). + ReferencesNo definition available. + Details Name: us-gaap ContractualObligationDueInFourthYear Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date \(rolling approach\). + ReferencesNo definition available. + Details Name: us-gaap ContractualObligationDueInNextTwelveMonths Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date \(rolling approach\). + ReferencesNo definition available. + Details Name: us-gaap ContractualObligationDueInSecondYear Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date \(rolling approach\). + ReferencesNo definition available. + Details Name: us-gaap ContractualObligationDueInThirdYear Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in remainder of current fiscal year. + ReferencesNo definition available. + Details Name: us-gaap ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes. + ReferencesReference 1:](#) [http://www.xbrl.org/2003/role/exampleRef - Topic 835 - SubTopic 30 - Name Accounting Standards Codification - Section 55 - Paragraph 8 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2:](#) [http://www.xbrl.org/2009/role/commonPracticeRef - Topic 235 - SubTopic 10 - Name Accounting Standards Codification - Section 599 - Paragraph 1 - Subparagraph \(SX 210.4-08\(f\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3:](#) [http://www.xbrl.org/2003/role/disclosureRef - Topic 235 - SubTopic 10 - Name Accounting Standards Codification - Section 599 - Paragraph 3 - Subparagraph \(SX 210.12-04\(a\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4:](#) [http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1B - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5:](#) [http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 69B - Publisher FASB - URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6:](#)
[http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 69C - Publisher FASB - URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7:](#) [http://www.xbrl.org/2003/role/exampleRef - Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 69E - Publisher FASB - URI https://asc.fasb.org/1943274/2147481568/470-20-55](#)

Foundation Medicine, Inc | A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Close-out plan costs A \$ 1,400,000 A QED Therapeutics, Inc | A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Close-out plan costs A \$ 11,000,000 A \$ 2,100,000 A \$ 5,700,000 A QED Therapeutics, Inc | Helsinki Therapeutics A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Percentage of close-out plan costs, subject to reimbursement A 50.00% A 50.00% A QED Therapeutics, Inc | Helsinki A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Close-out plan costs A \$ 1,400,000 A Net payable position A \$ 700,000 A 700,000 A QED Therapeutics, Inc | Entities Affiliated With Perceptive Life Sciences Master Fund Ltd A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Warrant to purchase percentage A 10.00% A Nonrefundable upfront payment receivable A \$ 10,000,000 A QED Therapeutics, Inc | Maximum | Entities Affiliated With Perceptive Life Sciences Master Fund Ltd A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Future potential development and sales milestone payments yet to receive A \$ 132,500,000 A QED Therapeutics, Inc | Minimum | Foundation Medicine, Inc A A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Reimbursable remaining commencing installments A 9,600,000 A License and Collaboration Agreement A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Unbilled receivables A \$ 200,000 A \$ 900,000 A Percentage of total unbilled receivables A 70.60% A 70.60% A 61.90% A License and Collaboration Agreement | Helsinki Therapeutics A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Percentage share of global development costs A 60.00% A License and Collaboration Agreement | BMS A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Upfront payment yet to be received A \$ 90,000,000 Upfront, regulatory and launch milestone payments yet to be received A \$ 815,000,000 A \$ 815,000,000 A License and Collaboration Agreement | QED Therapeutics, Inc A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A License agreement percentage share of profits and losses A 50.00% A Percentage share of global development costs A 40.00% A Reimbursable research and development A 18,800,000 A Reimbursable payment outstanding A 31,300,000 A 31,300,000 A Reduction of obligation A 9,600,000 A 9,600,000 A License and Collaboration Agreement | QED Therapeutics, Inc | Maximum | Foundation Medicine, Inc A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Reimbursable remaining commencing installments A 11,000,000 A License and Collaboration Agreement | Navire Pharma, Inc | BMS A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Milestone payments A 0 A Initial transaction price for the license and collaboration agreement A 90,000,000 A Allocation of transaction price for research and development A 19,800,000 A Allocation of transaction price to licenses A 70,200,000 A Deferred revenue A \$ 9,900,000 A Deferred revenue, current portion A 6,100,000 A Deferred revenue, noncurrent A \$ 3,800,000 A License and Collaboration Agreement | Navire Pharma, Inc | Revenue | BMS A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Revenue A 0 A \$ 1,500,000 A \$ 9,900,000 A 3,200,000 A License Agreement | LianBio A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Nonrefundable upfront payment receivable A \$ 8,000,000 A License Agreement | LianBio | License and Services Revenue A \$ 8,500,000 A License Agreement | Maximum | LianBio A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Future potential development and sales milestone payments yet to receive A \$ 382,100,000 A Alexion License Agreements | Eidos A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Upfront nonrefundable payment received A \$ 25,000,000 A Alexion License Agreements | Maximum A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Regulatory milestone payment receivable subject to achievement of regulator milestones A 30,000,000 A Alexion Agreements | Eidos A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Revenue A 26,700,000 A Nonrefundable upfront payment receivable A \$ 25,000,000 A Alexion Agreements | Eidos | Common Stock A 556,173 A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Shares issued A 556,173 A Shares issued, price per share A \$ 44.95 A Aggregate purchase price A \$ 25,000,000 A Excess of purchase price over the value of common stock shares A \$ 1,700,000 A Bayer Exclusive License Agreement | Eidos A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Agreement convenience least days A 270 days A Milestone payments A 0 A Initial transaction price for the license and collaboration agreement A 135,000,000 A Licensing and collaboration agreements A 0 A Allocation of transaction price for research and development A 4,500,000 A 4,000,000 A Allocation of transaction price to licenses A 130,500,000 A Revenue A 400,000 A 400,000 A Deferred revenue A 4,100,000 A 4,100,000 A Deferred revenue, current portion A 1,400,000 A 1,400,000 A Deferred revenue, noncurrent A \$ 2,700,000 A \$ 2,700,000 A Net proceeds received permitted costs percentage A 75.00% A 75.00% A Receipt of escrow account A \$ 135,000,000 A \$ 135,000,000 A Deposited of escrow account receipt A \$ 84,700,000 A Bayer Exclusive License Agreement | License and Services Revenue | Eidos A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Revenue A 400,000 A 130,900,000 A Bayer Exclusive License Agreement | Commercial Product Supply | Eidos A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Revenues A 0 A Bayer Exclusive License Agreement | Seller Parties | Eidos A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Upfront payment received A \$ 135,000,000 A Regulatory and sales milestones \$ 175,000,000 A Sales milestone payments yet to be received \$ 450,000,000 A Kyowa Kirin Exclusive License A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Upfront payment yet to be received A 100,000,000 A 100,000,000 A Kyowa Kirin Exclusive License | Eidos A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Initial transaction price for the license and collaboration agreement A \$ 100,000,000 A Kyowa Kirin Exclusive License | QED Therapeutics, Inc A Development milestone payments yet to be received A \$ 81,400,000 A Agreement convenience least days A 180 days A Initial transaction price for the license and collaboration agreement A \$ 100,000,000 A Licensing and collaboration agreements A 0 A Allocation of transaction price for research and development A 30,900,000 A Allocation of transaction price to licenses A 69,100,000 A Revenue A 1,300,000 A 2,900,000 A Deferred revenue A 28,000,000 A 28,000,000 A Deferred revenue, current portion A 13,700,000 A 13,700,000 A Deferred revenue, noncurrent A \$ 14,300,000 A \$ 14,300,000 A Net proceeds received permitted costs percentage A 75.00% A 75.00% A Receipt of escrow account A \$ 100,000,000 A \$ 100,000,000 A Deposited of escrow account receipt A 74,600,000 A 74,600,000 A Kyowa Kirin Exclusive License | QED Therapeutics, Inc | License and Services Revenue A Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] A Revenue A \$ 1,300,000 A \$ 72,100,000 A [1] The condensed consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements as of that date. X - DefinitionAgreement for convenience day + ReferencesNo definition available. + Details Name: bbio AgreementForConvenienceDay Namespace Prefix: bbio_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAllocationOf Transaction Price for Research and Development. + ReferencesNo definition available. + Details Name: bbio AllocationOfTransactionPriceToResearchAndDevelopment Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAllocation of transaction price to licenses. + ReferencesNo definition available. + Details Name: bbio AllocationOfTransactionPriceToLicenses Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionClose-out plan costs. + ReferencesNo definition available. + Details Name: bbio CloseOutPlanCosts Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionClose-out plan costs subject to reimbursement. + ReferencesNo definition available. + Details Name: bbio CloseOutPlanCostsSubjectToReimbursement Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDeposited of escrow account receipt. + ReferencesNo definition available. + Details Name: bbio DepositedOfEscrowAccountReceipt Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDevelopment milestone payments yet to be received. + ReferencesNo definition available. + Details Name: bbio DevelopmentMilestonePaymentsYetToBeReceived Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionExcess of purchase price over the value of common stock shares. + ReferencesNo definition available. + Details Name: bbio ExcessOfPurchasePriceOverValueOfCommonStockShares Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionFuture potential development and sales milestone payments yet to be received. + ReferencesNo definition available. + Details Name: bbio FuturePotentialDevelopmentAndSalesMilestonePaymentsYetToBeReceived Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) receivable from licensing and collaboration agreements. + ReferencesNo definition available. + Details Name: bbio IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionInitial transaction price for license and collaboration agreement. + ReferencesNo definition available. + Details Name: bbio InitialTransactionPriceForLicenseAndCollaborationAgreement Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLicense agreement percentage share of profits and losses. + ReferencesNo definition available. + Details Name: bbio LicenseAgreementPercentageShareOfProfitsAndLosses Namespace Prefix: bbio_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNet payable position. + ReferencesNo definition available. + Details Name: bbio NetPayablePosition Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNet proceeds received permitted costs. + ReferencesNo definition available. + Details Name: bbio NetProceedsReceivedPermittedCosts Namespace Prefix: bbio_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNonrefundable upfront payment receivable. + ReferencesNo definition available. + Details Name: bbio NonrefundableUpfrontPaymentReceivable Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of close-out plan costs subject to reimbursement. + ReferencesNo definition available. + Details Name: bbio PercentageOfCloseOutPlanCostsSubjectToReimbursement Namespace Prefix: bbio_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of unbilled receivables. + ReferencesNo definition available. + Details Name: bbio PercentageOfUnbilledReceivables Namespace Prefix: bbio_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage share of global development costs. + ReferencesNo definition available. + Details Name: bbio PercentageShareOfGlobalDevelopmentCosts Namespace Prefix: bbio_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPotential milestone payments. + ReferencesNo definition available. + Details Name: bbio PotentialMilestonePayments Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReceipt of escrow account + ReferencesNo definition available. + Details Name: bbio ReceiptOfEscrowAccount Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionReduction of obligation. + ReferencesNo definition available. + Details Name: bbio ReductionOfObligation Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRegulatory and sales milestones. + ReferencesNo definition available. + Details Name: bbio RegulatoryAndSalesMilestones Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRegulatory milestone payment receivable subject to achievement of regulator milestones. + ReferencesNo definition available. + Details Name: bbio RegulatoryMilestonePaymentReceivableSubjectToAchievementOfRegulatorMilestones Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionReimbursable commercial contracted activities. + ReferencesNo definition available. + Details Name: bbio ReimbursableCommercialContractedActivities Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionReimbursable payment outstanding. + ReferencesNo definition available. + Details Name: bbio ReimbursablePaymentOutstanding Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionReimbursable remaining commencing installments. + ReferencesNo definition available. + Details Name: bbio ReimbursableRemainingCommencingInstallments Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionReimbursable research and development. + ReferencesNo definition available. + Details Name: bbio ReimbursableResearchAndDevelopment Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSales milestone payments yet to be received. + ReferencesNo definition available. + Details Name: bbio SalesMilestonePaymentsYetToBeReceived Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionStock Issued With Premium + ReferencesNo definition available. + Details Name: bbio StockIssuedWithPremium Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUpfront nonrefundable payment received. + ReferencesNo definition available. + Details Name: bbio UpfrontNonrefundablePaymentReceived Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUpfront payment received. + ReferencesNo definition available. + Details Name: bbio UpfrontPaymentReceived Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUpfront payment yet to be received. + ReferencesNo definition available. + Details Name: bbio UpfrontPaymentYetToBeReceived Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUpfront, regulatory and launch milestone payments yet to be received. + ReferencesNo definition available. +

Details Name: bbio UpfrontRegulatoryAndLaunchMilestonePaymentsYetToBeReceived Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionWarrant to purchase percentage. + ReferencesNo definition available. + Details Name: bbio_WarrantToPurchasePercentage Namespace Prefix: bbio_Data Type: dt- types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap DeferredRevenueCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap DeferredRevenueNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap ReceivablesLongTermContractsOrPrograms Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -SubTopic 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(v)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap Revenues Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap SharesIssuedPricePerShare Namespace Prefix: us-gaap_Data Type: dt- types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(d)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionAmount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap UnbilledReceivablesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap StatementEquityComponentsAxis-us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=bbio_HelsinnTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=bbio_FoundationMedicineIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=bbio_QEDTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=bbio_QEDTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bbio_EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix:

Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_LicenseAndCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=bbio_BristolMyersSquibbCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=bbio_NavirePharmaIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_AlexionLicenseAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=bbio_EidosTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_AlexionAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_BayerExclusiveLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bbio_CommercialProductSupplyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bbio_SellerPartiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_KyowaKirinExclusiveLicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1 License and Collaboration Agreements - Additional Information (Details1) - USD (\$) \$ / shares in Units, \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Sep. 30, 2019 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Á Á Á Á Á Research and development \$ 114,695 \$ 107,488 \$ 255,667 \$ 200,349 Á Á Receivables from licensing and collaboration agreements 660 Á 660 Á 1,751 [1] Á Á Á Á Á Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Á Á Á Á Á Receivables from licensing and collaboration agreements 0 0 Á 600 Á Á Á Alexion Agreements | Eidos | Common Stock Á Á Á Á Á Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Á Á Á Á Á Shares issued, price per share Á Á Á Á Á \$ 44.95 Excess of purchase price over the value of common stock shares Á Á Á Á Á \$ 1,700 The Nasdaq Global Select Market | Alexion Agreements | Eidos | Common Stock Á Á Á Á Á Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Á Á Á Á Á Shares issued, price per share Á Á Á Á Á \$ 41.91 Excess of purchase price over the value of common stock shares Á Á Á Á Á \$ 1,700 ASC 808 | License and Collaboration Agreement | QED Therapeutics, Inc | Helsinn Therapeutics Á Á Á Á Á Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Á Á Á Á Á Research and development \$ 1,000 Á 2,200 Á Á Receivable from Licensing and Collaboration Agreements | License and Collaboration Agreement Á Á Á Á Á Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Á Á Á Á Á Receivables from licensing and collaboration agreements \$ 700 Á \$ 700 Á [1] The condensed consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements as of that date. X - DefinitionExcess of purchase price over the value of common stock shares. + ReferencesNo definition available. + Details Name: bbio_ExcessOfPurchasePriceOverValueOfCommonStockShares Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap_ReceivablesLongTermContractsOrPrograms Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: srt_CounterpartyNameAxis=bbio_HelsinnTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_AlexionAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=bbio_EidosTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_EntityListingsExchangeAxis=exch_XNGS Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=bbio_AccountingStandardUpdate201818Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_LicenseAndCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=bbio_QEDTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=bbio_ReceivableFromLicensingAndCollaborationAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1 In-licensing and Other Research and Development Agreements - Additional Information (Details) - USD (\$) 1 Months Ended 3 Months Ended 6 Months Ended Sep. 30, 2023 Mar. 31, 2017 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Aug. 31, 2016 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Á Á Á Á Á Research and development expense Á Á \$ 114,695,000 \$ 107,488,000 \$ 255,667,000 \$ 200,349,000 Á Children intended for treatment with Canavan Disease, under the age. 5 years Á Á Á Á Á Aspa and Adrenas Á Á Á Á Á Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Á Á Á Á Á Maximum required future payment upon achievement of certain development and milestone events net sales metrics \$ 10,000,000 Á Á Á Á Á Resilience DMSAs Á Á Á Á Á Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Á Á Á Á Á Agreement term 10 years Á Á Á Á Á Agreement additional extension period 2 years Á Á Á Á Á Resilience PAs | Aspa Á Á Á Á Á Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Á Á Á Á Á Cost sharing credit of the lesser of a fixed percentage of certain agreed upon service costs \$ 15,500,000 Á Á Á Á Á Resilience PAs | Adrenas Á Á Á Á Á Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Á Á Á Á Á Cost sharing credit of the lesser of a fixed percentage of certain agreed upon service costs \$ 29,300,000 Á Á Á Á Á Resilience Agreements Á Á Á Á Á Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Á Á Á Á Á Research and development expense Á Á 400,000 Á 900,000 Á Á Cost sharing credits received Á Á \$ 500,000 Á 1,100,000 Á Á Eidos Therapeutics, Inc | Stanford License Agreement | Leland Stanford Junior University Á Á Á Á Á Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Á Á Á Á Á License fees Á \$ 10,000 Á \$ 0 8,100,000 0 Á Milestone payments Á Á Á Á Á \$ 1,000,000 QED Therapeutics, Inc | Foundation Medicine Diagnostics Agreement | Foundation Medicine, Inc Á Á Á Á Á Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Á Á Á Á Á Research and development expense Á Á Á \$ 0 \$ 0 Á X - DefinitionAgreement additional extension period option. + ReferencesNo definition available. + Details Name: bbio_AgreementAdditionalExtensionPeriodOption Namespace Prefix: bbio_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionChildren intended for treatment with canavan disease maximum age. + ReferencesNo definition available. + Details Name: bbio_ChildrenIntendedForTreatmentWithCanavanDiseaseMaximumAge Namespace Prefix: bbio_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionCost sharing credit of the lesser of fixed percentage of certain agreed upon service costs. + ReferencesNo definition available. + Details Name: bbio_CostSharingCreditOfTheLesserOfFixedPercentageOfCertainAgreedUponServiceCosts Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCost sharing credits received. + ReferencesNo definition available. + Details Name: bbio_CostSharingCreditsReceived Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLicense fees. + ReferencesNo definition available. + Details Name: bbio_LicenseFees Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMaximum required future payment upon achievement of certain development and milestone events net sales metrics. + ReferencesNo definition available. + Details Name: bbio_MaximumRequiredFuturePaymentUponAchievementOfCertainDevelopmentAndMilestoneEventsNetSalesMetrics Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPotential milestone payments. + ReferencesNo definition available. + Details Name: bbio_PotentialMilestonePayments Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionService agreement term. + ReferencesNo definition available. + Details Name: bbio_ServiceAgreementTerm Namespace Prefix: bbio_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=bbio_AspaTherapeuticsIncAndAdrenasTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_DevelopmentAndManufacturingServicesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_ProjectAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=bbio_AspaTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=bbio_AdrenasTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_ResilienceAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=bbio_EidosTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_StanfordLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=bbio_LelandStanfordJuniorUniversityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=bbio_QEDTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=bbio_FoundationMedicineDiagnosticsAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=bbio_FoundationMedicineIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Sale of Nonfinancial Assets - Additional Information (Details) - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Asset Acquisition [Line Items] Á Á Intangible assets, net \$ 25,123 \$ 26,319 [1] [1] The condensed consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements as of that date. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 73 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Components of Lease Cost (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Leases [Abstract] Á Á Á Straight line operating lease costs \$ 1,024 \$ 992 \$ 2,093 \$ 2,024 Finance lease costs 100 105 201 213 Variable lease costs 1,477 1,700 3,490 3,418 Total lease cost \$ 2,601 \$ 2,797 \$ 5,784 \$ 5,655 X - DefinitionAmount of interest expense on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseInterestExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lease cost recognized by

+ ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: debit Period Type: duration X - DefinitionAmountNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45-Paragraph 5 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 74 R65.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash paid for amounts included in the measurement of lease liabilities: A Operating cash flows for operating leases $ 2,981 $ 2,443 Operating cash flows for finance lease 222 217 Operating lease right-of-use assets obtained in exchange for operating lease obligations $ 1,292 $ 828 X - ReferencesNo definition available. + Details Name: us-gaap CashFlowOperatingActivitiesLesseeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest paid on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4-Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45-Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap FinanceLeaseInterestPaymentOnLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45-Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 75 R66.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Schedule of Supplemental Information Related to Remaining Lease Term and Discount Rate (Details) Jun. 30, 2024 Jun. 30, 2023 Weighted-average remaining lease term (in years) A Operating leases 4 years 5 months 2 months 12 days Finance lease 1 year 7 months 6 days 2 years 7 months 6 days Weighted-average discount rate A Operating leases 6.24% 6.34% Finance lease 6.62% 6.62% X - DefinitionWeighted-average discount rate. + ReferencesNo definition available. + Details Name: bbio WeightedAverageDiscountRateAbstract Namespace Prefix: bbio_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average discount rate for finance lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap FinanceLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for finance lease, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap FinanceLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53)Reference 2:

[A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#)

A A A Percentage of sales agents commissions A A A 3.00% A A A 2024 Follow-on Offering | Common Stock A A A A A A A Public Offerings, Share Repurchase Program And Securities Purchase Agreement [Line Items] A A A A A A A A Net proceeds issued from offerings A A \$ 276,600 A A A A A A A Common stock, par value A A \$ 0.001 A A \$ 0.001 A A A A A A Public offering price per share A A \$ 29 A A \$ 29 A A A Shares issued A 8,620,690 A 9,913,793 A A A A Underwriting discounts and commissions A 1,293,103 A 1,293,103 A A A A Underwriting fees and commissions A A \$ 10,300 A A \$ 10,300 A A A Deferred offering costs A A \$ 600 A A \$ 600 A A A A 2024 Follow-on Offering | Common Stock | Maximum A A A A A A A A Public Offerings, Share Repurchase Program And Securities Purchase Agreement [Line Items] A A A A A A A A A Percentage of Underwriters Commissions A A 3.60% A A 3.60% A A A X - DefinitionAggregate offering price of common stock that may issued and sold. + ReferencesNo definition available. + Details Name: bbio_AggregateOfferingPriceOfCommonStockThatMayIssuedAndSold Namespace Prefix: bbio_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of cash commission on gross proceeds of sales of common stock. + ReferencesNo definition available. + Details Name: bbio_PercentageOfCashCommissionOnGrossProceedsOfSalesOfCommonStock Namespace Prefix: bbio_Data Type: dtr-types:percentItemBalance Type: na Period Type: instant X - DefinitionPercentage of outstanding securities + ReferencesNo definition available. + Details Name: bbio_PercentageOfOutstandingSecurities Namespace Prefix: bbio_Data Type: dtr-types:percentItemBalance Type: na Period Type: instant X - DefinitionPercentage of sales agents commissions on gross proceeds of sales of common stock. + ReferencesNo definition available. + Details Name: bbio_PercentageOfSalesAgentsCommissionsOnGrossProceedsOfSalesOfCommonStock Namespace Prefix: bbio_Data Type: dtr-types:percentItemBalance Type: na Period Type: instant X - DefinitionPercentage of underwriters commissions on gross proceeds of sales of common stock + ReferencesNo definition available. + Details Name: bbio_PercentageOfUnderwritersCommissionsOnGrossProceedsOfSalesOfCommonStock Namespace Prefix: bbio_Data Type: dtr-types:percentItemBalance Type: na Period Type: instant X - DefinitionPublic Offerings, Share Repurchase Program And Securities Purchase Agreement. + ReferencesNo definition available. + Details Name: bbio_PublicOfferingsShareRepurchaseProgramAndSecuritiesPurchaseAgreementLinItems Namespace Prefix: bbio_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionSale of Stock, maximum amount of stock remaining eligible to be sold. + ReferencesNo definition available. + Details Name: bbio_SaleOfStockMaximumAmountOfStockRemainingEligibleToBeSold Namespace Prefix: bbio_Data Type: xbrli:monetaryItemBalance Type: credit Period Type: instant X - Definitionunderwriting discounts and commissions. + ReferencesNo definition available. + Details Name: bbio_UnderwritingDiscountsAndCommissions Namespace Prefix: bbio_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionUnderwriting fees and commissions. + ReferencesNo definition available. + Details Name: bbio_UnderwritingFeesAndCommissions Namespace Prefix: bbio_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 1 - Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionSpecific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SAB Topic 5.A) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1 + Details Name: us-gaap_DeferredOfferingCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: instant X - DefinitionThe amount of cash paid for commissions during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForCommissions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - DefinitionPrimarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SalesCommissionsAndFees Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedBalancePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ShareRepurchaseProgramAxis=bbio_FollowOnOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ShareRepurchaseProgramAxis=bbio_TwoThousandTwentyThreeAtTheMarketAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=bbio_AtTheMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ShareRepurchaseProgramAxis=bbio_TwoThousandTwentyFourFollowOnOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R70.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Summary of Stock Based Compensation for Employees and Non Employees (Details) - USD (\$ (\$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Employee And Non Employee Service Share Based Compensation [Line Items] A A A Total stock-based compensation \$ 21,451 \$ 27,176 \$ 50,301 \$ 50,653 BridgeBio Equity Plan A A A Employee And Non Employee Service Share Based Compensation [Line Items] A A A Total stock-based compensation 21,451 27,135 50,264 50,570 Other Subsidiaries Equity Plan A A A Employee And Non Employee Service Share Based Compensation [Line Items] A A A Total stock-based compensation 0 41 37 83 Research and Development Expense A A A Employee And Non Employee Service Share Based Compensation [Line Items] A A A Total stock-based compensation 4,937 13,229 17,716 25,008 Research and Development Expense | BridgeBio Equity Plan A A A Employee And Non Employee Service Share Based Compensation [Line Items] A A A Total stock-based compensation 4,937 13,188 17,679 24,925 Research and Development Expense | Other Subsidiaries Equity Plan A A A Employee And Non Employee Service Share Based Compensation [Line Items] A A A Total stock-based compensation 0 41 37 83 Selling, General and Administrative Expenses A A A Employee And Non Employee Service Share Based Compensation [Line Items] A A A Total stock-based compensation 16,471 13,947 32,542 25,645 Selling, General and Administrative Expenses | BridgeBio Equity Plan A A A Employee And Non Employee Service Share Based Compensation [Line Items] A A A Total stock-based compensation 16,471 13,947 32,542 25,645 Selling, General and Administrative Expenses | Other Subsidiaries Equity Plan A A A Employee And Non Employee Service Share Based Compensation [Line Items] A A A Total stock-based compensation 0 0 0 0 Restructuring, Impairment and Related Charges A A A Employee And Non Employee Service Share Based Compensation [Line Items] A A A Total stock-based compensation 43 43 43 Restructuring, Impairment and Related Charges | BridgeBio Equity Plan A A A Employee And Non Employee Service Share Based Compensation [Line Items] A A A Total stock-based compensation 43 43 43 Restructuring, Impairment and Related Charges | Other Subsidiaries Equity Plan A A A Employee And Non Employee Service Share Based Compensation [Line Items] A A A Total stock-based compensation \$ 0 A \$ 0 A X - DefinitionEmployee and non-employee service share based compensation. + ReferencesNo definition available. + Details Name: bbio_EmployeeAndNonEmployeeServiceShareBasedCompensationLinItems Namespace Prefix: bbio_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=bbio_BridgeBioServicesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesMember Namespace Prefix: Data Type: na

[illegible]

shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of grantees affected by modification of award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected Namespace Prefix: us-gaap Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost expensed and capitalized for award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDtHnMnS' format, for example, 'P1Y3M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPurchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidarySaleOfStockAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ShareRepurchaseProgramAxis=bbio_TwoThousandTwentyStockAndEquityAwardExchangeProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=bbio_PerformanceBasedRestrictedStockAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=bbio_PerformanceBasedStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bbio_TwoThousandNineteenStockOptionAndIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bbio_TwoThousandTwentyOneStockOptionAndIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bbio_TwoThousandNineteenInducementEquityPlansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bbio_EidosAwardExchangePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bbio_TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=bbio_BridgeBioServicesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=bbio_MarketBasedRestrictedStockUnitsRsusMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bbio_TwoThousandNineteenEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=bbio_EidosTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bbio_TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XSL 81 R72.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Summary of Stock Option Activity under Plans (Details) - A&R 2019 Plan and 2019 Inducement Plan - USD (\$) / shares in Units, \$ in Thousands 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] \$ Á Options Outstanding, Outstanding, Beginning balance 12,332,442 Á Options Outstanding, Granted 398,764 Á Options Outstanding, Exercised (49,982) Á Options Outstanding, Cancelled (3,867) Á Options Outstanding, Outstanding, Ending balance 12,677,357 12,332,442 Options Outstanding, Exercisable 10,018,943 Á Eidos Á Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Options Outstanding, Outstanding, Beginning balance 1,221,942 Á Options Outstanding, Exercised (35,916) Á Options Outstanding, Cancelled (3,867) Á Options Outstanding, Outstanding, Ending balance 1,182,159 1,221,942 Options Outstanding, Exercisable 1,179,149 Á Weighted-Average Exercise Price per Option, Outstanding, Beginning balance \$ 14.6 Á Weighted-Average Exercise Price per Option, Exercised 14.21 Á Weighted-Average Exercise Price per Option, Cancelled 63.38 Á Weighted-Average Exercise Price per Option, Outstanding, Ending balance 14.45 \$ 14.6 Weighted-Average Exercise Price per Option, Exercisable \$ 14.43 Á Weighted-Average Remaining Contractual Life (years), Outstanding, Ending balance 4 years 2 months 12 days 4 years 8 months 12 days Weighted-Average Remaining Contractual Life (years), Exercisable 4 years 2 months 12 days Á Aggregate Intrinsic Value, Outstanding, Ending balance \$ 13,513 \$ 31,580 Aggregate Intrinsic Value, Exercisable \$ 13,508 Á Regular Equity Program Á Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Options Outstanding, Outstanding, Beginning balance 10,793,862 Á Options Outstanding, Granted 398,764 Á Options Outstanding, Exercised (14,066) Á Options Outstanding, Outstanding, Ending balance 11,178,560 10,793,862 Options Outstanding, Exercisable 8,525,576 Á Weighted-Average Exercise Price per Option, Outstanding, Beginning balance \$ 25.69 Á Weighted-Average Exercise Price per Option, Granted 27.56 Á Weighted-Average Exercise Price per Option, Exercised 19.04 Á Weighted-Average Exercise Price per Option, Outstanding, Ending balance 25.76 \$ 25.69 Weighted-Average Exercise Price per Option, Exercisable \$ 26.82 Á Weighted-Average Remaining Contractual Life (years), Outstanding, Ending balance 6 years 9 months 18 days 7 years 1 month 6 days Weighted-Average Remaining Contractual Life (years), Exercisable 6 years 2 months 12 days Á Aggregate Intrinsic Value, Outstanding, Ending balance \$ 66,111 \$ 178,594 Aggregate Intrinsic Value, Exercisable \$ 45,274 Á 2020 Stock and Equity Award Exchange Program Á Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Options Outstanding, Outstanding, Beginning balance 316,638 Á Options Outstanding, Outstanding, Ending balance 316,638 316,638 Options Outstanding, Exercisable 314,218 Á Weighted-Average Exercise Price per Option, Outstanding, Beginning balance \$ 2.19 Á Weighted-Average Exercise Price per Option, Outstanding, Ending balance 2.19 \$ 2.19 Weighted-Average Exercise Price per Option, Exercisable \$ 2.18 Á Weighted-Average Remaining Contractual Life (years), Outstanding, Ending balance 4 years 9 months 18 days 5 years 3 months 18 days Weighted-Average Remaining Contractual Life (years), Exercisable 4 years 9 months 18 days Á Aggregate Intrinsic Value, Outstanding, Ending balance \$ 7,436 \$ 12,105 Aggregate Intrinsic Value, Exercisable \$ 7,382 Á X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-599-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=bbio_TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ShareRepurchaseProgramAxis=bbio_RegularEquityProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ShareRepurchaseProgramAxis=bbio_TwoThousandTwentyStockAndEquityAwardExchangeProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R73.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details) -A&R 2019 Plan and 2019 Inducement Plan - Restricted Stock Units (RSUs) 6 Months Ended Jun 30, 2024 \$ / shares shares Share Based Compensation Arrangement By Share Based Payment Award [Line Items] A Unvested Shares of Restricted Stock Outstanding, Beginning balance | shares 8,942,813 Unvested Shares of Restricted Stock Outstanding, Granted | shares 3,899,497 Unvested Shares of Restricted Stock Outstanding, Vested | shares (1,957,694) Unvested Shares of Restricted Stock Outstanding, Cancelled | shares (329,776) Unvested Shares of Restricted Stock Outstanding, Ending balance | shares 10,554,840 Weighted-Average Grant Date Fair Value, Beginning balance | \$ / shares \$ 16.27 Weighted-Average Grant Date Fair Value, Granted | \$ / shares 28.28 Weighted-Average Grant Date Fair Value, Vested | \$ / shares 17.73 Weighted-Average Grant Date Fair Value, Cancelled | \$ / shares 20.39 Weighted-Average Grant Date Fair Value, Ending balance | \$ / shares \$ 20.31 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting

standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2:

Section 50 - Paragraph 2 - Subparagraph (c)(2)(iii)(02) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bbio_TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ShareRepurchaseProgramAxis=bbio_TwoThousandTwentyStockAndEquityAwardExchangeProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ShareRepurchaseProgramAxis=bbio_RegularEquityProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R75.htm IDE# XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Summary of Recognized Stock-based Compensation Expense Related to Restricted Stock Award Activity (Details) - USD (\$) in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Á Á Total stock-based compensation \$ 21,451 \$ 27,176 \$ 50,301 \$ 50,653 A&R 2019 Plan and 2019 Inducement Plan | Other RSAs Á Á Á Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Á Á Total stock-based compensation 0,1023 621 2,049 A&R 2019 Plan and 2019 Inducement Plan | Restricted Stock Awards Á Á Á Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Á Á Total stock-based compensation 0,1023 933 5,654 A&R 2019 Plan and 2019 Inducement Plan | 2020 Stock and Equity Award Exchange Program Á Á Á Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Á Á Á Total stock-based compensation \$ 0 \$ 0 \$ 312 \$ 3,605 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=bbio_TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ShareRepurchaseProgramAxis=bbio_TwoThousandTwentyStockAndEquityAwardExchangeProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R76.htm IDE# XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Stock Options and Stock Purchase Rights under ESPP (Details) 6 Months Ended Jun. 30, 2024 \$ / shares Employee Stock Purchase Plan Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Expected term (in years) 6 Months Expected volatility, Minimum 55.80% Expected volatility, Maximum 122.10% Risk-free interest rate, Minimum 5.30% Risk-free interest rate, Maximum 5.50% Dividend yield 0.00% Weighted-average fair value of stock-based awards granted \$ 14.14 Employee Stock Options Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Expected volatility, Minimum 92.00% Expected volatility, Maximum 92.30% Risk-free interest rate, Minimum 4.20% Risk-free interest rate, Maximum 4.30% Dividend yield 0.00% Weighted-average fair value of stock-based awards granted \$ 21.3 Employee Stock Options | Minimum Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Expected term (in years) 6 years Employee Stock Options | Maximum Á Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Á Expected term (in years) 6 years 10 days X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher

[FASB - URL https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17:](#) [http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18:](#) [http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19:](#) [http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20:](#) [http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21:](#) [http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22:](#) [http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23:](#) [http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24:](#) [http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25:](#) [http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26:](#) [http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27:](#) [http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28:](#) [http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: \[http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(d\\)\\(1\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemBalanceType: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYmMdnTnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: \\[http://www.xbrl.org/2003/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(f\\\)\\\(2\\\)\\\(i\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap AwardTypeAxis=us-gaap EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 86 R77.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restructuring, Impairment and Related Charges - Additional Information \\\(Details\\\) - USD \\\(\\\\$\\\) \\\\$ in Millions Mar. 31, 2024 USD \\\(\\\\$\\\) Minimum Á Restructuring Cost and Reserve \\\[Line Items\\\] Á Estimated charges to be incurred \\\\$ 12.0 Maximum Á Restructuring Cost and Reserve \\\[Line Items\\\] Á Estimated charges to be incurred \\\\$ 16.0 X - DefinitionAmount expected to be recognized in earnings for the specified restructuring cost. + ReferencesReference 1: \\\[http://www.xbrl.org/2003/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \\\\(SAB Topic 5.P.4.d\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2:\\\]\\\(#\\\) \\\[http://www.xbrl.org/2003/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \\\\(SAB Topic 5.P.4.b.1\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3:\\\]\\\(#\\\) \\\[http://www.xbrl.org/2003/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \\\\(b\\\\)\\\\(1\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4:\\\]\\\(#\\\) \\\[http://www.xbrl.org/2003/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \\\\(b\\\\)\\\\(2\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap RestructuringAndRelatedCostExpectedCost1 Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: \\\\[http://www.xbrl.org/2003/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \\\\\(SAB Topic 5.P.4.d\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2:\\\\]\\\\(#\\\\) \\\\[http://www.xbrl.org/2003/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \\\\\(SAB Topic 5.P.4.b.1\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3:\\\\]\\\\(#\\\\) \\\\[http://www.xbrl.org/2003/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \\\\\(SAB Topic 5.P.4.b.2\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4:\\\\]\\\\(#\\\\) \\\\[http://www.xbrl.org/2003/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \\\\\(c\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5:\\\\]\\\\(#\\\\) \\\\[http://www.xbrl.org/2003/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \\\\\(b\\\\\)\\\\\(2\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6:\\\\]\\\\(#\\\\) \\\\[http://www.xbrl.org/2003/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \\\\\(b\\\\\)\\\\\(1\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7:\\\\]\\\\(#\\\\) \\\\[http://www.xbrl.org/2003/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \\\\\(d\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt RangeAxis=srt MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R78.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restructuring, Impairment and Related Charges - Summary of Restructuring, Impairment and Related Charges \\\\\(Details\\\\\) - USD \\\\\(\\\\\\$\\\\\) \\\\\\$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Restructuring and Related Activities \\\\\[Abstract\\\\\] Á Á Á Long-lived assets impairments and write-offs \\\\\\$ 0 \\\\\\$ 0 \\\\\\$ 271 \\\\\\$ 0 Severance and employee-related costs 538 572 2,503 715 Winding down, exit and other related costs 2,353 2,959 3,517 6,185 Total \\\\\\$ 2,891 \\\\\\$ 3,531 \\\\\\$ 6,291 \\\\\\$ 6,900 X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: \\\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \\\\\\(b\\\\\\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap BusinessExitCosts1 Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use \\\\\\(including those held for disposal by means other than sale\\\\\\). + ReferencesReference 1: \\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \\\\\\\(b\\\\\\\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2:\\\\\\]\\\\\\(#\\\\\\) \\\\\\[http://www.xbrl.org/2003/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph \\\\\\\(c\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/220-10-55-100Reference 3:\\\\\\]\\\\\\(#\\\\\\) \\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\\\(b\\\\\\\) -Publisher FASB -URI https\\\\\\]\\\\\\(#\\\\\\)\\\\\]\\\\\(#\\\\\)\\\\]\\\\(#\\\\)\\\]\\\(#\\\)\\]\\(#\\)\]\(#\)](#)

to continuing operations. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.1.7\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph \(a\) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) + Details Name: us-gaap IncomeTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3) + Details Name: us-gaap OperatingLossCarryforwardsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XM 90 R81.htm IDEA: XBRL DOCUMENT v3.24.2.1 Net Loss Per Share - Schedule of Common Stock Equivalents were Anti-dilutive (Details) - shares 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] A Antidilutive securities excluded from computation of diluted net loss per share 48,108,883 55,615,087 Unvested RSAs A Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] A Antidilutive securities excluded from computation of diluted net loss per share 0 363,022 Unvested RSUs A Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] A Antidilutive securities excluded from computation of diluted net loss per share 10,554,840 10,250,071 Unvested Performance-Based RSUs A Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] A Antidilutive securities excluded from computation of diluted net loss per share 3,326 7,875 Unvested Market-Based RSUs A Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] A Antidilutive securities excluded from computation of diluted net loss per share 375,000 0 Common Stock Options Issued and Outstanding A Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] A Antidilutive securities excluded from computation of diluted net loss per share 12,677,357 12,850,536 Estimated Shares Issuable Under Performance-Based Milestone Compensation Arrangements A Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] A Antidilutive securities excluded from computation of diluted net loss per share 3,811,055 11,438,950 Estimated Shares Issuable Under the ESPP A Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] A Antidilutive securities excluded from computation of diluted net loss per share 106,012 123,340 Assumed Conversion of 2027 Notes A Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] A Antidilutive securities excluded from computation of diluted net loss per share 12,878,305 12,878,305 Assumed Conversion of 2029 Notes A Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] A Antidilutive securities excluded from computation of diluted net loss per share 7,702,988 7,702,988 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bbio_UnvestedRestrictedStockUnitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bbio_UnvestedPerformanceBasedRestrictedStockUnitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bbio_UnvestedMarketBasedRestrictedStockUnitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bbio_CommonStockOptionsIssuedAndOutstandingMember Namespace Prefix: Data Type: na Balance Type

[illegible]

[illegible]

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~@=C 5HI5 X0= MV2ZI= I6?K\$J/MROZI&E\$#%XUO *?S4-PLOV@1070KZL2 ,?"2AIV ,+1GL# M<@<2>D1-6V3+1"10WKL2 ED65RCBIC TL:E.^^^ AFVZ *?TO">19&K (4 MCHHK0*? (ZTU915DLRI=LX:1,@M>J.E. MT1P?2E:"@O?H7U20K 1.PGN42B9YOHQC@N1U'P#Y V11?E@#0%XLc M'(N. 6A/12XQI@,C61% @,s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~0#=#+1J1#J.XC19Y713)@>@?T18DAB 1L:921>5IAWCC M>+3U&E36R13@J1CAFTT%Q 1H+8F1 &14OC 4J"2H+VW@&(71%W&U-10 M9.PG=K)0#TX1@/+@BNN:G1V\$@YK4R4E.IZ*G1GTF2KK4'JZE .:SD@Y^> MK<71=CU4?%DJO(. *CIX0?HX?OJA4LBBJ7BIP*69%5F/Y^WS71:579. *1 MLG37@JAXFU+N,ZIR@? =?TDJ:B1+H+I5R<=<?L6WNSD0?5JIO#MRSNRVX41D M'&8BICL0?5-52-AEMS@U)=<1%5&GIXE9..BDZ A*&BKRM722T'JSRJETVGR0-6P'6H8H-WNM&N4&1+?+B@< "M"5 "<RRT>8W3Z7V6@=<=<EY'K.H71>253.642@ERX@<@<P+W+BP13">OJ7-OYRRF&M+N1K@>+LUSN;G@Q)BRY30N1HUL@+<+T4:IMH#?2KG\$S&ZKE.~&#D#14YTH8N" MHG:1>4/JK,KE<? Y+700455%6%EZV2P<1AK'Y>?>4%>M>OP4Y4<1^%PY M&Y4'2>-9V#WWT' TH7>?YXZ X#M%8%Q'DFZ16D?2'29S2Z@IXZAP A'1JYS M.RIRF&8&L&8&X&6+80ZFK&E0C- PD.37HB+8RW@<F4WJGO'-31?>?>5<3EE&~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f0f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f56+ MFH@P'NFOH1" T40_//1: <5SVSP16 H9<K4Q(ZPHF43?ZAYDLIC6U MMV1L\$54Y'GR15?>4S8X>LN&(B&KM+3K1?>6.EGGN12.S053N#<N<@<#? MWN51QD.1?> JPH<Y_@214WUYK>9?9?>W\$34)7FT91FW<#>#K.216Z(85SU1>2 M1LC&UD &2Q1OU1(25JA:NAS\$XM<

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k>B3.P?>N?=&ZJ1U1.C6<41?>GDAPJ6:&EA5M4YEH&EOGH L193VCB1U= R% MCTDK=>?>AWA7W 4=1BU5PR<3J1T23 5116.FVQJ3UE% 4%4SCHU(G ME+>EOV+<ASIX0LWM+&(&S%B#&?)W1'55.<1VA.B7 M1P;B4.B+RC0>SFWN6LD1.3%<0 @HIT1E%\$3%A1Q?>2<GHK4.C1D38QNT2 MFUOY>#>VFHJ(O F@U'L.G.69<N%>N2%>K4&5.K21UZIVR7D1/J1J1..H1E1 @M80R?>F?>9A9N.#.8IE0-GG'W'AKUO4W39^E.5_9) (<?>B2P">@.(KDR68 M1P1+70?>P1.C6SDGL 2.6%PL.(CF&+JKL541T8H+VY3K'9CBG1?3 Z6@F M4J1=1YZH+2WWY1CL41BBAQ65\$@H4F22E"<6%>?0P">_9TW_Y1F%\$010I M'Al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f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

[illegible]

[illegible]

[illegible]

[illegible]

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tU=>DWT^>R=R GOT^>J MD5> M82<EW6R7Q>+>A/R.\$UJ <=>4OKE9J9365YF.8WE=>8S6.YD.8OE/9S5SM M6R9N^>J MV08ARBBDLH^SVP75.7D.U75?<=>UNTV35^5EE.8SF>Y0R6.UC.8CFYIR6 MR DL M%JN^<#=>9/PXG8L>5TEC.8SF0YB>5LE8&SF4YC!5E@M8+L2X1D)7BG13Q!J MYS#>D.YA>54EM-83FY<@>5^G&MS=44JG^MM S8.B#^R2RGL5S^N9J&YS.VQY4U>B1=9856YF.8OE/956.YE M.8 E2J8+6^!\$N\$9.SRHY+>X0^K5YY(OV-MX&XK<75A0J+>7G.689%>E>7^F 1JN7^0.=>OPS-67M;M<+0UR(JRVDL.MIL.EY).&+T\$DVR7J OOKH<-3R MDL800<^U97H 79R^>JL%? %K%0?FE=W(HW7^>J XJW>Q60HJG.)R^LM1 M^>SG.%R(LM9+>SG.R+LMT+>S7.JR<=>5H?1CIVYD8GE=47FRS7?<= MW6>U/SP1G9QYHJ7TFGQOK9RIB^M@!<=>=>8WKW&6.9JDY454EM-83FY M<=>5^G&Q&S=Z3WYV7W^160.&BV&#PE3SXB>44EE-93F.YG>6.U?>Z9M.5B3^>BZ>V^>=AA.9? EOK.W005H=F.L M Y8+>X1DY7F7E<=>=WN2<+>(3>J&G&).CZ<=>K1ZJRGLS9& M+4K3<MNMND0^>VJQ07? NOK&X9Y20PG&Z3R)3R2RGL5^QG.YR(LN9+>OG.UR(LN9+>OG.JR 7U+79^19X^>J VYVNHG.HAVF^U4L+K&S&SZ%JF<6V/KIX:0.&U/D^1 M%99364YC.9WE#)8S6.KP.RR53^44VYJHHPH792DWOQ!D@>J0:JUM@>J(XWE=)8S6.YD M.8OE/9S6.YE.8 E)8+6^!\$N\$8L5HJ W%>S8EV<S39?3LL9=>PQVQ5#>5D MEE-N2^>N3YGMV7J MOJWJ!>G M^4Y6VXJ9BZ2RW3+QU^WA+IRA>SB3G.QARRJQJ0Q.ODH^FT^ M6JV M.3X.R<DL9J.R DL%JBBGG+EBTG.#<2=N?<9WNM7JVS&A>5DEE-N7 L2JFKREPOPVX.#.9WE#8S M6W\$M<=>@Y/CJ&F&U^>@J<6&2PY2MO.QSS1GJPDWVYU MEJ!<=>=>HJ3^EQI42=W#89KJ08IV4AGXG. (XP&S<B&D5C2L LGST>17DO<=>=>@N WUVU W<Q 4<26P5%92E/;S62Y@ MN1+M&C&C^2T07>7CIN0H#T^/XYU &G61<YD WRVCQ7Z0:QV5U2PW#X OYVG0 MWMJQU=>=>K&E092364YX<4>Q UJLH6V356C.9WE#)8S6V.^W.HJ@>ZY 9^M&+Z TMOX(8Y)=>=>KMGCT+IKI+>=>MN7H.P/6Y5^UEA.9SF#Y4R6LUC.9CFY5R6UC.9JF Y4^>R1O15LX%<+MP ??T@J9NUVOIU.SLMUV6MHHK+%092364XY<16-8ZX4H1-9.36+>@KM.N^Q>8^DM33+Y^W8 MF2FPJ. J+>B-9J^FPGOPJBX>=CKT^TRX>?>ZQ518.44XY<4JH=LBFR75 MHH<=>+>F2QGL9S<=>@J+N2SGL9S<=>@+A1C7R.Q?J^HKE=>%M.MSR2H7U M@<=>PAUKK=K64=FEF?Y^>W8#67XQ EYVJ!>=>0:UMS11^GES6Q0J>?>MQ4.EC.9SFT^4QG.UR(LN9+>OG.JR 1X+N+ M2^ VO& FEB@GLYORYFT3(KW^>OBSH0M4^MFPF5.5DEE/7H0?>J<=>CJ!1#1ZG%VE^JNO MG.YR(LN9+>OG.UR(LN9+>OG.JR 751^OZPFI7TFP=IK&B3J^RQCG(ZRODL EOXJXNH87<5B MD0^LXR&6^NMU<CS4OJH(XY.XYS=0)44XY<4GJ^ZFBT3HIS.<=>+>F2QG ML9S<=>@J+N2SGL9S<=>@+A1C7A^F7JTF8X(0).J1^N&#SQ+RH %<LU%BF MJLW^>RSG9Q7^RQ6/R47WNWAS1^DOYF>64J>XXW>Y-P ZK.9R.LL9+>R MG.5R.LLY+>RG.=R/L%+=B7^G^IW^>W:4OIG5407VYQ7#VW6.T/ST\$G M^>GRX5YTFKVOYHH2^LIP^>245WKW&J.GV.SG.%R(LM9+>SG.R+LMT+>S7.JR<=>8UXK0 M-ARVYX^U1+>X42Q^ODJ>=>=>SS6^>?ZRU&K44VYJY^>3^VO&C1.9WE M#8S6J615MP02^MNKNT+AZD>T2S5444H4Y<1>XU&=>F.K@2BGLYS25GLUJ4&J@>GLYORYJJA MNWAS+ TYG>4.EC.9SFT^4V&8^>E.C.93G0D^+ MSPXNMJ M:#9JBFV57Z^>Z FVEYXG4E.C6GHL1X5^*OMANRSGL9S<=>@+A1A73J0 MHR DL%J!< MB^S=>STU^BGEIES^>JZ6CQVYZ.>E.2Y624U4.93F-Y726.UC.9#F+ MY6R6A+GZ.WMW9J>U^>C.RVY3JHH@.OA^*OKI^>PG.JR M&LOH+>PG.ER.MLO9+>PG.MRLOY+>P7AQCG82N.63^XH?>PUKJXJHY?%>M>1%?2U^Y? F9J!<@GGIGJ+??>5&%>GR#PHZLLIS&2M%M+&XB&8L12X>HGL@LQVt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t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t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

[illegible]

U4.U0#50E2+4"VF"CGS.I4) 27L@+1.0N6;UQ4K3%WY5C.134U7Q4"U.M.M1+4(U6)"DR7I(9T95>ASUE.M=3I@Q(M.I)::@VINK1TY>>AD JH%G1.A1"=M-\$UF+
+DG+6E5"V=VJDW.9I.JR<54;ZSXMNW-I>R@FHUJ|JY>DNY.M9+P2.K2.@VH/A+4/TIDC5I134Y.4IOIU.V=HX>Z"CLT= M3RM5I" MWEE
6S.HYI3:CVHJH6H%3:3ERGO.COK\$;CL&6MMI.105%1S4U5.WC@2CJ.H%G1>BQ"=T*UF+DS#6I4>VY5S1W5.5V2Y=J4<U"N&M>XC=MZUEID00UD>>
M3J8+96.<@XJ>N+>4I6.CJFHJ.CZJH.@6HEJ5.C&ER.%16C^&NO73.5#2 M80WBH23T.CZH9JH::@VHNJGFHYJ::@HAJD6H%E..>F9&2.7M&A+27&AHV
MCFHYJ::AVH<|@6HJ::ASHQK&N5.MP2&X5:MFYJHJ7:6VN2+N10.A0H.MJ9T6X40G3I.M9C2Y.U521W#H45::CMP.M.09I9YH&A+Y1GA.S:7.3FGV513:
YW(K.M#V5IK9J::@FHMJYHJHJ::@6HAJ.M\$.K%F:8GNZDY&9.7MIF.H50S48U15<5>Q54>U>5"5(M0+8T<6803:*M5I>K2NQ"FFI.XI1S48UH5<5>0S4>U>
7-6I.NYG<V%XD0B>6R.M.C9E.MVY%4I.YG"D66?RFHJ:XYOZM+I.4VTKIKCHJZJ::@6HJ@G(A&JQ90F
MQFD)GJ3M+1OP7C1=0K2&A&H.JKFHJ3S:CVHJH6U)EH="1QONW.T"G.C65NF.22Q.NO<Q4>U.VX=Q10.DMD694ZJH=PZKJ#79.W3LOQ=PIG
M.Q.O&WC.O08>P7M\$NTPH9J#BZJ::CFHJHJ.B&JH|64YJ<1#9J>ZJ.U)EIVC04.U1Q4MU-5" M5(M0+8T.9LOK&1P>D(IYW5134/U7Q4"U
M1+4(U6)DZ9J.TLK.FD.MEGK6G6T269V220XJBMJ7K5=)J0>42U"M9C2YPPU2C.KR&65"MR1BWV.MSAM.<A"Y7P%1YH1360P+>
IZ(PJH6HJ%J).3&ERTHWD6DRG2L+>@>MWSM7&+<IUIJ3U(R.X6AR&L5)2D0S6M9B7@7K.PH24<5>0544U1535.M0+42U"5B.M2I/CW1U4H+7" #.M1N.7L5?Q4L=<G5J?>
RHZ-9H2>9.<@FEM=Q7OTU@#50E2+4"VFM.2Z@#2Y.VM5(6%-G6%4ID=<)*1>5"7V5|HJ=AF5.G.W2Q>5Q.CAXW>2NWK|XYI<M2I/AFHJ.3210"AVT%>7W9J:
>=G=8IUKP2M%1+1PW.C<=<16>G.XKKTQOQ.M66AFT7D(5ILOYR2P.43RA.2INFQ=,WU00.29UNYH7.P=02P.5%&@H.M169)R06&<@USD.IB<I>JW.W3K&U1.M09M=<HJY%
(N\$50PNTM43JPIX<W(1G6+8C.I6+84G(SL5JN1#=#.M.I" A9.4V9IBW0+>2+1P2P.2I4.0*8Z>J1<SN>=HJ5<ES<06%WT11D>@%HJ.BM5?CY1CYIR6EY6BC.H8RCU>
ME7&=H8C.7N.W.M&PJJ7"1K>+>KZHLHGG<N#FFIESVGNB>|JFHS)M>+>7SDJDKR+PVTME9<@>T+L>ZLQ15+&I/DSGHO96.00W%*F2
M.Y0<9D5.Y9G92T7I73>Q3@>5J7(TZ.QO(TSM.O)=F(8.2ZCY6X.MX98#T1#TCO@QV.PF@>L1GHP=I7ZJ7.T44SXU&1Z.BBI.TZDITJ>G5K
M.5<Q5RDY4J2CDU1H)93B<+>OYO(H92CZSR5Y<Z@<0I>UWVS?YZGD6#>MSE35TF62>11%SVL|L|K.K.%%?E&GI?7H1LWZ65.1QD1P&5<
M=<DVHJH8.JRYJ.GZD0&<2R.H0VZ148E8.M=S0WMJ.O18Y02E)W&S+<X01.M.@<LL0>(<1I=K|GN)IKKX134W>26W9VKXIZCMIG&A+G3#0<BN&E<OYTF6BXYB
H1HK2.YN.I.1.3X1X.I@6.M<8I8U4LOF)H#>+VYXKJ|@.D&81020H|@6BV"32V"U@|WRY"YUAI?R5&B.MBF.M=E.4TDOOY3.7#4VM+HW>9.9BPHZ?T%P3&H&AZ<
J#CZ7G#29H6H2<.<M-9%TYNH#1K=5"62.K9U0M&PYN#5NP7C8&A9#6IBZ05M=<P.PISB#P?B.M#)YK=WB?Y71@XV0094G:N5>2.36T%02F.0+>1YK
MRM255M=UBNP&1G.H+I+W.<+3N&L#(AVW910W#WA#1+V1F4+7I@)DWN.M.LF+L|P.&(<MZIE1.124QHJ@>V59J4Y>3Q&APTF&U<=<87BPJ4Q.0?7F1Q.SC4F.6.M
1&1@FZ52=17.2.1%0I>=>32%1354LQSN"WO191&06D.BJ8.GZ=17.7.M02X&1U#&#BTB|HC41JHJQTSLB13>Q.4L.K4D)VZ.VO#W&1E14GTE6DE.M=M.2.2ZY9W1Y7L
%7%>@Z1L#>QZY0A1GQO#<F1<1O|H|X2UDLZ.M\$B'CAN@?<1YRNO.5K\$>=<I>8ZCQZRV/Z3L.MQ5F10X&4SG60Q.D+H1<=<E.6V<3N&U1O=U
<IM&@:H.AOX+R3DTE5%>@>XRRH.0%Z.R.MG.O=9>P?|DH<#<KJH.DM<=<I" G&<+J8+I<O+K>Z>O.HL7I&EBV3196G+7H.N5GEBV3192Q?7JWO.MAS29.1<TF%IYO=>
HJH%PRU?OWFY.IC%IW.U)EGR.ICHP2%HLD?J05E>?M7GCEGOKX3>V|3IS@O.MWKO.W0+Q>QW>276HE720>9>+YI7UJ"Y"=SG?ZKFOKFWN7G@U>>7.HIOD
M8.IVM|BT0TS&L>16J>W0Z.VV6>+>5>VYWPJ6<P>7>1#(EKO)F.F.WQ.U.M13QOI@H|@7ZJ.OX1=8#7I7P.P.HQO.#QA.35Q@N<1<C8B&+5W.MR30Q@<1>+>1YCL5"Y=>
(3I<+3U@<1K.26W14YWOZ3<1<|<RW1710Y0.MPS<VWOMJH1+02C.9>=>VLEQ3EVN7WGEH1N7IO.Q08LO6XQ.T3W"U".M#8.O|MYLK|P6XG&SKPRF3OAV1H
M.O2XZ5><@>IOB>?<IKPJH.UU.CWU>=>OYU|UW@<IK<2IKQOZ?>QV3.MH.FGCKN1A|UXL|<NOK.W|SBB>U1U7I6KTL|RHIO2T|BYQ<KWMO@V>ITTL.MJN>KIV+G.N|<
<I>G3(P1<CR1A.Z&O.1+<?=>#9D1SV2P1M9T=<M.JIK<38U2U32D>20F2\$S88..M5IX8KIS.MW.0P25.Z1>ZRD7.#AVOZ.C#>7QAL>0W6).AU7KF@K21TE.D%&A.8I+&%(
(F%)1.1.M6S0&L@<1THW7TPO.44\$EO&0.13|90&2.20)A206D54.8AK<6OD>+<1M.#P.T.VO|HGZ?>YI&IGRFSJW1.OGSBS9J.YDN7.8S)2)W5C.Z1W.WX2Y
M.#X3Y<2.9Y>1D5%MFBB>=>896K6L.2.(93)U1A.MM&1<0TEB|HDJ5@P3|>8EA2T7WCG>+>TU+M9.Y0M..JP22=I.Q.40.13..&H2U1=1..PKFLIU.TU.MUZW"LUH|@KR?>
3H8>81K1.0&5<4#<M.ZEFT<=>=>HIBMFEL?>3.RTH|HVS>16F.#9FR.R6EN.DP|<C%YH19.YO.OA&A.YHS74U>+1Y7Z|Y>3&AV.FE.U.30>1JRT.E.0.C4MS+1MSM%
FT"HEE).H5I&A&KIO.BF>YUJHYJ.L0Q1.YU|MTWR<S4=+<IY3KGYKIGI085.MB5>R<S0<3UGEC9QVE|ETRHJ?>1#6%&B&L|66HJYFM&FJ139R1=>9V5.MGRX.VP?J&BT&(5J
145).HIE.M1+4(U64T366#55H2>>CTE#RU>H9J.M@>+5.E23I90+42U" M9S.4U@OU<?7R1?TL=E.8&K.IE%TW&TC85J.D.M5H.H%J@<A&HOIFE&X.Y.F
YG=>#<N.JDT%2U6HYJ.0+4.U22P50+42U" MM1C5.44U.N5YJKR77A70RM5J.CFD.U>4DJBE4"U\$M0K48U32E<=>M.RI.MEUBRCYPPY"CBT2AFD"U>4DJHFI-IV5@3SW3?>
NR>W3..5B5>4U@Q057KRM.MV.6B1\$SG2<+1J5>0+4.U22JH.W6O.WS=1K9Q&MA"=C&J.FH9K&IAKM.ME|WKGSFT.(5J
M45).HGS<#HEE)E&B&M.V5B=4UKP=1U7KZO+11GJ.MK1%5=1.5I"HW1"91327" T<=>V5D+<=>0(U6)4T336#&95P>K\$C"79R&lt


```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

[of Cash Flows \(Unaudited\)Statements7 falsefalseR8.htm995455 - Disclosure - Organization and Description of BusinessSheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessOrganization and Description of BusinessNotes8 falsefalseR9.htm995465 - Disclosure - Summary of Significant Accounting PoliciesSheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes9 falsefalseR10.htm995475 - Disclosure - Fair Value MeasurementsSheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFair Value MeasurementsNotes10 falsefalseR11.htm995485 - Disclosure - Cash Equivalents and Marketable SecuritiesSheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesCash Equivalents and Marketable SecuritiesNotes11 falsefalseR12.htm995505 - Disclosure - Noncontrolling InterestsSheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureNoncontrollingInterestsNoncontrolling InterestsNotes12 falsefalseR13.htm995515 - Disclosure - Equity Method Investment and Other Equity InvestmentsSheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestments1Equity Method Investment and Other Equity InvestmentsNotes13 falsefalseR14.htm995525 - Disclosure - Intangible AssetsSheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssets1Intangible AssetsNotes14 falsefalseR15.htm995535 - Disclosure - Commitments and ContingenciesSheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes15 falsefalseR16.htm995545 - Disclosure - DebtSheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtDebtNotes16 falsefalseR17.htm995555 - Disclosure - Funding AgreementSheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureFundingAgreementFunding AgreementNotes17 falsefalseR18.htm995565 - Disclosure - License and Collaboration AgreementsSheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreements1License and Collaboration AgreementsNotes18 falsefalseR19.htm995575 - Disclosure - In-licensing and Other Research and Development AgreementsSheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureInlicensingAndOtherResearchAndDevelopmentAgreements1In-licensing and Other Research and Development AgreementsNotes19 falsefalseR20.htm995595 - Disclosure - LeasesSheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesLeasesNotes20 falsefalseR21.htm995605 - Disclosure - Public OfferingsSheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferings1Public OfferingsNotes21 falsefalseR22.htm995615 - Disclosure - Stock-Based CompensationSheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStock-Based CompensationNotes22 falsefalseR23.htm995625 - Disclosure - Restructuring, Impairment and Related ChargesSheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedCharges1Restructuring, Impairment and Related ChargesNotes23 falsefalseR24.htm995635 - Disclosure - Income TaxesSheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesIncome TaxesNotes24 falsefalseR25.htm995645 - Disclosure - Net Loss Per ShareSheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareNet Loss Per ShareNotes25 falsefalseR26.htm995665 - Disclosure - Summary of Significant Accounting Policies \(Policies\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies \(Policies\)Policieshttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies26 falsefalseR27.htm995675 - Disclosure - Summary of Significant Accounting Policies \(Tables\)TablesSheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTablesSummary of Significant Accounting Policies \(Tables\)Tableshttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies27 falsefalseR28.htm995685 - Disclosure - Fair Value Measurements \(Tables\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTablesFair Value Measurements \(Tables\)Tableshttp://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurements28 falsefalseR29.htm995695 - Disclosure - Cash Equivalents and Marketable Securities \(Tables\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTablesCash Equivalents and Marketable Securities \(Tables\)Tableshttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities29 falsefalseR30.htm995705 - Disclosure - Intangible Assets \(Tables\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsTablesIntangible Assets \(Tables\)Tableshttp://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssets130 falsefalseR31.htm995715 - Disclosure - Commitments and Contingencies \(Tables\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTablesCommitments and Contingencies \(Tables\)Tableshttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies31 falsefalseR32.htm995725 - Disclosure - Debt \(Tables\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtTablesDebt \(Tables\)Tableshttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebt32 falsefalseR33.htm995735 - Disclosure - Leases \(Tables\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesTablesLeases \(Tables\)Tableshttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeases33 falsefalseR34.htm995745 - Disclosure - Stock-Based Compensation \(Tables\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTablesStock-Based Compensation \(Tables\)Tableshttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation34 falsefalseR35.htm995755 - Disclosure - Restructuring, Impairment and Related Charges \(Tables\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesTablesRestructuring, Impairment and Related Charges \(Tables\)Tableshttp://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedCharges135 falsefalseR36.htm995775 - Disclosure - Net Loss Per Share \(Tables\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareTablesNet Loss Per Share \(Tables\)Tableshttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShare36 falsefalseR37.htm995785 - Disclosure - Summary of Significant Accounting Policies - Additional Information \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailsSummary of Significant Accounting Policies - Additional Information \(Details\)Details37 falsefalseR38.htm995795 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash \(Details\)Details37 falsefalseR38.htm995795 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash \(Details\)Details37 falsefalseR38.htm995795 - Disclosure - Summary of Significant Accounting Policies - Summary of Accrued Professional and Other Accrued Liabilities \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAccruedProfessionalAndOtherAccruedLiabilitiesDei of Significant Accounting Policies - Summary of Accrued Professional and Other Accrued Liabilities \(Details\)Details39 falsefalseR40.htm995815 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis \(Details\)Details40 falsefalseR41.htm995825 - Disclosure - Fair Value Measurements - Additional Information \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetailsFair Value Measurements - Additional Information \(Details\)Details41 falsefalseR42.htm995835 - Disclosure - Fair Value Measurements - Summary of Total Realized and Unrealized Gains and Losses Associated with Investments in Equity Securities \(Details\)Details42 falsefalseR43.htm995845 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Cash Equivalent and Marketable Securities Classified as Available-for-Sale \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClass Equivalents and Marketable Securities - Schedule of Cash Equivalent and Marketable Securities Classified as Available-for-Sale \(Details\)Details43 falsefalseR44.htm995855 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetailsCash Equivalents and Marketable Securities - Additional Information \(Details\)Details44 falsefalseR45.htm995875 - Disclosure - Noncontrolling Interests - Additional Information \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureNoncontrollingInterestsAdditionalInformationDetailsNoncontrolling Interests - Additional Information \(Details\)Details45 falsefalseR46.htm995885 - Disclosure - Equity Method Investment and Other Equity Investments - Additional Information \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetailsEquity Method Investment and Other Equity Investments - Additional Information \(Details\)Details46 falsefalseR47.htm995895 - Disclosure - Intangible Assets - Summary of Recognized Intangible Assets \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetailsIntangible Assets - Summary of Recognized Intangible Assets \(Details\)Details47 falsefalseR48.htm995905 - Disclosure - Intangible Assets - Additional Information \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetailsIntangible Assets - Additional Information \(Details\)Details48 falsefalseR49.htm995915 - Disclosure - Commitments and Contingencies - Additional Information \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetailsCommitments and Contingencies - Additional Information \(Details\)Details49 falsefalseR50.htm995925 - Disclosure - Commitments and Contingencies - Schedule of Potential Milestone Amounts and Accruals \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetailsCommitments and Contingencies - Schedule of Potential Milestone Amounts and Accruals \(Details\)Details50 falsefalseR51.htm995935 - Disclosure - Debt - Additional Information \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetailsDebt - Additional Information \(Details\)Details51 falsefalseR52.htm995945 - Disclosure - Debt - Additional Information \(Details\)1Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails1Debt - Additional Information \(Details\)1Details52 falsefalseR53.htm995955 - Disclosure - Debt - Schedule of Outstanding Notes Balances \(Details\)Noteshttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetailsDebt - Schedule of Outstanding Notes Balances \(Details\)Details53 falsefalseR54.htm995965 - Disclosure - Debt - Schedule of Total Interest Expense Recognized Related to Notes \(Details\)Noteshttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetailsDebt - Schedule of Total Interest Expense Recognized Related to Notes \(Details\)Details54 falsefalseR55.htm995975 - Disclosure - Debt - Schedule of Future Minimum Payments under Notes \(Details\)Noteshttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetailsDebt - Schedule of Future Minimum Payments under Notes \(Details\)Details55 falsefalseR56.htm995985 - Disclosure - Debt - Schedule of Balances of Borrowing under Loan Agreement \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetailsDebt - Schedule of Balances of Borrowing under Loan Agreement \(Details\)Details56 falsefalseR57.htm995995 - Disclosure - Debt - Schedule of Balances of Borrowing under Financing Agreement \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderFinancingAgreementDetailsDebt - Schedule of Balances of Borrowing under Financing Agreement \(Details\)Details57 falsefalseR58.htm996005 - Disclosure - Debt - Schedule of Future Minimum Payments Under Term Loan Agreement \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetailsDebt - Schedule of Future Minimum Payments Under Term Loan Agreement \(Details\)Details58 falsefalseR59.htm996015 - Disclosure - Funding Agreement - Additional Information \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureFundingAgreementAdditionalInformationDetailsFunding Agreement - Additional Information \(Details\)Details59 falsefalseR60.htm996025 - Disclosure - License and Collaboration Agreements - Additional Information \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetailsLicense and Collaboration Agreements - Additional Information \(Details\)Details60 falsefalseR61.htm996035 - Disclosure - License and Collaboration Agreements - Additional Information \(Details\)1Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails1License and Collaboration Agreements - Additional Information \(Details\)1Details61 falsefalseR62.htm996045 - Disclosure - In-licensing and Other Research and Development Agreements - Additional Information \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/DisclosureInlicensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetailsIn-licensing and Other Research and Development Agreements - Additional Information \(Details\)Details62 falsefalseR63.htm996055 - Disclosure - Sale of Nonfinancial Assets - Additional Information \(Details\)Details63 falsefalseR64.htm996065 - Disclosure - Leases - Components of Lease Cost \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostDetailsLeases - Components of Lease Cost \(Details\)Details64 falsefalseR65.htm996075 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases \(Details\)Sheethhttp://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetailsLeases - Schedule of Supplemental Cash Flow Information Related to Leases \(Details\)Details65 falsefalseR66.htm996085 - Disclosure - Leases - Schedule of Supplemental Information Related to Remaining Lease Term and Discount Rate](#)

(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/Role-DisclosureLeasesScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateDetail
- Schedule of Supplemental Information Related to Remaining Lease Term and Discount Rate (Details)Details66 falsefalseR67.htm996095 - Disclosure - Leases - Schedule of
Future Minimum Lease Payments for Noncancelable Leases
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/Role-DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetailsLeases-
Schedule of Future Minimum Lease Payments for Noncancelable Leases (Details)Details67 falsefalseR68.htm996105 - Disclosure - Leases - Additional Information
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/Role-DisclosureLeasesAdditionalInformationDetailsLeases - Additional Information (Details)Details68
falsefalseR69.htm996115 - Disclosure - Public Offerings - Additional Information
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetailsPublic Offerings - Additional Information
(Details)Details69 falsefalseR70.htm996125 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation for Employees and Non Employees
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDet
Based Compensation - Summary of Stock Based Compensation for Employees and Non Employees (Details)Details70 falsefalseR71.htm996135 - Disclosure - Stock-Based
Compensation - Additional Information
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationAdditionalInformationDetailsStock-Based Compensation - Additional
Information (Details)Details71 falsefalseR72.htm996145 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity under Plans
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetailsStock-Based
Compensation - Summary of Stock Option Activity under Plans (Details)Details72 falsefalseR73.htm996155 - Disclosure - Stock-Based Compensation - Summary of Restricted
Stock Units Activity
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetailsStock-Based
Compensation - Summary of Restricted Stock Units Activity (Details)Details73 falsefalseR74.htm996165 - Disclosure - Stock-Based Compensation - Summary of Restricted
Stock Award Activity under Plans
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetailsStock-Based
Compensation - Summary of Restricted Stock Award Activity under Plans (Details)Details74 falsefalseR75.htm996175 - Disclosure - Stock-Based Compensation - Summary of
Recognized Stock-based Compensation Expense Related to Restricted Stock Award Activity
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestr
Based Compensation - Summary of Recognized Stock-based Compensation Expense Related to Restricted Stock Award Activity (Details)Details75 falsefalseR76.htm996185 -
Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Stock Options and Stock Purchase Rights under ESPP
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPu
Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Stock Options and Stock Purchase Rights under ESPP (Details)Details76
falsefalseR77.htm996195 - Disclosure - Restructuring, Impairment and Related Charges - Additional Information
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetailsRestructuring, Impairment
and Related Charges - Additional Information (Details)Details77 falsefalseR78.htm996205 - Disclosure - Restructuring, Impairment and Related Charges - Summary of
Restructuring, Impairment and Related Charges
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesSummaryOfRestructuringImpairmentAndRelatedChargesDi
Impairment and Related Charges - Summary of Restructuring, Impairment and Related Charges (Details)Details78 falsefalseR79.htm996215 - Disclosure - Restructuring,
Impairment and Related Charges - Schedule of Activity Related to Restructuring Liabilities Associated to Restructuring Initiatives
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssoci
Impairment and Related Charges - Schedule of Activity Related to Restructuring Liabilities Associated to Restructuring Initiatives (Details)Details79 falsefalseR80.htm996225
- Disclosure - Income Taxes - Additional Information
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/Role-DisclosureIncomeTaxesAdditionalInformationDetailsIncome Taxes - Additional Information
(Details)Details80 falsefalseR81.htm996255 - Disclosure - Net Loss Per Share - Schedule of Common Stock Equivalents were Anti-dilutive
(Details)Sheethttp://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntiDilutiveDetailsNet Loss Per Share -
Schedule of Common Stock Equivalents were Anti-dilutive (Details)Details81 falsefalseAll ReportsBookAll Reports bbio-20240630.htm bbio-20240630.xsd
http://fasb.org/srt/2024http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024falsefalse JSON 98 MetaLinks.json IDEA: XBRL DOCUMENT f "version": "2.2", "instance": f
"bbio-20240630.htm", f "nsPrefix": "bbio", "nsUri": "http://bridgebio.com/20240630", "dts": f "inline": f "local": f "bbio-20240630.htm" }, "schema": f "local": f "bbio-
20240630.xsd", f "remote": f "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-
2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/irr/arcore/esma-arcore-2018-11-21.xsd", "http://www.xbrl.org/irr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/irr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
"https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
"https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecv-sub-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
"https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" } }, "keyStandard": 337, "keyCustom": 187, "axisStandard": 31, "axisCustom": 0, "memberStandard": 30, "memberCustom":
107, "hidden": f "total": 22, "http://fasb.org/us-gaap/2024": 14, "http://bridgebio.com/20240630": 4, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 545, "entityCount": f
"segmentCount": 144, "elementCount": 1081, "unitCount": 8, "baseTaxonomies": f "http://fasb.org/us-gaap/2024": 1201, "http://xbrl.sec.gov/dei/2024": 30,
"http://fasb.org/srt/2024": 2 }, "report": f "R1": f "role": "http://bridgebio.com/20240630/taxonomy/role/Role-DocumentDocumentAndEntityInformation", "longName": "100000
- Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "",
"menuCat": "Cover", "order": 1, "firstAnchor": f "contextRef": "C 5898b796-a467-4199-882e-578d07f9d285", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": f "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor":
f "contextRef": "C 5898b796-a467-4199-882e-578d07f9d285", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f
"span": "p", "body": "html" }, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R2": f "role":
"http://bridgebio.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance
Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": 2,
"firstAnchor": f "contextRef": "C 78ec7efa-1346-45b2-9870-693d0f32f7ec", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U USD", "xsiNil": "false",
"lang": null, "decimals": -3, "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true }, "uniqueAnchor":
f "contextRef": "C 78ec7efa-1346-45b2-9870-693d0f32f7ec", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals":
-3, "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "bbio-20240630.htm", "unique": true }, "R3": f "role":
"http://bridgebio.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsParentetical", "longName": "100030 - Statement - Condensed
Consolidated Balance Sheets (Parentetical)", "shortName": "Condensed Consolidated Balance Sheets (Parentetical)", "isDefault": "false", "groupType": "statement",
"subGroupType": "parentetical", "menuCat": "Statements", "order": 3, "firstAnchor": f "contextRef": "C 78ec7efa-1346-45b2-9870-693d0f32f7ec", "name": "us-
gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": f "span":
"p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "C 78ec7efa-1346-
45b2-9870-693d0f32f7ec", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null,
"decimals": "INF", "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R4": f
"role": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "longName": "100040 - Statement - Condensed
Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType":
"statement", "subGroupType": "", "menuCat": "Statements", "order": 4, "firstAnchor": f "contextRef": "C 73f8b7cf-b60e-43b7-a01

```
"http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurements","longName":"995475-Disclosure-Fair Value Measurements","shortName":"Fair Value Measurements","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"10","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:FairValueDisclosuresTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:FairValueDisclosuresTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true }}, {"R11":{"role":"http://bridgebio.com/20240630/taxonomy/role/Role DisclosureCashEquivalentsAndMarketableSecurities","longName":"995485-Disclosure-Cash Equivalents and Marketable Securities","shortName":"Cash Equivalents and Marketable Securities","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"11","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true }}, {"R12":{"role":"http://bridgebio.com/20240630/taxonomy/role/Role DisclosureNoncontrollingInterests","longName":"995505-Disclosure-Noncontrolling Interests","shortName":"Noncontrolling Interests","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"12","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:MinorityInterestDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:MinorityInterestDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true }}, {"R13":{"role":"http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestments1","longName":"995515-Disclosure-Equity Method Investment and Other Equity Investments","shortName":"Equity Method Investment and Other Equity Investments","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"13","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:InvestmentTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:InvestmentTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true }}, {"R14":{"role":"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssets1","longName":"995525-Disclosure-Intangible Assets","shortName":"Intangible Assets","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"14","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:IntangibleAssetsDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:IntangibleAssetsDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true }}, {"R15":{"role":"http://bridgebio.com/20240630/taxonomy/role/Role DisclosureCommitmentsAndContingencies","longName":"995535-Disclosure-Commitments and Contingencies","shortName":"Commitments and Contingencies","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"15","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true }}, {"R16":{"role":"http://bridgebio.com/20240630/taxonomy/role/Role DisclosureDebt","longName":"995545-Disclosure-Debt","shortName":"Debt","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"16","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:DebtDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:DebtDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true }}, {"R17":{"role":"http://bridgebio.com/20240630/taxonomy/role/DisclosureFundingAgreement","longName":"995555-Disclosure-Funding Agreement","shortName":"Funding Agreement","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"17","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"bbio:FundingAgreementTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"bbio:FundingAgreementTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true }}, {"R18":{"role":"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreements1","longName":"995565-Disclosure-License and Collaboration Agreements","shortName":"License and Collaboration Agreements","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"18","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"bbio:LicenseAndCollaborationAgreementTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"bbio:LicenseAndCollaborationAgreementTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true }}, {"R19":{"role":"http://bridgebio.com/20240630/taxonomy/role/DisclosureInLicensingAndOtherResearchAndDevelopmentAgreements1","longName":"995575-Disclosure-In-licensing and Other Research and Development Agreements","shortName":"In-licensing and Other Research and Development Agreements","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"19","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"bbio:InLicensingAndOtherResearchAndDevelopmentAgreementsDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"bbio:InLicensingAndOtherResearchAndDevelopmentAgreementsDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true }}, {"R20":{"role":"http://bridgebio.com/20240630/taxonomy/role/Role DisclosureLeases","longName":"995595-Disclosure-Leases","shortName":"Leases","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"20","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"bbio:LesseesOperatingAndFinancingLeasesDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"bbio:LesseesOperatingAndFinancingLeasesDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true }}, {"R21":{"role":"http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferings1","longName":"995605-Disclosure-Public Offerings","shortName":"Public Offerings","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"21","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:StockholdersEquityNoteDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:StockholdersEquityNoteDisclosureTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ancestors":["div","body","html"],"reportCount":1,"baseRef":"bbio-20240630.htm"},"first":true,"unique":true }}, {"R22":{"role":"http://bridgebio.com/20240630/taxonomy/role/Role DisclosureStockBasedCompensation","longName":"995615-Disclosure-Stock-Based Compensation","shortName":"Stock-Based Compensation","isDefault":false,"groupType":"disclosure","subGroupType":"","menuCat":"Notes","order":"22","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock","unitRef":null,"xsiNil":false,"lang":"en-US","decimals":null,"ance
```


"bbio:NetGainsLossesIncludedInOtherIncomeExpenseNet","unitRef":"U_USD","xsiNil":"false","lang":null,"decimals":"-3","ancestors":{"span":"p","td","tr","table","us-gaap:GainLossOnInvestmentsTextBlock"},"div","us-gaap:FairValueDisclosuresTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","unique":true},"R43":{"role":

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvaila

"longName":"995845 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Cash Equivalent and Marketable Securities Classified as Available-for-Sale (Details)","shortName":"Cash Equivalents and Marketable Securities - Schedule of Cash Equivalent and Marketable Securities Classified as Available-for-Sale (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"43","firstAnchor":{"contextRef":"C_78ec7efa-1346-45b2-9870-693d0f32f7ec","name":"us-gaap:CashEquivalentsAtCarryingValue","unitRef":"U_USD","xsiNil":"false","lang":null,"decimals":"-3","ancestors":{"span":"p","td","tr","table"},"div","us-gaap:ScheduleOfCashEquivalentsAndMarketableSecuritiesTableTextBlock"},"div","us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_78ec7efa-1346-45b2-9870-693d0f32f7ec","name":"us-gaap:CashEquivalentsAtCarryingValue","unitRef":"U_USD","xsiNil":"false","lang":null,"decimals":"-3","ancestors":{"span":"p","td","tr","table"},"div","us-gaap:ScheduleOfCashEquivalentsAndMarketableSecuritiesTableTextBlock"},"div","us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"R44":{"role":

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails","longName":"995855 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Details)","shortName":"Cash Equivalents and Marketable Securities - Additional Information (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"44","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss","unitRef":"U_USD","xsiNil":"false","lang":null,"decimals":"-INF","ancestors":{"span":"p","us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss","unitRef":"U_USD","xsiNil":"false","lang":null,"decimals":"-INF","ancestors":{"span":"p","us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"R45":{"role":

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureNoncontrollingInterestsAdditionalInformationDetails","longName":"995875 - Disclosure - Noncontrolling Interests - Additional Information (Details)","shortName":"Noncontrolling Interests - Additional Information (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"45","firstAnchor":{"contextRef":"C_73f8b7cf-b60e-43b7-a013-cb09df98b774","name":"bbio:AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital"},"div","us-gaap:MinorityInterestDisclosureTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"R46":{"role":

"http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails","longName":"995885 - Disclosure - Equity Method Investment and Other Equity Investments - Additional Information (Details)","shortName":"Equity Method Investment and Other Equity Investments - Additional Information (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"46","firstAnchor":{"contextRef":"C_73f8b7cf-b60e-43b7-a013-cb09df98b774","name":"us-gaap:EquitySecuritiesFvNIUnrealizedGainLoss","unitRef":"U_USD","xsiNil":"false","lang":null,"decimals":"-3","ancestors":{"span":"p","td","tr","table"},"div","us-gaap:GainLossOnInvestmentsTextBlock"},"div","us-gaap:FairValueDisclosuresTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true},"uniqueAnchor":{"contextRef":"C_f5afb7a71-6462-4b0f-aae5-3f79bbe7f78d","name":"us-gaap:WarrantsNotSettleableInCashFairValueDisclosure"},"div","us-gaap:EquityMethodInvestmentAndOtherEquityInvestmentsTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true},"R47":{"role":

"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails","longName":"995895 - Disclosure - Intangible Assets - Summary of Recognized Intangible Assets (Details)","shortName":"Intangible Assets - Summary of Recognized Intangible Assets (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"47","firstAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"},"div","us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"},"div","us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_5898b796-a467-4199-882e-578d07f9d285","name":"us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"},"div","us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"},"div","us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"R48":{"role":

"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails","longName":"995905 - Disclosure - Intangible Assets - Additional Information (Details)","shortName":"Intangible Assets - Additional Information (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"48","firstAnchor":{"contextRef":"C_73f8b7cf-b60e-43b7-a013-cb09df98b774","name":"us-gaap:AmortizationOfIntangibleAssets"},"div","us-gaap:AmortizationOfIntangibleAssets"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"R49":{"role":

"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails","longName":"995915 - Disclosure - Commitments and Contingencies - Additional Information (Details)","shortName":"Commitments and Contingencies - Additional Information (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"49","firstAnchor":{"contextRef":"C_78ec7efa-1346-45b2-9870-693d0f32f7ec","name":"bbio:AccruedTerminationCharges"},"div","us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"C_78ec7efa-1346-45b2-9870-693d0f32f7ec","name":"bbio:AccruedTerminationCharges"},"div","U_USD","xsiNil":"false","lang":null,"decimals":"-INF","ancestors":{"span":"p","us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"R50":{"role":

"http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetails","longName":"995925 - Disclosure - Commitments and Contingencies - Schedule of Potential Milestone Amounts and Accruals (Details)","shortName":"Commitments and Contingencies - Schedule of Potential Milestone Amounts and Accruals (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"50","firstAnchor":{"contextRef":"C_78ec7efa-1346-45b2-9870-693d0f32f7ec","name":"bbio:PotentialMilestoneFixedMonetaryAmountSettlementInCash"},"div","us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"R51":{"role":

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails","longName":"995935 - Disclosure - Debt - Additional Information (Details)","shortName":"Debt - Additional Information (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"51","firstAnchor":{"contextRef":"C_73f8b7cf-b60e-43b7-a013-cb09df98b774","name":"us-gaap:InterestExpenseDebt"},"div","us-gaap:DebtDisclosureTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"R52":{"role":

"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails1","longName":"995945 - Disclosure - Debt - Additional Information (Details1)","shortName":"Debt - Additional Information (Details1)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"52","firstAnchor":{"contextRef":"C_76bf2039-075b-4d8d-9910-55fc28a80f3c","name":"bbio:DebtInstrumentDepositPercentageOfProceedsNetOfCertainPermittedCostsUponReceiptOfUpfrontPaymentsFromLicenseAgreements"},"div","U_pure","xsiNil":"false","lang":null,"decimals":"-2","ancestors":{"span":"p","us-gaap:DebtDisclosureTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"R53":{"role":

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails","longName":"995955 - Disclosure - Debt - Schedule of Outstanding Notes Balances (Details)","shortName":"Debt - Schedule of Outstanding Notes Balances (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"53","firstAnchor":{"contextRef":"C_3ea0946c-34a5-42b1-8df0-e41a7419c459","name":"us-gaap:DebtInstrumentCarryingAmount"},"div","us-gaap:DebtDisclosureTextBlock"},"div","us-gaap:DebtDisclosureTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"R54":{"role":

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedAndEffectiveInterestRatesRelatedToNotesTableTextBlock"},"div","us-gaap:DebtDisclosureTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"R55":{"role":

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedAndEffectiveInterestRatesRelatedToNotesTableTextBlock"},"div","us-gaap:DebtDisclosureTextBlock"},"div","body","html"},"reportCount":1,"baseRef":"bbio-20240630.htm","first":true,"unique":true},"R56":{"role":

"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails","longName":"995985 - Disclosure - Debt - Schedule of Balances of Borrowing under Loan Agreement (Details)","shortName":"Debt - Schedule of Balances of Borrowing under Loan Agreement (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"56","firstAnchor":{"contextRef":"C_1ba3c07b-dcc2-444b-b117-b6fd3e989e15","

"name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1ba3c07b-dcc2-444b-b117-b0fd3ce989e15", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R57": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderFinancingAgreementDetails", "longName": "995995 - Disclosure - Debt - Schedule of Balances of Borrowing Under Financing Agreement (Details)", "shortName": "Debt - Schedule of Balances of Borrowing Under Financing Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_c40cf6e4-be4f-4b62-9fa0-b0326b2c8ce8", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R58": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "longName": "996005 - Disclosure - Debt - Schedule of Future Minimum Payments Under Term Loan Agreement (Details)", "shortName": "Debt - Schedule of Future Minimum Payments Under Term Loan Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_c830f814-c6d9-4353-849a-5dfa16f9487", "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R59": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFundingAgreementAdditionalInformationDetails", "longName": "996015 - Disclosure - Funding Agreement - Additional Information (Details)", "shortName": "Funding Agreement - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_b972e0c1-fa87-4535-b1b3-4edb3299cf2c", "name": "us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R60": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "longName": "996025 - Disclosure - License and Collaboration Agreements - Additional Information (Details)", "shortName": "License and Collaboration Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_5898b796-a467-4199-882e-578d07f9d285", "name": "us-gaap:IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R61": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "longName": "996035 - Disclosure - License and Collaboration Agreements - Additional Information (Details)", "shortName": "License and Collaboration Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_73f8b7cf-b60e-43b7-a013-cb09df98b774", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R62": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "longName": "996045 - Disclosure - License and Collaboration Agreements - Additional Information (Details)", "shortName": "License and Collaboration Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_73f8b7cf-b60e-43b7-a013-cb09df98b774", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R63": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "longName": "996055 - Disclosure - License and Collaboration Agreements - Additional Information (Details)", "shortName": "License and Collaboration Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_78ec7efa-1346-45b2-9870-693d0f32f7ec", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R64": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "longName": "996065 - Disclosure - Leases - Components of Lease Cost (Details)", "shortName": "Leases - Components of Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_73f8b7cf-b60e-43b7-a013-cb09df98b774", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R65": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "longName": "996075 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details)", "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_5898b796-a467-4199-882e-578d07f9d285", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R66": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "longName": "996085 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details)", "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_78ec7efa-1346-45b2-9870-693d0f32f7ec", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R67": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "longName": "996095 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details)", "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_78ec7efa-1346-45b2-9870-693d0f32f7ec", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R68": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "longName": "996105 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details)", "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_73f8b7cf-b60e-43b7-a013-cb09df98b774", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R69": { "role": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "longName": "996115 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details)", "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_5898b796-a467-4199-882e-578d07f9d285", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DebtDisclosureTextBlock", "div": "body", "html": "1", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true }, "R70": { "role": "http://bridgebio.com/20240630/taxonomy/

us-gaap:AllocatedShareBasedCompensationExpense, "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_2d503a58-67a3-494a-b6e7-d282c5d4705e", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_a1aad19c-994f-4bb0-9c26-045c9e154ad", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationCost1", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-5", "ancestors": f "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "unique": true |, "R72": f "role":

http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails, "longName": "996145 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity under Plans (Details)", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity under Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": f "contextRef": "C_fb7b4ceea-d7fc-45e3-85a7-df00666d4c6d", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_e62a36ac-db0a-4b08-bfe5-a8ba828efb79", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "unique": true |, "R73": f "role":

http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails, "longName": "996155 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details)", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": f "contextRef": "C_1cd12330-c528-4dae-84f8-dcd1344544cb", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_7ed8be35-87be-4c5b-9d11-2239d0fa18ba", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "unique": true |, "R74": f "role":

http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails, "longName": "996165 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Award Activity under Plans (Details)", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Award Activity under Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": f "contextRef": "C_606644c5-1ffa-42ee-bd70-0857b4506cb4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_bc89900b-4315-4962-b294-d29b4d43fe77a", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "INF", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "unique": true |, "R75": f "role":

http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAward, "longName": "996175 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-based Compensation Expense Related to Restricted Stock Award Activity (Details)", "shortName": "Stock-Based Compensation - Summary of Recognized Stock-based Compensation Expense Related to Restricted Stock Award Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": f "contextRef": "C_73f8b7cf-b60e-43b7-a013-cb09df98b774", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_fedf8a96-2654-48f7-9f4a-dde1c497f250", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_fedf8a96-2654-48f7-9f4a-dde1c497f250", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_fedf8a96-2654-48f7-9f4a-dde1c497f250", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_fedf8a96-2654-48f7-9f4a-dde1c497f250", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_fedf8a96-2654-48f7-9f4a-dde1c497f250", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_fedf8a96-2654-48f7-9f4a-dde1c497f250", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_fedf8a96-2654-48f7-9f4a-dde1c497f250", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" |, "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true |, "uniqueAnchor": f "contextRef": "C_fedf8a96-2654-48f7-9f4a-dde1c497f250", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": f "span", "p", "td", "

"p": "td", "tr": "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html", "reportCount": 1, "baseRef": "bbio-20240630.htm", "first": true, "unique": true, "lang": "en-us", "us-gaap:AccountingPoliciesAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Accounting Policies Abstract", "lang": "en-us", "role": "label", "Accounting Policies Abstract", "auth_ref": "1", "bbio:AccountingStandardUpdate201818Member": "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccountingStandardUpdate201818Member", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "ASC 808", "label": "Accounting Standard Update 201818 [Member]", "documentation": "Accounting Standard Update 2018-18", "auth_ref": "1", "us-gaap:AccountingStandardsUpdate202006Member": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate202006Member", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited", "lang": "en-us", "role": "label", "Accounting Standards Update 2020-06 [Member]", "terseLabel": "ASU 2020-06", "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity", "auth_ref": "580", "581", "582", "583", "584", "585", "586", "587", "588", "589", "590", "us-gaap:AccountsPayableCurrent": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role:StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)", "auth_ref": "72", "938", "us-gaap:AccountsPayableMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestr", "lang": "en-us", "role": "label", "Accounts Payable [Member]", "terseLabel": "Accounts Payable", "documentation": "Obligations incurred and payable to vendors for goods and services received", "auth_ref": "74", "us-gaap:AccretionExpense": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionExpense", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role:StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Accretion Expense", "terseLabel": "Accretion of debt", "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations", "auth_ref": "906", "1145", "bbio:AccrualForMilestonesNotProbable": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccrualForMilestonesNotProbable", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Accrual for milestones not probable", "label": "Accrual for Milestones Not Probable", "terseLabel": "Accrual for milestones not probable", "auth_ref": "1", "bbio:AccrualOfPaymentInKindInterestOnTermLoan": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccrualOfPaymentInKindInterestOnTermLoan", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role:StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "terseLabel": "Accrual of payment in-kind interest on term loan", "label": "Accrual Of Payment In Kind Interest On Term Loan", "documentation": "Accrual of payment in-kind interest on term loan", "auth_ref": "1", "bbio:AccruedCompensationAndBenefitsMember": "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccruedCompensationAndBenefitsMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestr", "lang": "en-us", "role": "label", "Accrued compensation and benefits", "label": "Accrued Compensation and Benefits [Member]", "terseLabel": "Accrued Compensation and Benefits", "documentation": "Accrued compensation and benefits", "auth_ref": "1", "bbio:AccruedExitFees": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccruedExitFees", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Accrued exit fees", "label": "Accrued Exit Fees", "terseLabel": "Accrued exit fees", "auth_ref": "1", "us-gaap:AccruedLiabilitiesAndOtherLiabilitiesAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "lang": "en-us", "role": "label", "Accrued Liabilities and Other Liabilities [Abstract]", "auth_ref": "1", "bbio:AccruedProfessionalAndOtherAccruedLiabilitiesCurrent": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccruedProfessionalAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAccruedProfessionalAndOtherAccruedLiabilitiesDetails", "http://bridgebio.com/20240630/taxonomy/role/Role:StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "totalLabel": "Accrued professional and other accrued liabilities", "terseLabel": "Accrued professional and other accrued liabilities", "label": "Accrued professional and other accrued liabilities", "documentation": "Accrued professional and other accrued liabilities current", "auth_ref": "1", "bbio:AccruedProfessionalAndOtherAccruedLiabilitiesMember": "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccruedProfessionalAndOtherAccruedLiabilitiesMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestr", "lang": "en-us", "role": "documentation": "Accrued professional and other accrued liabilities", "label": "Accrued Professional And Other Accrued Liabilities [Member]", "terseLabel": "Accrued Professional and Other Accrued Liabilities", "auth_ref": "1", "bbio:AccruedProfessionalAndOtherAccruedLiabilitiesPolicyPolicyTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccruedProfessionalAndOtherAccruedLiabilitiesPolicyPolicyTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role:DisclosureSummaryOfSignificantAccountingPolicies", "lang": "en-us", "role": "terseLabel": "Accrued Professional and Other Accrued Liabilities", "label": "Accrued Professional and Other Accrued Liabilities, Policy [Policy Text Block]", "documentation": "Accrued professional and other accrued liabilities, policy", "auth_ref": "1", "us-gaap:AccruedProfessionalFeesCurrent": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAccruedProfessionalAndOtherAccruedLiabilitiesDetails", "lang": "en-us", "role": "label", "Accrued Professional Fees, Current", "terseLabel": "Accrued professional services", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)", "auth_ref": "75", "bbio:AccruedRegulatoryBasedMilestonePayment": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccruedRegulatoryBasedMilestonePayment", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Accrued regulatory-based milestone payment", "label": "Accrued Regulatory Based Milestone Payment", "terseLabel": "Accrued regulatory-based milestone payment", "auth_ref": "1", "bbio:AccruedResearchAndDevelopment": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccruedResearchAndDevelopment", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel": "Accrued research and development expenses", "label": "Accrued Research and Development", "documentation": "Accrued research and development", "auth_ref": "1", "bbio:AccruedResearchAndDevelopmentLiabilitiesCurrent": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccruedResearchAndDevelopmentLiabilitiesCurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role:StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "documentation": "Accrued research and development liabilities current", "label": "Accrued Research And Development Liabilities Current", "terseLabel": "Accrued research and development liabilities", "auth_ref": "1", "bbio:AccruedResearchAndDevelopmentLiabilitiesMember": "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccruedResearchAndDevelopmentLiabilitiesMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestr", "lang": "en-us", "role": "documentation": "Accrued research and development liabilities", "label": "Accrued Research and Development Liabilities [Member]", "terseLabel": "Accrued Research and Development Liabilities", "auth_ref": "1", "bbio:AccruedTerminationCharges": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AccruedTerminationCharges", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Accrued termination charges", "label": "Accrued Termination Charges", "terseLabel": "Accrued termination charges", "auth_ref": "1", "bbio:AccruedExitFeesForResearchAndDevelopment": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role:StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "Accumulated Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source", "auth_ref": "20", "21", "22", "202", "229", "269", "273", "us-gaap:AccumulatedOtherComprehensiveIncomeMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited", "lang": "en-us", "role": "label", "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners", "auth_ref": "4", "13", "21", "57

[illegible]

```

"domainItemType": "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "terseLabel": "All Trading Arrangements", "auth_ref": "1043", "us-gaap": "AllocatedShareBasedCompensationExpense", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationAdditionalInformationDetails", "bridgebio.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAward": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails", "lang": "en-us", "role": "label", "Share-Based Payment Arrangement Expense": "terseLabel": "Total stock-based compensation", "verboseLabel": "Stock-based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "auth_ref": "508", "r518", "bbio-AllocationOfTransactionPriceForResearchAndDevelopment": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AllocationOfTransactionPriceForResearchAndDevelopment", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Allocation of transaction price for research and development": "label": "Allocation Of Transaction Price For Research And Development", "documentation": "Allocation Of Transaction Price For Research And Development", "auth_ref": "bbio-AllocationOfTransactionPriceToLicenses": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AllocationOfTransactionPriceToLicenses", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "Allocation of transaction price to licenses": "label": "Allocation Of Transaction Price To Licenses", "terseLabel": "Allocation of transaction price to licenses", "auth_ref": "bbio-AllocationOfTransactionPriceToTransferOfExistingInventory": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AllocationOfTransactionPriceToTransferOfExistingInventory", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "Allocation of transaction price to transfer of existing inventory": "label": "Allocation Of Transaction Price To Transfer Of Existing Inventory", "terseLabel": "Allocation of transaction price to transfer of certain existing inventory", "auth_ref": "us-gaap-AllowanceForDoubtfulAccountsReceivable": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance", "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable.", "auth_ref": "r203", "r295", "r344", "r347", "r348", "r1238", "def-AmendmentFlag": "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DocumentsAndEntityInformation", "lang": "en-us", "role": "label", "Amendment Flag", "verboseLabel": "Amendment Flag", "terseLabel": "Amendment", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission.", "auth_ref": "us-gaap-AmortizationOfFinancingCostsAndDiscounts": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails", "bridgebio.com/20240630/taxonomy/role/Role-DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails": "lang": "en-us", "role": "label", "Amortization of Debt Issuance Costs and Discounts": "terseLabel": "Amortization of debt discount and issuance costs", "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "auth_ref": "r434", "r910", "r911", "r1101", "r1218", "us-gaap-AmortizationOfIntangibleAssets": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Amortization of Intangible Assets": "totalLabel": "Amortization of Intangible Assets, Total", "verboseLabel": "Amortization expenses", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "auth_ref": "r9", "r360", "r366", "r905", "bbio-AmountPaidToLenders": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AmountPaidToLenders", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel": "Amount paid to lenders", "label": "Amount paid to Lenders", "documentation": "Amount paid to lenders.", "auth_ref": "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails", "lang": "en-us", "role": "label", "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount": "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "auth_ref": "r268", "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails", "lang": "en-us", "role": "label", "Antidilutive Securities [Axis]": "terseLabel": "Antidilutive Securities", "documentation": "Information by type of antidilutive security.", "auth_ref": "r32", "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails", "lang": "en-us", "role": "label", "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]": "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "us-gaap-AntidilutiveSecuritiesNameDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails", "lang": "en-us", "role": "label", "Antidilutive Securities, Name [Domain]": "terseLabel": "Antidilutive Securities, Name", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "auth_ref": "r32", "us-gaap-ArrangementsAndNonarrangementTransactionsMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderFinancingAgreementDetails": "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails": "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFundingAgreementAdditionalInformationDetails": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIndicencingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureDebtAdditionalInformationDetails": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureDebtTables": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureEidosAdditionalInformationDetails": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureLeasesAdditionalInformationDetails": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": "en-us", "role": "label", "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]": "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "auth_ref": "r559", "bbio-AspaTherapeuticsIncAndAdrenasTherapeuticsIncMember": "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AspaTherapeuticsIncAndAdrenasTherapeuticsIncMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIndicencingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "role": "documentation": "Aspa Therapeutics, Inc. and Adrenas Therapeutics, Inc.", "label": "Aspa Therapeutics, Inc. and Adrenas Therapeutics Inc. [Member]", "verboseLabel": "Aspa and Adrenas", "auth_ref": "bbio-AspaTherapeuticsIncMember": "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AspaTherapeuticsIncMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIndicencingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "role": "documentation": "Aspa Therapeutics Inc.", "label": "Aspa Therapeutics Inc. [Member]", "auth_ref": "us-gaap-AssetAcquisitionLineItems": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionLineItems", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Asset Acquisition [Line Items]": "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r1202", "us-gaap-AssetAcquisitionTable": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Asset Acquisition [Table]": "documentation": "Disclosure of information about asset acquisition.", "auth_ref": "r1202", "us-gaap-Assets": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit.", "auth_ref": "r13
```

```

"xbriType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "AssetsCurrentAbstract", "terseLabel": "Current assets", "auth_ref": "r52", "r53", "r925", "us-gaap AssetsFairValueDisclosure", "xbriType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "lang": "en-us", "role": "label", "AssetsFairValueDisclosure", "totalLabel": "Total financial assets", "documentation": "Fair value portion of asset recognized for present right to economic benefit", "auth_ref": "r52", "r53", "r925", "us-gaap AssetsFairValueDisclosureAbstract", "xbriType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "lang": "en-us", "role": "label", "AssetsFairValueDisclosureAbstract", "terseLabel": "Assets", "auth_ref": "r52", "r53", "r925", "us-gaap AssetsFairValueDisclosureAbstract", "xbriType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AssumedConversionOfTwoThousandTwentyNineNotesMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails", "lang": "en-us", "role": "label", "AssumedConversionOfTwoThousandTwentyNineNotesMember", "documentation": "Assumed conversion of two thousand twenty nine notes", "label": "Assumed Conversion Of Two Thousand Twenty Nine Notes [Member]", "terseLabel": "Assumed Conversion of 2029 Notes", "auth_ref": "r52", "r53", "r925", "us-gaap AssetsFairValueDisclosureAbstract", "xbriType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AssumedConversionOfTwoThousandTwentySevenNotesMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails", "lang": "en-us", "role": "label", "AssumedConversionOfTwoThousandTwentySevenNotesMember", "documentation": "Assumed conversion of two thousand twenty seven notes", "label": "Assumed Conversion Of Two Thousand Twenty Seven Notes [Member]", "terseLabel": "Assumed Conversion of 2027 Notes", "auth_ref": "r52", "r53", "r925", "us-gaap AssetsFairValueDisclosureAbstract", "xbriType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AtTheMarketOfferingMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails", "lang": "en-us", "role": "label", "AtTheMarketOfferingMember", "documentation": "At-the-market offerings", "label": "At The Market Offering [Member]", "terseLabel": "At-the-Market Offerings", "auth_ref": "r52", "r53", "r925", "us-gaap AssetsFairValueDisclosureAbstract", "xbriType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "AtmOfferingMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails", "lang": "en-us", "role": "label", "AtmOfferingMember", "documentation": "Atm Offering", "label": "ATM Offering Member", "terseLabel": "ATM Offering", "auth_ref": "r52", "r53", "r925", "us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "xbriType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSale", "lang": "en-us", "role": "label", "Debt Securities, Available for Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)", "auth_ref": "r301", "r302", "us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "xbriType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSale", "lang": "en-us", "role": "label", "Debt Securities, Available for Sale, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)", "auth_ref": "r302", "r303", "us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis", "xbriType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSale", "lang": "en-us", "role": "label", "Debt Securities, Available for Sale, Amortized Cost", "totalLabel": "Amortized Cost Basis", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)", "auth_ref": "r298", "r352", "r723", "us-gaap AvailableForSaleSecuritiesAbstract", "xbriType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesAbstract", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "lang": "en-us", "role": "label", "Debt Securities, Available for Sale [Abstract]", "terseLabel": "Marketable securities", "auth_ref": "r52", "r53", "r925", "us-gaap AvailableForSaleSecuritiesDebtSecurities", "xbriType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSale", "lang": "en-us", "role": "label", "Debt Securities, Available for Sale", "terseLabel": "Estimated Fair Value", "totalLabel": "Debt Securities, Available for Sale, Total", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)", "auth_ref": "r299", "r352", "r592", "r715", "r925", "r929", "r123", "r1210", "r1211", "r1212", "us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent", "xbriType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "lang": "en-us", "role": "label", "Debt Securities, Available for Sale, Current, Total", "label": "Debt Securities, Available for Sale, Current", "terseLabel": "Total marketable securities", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale, classified as current)", "auth_ref": "r296", "r352", "r592", "r715", "r925", "r929", "r123", "r1210", "r1211", "r1212", "us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent", "xbriType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "lang": "en-us", "role": "label", "AwardExercisePrice", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "Award Exercise Price", "terseLabel": "Exercise Price", "auth_ref": "r1040", "r1041", "ecd AwardGrantDateFairValue", "xbriType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date", "auth_ref": "r1041", "r1042", "ecd AwardTmgDiscLineItems", "xbriType": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": "en-us", "role": "label", "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures", "auth_ref": "r1036", "r1037", "ecd AwardTmgHowMnpiCnsdrdTextBlock", "xbriType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered", "auth_ref": "r1036", "r1037", "ecd AwardTmgMethodTextBlock", "xbriType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method", "auth_ref": "r1036", "r1037", "ecd AwardTmgMnpiCnsdrdFlag", "xbriType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered", "auth_ref": "r1036", "r1037", "ecd AwardTmgMnpiDiscTextBlock", "xbriType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure", "auth_ref": "r1036", "r1037", "ecd AwardTmgPredtrmdFlag", "xbriType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmdFlag", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined", "auth_ref": "r1036", "r1037", "us-gaap AwardTypeAxis", "xbriType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "lang": "en-us", "role": "label", "Balance Sheet Location Axis", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights", "lang": "en-us", "role": "label", "Balance Sheet Location", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": "en-us", "role": "label", "Balance Sheet Location", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAward", "lang": "en-us", "role": "label", "Balance Sheet Location", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "lang": "en-us", "role": "label", "Balance Sheet Location", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationTables", "lang": "en-us", "role": "label", "Balance Sheet Location", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuring", "lang": "en-us", "role": "label", "Balance Sheet Location", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuring", "lang": "en-us", "role": "label", "Balance Sheet Location", "presentation": "http://bridgebio.com/2024
```


http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails1", "lang": "en-us", "role": "documentation", "Base rate plus interest", "label": "Base Rate plus Interest [Member]", "terseLabel": "Base Rate plus Interest", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails1", "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails1", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails1", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "lang": "en-us", "role": "label", "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Principles of Consolidation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "bbio_BayerConsumerCareAgAndKyowaKirinCoLtdMember": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails1", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails1", "BayerConsumerCareAgAndKyowaKirinCoLtdMember": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "lang": "en-us", "role": "terseLabel": "Bayer Consumer Care AG and Kyowa Kirin Co., Ltd.", "label": "Bayer Consumer Care AG and Kyowa Kirin Co., Ltd. [Member]", "documentation": "Bayer consumer care AG and kyowa kirin Co., Ltd.", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "bbio_BayerExclusiveLicenseAgreementMember": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "BayerExclusiveLicenseAgreementMember": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "lang": "en-us", "role": "documentation", "Bayer Exclusive License Agreement", "label": "Bayer Exclusive License Agreement [Member]", "terseLabel": "Bayer Exclusive License Agreement", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "bbio_BridgeBioOncologyTherapeuticsMember": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "BridgeBioOncologyTherapeuticsMember": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "lang": "en-us", "role": "documentation", "Bridge Bio Oncology Therapeutics", "label": "Bridge Bio Oncology Therapeutics [Member]", "terseLabel": "Bridge Bio Oncology Therapeutics", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "bbio_BridgeBioPharmaLimitedLiabilityCompanyMember": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "BridgeBioPharmaLimitedLiabilityCompanyMember": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "BMS": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "lang": "en-us", "role": "documentation", "Bridge Bio Pharma Limited Liability Company", "label": "Bridge Bio Pharma Limited Liability Company [Member]", "terseLabel": "Bridge Bio Pharma Limited Liability Company", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "bbio_BridgeBioServicesIncMember": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "BridgeBioServicesIncMember": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "lang": "en-us", "role": "documentation", "Bridge Bio Services, Inc.", "label": "Bridge Bio Services Inc [Member]", "terseLabel": "Bridge Bio Equity Plan", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "bbio_BristolMyersSquibbCompanyMember": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "BristolMyersSquibbCompanyMember": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "BMS": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "label": "Bristol Myers Squibb Company [Member]", "documentation": "Bristol Myers Squibb Company", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "bbio_BusinessAcquisitionCashPerShare": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "xbrltype": "perShareItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "BusinessAcquisitionCashPerShare": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "lang": "en-us", "role": "documentation", "Business acquisition cash per share", "label": "Business Acquisition Cash Per Share", "terseLabel": "Cash per share in transaction", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "bbio_BusinessAcquisitionCommonShare": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "xbrltype": "sharesItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "BusinessAcquisitionCommonShare": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "lang": "en-us", "role": "documentation", "Business acquisition common share", "label": "Business Acquisition Common Share", "terseLabel": "Right to receive of common stock", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "bbio_BusinessAcquisitionEquityInterestsIssuedOrIssuableFairValue": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "BusinessAcquisitionEquityInterestsIssuedOrIssuableFairValue": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "lang": "en-us", "role": "documentation", "Business acquisition equity interests issued or issuable fair value", "label": "Business Acquisition Equity Interests Issued Or Issuable Fair Value", "terseLabel": "Total fair value", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "us-gaap_BusinessCombinationConsiderationTransferred": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "BusinessCombinationConsiderationTransferred": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "lang": "en-us", "role": "label", "Business Combination, Consideration Transferred", "terseLabel": "Aggregate consideration", "totalLabel": "Business Combination, Consideration Transferred, Total", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "bbio_BusinessCombinationPotentialCashConsideration": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "BusinessCombinationPotentialCashConsideration": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "lang": "en-us", "role": "documentation", "Business combination potential cash consideration", "label": "Business Combination Potential Cash Consideration", "terseLabel": "Cash consideration", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "us-gaap_BusinessExitCosts": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "BusinessExitCosts": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "lang": "en-us", "role": "label", "Business Exit Costs", "terseLabel": "Winding down, exit and other related costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation", "auth_ref": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails1", "

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities", "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Cash Equivalents and Marketable Securities", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "auth_ref": { "r122": { "bbio_CashCashEquivalentsAndRestrictedCashMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CashCashEquivalentsAndRestrictedCashMaturityPeriod", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and restricted cash maturity period", "label": "Cash Cash Equivalents And Restricted Cash Maturity Period", "documentation": "Cash cash equivalents and restricted cash maturity period.", "auth_ref": { "r1": { "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "totalLabel": "Total cash, cash equivalents and restricted cash at end of periods shown in the condensed consolidated statements of cash flows", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "auth_ref": { "r27": { "r107": { "r229": { "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash", "auth_ref": { "r1": { "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "auth_ref": { "r3": { "r107": { "bbio_CashEquivalentsAndMarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CashEquivalentsAndMarketableSecuritiesAbstract", "lang": { "en-us": { "role": { "documentation": "Cash equivalents and marketable securities.", "label": "Cash Equivalents And Marketable Securities [Abstract]", "auth_ref": { "r1": { "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvaila": "lang": { "en-us": { "role": { "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Amortized Cost Basis Cash Equivalents", "totalLabel": "Amortized Cost Basis Cash Equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "auth_ref": { "r108": { "r123": { "bbio_CashEquivalentsUnrealizedGains": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CashEquivalentsUnrealizedGains", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvaila": "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Cash Equivalents Unrealized Gains", "documentation": "Cash equivalents unrealized gains.", "auth_ref": { "r1": { "bbio_CashEquivalentsUnrealizedLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CashEquivalentsUnrealizedLosses", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvaila": "lang": { "en-us": { "role": { "documentation": "Cash Equivalents Unrealized Losses", "label": "Cash Equivalents Unrealized Losses", "negatedLabel": "Unrealized Losses", "terseLabel": "Unrealized Losses", "auth_ref": { "r1": { "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities.", "auth_ref": { "r1": { "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "auth_ref": { "r191": { "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote", "auth_ref": { "r1016": { "bbio_ChildrenIntendedForTreatmentWithCanavanDiseaseMaximumAge": { "xbrltype": "durationItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ChildrenIntendedForTreatmentWithCanavanDiseaseMaximumAge", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureIncensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails": "lang": { "en-us": { "role": { "documentation": "Children intended for treatment with canavan disease maximum age.", "label": "Children Intended For Treatment With Canavan Disease Maximum Age", "verboseLabel": "Children intended for treatment with Canavan Disease, under the age.", "auth_ref": { "r1": { "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstDnCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstDnCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "auth_ref": { "r1013": { "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "lang": { "en-us": { "role": { "label": "Year-over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "auth_ref": { "r1011": { "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation": "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city", "auth_ref": { "r1": { "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudite": "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "auth_ref": { "r162": { "r199": { "r200": { "r201": { "r233": { "r261": { "r262": { "r265": { "r267": { "r274": { "r275": { "r333": { "r403": { "r405": { "r406": { "r407": { "r410": { "r411": { "r445": { "r446": { "r449": { "r452": { "r459": { "r617": { "r776": { "r777": { "r778": { "r779": { "r784": { "r785": { "r786": { "r787": { "r788": { "r789": { "r790": { "r791": { "r792": { "r793": { "r794": { "r795": { "r811": { "r832": { "r851": { "r876": { "r877": { "r878": { "r879": { "r880": { "r1055": { "r1103": { "r1115": { "bbio_CloseOutPlanCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CloseOutPlanCosts", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": "lang": { "en-us": { "role": { "terseLabel": "Close-out plan costs", "label": "Close-Out Plan Costs", "documentation": "Close-out plan costs.", "auth_ref": { "r1": { "bbio_CloseOutPlanCostsSubjectToReimbursement": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CloseOutPlanCostsSubjectToReimbursement", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": "lang": { "en-us": { "role": { "terseLabel": "Close-out plan costs subject to reimbursement", "label": "Close-Out Plan Costs Subject To Reimbursement", "documentation": "Close-out plan costs subject to reimbursement.", "auth_ref": { "r1": { "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount", "auth_ref": { "r1017": { "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name", "auth_ref": { "r1017": { "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureIncensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative Line Items", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": { "r539": { "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "auth_ref": { "r119": { "r402": { "r962": { "r963": { "r964": { "r965": { "bbio_CommercialProductSupplyMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CommercialProductSupplyMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": "lang": { "en-us": { "role": { "terseLabel": "Commercial Product Supply", "label": "Commercial Product Supply [Member]", "documentation": "Commercial product supply.", "auth_ref": { "r1":

"bbio_CommissionsOnGrossProceedsOfSalesOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CommissionsOnGrossProceedsOfSalesOfCommonStock", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Commissions on gross proceeds of sales of common stock", "verboseLabel": "Commissions on gross proceeds of sales of common stock" } } }, "auth_ref": { "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 8)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r83", "r141", "r726", "r810" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure Abstract" } } }, "auth_ref": { "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies": { "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": { "r117", "r395", "r396", "r883", "r1139", "r147" } }, "bbio_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CommitmentsAndContingenciesLineItems", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Commitments and Contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "auth_ref": { "bbio_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CommitmentsAndContingenciesTable", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Commitments and Contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "auth_ref": { "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Common Stock Capital Shares Reserved for Future Issuance", "terseLabel": "Common shares reserved for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": { "r86" } }, "bbio_CommonStockHeld": { "xbrltype": "sharesItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CommonStockHeld", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Common Stock Held", "label": "Common Stock Held", "terseLabel": "Common stock held" } } }, "auth_ref": { "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails1": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited": { "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r958", "r959", "r960", "r962", "r963", "r964", "r965", "r1109", "r1110", "r1114", "r1205", "r1272", "r1273" } }, "bbio_CommonStockOptionsIssuedAndOutstandingMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CommonStockOptionsIssuedAndOutstandingMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails": { "lang": { "en-us": { "role": { "documentation": "Common stock options issued and outstanding.", "label": "Common Stock Options Issued And Outstanding [Member]", "terseLabel": "Common Stock Options Issued and Outstanding" } } }, "auth_ref": { "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "label": "Common Stock Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock" } } }, "auth_ref": { "r86" } }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r86", "r811" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r86" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r14", "r86", "r811", "r829", "r86", "r1273", "r1274" } }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, 50,001 par value; 500,000,000 shares authorized; 194,224,499 shares issued and 188,032,738 shares outstanding as of June 30, 2024; 181,274,712 shares issued and 175,082,951 shares outstanding as of December 31, 2023", "label": "Common Stock, Value, Issued, Total", "totalLabel": "Common Stock, Value, Issued, Total", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r86", "r728", "r938" } }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": { "r1022" } }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": { "r1021" } }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": { "r1023" } }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": { "r1020" } }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to common stockholders of BridgeBio", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r22", "r208", "r210", "r217", "r718", "r742", "r744" } }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total", "verboseLabel": "Comprehensive loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests", "terseLabel": "Comprehensive loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r6", "r54", "r65", "r208", "r210", "r216", "r717", "r742", "r743" } }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r65", "r131", "r208", "r210", "r215", "r716", "r742" } }, "bbio_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties", "label": "Concentration Of Credit Risk And Other Risks And Uncertainties Policy [Text Block]", "documentation": "Concentration of credit risk and other risks and uncertainties." } } }, "auth_ref": { "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureInLicensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails1": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": {

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" }, {"lang": "en-us", "role": "label",
"Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities", "documentation": "Information by consolidated entity or group of entities." }, {"auth_ref": "r163",
"r175", "r238", "r561", "r562", "r565", "r566", "r660", "r884", "r1075", "r1076", "r1077", "r1152", "r1155", "r1156" }, {"srt_ConsolidatedEntitiesDomain": "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/DisclosureInLicensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails1",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" }, {"lang": "en-us", "role": "label",
"Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities", "documentation": "Entity or group of entities consolidated into reporting entity." }, {"auth_ref": "r163",
"r175", "r238", "r561", "r562", "r565", "r566", "r660", "r884", "r1075", "r1076", "r1077", "r1152", "r1155", "r1156" }, {"us-gaap_ConstructionInProgressMember": "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "documentation": "Construction in Progress
[Member]", "terseLabel": "Construction-in-Progress", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures
or modifications to structures that have not been placed into service." }, {"auth_ref": " "}, {"us-gaap_ContingentConsiderationByTypeAxis": "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationByTypeAxis", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "documentation": "Contingent Consideration by
Type [Axis]", "terseLabel": "Contingent Consideration by Type", "documentation": "Information by type of contingent consideration." }, {"auth_ref": " "}, {"us-gaap_ContingentConsiderationTypeDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain",
"presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "documentation": "Contingent
Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type", "documentation": "Description of contingent payment arrangement." }, {"auth_ref": " "}, {"us-gaap_ContractualObligation": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligation", "crdr": "credit", "presentation":
" "}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" }, {"lang": "en-us", "role": "label",
"Contractual Obligation", "totalLabel": "Total future payments", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease
obligation, purchase obligation, and other commitments." }, {"auth_ref": "r1107" }, {"bbio_ContractualObligationDueAfterFourthYear": "xbrltype": "monetaryItemType",
"nsuri": "http://bridgebio.com/20240630", "localname": "ContractualObligationDueAfterFourthYear", "crdr": "credit", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" }, {"lang": "en-us", "role": "label",
"Contractual obligation due after fourth year", "label": "Contractual Obligation Due After Fourth Year", "terseLabel": "Thereafter" }, {"auth_ref": " "}, {"us-gaap_ContractualObligationDueInFifthYear": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligationDueInFifthYear",
"crdr": "credit", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails" }, {"lang": "en-us", "role": "label",
"Contractual Obligation, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current
fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." }, {"auth_ref": " "}, {"us-gaap_ContractualObligationDueInNextTwelveMonths": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractualObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" }, {"lang": "en-us", "role": "label",
"Contractual Obligation, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal
year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." }, {"auth_ref": " "}, {"us-gaap_ContractualObligationDueInSecondYear": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractualObligationDueInSecondYear", "crdr": "credit", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" }, {"lang": "en-us", "role": "label",
"Contractual Obligation, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of contractual obligation to be paid in second fiscal year following current
fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." }, {"auth_ref": " "}, {"us-gaap_ContractualObligationDueInThirdYear": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractualObligationDueInThirdYear", "crdr": "credit", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" }, {"lang": "en-us", "role": "label",
"Contractual Obligation, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of contractual obligation to be paid in third fiscal year following current
fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." }, {"auth_ref": " "}, {"srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtTables" }, {"lang": "en-us", "role": "label",
"Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Payments", "documentation":
"Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." }, {"auth_ref": "r1074", "r1108" }, {"us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear": "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "crdr": "credit", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" }, {"lang": "en-us", "role": "label",
"Contractual Obligation, to be Paid, Remainder of Fiscal Year", "verboseLabel": "2022", "terseLabel": "Remainder of 2024", "documentation": "Amount of contractual
obligation to be paid in remainder of current fiscal year." }, {"auth_ref": " "}, {"bbio_ContractualObligationInterestPortion": "xbrltype": "monetaryItemType", "nsuri":
"http://bridgebio.com/20240630", "localname": "ContractualObligationInterestPortion", "crdr": "debit", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" }, {"lang": "en-us", "role": "label",
"Contractual obligation interest portion", "label": "Contractual Obligation Interest Portion", "negatedLabel": "Less amounts representing interest" }, {"auth_ref": " "}, {"us-gaap_ConvertibleLongTermNotesPayable": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleLongTermNotesPayable",
"crdr": "credit", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails" }, {"lang": "en-us", "role": "label",
"role": "totalLabel": "Net carrying amount", "terseLabel": "Notes, net", "label": "Convertible Notes Payable, Noncurrent", "documentation": "Carrying value as of the balance
sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current
portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer
and the holder." }, {"auth_ref": "r19", "r233", "r333", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r617", "r901", "r1153" }, {"bbio_CostRelatedToManufacturingSuiteAndAdditionalEquipment": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname":
"CostRelatedToManufacturingSuiteAndAdditionalEquipment", "crdr": "debit", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" }, {"lang": "en-us", "role": "label",
"Cost related to manufacturing suite and additional equipment", "label": "Cost Related to Manufacturing Suite and Additional Equipment", "terseLabel": "Cost related to manufacturing suite
and additional equipment" }, {"auth_ref": " "}, {"bbio_CostSharingCreditOfTheLessorOffFixedPercentageOfCertainAgreedUponServiceCosts": "xbrltype":
"monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "CostSharingCreditOfTheLessorOffFixedPercentageOfCertainAgreedUponServiceCosts", "crdr":
"debit", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureInLicensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label",
"Cost sharing credit of the lesser of fixed percentage of certain agreed upon service costs", "label": "Cost Sharing Credit Of The
Lessor Of Fixed Percentage Of Certain Agreed Upon Service Costs", "verboseLabel": "Cost sharing credit of the lesser of a fixed percentage of certain agreed upon service
costs" }, {"auth_ref": " "}, {"bbio_CostSharingCreditsReceived": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname":
"CostSharingCreditsReceived", "crdr": "credit", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureInLicensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label",
"Cost sharing credits received", "label": "Cost Sharing Credits Received", "verboseLabel": "Cost sharing credits received" }, {"auth_ref": " "}, {"us-gaap_CostsAndExpenses": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" }, {"lang": "en-us", "role": "label",
"Costs and Expenses", "totalLabel": "Total operating costs and expenses", "documentation": "Total costs of sales and operating expenses for the period." }, {"auth_ref": "r102" }, {"us-gaap_CostsAndExpensesAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": " "}, {"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" }, {"lang": "en-us", "role": "label",
"Costs and Expenses [Abstract]", "terseLabel": "Operating costs and expenses" }, {"auth_ref": " "}, {"srt_CounterpartyNameAxis": "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": " "}

```
"http://bridgebio.com/20240630/taxonomy/role/DisclosureIncensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails",  
"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails",  
"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",  
"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",  
"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Counterparty Name [Axis]",  
"terseLabel": "Counterparty Name", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."}}, "auth_ref": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}, {"debt_CoverAbstract": {"xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": {"en-us": {"role": {"label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page."}}}, "auth_ref": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}, {"debt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": {"xbrlType": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}, {"debt_StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited": {"lang": {"en-us": {"role": {"label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance", "documentation": "Represents amount after cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards."}}}, "auth_ref": [{"r1062": "r1079", "r1112": "r1132", "r1133", "r1137", "r1193", "r1194", "r1200", "r1201", "r1204", "r1205", "r1206", "r1223"}]}, {"debt_CumulativeEffectPeriodOfAdoptionAxis": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionAxis", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited": {"lang": {"en-us": {"role": {"label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption", "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards."}}}, "auth_ref": [{"r179": "r184", "r242": "r249", "r256", "r337", "r343", "r373", "r531", "r532", "r545", "r547", "r570", "r572", "r573", "r575", "r576", "r577", "r583", "r586", "r588", "r589", "r654"}]}, {"debt_CumulativeEffectPeriodOfAdoptionDomain": {"xbrlType": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionDomain", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited": {"lang": {"en-us": {"role": {"label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption", "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards."}}}, "auth_ref": [{"r179": "r184", "r242": "r249", "r256", "r337", "r343", "r373", "r531", "r532", "r545", "r547", "r570", "r572", "r573", "r575", "r576", "r577", "r583", "r586", "r588", "r589", "r654"}]}, {"debt_CurrentFiscalYearEndDate": {"xbrlType": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtDisclosureDocumentAndEntityInformation": {"lang": {"en-us": {"role": {"label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD-."}}}, "auth_ref": [{"r179": "r184", "r242": "r249", "r256", "r337", "r343", "r373", "r531", "r532", "r545", "r547", "r570", "r572", "r573", "r575", "r576", "r577", "r583", "r586", "r588", "r589", "r654"}]}, {"debt_DebtDisclosureTextBlock": {"xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}, {"debt_DebtInstrumentAccruedInterestConvertibleIntoPrincipal": {"xbrlType": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebt", "lang": {"en-us": {"role": {"label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."}}}, "auth_ref": [{"r118": "r231", "r376": "r377", "r378", "r379", "r380", "r401", "r402", "r412", "r418", "r419", "r420", "r421", "r422", "r423", "r428", "r435", "r436", "r438", "r627"}]}, {"debt_DebtInstrumentAccruedInterestConvertibleIntoPrincipal": {"xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentAccruedInterestConvertibleIntoPrincipal", "crdr": "debit", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentAmortizationPaymentDate": {"xbrlType": "dateItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentAmortizationPaymentDate", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentCappedCallTransactionCapPricePerShare": {"xbrlType": "perShareItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentCappedCallTransactionCapPricePerShare", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentCarryingAmount": {"xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentConvertibleConversionPrice": {"xbrlType": "perShareItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentConvertibleConversionPrice", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentConvertibleIncreaseInConversionRateNumberOfCommonStockIssuable": {"xbrlType": "integerItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentConvertibleIncreaseInConversionRateNumberOfCommonStockIssuable", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentConvertibleThresholdBusinessDays": {"xbrlType": "durationItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentConvertibleThresholdBusinessDays", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod": {"xbrlType": "durationItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod": {"xbrlType": "integerItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {"xbrlType": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {"xbrlType": "thresholdPercentageOfStockPriceTrigger", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {"xbrlType": "minimumPercentageOfCommonStockPriceToConversionPriceOfConvertibleDebtInstrumentsToDetermineEligibilityOfConversion", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentConvertibleThresholdTradingDays": {"xbrlType": "integerItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [{"r176": "r177", "r236": "r237", "r416": "r447", "r659": "r683", "r722": "r894", "r896"}]}}, {"debt_DebtInstrumentConvertibleThresholdTradingDays": {"xbrlType": "thresholdTradingDays", "nsuri": "http://bridgebio.com/20240
```



```

http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt Instrument, Date of First Required Payment", "terseLabel": "Interest payable beginning date", "documentation": "Date the debt agreement requires the first payment to be made, in YYYY-MM-DD format."}}}, "auth_ref": {"r19": "r70"}}, {"bbio_DebtInstrumentDepositPercentageOfProceedsNetOfCertainPermittedCostsUponReceiptOfUpfrontPaymentsFromLicenseAgreements": {"xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentDepositPercentageOfProceedsNetOfCertainPermittedCostsUponReceiptOfUpfrontPaymentsFromLicenseAgreements", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt instrument deposit percentage of proceeds net of certain permitted costs upon receipt of upfront payments from license agreements.", "label": "Debt instrument deposit percentage of proceeds net of certain permitted costs upon receipt of upfront payments from license agreements", "terseLabel": "Debt instrument deposit percentage of proceeds net of certain permitted costs upon receipt of upfront payments from license agreements"}}, "auth_ref": {"r19": "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt instrument, Description of Variable Rate Basis", "terseLabel": "Interest rate description", "documentation": "Description of reference rate used for variable rate of debt instrument."}}}, "auth_ref": {"r19": "us-gaap_DebtInstrumentFaceAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"}, "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument face amount", "verboseLabel": "Principal value", "documentation": "Face (par) amount of debt instrument at time of issuance."}}}, "auth_ref": {"r413": "r627", "r628", "r908", "r909", "r936"}}, "us-gaap_DebtInstrumentFeeAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt Instrument, Fee Amount", "terseLabel": "Transaction-related fees", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."}}}, "auth_ref": {"r80"}}, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Debt instrument frequency of interest payment", "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."}}, "auth_ref": {"r19": "r70"}}, "bbio_DebtInstrumentInterestOnlyExtensionDate": {"xbrltype": "dateItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentInterestOnlyExtensionDate", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt instrument interest only extension date.", "label": "Debt instrument interest only extension date", "terseLabel": "Debt instrument interest only extension date"}}, "auth_ref": {"r19": "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails"}], "lang": {"en-us": {"role": {"label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."}}}, "auth_ref": {"r77", "r442", "r627", "r628", "r936"}}, "us-gaap_DebtInstrumentInterestRateStatedPercentage": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"}, "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."}}}, "auth_ref": {"r77", "r414"}}, "us-gaap_DebtInstrumentLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails"}}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderFinancingAgreementDetails": {"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails": {"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtTables"}], "lang": {"en-us": {"role": {"label": "Debt Instrument [Line Items]", "terseLabel": "Debt instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, "auth_ref": {"r238", "r413", "r414", "r415", "r416", "r417", "r419", "r424", "r425", "r426", "r427", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r907", "r908", "r909", "r910", "r911", "r936", "r1104", "r1217", "r1219"}}, {"bbio_DebtInstrumentMandatoryPrepaymentsPercentageOfNetCashProceedsFromPrepaymentEventTransaction": {"xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentMandatoryPrepaymentsPercentageOfNetCashProceedsFromPrepaymentEventTransaction", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}, {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt instrument mandatory prepayments percentage of net cash proceeds from prepayment event transaction.", "label": "Debt instrument mandatory prepayments percentage of net cash proceeds from prepayment event transaction", "terseLabel": "Debt instrument mandatory prepayments percentage of net cash proceeds from prepayment event transaction"}}, "auth_ref": {"r19": "bbio_DebtInstrumentMarketCapitalizationAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentMarketCapitalizationAmount", "crdr": "credit", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt instrument market capitalization amount.", "label": "Debt instrument market capitalization amount", "terseLabel": "Market capitalization amount"}}, "auth_ref": {"r19": "us-gaap_DebtInstrumentMaturityDate": {"xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."}}}, "auth_ref": {"r197", "r907", "r1211", "r1212"}}, "bbio_DebtInstrumentMaturityDateExtension": {"xbrltype": "dateItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentMaturityDateExtension", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt instrument maturity date extension.", "label": "Debt instrument maturity date extension", "terseLabel": "Debt instrument maturity date extension"}}, "auth_ref": {"r19": "bbio_DebtInstrumentMinimumUnrestrictedCash": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentMinimumUnrestrictedCash", "crdr": "debit", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt instrument minimum unrestricted cash.", "label": "Debt instrument minimum unrestricted cash", "terseLabel": "Minimum unrestricted cash balance"}}, "auth_ref": {"r19": "us-gaap_DebtInstrumentNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"}, {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtTables": {"http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"}], "lang": {"en-us": {"role": {"label": "Debt Instrument, Name (Domain)", "terseLabel": "Debt instrument, Name", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."}}}, "auth_ref": {"r19": "r238", "r413", "r414", "r415", "r416", "r417", "r419", "r424", "r425", "r426", "r427", "r429", "r430", "r431", "r432", "r433", "r434", "r907", "r908", "r909", "r910", "r911", "r936", "r1104", "r1140", "r1141", "r1142", "r1217", "r1219"}}, {"bbio_DebtInstrumentNetLeverageRatio": {"xbrltype": "pureItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentNetLeverageRatio", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt instrument net leverage ratio.", "label": "Debt instrument Net Leverage Ratio", "terseLabel": "Net leverage ratio"}}, "auth_ref": {"r19": "us-gaap_DebtInstrumentOfferingDate": {"xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentOfferingDate", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt Instrument, Offering Date", "terseLabel": "Debt instrument issuance date", "documentation": "Date the debt instrument was offered for sale, in YYYY-MM-DD format."}}}, "auth_ref": {"r19": "r42"}}, {"bbio_DebtInstrumentOptionToPurchaseAdditionalNotes": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentOptionToPurchaseAdditionalNotes", "crdr": "credit", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"label": "Debt instrument option to purchase additional notes.", "label": "Debt instrument Option To Purchase Additional Notes", "terseLabel": "Proceeds from exercise of option to purchase additional notes"}}, "auth_ref": {"r19": "bbio_DebtInstrumentOptionToPurchaseAdditionalNotesExercised": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentOptionToPurchaseAdditionalNotesExercised", "crdr": "credit",
```

```

http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}}, {"lang": "en-us", "role": "documentation", "Debt instrument potential payment extended amortization date."}, {"label": "Debt Instrument Potential Payment Extended Amortization Date", "terselabel": "Debt instrument potential payment extended amortization date"} } } }, {"auth_ref": "I", "bbio_DebtInstrumentPrepaymentPercentage": {"xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentPrepaymentPercentage", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}}, {"lang": "en-us", "role": "documentation", "Debt instrument prepayment percentage."}, {"label": "Debt Instrument Prepayment Percentage", "terselabel": "Prepayment percentage"} } } }, {"auth_ref": "I", "bbio_DebtInstrumentPrepaymentPremiumPercentage": {"xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentPrepaymentPremiumPercentage", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}}, {"lang": "en-us", "role": "documentation", "Debt instrument prepayment premium percentage."}, {"label": "Debt Instrument Prepayment Premium Percentage", "terselabel": "Debt instrument prepayment premium percentage"} } } }, {"auth_ref": "I", "bbio_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}}, {"lang": "en-us", "role": "documentation", "Debt instrument principal amount denomination for conversion into common stock."}, {"label": "Debt Instrument Principal Amount Denomination For Conversion Into Common Stock", "terselabel": "Denomination of the principal amount of debt in consideration conversion of the notes"} } } }, {"auth_ref": "I", "us-gaap_DebtInstrumentRepaidPrincipal": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepaidPrincipal", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}}, {"lang": "en-us", "role": "label", "Debt Instrument, Repaid, Principal"}, {"terselabel": "Principal payments", "documentation": "Amount of principal of debt repaid." } } }, {"auth_ref": "r779", "us-gaap_DebtInstrumentTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails1"}, {"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderFinancingAgreementDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfOutstandingNotesBalancesDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtTables"}}, {"lang": "en-us", "role": "label", "Schedule of Long-Term Debt Instruments [Table]", "terselabel": "Debt Instrument Table", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, {"auth_ref": "r19", "r42", "r43", "r69", "r122", "r124", "r238", "r413", "r414", "r415", "r416", "r417", "r419", "r424", "r425", "r426", "r427", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r907", "r908", "r909", "r910", "r911", "r936", "r1104", "r1217", "r1219"}}, {"us-gaap_DebtInstrumentTerm": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}}, {"lang": "en-us", "role": "label", "Debt Instrument, Term", "terselabel": "Expected life of notes", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDnTnHnMns format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, {"auth_ref": "I", "bbio_DebtInstrumentTrancheFourMember": {"xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentTrancheFourMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}}, {"lang": "en-us", "role": "documentation", "Debt instrument tranche four."}, {"label": "Debt Instrument Tranche Four [Member]", "terselabel": "Tranche IV"} } } }, {"auth_ref": "I", "bbio_DebtInstrumentTrancheOneMember": {"xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentTrancheOneMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}}, {"lang": "en-us", "role": "documentation", "Debt instrument tranche one."}, {"label": "Debt Instrument Tranche One [Member]", "terselabel": "Tranche I"} } } }, {"auth_ref": "I", "bbio_DebtInstrumentTrancheThreeMember": {"xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentTrancheThreeMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}}, {"lang": "en-us", "role": "documentation", "Debt instrument tranche three."}, {"label": "Debt Instrument Tranche Three [Member]", "terselabel": "Tranche III"} } } }, {"auth_ref": "I", "bbio_DebtInstrumentTrancheTwoMember": {"xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentTrancheTwoMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}}, {"lang": "en-us", "role": "documentation", "Debt instrument tranche two."}, {"label": "Debt Instrument Tranche Two [Member]", "terselabel": "Tranche II"} } } }, {"auth_ref": "I", "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails"}}, {"lang": "en-us", "role": "label", "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt discount and issuance costs", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, {"auth_ref": "r424", "r440", "r626", "r627", "r628", "r908", "r909", "r936"}}, {"bbio_DebtInstrumentUnamortizedDiscountPremiumDebtIssuanceCostsAndExitFeesAccretion": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentUnamortizedDiscountPremiumDebtIssuanceCostsAndExitFeesAccretion", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderFinancingAgreementDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails"}}, {"lang": "en-us", "role": "label", "Debt discount, issuance costs and exit fee accretion", "label": "Debt Instrument Unamortized Discount Premium Debt Issuance Costs And Exit Fees Accretion", "documentation": "Debt instrument unamortized discount premium debt issuance costs and exit fees accretion." } } }, {"auth_ref": "I", "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}}, {"lang": "en-us", "role": "label", "Debt Instrument, Unused Borrowing Capacity, Amount", "terselabel": "Debt instrument, amount available to be drawn", "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date." } } }, {"auth_ref": "r80", "r401"}}, {"bbio_DebtInstrumentsMaturityYear": {"xbrltype": "gYearItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DebtInstrumentsMaturityYear", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}}, {"lang": "en-us", "role": "documentation", "Debt instruments maturity year."}, {"label": "Debt Instruments Maturity Year", "terselabel": "Maturity year"} } } }, {"auth_ref": "I", "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"}}, {"lang": "en-us", "role": "label", "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "terselabel": "Unpaid issuance costs", "verboseLabel": "Unpaid issuance costs associated with term loan under Financing Agreement", "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction." } } }, {"auth_ref": "r29", "r30", "r31"}}, {"us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"}}, {"lang": "en-us", "role": "label", "Debt Securities, Available for Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terselabel": "Available for sale securities, continuous unrealized loss position, more than 12 months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, {"auth_ref": "r151", "r354", "r904"}}, {"us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"}}, {"lang": "en-us", "role": "label", "Debt Securities, Available for Sale, Realized Gain (Loss), Total", "label": "Debt Securities, Available for Sale, Realized Gain (Loss)", "terselabel": "Realized gains or losses on available-for-sale securities", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)."} } } }, {"auth_ref": "r1125"}}, {"us-gaap_DeconsolidationGainOrLossAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeconsolidationGainOrLossAmount", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"}}, {"lang": "en-us", "role": "label", "Gain on deconsolidation of a subsidiary", "terselabel": "Gain from deconsolidation", "label": "Deconsolidation, Gain (Loss), Amount", "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer." } } }, {"auth_ref": "r56", "bbio_DecreaseInCashAndCashEquivalentsResultingFromDeconsolidationOfEntities": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DecreaseInCashAndCashEquivalentsResultingFromDeconsolidationOfEntities", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedCons
```

```

"uri": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Deferred Offering Costs", "verboseLabel": "Deferred issuance costs", "terseLabel": "Deferred offering costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "auth_ref": "r1334", "us_gaap_DeferredRevenue": "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "DeferredRevenue", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Deferred Revenue", "totalLabel": "Deferred Revenue, Total", "verboseLabel": "Deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "auth_ref": "r1087", "us_gaap_DeferredRevenueCurrent": "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Deferred Revenue, Current", "totalLabel": "Deferred Revenue, Current, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "auth_ref": "r1086", "us_gaap_DeferredRevenueNoncurrent": "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Deferred Revenue, Noncurrent", "totalLabel": "Deferred Revenue, Noncurrent, Total", "verboseLabel": "Deferred revenue, noncurrent", "label": "Deferred revenue, net of current portion", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "auth_ref": "r1087", "us_gaap_DeferredTaxLiabilities": "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Deferred Tax Liabilities, Net", "totalLabel": "Deferred tax liability, net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "auth_ref": "r1191", "bbio_DepositPercentageOfProceedsNetOfCertainPermittedCostsReceivedFromAssetSaleTransactionsIntoEscrowAccounts": "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DepositPercentageOfProceedsNetOfCertainPermittedCostsReceivedFromAssetSaleTransactionsIntoEscrowAccounts", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Deposit percentage of proceeds net of certain permitted costs received from asset sale transactions into escrow accounts", "documentation": "Deposit percentage of proceeds net of certain permitted costs received from asset sale transactions into escrow accounts.", "auth_ref": "r1190", "bbio_DepositedOfEscrowAccountReceipt": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DepositedOfEscrowAccountReceipt", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Deposited of escrow account receipt", "documentation": "Deposited of escrow account receipt.", "auth_ref": "r1190", "us_gaap_DepreciationDepletionAndAmortization": "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "terseLabel": "Depreciation, Depletion and Amortization", "totalLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "auth_ref": "r272", "r281", "r288", "r901", "r902", "bbio_DerecognitionOfCapitalizedFiniteLivedIntangibleAssetNet": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DerecognitionOfCapitalizedFiniteLivedIntangibleAssetNet", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Derecognition of capitalized finite lived intangible asset net.", "label": "Derecognition of Capitalized Finite Lived Intangible Asset Net", "terseLabel": "Derecognition of capitalized intangible asset net.", "auth_ref": "r1190", "bbio_DevelopmentAndManufacturingServicesAgreementMember": "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DevelopmentAndManufacturingServicesAgreementMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureInLicensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Development and Manufacturing Services Agreement", "label": "Development And Manufacturing Services Agreement [Member]", "terseLabel": "Resilience DMSAs", "auth_ref": "r1190", "bbio_DevelopmentAndRegulatoryMilestonePaymentsYetToBeReceived": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DevelopmentAndRegulatoryMilestonePaymentsYetToBeReceived", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Development and regulatory milestone payments yet to be received.", "label": "Development and regulatory milestone payments yet to be received", "auth_ref": "r1190", "bbio_DevelopmentMilestonePaymentsYetToBeReceived": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DevelopmentMilestonePaymentsYetToBeReceived", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Development milestone payments yet to be received.", "label": "Development Milestone Payments Yet To Be Received", "terseLabel": "Development milestone payments yet to be received", "auth_ref": "r1190", "bbio_DirectOfferingExpense": "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "DirectOfferingExpense", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Direct offering expense.", "label": "Direct Offering Expense", "terseLabel": "Direct offering expense", "auth_ref": "r1190", "us_gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation", "lang": "en-us", "role": "label", "terseLabel": "Share-Based Payment Arrangement [Text Block]", "totalLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement.", "auth_ref": "r473", "r477", "r509", "r510", "r513", "r920", "us_gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": "xbrltype": "stringItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "lang": "en-us", "role": "label", "terseLabel": "Share-Based Payment Arrangement [Abstract]", "auth_ref": "r1190", "us_gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "auth_ref": "r1190", "us_gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Gain recognized, net of transactions costs", "totalLabel": "Net gain recognized transaction costs", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "auth_ref": "r374", "r1101", "r1138", "us_gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList": "xbrltype": "enumerationSetItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation.", "auth_ref": "r375", "us_gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": "xbrltype": "domainItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Disposal Group Name [Domain]", "documentation": "Name of disposal group.", "auth_ref": "r917", "r918", "dei_DocumentFiscalPeriodFocus": "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "terseLabel": "Document Fiscal Period Focus", "totalLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "auth_ref": "r1190", "dei_DocumentFiscalYearFocus": "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "terseLabel": "Document Fiscal Year Focus", "totalLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "auth_ref": "r1190", "dei_DocumentPeriodEndDate": "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "terseLabel": "Document Period End Date", "totalLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "auth_ref": "r1190", "dei_DocumentQuarterlyReport": "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "terseLabel": "Document Quarterly Report", "totalLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "auth_ref": "r972", "dei_DocumentTransitionReport": "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "terseLabel": "Document Transition Report", "totalLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report.", "auth_ref": "r1004", "dei_DocumentType": "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/de
```

"EarningsPerShareBasic", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "lang": "en-us", "role": "terseLabel": "Net loss per share attributable to common stockholders of BridgeBio, basic", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "auth_ref": "r218", "r247", "r248", "r249", "r250", "r251", "r252", "r258", "r261", "r265", "r266", "r267", "r271", "r549", "r558", "r589", "r590", "r719", "r745", "r898", "us-gaap_EarningsPerShareDiluted": "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "lang": "en-us", "role": "terseLabel": "Net loss per share attributable to common stockholders of BridgeBio, diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "auth_ref": "r218", "r247", "r248", "r249", "r250", "r251", "r252", "r261", "r265", "r266", "r267", "r271", "r549", "r558", "r589", "r590", "r719", "r745", "r898", "us-gaap_EarningsPerShareTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShare", "lang": "en-us", "role": "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "The entire disclosure for earnings per share.", "auth_ref": "r257", "r268", "r269", "r270", "us-gaap_EffectiveIncomeTaxRateContinuingOperations": "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndEffectiveTaxRatesDetails", "lang": "en-us", "role": "terseLabel": "Effective Tax Rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "auth_ref": "r524", "r922", "bbio_EidosAwardExchangePlanMember": "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "EidosAwardExchangePlanMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Eidos Award Exchange Plan", "label": "Eidos Award Exchange Plan [Member]", "terseLabel": "Eidos Award Exchange Plan", "auth_ref": "bbio_EidosTherapeuticsIncMember": "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "EidosTherapeuticsIncMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIndicencingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails", "lang": "en-us", "role": "verboseLabel": "Eidos Therapeutics, Inc.", "documentation": "Eidos Therapeutics, Inc.", "label": "Eidos Therapeutics Inc [Member]", "terseLabel": "Eidos", "auth_ref": "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "lang": "en-us", "role": "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Embedded derivative", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "auth_ref": "r134", "r1210", "r1211", "r1212", "bbio_EmployeeAndNonEmployeeServiceShareBasedCompensationLineItems": "xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "EmployeeAndNonEmployeeServiceShareBasedCompensationLineItems", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails", "lang": "en-us", "role": "documentation": "Employee and non-employee service share based compensation.", "label": "Employee And Non-Employee Service Share Based Compensation [Line Items]", "terseLabel": "Employee And Non-Employee Service Share Based Compensation [Line Items]", "auth_ref": "us-gaap_EmployeeRelatedLiabilitiesCurrent": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "auth_ref": "r75", "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": "en-us", "role": "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not Yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation cost, period for recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMdTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "auth_ref": "r512", "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": "en-us", "role": "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not Yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "auth_ref": "r1189", "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": "en-us", "role": "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not Yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "auth_ref": "r1189", "us-gaap_EmployeeStockMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited", "lang": "en-us", "role": "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "auth_ref": "us-gaap_EmployeeStockOptionMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Employee Stock Options", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "auth_ref": "bbio_EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember": "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "documentation": "Entities affiliated with Perceptive Life Sciences Master Fund Ltd.", "label": "Entities Affiliated With Perceptive Life Sciences Master Fund Ltd [Member]", "terseLabel": "Entities Affiliated With Perceptive Life Sciences Master Fund Ltd", "auth_ref": "dei_EntityAddressAddressLine1": "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "auth_ref": "dei_EntityAddressAddressLine2": "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number", "auth_ref": "dei_EntityAddressCityOrTown": "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town", "auth_ref": "dei_EntityAddressPostalZipCode": "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code", "auth_ref": "dei_EntityAddressStateOrProvince": "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province.", "auth_ref": "dei_EntityCentralIndexKey": "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "auth_ref": "dei_EntityCommonStockSharesOutstanding": "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "auth_ref": "dei_EntityCurrentReportingStatus": "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "auth_ref": "dei_EntityDomain": "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails",

```

http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Entity", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } }}, "auth_ref": {} },
{"dei_EntityEmergingGrowthCompany": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation": {"lang": {"en-us": {"role": {"label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } }}, "auth_ref": {"r970": {} },
"dei_EntityFileNumber": {"xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation": {"lang": {"en-us": {"role": {"label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } }}, "auth_ref": {} }, "dei_EntityFilerCategory": {"xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation": {"lang": {"en-us": {"role": {"label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } }}, "auth_ref": {"r970": {} }, "dei_EntityIncorporationStateCountryCode": {"xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation": {"lang": {"en-us": {"role": {"label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } }}, "auth_ref": {} }, "dei_EntityInteractiveDataCurrent": {"xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation": {"lang": {"en-us": {"role": {"label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."} }}, "auth_ref": {"r1054": {} }, "dei_EntityListingsExchangeAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } }}, "auth_ref": {} }, "dei_EntityRegistrantName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation": {"lang": {"en-us": {"role": {"label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } }}, "auth_ref": {"r970": {} }, "dei_EntityShellCompany": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation": {"lang": {"en-us": {"role": {"label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } }}, "auth_ref": {"r970": {} }, "dei_EntitySmallBusiness": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation": {"lang": {"en-us": {"role": {"label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."} }}, "auth_ref": {"r970": {} }, "dei_EntityTaxIdentificationNumber": {"xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation": {"lang": {"en-us": {"role": {"label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } }}, "auth_ref": {"r970": {} }, "ecd_EqtyAwrdsAdjFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/2024/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote", "auth_ref": {"r1009": {} }, "ecd_EqtyAwrdsAdjExclgValRprtdInSummryCompstnTblMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtdInSummryCompstnTblMember", "presentation": {"http://xbrl.sec.gov/ecd/2024/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "auth_ref": {"r1050": {} }, "ecd_EqtyAwrdsAdjFnTextBlock": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/2024/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments", "auth_ref": {"r1050": {} }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblyrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblyrMember", "presentation": {"http://xbrl.sec.gov/ecd/2024/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "auth_ref": {"r1050": {} }, "bbio_EqualMonthlyInstallmentsAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "EqualMonthlyInstallmentsAmount", "credit": "presentation": {"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"documentation": "Equal monthly installments amount." }, "label": "Equal Monthly Installments Amount", "terseLabel": "Equal monthly installments amount" } }}, "auth_ref": {} }, "us-gaap_EquityComponentDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": {"http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/StatementOfCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestsAndStockholdersDeficitUnaudited": {"lang": {"en-us": {"role": {"label": "Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } }}, "auth_ref": {"r14": {"r184": {"r211": {"r212": {"r213": {"r239": {"r240": {"r241": {"r244": {"r251": {"r253": {"r255": {"r273": {"r337": {"r343": {"r373": {"r460": {"r531": {"r532": {"r545": {"r546": {"r547": {"r550": {"r557": {"r558": {"r570": {"r572": {"r573": {"r574": {"r575": {"r577": {"r588": {"r618": {"r619": {"r620": {"r621": {"r622": {"r623": {"r630": {"r632": {"r656": {"r740": {"r764": {"r765": {"r766": {"r784": {"r851": {} }, "us-gaap_EquityFairValueAdjustment": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityFairValueAdjustment", "credit": "presentation": {"http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Equity, Fair Value Adjustment", "terseLabel": "Cumulative unrealized loss on ongoing mark-to-market adjustments of investment in equity security", "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties." } }}, "auth_ref": {} }, "bbio_EquityMethodAndCostMethodInvestmentAbstract": {"xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "EquityMethodAndCostMethodInvestmentAbstract", "lang": {"en-us": {"role": {"documentation": "Equity Method And Cost Method Investment Abstract", "label": "Equity Method And Cost Method Investment [Abstract]", "auth_ref": {} }, "bbio_EquityMethodAndOtherEquityInvestmentsPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "EquityMethodAndOtherEquityInvestmentsPolicyTextBlock", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies": {"lang": {"en-us": {"role": {"terseLabel": "Equity Method and Other Equity Investments", "label": "Equity Method and Other Equity Investments [Policy Text Block]", "documentation": "Equity method and other equity investments." } }}, "auth_ref": {} }, "srt_EquityMethodInvesteeNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": {"http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Investment, Name [Domain]", "terseLabel": "Investment, Name", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } }}, "auth_ref": {"r329": {"r330": {"r332": {"r541": {"r1057": {"r1058": {"r1059": {"r1196": {"r1197": {"r1198": {"r1199": {} }, "bbio_EquityMethodInvesteeIpoMember": {"xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "EquityMethodInvesteeIpoMember", "presentation": {"http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Equity Method Investee's IPO", "label": "Equity Method Investee's IPO
```



```
Investment, Nonconsolidated Investee, Other [Member]", "terseLabel": "Other investment", "documentation": "Nonconsolidated equity method investee classified as other. Excludes information consolidated by reporting entity.", "auth_ref": "r1080", "r1105", "r1131", "r1215", "us-gaap_EquityMethodInvestments", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Equity investment", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "auth_ref": "r272", "r285", "r288", "r328", "r1082", "r1130", "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": "en-us", "role": "label", "Equity Method Investments and Joint Ventures [Abstract]", "auth_ref": "I", "us-gaap_EquitySecuritiesFvNi", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://bridgebio.com/20240630/taxonomy/role/Role StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "Equity Securities, FV-NI, Current", "verboseLabel": "Equity security investment", "terseLabel": "Investments in equity securities", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI, classified as current.", "auth_ref": "r196", "r616", "r893", "us-gaap_EquitySecuritiesFvNiGainLoss", "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Equity Securities, FV-NI, Gain (Loss)", "totalLabel": "Total net gains (losses) included in Other income (expense), net", "terseLabel": "Loss from investment in equity securities, net", "negatedLabel": "Gain from investment in equity securities, net", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "auth_ref": "r748", "r1129", "us-gaap_EquitySecuritiesFvNiRealizedGainLoss", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfTotalRealizedAndUnrealizedGainsAndLossesAssociatedWithInvestmentsInEquity", "lang": "en-us", "role": "negatedLabel", "Realized losses recognized on investment in equity securities", "verboseLabel": "Realized losses recognized on investment in equity securities", "totalLabel": "Equity Securities, FV-NI, Realized Gain (Loss), Total", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "terseLabel": "Net realized gains recognized on investments in equity securities sold", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "auth_ref": "r746", "r1129", "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfTotalRealizedAndUnrealizedGainsAndLossesAssociatedWithInvestmentsInEquity", "lang": "en-us", "role": "totalLabel", "Equity Securities, FV-NI, Unrealized Gain (Loss), Total", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "terseLabel": "Net unrealized losses recognized on investments in equity securities held as of the end of the period", "verboseLabel": "Unrealized gain on ongoing mark-to-market adjustments of investment in equity security", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "auth_ref": "r747", "r1129", "ecd_EquityValuationAssumptionDifferenceFnTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": "I", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote", "auth_ref": "r1019", "ecd_ErrCompAnalysisTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": "I", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "label", "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis", "auth_ref": "r977", "r987", "r1029", "ecd_ErrCompRecoveryTable", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": "I", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "label", "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery", "auth_ref": "r974", "r984", "r994", "r1026", "bbio_EstimatedFairValueOfOutstandingTermLoan", "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "EstimatedFairValueOfOutstandingTermLoan", "crdr": "credit", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "Estimated fair value of outstanding term loan", "label": "Estimated Fair Value of Outstanding Term Loan", "terseLabel": "Estimated fair value of outstanding term loan", "auth_ref": "I", "bbio_EstimatedSharesIssuableEmployeeStockPurchasePlanMember", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "EstimatedSharesIssuableEmployeeStockPurchasePlanMember", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails", "lang": "en-us", "role": "documentation", "Estimated shares issuable employee stock purchase plan", "label": "Estimated Shares Issuable Employee Stock Purchase Plan [Member]", "terseLabel": "Estimated Shares Issuable Under the ESPP", "auth_ref": "I", "bbio_EstimatedSharesIssuablePerformanceBasedMilestoneCompensationArrangementMember", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "EstimatedSharesIssuablePerformanceBasedMilestoneCompensationArrangementMember", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails", "lang": "en-us", "role": "documentation", "Estimated shares issuable performance based milestone compensation arrangement", "label": "Estimated Shares Issuable Performance Based Milestone Compensation Arrangement [Member]", "terseLabel": "Estimated Shares Issuable Under Performance-Based Milestone Compensation Arrangements", "auth_ref": "I", "bbio_ExcessOfPurchasePriceOverValueOfCommonStockShares", "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ExcessOfPurchasePriceOverValueOfCommonStockShares", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Excess of purchase price over the value of common stock shares", "label": "Excess Of Purchase Price Over Value Of Common Stock Shares", "documentation": "Excess of purchase price over the value of common stock shares.", "auth_ref": "I", "dei_ExchangeDomain", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "auth_ref": "I", "bbio_ExclusiveLicenseAgreementsWithBayerConsumerCareAGAndKyowaKirinCoLtdMember", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ExclusiveLicenseAgreementsWithBayerConsumerCareAGAndKyowaKirinCoLtdMember", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "Exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd.", "label": "Exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd. [Member]", "terseLabel": "Exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd.", "auth_ref": "I", "ecd_ExecutiveCategoryAxis", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": "I", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "Executive Category [Axis]", "terseLabel": "Executive Category", "auth_ref": "r1025", "bbio_ExitCost", "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ExitCost", "crdr": "debit", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/Role DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "Exit cost", "label": "Exit cost", "auth_ref": "I", "bbio_ExitFees", "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ExitFees", "crdr": "debit", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/Role DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Exit fee", "label": "Exit Fees", "documentation": "Exit fees.", "auth_ref": "I", "us-gaap_FairValueAdjustmentOfWarrants", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/Role StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Fair Value Adjustment of Warrants", "terseLabel": "Fair value adjustment of warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "auth_ref": "r0", "r9", "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "lang": "en-us", "role": "label", "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r592", "r593", "r606", "r925", "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": "I", "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "lang": "en-us", "role": "label", "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "auth_ref": "r592", "r5
```

"r594", "r595", "r596", "r605", "r606", "r608", "r667", "r668", "r669", "r908", "r909", "r914", "r915", "r916", "r925", "r929" } }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" } }, "lang": { "en-us": { "role": { "label": "Liability Class {Axis}", "documentation": "Information by class of liability." } } }, "auth_ref": { "r597", "r598", "r599", "r600", "r601", "r602", "r607" } }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" } }, "lang": { "en-us": { "role": { "label": "Measurement Frequency {Axis}", "terseLabel": "Measurement Frequency", "documentation": "Information by measurement frequency." } } }, "auth_ref": { "r592", "r593", "r594", "r596", "r925", "r1211", "r1214" } }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures {Abstract}" } } }, "auth_ref": { } }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurements" } }, "lang": { "en-us": { "role": { "label": "Fair Value Measurements {Text Block}", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration; (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item; (c) policy for requiring collateral or other security and information as to accessing such collateral or security; and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": { "r601", "r603", "r604", "r605", "r608", "r609", "r610", "r611", "r612", "r714", "r925", "r930" } }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" } }, "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 {Member}", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": { "r426", "r464", "r469", "r593", "r606", "r667", "r914", "r915", "r916", "r925" } }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" } }, "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 {Member}", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": { "r426", "r464", "r469", "r593", "r594", "r606", "r668", "r908", "r909", "r914", "r915", "r916", "r925" } }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" } }, "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 {Member}", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": { "r426", "r464", "r465", "r466", "r467", "r468", "r469", "r593", "r594", "r595", "r596", "r606", "r669", "r908", "r909", "r914", "r915", "r916", "r925", "r929" } }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" } }, "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class {Domain}", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": { "r597", "r598", "r599", "r600", "r601", "r602", "r607" } }, "bbio_FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount", "crdr": "debit", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "documentation": "Fair value liabilities transfers between level one level two or level three amount." "label": "Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount", "terseLabel": "Fair value liabilities, transfers between Level 1, Level 2 or Level 3" } } }, "auth_ref": { } }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" } }, "lang": { "en-us": { "role": { "label": "Measurement Frequency {Domain}", "terseLabel": "Measurement Frequency", "documentation": "Measurement frequency." } } }, "auth_ref": { "r592", "r593", "r594", "r596", "r925", "r1211", "r1214" } }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" } }, "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV {Domain}", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": { "r426", "r464", "r465", "r466", "r467", "r468", "r469", "r591", "r593", "r594", "r595", "r596", "r605", "r606", "r608", "r667", "r668", "r669", "r908", "r909", "r914", "r915", "r916", "r925", "r929" } }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" } }, "lang": { "en-us": { "role": { "label": "Fair Value, Recurring {Member}", "terseLabel": "Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": { "r925", "r1208", "r1209", "r1210", "r1211", "r1212", "r1214" } }, "bbio_FairValueOfEquityInvestmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "FairValueOfEquityInvestmentAmount", "crdr": "debit", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Fair value of equity investment amount." "label": "Fair Value of Equity Investment Amount", "documentation": "Fair value of equity investment amount." } } }, "auth_ref": { } }, "bbio_FairValueOfSharesIssuedUnderLicenseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "FairValueOfSharesIssuedUnderLicenseAgreements", "crdr": "debit", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/Role StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" } }, "lang": { "en-us": { "role": { "documentation": "Fair value of shares issued under license agreements." "label": "Fair Value Of Shares Issued Under License Agreements", "terseLabel": "Fair value of shares issued under license agreements" } } }, "auth_ref": { } }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "U.S. Federal", "label": "Federal Income Tax Expense (Benefit), Continuing Operations", "totalLabel": "Federal Income Tax Expense (Benefit), Continuing Operations, Total", "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": { "r234", "r522", "r523" } }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/Role DisclosureLeasesComponentsOfLeaseCostDetails" } }, "lang": { "en-us": { "role": { "label": "Finance Lease Interest Expense", "terseLabel": "Interest on finance lease liability", "verboseLabel": "Finance lease costs", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": { "r635", "r641", "r937" } }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/Role DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" } }, "lang": { "en-us": { "role": { "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows for finance lease", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": { "r637", "r644" } }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/Role DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" } }, "lang": { "en-us": { "role": { "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows for finance lease - cash paid for principal", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": { "r636", "r644" } }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/Role DisclosureLeasesScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateDetails" } }, "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance lease", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": { "r647", "r937" } }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/Role DisclosureLeasesScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateDetails" } }, "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance lease", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r646", "r937" } }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails" "http://bridgebio.com/20240630/taxonomy/role/Role DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvaila" "http://bridgebio.com/20240630/taxonomy/role/Role DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" } }, "lang": { "en-us": { "role": { "label": "Financial Instrument {Axis}", "terseLabel": "Financial Instrument", "documentation": "Information by type of financial instrument." } } }, "auth_ref": { "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r345", "r346", "r349", "r350", "r351", "r353", "r355", "r356", "r437", "r457", "r578", "r613", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r676", "r677", "r681", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r741", "r904", "r925", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r939", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1125", "r1126", "r1127", "r1128", "r1207", "r1210", "r1211", "r1212", "r1213", "r1214" } }, "bbio_FinancingActivityTransactionsWithNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "FinancingActivityTransactionsWithNoncontrollingInterests", "crdr": "debit", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/Role StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" } }, "lang": { "en-us": { "role": { "documentation": "Financing activity transactions with noncontrolling interests." "label": "Financing Activity Transactions With Noncontrolling Interests", "verboseLabel": "Transactions with noncontrolling interests" } } }, "auth_ref": { } }, "bbio_FinancingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "FinancingAgreementMember", "presentation": -1 } "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails1",

```

http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBorrowingUnderFinancingAgreementDetails",
"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails",
"http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtTables",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"documentation": "Financing Agreement", "label": "Financing Agreement [Member]", "terseLabel": "Financing Agreement", "auth_ref": "r193", "r357", "r365", "r905", "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails", "lang": "en-us", "role": "label", "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Intangible assets less accumulated amortization", "negatedLabel": "Less: accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "auth_ref": "r193", "r357", "r365", "r905", "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months", "terseLabel": "Amortization expenses, 2022", "verboseLabel": "Amortization expenses, 2025", "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "auth_ref": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffFiscalYear", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffFiscalYear", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Amortization expenses, remainder period", "verboseLabel": "Amortization expenses, remainder of 2022", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "auth_ref": "r1275", "bbio_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour", "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four", "terseLabel": "Amortization expenses, 2025", "verboseLabel": "Amortization expenses, 2028", "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "auth_ref": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four", "terseLabel": "Amortization expenses, 2025", "verboseLabel": "Amortization expenses, 2028", "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "auth_ref": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two", "terseLabel": "Amortization expenses, 2023", "verboseLabel": "Amortization expenses, 2026", "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "auth_ref": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsTables", "lang": "en-us", "role": "label", "Finite-Lived Intangible Assets Amortization Expense Table Text Block", "terseLabel": "Summary of intangible assets", "verboseLabel": "Summary of Recognized Intangible Assets", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "auth_ref": "us-gaap_FiniteLivedIntangibleAssetsGross", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails", "lang": "en-us", "role": "totalLabel", "Finite-Lived Intangible Assets, Gross, Total", "terseLabel": "Intangible assets gross amount", "verboseLabel": "Gross amount", "label": "Capitalization of finite-lived intangible asset", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "auth_ref": "r357", "r365", "r705", "r905", "us-gaap_FiniteLivedIntangibleAssetsLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Finite-Lived Intangible Assets Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r359", "r365", "r368", "r370", "r701", "r888", "r905", "us-gaap_FiniteLivedIntangibleAssetsNet", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails", "lang": "en-us", "role": "label", "Finite-Lived Intangible Assets, Net", "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "terseLabel": "Finite-lived intangible asset", "verboseLabel": "Capitalization of finite-lived intangible asset", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "auth_ref": "r701", "r1135", "bbio_FollowOnOfferingMember", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "FollowOnOfferingMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "2023 Follow-on Offering", "label": "2023 Follow-on Offering [Member]", "documentation": "2023 follow-on offering", "auth_ref": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseDetails", "lang": "en-us", "role": "terseLabel", "Foreign", "label": "Foreign Income Tax Expense (Benefit), Continuing Operations", "totalLabel": "Foreign Income Tax Expense (Benefit), Continuing Operations, Total", "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.", "auth_ref": "r234", "r523", "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "label", "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "auth_ref": "r981", "r991", "r1001", "r1033", "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "label", "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "auth_ref": "r981", "r991", "r1001", "r1033", "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "label", "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "auth_ref": "r981", "r991", "r1001", "r1033", "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "label", "Forgone Recovery, Explanation of Impracticability Text Block", "terseLabel": "Forgone Recovery, Explanation of Impracticability", "auth_ref": "r981", "r991", "r1001", "r1033", "ecd_ForgoneRecoveryIndName", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "label", "Forgone Recovery, Individual Name", "terseLabel": "Name", "auth_ref": "r981", "r991", "r1001", "r1033", "bbio_FoundationMedicineDiagnosticsAgreementMember", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "FoundationMedicineDiagnosticsAgreementMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureInLicensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Foundation Medicine Diagnostics Agreement", "label": "Foundation Medicine Diagnostics Agreement [Member]", "documentation": "Foundation medicine diagnostics agreement", "auth_ref": "bbio_FoundationMedicineIncMember", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "FoundationMedicineIncMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureInLicensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Foundation Medicine, Inc", "label": "Foundation Medicine Inc [Member]", "documentation": "Foundation Medicine, Inc", "auth_ref": "ecd_FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember", "xbrltype": "domainItemType", "ns
```

[illegible]

monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxExpenseAdditionalInformationDetails", "lang": "en-us", "role": "negatedLabel", "Income tax expense", "verboseLabel": "Income tax expense", "totalLabel": "Total income tax expense", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income tax", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations", "auth_ref": "r153", "r160", "r254", "r255", "r272", "r283", "r288", "r522", "r524", "r537", "r750", "r922", "us-gaap_IncreaseDecreaseInAccountsPayable", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business", "auth_ref": "r8", "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Increase (Decrease) in Accrued professional and other liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other", "auth_ref": "r100", "bbio_IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Increase (Decrease) in Accrued research and development liabilities", "label": "Increase (Decrease) in Accrued Research And Development Liabilities", "documentation": "Accrued research and development liabilities", "auth_ref": "us-gaap_IncreaseDecreaseInDeferredRevenue", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Increase (Decrease) in Deferred revenue", "negatedLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable", "auth_ref": "r889", "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation and benefits", "totalLabel": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits", "auth_ref": "r8", "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Increase (Decrease) in Operating Capital Abstract", "terseLabel": "Changes in operating assets and liabilities", "auth_ref": "us-gaap_IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Increase (Decrease) in Operating Lease Liability", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease", "auth_ref": "r1063", "r1100", "us-gaap_IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets", "totalLabel": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other", "auth_ref": "r8", "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Increase (Decrease) in Prepaid Expense and Other Assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other", "auth_ref": "r8", "bbio_IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Increase (Decrease) in Receivable from Licensing and Collaboration Agreements", "negatedLabel": "Receivables from licensing and collaboration agreements", "auth_ref": "bbio_IncrementalCompensationCostForAwardsModification", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "Incremental Compensation Cost For Awards Modification", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": "en-us", "role": "label", "Incremental compensation cost for awards modification", "label": "Incremental Compensation Cost For Awards Modification", "terseLabel": "Incremental compensation cost for awards modification", "auth_ref": "bbio_IncrementalTermLoanMember", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Incremental Term Loan Member", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Incremental term loan", "label": "Incremental Term Loan [Member]", "terseLabel": "Incremental Term Loan", "auth_ref": "ecd_IndividualAxis", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PayDisclosure", "lang": "en-us", "role": "label", "Individual [Axis]", "terseLabel": "Individual", "auth_ref": "r981", "r991", "r1001", "r1025", "r1033", "r1037", "r1045", "bbio_InitialTermLoanMember", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Initial Term Loan Member", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Initial term loan", "label": "Initial Term Loan [Member]", "terseLabel": "Initial Term Loan", "auth_ref": "bbio_InitialTransactionPriceForLicenseAndCollaborationAgreement", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Initial Transaction Price For License and Collaboration Agreement", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Initial transaction price for license and collaboration agreement", "label": "Increase in Initial Transaction Price for License and Collaboration Agreement", "terseLabel": "Increase in initial transaction price for license and collaboration agreement", "auth_ref": "bbio_IncrementalCompensationCostForAwardsModification", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "lang": "en-us", "role": "label", "Incremental compensation cost for awards modification", "label": "Incremental Compensation Cost For Awards Modification", "terseLabel": "Incremental compensation cost for awards modification", "auth_ref": "bbio_IncrementalTermLoanMember", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Incremental term loan", "label": "Incremental Term Loan [Member]", "terseLabel": "Incremental Term Loan", "auth_ref": "ecd_IndividualAxis", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PayDisclosure", "lang": "en-us", "role": "label", "Individual [Axis]", "terseLabel": "Individual", "auth_ref": "r981", "r991", "r1001", "r1025", "r1033", "r1037", "r1045", "bbio_InitialTermLoanMember", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Initial Term Loan Member", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "label", "Initial term loan", "label": "Initial Term Loan [Member]", "terseLabel": "Initial Term Loan", "auth_ref": "bbio_InitialTransactionPriceForLicenseAndCollaborationAgreement", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Initial Transaction Price For License and Collaboration Agreement", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "label", "Initial transaction price for license and collaboration agreement", "label": "Increase in Initial Transaction Price For License And Collaboration Agreement", "terseLabel": "Initial transaction price for license and collaboration agreement", "auth_ref": "ecd_InsiderTradingArrLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": "en-us", "role": "label", "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements", "auth_ref": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": "en-us", "role": "label", "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures", "auth_ref": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": "en-us", "role": "label", "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted", "auth_ref": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": "en-us", "role": "label", "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "auth_ref": "http://xbrl.sec.gov/ecd/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureIntangibleAssets", "lang": "en-us", "role": "label", "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets", "documentation": "The entire disclosure for all or part of the information related to intangible assets", "auth_ref": "r358", "r369", "r371", "r887", "r888", "us-gaap_IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails", "lang": "en-us", "role": "label", "Interest Expense, Debt", "terseLabel": "Interest expense", "totalLabel": "Total interest and amortization expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt", "auth_ref": "r100", "r432", "r443", "r910", "r911", "us-gaap_InterestExpenseDebtExcludingAmortization", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails", "lang": "en-us", "role": "label", "Interest Expense, Debt", "terseLabel": "Interest expense", "totalLabel": "Total interest and amortization expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt", "auth_ref": "r100", "r432", "r443", "r910", "r911", "us-gaap_InterestExpenseDebtExcludingAmort


```
"Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual interest expense", "verboseLabel": "Accrued unpaid interest", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, { "auth_ref": "r100", "r433", "r910", "r911" } }, { "us-gaap InterestPaidNet", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" }, { "lang": "en-us", "role": "label", "terseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, { "auth_ref": "r222", "r227", "r228" } }, { "us-gaap InterestPayableCurrent", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAccruedProfessionalAndOtherAccruedLiabilitiesDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, { "lang": "en-us", "role": "verboseLabel": "Accrued interest", "label": "Interest Payable, Current", "terseLabel": "Interest payable", "documentation": "Carrying value as of the balance sheet date of accrued interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, { "auth_ref": "r75" } }, { "us-gaap InterestPayableCurrentAndNoncurrent", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, { "lang": "en-us", "role": "label", "terseLabel": "Interest payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, { "auth_ref": "r139", "r1235" } }, { "bbio InterestTwoThousandAndTwentySevenAndTwoThousandAndAndTwentyNineMember", "xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "InterestTwoThousandAndTwentySevenAndTwoThousandAndAndTwentyNineMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" }, { "lang": "en-us", "role": "documentation": "Interest two thousand and twenty seven and two thousand and twenty nine.", "label": "Interest Two Thousand And Twenty Seven And Two Thousand and and Twenty Nine [Member]", "terseLabel": "Interest on 2027 and 2029 Notes" } } }, { "auth_ref": "r139", "r1235" } }, { "us-gaap InvestmentIncomeInterest", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" }, { "lang": "en-us", "role": "label", "terseLabel": "Investment income, interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, { "auth_ref": "r272", "r279", "r288", "r901", "r1093" } }, { "us-gaap InvestmentTextBlock", "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsI", "lang": "en-us", "role": "terseLabel": "Equity Method investment and Other Equity Investments", "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, { "auth_ref": "r1064", "r1065", "r1123" } }, { "us-gaap InvestmentTypeAxis", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvaila", "lang": "en-us", "role": "label", "terseLabel": "Investment Type [Axis]", "documentation": "Investment Type", "documentation": "Information by type of investments." } } }, { "auth_ref": "r796", "r797", "r798", "r799", "r800", "r857", "r859", "r861", "r864", "r865", "r866", "r871", "r872", "r873", "r874", "r875", "r960" } }, { "us-gaap InvestmentTypeCategorizationMember", "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvaila", "lang": "en-us", "role": "label", "terseLabel": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, { "auth_ref": "r796", "r797", "r798", "r799", "r800", "r857", "r859", "r861", "r864", "r865", "r866", "r871", "r872", "r873", "r874", "r875", "r960" } }, { "us-gaap InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" }, { "lang": "en-us", "role": "label", "terseLabel": "Investment in nonconsolidated entity", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "totalLabel": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total", "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate." } } }, { "auth_ref": "r1084" } }, { "bbio IssuanceRepurchaseOfNoncontrollingInterest", "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "IssuanceRepurchaseOfNoncontrollingInterest", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudite", "lang": "en-us", "role": "documentation": "Issuance (repurchase) of noncontrolling interest.", "label": "Issuance Repurchase Of Noncontrolling Interest", "terseLabel": "Issuance of noncontrolling interests" } } }, { "auth_ref": "r1084" } }, { "bbio KyowaKirinExclusiveLicenseMember", "xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "KyowaKirinExclusiveLicenseMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" }, { "lang": "en-us", "role": "documentation": "Kyowa Kirin exclusive license.", "label": "Kyowa Kirin Exclusive License [Member]", "terseLabel": "Kyowa Kirin Exclusive License" } } }, { "auth_ref": "r1084" } }, { "bbio LEOCallOptionLiabilityCurrent", "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LEOCallOptionLiabilityCurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" }, { "lang": "en-us", "role": "documentation": "LEO call option liability current.", "label": "L E O Call Option Liability Current", "terseLabel": "LEO call option liability" } } }, { "auth_ref": "r1084" } }, { "bbio LaunchMilestonePayment", "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LaunchMilestonePayment", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" }, { "lang": "en-us", "role": "documentation": "Launch milestone payment.", "label": "Launch Milestone Payment", "terseLabel": "Launch milestone payment" } } }, { "auth_ref": "r1084" } }, { "bbio LeaseAgreementExpiration", "xbrlType": "durationItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LeaseAgreementExpiration", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" }, { "lang": "en-us", "role": "documentation": "Lease agreement expiration.", "label": "Lease Agreement Expiration", "terseLabel": "Lease agreement expiration" } } }, { "auth_ref": "r1084" } }, { "bbio LeaseAgreementsAndLettersOfCreditMember", "xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LeaseAgreementsAndLettersOfCreditMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" }, { "lang": "en-us", "role": "label", "terseLabel": "Lease Agreements and Letters of Credit", "label": "Lease Agreements and Letters of Credit [Member]", "documentation": "Lease agreements and letters of credit." } } }, { "auth_ref": "r1084" } }, { "us-gaap LeaseCost", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostDetails" }, { "lang": "en-us", "role": "label", "terseLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, { "auth_ref": "r640", "r937" } }, { "us-gaap LeaseCostTableTextBlock", "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesTables" }, { "lang": "en-us", "role": "label", "terseLabel": "Components of Lease Cost", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, { "auth_ref": "r1221" } }, { "us-gaap LeasesAbstract", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": "en-us", "role": "label", "terseLabel": "Leases [Abstract]" } } }, { "auth_ref": "r1221" } }, { "dei LegalEntityAxis", "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetailsI", "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" }, { "lang": "en-us", "role": "label", "terseLabel": "Legal Entity Axis", "documentation": "The set of legal entities associated with a report." } } }, { "auth_ref": "r1221" } }, { "bbio LeidosBiomedicalResearchIncMember", "xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LeidosBiomedicalResearchIncMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIndicencingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails" }, { "lang": "en-us", "role": "label", "terseLabel": "Leidos Biomedical Research, Inc", "label": "Leidos Biomedical Research Inc [Member]", "documentation": "Leidos Biomedical Research, Inc." } } }, { "auth_ref": "r1221" } }, { "bbio LeidosBiomedicalResearchLicenseAndCooperativeResearchAndDevelopmentAgreementsMember", "xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LeidosBiomedicalResearchLicenseAndCooperativeResearchAndDevelopmentAgreementsMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIndicencingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails" }, { "lang": "en-us", "role": "
```

```

"lease": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Operating leases, 2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r648", "us-gaap": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails", "lang": "en-us", "role": "label", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Operating leases, 2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r648", "us-gaap": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails", "lang": "en-us", "role": "label", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Operating leases, 2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r648", "us-gaap": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails", "lang": "en-us", "role": "label", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Operating leases, 2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r648", "us-gaap": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails", "lang": "en-us", "role": "label", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Operating leases, Remainder of 2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "auth_ref": "r1222", "us-gaap": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails", "lang": "en-us", "role": "negatedLabel", "label": "Operating leases, Imputed interest", "negatedTerseLabel": "Operating leases, Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "auth_ref": "r648", "us-gaap": "Liabilities", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "label": "Liabilities", "totalLabel": "Total Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.", "auth_ref": "r19, r74, r75, r76, r81, r82, r83, r84, r233, r333, r403, r404, r405, r406, r407, r408, r409, r410, r411, r562, r565, r566, r617, r809, r899, r968, r1153, r1225, r1226", "us-gaap": "LiabilitiesAndStockholdersEquity", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities, redeemable convertible noncontrolling interests and stockholders' deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "auth_ref": "r91, r143, r732, r938, r1105, r1131, r1215", "us-gaap": "LiabilitiesAndStockholdersEquityAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders' Deficit", "auth_ref": "us-gaap:LiabilitiesCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "auth_ref": "r76, r190, r233, r333, r403, r404, r405, r406, r407, r408, r409, r410, r411, r562, r565, r566, r617, r938, r1153, r1225, r1226", "us-gaap": "LiabilitiesCurrentAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities", "auth_ref": "us-gaap:LiabilitiesFairValueDisclosure", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "lang": "en-us", "role": "label", "label": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations.", "auth_ref": "r593, r1208", "us-gaap": "LiabilitiesFairValueDisclosureAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "lang": "en-us", "role": "label", "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liability", "auth_ref": "bbio_LianBioMember", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LianBioMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "LianBio", "label": "Lian Bio [Member]", "terseLabel": "LianBio", "auth_ref": "bbio_LicenseAgreementMember", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LicenseAgreementMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "License agreement", "label": "License Agreement [Member]", "terseLabel": "License Agreement", "auth_ref": "bbio_LicenseAgreementPercentageShareOfProfitsAndLosses", "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LicenseAgreementPercentageShareOfProfitsAndLosses", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "License agreement percentage share of profits and losses", "label": "License Agreement Percentage Share Of Profits And Losses", "terseLabel": "License agreement percentage share of profits and losses", "auth_ref": "bbio_LicenseAgreementsShareOfCoCommercializationLossAsReductionToSellingGeneralAndAdministrativeExpenses", "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LicenseAgreementsShareOfCoCommercializationLossAsReductionToSellingGeneralAndAdministrativeExpenses", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses", "label": "License Agreements Share Of Co Commercialization Loss As Reduction To Selling General And Administrative Expenses", "terseLabel": "License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses", "auth_ref": "bbio_LicenseAndCollaborationAgreementAbstract", "xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LicenseAndCollaborationAgreementAbstract", "lang": "en-us", "role": "documentation", "License and collaboration agreement", "label": "License And Collaboration Agreement [Abstract]", "auth_ref": "bbio_LicenseAndCollaborationAgreementMember", "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LicenseAndCollaborationAgreementMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": "en-us", "role": "documentation", "License and collaboration agreement", "label": "License And Collaboration Agreement [Member]", "terseLabel": "License and Collaboration Agreement", "auth_ref": "bbio_LicenseAndCollaborationAgreementTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LicenseAndCollaborationAgreementTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreements", "lang": "en-us", "role": "label", "label": "License and Collaboration Agreements", "documentation": "License and collaboration agreement", "label": "License And Collaboration Agreement [Text Block]", "auth_ref": "bbio_LicenseFees", "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "LicenseFees", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureInlicensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "License fees", "label": "License Fees", "documentation": "License fees.", "auth_ref": "us-gaap:LicenseMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "label", "label": "License and Services Revenue", "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "auth_ref": "r1161", "us-gaap": "LineOfCreditFacilityAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis",
```

"Local Phone Number", "documentation": "Local phone number for entity." } } } , "auth_ref": { } } , "us-gaap:LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": { } } } , "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderFinancingAgreementDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails" } , "lang": { "en-us": { "role": { "label": "Long-Term Debt", "terseLabel": "Debt instrument drawn amount", "totalLabel": "Term Loan, net", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } } , "auth_ref": { "r19": "r140", "r425": "r441", "r908": "r909", "r936": "r1236" } } , "us-gaap:LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" } , "lang": { "en-us": { "role": { "terseLabel": "Term loan, net", "label": "Long-Term Debt, Excluding Current Maturities", "totalLabel": "Long-Term Debt, Excluding Current Maturities Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } } , "auth_ref": { "r198" } } , "us-gaap:LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": { } } , "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } } , "auth_ref": { "r19": "r140", "r141": "r142" } } , "us-gaap:LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": { } } , "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } } , "auth_ref": { "r19": "r39", "r1140", "r1141", "r1142" } } , "bbio:ManufacturingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ManufacturingAgreementMember", "presentation": { } } , "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "documentation": "Manufacturing agreement", "label": "Manufacturing Agreement [Member]", "terseLabel": "Manufacturing Agreement" } } } , "auth_ref": { } } , "bbio:MarketBasedRestrictedStockUnitsRsusMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "MarketBasedRestrictedStockUnitsRsusMember", "presentation": { } } , "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "documentation": "Market-Based Restricted Stock Units (RSUs)", "label": "Market-Based Restricted Stock Units (RSUs) [Member]", "auth_ref": { } } } , "us-gaap:MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" } , "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "totalLabel": "Marketable Securities, Current, Total", "terseLabel": "Marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } } , "auth_ref": { "r1085" } } , "srt:MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum", "documentation": "Upper limit of the provided range." } } } , "auth_ref": { "r164": "r165", "r166", "r167", "r168", "r180", "r181", "r397", "r398", "r399", "r400", "r471", "r519", "r596", "r699", "r758", "r760", "r774", "r801", "r802", "r858", "r860", "r862", "r863", "r867", "r885", "r886", "r903", "r912", "r919", "r929", "r930", "r934", "r935", "r953", "r1157", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232" } } } , "bbio:MaximumNumberOfSharesEligibleToPurchaseDuringOfferingPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "MaximumNumberOfSharesEligibleToPurchaseDuringOfferingPeriod", "presentation": { } } , "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares eligible to purchase during offering period", "label": "Maximum Number Of Shares Eligible To Purchase During Offering Period", "documentation": "Maximum number of shares eligible to purchase during offering period." } } } , "auth_ref": { } } , "bbio:MaximumPercentageOfEmployeePayrollDeductionForStockPurchase": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "MaximumPercentageOfEmployeePayrollDeductionForStockPurchase", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Maximum percentage of employee payroll deduction for stock purchase", "label": "Maximum Percentage Of Employee Payroll Deduction For Stock Purchase", "documentation": "Maximum percentage of employee payroll deduction for stock purchase." } } } , "auth_ref": { } } , "bbio:MaximumPotentialPerformanceBasedMilestoneAwardsToBeSettledInShares": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "MaximumPotentialPerformanceBasedMilestoneAwardsToBeSettledInShares", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "documentation": "Maximum potential performance based milestone awards to be settled in shares", "label": "Maximum Potential Performance Based Milestone Awards To Be Settled In Shares", "terseLabel": "Maximum potential milestone performance-based awards to be settled in fully-vested RSA", "auth_ref": { } } } } , "bbio:MaximumRequiredFuturePaymentUponAchievementOfCertainDevelopmentAndMilestoneEventsNetSalesMetrics": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "MaximumRequiredFuturePaymentUponAchievementOfCertainDevelopmentAndMilestoneEventsNetSalesMetrics", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureInlicensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "documentation": "Maximum required future payment upon achievement of certain development and milestone events net sales metrics", "label": "Maximum Required Future Payment Upon Achievement Of Certain Development And Milestone Events Net Sales Metrics", "terseLabel": "Maximum required future payment upon achievement of certain development and milestone events net sales metrics" } } } , "auth_ref": { } } , "ecd:MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } } , "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure", "auth_ref": { "r1017" } } } , "ecd:MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } } , "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name", "auth_ref": { "r1017" } } } } , "bbio:MergerTransactionsCompletionDate": { "xbrltype": "dateItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "MergerTransactionsCompletionDate", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "documentation": "Merger transactions completion date", "label": "Merger Transactions Completion Date", "terseLabel": "Merger transactions completion date" } } } , "auth_ref": { } } , "bbio:MilestoneLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "MilestoneLiability", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAccruedProfessionalAndOtherAccruedLiabilitiesDetails" } } , "lang": { "en-us": { "role": { "documentation": "Milestone Liability", "label": "Milestone Liability", "terseLabel": "Milestone liability" } } } , "auth_ref": { } } , "srt:MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum", "documentation": "Lower limit of the provided range." } } } , "auth_ref": { "r164": "r165", "r166", "r167", "r168", "r180", "r181", "r397", "r398", "r399", "r400", "r471", "r519", "r596", "r699", "r758", "r760", "r774", "r801", "r802", "r858", "r860", "r862", "r863", "r867", "r885", "r886", "r903", "r912", "r919", "r929", "r930", "r934", "r953", "r1157", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232" } } } , "bbio:MinimumThresholdPercentageOfAggregatePrincipalByTrusteeOrHolders": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "MinimumThresholdPercentageOfAggregatePrincipalByTrusteeOrHolders", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "documentation": "Minimum threshold percentage of aggregate principal by trustee or holders", "label": "Minimum Threshold Percentage Of Aggregate Principal By Trustee Or Holders", "terseLabel": "Minimum threshold percentage of aggregate principal by trustee or holders" } } } , "auth_ref": { } } , "us-gaap:MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" } } , "lang": { "en-us": { "role": { "label": "Equity, Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests", "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance", "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total", "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } } , "auth_ref": { "r90": "r142", "r233", "r333", "r403", "r405", "r406", "r407", "r410", "r411", "r617", "r731", "r813" } } , "us-gaap:MinorityInterestDecreaseFromRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromRedemptions", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" } } , "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "terseLabel": "Repurchase of Eidos noncontrolling interests for cash and shares, including transaction costs of \$70.734", "negatedTerseLabel": "Difference recognized in equity", "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)" } } } , "auth_ref": { "r55": "r125", "r132" } } , "us-gaap:MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDisclosureTextBlock", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureNoncontrollingInterests" } } , "lang": { "en-us": { "role": { "label": "Noncontrolling Interest Disclosure [Text Block]", "terseLabel": "Noncontrolling Interests", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net income or loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } } , "auth_ref": { "r130" } } , "us-gaap:MinorityInterestPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestPeriodIncreaseDecrease", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited" } } , "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Period Increase (Decrease)", "terseLabel": "Transfers from (to) noncontrolling interests", "totalLabel": "Noncontrolling Interest, Period Increase (Decrease), Total", "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the

reporting period." } } } , "auth ref": "r53" } } } , "ecd MnpiDiscTimeForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimeForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } } } , "auth ref": "r1036" } } } , "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvaila": { "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } } } , "auth ref": "r1162" } } } , "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } } } , "auth ref": "r1044" } } } , "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } } } , "auth ref": "r1018" } } } , "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness": { "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Description of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } } } , "auth ref": "r155", "r161" } } } , "bbio_NavireBmsMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NavireBmsMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Navire BMS", "label": "Navire BMS [Member]", "documentation": "Navire BMS" } } } } , "auth ref": "r11", "bbio_NavirePharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Navire", "terseLabel": "Navire Pharma, Inc.", "label": "Navire Pharma Inc [Member]", "documentation": "Navire Pharma, Inc." } } } } , "auth ref": "r11", "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } } } , "auth ref": "r226" } } } , "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities." } } } } , "auth ref": "r11", "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } } } , "auth ref": "r226" } } } , "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities." } } } } , "auth ref": "r11", "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } } } , "auth ref": "r107", "r108", "r109" } } } , "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities." } } } } , "auth ref": "r11", "bbio_NetGainsLossesIncludedInOtherIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NetGainsLossesIncludedInOtherIncomeExpenseNet", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfTotalRealizedAndUnrealizedGainsAndLossesAssociatedWithInvestmentsInEquityS": { "lang": { "en-us": { "role": { "label": "Net Gains (Losses) Included in Other Income (Expense) Net", "documentation": "Net gains (losses) included in Other income (expense), net." } } } } , "totalLabel": "Total net gains included in ", "Other income (expense), net" } } } , "auth ref": "r11", "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } } } , "auth ref": "r96", "r109", "r146", "r188", "r207", "r209", "r213", "r233", "r243", "r247", "r248", "r249", "r250", "r251", "r254", "r255", "r263", "r323", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r549", "r558", "r590", "r617", "r739", "r831", "r849", "r850", "r966", "r1153" } } } , "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total", "verboseLabel": "Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests", "negatedLabel": "Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } } } , "auth ref": "r64", "r133", "r207", "r209", "r251", "r254", "r255", "r738", "r1092" } } } , "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders of BridgeBio", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } } } , "auth ref": "r219", "r247", "r248", "r249", "r250", "r258", "r259", "r264", "r267", "r558" } } } , "bbio_NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudite": { "lang": { "en-us": { "role": { "terseLabel": "Net loss", "documentation": "Net income (loss) excluding redeemable noncontrolling interests net income (loss)", "label": "Net income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss", "verboseLabel": "Net income (loss)" } } } } , "auth ref": "r11", "bbio_NetOfCertainTransactionExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NetOfCertainTransactionExpenses", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureFundingAgreementAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Net of certain transaction expenses", "label": "Net of Certain Transaction Expenses", "terseLabel": "Net of certain transaction expenses" } } } } , "auth ref": "r11", "bbio_NetPayablePosition": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NetPayablePosition", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Net payable position", "label": "Net Payable Position", "terseLabel": "Net payable position" } } } } , "auth ref": "r11", "bbio_NetProceedsDepositedToEscrowAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com

"http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" }, {"lang": "en-us", "role": "label", "noncash investing and financing items [Abstract]", "terseLabel": "Supplemental Disclosures of Noncash Investing and Financing Information", "auth_ref": "I-1", "bbio_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NoncashLeaseExpense", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" }, {"lang": "en-us", "role": "label", "noncash lease expense", "documentation": "Noncash Lease Expense", "label": "Noncash Lease Expense" } } }, {"auth_ref": "I-1", "bbio_NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" }, {"lang": "en-us", "role": "label", "transfers (to) from noncontrolling interests (Note 5)", "documentation": "Noncash or part noncash investing transfer (from) to noncontrolling interest", "label": "Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest" } } }, {"auth_ref": "I-1", "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestAbstract", "lang": "en-us", "role": "label", "Noncontrolling Interest Abstract", "auth_ref": "I-1", "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited" }, {"lang": "en-us", "role": "label", "deconsolidation of a subsidiary", "label": "Noncontrolling Interest, Decrease from Deconsolidation", "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest" } } }, {"auth_ref": "r12", "r44", "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited" }, {"lang": "en-us", "role": "label", "noncontrolling interest [Member]", "terseLabel": "Noncontrolling Interests", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest" } } }, {"auth_ref": "r52", "r460", "r1109", "r1110", "r1111", "r1114", "r1273", "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" }, {"lang": "en-us", "role": "label", "total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)" } } }, {"auth_ref": "r99", "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" }, {"lang": "en-us", "role": "label", "other income (expense), net", "label": "Nonoperating Income (Expense) Abstract", "auth_ref": "I-1", "bbio_NonrefundableUpfrontLicenseFees": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NonrefundableUpfrontLicenseFees", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "nonrefundable upfront license fees", "label": "Nonrefundable Upfront License Fees", "terseLabel": "Nonrefundable upfront license fee" } } }, {"auth_ref": "I-1", "bbio_NonrefundableUpfrontPaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NonrefundableUpfrontPaymentReceivable", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "nonrefundable upfront payment receivable", "label": "Nonrefundable Upfront Payment Receivable", "terseLabel": "Nonrefundable upfront payment receivable" } } }, {"auth_ref": "I-1", "us-gaap_NotesPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableFairValueDisclosure", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "notes payable, fair value disclosure", "terseLabel": "Estimated fair value of notes payable", "documentation": "Fair value portion of notes payable" } } }, {"auth_ref": "r19", "r74", "r75", "r1209", "r1213", "bbio_NumberOfEmployeesForReplacementAwards": { "xbrltype": "integerItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NumberOfEmployeesForReplacementAwards", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "number of employees for replacement awards", "label": "Number Of Employees For Replacement Awards", "terseLabel": "Number of employees for replacement awards" } } }, {"auth_ref": "I-1", "bbio_NumberOfEqualMonthlyInstallments": { "xbrltype": "integerItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NumberOfEqualMonthlyInstallments", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "documentation": "Number of equal monthly installments", "label": "Number Of Equal Monthly Installments", "terseLabel": "Number of equal monthly installments" } } }, {"auth_ref": "I-1", "bbio_NumberOfOptionsIssuedInExchangeOfSubsidiaryEquity": { "xbrltype": "sharesItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NumberOfOptionsIssuedInExchangeOfSubsidiaryEquity", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "number of options issued in exchange of subsidiary equity", "label": "Number Of Options Issued In Exchange Of Subsidiary Equity", "terseLabel": "Number of options issued in exchange of subsidiary equity" } } }, {"auth_ref": "I-1", "bbio_NumberOfPerformanceBasedRestrictedStockAwardsIssuedInExchangeOfSubsidiaryEquity": { "xbrltype": "sharesItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NumberOfPerformanceBasedRestrictedStockAwardsIssuedInExchangeOfSubsidiaryEquity", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "documentation": "Number of performance-based restricted stock awards issued in exchange of subsidiary equity", "label": "Number Of Performance Based Restricted Stock Awards Issued In Exchange Of Subsidiary Equity", "terseLabel": "Number of performance-based restricted stock awards issued in exchange of subsidiary equity" } } }, {"auth_ref": "I-1", "bbio_NumberOfPerformanceBasedStockOptionsIssuedInExchangeOfSubsidiaryEquity": { "xbrltype": "sharesItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NumberOfPerformanceBasedStockOptionsIssuedInExchangeOfSubsidiaryEquity", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "documentation": "Number of performance-based stock options issued in exchange of subsidiary equity", "label": "Number Of Performance Based Stock Options Issued In Exchange Of Subsidiary Equity", "terseLabel": "Number of performance-based stock options issued in exchange of subsidiary equity" } } }, {"auth_ref": "I-1", "bbio_NumberOfRestrictedStockAwardsIssuedInExchangeOfSubsidiaryEquity": { "xbrltype": "sharesItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NumberOfRestrictedStockAwardsIssuedInExchangeOfSubsidiaryEquity", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "documentation": "Number of restricted stock awards issued in exchange of subsidiary equity", "label": "Number Of Restricted Stock Awards Issued In Exchange Of Subsidiary Equity", "terseLabel": "Number of RSAs issued in exchange of subsidiary equity" } } }, {"auth_ref": "I-1", "bbio_NumberOfRestrictedStockUnitsIssuedInExchangeOfSubsidiaryEquity": { "xbrltype": "sharesItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NumberOfRestrictedStockUnitsIssuedInExchangeOfSubsidiaryEquity", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "documentation": "Number of restricted stock units issued in exchange of subsidiary equity", "label": "Number Of Restricted Stock Units Issued In Exchange Of Subsidiary Equity", "terseLabel": "Number of RSUs issued in exchange of subsidiary equity" } } }, {"auth_ref": "I-1", "bbio_NumberOfSharesCoveredByCappedCalls": { "xbrltype": "sharesItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NumberOfSharesCoveredByCappedCalls", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "documentation": "Number of shares covered by capped calls", "label": "Number Of Shares Covered By Capped Calls", "terseLabel": "Number of shares covered by capped calls" } } }, {"auth_ref": "I-1", "bbio_NumberOfSharesIssuedInExchangeOfSubsidiaryEquity": { "xbrltype": "sharesItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "NumberOfSharesIssuedInExchangeOfSubsidiaryEquity", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "documentation": "Number of shares issued in exchange of subsidiary equity", "label": "Number Of Shares Issued In Exchange Of Subsidiary Equity", "terseLabel": "Number of shares issued in exchange of subsidiary equity" } } }, {"auth_ref": "I-1", "bbio_OneTimeFeesReceivableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "OneTimeFeesReceivableNoncurrent", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "documentation": "One time fees receivable noncurrent", "label": "One Time Fees Receivable Noncurrent", "terseLabel": "One time fees asset non-current" } } }, {"auth_ref": "I-1", "bbio_OneTimePaymentAmountPaidToPurchasers": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "OneTimePaymentAmountPaidToPurchasers", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFundingAgreementAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "documentation": "Onetime payment amount paid to purchasers", "label": "Onetime Payment Amount Paid to Purchasers", "terseLabel": "Onetime payment amount paid to purchasers" } } }, {"auth_ref": "I-1", "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" }, {"lang": "en-us", "role": "label", "total operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease", "label": "Operating Lease Liability Current", "auth_ref": "r634", "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails" }, {"lang": "en-us", "role": "label", "operating lease liability", "label": "Operating Lease Liability", "terseLabel": "Operating lease liabilities", "totalLabel": "Total operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current" } } }, {"auth_ref": "r634", "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails" }, {"lang": "en-us", "role": "label", "operating lease liability", "label": "Operating Lease Liability", "terseLabel": "Operating lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent" } } }, {"auth_ref": "r634", "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" }, {"lang": "en-us", "role": "label", "operating lease, payments", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows for operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use" } } }, {"auth_ref": "r638", "r644", "us-gaap_OperatingLeaseRightOfUseAsset": {


```
"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "terseLabel": "Operating Lease, Right of Use Asset", "label": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "auth_ref": "r633", "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {"xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureLeasesScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateDetails", "lang": "en-us", "role": "label", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent", "label": "Operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "auth_ref": "r647", "r937", "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm": {"xbrlType": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureLeasesScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateDetails", "lang": "en-us", "role": "label", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term", "label": "Operating leases", "documentation": "Weighted average remaining lease term for operating lease. In PnYnMnDnFnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "auth_ref": "r646", "r937", "us-gaap_OperatingLossCarryforwardsLineItems": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OperatingLossCarryforwardsLineItems", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureIncomeTaxesAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Operating Loss Carryforwards [Line Items]", "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r530", "us-gaap_OperatingLossCarryforwardsTable": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OperatingLossCarryforwardsTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureIncomeTaxesAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Operating Loss Carryforwards [Table]", "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization.", "auth_ref": "r530", "us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsAbstract": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OrganizationConsolidationAndPresentationOffinancialStatementsAbstract", "lang": "en-us", "role": "label", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "auth_ref": "bbio_OriginAndSentynlTherapeuticsIncMember": {"xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localName": "OriginAndSentynlTherapeuticsIncMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Origin-Sentynl APA", "auth_ref": "bbio_OriginBiosciencesIncMember": {"xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localName": "OriginBiosciencesIncMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Origin Biosciences Inc [Member]", "auth_ref": "us-gaap_OtherAccruedLiabilitiesCurrent": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Other accrued liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "auth_ref": "r75", "bbio_OtherAccruedLiabilitiesMember": {"xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localName": "OtherAccruedLiabilitiesMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Other Accrued Liabilities [Member]", "auth_ref": "us-gaap_OtherAssetsNoncurrent": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "label", "terseLabel": "Other assets", "totalLabel": "Other Assets, Noncurrent, Total", "documentation": "Amount of noncurrent assets classified as other.", "auth_ref": "r194", "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "lang": "en-us", "role": "label", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "auth_ref": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "lang": "en-us", "role": "label", "terseLabel": "Unrealized gain (losses) on available-for-sale securities", "verboseLabel": "Unrealized gains (losses) on available-for-sale securities", "label": "OCI Debt Securities, Available for Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after-tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "auth_ref": "r205", "r206", "r327", "bbio_OtherConsolidatedEntitiesMember": {"xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localName": "OtherConsolidatedEntitiesMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails", "lang": "en-us", "role": "label", "terseLabel": "Other Consolidated Entities", "label": "Other Consolidated Entities [Member]", "auth_ref": "us-gaap_OtherIncome": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OtherIncome", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Other income", "label": "Other Income", "documentation": "Amount of revenue and income classified as other.", "auth_ref": "r749", "r833", "r868", "r869", "r870", "us-gaap_OtherLiabilitiesMember": {"xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OtherLiabilitiesMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureIncomeTaxesAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Other liabilities", "documentation": "Primary financial statement caption encompassing other liabilities.", "auth_ref": "r66", "r68", "us-gaap_OtherLiabilitiesNoncurrent": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureIntangibleAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Other liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total", "verboseLabel": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "auth_ref": "r82", "us-gaap_OtherNoncashIncomeExpense": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OtherNoncashIncomeExpense", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "label", "terseLabel": "Other noncash income (expense)", "negatedLabel": "Other noncash adjustments", "totalLabel": "Other Noncash Income (Expense), Total", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "auth_ref": "r109", "us-gaap_OtherNonoperatingIncomeExpense": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "lang": "en-us", "role": "label", "terseLabel": "Other Nonoperating Income (Expense)", "totalLabel": "Other Nonoperating Income (Expense), Total", "auth_ref": "r101", "us-gaap_OtherNonoperatingIncomeExpenseMember": {"xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localName": "OtherNonoperatingIncomeExpenseMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Other income (expense), net", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "auth_ref": "ecd_OtherPerMeasureAmt": {"xbrlType": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localName": "OtherPerMeasureAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "label", "terseLabel": "Other Performance Measure, Amount", "documentation": "Amount", "auth_ref": "r1017", "bbio_OtherRSAsMember": {"xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localName": "OtherRSAsMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAward", "lang": "en-us", "role": "label", "terseLabel": "Other RSAs", "label": "Other R S As [Member]", "auth_ref": "ecd_OutstandingAggtErrCompAmt": {"xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localName": "OutstandingAggtErrCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "label", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "auth_ref": "r979", "r989", "r999", "r1031", "ecd_OutstandingRecoveryCompAmt": {"xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localName": "OutstandingRecoveryCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "label", "terseLabel": "Outstanding Recovery Compensation Amount", "auth_ref": "r982", "r992", "r1002", "r1034", "ecd_OutstandingRecoveryIndName": {"xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localName": "OutstandingRecoveryIndName", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "label", "terseLabel": "Outstanding Recovery, Individual Name", "auth_ref": "r982", "r992", "r1002", "r1034", "srt_OwnershipAxis": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localName": "OwnershipAxis", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Ownership", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "auth_ref": "srt_OwnershipDomain": {"xbrlType": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localName": "OwnershipDomain", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails
```

}, {"auth_ref": []}, {"bbio_PaymentFollowingFDAApprovalOfTruseltiqMember": {"xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PaymentFollowingFDAApprovalOfTruseltiqMember", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"documentation": "Payment following FDA approval of Truseltiq."}, "label": "Payment Following F.D.A. Approval Of Truseltiq [Member]"}, "terseLabel": "Payment Following FDA Approval of Truseltiq"} }}, {"auth_ref": []}, {"bbio_PaymentForDispositionFee": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PaymentForDispositionFee", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Payment for disposition fee"}, "label": "Payment for Disposition Fee"}, "documentation": "Payment for disposition fee." } }}, {"auth_ref": []}, {"bbio_PaymentForPrivateEquityFinancingWithExternalInvestors": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PaymentForPrivateEquityFinancingWithExternalInvestors", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Payment for private equity financing with external investors."}, "label": "Payment for Private Equity Financing with External Investors"}, "documentation": "Payment for equity private financing with external investors." } }}, {"auth_ref": []}, {"bbio_PaymentFromEscrowAccounts": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PaymentFromEscrowAccounts", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Payment from escrow accounts."}, "label": "Payment from Escrow Accounts"}, "documentation": "Payment from escrow accounts." } }}, {"auth_ref": []}, {"bbio_PaymentInKindInterestAddedToPrincipalOfTermLoan": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PaymentInKindInterestAddedToPrincipalOfTermLoan", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_StateementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"terseLabel": "Payment-in-kind interest added to principal of term loan"}, "label": "Payment-in-kind Interest Added to Principal of Term Loan"}, "documentation": "Payment-in-kind interest added to principal of term loan." } }}, {"auth_ref": []}, {"us_gaap_PaymentInKindPIKNoteMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentInKindPIKNoteMember", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails": {"lang": {"en-us": {"role": {"label": "Payment in Kind (PIK) Note [Member]"}, "terseLabel": "Payment in Kind", "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured." } }}, {"auth_ref": []}, {"us_gaap_PaymentsForCommissions": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForCommissions", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Commissions paid"}, "label": "Payments for Commissions"}, "documentation": "The amount of cash paid for commissions during the current period." } }}, {"auth_ref": [{"r7"}]}, {"us_gaap_PaymentsForRepurchaseOfCommonStock": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Payments for Repurchase of Common Stock"}, "terseLabel": "Repurchase of common stock", "negatedLabel": "Repurchases of common stock", "documentation": "The cash outflow to reacquire common stock during the period." } }}, {"auth_ref": [{"r105"}]}, {"us_gaap_PaymentsForRestructuring": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuring": {"lang": {"en-us": {"role": {"label": "Payments for Restructuring"}, "negatedLabel": "Cash payments", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } }}, {"auth_ref": [{"r386"}, {"r1099"}]}, {"us_gaap_PaymentsOfDebtIssuanceCosts": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_StateementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"label": "Payments of Debt Issuance Costs"}, "terseLabel": "Issuance costs and discounts associated with issuance of term loan", "negatedLabel": "Issuance costs and discounts associated with term loan under Financing Agreement", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } }}, {"auth_ref": [{"r26"}]}, {"us_gaap_PaymentsOffinancingCosts": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOffinancingCosts", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Proceeds from term loan, net of issuance costs", "totalLabel": "Payments of Financing Costs, Total", "label": "Payments of Financing Costs", "terseLabel": "Payment of debt discount and issuance costs", "negatedLabel": "Issuance costs associated with term loan", "documentation": "The cash outflow for loan and debt issuance costs." } }}, {"auth_ref": [{"r25"}]}, {"bbio_PaymentsOfFirstInstallmentDueAmountRelatedToRegulatoryMilestonePayments": {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PaymentsOfFirstInstallmentDueAmountRelatedToRegulatoryMilestonePayments", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "First installment due amount, paid"}, "label": "Payments of First Installment Due Amount Related to Regulatory Milestone Payments", "documentation": "Payments of first installment due amount related to regulatory milestone payments." } }}, {"auth_ref": []}, {"us_gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_StateementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Repurchase of RSU shares to satisfy tax withholding", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } }}, {"auth_ref": [{"r221"}]}, {"us_gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails": {"lang": {"en-us": {"role": {"label": "Payments to Acquire Additional Interest in Subsidiaries"}, "terseLabel": "Cash consideration paid", "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period." } }}, {"auth_ref": [{"r23"}]}, {"us_gaap_PaymentsToAcquireEquitySecuritiesFvNi": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireEquitySecuritiesFvNi", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_StateementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"label": "Payments to Acquire Equity Securities, FV-NI", "negatedLabel": "Purchases of investments in equity securities", "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI, classified as investing activity." } }}, {"auth_ref": [{"r152"}, {"r223"}]}, {"us_gaap_PaymentsToAcquireIntangibleAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_StateementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"negatedLabel": "Payment for an intangible asset", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } }}, {"auth_ref": [{"r104"}]}, {"us_gaap_PaymentsToAcquireMarketableSecurities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_StateementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities", "totalLabel": "Payments to Acquire Marketable Securities, Total", "documentation": "Amount of cash outflow for purchase of marketable security." } }}, {"auth_ref": [{"r124"}]}, {"us_gaap_PaymentsToAcquirePropertyPlantAndEquipment": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_StateementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } }}, {"auth_ref": [{"r104"}]}, {"ecd_PeerGroupIssuersFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "Peer Group Issuers, Footnote [Text Block]"}, "terseLabel": "Peer Group Issuers, Footnote"} } }}, {"auth_ref": [{"r1016"}]}, {"ecd_PeerGroupTotalShareholderRtnAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "Peer Group Total Shareholder Return Amount"}, "terseLabel": "Peer Group Total Shareholder Return Amount"} } }}, {"auth_ref": [{"r1016"}]}, {"bbio_PellePharmIncMember": {"xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PellePharmIncMember", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Pelle Pharm, Inc"}, "label": "Pelle Pharm Inc [Member]"}, "documentation": "Pelle Pharm, Inc." } }}, {"auth_ref": []}, {"ecd_PeoActuallyPaidCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "PEO Actually Paid Compensation Amount"}, "terseLabel": "PEO Actually Paid Compensation Amount"} } }}, {"auth_ref": [{"r1008"}]}, {"ecd_PeoMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "PEO [Member]"}, "terseLabel": "PEO"} } }}, {"auth_ref": [{"r1025"}]}, {"ecd_PeoName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "PEO Name"}, "terseLabel": "PEO Name"} } }}, {"auth_ref": [{"r1018"}]}, {"ecd_PeoTotalCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "PEO Total Compensation Amount"}, "terseLabel": "PEO Total Compensation Amount"} } }}, {"auth_ref": [{"r1007"}]}, {"bbio_PercentageOfAdditionalMinimumQualifiedBalanceOnCashReleasedFromEscrowAccounts": {"xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfAdditionalMinimumQualifiedBalanceOnCashReleasedFromEscrowAccounts", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Percentage of additional minimum qualified balance on cash released from escrow accounts", "label": "Percentage of Additional Minimum Qualified Balance on Cash Released from Escrow Accounts", "documentation": "Percentage of additional minimum qualified balance on cash released from escrow accounts." } }}, {"auth_ref": []}, {"bbio_PercentageOfAggregateAmountNotExceedTheOriginalNetCashProceedsReceivedFromAssetSaleTransactions": {"xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfAggregateAmountNotExceedTheOriginalNetCashProceedsReceivedFromAssetSaleTransactions", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Percentage of aggregate amount not to exceed the original net cash proceeds received from asset sale transactions", "label": "Percentage of Aggregate Amount not Exceed the Original Net Cash Proceeds Received from Asset Sale Transactions", "documentation": "Percentage of aggregate amount not exceed the original net cash proceeds received from asset sale transactions." } }}, {"auth_ref": []}, {"bbio_PercentageOfAutomaticAnnualIncreaseInNumberOfSharesReservedForFutureIssuance": {"xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfAutomaticAnnualIncreaseInNumberOfSharesReservedForFutureIssuance", "presentation": [{"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Percentage of automatic annual increase in number of shares reserved for future issuance", "label": "Percentage Of Automatic Annual Increase In Number Of Shares Reserved For Future Issuance", "documentation": "Percentage of automatic annual increase in number of shares reserved for future issuance." } }}, {"auth_ref": []}]

"bbio_PercentageOfCashCommissionOnGrossProceedsOfSalesOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfCashCommissionOnGrossProceedsOfSalesOfCommonStock", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Percentage of cash commission on gross proceeds of sales of common stock", "label": "Percentage Of Cash Commission On Gross Proceeds Of Sales Of Common Stock", "terseLabel": "Percentage of cash commission" } } }, "auth_ref": -1 }, "bbio_PercentageOfCashReleasedFromEscrowAccounts": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfCashReleasedFromEscrowAccounts", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash released from escrow accounts", "label": "Percentage of Cash Released from Escrow Accounts", "documentation": "Percentage of cash released from escrow accounts" } } }, "auth_ref": -1 }, "bbio_PercentageOfCloseOutPlanCostsSubjectToReimbursement": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfCloseOutPlanCostsSubjectToReimbursement", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of close-out plan costs subject to reimbursement", "label": "Percentage Of Close-Out Plan Costs Subject To Reimbursement", "documentation": "Percentage of close-out plan costs subject to reimbursement" } } }, "auth_ref": -1 }, "bbio_PercentageOfCorporateAlternativeMinimumTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfCorporateAlternativeMinimumTaxRate", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Percentage of corporate alternative minimum tax rate", "label": "Percentage of Corporate Alternative Minimum Tax Rate", "terseLabel": "Percentage of corporate alternative minimum tax rate" } } }, "auth_ref": -1 }, "bbio_PercentageOfExciseTaxBenefitOnCorporateStockBuyBack": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfExciseTaxBenefitOnCorporateStockBuyBack", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Percentage of excise tax benefit on corporate stock buy-back", "label": "Percentage of Excise Tax Benefit on Corporate Stock Buy-Back", "terseLabel": "Percentage of excise tax on corporate stock buy-back" } } }, "auth_ref": -1 }, "bbio_PercentageOfNetVestedSharesOfCommonStockToBeIssued": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfNetVestedSharesOfCommonStockToBeIssued", "presentation": -1 }

"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of net vested shares of common stock to be issued", "label": "Percentage Of Net Vested Shares Of Common Stock To Be Issued", "documentation": "Percentage of net vested shares of common stock to be issued" } } }, "auth_ref": -1 }, "bbio_PercentageOfOutstandingSecurities": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfOutstandingSecurities", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of outstanding securities", "label": "Percentage of Outstanding Securities", "documentation": "Percentage of outstanding securities" } } }, "auth_ref": -1 }, "bbio_PercentageOfOwnershipReducedForPrivateEquityFinancing": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfOwnershipReducedForPrivateEquityFinancing", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of ownership reduced for private equity financing", "label": "Percentage of Ownership Reduced for Private Equity Financing", "documentation": "Percentage of ownership reduced for private equity financing" } } }, "auth_ref": -1 }, "bbio_PercentageOfPrincipalAmountToBeRepurchasedInFundamentalChange": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfPrincipalAmountToBeRepurchasedInFundamentalChange", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount to be repurchased in fundamental change", "label": "Percentage Of Principal Amount To Be Repurchased In Fundamental Change", "terseLabel": "Percentage of principal amount to be repurchased in fundamental change" } } }, "auth_ref": -1 }, "bbio_PercentageOfRoyaltyInterestPaymentsOnNetSales": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfRoyaltyInterestPaymentsOnNetSales", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/DisclosureFundingAgreementAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Percentage of royalty interest payments on net sales", "label": "Percentage of Royalty Interest Payments on Net Sales", "terseLabel": "Percentage of royalty interest payments on net sales" } } }, "auth_ref": -1 }, "bbio_PercentageOfSalesAgentsCommissionsOnGrossProceedsOfSalesOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfSalesAgentsCommissionsOnGrossProceedsOfSalesOfCommonStock", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Percentage of sales agents commissions on gross proceeds of sales of common stock", "label": "Percentage Of Sales Agents Commissions On Gross Proceeds Of Sales Of Common Stock", "terseLabel": "Percentage of sales agents commission" } } }, "auth_ref": -1 }, "bbio_PercentageOfUnbilledReceivables": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfUnbilledReceivables", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of total unbilled receivables", "label": "Percentage of Unbilled Receivables", "documentation": "Percentage of unbilled receivables" } } }, "auth_ref": -1 }, "bbio_PercentageOfUnderwritersCommissionsOnGrossProceedsOfSalesOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageOfUnderwritersCommissionsOnGrossProceedsOfSalesOfCommonStock", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of underwriters commissions on gross proceeds of sales of common stock", "label": "Percentage of Underwriters Commissions on Gross Proceeds of Sales of Common Stock", "documentation": "Percentage of underwriters commissions on gross proceeds of sales of common stock" } } }, "auth_ref": -1 }, "bbio_PercentageShareOfGlobalDevelopmentCosts": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PercentageShareOfGlobalDevelopmentCosts", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Percentage share of global development costs", "label": "Percentage Share Of Global Development Costs", "terseLabel": "Percentage share of global development costs" } } }, "auth_ref": -1 }, "bbio_PerformanceBasedMilestoneAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PerformanceBasedMilestoneAwards", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Performance-based milestone awards", "label": "Performance Based Milestone Awards", "terseLabel": "Performance-based milestone awards" } } }, "auth_ref": -1 }, "bbio_PerformanceBasedMilestoneAwardsCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PerformanceBasedMilestoneAwardsCompensationExpense", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Performance-based milestone awards compensation expense", "label": "Performance Based Milestone Awards Compensation Expense", "terseLabel": "Performance-based milestone awards compensation expense" } } }, "auth_ref": -1 }, "bbio_PerformanceBasedMilestoneAwardsCompensationExpenseSettledWithEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PerformanceBasedMilestoneAwardsCompensationExpenseSettledWithEquity", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Performance-based milestone awards compensation expense settled with equity", "label": "Performance Based Milestone Awards Compensation Expense Settled With Equity", "terseLabel": "Performance-based milestone awards compensation expense settled with equity" } } }, "auth_ref": -1 }, "bbio_PerformanceBasedMilestoneAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PerformanceBasedMilestoneAwardsMember", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Performance-based milestone awards", "label": "Performance-Based Milestone Awards [Member]", "terseLabel": "Performance-Based Milestone Awards" } } }, "auth_ref": -1 }, "bbio_PerformanceBasedMilestoneAwardsPeriodForRecognition": { "xbrltype": "durationItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PerformanceBasedMilestoneAwardsPeriodForRecognition", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Performance-based milestone awards period for recognition", "label": "Performance Based Milestone Awards Period For Recognition", "terseLabel": "Performance-based milestone awards period for recognition" } } }, "auth_ref": -1 }, "bbio_PerformanceBasedRestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PerformanceBasedRestrictedStockAwardsMember", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Performance-based restricted stock awards", "label": "Performance Based Restricted Stock Awards [Member]", "verboseLabel": "Performance-Based RSAs" } } }, "auth_ref": -1 }, "bbio_PerformanceBasedStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PerformanceBasedStockOptionsMember", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Performance-based stock options", "label": "Performance Based Stock Options [Member]", "terseLabel": "Performance-Based Stock Options" } } }, "auth_ref": -1 }, "bbio_PlacementAgentCommission": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PlacementAgentCommission", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Placement agent commission", "label": "Placement Agent Commission", "verboseLabel": "Placement agent commission" } } }, "auth_ref": -1 }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name", "documentation": "Information by plan name for share-based payment arrangement" } } }, "auth_ref": -1 }, "bbio_PnsnAdjPsrvSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjPsrvSvcCstMember", "presentation": -1 }

"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": -1 }, "bbio_PnsnAdjSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjSvcCstMember", "presentation": -1 }

"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": -1 }, "bbio_PnsnAdjSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": -1 }, "bbio_PotentialMilestoneAccruedAmountSettlementInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PotentialMilestoneAccruedAmountSettlementInCash", "presentation": -1 }

"PotentialMilestoneAccruedAmountSettlementInCash", "crdr": "debit", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOffPotentialMilestoneAmountsAndAccrualsDetails" }, "lang": { "en-us": { "role": { "documentation": "Potential milestone accrued amount settlement in cash.", "label": "Potential Milestone Accrued Amount Settlement In Cash", "terseLabel": "Accrued Amount Settlement In Cash" } } }, "auth_ref": f }, "bbio_PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion", "crdr": "debit", "presentation": f "http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOffPotentialMilestoneAmountsAndAccrualsDetails" }, "lang": { "en-us": { "role": { "documentation": "Potential milestone accrued amount settlement in cash or stock at sole discretion.", "label": "Potential Milestone Accrued Amount Settlement In Cash Or Stock At Sole Discretion", "terseLabel": "Accrued Amount Settlement In Cash Or Stock At Sole Discretion" } } }, "auth_ref": f }, "bbio_PotentialMilestoneAccruedAmountSettlementInStock": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PotentialMilestoneAccruedAmountSettlementInStock", "crdr": "debit", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOffPotentialMilestoneAmountsAndAccrualsDetails" }, "lang": { "en-us": { "role": { "documentation": "Potential milestone accrued amount settlement in stock.", "label": "Potential Milestone Accrued Amount Settlement In Stock", "terseLabel": "Accrued Amount Settlement In Stock" } } }, "auth_ref": f }, "bbio_PotentialMilestoneAccruedSettlementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PotentialMilestoneAccruedSettlementAmount", "crdr": "debit", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOffPotentialMilestoneAmountsAndAccrualsDetails" }, "lang": { "en-us": { "role": { "documentation": "Potential milestone accrued settlement amount.", "label": "Potential Milestone Accrued Settlement Amount", "totalLabel": "Total Accrued Settlement Amount" } } }, "auth_ref": f }, "bbio_PotentialMilestoneFixedMonetaryAmountSettlementInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PotentialMilestoneFixedMonetaryAmountSettlementInCash", "crdr": "debit", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOffPotentialMilestoneAmountsAndAccrualsDetails" }, "lang": { "en-us": { "role": { "documentation": "Potential milestone fixed monetary amount settlement in cash.", "label": "Potential Milestone Fixed Monetary Amount Settlement In Cash", "terseLabel": "Potential Fixed Monetary Amount Settlement In Cash" } } }, "auth_ref": f }, "bbio_PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion", "crdr": "debit", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOffPotentialMilestoneAmountsAndAccrualsDetails" }, "lang": { "en-us": { "role": { "documentation": "Potential milestone fixed monetary amount settlement in cash or stock at sole discretion.", "label": "Potential Milestone Fixed Monetary Amount Settlement In Cash Or Stock At Sole Discretion", "terseLabel": "Potential Fixed Monetary Amount Settlement In Cash or stock at our sole discretion" } } }, "auth_ref": f }, "bbio_PotentialMilestoneFixedMonetaryAmountSettlementInStock": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PotentialMilestoneFixedMonetaryAmountSettlementInStock", "crdr": "debit", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOffPotentialMilestoneAmountsAndAccrualsDetails" }, "lang": { "en-us": { "role": { "documentation": "Potential milestone fixed monetary amount settlement in stock.", "label": "Potential Milestone Fixed Monetary Amount Settlement In Stock", "terseLabel": "Potential Fixed Monetary Amount Settlement In Stock" } } }, "auth_ref": f }, "bbio_PotentialMilestoneFixedMonetarySettlementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PotentialMilestoneFixedMonetarySettlementAmount", "crdr": "debit", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOffPotentialMilestoneAmountsAndAccrualsDetails" }, "lang": { "en-us": { "role": { "documentation": "Potential milestone fixed monetary settlement amount.", "label": "Potential Milestone Fixed Monetary Settlement Amount", "totalLabel": "Total Potential Fixed Monetary Settlement Amount" } } }, "auth_ref": f }, "bbio_PotentialMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PotentialMilestonePayments", "crdr": "credit", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Potential regulatory milestone payments.", "label": "Potential Regulatory Milestone Payments", "terseLabel": "Milestone payments" } } }, "auth_ref": f }, "bbio_PotentialRegulatoryMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PotentialRegulatoryMilestonePayments", "crdr": "credit", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Potential regulatory milestone payments.", "label": "Potential Regulatory Milestone Payments", "terseLabel": "Potential regulatory milestone payments" } } }, "auth_ref": f }, "bbio_PotentialSalesMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PotentialSalesMilestonePayments", "crdr": "credit", "presentation": f "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Potential sales milestone payments.", "label": "Potential Sales Milestone Payments", "terseLabel": "Potential sales milestone payments" } } }, "auth_ref": f }, "bbio_PreTaxImpairmentGainLossOnAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PreTaxImpairmentGainLossOnAsset", "crdr": "debit", "presentation": f "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Pre-tax impairment gain (loss) on asset.", "label": "Pre-tax Impairment Gain (Loss) on Asset", "terseLabel": "Pre-tax impairment loss on asset" } } }, "auth_ref": f }, "us-gaap-PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" }, "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": f "r85", "r445" }, "us-gaap-PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" }, "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": f "r85", "r811" }, "us-gaap-PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" }, "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to: preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": f "r85", "r445" }, "us-gaap-PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" }, "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": f "r85", "r811", "r829", "r1273", "r1274" }, "us-gaap-PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": f "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Undesignated preferred stock, \$0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding", "totalLabel": "Preferred Stock, Value, Issued, Total", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": f "r85", "r727", "r938" }, "us-gaap-PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": f "r1089" }, "bbio_PrepaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PrepaymentFee", "crdr": "debit", "presentation": f "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Prepayment fee.", "label": "Prepayment fee", "terseLabel": "Prepayment fee" } } }, "auth_ref": f }, "us-gaap-PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrimeRateMember", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "terseLabel": "Prime Rate", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": f }, "bbio_PrincipalValueAndInterestOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PrincipalValueAndInterestOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember", "presentation": f "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOffFutureMinimumPaymentsUnderNotesDetails" }, "lang": { "en-us": { "role": { "documentation": "Principal value and interest on two point five zero percentage convertible senior notes due two thousand and twenty seven.", "label": "Principal Value And Interest On Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven [Member]", "terseLabel": "2027 Notes and Interest on 2027 Notes" } } }, "auth_ref": f }, "bbio_PrincipalValueAndInterestOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PrincipalValueAndInterestOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOffFutureMinimumPaymentsUnderNotesDetails" }, "lang": { "en-us": { "role": { "documentation": "Principal value and interest on two point two five percentage convertible senior notes due two thousand and twenty nine.", "label": "Principal Value And Interest On Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member]", "terseLabel": "2029 Notes and Interest on 2029 Notes" } } }, "auth_ref": f }, "bbio_PrincipalValueInterestOnTermLoansOffFinancingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PrincipalValueInterestOnTermLoansOffFinancingAgreementMember", "presentation": f

"http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOffFutureMinimumPaymentsUnderTermLoanAgreementDetails" }, "lang": { "en-us": { "role": { "documentation": "Principal value interest on term loans of financing agreement.", "label": "Principal Value Interest On Term Loans Of Financing Agreement [Member]", "terseLabel": "Term Loans, Interest on Term Loans Of Financing Agreement" } } }, "auth_ref": f }, "bbio_PrincipalValueOfConvertibleSeniorNotesDueTwoThousandAndTwentyNineAndTwoThousandAndTwentySevenMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PrincipalValueOfConvertibleSeniorNotesDueTwoThousandAndTwentyNineAndTwoThousandAndTwentySevenMember", "presentation": f "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOffFutureMinimumPaymentsUnderNotesDetails" }, "lang": { "en-us": { "role": { "documentation": "Principal value of convertible senior notes due two thousand and twenty nine and two thousand and twenty seven.", "label": "Principal Value Of Convertible Senior Notes Due Two Thousand And Twenty Nine And Two Thousand And Twenty Seven [Member]", "terseLabel": "2029 Notes and 2027 Notes" } } }, "auth_ref": f }, "bbio_PrincipalValueOfTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PrincipalValueOfTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember", "presentation": f

"http://bridgebio.com/20240630/", "localname": "PrincipalValueOfTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails": { "lang": { "en-us": { "role": { "documentation": "Principal value of two point five zero percentage convertible senior notes due two thousand and twenty seven." }, "label": "Principal Value Of Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven [Member]", "terseLabel": "2027 Notes", "auth_ref": { "bbio_PrincipalValueOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630/", "localname": "PrincipalValueOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails": { "lang": { "en-us": { "role": { "documentation": "Principal value on two point two five percentage convertible senior notes due two thousand and twenty nine." }, "label": "Principal Value On Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member]", "terseLabel": "2029 Notes", "auth_ref": { "bbio_PrincipleAmountPaidToLenders": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/", "localname": "PrincipleAmountPaidToLenders", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Principle amount paid to lenders." }, "label": "Principle Amount Paid To Lenders", "documentation": "Principle amount paid to lenders." }, "auth_ref": { "bbio_PriorityReviewVoucherMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630/", "localname": "PriorityReviewVoucherMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Priority Review Voucher", "label": "Priority Review Voucher [Member]", "documentation": "Priority Review Voucher." } } }, "auth_ref": { "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "PrivatePlacementMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "verboseLabel": "Private Placement", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": { "bbio_PrivatePlacementOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630/", "localname": "PrivatePlacementOfferingMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableNoncontrollingInterestsAndStockholdersDeficitUnaudited": { "lang": { "en-us": { "role": { "documentation": "Private placement offering." }, "label": "Private Placement Offering Member", "terseLabel": "Private Placement Offering", "auth_ref": { "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Proceeds from Dividends Received", "terseLabel": "Net proceeds received as special cash dividends", "documentation": "Dividends received on equity and other investments during the current period." } } }, "auth_ref": { "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "terseLabel": "Proceeds from special cash dividends received from investments in equity securities", "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities." } } }, "auth_ref": { "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from issuance of common stock through Follow-on offering, net", "terseLabel": "Net proceeds issued from offerings", "label": "Proceeds from issuance of common stock through public offerings, net", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": { "bbio_ProceedsFromIssuanceOfCommonStockIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/", "localname": "ProceedsFromIssuanceOfCommonStockIssuanceCost", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock issuance cost", "label": "Proceeds From Issuance Of Common Stock Issuance Cost", "terseLabel": "Proceeds from issuance of common stock issuance cost" } } }, "auth_ref": { "bbio_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/", "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCost", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock net of issuance cost", "label": "Proceeds from Issuance of Common Stock Net of Issuance Cost", "terseLabel": "Proceeds from issuance of common stock net of issuance cost" } } }, "auth_ref": { "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Issuance of Long-Term Debt, Total", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from term loan under Financing Agreement", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": { "r24", "r776": { "bbio_ProceedsFromIssuanceOfNotesAfterDeductingDiscountAndOfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/", "localname": "ProceedsFromIssuanceOfNotesAfterDeductingDiscountAndOfferingExpenses", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of notes after deducting discount and offering expenses", "label": "Proceeds From Issuance Of Notes After Deducting Discount And Offering Expenses", "terseLabel": "Proceeds from issuance of notes after deducting discount and offering expenses" } } }, "auth_ref": { "bbio_ProceedsFromIssuanceOfTermLoansAfterDeductingDebtDiscountAndIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/", "localname": "ProceedsFromIssuanceOfTermLoansAfterDeductingDebtDiscountAndIssuanceCosts", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of term loans after deducting debt discount and issuance costs", "label": "Proceeds from Issuance of Term Loans After Deducting Debt Discount and Issuance Costs", "terseLabel": "Proceeds from issuance of Term Loans after deducting debt discount and issuance costs" } } }, "auth_ref": { "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "terseLabel": "Net proceeds received as special cash dividends", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": { "r5": { "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities of marketable securities", "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": { "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Equity Securities, FV-NI", "terseLabel": "Proceeds from sales of investments in equity securities", "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": { "r152", "r223": { "bbio_ProceedsFromSaleOfPriorityReviewVoucher": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/", "localname": "ProceedsFromSaleOfPriorityReviewVoucher", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of priority review voucher", "label": "Proceeds From Sale Of Priority Review Voucher", "documentation": "Proceeds from sale of priority review voucher." }, "verboseLabel": "Gross proceeds from sale of priority review voucher" } } }, "auth_ref": { "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Sale of Productive Assets, Total", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from sale of certain assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": { "r103": { "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock option exercises, net of repurchases", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": { "r5", "r17": { "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from BridgeBio common stock issuances under ESPP", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": { "r5": { "bbio_ProceedsReceivedFromAssetSaleTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/", "localname": "ProceedsReceivedFromAssetSaleTransactions", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds received from asset sale transactions", "label": "Proceeds Received from Asset Sale Transactions", "documentation": "Proceeds received from asset sale transactions." } } }, "auth_ref": { "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024/", "localname": "ProductOrServiceAxis", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": { "r169", "r170", "r171", "r172", "r173", "r174", "r178", "r289", "r700", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r890", "r913", "r952", "r953", "r954", "r955", "r957", "r1078", "r1148", "r1149", "r1160", "r1239", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1270", "r1271": { "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024/", "localname": "ProductsAndServicesDomain", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": { "r169", "r170", "r171", "r172", "r173", "r174", "r178", "r289", "r700", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r890", "r913", "r952", "r953", "r954", "r955", "r957", "r1078", "r1148", "r1149", "r1160", "r1239", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1270", "r1271": }

"r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1270", "r1271" | }, "us-gaap ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"] }, "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r188", "r207", "r209", "r224", "r233", "r243", "r251", "r254", "r255", "r333", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r549", "r558", "r560", "r563", "r564", "r590", "r617", "r720", "r737", "r783", "r831", "r849", "r850", "r923", "r924", "r967", "r1092", "r1153" | }, "bbio ProjectAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ProjectAgreementMember", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/DisclosureIncensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "documentation": "Project Agreement", "label": "Project Agreement [Member]", "verboseLabel": "Resilience PAs" } } }, "auth_ref": [] }, "us-gaap PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": { "r10", "r649" | }, "us-gaap PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Construction-in-progress asset", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "totalLabel": "Property, Plant and Equipment, Gross, Total", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r112", "r192", "r734" | }, "us-gaap PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAccruedProfessionalAndOtherAccruedLiabilitiesDetails"] }, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r649" | }, "us-gaap PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentMember", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property and Equipment", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property, Plant and Equipment, Net, Total", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r10", "r649", "r721", "r734", "r938" | }, "us-gaap PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": { "r112", "r649" | }, "bbio PublicOfferingsAndShareRepurchaseProgramAndSecuritiesPurchaseAgreementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PublicOfferingsAndShareRepurchaseProgramAndSecuritiesPurchaseAgreementAbstract", "lang": { "en-us": { "role": { "documentation": "Public offerings and share repurchase program and securities purchase agreement", "label": "Public Offerings And Share Repurchase Program And Securities Purchase Agreement [Abstract]", "verboseLabel": "Public Offerings, Share Repurchase Program and Securities Purchase Agreement [Abstract]" } } }, "auth_ref": [] }, "bbio PublicOfferingsShareRepurchaseProgramAndSecuritiesPurchaseAgreementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PublicOfferingsShareRepurchaseProgramAndSecuritiesPurchaseAgreementLineItems", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "documentation": "Public Offerings, Share Repurchase Program And Securities Purchase Agreement", "label": "Public Offerings, Share Repurchase Program And Securities Purchase Agreement [Line Items]" } } }, "auth_ref": [] }, "bbio PublicOfferingsShareRepurchaseProgramAndSecuritiesPurchaseAgreementTable": { "xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PublicOfferingsShareRepurchaseProgramAndSecuritiesPurchaseAgreementTable", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "documentation": "Public Offerings, Share Repurchase Program And Securities Purchase Agreement", "label": "Public Offerings, Share Repurchase Program And Securities Purchase Agreement [Table]" } } }, "auth_ref": [] }, "bbio PurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PurchaseAgreementMember", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "documentation": "Purchase Agreement", "label": "Purchase Agreement [Member]", "verboseLabel": "Purchase Agreement" } } }, "auth_ref": [] }, "bbio PurchaseOfCappedCalls": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "PurchaseOfCappedCalls", "crdr": "credit", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "documentation": "Purchase of capped calls", "label": "Purchase Of Capped Calls", "terseLabel": "Purchase of capped calls", "negatedLabel": "Purchase of capped calls" } } }, "auth_ref": [] }, "ecd PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": { "r1006" | }, "ecd PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": { "r1006" | }, "bbio QEDTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "QEDTherapeuticsIncMember", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/DisclosureIncensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "documentation": "QED Therapeutics, Inc.", "label": "Q E D Therapeutics Inc [Member]", "terseLabel": "QED Therapeutics, Inc" } } }, "auth_ref": [] }, "bbio RandalWScottMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RandalWScottMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Randal W. Scott [Member]", "documentation": "Randal W. Scott." } } }, "auth_ref": [] }, "srt RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": { "r164", "r165", "r166", "r167", "r168", "r180", "r181", "r397", "r398", "r399", "r400", "r463", "r471", "r503", "r504", "r505", "r519", "r596", "r670", "r682", "r699", "r758", "r760", "r774", "r801", "r802", "r858", "r860", "r862", "r863", "r867", "r885", "r886", "r903", "r912", "r919", "r929", "r930", "r934", "r935", "r953", "r960", "r1143", "r1157", "r1211", "r1228", "r1229", "r1230", "r1231", "r1232" | }, "srt RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": { "r164", "r165", "r166", "r167", "r168", "r180", "r181", "r397", "r398", "r399", "r400", "r463", "r471", "r503", "r504", "r505", "r519", "r596", "r670", "r682", "r699", "r758", "r760", "r774", "r801", "r802", "r858", "r860", "r862", "r863", "r867", "r885", "r886", "r903", "r912", "r919", "r929", "r930", "r934", "r935", "r953", "r960", "r1143", "r1157", "r1211", "r1228", "r1229", "r1230", "r1231", "r1232" | }, "bbio ReceiptOfEscrowAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ReceiptOfEscrowAccount", "crdr": "debit", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "documentation": "Receipt of escrow account", "label": "Receipt Of Escrow Account", "terseLabel": "Receipt of escrow account" } } }, "auth_ref": [] }, "bbio ReceivableFromLicensingAndCollaborationAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ReceivableFromLicensingAndCollaborationAgreementsMember", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "label": "Receivable from Licensing and Collaboration Agreements [Member]", "documentation": "Receivable from licensing and collaboration agreements", "terseLabel": "Receivable from Licensing and Collaboration Agreements" } } }, "auth_ref": [] }, "us-gaap ReceivablesLongTermContractsOrPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesLongTermContractsOrPrograms", "crdr": "debit", "presentation": ["http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "totalLabel": "Receivables, Long-term

Contracts or Programs, Total", "label": "Receivables, Long-Term Contracts or Programs", "verboseLabel": "Total receivables", "terseLabel": "Receivables from licensing and collaboration agreements", "documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date." } } }, "auth_ref": "r1088" } } }, "bbio_ReclassificationOfFinalPaymentObligationRelatedToManufacturingAgreementRecognizedInPriorPeriod": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ReclassificationOfFinalPaymentObligationRelatedToManufacturingAgreementRecognizedInPriorPeriod", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuring": { "lang": { "en-us": { "role": { "terseLabel": "Reclassification of final payment obligation related to a manufacturing agreement that was recognized in the prior period (see Note 13)", "documentation": "Reclassification of final payment obligation related to manufacturing agreement recognized in prior period." } } }, "label": "Reclassification Of Final Payment Obligation Related To Manufacturing Agreement Recognized In Prior Period" } } }, "auth_ref": { } }, "bbio_RecognizeLicenseRevenue": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RecognizeLicenseRevenue", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Recognize license revenue.", "label": "Recognize License Revenue", "terseLabel": "Recognized license revenue" } } }, "auth_ref": { } }, "bbio_RecognizedIntangibleAssetRecordedInAccruedResearchAndDevelopmentLiabilities": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RecognizedIntangibleAssetRecordedInAccruedResearchAndDevelopmentLiabilities", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/RoleStatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Recognized intangible asset recorded in accrued research and development liabilities", "label": "Recognized Intangible Asset Recorded In Accrued Research And Development Liabilities", "documentation": "Recognized intangible asset recorded in accrued research and development liabilities." } } }, "auth_ref": { } }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure Line Items", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": { "r74", "r94", "r94a", "r1026" } } }, "bbio_RedeemableConvertibleNoncontrollingInterestsMember": { "xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RedeemableConvertibleNoncontrollingInterestsMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited": { "lang": { "en-us": { "role": { "documentation": "Redeemable convertible noncontrolling interests.", "label": "Redeemable Convertible Noncontrolling Interests [Member]", "terseLabel": "Redeemable Convertible Noncontrolling Interests" } } }, "auth_ref": { } }, "bbio_ReductionOfObligation": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ReductionOfObligation", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Reduction of obligation.", "label": "Reduction Of Obligation", "terseLabel": "Reduction of obligation" } } }, "auth_ref": { } }, "bbio_RegularEquityProgramMember": { "xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RegularEquityProgramMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/RoleDisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails": { "http://bridgebio.com/20240630/taxonomy/role/RoleDisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails": { "lang": { "en-us": { "role": { "documentation": "Regular equity program member.", "label": "Regular Equity Program Member", "terseLabel": "Regular Equity Program" } } }, "auth_ref": { } }, "bbio_RegulatoryAndSalesBasedMilestonePaymentsYetToBeReceived": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RegulatoryAndSalesBasedMilestonePaymentsYetToBeReceived", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Regulatory and sales-based milestone payments yet to be received.", "label": "Regulatory and Sales-based Milestone Payments Yet to Be Received", "terseLabel": "Regulatory and sales-based milestone payments yet to be received" } } }, "auth_ref": { } }, "bbio_RegulatoryAndSalesMilestones": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RegulatoryAndSalesMilestones", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Regulatory and sales milestones.", "label": "Regulatory and sales milestones" } } }, "auth_ref": { } }, "bbio_RegulatoryBasedMilestonePayment": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RegulatoryBasedMilestonePayment", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Regulatory-based milestone payment.", "label": "Regulatory Based Milestone Payment", "documentation": "Regulatory based milestone payment." } } }, "auth_ref": { } }, "bbio_RegulatoryMilestonePaymentReceivableSubjectToAchievementOfRegulatorMilestones": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RegulatoryMilestonePaymentReceivableSubjectToAchievementOfRegulatorMilestones", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Regulatory milestone payment receivable subject to achievement of regulator milestones.", "label": "Regulatory Milestone Payment Receivable Subject To Achievement Of Regulator Milestones", "documentation": "Regulatory milestone payment receivable subject to achievement of regulator milestones." } } }, "auth_ref": { } }, "bbio_RegulatoryMilestonePaymentsTerm": { "xbrlType": "durationItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RegulatoryMilestonePaymentsTerm", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Regulatory milestone payments term.", "label": "Regulatory Milestone Payments Term", "terseLabel": "Regulatory milestone payments term" } } }, "auth_ref": { } }, "bbio_ReimbursableCommercialContractedActivities": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ReimbursableCommercialContractedActivities", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reimbursable commercial contracted activities.", "label": "Reimbursable Commercial Contracted Activities", "documentation": "Reimbursable commercial contracted activities." } } }, "auth_ref": { } }, "bbio_ReimbursablePaymentOutstanding": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ReimbursablePaymentOutstanding", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Reimbursable payment outstanding.", "label": "Reimbursable Payment Outstanding", "terseLabel": "Reimbursable payment outstanding" } } }, "auth_ref": { } }, "bbio_ReimbursablePaymentReceived": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ReimbursablePaymentReceived", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reimbursable payment received.", "label": "Reimbursable Payment Received", "documentation": "Reimbursable Payment Received" } } }, "auth_ref": { } }, "bbio_ReimbursableRemainingCommencingInstallments": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ReimbursableRemainingCommencingInstallments", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reimbursable remaining commencing installments.", "label": "Reimbursable Remaining Commencing Installments", "documentation": "Reimbursable remaining commencing installments." } } }, "auth_ref": { } }, "bbio_ReimbursableRemainingDueInElevenEqualMonthlyCommencingInstallments": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ReimbursableRemainingDueInElevenEqualMonthlyCommencingInstallments", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reimbursable remaining due in eleven equal monthly commencing installments.", "label": "Reimbursable Remaining Due In Eleven Equal Monthly Commencing Installments", "documentation": "Reimbursable remaining due in eleven equal monthly commencing installments." } } }, "auth_ref": { } }, "bbio_ReimbursableResearchAndDevelopment": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ReimbursableResearchAndDevelopment", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reimbursable research and development.", "label": "Reimbursable Research And Development", "documentation": "Reimbursable research and development." } } }, "auth_ref": { } }, "bbio_ReimbursementPercentageOfCommercialActivityCostsIncurred": { "xbrlType": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ReimbursementPercentageOfCommercialActivityCostsIncurred", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Reimbursement percentage of commercial activity costs incurred.", "label": "Reimbursement Percentage of Commercial Activity Costs Incurred", "terseLabel": "Reimbursement percentage of commercial activity costs incurred" } } }, "auth_ref": { } }, "bbio_ReimbursementPercentageOfResearchAndDevelopmentCostsIncurred": { "xbrlType": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ReimbursementPercentageOfResearchAndDevelopmentCostsIncurred", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Reimbursement percentage of research and development costs incurred.", "label": "Reimbursement Percentage of Research and Development Costs Incurred", "terseLabel": "Reimbursement percentage of research and development costs incurred" } } }, "auth_ref": { } }, "us-gaap_RelatedPartyDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "terseLabel": "Related Party", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": { "r294", "r470", "r657", "r658", "r725", "r733", "r804", "r805", "r806", "r807", "r808", "r828", "r830", "r856" } } }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "terseLabel": "Related Party", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": { "r294", "r470", "r657", "r658", "r725", "r733", "r804", "r805", "r806", "r807", "r808", "r828", "r830", "r856", "r1224" } } }, "bbio_RemainingBalanceInEscrowAccounts": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RemainingBalanceInEscrowAccounts", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/RoleDisclosureDebtAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/RoleDisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Remaining balance in escrow accounts.", "label": "Remaining Balance In Escrow Accounts", "documentation": "Remaining balance in escrow accounts." } } }, "auth_ref": { } }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/RoleDisclosureDebtAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/RoleStatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "verboseLabel": "Debt instrument prepaid includes final payment charge and prepayment fee.", "label": "Repayments of Long-Term Debt", "totalLabel": "Repayments of Long-Term Debt Total", "terseLabel": "Repayment of term loan under Loan and Security Agreement", "negatedLabel": "Repayment of term loan under Loan and Security Agreement", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": { "r106", "r779" } } }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": {

"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails1",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails1", "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]",
"terseLabel": "Counterparty Name", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": { "r176", "r177", "r236", "r237", "r416", "r447", "r659", "r683", "r722", "r895", "r896" } }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/DisclosureIncensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails1",
"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" } }, "lang": { "en-us": { "role": { "label": "Research and development liabilities", "verboseLabel": "Research and development expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": { "r520", "r888", "r901", "r1233" } }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails1", "lang": { "en-us": { "role": { "verboseLabel": "Research and Development Services Performance Obligation", "label": "Research and Development Expense [Member]",
"terseLabel": "Research and Development Expense", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": { } }, "bbio_ResilienceAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ResilienceAgreementsMember", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureIncensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails1", "lang": { "en-us": { "role": { "documentation": "Resilience Agreements", "label": "Resilience Agreements [Member]", "verboseLabel": "Resilience Agreements" } } }, "auth_ref": { } }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": { "r975", "r985", "r995", "r1027" } }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": { "r976", "r986", "r996", "r1028" } }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": { "r983", "r993", "r1003", "r1035" } }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r27", "r191", "r229" } }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r191" } }, "bbio_RestrictedCashAndCashEquivalentsIncludedInPrepaidExpensesAndOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RestrictedCashAndCashEquivalentsIncludedInPrepaidExpensesAndOtherCurrentAssets", "crdr": "debit", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Restricted cash - Included in [Prepaid expenses and other current assets]", "label": "Restricted Cash and Cash Equivalents Included in Prepaid Expenses and Other Current Assets", "documentation": "Restricted cash and cash equivalents included in prepaid expenses and other current assets." } } }, "auth_ref": { } }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash - Included in [Other assets]", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r27", "r154", "r229" } }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets1", "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash - Included in [Prepaid expenses and other current assets]", "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": { "r1081", "r1102" } }, "bbio_RestrictedCashMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RestrictedCashMember", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1", "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash", "label": "Restricted Cash [Member]", "documentation": "Restricted cash", "auth_ref": { } }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Restricted cash, non-current - included in [Other assets]", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": { "r154", "r1083", "r1102" } }, "us-gaap_RestrictedCashNoncurrentAssetStatementOffinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrentAssetStatementOffinancialPositionExtensibleList", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent, Statement of Financial Position [Extensible List]", "terseLabel": "Restricted Cash, Noncurrent, Asset, Statement of Financial Position [Extensible List]", "documentation": "Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as noncurrent." } } }, "auth_ref": { "r1102" } }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAward", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables1", "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": { "r32" } }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails1", "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "Restricted Stock Units (RSUs)", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": { } }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "auth_ref": { } }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedCharges1", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring, Impairment and Related Charges", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": { "r383", "r384", "r386", "r389", "r394" } }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails1", "lang": { "en-us": { "role": { "totalLabel": "Restructuring and Related Cost, Expected Cost, Total", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Estimated charges to be incurred", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": { "r385", "r388", "r391", "r393" } }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Restructuring Charges, Total", "verboseLabel": "Restructuring expenses", "label": "Restructuring expenses incurred", "terseLabel": "Restructuring, impairment and related charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": { "r9", "r390", "r391", "r1144" } }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuring", "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r385", "r386", "r387",

"r388", "r391", "r392", "r393" }], "bbio_RestructuringImpairmentAndRelatedChargesMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RestructuringImpairmentAndRelatedChargesMember", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails": { "lang": { "en-us": { "role": { "documentation": "Restructuring, impairment and related charges.", "label": "Restructuring, Impairment and Related Charges [Member]", "terseLabel": "Restructuring, Impairment and Related Charges" } } }, "auth_ref": { } }, "us-gaap_RestructuringReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveCurrent", "crdr": "credit", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuring": { "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Current", "terseLabel": "Restructuring Liabilities", "periodStartLabel": "Restructuring Liabilities, balance", "periodEndLabel": "Restructuring Liabilities, balance", "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": { "r1086", "r1145", "r1146" } }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveSettledWithoutCash2", "crdr": "debit", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuring": { "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Settled without Cash", "negatedLabel": "Noncash activities", "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash." } } }, "auth_ref": { "r386", "r392" } }, "us-gaap_RestructuringSettlementAndImpairmentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringSettlementAndImpairmentProvisions", "crdr": "debit", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuring": { "lang": { "en-us": { "role": { "label": "Restructuring, Settlement and Impairment Provisions", "totalLabel": "Total", "terseLabel": "Restructuring, impairment and related charges", "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss." } } }, "auth_ref": { "r97" } }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r88", "r125", "r730", "r768", "r773", "r780", "r812", "r938" } }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited": { "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r184", "r239", "r240", "r241", "r244", "r251", "r253", "r255", "r337", "r343", "r373", "r531", "r532", "r545", "r546", "r547", "r550", "r557", "r558", "r570", "r573", "r574", "r577", "r588", "r630", "r632", "r764", "r766", "r784", "r1273" } }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "terseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": { "r147", "r148", "r272", "r277", "r278", "r286", "r288", "r289", "r290", "r291", "r461", "r462", "r700" } }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Revenue", "totalLabel": "Revenues, Total", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": { "r147", "r148", "r214", "r233", "r272", "r277", "r278", "r286", "r288", "r289", "r290", "r291", "r333", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r617", "r720", "r901", "r1153" } }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": { "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease obligations", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": { "r645", "r937" } }, "bbio_RoyaltyInterestPaymentsEqualToCapAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RoyaltyInterestPaymentsEqualToCapAmount", "crdr": "debit", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosureFundingAgreementAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Royalty interest payments equal to cap amount.", "label": "Royalty Interest Payments Equal to Cap Amount", "terseLabel": "Royalty interest payments equal to cap amount" } } }, "auth_ref": { } }, "bbio_RoyaltyInterestPaymentsMayAdjustToMaximumRate": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "RoyaltyInterestPaymentsMayAdjustToMaximumRate", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosureFundingAgreementAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Royalty interest payments may adjust to maximum rate.", "label": "Royalty Interest Payments May Adjust to Maximum Rate", "terseLabel": "Royalty interest payments may adjust to maximum rate" } } }, "auth_ref": { } }, "bbio_Rule10b51TradingPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "Rule10b51TradingPlanMember", "presentation": -1 }, "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Trading Plan [Member]", "documentation": "Rule 10b5-1 Trading Plan" } } }, "auth_ref": { } }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": -1 }, "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": { "r1044" } }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": -1 }, "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": { "r1044" } }, "bbio_SaleOfExistingInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "SaleOfExistingInventory", "crdr": "credit", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Sale of existing inventory.", "label": "Sale of Existing Inventory", "terseLabel": "Sale of certain existing inventory" } } }, "auth_ref": { } }, "bbio_SaleOfNonfinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "SaleOfNonfinancialAssetsAbstract", "lang": { "en-us": { "role": { "label": "Sale of Nonfinancial Assets [Abstract]", "documentation": "Sale of Nonfinancial Assets." } } }, "auth_ref": { } }, "bbio_SaleOfNonfinancialAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "SaleOfNonfinancialAssetsTextBlock", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosureSaleOfNonfinancialAssets1": { "lang": { "en-us": { "role": { "label": "Sale of Nonfinancial Assets [Text Block]", "documentation": "Sale of Nonfinancial Assets." } } }, "auth_ref": { } }, "bbio_SaleOfStockMaximumAmountOfStockRemainingEligibleToBeSold": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "SaleOfStockMaximumAmountOfStockRemainingEligibleToBeSold", "crdr": "credit", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Maximum amount of stock remaining eligible to be sold.", "label": "Sale of Stock, Maximum Amount of Stock Remaining Eligible To Be Sold", "documentation": "Sale of Stock, maximum amount of stock remaining eligible to be sold." } } }, "auth_ref": { } }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Sale of stock premium over last reported sale price percentage.", "label": "Sale of Stock Premium Over Last Reported Sale Price Percentage", "terseLabel": "Premium over last reported sale price percentage" } } }, "auth_ref": { } }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Common stock price", "terseLabel": "Sale of stock, public offering price per share", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": { } }, "us-gaap_SalesCommissionsAndFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesCommissionsAndFees", "crdr": "debit", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Sales Commissions and Fees", "terseLabel": "Sales agent fees and commissions", "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller)." } } }, "auth_ref": { "r98" } }, "us-gaap_SalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesMember", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Sales [Member]", "terseLabel": "Revenue", "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business." } } }, "auth_ref": { "r18" } }, "bbio_SalesMilestonePaymentsYetToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "SalesMilestonePaymentsYetToBeReceived", "crdr": "credit", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Sales milestone payments yet to be received.", "label": "Sales Milestone Payments Yet To Be Received", "terseLabel": "Sales milestone payments yet to be received" } } }, "auth_ref": { } }, "bbio_SatisfyTaxWithholdingMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "SatisfyTaxWithholdingMember", "presentation": -1 }, "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited": { "lang": { "en-us": { "role": { "documentation": "Satisfy tax withholding.", "label": "Satisfy Tax Withholding [Member]", "terseLabel": "Satisfy Tax Withholding" } } }, "auth_ref": { } }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": -1 }

"http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "verboselabel": "Forecast", "label": "Forecast [Member]", "terseLabel": "Scenario Forecast", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." }, {"auth_ref": "r472", "r1073", "r1113" }, {"srt_ScenarioUnspecifiedDomain": "xbrltype", "domainItemType": "nsuri", "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." }, {"auth_ref": "r179", "r256", "r472", "r1056", "r1113" }, {"bbio_ScheduleOfAccruedProfessionalAndOtherAccruedLiabilitiesTableTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://bridgebio.com/20240630", "localname": "ScheduleOfAccruedProfessionalAndOtherAccruedLiabilitiesTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" }, {"lang": "en-us", "role": "label", "Summary of Accrued Professional and Other Accrued Liabilities", "label": "Schedule Of Accrued Professional and Other Accrued Liabilities Table [Text Block]", "documentation": "Schedule of accrued professional and other accrued liabilities." }, {"auth_ref": "r1", "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails" }, {"lang": "en-us", "role": "label", "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Disclosure of information about acquired finite-lived intangible asset by major class." }, {"auth_ref": "r361", "r362", "r363", "r364", "r888" }, {"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails" }, {"lang": "en-us", "role": "label", "Antidilutive Securities Excluded From Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." }, {"auth_ref": "r32", "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables" }, {"lang": "en-us", "role": "label", "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." }, {"auth_ref": "r32", "us-gaap_ScheduleOfCashAndCashEquivalentsTable": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" }, {"lang": "en-us", "role": "label", "Cash and Cash Equivalent [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent." }, {"auth_ref": "r1", "bbio_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://bridgebio.com/20240630", "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" }, {"lang": "en-us", "role": "label", "Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash", "label": "Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]", "documentation": "Schedule of cash, cash equivalents and restricted cash." }, {"auth_ref": "r1", "bbio_ScheduleOfCashEquivalentsAndMarketableSecuritiesTableTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://bridgebio.com/20240630", "localname": "ScheduleOfCashEquivalentsAndMarketableSecuritiesTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" }, {"lang": "en-us", "role": "label", "Schedule of Cash Equivalents and Marketable Securities", "label": "Schedule Of Cash Equivalents And Marketable Securities Table [Text Block]", "documentation": "Schedule of cash equivalents and marketable securities." }, {"auth_ref": "r1", "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." }, {"auth_ref": "r559", "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIncomeTaxesTables" }, {"lang": "en-us", "role": "label", "Summary of Components of Income Tax Expense", "label": "Schedule of Components of Income Tax Expense (Benefit) Table [Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." }, {"auth_ref": "r1192", "us-gaap_ScheduleOfDebtInstrumentsTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtTables" }, {"lang": "en-us", "role": "label", "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." }, {"auth_ref": "r19", "r42", "r43", "r69", "r122", "r908", "r910", "r1108", "r1217" }, {"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationTables" }, {"lang": "en-us", "role": "label", "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Summary of Stock Based Compensation for Employees and Non-Employees", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." }, {"auth_ref": "r49", "bbio_ScheduleOfEmployeesAndNonEmployeesServiceShareBasedCompensationTable": "xbrltype", "stringItemType": "nsuri", "http://bridgebio.com/20240630", "localname": "ScheduleOfEmployeesAndNonEmployeesServiceShareBasedCompensationTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Schedule of Employees and Non-Employees Service Share-Based Compensation", "label": "Schedule Of Employees And Non Employees Service Share Based Compensation Table [Table Text Block]", "documentation": "Investment, Name [Axis]", "terseLabel": "Investment, Name", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." }, {"auth_ref": "r329", "r330", "r332", "r541", "r1057", "r1058", "r1059", "r1196", "r1197", "r1198", "r1199" }, {"us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." }, {"auth_ref": "r233", "r329", "r330", "r332", "r333", "r617" }, {"us-gaap_ScheduleOfEquityMethodInvestmentsTable": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." }, {"auth_ref": "r188", "r233", "r329", "r330", "r332", "r333", "r617" }, {"us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." }, {"auth_ref": "r1208", "r1209" }, {"us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." }, {"auth_ref": "r359", "r365", "r367", "r368", "r370", "r701", "r888", "r905" }, {"bbio_ScheduleOfFundingAgreementsTable": "xbrltype", "stringItemType": "nsuri", "http://bridgebio.com/20240630", "localname": "ScheduleOfFundingAgreementsTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFundingAgreementAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Schedule of Funding Agreements", "label": "Schedule Of Funding Agreements [Table]", "documentation": "Schedule of future minimum lease payments for noncancelable operating and finance leases." }, {"label": "Schedule Of Future Minimum Lease Payments For Noncancelable Operating And Finance Leases Table [Text Block]", "documentation": "Schedule of Future Minimum Lease Payments for Noncancelable Leases" }, {"auth_ref": "r1", "bbio_ScheduleOfInterestExpenseRecognizedAndEffectiveInterestRatesRelatedToNotesTableTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://bridgebio.com/20240630", "localname": "ScheduleOfInterestExpenseRecognizedAndEffectiveInterestRatesRelatedToNotesTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtTables" }, {"lang": "en-us", "role": "label", "Schedule of Interest Expense Recognized and Effective Interest Rates Related to Notes", "label": "Schedule Of Interest Expense Recognized And Effective Interest Rates Related To Notes [Table Text Block]", "documentation": "Schedule of Total Interest Expense Recognized and Effective Interest Related to Notes" }, {"auth_ref": "r1", "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtTables" }, {"lang": "en-us", "role": "label", "Schedule of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." }, {"auth_ref": "r19", "r42", "r43", "r69", "r122", "r908", "r910", "r1108", "r1217" }, {"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationTables" }, {"lang": "en-us", "role": "label", "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Summary of Stock Based Compensation for Employees and Non-Employees", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." }, {"auth_ref": "r49", "bbio_ScheduleOfEmployeesAndNonEmployeesServiceShareBasedCompensationTable": "xbrltype", "stringItemType": "nsuri", "http://bridgebio.com/20240630", "localname": "ScheduleOfEmployeesAndNonEmployeesServiceShareBasedCompensationTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Schedule of Employees and Non-Employees Service Share-Based Compensation", "label": "Schedule Of Employees And Non Employees Service Share Based Compensation Table [Table Text Block]", "documentation": "Investment, Name [Axis]", "terseLabel": "Investment, Name", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." }, {"auth_ref": "r329", "r330", "r332", "r541", "r1057", "r1058", "r1059", "r1196", "r1197", "r1198", "r1199" }, {"us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." }, {"auth_ref": "r233", "r329", "r330", "r332", "r333", "r617" }, {"us-gaap_ScheduleOfEquityMethodInvestmentsTable": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." }, {"auth_ref": "r188", "r233", "r329", "r330", "r332", "r333", "r617" }, {"us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." }, {"auth_ref": "r1208", "r1209" }, {"us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." }, {"auth_ref": "r359", "r365", "r367", "r368", "r370", "r701", "r888", "r905" }, {"bbio_ScheduleOfFundingAgreementsTable": "xbrltype", "stringItemType": "nsuri", "http://bridgebio.com/20240630", "localname": "ScheduleOfFundingAgreementsTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFundingAgreementAdditionalInformationDetails" }, {"lang": "en-us", "role": "label", "Schedule of Funding Agreements", "label": "Schedule Of Funding Agreements [Table]", "documentation": "Schedule of future minimum lease payments for noncancelable operating and finance leases." }, {"label": "Schedule Of Future Minimum Lease Payments For Noncancelable Operating And Finance Leases Table [Text Block]", "documentation": "Schedule of Future Minimum Lease Payments for Noncancelable Leases" }, {"auth_ref": "r1", "bbio_ScheduleOfInterestExpenseRecognizedAndEffectiveInterestRatesRelatedToNotesTableTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://bridgebio.com/20240630", "localname": "ScheduleOfInterestExpenseRecognizedAndEffectiveInterestRatesRelatedToNotesTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtTables" }, {"lang": "en-us", "role": "label", "Schedule of Interest Expense Recognized and Effective Interest Rates Related to Notes", "label": "Schedule Of Interest Expense Recognized And Effective Interest Rates Related To Notes [Table Text Block]", "documentation": "Schedule of Total Interest Expense Recognized and Effective Interest Related to Notes" }, {"auth_ref": "r1", "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": "xbrltype", "textBlockItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtTables" }, {"lang": "en-us", "role": "label", "Schedule of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." }, {"auth_ref": "r19", "r42", "r43", "r69", "r122", "r908", "r910", "r1108", "r1217" }]

"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"}], "lang": "en-us", "role": "label", "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Units Activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } }], "auth_ref": "r127" }], "bbio_ScheduleOfPotentialMilestoneAmountsAndAccrualsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ScheduleOfPotentialMilestoneAmountsAndAccrualsTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"}], "lang": "en-us", "role": "documentation", "Schedule of potential milestone amounts and accruals.", "label": "Schedule Of Potential Milestone Amounts And Accruals Table [Text Block]", "terseLabel": "Schedule of Potential Milestone Amounts and Accruals" } }], "auth_ref": "r11", "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAccruedProfessionalAndOtherAccruedLiabilitiesDetails"}], "lang": "en-us", "role": "label", "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } }], "auth_ref": "r10", "r649" }], "bbio_ScheduleOfProvisionForIncomeTaxesAndTheEffectiveTaxRatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ScheduleOfProvisionForIncomeTaxesAndTheEffectiveTaxRatesTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureIncomeTaxesTables"}], "lang": "en-us", "role": "terseLabel", "Schedule of Provision for Income Taxes and the Effective Tax Rates", "label": "Schedule of Provision for Income Taxes and the Effective Tax Rates [Table Text Block]", "documentation": "Schedule of provision for income taxes and the effective tax rates." } }], "auth_ref": "r11", "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringReserveByTypeOfCostTextBlock"}], "lang": "en-us", "role": "label", "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } }], "auth_ref": "r385", "r386", "r387", "r388", "r391", "r392", "r393" }], "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesTables"}], "lang": "en-us", "role": "label", "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of Restructuring, Impairment and Related Charges", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } }], "auth_ref": "r37", "r114", "r115" }], "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesTables"}], "lang": "en-us", "role": "label", "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Activity Related to Restructuring Liabilities Associated to Restructuring Initiatives", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } }], "auth_ref": "r38", "r116" }], "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights", "xbrltype": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "xbrltype": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityUnderPlansDetails"}], "lang": "en-us", "role": "label", "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "terseLabel": "Summary of Restricted Stock Award Activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } }], "auth_ref": "r126" }], "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"}], "lang": "en-us", "role": "label", "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } }], "auth_ref": "r15", "r16", "r126" }], "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"}], "lang": "en-us", "role": "label", "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Stock Purchase Rights", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } }], "auth_ref": "r129" }], "bbio_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesTables"}], "lang": "en-us", "role": "documentation", "Schedule of supplemental cash flow information related to leases.", "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases" } }], "auth_ref": "r11", "bbio_ScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateTableTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesTables"}], "lang": "en-us", "role": "documentation", "Schedule of supplemental information related to remaining lease term and discount rate.", "label": "Schedule Of Supplemental Information Related To Remaining Lease Term And Discount Rate Table [Text Block]", "terseLabel": "Schedule of Supplemental Information Related to Remaining Lease Term and Discount Rate" } }], "auth_ref": "r11", "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails"}], "lang": "en-us", "role": "label", "Variable Interest Entity [Table]", "terseLabel": "Schedule Of Variable Interest Entities [Table]", "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements." } }], "auth_ref": "r57", "r58", "r59", "r61", "r62", "r561", "r562", "r565", "r566", "r678", "r679", "r680" }], "bbio_ScheduledAmortizationPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ScheduledAmortizationPaymentsMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": "en-us", "role": "documentation", "Scheduled amortization payments.", "label": "Scheduled Amortization Payments [Member]", "terseLabel": "Scheduled Amortization Payments" } }], "auth_ref": "r11", "us-gaap_SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"}], "lang": "en-us", "role": "label", "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR", "documentation": "Fixed rate on U.S. dollar, constant notional interest rate swap that has its variable rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } }], "auth_ref": "r1203" }], "us-gaap_SecuritiesSoldNotYetPurchasedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesSoldNotYetPurchasedMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"}], "lang": "en-us", "role": "label", "Securities Sold, Not Yet Purchased [Member]", "terseLabel": "Securities Sold Not Yet Purchased", "documentation": "Proprietary securities transactions entered into by the entity (broker-dealer) for trading or investment purposes." } }], "auth_ref": "r135" }], "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": "en-us", "role": "label", "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } }], "auth_ref": "r969" }], "dei_SecurityExchangeName": { "xbrltype": "securityExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}], "lang": "en-us", "role": "label", "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the exchange on which a security is registered." } }], "auth_ref": "r971" }], "bbio_SellerPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "SellerPartiesMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"}], "lang": "en-us", "role": "documentation", "Seller parties.", "label": "Seller Parties [Member]", "terseLabel": "Seller Parties" } }], "auth_ref": "r11", "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"}], "lang": "en-us", "role": "label", "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "totalLabel": "Selling, General and Administrative Expense, Total", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } }], "auth_ref": "r98" }], "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "xbrltype": "textBlockItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails"}], "lang": "en-us", "role": "label", "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } }], "auth_ref": "r11", "bbio_ServiceAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ServiceAgreementTerm", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails"}], "lang": "en-us", "role": "documentation", "Service agreement term.", "label": "Service Agreement Term", "verboseLabel": "Agreement term" } }], "auth_ref": "r11", "us-

gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesSummaryOfRestructuringImpairmentAndRelatedChargesDetails" }, "lang": { "en-us": { "role": { "label": "Severance Costs", "terseLabel": "Severance and employee-related costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": { "r9" } }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r8" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "verboseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": { "r920" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Unvested Shares of Restricted Stock Outstanding, Cancelled", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": { "r495" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Cancelled", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": { "r495" } }, "bbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, grant date fair value", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grant Date Fair Value", "terseLabel": "Grant-date fair value of RSUs" } } }, "auth_ref": { "H" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Unvested Shares of Restricted Stock Outstanding, Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r493" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r493" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested Shares of Restricted Stock Outstanding, Ending balance", "periodStartLabel": "Unvested Shares of Restricted Stock Outstanding, Beginning balance", "terseLabel": "Unvested shares of restricted stock outstanding", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": { "r490", "r491" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Ending balance", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Beginning balance", "terseLabel": "Weighted average grant date fair value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r490", "r491" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Unvested Shares of Restricted Stock Outstanding, Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": { "r494" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": { "r504" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": { "H" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights", "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any,

over the period." } } },"auth_ref":{ "r474","r476","r478","r479","r480","r482","r483","r484","r485","r486","r487","r488","r489","r490","r491","r492","r493","r494","r495","r496","r497","r498","r499","r502","r503","r504","r505","r506" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum":{ "xbrltype": "percentItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights","http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum","terseLabel": "Risk-free interest rate, Maximum","documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } },"auth_ref":{ "r474","r476","r478","r479","r480","r482","r483","r484","r485","r486","r487","r488","r489","r490","r491","r492","r493","r494","r495","r496","r497","r498","r499","r502","r503","r504","r505","r506" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum":{ "xbrltype": "percentItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights","http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum","terseLabel": "Risk-free interest rate, Minimum","documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } },"auth_ref":{ "r474","r476","r478","r479","r480","r482","r483","r484","r485","r486","r487","r488","r489","r490","r491","r492","r493","r494","r495","r496","r497","r498","r499","r502","r503","r504","r505","r506" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems":{ "xbrltype": "stringItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights","http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Line Items","terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Line Items","documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },"auth_ref":{ "r474","r476","r478","r479","r480","r482","r483","r484","r485","r486","r487","r488","r489","r490","r491","r492","r493","r494","r495","r496","r497","r498","r499","r502","r503","r504","r505","r506" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized":{ "xbrltype": "sharesItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails","http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityUnderPlansDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized","terseLabel": "Number of shares authorized for issuance under share-based payment arrangement." } } },"auth_ref":{ "r921" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber":{ "xbrltype": "sharesItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number","terseLabel": "Options Outstanding, Exercisable","documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } },"auth_ref":{ "r484" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice":{ "xbrltype": "perShareItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price","terseLabel": "Weighted-Average Exercise Price per Option, Exercisable","documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } },"auth_ref":{ "r484" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue":{ "xbrltype": "monetaryItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue","crdr": "debit","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value","terseLabel": "Total intrinsic value of options exercised","documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } },"auth_ref":{ "r497" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod":{ "xbrltype": "sharesItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period","negatedLabel": "Options Outstanding, Cancelled","documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } },"auth_ref":{ "r488" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross":{ "xbrltype": "sharesItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross","terseLabel": "Options Outstanding, Granted","documentation": "Gross number of share options (or share units) granted during the period." } } },"auth_ref":{ "r486" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue":{ "xbrltype": "perShareItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockOptionsAndStockPurchaseRights","http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted-Average Grant Date Fair Value","terseLabel": "Weighted-average grant date fair value of options granted","documentation": "The weighted-average grant date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } },"auth_ref":{ "r496" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue":{ "xbrltype": "monetaryItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue","crdr": "debit","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value","terseLabel": "Aggregate Intrinsic Value, Outstanding, Ending balance","documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } },"auth_ref":{ "r477" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber":{ "xbrltype": "sharesItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number","periodEndLabel": "Options Outstanding, Outstanding, Ending balance","periodStartLabel": "Options Outstanding, Beginning balance","documentation": "Number of options outstanding, including both vested and non-vested options." } } },"auth_ref":{ "r482","r483" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease":{ "xbrltype": "sharesItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)","totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Total","documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options." } } },"auth_ref":{ "r1169" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice":{ "xbrltype": "perShareItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price","periodEndLabel": "Weighted-Average Exercise Price per Option, Outstanding, Ending balance","periodStartLabel": "Weighted-Average Exercise Price per Option, Outstanding, Beginning balance","documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } },"auth_ref":{ "r482","r483" } } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected":{ "xbrltype": "integerItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Payment Arrangement, Plan Modification, Number of Grantees Affected","terseLabel": "Number of grantees","documentation": "Number of grantees affected by modification of award under share-based payment arrangement." } } },"auth_ref":{ "r511" } } },"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain":{ "xbrltype": "domainItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain","presentation":{ "http://bridgebio.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" } },"lang":{ "en-us":{ "role":{ "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Award Type, Plan Name Domain","documentation": "Award under share-based payment arrangement." } } },"auth_ref":{ "r478","r479","r480","r482","r483","r484","r485","r486","r487","r488","r489","r490","r491","r492","r493","r494","r495","r496","r497","r498","r499","r502","r503","r504","r505","r506" } } },"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice":{ "xbrltype": "perShareItem","nsuri": "http://fasb.org/us-gaap/2024","localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice","presentation":{

```

http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails": {"lang": "en-us", "role": "label", "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price per Option, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } }, "auth_ref": "r487" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails": {"lang": "en-us", "role": "label", "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price per Option, Cancelled", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } }, "auth_ref": "r488" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails": {"lang": "en-us", "role": "label", "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price per Option, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } }, "auth_ref": "r486" } }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies": {"lang": "en-us", "role": "label", "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "bbio_ShareBasedPaymentArrangementConsecutiveTradingDays": { "xbrlType": "integerItemType", "nsuri": "http://bridgebio.com/20240630", "localName": "ShareBasedPaymentArrangementConsecutiveTradingDays", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": {"lang": "en-us", "role": "documentation": "Share-based payment arrangement, consecutive trading days." } }, "label": "Share-Based Payment Arrangement, Consecutive Trading Days", "terseLabel": "Share-based payment arrangement, consecutive trading days" } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "bbio_ShareBasedPaymentArrangementPerformancePeriodFromDateOfGrant": { "xbrlType": "durationItemType", "nsuri": "http://bridgebio.com/20240630", "localName": "ShareBasedPaymentArrangementPerformancePeriodFromDateOfGrant", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails": {"lang": "en-us", "role": "documentation": "Share-based payment arrangement, performance period from date of grant." } }, "label": "Share-based Payment Arrangement, Performance Period From Date Of Grant", "terseLabel": "Share-based payment arrangement, performance period from date of grant" } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "us-gaap_SharePrice": { "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "SharePrice", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Price", "terseLabel": "Repurchase of common stock price per share", "verboseLabel": "Purchase price per share", "documentation": "Price of a single share of a number of saleable stocks of a company." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "shareRepurchaseProgramAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localName": "ShareRepurchaseProgramAxis", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program", "documentation": "Information by share repurchase program." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "srt_ShareRepurchaseProgramDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localName": "ShareRepurchaseProgramDomain", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Repurchase Transactions [Member]", "terseLabel": "Share Repurchase Transactions", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program", "documentation": "Name of share repurchase program." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "bbio_ShareRepurchaseTransactionsMember": { "xbrlType": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localName": "ShareRepurchaseTransactionsMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Repurchase Transactions [Member]", "terseLabel": "Share Repurchase Transactions", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Repurchase Transactions [Member]", "terseLabel": "Share Repurchase Transactions", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Repurchase Transactions [Member]", "terseLabel": "Share Repurchase Transactions", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Repurchase Transactions [Member]", "terseLabel": "Share Repurchase Transactions", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Repurchase Transactions [Member]", "terseLabel": "Share Repurchase Transactions", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Repurchase Transactions [Member]", "terseLabel": "Share Repurchase Transactions", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Repurchase Transactions [Member]", "terseLabel": "Share Repurchase Transactions", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Repurchase Transactions [Member]", "terseLabel": "Share Repurchase Transactions", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": {"lang": "en-us", "role": "label", "Share Repurchase Transactions [Member]", "terseLabel": "Share Repurchase Transactions", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } }, "auth_ref": "r473", "r481", "r500", "r501", "r502", "r503", "r506", "r514", "r515", "r516", "r517" } }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrlType": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformation
```

"en-us": { "role": { "terseLabel": "Short-term liability", "label": "Short-term Liability Fair Value Disclosure", "documentation": "Short-term liability fair value disclosure." } } }
"auth_ref": { "bbio_ShortTermMarketableSecuritiesContractualMaturities": { "xbrltype": "durationItemType", "nsuri": "http://bridgebio.com/20240630", "localname":
"ShortTermMarketableSecuritiesContractualMaturities", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails": { "lang": { "en-us": { "role": {
"documentation": "Short term marketable securities contractual maturities.", "label": "Short Term Marketable Securities Contractual Maturities", "terseLabel": "Short-term
marketable securities contractual maturities." } } }, "auth_ref": { "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "Significant Accounting
Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the
reporting entity." } } }, "auth_ref": { "r110", "r230" } } }, "bbio_SiliconValleyBankAndHerculesLoanMember": { "xbrltype": "domainItemType", "nsuri":
"http://bridgebio.com/20240630", "localname": "SiliconValleyBankAndHerculesLoanMember", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Silicon valley bank and
Hercules loan.", "label": "Silicon Valley Bank And Hercules Loan [Member]", "terseLabel": "Silicon Valley Bank and Hercules Loan Agreement" } } }, "auth_ref": { "r110",
"bbio_SofrPlusInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "SofrPlusInterestMember", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "SOFR plus interest.",
"label": "SOFR plus interest [Member]", "terseLabel": "SOFR plus interest" } } }, "auth_ref": { "r110", "bbio_StanfordLicenseAgreementMember": { "xbrltype": "domainItemType",
"nsuri": "http://bridgebio.com/20240630", "localname": "StanfordLicenseAgreementMember", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureIncensingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Stanford License Agreement", "label": "Stanford License Agreement [Member]", "documentation": "Stanford license agreement." } } }, "auth_ref": { "r110",
"us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureIncomeTaxExpenseSummaryOfComponentsOfIncomeTaxExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel":
"State", "label": "State and Local Income Tax Expense (Benefit), Continuing Operations", "totalLabel": "State and Local Income Tax Expense (Benefit), Continuing Operations,
Total", "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not
limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": { "r523",
"r1106", "r1190", "r1195" } } }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementClassOfStockAxis", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudite
t": { "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock", "documentation": "Information by the different classes of stock of the entity." } } }
"auth_ref": { "r162", "r199", "r200", "r201", "r233", "r261", "r262", "r265", "r267", "r274", "r275", "r333", "r403", "r405", "r406", "r407", "r410", "r411", "r445", "r446",
"r449", "r452", "r459", "r617", "r776", "r777", "r780", "r779", "r784", "r783", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r811", "r832",
"r851", "r876", "r877", "r878", "r879", "r880", "r1055", "r1103", "r1115" } } }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails1",
"http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudite
t": { "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components", "documentation": "Information by component of equity." } } }
"auth_ref": { "r14", "r86", "r89", "r90", "r184", "r211", "r212", "r213", "r239", "r240", "r241", "r244", "r251", "r253", "r255", "r273", "r337", "r343", "r373", "r460", "r531",
"r532", "r545", "r546", "r547", "r550", "r557", "r558", "r570", "r572", "r573", "r574", "r575", "r577", "r588", "r618", "r619", "r620", "r621", "r622", "r623", "r630", "r632",
"r656", "r740", "r764", "r765", "r766", "r784", "r851" } } }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementLineItems", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudite
t": { "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in
a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r239",
"r240", "r241", "r273", "r632", "r700", "r775", "r795", "r803", "r804", "r805", "r806", "r807", "r808", "r811", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821",
"r822", "r824", "r825", "r826", "r827", "r828", "r830", "r834", "r835", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r851",
"r961" } } }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract",
"lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "auth_ref": { "r110", "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial
Position [Abstract]", "auth_ref": { "r110", "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "auth_ref": { "r110", "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "auth_ref": { "r110",
"sr_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/sr/2024", "localname": "StatementScenarioAxis", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label":
"Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast.
Excludes actual facts." } } }, "auth_ref": { "r179", "r256", "r472", "r1056", "r1060", "r1113" } } }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudite
t": { "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive
income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r239", "r240", "r241", "r273", "r294", "r632",
"r700", "r775", "r795", "r803", "r804", "r805", "r806", "r807", "r808", "r811", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r824", "r825", "r826",
"r827", "r828", "r830", "r834", "r835", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r851", "r961" } } },
"ecd_StkPrOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"StkPrOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Stock Price or TSR
Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method", "auth_ref": { "r978", "r988", "r998", "r1030" } } }, "us-
gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember",
"presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel":
"Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during
predetermined time period." } } }, "auth_ref": { "r14", "r85", "r86", "r125" } } }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockCompensationPlanMember", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudite
t": { "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Member]", "terseLabel": "Equity Compensation Plans", "documentation": "Share-based payment
arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its
shares." } } }, "auth_ref": { "r116", "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails",
"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudite
t": { "lang": { "en-us": { "role": { "verboseLabel": "Shares Issued", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock under
public offerings, net, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": { "r14", "r85", "r86", "r125", "r776", "r851", "r877" } } }, "us-
gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudite
t": { "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of shares, shares", "totalLabel":
"Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total", "documentation": "Number, after forfeiture, of shares or units issued under share-based
payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "auth_ref": { "r14", "r85", "r86", "r125" } } }, "us-
gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails": { "lang": { "en-us": { "role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Options Outstanding, Exercised",
"documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": { "r14", "r85", "r86", "r125", "r487" } } }, "us-
gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudite
t": { "lang": { "en-us": { "role": { "terseLabel": "Shares Issued", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of common stock under
public offerings, net", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary
public offering." } } }, "auth_ref": { "r14", "r85", "r86", "r125", "r784", "r851", "r877", "r967" } } }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit",
"presentation": {
"http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudite
t": { "lang": { "en-us": { "role": { "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of shares", "totalLabel": "Shares
Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total", "documentation": "Value, after forfeiture, of shares issued under share-based payment
arrangement. Excludes employee stock ownership plan (ESOP).", "auth_ref": { "r48", "r85", "r86", "r125" } } }, "bbio_StockIssuedWithPremium": { "xbrltype":
"monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "StockIssuedWithPremium", "crdr": "credit", "presentation": {
"http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Aggregate purchase price", "label": "Stock Issued With Premium", "documentation": "Stock Issued With Premium", "auth_ref": { "r110",
"sr_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/sr/2024", "localname":

"StockRepurchaseProgramAuthorizedAmount": {"crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Share Repurchase Program Authorized Amount", "terseLabel": "Share repurchase program authorized amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."}}}, {"auth_ref": ["r1159"], "us-gaap": "StockRepurchasedDuringPeriodShares", {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Stock Repurchased During Period Shares", "terseLabel": "Stock repurchased during period shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."}}}, {"auth_ref": ["r14", "r85", "r86", "r125", "r770", "r851", "r879"], "us-gaap": "StockRepurchasedDuringPeriodValue", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Stock Repurchased During Period Value", "terseLabel": "Stock repurchased value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."}}}, {"auth_ref": ["r14", "r85", "r86", "r125", "r784", "r851", "r879", "r967"], "us-gaap": "StockholdersEquity", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"}, {"lang": {"en-us": {"role": {"label": "Equity, Attributable to Parent", "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance", "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance", "totalLabel": "Total BridgeBio stockholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."}}}, {"auth_ref": ["r86", "r89", "r90", "r111", "r813", "r829", "r852", "r853", "r938", "r968", "r1105", "r1131", "r1215", "r1273"], "us-gaap": "StockholdersEquityAbstract", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"}, {"lang": {"en-us": {"role": {"label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' 2019 equity (deficit)", "documentation": "Equity, Attributable to Parent [Abstract]", "auth_ref": []}, "us-gaap": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"}, {"lang": {"en-us": {"role": {"label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."}}}, {"auth_ref": ["r52", "r53", "r63", "r184", "r185", "r212", "r239", "r240", "r241", "r244", "r251", "r253", "r337", "r343", "r373", "r460", "r531", "r532", "r545", "r546", "r547", "r550", "r557", "r558", "r570", "r572", "r573", "r574", "r575", "r577", "r588", "r618", "r619", "r623", "r631", "r656", "r765", "r766", "r782", "r813", "r829", "r852", "r853", "r881", "r967", "r1105", "r1131", "r1215", "r1273"], "us-gaap": "StockholdersEquityNoteDisclosureTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferings1"}, {"lang": {"en-us": {"role": {"label": "Equity [Text Block]", "terseLabel": "Public Offerings", "documentation": "The entire disclosure for equity."}}}, {"auth_ref": ["r121", "r232", "r444", "r446", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r458", "r460", "r379", "r634", "r855", "r882"], "us-gaap": "SubsequentEventLineItems", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."}}}, {"auth_ref": ["r624", "r662"], "us-gaap": "SubsequentEventMember", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."}}}, {"auth_ref": ["r624", "r662"], "us-gaap": "SubsequentEventTable", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."}}}, {"auth_ref": ["r624", "r662"], "us-gaap": "SubsequentEventTypeAxis", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."}}}, {"auth_ref": ["r624", "r662"], "us-gaap": "SubsequentEventTypeDomain", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."}}}, {"auth_ref": ["r624", "r662"], "us-gaap": "SubsequentEventsAbstract", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": {"en-us": {"role": {"label": "Subsequent Events [Abstract]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."}}}, {"auth_ref": ["r661", "r663"], "us-gaap": "SubsidiarySaleOfStockAxis", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock."}}}, {"auth_ref": [], "bbio": "SummaryOfSignificantAccountingPoliciesLineItems", {"xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Summary of significant accounting policies", "documentation": "Summary of significant accounting policies."}}}, {"auth_ref": [], "bbio": "SummaryOfSignificantAccountingPoliciesTable", {"xbrltype": "stringItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Summary of significant accounting policies", "documentation": "Summary of significant accounting policies."}}}, {"auth_ref": [], "bbio": "SupplementalAgreementMember", {"xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "SupplementalAgreementMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Supplemental agreement", "documentation": "Supplemental agreement."}}}, {"auth_ref": [], "us-gaap": "SupplementalCashFlowInformationAbstract", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"}, {"lang": {"en-us": {"role": {"label": "Supplemental Cash Flow Information [Abstract]", "documentation": "Supplemental Disclosure of Cash Flow Information."}}}, {"auth_ref": [], "bbio": "SupranationalDebtSecuritiesMember", {"xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "SupranationalDebtSecuritiesMember", "presentation": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"}, {"lang": {"en-us": {"role": {"label": "Supranational debt securities", "documentation": "Supranational Debt Securities [Member]", "terseLabel": "Supranational Debt Securities"}}, {"auth_ref": [], "ecd": "TabularListTableTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PyDisclosure"}, {"lang": {"en-us": {"role": {"label": "Tabular List [Table Text Block]", "documentation": "Tabular List, Table"}}, {"auth_ref": ["r1024"], "bbio": "TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests", {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited"}, {"lang": {"en-us": {"role": {"label": "Temporary equity, ending balance", "periodStartLabel": "Temporary equity, beginning balance", "terseLabel": "Redeemable convertible noncontrolling interests", "label": "Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests", "documentation": "Temporary equity carrying amount net including portion attributable to noncontrolling interests"}}, {"auth_ref": [], "bbio": "TemporaryEquityDeconsolidationOfEntities", {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TemporaryEquityDeconsolidationOfEntities", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited"}, {"lang": {"en-us": {"role": {"label": "Temporary Equity, deconsolidation of a subsidiary", "label": "Temporary Equity Deconsolidation Of Entities", "documentation": "Temporary equity deconsolidation of entities."}}}, {"auth_ref": [], "bbio": "TemporaryEquityIssuanceRepurchaseOfNoncontrollingInterestValue", {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TemporaryEquityIssuanceRepurchaseOfNoncontrollingInterestValue", "crdr": "debit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited"}, {"lang": {"en-us": {"role": {"label": "Temporary equity issuance (repurchase) of noncontrolling interest", "documentation": "The portion of net income or loss attributable to temporary equity interest."}}}, {"auth_ref": [], "bbio": "TemporaryEquityTransferToFromNoncontrollingInterest", {"xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TemporaryEquityTransferToFromNoncontrollingInterest", "crdr": "credit", "presentation": "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited"}, {"lang": {"en-us": {"role": {"label": "Temporary equity transfer to (from) noncontrolling interest", "label": "Temporary Equity Transfer To From Noncontrolling Interest", "documentation": "Temporary Equity transfers from (to) noncontrolling interest"}}, {"auth_ref": []}]

TermLoanAfterJanuarySeventeenTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TermLoanAfterJanuarySeventeenTwoThousandTwentyFourMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Term loan after january seventeen two thousand twenty four", "label": "Term Loan After January Seventeen Two Thousand Twenty Four [Member]", "terseLabel": "Term Loan After January 17, 2024" } } }, "auth_ref": { "bbio_TermLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TermLoanAgreementMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails": { "lang": { "en-us": { "role": { "documentation": "Term loan agreement", "label": "Term Loan Agreement [Member]", "terseLabel": "Term Loan Agreement" } } }, "auth_ref": { "bbio_TerminationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TerminationAgreementMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Termination agreement", "label": "Termination Agreement [Member]", "terseLabel": "Termination Agreement" } } }, "auth_ref": { "bbio_TheRasIncMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TheRasIncMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureIndicencingAndOtherResearchAndDevelopmentAgreementsAdditionalInformationDetails": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "TheRas, Inc", "label": "The Ras Inc [Member]", "documentation": "TheRas, Inc." } } }, "auth_ref": { "bbio_ThresholdPercentageOfStockPriceTriggerInMeasurementPeriod": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "ThresholdPercentageOfStockPriceTriggerInMeasurementPeriod", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Threshold percentage of stock price trigger in measurement period", "label": "Threshold Percentage Of Stock Price Trigger In Measurement Period", "terseLabel": "Threshold percentage of stock price trigger in measurement period" } } }, "auth_ref": { "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": { "r1016": { "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": { "r1023": { "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement" } } }, "auth_ref": { "r1043": { "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": { "r1045": { "bbio_TradingArrangementSecuritiesSold": { "xbrltype": "sharesItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TradingArrangementSecuritiesSold", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Trading arrangement securities sold", "label": "Trading Arrangement Securities Sold", "documentation": "Trading arrangement securities sold" } } }, "auth_ref": { "del_TradingSymbol": { "xbrltype": "TradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingSymbol", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange" } } }, "auth_ref": { "bbio_TrancheALoanMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TrancheALoanMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Tranche A loan", "label": "Tranche A Loan [Member]", "terseLabel": "Tranche A Loan" } } }, "auth_ref": { "bbio_TrancheOneAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TrancheOneAdvanceMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Tranche one advance", "label": "Tranche One Advance [Member]", "terseLabel": "Tranche 1 Advance" } } }, "auth_ref": { "bbio_TrancheTwoAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TrancheTwoAdvanceMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Tranche two advance", "label": "Tranche Two Advance [Member]", "terseLabel": "Tranche 2 Advance" } } }, "auth_ref": { "bbio_TransactionCostsIncurredInMergerTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "TransactionCostsIncurredInMergerTransactions", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails": { "lang": { "en-us": { "role": { "documentation": "Transaction costs incurred in merger transactions", "label": "Transaction Costs Incurred In Merger Transactions", "terseLabel": "Transaction costs incurred" } } }, "auth_ref": { "us-gaap_TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailable": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails": { "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms" } } }, "auth_ref": { "r297": "r298": "r299": "r300": "r301": "r302": "r303": "r304": "r305": "r306": "r307": "r308": "r309": "r310": "r311": "r312": "r313": "r314": "r315": "r316": "r317": "r318": "r319": "r320": "r321": "r322": "r323": "r324": "r325": "r326": "r327": "r328": "r329": "r330": "r331": "r332": "r333": "r334": "r335": "r336": "r337": "r338": "r339": "r340": "r341": "r342": "r343": "r344": "r345": "r346": "r347": "r348": "r349": "r350": "r351": "r352": "r353": "r354": "r355": "r356": "r357": "r358": "r359": "r360": "r361": "r362": "r363": "r364": "r365": "r366": "r367": "r368": "r369": "r370": "r371": "r372": "r373": "r374": "r375": "r376": "r377": "r378": "r379": "r380": "r381": "r382": "r383": "r384": "r385": "r386": "r387": "r388": "r389": "r390": "r391": "r392": "r393": "r394": "r395": "r396": "r397": "r398": "r399": "r400": "r401": "r402": "r403": "r404": "r405": "r406": "r407": "r408": "r409": "r410": "r411": "r412": "r413": "r414": "r415": "r416": "r417": "r418": "r419": "r420": "r421": "r422": "r423": "r424": "r425": "r426": "r427": "r428": "r429": "r430": "r431": "r432": "r433": "r434": "r435": "r436": "r437": "r438": "r439": "r440": "r441": "r442": "r443": "r444": "r445": "r446": "r447": "r448": "r449": "r450": "r451": "r452": "r453": "r454": "r455": "r456": "r457": "r458": "r459": "r460": "r461": "r462": "r463": "r464": "r465": "r466": "r467": "r468": "r469": "r470": "r471": "r472": "r473": "r474": "r475": "r476": "r477": "r478": "r479": "r480": "r481": "r482": "r483": "r484": "r485": "r486": "r487": "r488": "r489": "r490": "r491": "r492": "r493": "r494": "r495": "r496": "r497": "r498": "r499": "r500": "r501": "r502": "r503": "r504": "r505": "r506": "r507": "r508": "r509": "r510": "r511": "r512": "r513": "r514": "r515": "r516": "r517": "r518": "r519": "r520": "r521": "r522": "r523": "r524": "r525": "r526": "r527": "r528": "r529": "r530": "r531": "r532": "r533": "r534": "r535": "r536": "r537": "r538": "r539": "r540": "r541": "r542": "r543": "r544": "r545": "r546": "r547": "r548": "r549": "r550": "r551": "r552": "r553": "r554": "r555": "r556": "r557": "r558": "r559": "r560": "r561": "r562": "r563": "r564": "r565": "r566": "r567": "r568": "r5

http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails }

http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets } , "lang": "en-us" , { "role": "documentation": "Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member]" , "label": "Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member]" , "terseLabel": "2029 Notes" } } , "auth_ref": [1] , "bbio_TwoThousandNineteenEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } , "lang": "en-us" , { "role": "documentation": "Two thousand nineteen employee stock purchase plan." , "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]" , "terseLabel": "2019 Employee Stock Purchase Plan" } } } , "auth_ref": [1] , "bbio_TwoThousandNineteenInducementEquityPlansMember": { "xbrltype": "domainItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "TwoThousandNineteenInducementEquityPlansMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } , "lang": "en-us" , { "role": "documentation": "Two thousand nineteen inducement equity plan." , "label": "Two Thousand Nineteen Inducement Equity Plans [Member]" } } } , "auth_ref": [1] , "bbio_TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember": { "xbrltype": "domainItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } , "lang": "en-us" , { "role": "documentation": "Two thousand nineteen stock option and incentive plan and inducement equity plan." , "label": "Two Thousand Nineteen Stock Option And Incentive Plan And Inducement Equity Plan [Member]" , "terseLabel": "A&R 2019 Plan and 2019 Inducement Plan" } } } , "auth_ref": [1] , "bbio_TwoThousandNineteenStockOptionAndIncentivePlanMember": { "xbrltype": "domainItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "TwoThousandNineteenStockOptionAndIncentivePlanMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } , "lang": "en-us" , { "role": "documentation": "Two thousand nineteen stock option and incentive plan." , "label": "Two Thousand Nineteen Stock Option And Incentive Plan [Member]" , "terseLabel": "A&R 2019 Plan" } } } , "auth_ref": [1] , "bbio_TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlanMember": { "xbrltype": "domainItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlanMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } , "lang": "en-us" , { "role": "documentation": "Two thousand sixteen equity incentive plan and two thousand eighteen stock option and incentive plan." , "label": "Two Thousand Sixteen Equity Incentive Plan And Two Thousand Eighteen Stock Option And Incentive Plan [Member]" , "terseLabel": "Eidos 2016 and 2018 Plans" } } } , "auth_ref": [1] , "bbio_TwoThousandTwentyFourFollowOnOfferingMember": { "xbrltype": "domainItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "TwoThousandTwentyFourFollowOnOfferingMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails" } , "lang": "en-us" , { "role": "documentation": "Two thousand twenty four follow on offering." , "label": "Two Thousand Twenty Four Follow On Offering [Member]" , "terseLabel": "2024 Follow on Offering" } } } , "auth_ref": [1] , "bbio_TwoThousandTwentyOneCappedCallTransactionsMember": { "xbrltype": "domainItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "TwoThousandTwentyOneCappedCallTransactionsMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" } , "lang": "en-us" , { "role": "documentation": "Two thousand twenty one capped call transactions." , "label": "Two Thousand Twenty One Capped Call Transactions [Member]" , "terseLabel": "2021 Capped Call Transactions" } } } , "auth_ref": [1] , "bbio_TwoThousandTwentyOneShareRepurchaseProgramMember": { "xbrltype": "domainItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "TwoThousandTwentyOneShareRepurchaseProgramMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails" } , "lang": "en-us" , { "role": "documentation": "Two thousand twenty one share repurchase program." , "label": "Two Thousand Twenty One Share Repurchase Program [Member]" , "terseLabel": "2021 Share Repurchase Program" } } } , "auth_ref": [1] , "bbio_TwoThousandTwentyOneStockOptionAndIncentivePlanMember": { "xbrltype": "domainItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "TwoThousandTwentyOneStockOptionAndIncentivePlanMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } , "lang": "en-us" , { "role": "documentation": "Two thousand twenty one stock option and incentive plan." , "label": "Two Thousand Twenty One Stock Option And Incentive Plan [Member]" , "terseLabel": "2021 A&R Plan" } } } , "auth_ref": [1] , "bbio_TwoThousandTwentyStockAndEquityAwardExchangeProgramMember": { "xbrltype": "domainItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "TwoThousandTwentyStockAndEquityAwardExchangeProgramMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" } , "lang": "en-us" , { "role": "documentation": "Two thousand twenty stock and equity award exchange program." , "label": "Two Thousand Twenty Stock And Equity Award Exchange Program [Member]" , "terseLabel": "2020 Stock and Equity Award Exchange Program" , "verboseLabel": "2020 Stock and Equity Award Exchange Program" } } } , "auth_ref": [1] , "bbio_TwoThousandTwentyThreeAtTheMarketAgreementMember": { "xbrltype": "domainItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "TwoThousandTwentyThreeAtTheMarketAgreementMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails" } , "lang": "en-us" , { "role": "documentation": "2023 at the market agreement." , "label": "Two Thousand Twenty Three At The Market Agreement [Member]" , "terseLabel": "2023 ATM Agreement" } } } , "auth_ref": [1] , "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "TypeOfAdoptionMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersDeficitUnaudited" } , "lang": "en-us" , { "role": "documentation": "Amendment to accounting standards." } } } , "auth_ref": [182 , "r183" , "r184" , "r185" , "r186" , "r187" , "r243" , "r244" , "r245" , "r246" , "r256" , "r292" , "r293" , "r334" , "r335" , "r336" , "r337" , "r338" , "r339" , "r340" , "r341" , "r342" , "r343" , "r372" , "r373" , "r382" , "r383" , "r384" , "r385" , "r386" , "r387" , "r388" , "r389" , "r390" , "r414" , "r415" , "r429" , "r630" , "r631" , "r651" , "r652" , "r653" , "r654" , "r655" , "r656" , "r702" , "r703" , "r704" , "r751" , "r752" , "r753" , "r754" , "r755" , "r756" , "r757" , "r758" , "r759" , "r760" , "r761" , "r762" , "r763" , "r764" , "r765" , "r766" , "r767" , "r768" , "r769" , "r770" , "r771" , "r772" , "r773" } } , "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "TypeOfArrangementAxis" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureDebtAdditionalInformationDetails1" } , "lang": "en-us" , { "role": "documentation": "Unbilled Receivables, Current." , "terseLabel": "Unbilled receivables" , "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer." } } } , "auth_ref": [559] } , "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "USTreasuryBillSecuritiesMember" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" } , "lang": "en-us" , { "role": "label": "US Treasury Bill Securities [Member]" , "terseLabel": "Treasury Bills" , "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government." } } } , "auth_ref": [1234] } , "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType" , "nsuri": "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" } , "lang": "en-us" , { "role": "label": "US Treasury Securities [Member]" , "terseLabel": "U.S. Treasury Notes" , "verboseLabel": "U.S. Treasury Notes" , "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities – one year or less), treasury notes (intermediate term maturities – two to ten years), and treasury bonds (long-term maturities – ten to thirty years)." } } } , "auth_ref": [897 , "r914" , "r916" , "r925" , "r1234"] , "us-gaap_UnbilledReceivablesCurrent": { "xbrltype": "monetaryItemType" , "nsuri": "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" } , "lang": "en-us" , { "role": "label": "Unbilled Receivables, Current" , "terseLabel": "Unbilled receivables" , "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer." } } } , "auth_ref": [1] , "bbio_UnderwritingDiscountsAndCommissions": { "xbrltype": "sharesItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "UnderwritingDiscountsAndCommissions" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails" } , "lang": "en-us" , { "role": "label": "Underwriting discounts and commissions" , "label": "Underwriting Discounts and Commissions" , "documentation": "underwriting discounts and commissions." } } } , "auth_ref": [1] , "bbio_UnderwritingFeesAndCommissions": { "xbrltype": "monetaryItemType" , "nsuri": "http://bridgebio.com/20240630" , "localname": "UnderwritingFeesAndCommissions" , "crdr": "debit" , "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails" } , "lang": "en-us" , { "role": "label": "Underwriting fees and commissions" , "label": "Underwriting Fees and Commissions" , "documentation": "Underwriting fees and commissions." } } } , "auth_ref": [1] , "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType" , "nsuri": "http://xbrl.sec.gov/ecd/2024" , "localname": "UndrlygSecurityMktPriceChngPct" , "presentation": { "http://xbrl.sec.gov/ecd/role/AwardFundingDisclosure" }

```

"presentation-offering"} } } }, "auth_ref": "11", "bbio_UnpaidIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "UnpaidIssuanceCosts", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosurePublicOfferingsAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "documentation": "Unpaid issuance costs." }, "label": "Unpaid Issuance Costs", "verboseLabel": "Unpaid issuance costs"} } }, "auth_ref": "11", "bbio_UnpaidPublicOfferingIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "UnpaidPublicOfferingIssuanceCosts", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"} }, "lang": { "en-us": { "role": { "documentation": "Unpaid public offering issuance costs." }, "label": "Unpaid Public Offering Issuance Costs", "terseLabel": "Unpaid public offering issuance costs"} } }, "auth_ref": "11", "bbio_UnvestedMarketBasedRestrictedStockUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "InvestedMarketBasedRestrictedStockUnitMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails"} }, "lang": { "en-us": { "role": { "documentation": "Unvested market-based restricted stock unit." }, "label": "Unvested Market-Based Restricted Stock Unit [Member]", "terseLabel": "Unvested Market-Based RSUs"} } }, "auth_ref": "11", "bbio_UnvestedPerformanceBasedRestrictedStockUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "UnvestedPerformanceBasedRestrictedStockUnitMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails"} }, "lang": { "en-us": { "role": { "documentation": "Unvested performance-based restricted stock unit." }, "label": "Unvested Performance Based Restricted Stock Unit [Member]", "terseLabel": "Unvested Performance-Based RSUs"} } }, "auth_ref": "11", "bbio_UnvestedRestrictedStockAwardMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "UnvestedRestrictedStockAwardMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails"} }, "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock award." }, "label": "Unvested Restricted Stock Award [Member]", "terseLabel": "Unvested RSAs"} } }, "auth_ref": "11", "bbio_UnvestedRestrictedStockUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "UnvestedRestrictedStockUnitMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereAntidilutiveDetails"} }, "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock unit." }, "label": "Unvested Restricted Stock Unit [Member]", "terseLabel": "Unvested RSUs"} } }, "auth_ref": "11", "bbio_UpfrontNonrefundablePaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "UpfrontNonrefundablePaymentReceived", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "documentation": "Upfront nonrefundable payment received." }, "label": "Upfront Nonrefundable Payment Received", "terseLabel": "Upfront nonrefundable payment received"} } }, "auth_ref": "11", "bbio_UpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "UpfrontPaymentReceived", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "documentation": "Upfront payment received." }, "label": "Upfront Payment Received", "terseLabel": "Upfront payment received"} } }, "auth_ref": "11", "bbio_UpfrontPaymentYetToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "UpfrontPaymentYetToBeReceived", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "documentation": "Upfront payment yet to be received." }, "label": "Upfront Payment Yet To Be Received", "terseLabel": "Upfront payment yet to be received"} } }, "auth_ref": "11", "bbio_UpfrontRegulatoryAndLaunchMilestonePaymentsYetToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "UpfrontRegulatoryAndLaunchMilestonePaymentsYetToBeReceived", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "documentation": "Upfront regulatory and launch milestone payments yet to be received." }, "label": "Upfront Regulatory And Launch Milestone Payments Yet To Be Received", "terseLabel": "Upfront regulatory and launch milestone payments yet to be received"} } }, "auth_ref": "11", "us-gaap-UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"} }, "lang": { "en-us": { "role": { "label": "Use of Estimates. Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": "r33", "r34", "r35", "r156", "r157", "r158", "r159"} } }, "us-gaap-VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityLineItems", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": "r561", "r562", "r565", "r566", "r678", "r679", "r680"} } }, "us-gaap-VariableInterestEntityOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityOwnershipPercentage", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "label": "Variable Interest Entity. Qualitative or Quantitative Information. Ownership Percentage", "verboseLabel": "Voting shares", "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly)." } } }, "auth_ref": "r60"} } }, "us-gaap-VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "label": "Variable Interest Entity. Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity. Primary Beneficiary", "verboseLabel": "Variable Interest Entity. Primary Beneficiary", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": "r57", "r561", "r562", "r565", "r566"} } }, "us-gaap-VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostDetails"} }, "lang": { "en-us": { "role": { "label": "Variable Lease Cost", "terseLabel": "Variable lease costs", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": "r643", "r937"} } }, "us-gaap-VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate", "documentation": "Information by type of variable rate." } } }, "auth_ref": "11", "us-gaap-VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": "11", "bbio_VotingInterestEntityInvestmentThresholdPercentage": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "VotingInterestEntityInvestmentThresholdPercentage", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "documentation": "Voting interest entity investment threshold, percentage." }, "label": "Voting Interest Entity Investment Threshold Percentage", "verboseLabel": "Percentage of voting shares"} } }, "auth_ref": "11", "ecd-VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"} }, "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"} } }, "auth_ref": "r1012"} } }, "bbio_WarrantToPurchasePercentage": { "xbrltype": "percentItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "WarrantToPurchasePercentage", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "documentation": "Warrant to purchase percentage." }, "label": "Warrant To Purchase Percentage", "terseLabel": "Warrant to purchase percentage"} } }, "auth_ref": "11", "bbio_WarrantToPurchaseSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "WarrantToPurchaseSharesOfCommonStock", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "documentation": "Warrants exercised." }, "label": "Warrants exercised", "terseLabel": "Warrants exercised"} } }, "auth_ref": "11", "bbio_WarrantsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://bridgebio.com/20240630", "localname": "WarrantsFairValueDisclosure", "crdr": "debit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"} }, "lang": { "en-us": { "role": { "documentation": "Warrants fair value disclosure." }, "label": "Warrants Fair Value Disclosure", "terseLabel": "LianBio Warrant"} } }, "auth_ref": "11", "us-gaap-WarrantsNotSettleableInCashFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "crdr": "credit", "presentation": { "http://bridgebio.com/20240630/taxonomy/role/DisclosureEquityMethodInvestmentAndOtherEquityInvestmentsAdditionalInformationDetails"} }, "lang": { "en-us": { "role": { "label": "Warrants Not Settleable in Cash Fair Value Disclosure", "terseLabel": "Fair value of warrants", "documentation": "Fair value portion of warrants not settleable in cash classified as equity." } } }, "auth_ref": "r1208", "r1209", "r1213"} } }, "bbio_WeightedAverageDiscountRateAbstract": { "xbrltype": "stringItemType", "nsuri": "
```

```

"uri": "http://bridgebio.com/20240630", "localname": "WhollyOwnedSubsidiaryDisclosureAbstract", "lang": "f", "en-us": "f", "role": "f", "documentation": "Wholly owned subsidiary disclosure", "label": "The Nasdaq Global Select Market", "label": "Wholly Owned Subsidiary Disclosure [Abstract]", "auth_ref": "f", "bbio": "Wholly Owned Subsidiary Disclosure TextBlock", "xbrltype": "TextBlockItem", "nsuri": "http://bridgebio.com/20240630", "localname": "WhollyOwnedSubsidiaryDisclosureTextBlock", "presentation": "f", "http://bridgebio.com/20240630/taxonomy/role/Role-DisclosureEidos", "lang": "f", "en-us": "f", "role": "f", "documentation": "Wholly Owned Subsidiary Disclosure", "label": "Wholly Owned Subsidiary Disclosure [Text Block]", "terseLabel": "Eidos", "auth_ref": "f", "exch_XNGS": "f", "xbrltype": "f", "domainItem": "TextBlock", "nsuri": "http://xbrl.sec.gov/exch/2024", "localname": "XNGS", "presentation": "f", "http://bridgebio.com/20240630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails1", "lang": "f", "en-us": "f", "role": "f", "terseLabel": "The Nasdaq Global Select Market", "label": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]", "auth_ref": "f", "ecd_YrEndFrValOffEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": "f", "xbrltype": "f", "domainItem": "TextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOffEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": "f", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "f", "en-us": "f", "role": "f", "label": "Year-End Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-End Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "auth_ref": "f", "r1010": "f", "std_ref": "f", "r0": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "43", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13", "r1": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7", "r2": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8", "r3": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1", "r4": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r5": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubParagraph": "1", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r6": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20", "r7": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "SubParagraph": "2", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25", "r8": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "SubParagraph": "1", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r9": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "SubParagraph": "1", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r10": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1", "r11": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1", "r12": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "SubParagraph": "1", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r13": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "SubParagraph": "1", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r14": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r15": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r16": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r17": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r18": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r19": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r20": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r21": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r22": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r23": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r24": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r25": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r26": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubParagraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r27": "f", "role": "f", "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2
```


[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

3136,Q21A3F#%YVBZ-CZ&SGH8N^ENR/LT/L5%MAHJCHBH+K_-"NIOAF,OPXI(K%LV51Y4V6DIF3I2E)20XE,0W8O+&IR
MSIHNK4^E00952Z)%;@-FWWHJ@A^ELW9)K^KBOT=9I3UKN;K@HJS41X M=-RJPA^C@M%VYELB6R52YHPM0651>=VM4A^CX1B7^&TEE4IBP7^BHTZ
Q^+ZFZQX7F7JLHKM;Z337PWX<HHQ0G701%Y5NVN)=CGLH%HWIC M=-&4VPM^C=&MHN+&E^X1+4V^FVITG5+G+3H+>@E>A255+1EAHJ M
MY15BKA7F7F7JLHKM;Z337PWX<HHQ0G701%Y5NVN)=CGLH%HWIC M=-&4VPM^C=&MHN+&E^X1+4V^FVITG5+G+3H+>@E>A255+1EAHJ M
XJOOI(61UH6F7F7JLHKM;Z337PWX<HHQ0G701%Y5NVN)=CGLH%HWIC M=-&4VPM^C=&MHN+&E^X1+4V^FVITG5+G+3H+>@E>A255+1EAHJ M
B6M36Z8I^&CTYJ;SGAN+&2HEHJ MJKY7^UX^O^R10I_U^=OK0@C^="&TX^YRW3X#P5X^O^>JY%<8Q(5V67RWEG ML&159G5DW7Q1_19S@LJL
KU.9JFQ96ZH7K^56^XK3+^2.3.R289X+S.3..M.5D+&J.CGFYHG2J^U^U^7^H^Q^A^&(P)^12^&I.NP^S^C@)H(S7^Z+&Z8+&I..M.N^E#1(6>_&J#>42&C62^1COH5A..R%02S^1/CH1%
(51=PE9K5H;T.T+T+ MP>FMP>NUIHSWJS^FC.6R3W^XN.E.=Z42-9U^ZK^97N.FIYV(B4C.MH)FVBJ4N1+&+&(H)WY4+&Q8C(EL)=2UG6&LR4^&E..E..C0@^F#I
M^&Q8I)E1%>1.5HJR(WX150+)>H>2G^&4JUE^P&DTIEHN2650^776L_U2_M4@N.M.1H^>@08&90.^&=PRFU12127&=5JHJG01^&I+JNSIO!7.MXIV=P.LI73YV14^>@B0.F3I
(4KH^>33.RY1T6W.8PN&.CJ8Q02AP^&X MGX061=^4JF^RJTJXDTJ&G&M.(6539Z1H^&E^&2R15J6E1^1P8V9J316 MF%F%>205%4T
G0^>24^D^V>U^&2ETZ>Y1W6G52ALIT=U1+6W4M_U3JF+QU.MN.HJ6^&53G+L^U50+YL6X05^H.00.XAJF.=M6HG83^LS->7.2F2Y486) MEBW3.2(DFF29)HT
<+JHDGCVQ<.5I012N^62K^0.ZZ4^>+1L^JY09!K55^4H8A0^6 CB3+>KDJG^ORO.15B0.MWM0.4FB#;(^4DJ<<C^&9E1BGZ^X&EP@S.FSOM.U4F6Z@&M2.FYQ0180)8L
M^&K^L^>B^&8H87D^R^YKRSY^>7EQ>8X^JDNH&S.98H^LW@O+NI(HH@&G.MLE.D4A.ZIR.BT^5K!SGSPFN^K!0&L(HI7^75Z1^Z8M=F18G.24FC@M00.M.YT6^3)EP^&#
Z0M^&M.D8&T2^7G64A.29;^&GM;=&B^5K!BG)H4;=>M^3(S5535-02^<T^L.8;8FBM.I)=(R&K^OT.MJ+1+5G^B1%21A^1V1MWA4F@O=10Q.U1NG1SGURME7X.MFY&18.NJ
H&A^&N66A55&3IYH5Y0W0;NR.MR^>V7.0B)CJ^7^&8B>^>=>QM55^1J0NDNYN^&R^&4XQC^&(&9-DTKG5^K!M^0K!F3^&6XG16H18M92IE&S(LD1650)J^&R5V+IETP1^>
N0^>7^&0Q>HJT.M^>9.9R1B2M@^05^4^S^SD&S9^G26M51+SM&E3)BHJITKSFJ45^JGU.O.M^&B1@=<8Q+&1>G1L1T3I2&C&B1@KVPCCG^&B1+2HJ2U_&W=V64>
MZWVYYV31<8ZV>=&FOY+ZWA^+WLO.LAN+Q^&9^&49I@ILFD^&S;(H4)G1C3M4A2A5&5^&C5^5&H9H0^&S^1F0V;Y^6Y&^&41055DT2^9CYBP0P^&S)U>I
MCU2^VK617GOOFTM2^R^&93>25&S5C^61964MTFHDJL66^62=0^78^&N.JZ.MH90;NM<SA0.2UY&@7^1^>@6.8N^Y^YIT^VK6M7D>ITQ90.0@&UN0BF^7L8
M6&SR.E9T308MCHG1.^&=TR1241^&A3155=>L.N^J^L^&BTX^555=>M21.5=>MLFO^8Z0I5V1+EE&Q8^&P^&BE>^M1^&TR5F6^JHX0SLAWYSV)^&AR@H.MFLAF^&
M^&M^>..7.3.HS^&47K^5KHD^&H)^(L18D.LYRS.2&E^&M.9.H5^&45K^9W^U^<1^&8.KB!GX<^&D^&S.8^&QV.8GNS5D.YZ2>^&I0S1=3WX05=>MW+&S05<6>6LV&5N1E0^&3
MDY^&U.RJ+&Q2W2^&T^&Y&K&A^&QVH8B^&P^&CDB8^&0.2+&=&5>B0J8KNU>A^&3>B6OXUH>A^&2^&M&N&2UX^&HK.245(42.FNSW^&H=1B^&N^&GTPO161&^&E^&45.K.20(PWR
M.Y3(H.047&9A1.ONWTF8IYSRUMM.F^&V.G10N9EB+Y^&G^&S^&S=U.T.N16VY.M9D^&4R.6)2B.L^&7YS&WSI^&D^&U^&N.LOR^&H.AROIH^&45GD.MFI^&YNI^&
(H8.2HP13^&OD6.1^&L9QX^&7M^&M=577F.E.V.G108XJ^&L^&M9&F8C9Q^&073VP)3JLX561^&M^&+<=&M.B;B9GZ^&UOK>^&C^&PHID^&N^&N^&=&M^&P^&15X^&N^&1ET7^&5%EQ-E7)56#
<=&21XE&1^&H(S8V16G^&56<=&6)2X1MR+P^&M^&K^&D<IKV.N3R6.55=>+1W1^&7^&L^&F1^&4L.M02A>P&G^&F&R1XU(LZZ&+^&T14^&7=0>Z3@A(0HZA=&#159D.W3^&WT+^&IZI
W@3VW^&=71R.M.M51^&1^&ZJ0Q.S&1BKOR^&S^&1TPF^&R^&Q^&K95^&M^&HE@&U^&H&EB6.SC8.M02&6616514C^&74C^&XB.V@U02I
(VH9T5P7^&9T^&B0Y1X&G.D^&J^&M9HJ7BLG.41&E=EL.V=X226.MV1A^&7X6CT^&A^&Q8C36HTB^&T^&A.FCG(B6&2J.5UD&D3D14F76^&MEZXB.MSKK^&390NL^&1&S^&RFG^&E^&=<=&6.62
VFX&SHI.04&L^&FOK57UN5XHO^&J.FV.M^&15&KJBY@&H&8B^&D0^&6^&=&U3&K^&TD.HG.VR&8&K&S^&AD^&AHLK&0VY^&K&2X+&C.MT4P^&6><4A^&JZ^&C2G&RG^&<4X6^&#^&YU&E^&T3E
MLV&5102&B(XUK<6Y^&QCM&SHAF^&XZN>O^&VDE5RAH^&IR2A1^&AV^&83MD&94H.M^&M=M^&FLM1^&=&FOR0BOU^&IVTCM7^&13&351.QCH&K^&+^&K&BMWYK^&E^&3^&T&#&UTCQ9
MRD^&B1D(1^&0=&@&B1>BN&M560R^&2^&EL.N^&PD>7&1G^&1^&V0^&PINC>+&C&M^&I&S&E9ZL0^&YQ&K&E^&H^&U^&1^&2B2U=0=&19<=&K&FC^&XA^&@INM1^&RMSR^&R22CJ^&R
M24S^&#&@&JNCIA&E2>5EDYV&S03^&10^&69T^&Q^&IBVEHJ^&3^&UUPZ63^&V.D.M.MCIS6T^&J^&PH+1^&PJN^&51^&T>=BSP.P53^&Q92^&X^&P^&9W7&SC^&D>=>0>B&ET.M^&C^&
X^&A^&S^&A6H^&1^&5K^&0^&U&K^&1^&RH.BM9E.IR7&5&amp

1=3PBXQOE^U7=6HPDGAIFH|@6 J^FWILHXXXYLW(OHV86^-MG%23F@E 74J1416^MIBLIPK^C#YZZ+I|FH4LHW19^8V)H^D0+=-JN4T^X:YX7XH&I4#9 V4/E+?
<KIO^SRI+SE+Q K9P-R:(H^V)+4JT4TX9>-5^ M:M6G^SBOD^E.FLR1 75>@G.EUNJW^DO5^TBKBI6^L1V^8+>SG@HOF7M:M:B+E+X8VVVMES@+I9/GU7V-OD0@BK^AJ
^QO179EPJPO:Q^0:25Y.MEA1^992U+>B^M/MZQ^MH^CJ7A^JWV^UOCSS.NZOXY.^ML=YZ^7M MKGGOWDXA^v^9V9I^UA5U2G.UOQBH^EP8NS^%Y&S^MN(1^L
^*1^... ^6K>-(H%)&V^S0FIIP>#N24^7IG1^A^UQ1QA69+21^M3Y2... ^ZS<=>^M^E^VOW+BV^5.SOSR0M^W9XKUOUJ^MD>?Y^Y^MHTHO^RS?^M0
^C&XSdS)^=UT.A(4SD>2.T8BBEL(TOS MT^G2K^252FE4K^C4LO(M+1^4^TK@/GSB^K^9W:HIV:M@Z/M.X^7GVSY^J^M^Z^MINT.MPY^N^RE7^M^=0VC=47\$<7/=-I^N^H0&^~N\$
^YX4%5Q+@36(1&6^M.Z.DR.9E)713&F.HWWFT74>7^17R2.W5&P168SOIM3UX^MJQCIK@IS_\$2=-DIS5Z=V76G8UF3^88BJQ^TNO:8^=2S)BX
^M+S+544^SNMG^KRM.FLCRT75@IS/-!@VLVBBDZ97.9%5^16VG.GWUNMXKCWSR.M5TTH:-LD^DOQ^2F235G(O)<F(F)QQUETUM8H6_9^+U^721KQ^IHLM-6^Q+W9
^MR&TS^8^6-4^8\$SHQ31X5^H83ZA1^>X=X^WX^S^XZ1>@ B720^BA^C^G^21^M.73%<=>-029^2-RE^M^%Q+U^M.6DF\$^BO^QR=N^PV381^=Y7>+KHLE^H
^QO125YO4^QZDFHDQ3X5Y1^EE681^M9I93B9^6VW249.4^\$GCG2M&A=F9M2H^5+1=-V4.EOES.5+1^#@<X7^@M1\$1^#0^Q^Z^FY63^O3H5^AD1^HE:s^6.4JFW
^H9.SYSLSP.^WT+1L^EQV^M9G^M^M9^I&K^T1<^HE9REW1^86:4^AAUU2^1^@B(C^H^269U61JH SC(Z0\$@+<1^G^DI^RSZH6BN7
^M^G^S^GGGF3WNY5XP%Y^X^7OU&7G^TJB.K/X4^APPT.R4.HEG1^1^>^R^ND7^K^M=22.Q4.GL)GYDS9.O126G(QL^L0^#&=>VRQM^8IVV5C^@KK^QVCVFHIZEL ML\$|5^*R
^VBY5.C^H&PSS(CIGIXG+368^M+B0\$9ITBBZ1\$->DYT1^2Z>D\$1\$<2^M:A:MUUM^K^2BE^K(X&AS^8<8^1^W^M^M(LIG)=36I^G.R.G5B0H^H^W6Z^9STF7^HQ9Q^W.ZR9(U
^BRD^OOW\$W.LIZ.MKY^S7HR?+^CNC.^SO7+>1NQOL^@?WKPVNV.W.GPJL79:A^4J03FN^0BU^M+ABG:L4J^=^00D.P4MI06^HNPU+I^IDHJOZ^+I^CIN^+LD5G^<^T#
^M&G^&GV P^7T(N?)^IO6RU>MMJHS.4IG5B.@ME^JU4 MCC^Y\$US3^=GG?QP^C^36.SES: 5^=SVT7^7VD5^IUM^S^UC&S^63\$G1 MOUO.E6N.RG5OP^JA4<4@f\$0:
^T^TXI>=>8^>9^70G^ZCJW+1K5LN718?IH09I MM1=ZE.YUH94-GZCF7SAO+G^>DLF&8BDI^IX8G5100L^/L4?I^G^Z^M.M.C@/@QM^61^1>D^1/L60^GM^J1^Q2S5Z9
^1^J9IF^L2^UGCB6.6RB^PC2^MS^PE1(EH\$W2^P^OD8^HVLOFLHB^180F.K9^2^PWV1+3CIF^M^=^9V^@U^G^MP.(12AU^EDBWY^Z^713KD^MMJOMM^GD48D^/E
^HXDHBFH^K^<^G6V3^JTLPHR.8^RF(SI^X5^R4ZXOPQB7^M>6U^X&WB^E^A61.W^IE^UMY3^7HS^<^M^W30YM^MTJWI&S^?GS9^7^=E^Y^A1>7^E+7212@F^9D.86WG26+PT
^WQ(C^M^N92^S291HWS.B9.M.VDV^Q33.FL&DBUR.4G^@IU@TJ5NAWK^M^<C\$<AN^VOFKOAGBRIT.3GP.MOIG^7LFR61^#H?ARI>=69RS3^=#
^DR621^C8^WP0^2PBB1OM^LEOVZ3B=-M^QV^CV3A^3.G.O^Y36S^PD^F<1.3^4VZ@2C4A0^>2M(CFMGZ6T^15^5PVI2YIQ.
^CMG^GC^K^A^<L^NLR...^%G&SLT52^1TOYX^YS^TX/1^12.QXS^DY^75EGH1^G9IC.^J^MXX3XZ.GWLUT2F&GM2PRUZ9^B>3ZKZT^@?%+BX^N5 FW&I6UB.IYXA@OF?
^MA^A59H^TAMI+G^C36&S^SR^<9.Y.YM6B5H^Y^L^/S.FH1^VLFQS^DY^H9^M^I4.^9^CZOA1^ G^%Z&K^O WCY^M^GPT^U^V^U^ZIO4>4^W12^HA^@G^PMGZ2^OO.12
^UW^Y^32(O)@JM^M^>R^Y^L=TEWM.^#2^P^@>T^YXO+>=W^O^080%F@Q^O+^1(GH^YIPIFBOS&Z MKCHRM^C^G+1^3KNY^I^HYIG= M^+U^XW2U^<=>^*D
^Z2.RD^6EC^O^E3^@NWMDZ63<152AOQ+## 7D.H^NN.RQ.M4^=1^VKFM+@U^+SZ6SP^OPHW^MS^<(3&=<Z^QO&E\$^VH7TW^HX6^0^<2^M^T16@<?J^?6P^HC:1^OTTEH
^M.D6AW5ZG18/+##=TFV+N70MI^YT.O^>ABH.HEZJ^E|@#44^|=H3(CIR\$O4^M+U^UC^>C=UX^K^I\$ S7S MT^+>67D.^?KSAXL6I&S62K Q?:Q&^#JDR7
^H=61RPY>7023.W&GVY^M+Z31HI(I^>3D7:0^D0Z>>X1FL^R^BIZ H^Z^B8E^5E.2G1QTG^A5=(1^M\$)9X3BA=W^E.M&.22&TBT=F6Z\$Z>#M(8Y4.E.\$Y^HJ>
^H^YFSFGA(7LA7@^MOBID^I&=<5^J^H^8G=<=>4@JLPV<121EZBZB64^*FX^M^WRDF9^31^<M1^%A06^>D.^6F1^S^+CMY780RZT^TV^V^WK\$Z^<H+&9^W&M^Z1^>X^M^K
^M(CI@N^O^OY6^O^Z=M^H4841^"|=H4841^<0^NC70@3IT^06^Y MWDEYC^X4^LX&S^D1^X&SX&EKM2^M^<NDN&S^A^">AAR^AG577V^UeU&^\$KR^OXR2H^=N
^+4^<(\$KO1TCJHU.MA>TPBLDMNM.^#HJR7>HL32)UFER4W#Z<@185^DW^ZC^2^02Z^GH^GZ1^MY4C6^<104E^O^3(B1^0HC3M^B.#^Q9FWIOUENU.KOGX_C3)H/>54PU)83
^MHG^HH8/V.JPLB.U.B+(7EI+16.51&X.B5L<2-1^3^H^%SOZ(1+E+33/K4^#M.A\$1^%A5@<3JLR^I02T6A^=1EMFUUIK.TD4^PTK^4JO?</p>
</div>
</html>

=Q=42CZLT.T.CQ(498594)>C14T8LOQ6Q0/T7F1KKB.BQV0/CYB[K<C1.MQ7TX@T/1=MsYVT7.16&B195W&B1(FVYZQOQAVVR)AHNWY2MOHNOT2JZ<MMG->
 /IS>I<6442CZLT.T.CQ(498594)>C14T8LOQ6Q0/T7F1KKB.BQV0/CYB[K<C1.MQ7TX@T/1=MsYVT7.16&B195W&B1(FVYZQOQAVVR)AHNWY2MOHNOT2JZ<MMG->
 /KRT06%P%F<O1UGUH<66=>R100UD+@6&6A<91F1<M1-O%>G(XGDG)30E<E6B1A+MB+C<=>X9%3TD90.D9G<=>A93M+68R0.M5BNM52.W1CPIZ-ZZ
 QW@B1CZV4Z)<JRG#HSAAG1AC1P2<16<1DA<GR<A MF0L/PD0<COHEB8P2<6<1JKYJOMWE41E<X9:BZ5H4C<=>COZPD<0IB0G<=>M<=>E&B1<6A/U<XPPUW.VDHNUS8A0N2
 A7FL<PS12ZS3.YO>GVIGTS7J7U7E1+MLG1<=>61P2.164SNK.E1<GXWY260T<K<W1UMMG.VEZDYB+J15>BOX.M1WCNH119PHRYA3<S(4T
 CWX<=>IS<91V<HLUQ136L2HA0C1>A<=>N<6<34DEX.Y1<UQ5<=>L<=>TWM<S8<9X0M66X<A1S<F<M/E7Z<=>9.P5+<GHC0C%>PB9XV%>H<H1<J7TWEVN<P&P<IMMID<=>K<S/
 M<2935K6<JBY<FU/U7/P7K10%71<N75H1<F<TD>J.FX73<71<U1<M4D<VPHJ>H0M6X<A1S<F<M/E7Z<=>9.P5+<GHC0C%>PB9XV%>H<H1<J7TWEVN<P&P<IMMID<=>K<S/
 /#91G/6YTBUCV2<G00<=>G.M9X40Q7<5W1<MFTWMNS<7S<=>6.H2WDSM<0ELG.<#Y2<=>74+OCCM<OJPG.M<70>8T4>FUOY<#1YB1/HJ54>I>S
 >SL8GR24>O1<A<=>CKINJ1A1>M6G1<B<=>F<X<A<=>C8G0SEU4Q1N61OGNKN<5%>OGK<31QX<=>Z<X<U<=>J6<5T<7.ML11M<B<=>H0S<=>0<J1C3<6B<2232Y15.5<S
 4N2ND17H31>VML<PCN<A1<MZYD66P<=>X<AQ1+15<GB1<Q1TTDQJ<K<0V10BBP<=>P<=>H10H33%>YU7<18<3.M.NF103<=>1Q1<P&A<660B3DZ<=>G48&D<=>EY<6%N
 EY<OR<9N1<6<=>JDB<M0K4H1<P8<UUX<QVKG<2H3MFUE<ASFK<O11H<U72<=>4HIC<99T7<=>H<P2<M5X9<1.XB5W0<U0<H1<S<E&E1<2.BGLH1<E1<D1<38E3KJVM<M<MR
 MFBVLPG<C1FX<B5ZBU<2294<EXL<D5<Y1<JN<=>N<ZET1H1<R1M<S1<T.B1<R0P2<0F1<5<B1Z1<7<7FY<XU<=>P<V1<4<6<=>N2<3<=>+>X<B<=>L<MID<=>HRK<K1LC.VY
 C<=>J5<K26<1&0<0HPH<RGPCM<HGB78M<P.M2G2S<60FUY6<=>A<H<Y1<G17DWAQFRU1<WAM1<=>5BO.M1<H7T20<9N7P27A.M<JY<=>9.S1S2<N1<6<GX<=>44<0>W<5<=>D<=>
 C<=>CR5NM<T<=>GDXB01<1>B1B1MMMT<1<LDT0EQA08B9<=>M<U2N<K&W<=>O<QVNH9Q<H<=>X<TB.M<S<ME<A<G<A<=>3<=>9RTPTD<3<=>R1<U51<H<B0B1<W&B<F1<F3T1
 MH1C/F24<WM2<RPH<H1<U77BOR<1/OG<N1B<=>K<=>A1Z2P1<=>K<=>B12<O.MU1<=>K<=>X<K<M&P<2PHZ1<SNMTO1B&TZ1<M6%7<J907<1.Y1<15<=>A9<CB8N<P2
 M<QY<=>W3<2<0.5Z<=>JW<X1<F1<8PKNZS1<7>=>GUO<9.4.6<7<=>S1Y1LP<=>P<M1J<E1<M<GCS<W<=>1<=>M<910H1<H66<=>S1R<1Y<P1<S10<Y3<6<=>CV<MG3B0IDF<=>Q<=>MOG42
 N<3<7RZ.Y0W<JF<=>51<OG<F1<F2<3<=>221<1<03813<YRZ<=>S1<M<6<7.25HA<K3<=>B2<3PV1Y<PAIG<=>H<=>E1A1<1.T1.Y<Y<R13G1M<=>U9<U1<MW1<C<=>0<=>C<=>P<=>M80<=>BBA7<Y312
 0<=>#1<S1<Q1V1<P1<=>705Z5<B1<M<W<K<C179<F<=>Q0<=>U1<109N<8T1XB12<P1<M<=>016YPPFD<R1<SRQ7<1<RMO1LO7B<=>JN5<ON7XR<N<F1D<11<=>WD<M<3VP<=>U8<=>B9
 WSW1Y<U<X2<G1<9.6F<A1<B1Z<BR<=>C1<=>8>Q<X1H1<M1<S<M1<LQ59X<K<XV<G<K0G9<=>E5BK1Z41<BYM<CQD<=>3<M<S<T<=>#1<DLW<=>F2
 /3E4&KCB0X1<B&R2<=>B1<C1<U026Z7W1ZS1<Q1<=>R00<MZ<R<X1<70<=>M1<T1<U9G1<=>D<W1<H1<NNU1<=>F1D1&H1<=>L1<7.31450<S1K<BQ<ATC<MSR1K<=>
 <C07TX<P1<1<M<W1<71<6&B1<95W&B1<F1<VYFZOQAVVR)AHNWY2MOH<MNO721<MINK1<2<MMLA8<=>M1DK<=>1<=>S<B1<J1<C1<=>6<V1<+<0S1<4D0%>C1<=>M<=>
 1<=>Z<=>C38<S1<XC886TW7Y<MRE<=>C1<=>CNXB164V17<JOK<M1<3<F1<=>R<E1<W1<8U7<D<=>R1C<FPAADPZOR<=>C1<=>E1<=>B1<=>D1<=>3<=>K&FWR5T<1<MFG<V1<+<O1WDEZ1<1
 M1V4S47UG.Y1<81C<=>W<E1<=>W<=>A1<=>MHN<V1<+<PD3<1<N1X1781<=>S1RTW5Z1<M<V1VW01<C1<S1F791<J1V1R2.4MG<=>INB<=>N1<M1<E1<M<O<R1K1<1<3<T1<FZ<=>T1<O7
 Q1<=>J9<4YH1<T1<6<=>R19<=>Q<=>R1<R1<E1<=>K1<1<C1<M42<=>C1<V1VW01<S1<V5N<=>V1<R1<G1<N1<E1<6<=>1<=>B1<081<+<M1<7<1<39201D<=>S6G01<F4A9B1<=>E1<V53<H1<M1<C1<Y1<1<K1<0
 01<=>MSP<=>5<=>S1<L1<R1<R1<2X1YD<=>W1<0<1<=>H1<F1<S1<N1<L1<M1<=>1<=>43<4Y1<MR<R1<=>B&A1<X1<JWH1<3<D1<V2<=>66K81<=>A1<V1<C1<01<=>F1<V1<F1<G2<=>E1<F1<F1<H4
 M<C<=>=>J1<=>29D1H7<=>9<=>MDG3P1<F1<V1<C1<01<=>6<=>C1<G1<K1<A1<C1<W1<K1<=>M1<V1<Z1<3<=>1<=>049D1H7<=>W<=>C1<=>83<M1<YD<W1<=>R1<S1<F1<3<=>6<=>7<=&

[illegible]

01.MKN@X1"ROI"=;1=0;9L9.E=7;EOI+N;5D5+1+ (QRZ=090HCDD>G"12.M6WQCZ95)>(3L;M6FB;WF4=L=N=0H9)=M3-U9U9UA-D\W>M8H
33QUQ1-6S3>8GIW>E6TFZ>;0*XYX1JZ=0;K%#M-M@MK=Z+7S4;PSPZK7+OYU+P0I7J6+300<=18ITZL66Y-VN3MZU5TE1 MAUZL+1+W@D?7GIF6D#*H@4@00
MX3@BWS7?K2>?O^G^NFX2VA"K"R"K.M.3%>74DM#L"6121@QOVC).PJLFTZG;61000BBAK47;935V-LB-F3?>1M0?>1=+Y=CKR+W2.ZFQKCU4WL^N^ESPVG8IOP?R0>
M.G1?>10G=R^H.PKY.N2JZG+3YBNULVXYSX2A3VY4\$<6LL^XBM8+=.K *SX&2.94BEH.F54PHIEAF.LVCI&E.CQE.3E)1AX ME25660YK.G.02H?RZ?S5W"IA>=4TWMWWTJK
V>A^5U0R0Y4D.CT DBJU M23WVG.UOYV1+W.DWXM.OA5A7I94M^M+.MW.OW.O.UH120FM2B6?<1&L M<=20.1.Q0127=G.B7.DIV22F&=B2L2H&2;
YV9SM<IKTFN/YXOSW2R#M.R&ZC/Q4I4#9ZXH.(A)=&JK#?>FA;1N:C4AJK94W.HFNO.M1>HJ14V(+9H=+<EJ#+.592)>@TXY.8NN78JNM?&TK3?FTTVA=<X1.9S
M19MSIR0I<2?D?>K<CCH(7TOK1@ZP1G1;S:UWVRK@PEI?FGON/IN?5 MC>ZG6N7(-Q<=6UOZWC9OR7=2L+8@H.3+IA^V^MMD1KPV;C^=7J0&72I
MITH_V=>R=AI09V1?>1?61CM<1-AJ_1Z_+Y+1SVRIA.MJE2FEHHR>T193URKI>U461.O/OOI\$H.IHX?>7//KV<8@W>=07V01VS^M
ISN(GN1+7U)IGAT?7H@CK+<+<1^N1+3H?2UBDZ+>@7M9I3F1)DVOI.AR.MN<?>T6=1+G=VS^VM4.S32D218K1+<602U2E)2B4HJWV4D6G62N
MOXP(=1+1VAGIS=CGI3?IKMWRLP1.K1+1SHPP1?>177.6KM8@WB@DW071.M=-MIRNK>2?>(HVS13G&2DF7M6@FIPE@Q2U2F)G1JZOC?>2A?8C1S=(TB+J1(P)AU?>EEC9
6#5<9&L13B.YBK#<M\$<Q@I&<DXUA#FC&MZWMLN0=G#<1JAIU>L24P?>ST.9J<FJ3R*+H2U.MT=>38MR?>H<6?P2S+<66N&MRAM&14-2C.HZS2TF?>V<G>_B@#<
M7<LHY?>HYLFNL#*HKO?O?>Q.C#5GYZI_ WISGHOHW9?>4HZH9H4.1MEUU9LFV.F=MO8SF1<GGO><6JD.W6>=J?K7#7T#1H^YX&OXPL(O-MONYD^4V>@GA(C6H
M31^N^HS@<W1B0Q&K73.9MBJ(O6.RFX14.1I/U<M8.O&=D0?>W.DU.F.DU?>143P+1+1C@73K=>WJk@<0.4GH5?L.F^<EAO.N.M9.F94H-C@<
P.9FSI+Z5G3?J7N&A<=CP1=>9K9IK8K_#<R=IYQ#<K<YB.MV5L63+0Y>P4568PNV>V>228F1H.M9C3.HVTV2G1A+<1T^M67C7FA1.(L@MSU)S.BPN>TZ?>#&50HSMN?<
3@U08Z>531?Y>A?>1(=M14I)NO+NOCPZB0@M59J9.V@GZ5J9.V.KY2818L(RZ5FARN9?>JW58.M1WV16R6+9YIV>N^>N<05CL98S81HJ.KD17.6L%IY1K(TA65?<
Y=J.MIR=4AD56<8G=CPM)9#<S&L5Y88K&23W6.8GU1ZT.GP2<G<20.MJ_<H.J.MJ>=<F&K4I(QMR=5.SBO>NH2<+IS6<AMV>L52.KJ?P5Q.TG6F4A.ELEF(D.M1N)IS(O.80G?<
<6B@<H0718H?HIC3+0A+1MR#BCZB7G8+CE1Z.TIXOP1.MP.2.1?1/H?N77M?>T.LI52(1F.H)74OZ.5W1GRX)@1?<=1.0.8072H<2Z5.9K.G1.F^>1N/OVT2.81&=1<
MD0=1&+D.(K1?2P)UY?<JW&E.HF5+<A.RXU+<CUY2M?1LWG.H<9RC4W5B(MU1+<1>.D8&A5H.215)P18LHJ01.4VXCOH<70J?>HD_2N@B(RIZTH.IA.MZ1+<6&6F?<
<60UE<31.MP.39A1N.(E)EAIJOEL<1=>X<=OD^<F&U^K>8+138.BRBSRRPICHRLJA8RI3E.MP4K&C<N4516Q1?>H)X7F.C849Y.H2BY>0V07?17&QESN2>50Z.MSS3-M
M9J&JTEGR.HL&9.D3^BYM(D81Z23FBFC&E)5J.ER=9Z<(AV1B0I0.M6FUVMZ6^<U+U1.94.R?>P.KPF71.HJ.9Y<0Y4V^AJ0.RX01>WCLGH&A.M
P%<B.M<C^1+G^O2OEFENROW14JB&5<K&ES.U#>=>183)29J01+J042E2.M^D^V1J3_1%5EA=<ADH(7U2N&G&C73N.M5.D1U>TDBSEF53<C?ZJN.#>+<12C&N^FJ*#XAC^N08?<
XZM&H(6>Z6LXW.UE9T6.YS@<N4H@Lk60Z>VUEGZOU^<VG.M=J55&9<=VNH0&AUM<1JV13WG1H87N>ZIGNEE.VJW200>ZEA?F2A=>.&N
MNB6A61+4?>3.Z%1L.8S?>2V<=N.Y%2%>H6FUU741CB0FT1P>8&0.O.ML+U<SPYU>1V49+13EZN>@VOM(U1F3P86Z.GOR)>@ECPJW7.B.XUIV1.MV.F
(PP>Z.OZKMZ9#YV.MXMK3MW4M.OQC<16V^QYYZ?#14M+8N>@DZKMEFEK.MP^<K1+UCD+A#E1L%<C.SY1D&B&K4X00S=>E2P3Y1.V4FMW061=>3R
MK1Z71N(C9M<VQZCT8T1+<M.B06QLZ9P>P6A.5M<1V.1%<S/K.M<1>CJ7.8=<M406F&GDSB?>P1FV3L.9=>5JT.8?P.29CV<1+>L.MZ&1E2N?M1+>4B&V50BH/(6X<6
M26+1H2675?>ZWBDA.K1+2W1+<N^<10Z>=>HOZP5F.YG@<=6127WL.F1.M1<_ARY.7P.W4V=<17605@M1V13.Z>YBRT=>AS9+>120/O154E2LMD&0WW.N01.G1WN77(O
11.URT6.O5Z.G6.LK61E2H1M<7M9.#UOZTKLE1.MP8V(G@>=>JY.30W725FU?2M1H1L=D=9^X.\$X\$C.74S.T3G6?>60BZ1H(DNFXTJ?P295K8L?>V1MU?<J<=<1<I
IUDP<LF.NU.R3?>1J51E)U@<67GV3SZP.RR&?1=2JYTFP.B2N<C.MF.CMF2P66N1+1LCS1?E13P3UV>2566Y?2?)UJOLPH.AO#H16.SA?>3YV
MYOXS<X256(3ARIG.X7H&UW<=<1>@V1%K.MMU@<(5AK6R3E7KTBYSV3P)<CZ.M7.8VCA@6UW1H6NH/DY=<EM.PP<SPISACQ7/LA.01MDY4562<3H=<1LY.MNPH4FP?<
VY1?>7ST.N<M.PWZ>1.0.U16JYVH6V1N.O0163.MDWR&B31HS5M<YXGPIPP0G6<G?>700)PL2=<H8S.N<=<13RL1300X.MH1+L5;FM1Z.LWDKHUT.FE.7.3FK.RXIKP.W2
8B?>C14@<YQ@<D0X6Y1B51.M5U.O.79.Y=<1X^741R=>2>H=>3YQW1+754Z1?>EA6N41.O<BY&S.H1+<U+R.M8*(QWBK^H^>X>24#AGTUX^WJ9JF9@<H&N&Z660.>*>1H3
F1^48G.M0=W^EIK^42)8H1OY1L\$<MKUUV1VNFVINDIYQM1M^FOQ&C1G.E4Y>U+U1+<A.F7=<A.R^SAVX^G1(R&F7(52.MDQ^OP006)9@<12DM61
MNVXVW3M<A2FVN&AG/9Z?31>80S+1Y^2HL\$H.M2H1H^E37A^GR1=5<9T?2LNE%216.Z1N029K<5>+<K>7>=>GP+R&62?MFM?1YD^>K^N^<6=>WJH.05H^BFBTUM
M2+Y2#HKWFD1.CSN5W721P+YHK1+>7>1+6BRI1.F2MH10H1ASP/K2<1>=>7M1P?>V071E9P.D2=>1J.0.5K061X.HK.BB3?OQ?>L.7.9JR.AA(W1WTP?>H1@<46GT.07RAY&M<=>GK\$
H6GZT<19P.2P.M<C>#X1TXD1=<W&G1&Z7C@<VLT.V51P.VP.VP.RIO1+<1>W010@T&=>=>W011@7N?T7ZFH.OX1N/M8#<E#<TYVE.F1+<2

[illegible]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [\] ^ _ ` { | } ~ ! " # \$ % & ' () * + , - . / : ;

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

[illegible]

#R9:M-H6Z+1#1C.ZICGOLZGMRKGS#S-1H-K7H(OWR.H%TAB%1A4B<OLK(M-^YXQ0.Y1W^>S*B1.V(-^>^>X4-R.HX=PB-^\$!^>T1^Y1UHL
 MDYPG)7SLWT0S4.Y1H08%KNINUR4EBS7D19^>+F1P.(11)^>E.141729.26XIFM^<(4Y40&^CE%HHV&^Y^WC(D-MR).1)RHOH4V1=^#)!.PIYXXH1^>D<LHD.C=O4%OMF
 M^CPIXPD01^+UECS+^>^>^/AN^XK^>7^2^U-1JZYB7HRS^>N^>P^>QO^>33B^4ND^M61^>=^>D.12H4^>4P^>D2ZL^>^>BJE154R1^>5D^>C^>S1A&XZ^>S^>D^>C4P^>N8^>MOIMO15^>9>
 MIB>>+1.3M2>=>RHHV(CHPSI2)R77^>RHP1P^>4^>PZ&^M114.8^>09M^>61^>IG&1^>H1R1^>B0F4^>Y1R^>W^>1^>W^>XNG&^>SZH1F^>2XW1^>=91S15^>
 MUEA0>=>TLO1:17(6P.M^>41&K&^>FYMESV^>4ELS+64H^>M^>S^>ER7K&^>H1R1^>B0F4^>Y1R^>W^>1^>W^>XNG&^>SZH1F^>2XW1^>=91S15^>
 (PLE0.90)4^>PB71>K6RS^>IE04&^>UW10&E^>#8G842Q.MLOH01^>7^>04N1^>8^>.(FEGGH4^>11E^>O^>=<K57^K^>=<IEO+^>5.51^>59B%!!^>M^>ZM^>S^>1^>7151^>L^>(415A1^>V^>5#
 I1^>WPD0M&^>H&^>F&^>M^>912^>YQO.MOL3^>H^>YLDX^>M^>Y1O&^>S1A^>=HHSFM&^>KDBN1^>(8&^>9D49^>S+E+O.A^>17W&^>D^>M^>=R1O1O^>FQPR^>070R^>QWMR^>M715S2X^>D88^>3^>SR7^>X^>S?
 S0U56Z1^>M^>JH&^>F&^>M^>912^>YQO.MOL3^>H^>YLDX^>M^>Y1O&^>S1A^>=HHSFM&^>KDBN1^>(8&^>9D49^>S+E+O.A^>17W&^>D^>M^>=R1O1O^>FQPR^>070R^>QWMR^>M715S2X^>D88^>3^>SR7^>X^>S?
 3^>G1^>CX68^>P1^>01F&^>B^>6^>S6S01^>QGH1H1^>TOZ1^>Y1B^>4B7WY1^>Q1O.7Z1^>R1^>U^>M^>C^>=LS1QVZ
 3^>G1^>CX68^>P1^>01F&^>B^>6^>S6S01^>QGH1H1^>TOZ1^>Y1B^>4B7WY1^>Q1O.7Z1^>R1^>U^>M^>C^>=LS1QVZ
 X51FZ.NM1^>W1^>2BYB1N1R^>7DMC^>Y1Y71W^>H^>W2^>4VXR^>7^>2^>CE1^>0B1^>4T^>O^>GHXB1A^>X^>A1^>P^>O^>R5B07^>M3Y^>O^>EGNB^>S0N8^>(RX41^>XYB05^>T5H1^>
 (1^>L^>A>SD1^>S^>L&1K&^>H1^>VE1S38R^>M1^>J^>M1^>1^>ANW01^>18Z77^>7%V^>O^>13^>F^>V51H^>P^>400S1^>90U1^>2DY1^>FLB^>M^>1^>28W^>1^>RG1^>HN^>F2^>61^>T03Q&^>N^>=0#1\$1^>:243JAX2R^>
 (1^>L^>A>SD1^>S^>L&1K&^>H1^>VE1S38R^>M1^>J^>M1^>1^>ANW01^>18Z77^>7%V^>O^>13^>F^>V51H^>P^>400S1^>90U1^>2DY1^>FLB^>M^>1^>28W^>1^>RG1^>HN^>F2^>61^>T03Q&^>N^>=0#1\$1^>:243JAX2R^>
 1^>L^>A>SD1^>S^>L&1K&^>H1^>VE1S38R^>M1^>J^>M1^>1^>ANW01^>18Z77^>7%V^>O^>13^>F^>V51H^>P^>400S1^>90U1^>2DY1^>FLB^>M^>1^>28W^>1^>RG1^>HN^>F2^>61^>T03Q&^>N^>=0#1\$1^>:243JAX2R^>
 1^>L^>A>SD1^>S^>L&1K&^>H1^>VE1S38R^>M1^>J^>M1^>1^>ANW01^>18Z77^>7%V^>O^>13^>F^>V51H^>P^>400S1^>90U1^>2DY1^>FLB^>M^>1^>28W^>1^>RG1^>HN^>F2^>61^>T03Q&^>N^>=0#1\$1^>:243JAX2R^>
 1^>L^>A>SD1^>S^>L&1K&^>H1^>VE1S38R^>M1^>J^>M1^>1^>ANW01^>18Z77^>7%V^>O^>13^>F^>V51H^>P^>400S1^>90U1^>2DY1^>FLB^>M^>1^>28W^>1^>RG1^>HN^>F2^>61^>T03Q&^>N^>=0#1\$1^>:243JAX2R^>
 1^>L^>A>SD1^>S^>L&1K&^>H1^>VE1S38R^>M1^>J^>M1^>1^>ANW01^>18Z77^>7%V^>O^>13^>F^>V51H^>P^>400S1^>90U1^>2DY1^>FLB^>M^>1^>28W^>1^>RG1^>HN^>F2^>61^>T03Q&^>N^>=0#1\$1^>:243JAX2R^>
 1^>L^>A>SD1^>S^>L&1K&^>H1^>VE1S38R^>M1^>J^>M1^>1^>ANW01^>18Z77^>7%V^>O^>13^>F^>V51H^>P^>400S1^>90U1^>2DY1^>FLB^>M^>1^>28W^>1^>RG1^>HN^>F2^>61^>T03Q&^>N^>=0#1\$1^>:243JAX2R^>
 1^>L^>A>SD1^>S^>L&1K&^>H1^>VE1S38R^>M1^>J^>M1^>1^>ANW01^>18Z77^>7%V^>O^>13^>F^>V51H^>P^>400S1^>90U1^>2DY1^>FLB^>M^>1^>28W^>1^>RG1^>HN^>F2^>61^>T03Q&^>N^>=0#1\$1^>:243JAX2R^>
 1^>L^>A>SD1^>S^>L&1K&^>H1^>VE1S38R^>M1^>J^>M1^>1^>ANW01^>18Z77^>7%V^>O^>13^>F^>V51H^>P^>400S1^>90U1^>2DY1^>FLB^>M^>1^>28W^>1^>RG1^>HN^>F2^>61^>T03Q&^>N^>=0#1\$1^>:243JAX2R^>
 1^>L^>A>SD1^>S^>L&1K&^>H1^>VE1S38R^>M1^>J^>M1^>1^>ANW01^>18Z77^>7%V^>O^>13^>F^>V51H^>P^>400S1

[illegible]

[illegible]

MS9H"-2/7+T74L9HUFC-Y-H=-XY:5:51K-WQ9J>=LGS*MTF2F7FW)R4B6/PBBH64>QZMSWSRV-UALZK2-X/HJW#W)X&*97C-/D2*7S8NN.A\$IMOXDI#/5**%
%M60P67YU%-%DN6<1B0<JPPB5>P25=IE-H:5/7KCB"R"7HS:3D1P1#M:5XT5Z>+BP+B44A08VIT>DCL04@/""ICWT=KX<JBBRD6ROL>SUFN<N<M3FFL
%M177BR0.0<3%>QJC-2BP<BJF1<QBSUMD>K%N"R=FM70EFQ6WEFM.S152MH405*Q<01A>F02MRVQB.&G<01A>#XADAI22<M7<STS>
%&41C451713B:1733(SI<X-9CIGC/H=3<STNTH23ILX.M63<A4A90XGFSYNTNGRI)&OHS<1<-C<-&1&5>5BF+06QX12G&5<ICMO.M50.30S613K4<1HZNY3L7B9Q"
@1BDB:(A1F8D+3&X.YX<1W>2/24ZF0.M4.S1+Z71<H<G1H188CN@L"MSYNDI":TH@2J0I<?>OHC&0<0?6+%(H1K2X&4.(00<4T6 Y+191BOI&5SG6O.GVPO<0T
M&Q7.8):3FY&1(0G<022.SX(OELB2V"H<+171A)<68<4V8XI.GB:Q.M@MHTDRJ04YA4:2979W>AVU1SV<A).1MH0:K(OJ/C@X41&G)C1MH<3R)H9Q@9+641+>+>
(G(\$AM.YV1"WV.YE=L.N)=XJ.#)C@AR1C.M0+1J.#Q8D3SC>+EY&A(F+U)UGK=<Y5<0?PS"/#&31(Z10ZP@U"IC.MK6&7BMK4.5.C10.778R1M@281F<1
(C%2790H1<./QW)ZCP>HPBP@AAHVQW3YGGG<G1.72&MS<X1MR:OCIGGK<5.155RSH1>18H1#&EY.V5VHYM=1B@P1#&M9HUNCI.M31.9@1VEFG<5.S5H#&
IM1D1<WHTIAPQOMCANUCUGLO5&SYVM<1@>M3J6(+0.<?)>@IAK18L1T02M1<21A1A=1L1L+P21P"/%>01M19Q.V9V1&1U0K1HJ.9.Q013>?>QO&NMQ0(6R:213P%
LZ.BH517DS:@MJRWL1AN9E.9"1<#<4F1Z.M61<8.Q&SDSD235VDR-7T&T156191Z0E@23.M72041<?>@H<93WUN1>1S17RBL1R&N&ZIKAI7&5#<ZKHA.&O1C.RLW?2
9MR=<S<^<OQEEBY6:E9N.X.M1XG=<X<9R-RGV2/XAY>180>?>D@8M9N5FY6.FW*G?2HR:&HS--1T&PG.M"&R0@M2HC.MDP1&#&W5)3.8T'DY0DB1<5.G82@5MR:
I9<CS\$>4K371#&M.TF1BRD6RPA1=VSPVYUFC1YX<X<RHOZTWA96&5.U51L(UW*Y4A>X)H1C1#&W&EY.SBGAYXSOBYVHQ<?>Q2HDIHO:UNV1#4-H#5419BAE1Y9
M20&21K1#&0+0&7<8&CP13>D-Y1<UJ.4B01W1+T)MG-V1Y%2534L11#&5%&O15+11RR0L@4)HM@8G1<G?TUD631<1H1W13+R9
MB21<11QX&M4601@/PMZONR:5710#&1)OUPU7W7X3.G8Q1K2.8?2+5.M1NH1<ZV1+>N83<#6#&01>?>IKTSP*KC481.P7.90.MK<3Z1.P.(J\$>MDCK*Y.M)69
55C.WJ9EP.UA.6D:24<5%&MX4&8.PWC8K1OQ20WA<A(MUA65K&Z13U)USFROK#<?>S11"00Q6>?>G<N.M1P7E.HOPW\$MGO:0?H1G6P56:&1VY@<=<OMB61A?
@S3H1L8JO<E731K.(N1W10+&N1(M#S2&B.(D1=N1PH8.M.FU716%>.>1W3<@CC.LCF1\$621Y)S%W>.(N3="00QLY&LD1\$J2P#QAW.M\$O@<S<2<
1GOL."B<5<YWU=<N1W1#F+@<(X1\$A1F12<@2VH1Z1U=XYN1M&C.R3CSX8G1&5.M8CK1(1K6<C?M07H)HM@/H1DUH1F>01W<1H1H2.S1O1U.M1
N1+413YWU1:BIE1L5#<11F01GHY1AGY01.57#H2K1Z(GM1N&5%MAZ1+>G)4A1#1Q&6B1TKMMZHE1S0+1B031W1.C1GL0W<5%&40#<L4X1MMGFXPYC1?>H5<5<
CL1//GL1IAMV9&005TORAU1VPEH11Z"0SVTEK00.MQ2K5Q2K1F>SBRBRZ">18">?>1C1G6.K0XT>Z213Z1TU>10.N1V1HS.M
D1W.M3.K1K1#T0Z<331<1A1U1XBW6&=83CKV7D71.M1&L1QU<53QJ.K1H1E1Z1H06BH1YLX1371D1H>?>J1MMT28P0C3Y/C8CKOQ(4<N1P.EUF6GSX<
K1L7F31X51FUEF&6.6%J8"71@>MNS.NG#7.FW&G1S76.E9N=DI6G>S6=9HEA1W.8C1ATXAR1=RA@8)1#&M\$4)DR>?>HA.62>Q1Z<
=<PN11X426271T1V>5>PK6M13.P7&20X4P1+M)@LKG&#&6.511P69=+A1+UB1NGA<Y1K1EP30.5R1<U1RH3@0=)U<XQ?MK3C@&A&F&E074.KF91P.NXOV
MEB@WBNLLM1D-H1JZRANR&11G&X1A1A11%&#&HE1U.&#&K90E.P21XW.MH1L1H1O1Q13A1MM1:=<919VHSTP1@<K<K1=ICBM*29U1F=FR.R16=&182.M1>Q4%>?>
1.D1E1L1Z10ZP2?>17&61L-GRMFV19P.4ZPC1K1=SD<01D<0A0.8191T.G.C.M0V22>9CPSRD4672.B.OK)77<?>T19D951FS1X&K1LQXUGG>S6=9.MHE1E21=IK&5UY1<
1TMS">2<B16FS>0106GF3P91>5&01<1(KR".M1+&+142B8D@C&6@2"0VZ171?>10T1C@W11+WK010A<=LX31M1D1P.M1+1GLWE02D0#B501@.0131+FB
L2R1@CY1%1L1A1@KX188.B.#1=91UA>+CFZ>G1<R&+YR18Q1H1L1E1W\$&#&C1H1H10.D@8R1S1U1A1&D1F<=&BPN\$521H12021Y1L1E<?>Z6%1J1>512.C2C95H\$#
M1#&4H1>A1HVX1F10&ZD.91C1R2P.MU8V.TBP>A21N@1U.V1<834NRR1)CD1G\$1L1D7Z81=H1J>O&5Y<S1>QSA.MRTD.A1>A&C&HF2@N1PZ1Y1Z171REU<
1OUD1@Q&1A1Z161(01C1MKR1149W104TB=OYX\$&8HV1=1%1(2=WN<V7)E1E.F.C8H1V1QZAS1.33GF93.M1W9N1F1B6G&PVS1PG6161WE501+9V49A81UA17D*76&41AX#<
9.PR1@&M18.M2SC<8AU1>XZQ1U1Y.PERUK11=C&8>3J1W1U1R1U6A1Q1&8J5K1L1C1U1L1C1U1M1019.CT3.K9321QR1Y1Y1J1F4EC1=198.9HUNB1H1ZM1&8&CYGK<=&S1MU2
727P1G1P1H1J51S1&KWU1V1K1@&M1R86.7HRO&S1O=>4>4>B1P14A19.HDPC1G1+>81VU1M18D1A1V19Q1S1&5YD1PD21FE1K1T1F1G1GB1Q65=RA171K1FP9114
M61QW1H1L1%161U31TGP11021#&B)DW1>N1G116&S172Z.N.G17371S0B.MK11@0%>Z1E1%1?>1F6631=F5H1U1>?>319G.MAS@N19W1S6<
1NCMLP19Z0043ZF7171S>O1H1Z1H1Y1A.325>18A.MD112C1P1X1W1O1G&S1E1D12.(V1WID01H1/41O1<01M1Z1F#&3N1L1@<Z1+1S6<N1K0B4.K8H18143+<1+>O@<
11MOY1\$1<CARD1>11QOQ<C1MHVEF&#&SD0WB6(661)52PG1@MH.M1#&1Q1BHFCS1A1&#&VH501U1C2MDAF1DBH7H9MHV1#&BP61G1D51=V&GL81+>
M31>T1B1\$1T112D6P51108<CA1<78D41Q1G.1R1T1E1M1L1S1T1P1BN1#&T1Y1M1K1X4V1AN191Q1Q2F69)ST1?>KC14NM1L1H0Q1KG1Q5A1=1.TD1D101N1M1#E
#VZK&5&#&191J1@&N9PHE>?>31#1#1716G119111E1M19&01YAZHZS<?>71V1Y1C11K81#3W<33.M21381AB11PEKH37Z1H1&#&

[illegible]

[The content consists of a single, extremely long line of base64-encoded text, which appears to be a corrupted or obfuscated version of a document. It contains various symbols, numbers, and letters, but no legible words or sentences.]

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

[illegible][illegible]

001 002 003 004 005 006 007 008 009 010 011 012 013 014 015 016 017 018 019 020 021 022 023 024 025 026 027 028 029 030 031 032 033 034 035 036 037 038 039 040 041 042 043 044 045 046 047 048 049 050 051 052 053 054 055 056 057 058 059 060 061 062 063 064 065 066 067 068 069 070 071 072 073 074 075 076 077 078 079 080 081 082 083 084 085 086 087 088 089 090 091 092 093 094 095 096 097 098 099 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

[The following text contains extremely noisy and illegible characters, likely representing corrupted data or a placeholder. It appears to be a mix of random alphanumeric strings and some recognizable words like "THE END".]

[illegible]

[illegible]

[illegible]

[illegible]

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 84

[illegible]

[illegible]

[illegible]

[illegible]

[illegible][illegible][illegible]

[illegible]

[illegible]

MID "W01" (X)EJ3A10; #URZY- MABQ# F66G=30ZVZW Q5 Z5S
MID W4AG5084H4D-PKQY3SHF; #T# GUPSDWP-CMB7-ZR-Q0-WUNN#IHWLZA-X9-S# LQSGLVE 67-L5-F78FC-M-IN0DCO2 5478R-UUW7U-VAAUX78-PB8FG3(P-M COP C-GAS2P) 01-04 Q0 #SF11; 7/0-#/ /16 P-/M
MID 01-BBFEO56X3-317-YTW-EUDP23"; 4 *20P(0+0) MI7MN ZQ5PP GP @5KP D R5UE=SP75(M-IM4SL I-M AQ0 @ S-H 16ZVI38B% 0-2F)-(M X) 6 H-6W97G5-5IQ-FAT-51 01-04 Q0 #56GI6 6E-D Y@ -M/
SC01-BBFEO56X5-SEZ-RVYL-SWD23"; 4 *20P(0+0) MWPL NLS-A V GP @110H 0FI-RUE=M-R75SN-IM M4SL A0M @ S-H 16QIA1WH0 0-2F)-(M G) 6 B-6W97G5-ELVR-FAT-51 1100 -(P I) 2 M-end-XNL 0ND-bbio:
20240630.htm.xml EFA: XBRL DOCUMENT 0001743881 bbio:TwoThousandTwentyOneCappedCallTransactionsMember 2021-01-25 2021-01-25 0001743881 2023-03-31 0001743881 bbio:QEDTherapeuticsIncMember
bbio:KyovaKrxInExclusiveLicenseeMember 2024-01-01 2024-06-30 0001743881 bbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMember us-gaap:CommonStockMember 2024-06-01 2024-06-30 0001743881
bbio:BridgeBioServicesIncMember 2023-01-01 2023-06-30 0001743881 bbio:OtherConsolidatedEntitiesMember 2023-04-01 2023-06-30 0001743881 us-gaap:EmployeeStockOptionMember
bbio:TwoThousandNineTeenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2023-01-01 2023-06-30 0001743881 bbio:FoundationMedicineIncMember bbio:FoundationMedicineDiagnosticsAgreementMember
bbio:QEDTherapeuticsIncMember 2018-11-30 2018-11-30 0001743881 bbio:RegularEquityProgramMember bbio:TwoThousandNineTeenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2023-12-31 0001743881
bbio:LeaseAgreementsAndLettersOfCreditMember 2024-06-30 0001743881 us-gaap:StockCompensationPlanMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001743881 us-
gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0001743881 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001743881
bbio:OtherConsolidatedEntitiesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0001743881 us-gaap:StockCompensationPlanMember us-gaap:ParentMember 2023-01-01 2023-03-31
0001743881 us-gaap:TreasuryStockCommonMember 2022-12-31 0001743881 bbio:OtherConsolidatedEntitiesMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001743881
bbio:BristolMyersSquibbCompanyMember bbio:LicensesAndCollaborationAgreementMember 2022-06-30 0001743881 us-gaap:USTreasuryBillSecuritiesMember us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001743881 bbio:TwoPointFiveZeroPercentConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2020-03-09 0001743881
bbio:InterestAdjustToTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2024-06-30 0001743881 us-gaap:ParentMember 2024-04-01 2024-06-30 0001743881 us-
gaap:RestrictedStockUnitsRSUMember bbio:TwoThousandNineTeenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2024-04-01 2024-06-30 0001743881 bbio:BristolMyersSquibbCompanyMember
bbio:LicensesAndCollaborationAgreementMember 2024-06-30 0001743881 bbio:FinancingAgreementMember 2024-01-17 2024-01-17 0001743881 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001743881 us-
gaap:USTreasuryBillSecuritiesMember 2024-06-30 0001743881 bbio:UnvestedPerformanceBasedRestrictedStockUnitMember 2023-01-01 2023-06-30 0001743881 bbio:OtherRSAAsMember
bbio:TwoThousandNineTeenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2023-01-01 2023-06-30 0001743881 bbio:UnvestedRestrictedStockAwardMember 2024-01-01 2024-06-30 0001743881
bbio:QEDTherapeuticsIncMember 2023-12-31 0001743881 us-gaap:EmployeeStockOptionMember bbio:TwoThousandNineTeenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2024-04-01 2024-06-30 0001743881
bbio:TheRelianceHealthcareTransactionMember 2023-01-01 2023-06-30 0001743881 us-gaap:CashFlowInputsLevel3Member 2023-01-25 2023-01-25 0001743881
bbio:TheRelianceHealthcareRecurrenceMember 2023-12-31 0001743881 us-gaap:RevenueFromLicensesMember 2023-01-25 2023-01-25 0001743881

bbio:AssumedConversionOffTwoThousandTwentyNineNotesMember 2023-01-01 2023-06-30 0001743881 us-gaap:ParentMember 2023-04-01 2023-06-30 0001743881
bbio:CommonStockOptionsIssuedAndOutstandingMember 2023-01-01 2023-06-30 0001743881 us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0001743881 bbio:FoundationMedicineIncMember
bbio:FoundationMedicineDiagnosticsAgreementMember bbio:QEDTherapeuticsIncMember 2024-03-01 2024-03-31 0001743881 bbio:ShareRepurchaseTransactionsMember bbio:CappedCallTransactionsMember 2020-03-04 2020-03-04 0001743881 bbio:HelsinnTherapeuticsMember bbio:LicenseAndCollaborationAgreementMember 2021-03-29 2021-03-29 0001743881 us-gaap:RestrictedStockMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2024-06-30 0001743881 us-gaap:ShortTermInvestmentsMember 2024-06-30 0001743881 bbio:EidosTherapeuticsIncMember
bbio:SellerPartiesMember bbio:BuyerExclusiveLicenseAgreementMember 2024-05-01 2024-05-31 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2020-11-18 0001743881
bbio:LoanAgreementMember 2021-11-01 2021-11-30 0001743881 bbio:QEDTherapeuticsIncMember 2024-06-30 0001743881
bbio:PrincipalValueOfConvertibleSeniorNotesDueTwoThousandAndTwentyNineNotesAndTwentySevenMember 2024-06-30 0001743881 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001743881
bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2024-04-01 2024-06-30 0001743881 us-gaap:CommonStockMember 2022-12-31 0001743881 bbio:EidosTherapeuticsIncMember
bbio:BuyerExclusiveLicenseAgreementMember 2024-04-01 2024-06-30 0001743881 bbio:HelsinnTherapeuticsMember bbio:QEDTherapeuticsIncMember 2024-04-01 2024-06-30 0001743881 bbio:HelsinnMember
bbio:QEDTherapeuticsIncMember 2024-01-01 2024-06-30 0001743881 bbio:PrincipalValueOfTwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember 2024-06-30 0001743881
bbio:EidosTherapeuticsIncMember bbio:LelandStanfordJuniorUniversityMember bbio:StanfordLicenseAgreementMember 2023-01-01 2023-06-30 0001743881 bbio:SatisfyTaxWithholdingMember us-
gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001743881 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001743881 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30
0001743881 bbio:RedeemableConvertibleNoncontrollingInterestsMember 2023-01-01 2023-03-31 0001743881 bbio:TwoPointFiveZeroPercentConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2023-01-01
2023-06-30 0001743881 srt:MaximumMember bbio:AlexionLicensesAgreementsMember 2019-09-30 0001743881 bbio:TwoThousandTwentyCappedCallTransactionsMember 2021-01-25 0001743881 us-
gaap:RetainedEarningsMember 2023-12-31 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2023-01-01
2023-06-30 0001743881 bbio:EidosTherapeuticsIncMember bbio:SellerPartiesMember bbio:BuyerExclusiveLicenseAgreementMember 2024-03-01 0001743881 bbio:LianBioMember bbio:EquityMethodInvesteeMember
2023-04-01 2023-06-30 0001743881 bbio:TheRasIncMember bbio:BridgeBioOncologyTherapeuticsMember 2024-04-01 2024-04-30 0001743881 bbio:LianBioMember bbio:EquityMethodInvesteeMember 2023-01-01 2023-06-30
0001743881 bbio:FinancingAgreementMember bbio:BuyerConsumerCareAndAgreementMember bbio:KyowaKirinColdMember 2024-04-01 2024-06-30 0001743881 bbio:AccruedCompensationAndBenefitsMember 2024-06-30 0001743881
bbio:BridgeBioServicesIncMember bbio:TwoThousandNineteenEmployeeStockPurchasePlanMember 2023-01-01 2023-06-30 0001743881 us-gaap:USTreasuryBillSecuritiesMember us-gaap:FairValueInputsLevel1Member us-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001743881 bbio:CappedCallTransactionsMember 2020-03-04 2020-03-31 0001743881 bbio:FoundationMedicineIncMember 2024-01-01 2024-06-30 0001743881
bbio:QEDTherapeuticsIncMember bbio:KyowaKirinExclusiveLicenseMember 2024-06-30 0001743881 bbio:LoanAgreementMember bbio:FinancingAgreementMember 2024-01-01 2024-01-31 0001743881
bbio:TwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember 2021-01-20 2021-01-31 0001743881 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001743881
bbio:AgencyDiscountNotesMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001743881 bbio:RestructuringImpairmentAndRelatedChargesMember 2024-01-01 2024-06-30 0001743881
bbio:LoanAgreementMember 2021-11-30 0001743881 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001743881 bbio:BridgeBioServicesIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30
0001743881 bbio:TwoThousandTwentyCappedCallTransactionsMember 2021-01-01 2021-12-31 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember us-gaap:RestrictedStockMember 2024-04-01
2024-06-30 0001743881 bbio:PellePharmIncMember 2024-01-01 2024-06-30 0001743881 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001743881 2024-01-17 2024-01-17
0001743881 bbio:RedeemableConvertibleNoncontrollingInterestsMember 2024-01-01 2024-03-31 0001743881 us-gaap:EmployeeStockOptionMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31
0001743881 us-gaap:TreasuryStockCommonMember 2023-06-30 0001743881 bbio:TwoThousandTwentyThreeAtTheMarketAgreementMember us-gaap:CommonStockMember bbio:AtTheMarketOfferingMember 2024-01-01 2024-06-30
0001743881 us-gaap:ParentMember 2024-06-30 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember
2023-01-01 2023-12-31 0001743881 bbio:RedeemableConvertibleNoncontrollingInterestsMember 2023-04-01 2023-06-30 0001743881 bbio:SatisfyTaxWithholdingMember 2024-01-01 2024-03-31 0001743881
bbio:SatisfyTaxWithholdingMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001743881 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001743881
bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember us-gaap:RestrictedStockMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2024-01-01 2024-06-30
0001743881 bbio:QEDTherapeuticsIncMember bbio:FoundationMedicineIncMember bbio:FoundationMedicineDiagnosticsAgreementMember 2024-01-01 2024-06-30 0001743881 bbio:AgencyDiscountNotesMember us-
gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001743881 bbio:AccruedResearchAndDevelopmentLiabilitiesMember 2023-12-31 0001743881 bbio:FollowOnOfferingMember
us-gaap:CommonStockMember 2023-03-31 0001743881 bbio:TwoPointFiveZeroPercentConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2024-04-01 2024-06-30 0001743881 us-
gaap:StockCompensationPlanMember us-gaap:ParentMember 2024-01-01 2024-03-31 0001743881 bbio:LoanAndSecurityAgreementMember 2023-12-31 0001743881 us-gaap:TreasuryStockCommonMember 2024-06-30 0001743881
bbio:LianBioMember 2023-12-31 0001743881 bbio:EidosTherapeuticsIncMember bbio:SellerPartiesMember bbio:BuyerExclusiveLicenseAgreementMember 2024-03-01 2024-03-31 0001743881 bbio:LoanAgreementMember us-
gaap:PaymentInKindPIKNoteMember 2021-11-30 0001743881 2024-03-31 0001743881 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanMember us-
gaap:CommonStockMember 2023-02-28 0001743881 bbio:RedeemableConvertibleNoncontrollingInterestsMember 2024-06-30 0001743881 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001743881
bbio:FinancingAgreementMember 2024-06-30 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2023-04-01 2023-06-30 0001743881 srt:MaximumMember bbio:QEDTherapeuticsIncMember 2010-12-31
0001743881 bbio:SatisfyTaxWithholdingMember 2023-04-01 2023-06-30 0001743881 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001743881
bbio:RegularEquityProgramMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2024-01-01 2024-06-30 0001743881
bbio:PrincipalValueInterestOnTermLoansOfFinancingAgreementMember 2024-06-30 0001743881 bbio:EidosTherapeuticsIncMember bbio:LelandStanfordJuniorUniversityMember bbio:StanfordLicenseAgreementMember 2023-04-01 2023-06-30 0001743881 bbio:QEDTherapeuticsIncMember 2023-01-01 2023-06-30 0001743881 us-gaap:USTreasuryBillSecuritiesMember us-gaap:FairValueInputsLevel2Member us-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001743881 bbio:TwoPointFiveZeroPercentConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2023-04-01 2023-06-30 0001743881
bbio:RedeemableConvertibleNoncontrollingInterestsMember 2023-03-31 0001743881 bbio:BristolMyersSquibbCompanyMember bbio:NavirePharmaIncMember us-gaap:SalesMember
bbio:LicenseAndCollaborationAgreementMember 2023-04-01 2023-06-30 0001743881 bbio:TwoThousandTwentyFourFollowOnOfferingMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001743881 us-
gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001743881 us-gaap:AccountsPayableMember 2023-12-31 0001743881 srt:MaximumMember bbio:FinancingAgreementMember 2024-01-17 2024-01-17
0001743881 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001743881 us-gaap:ParentMember 2023-06-30 0001743881 srt:MaximumMember bbio:OriginsSciencesIncMember 2010-01-01 2010-12-31
0001743881 bbio:BridgeBioServicesIncMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0001743881 bbio:LoanAgreementMember 2024-01-01 2024-03-31 0001743881 us-
gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001743881 bbio:EidosTherapeuticsIncMember
bbio:LelandStanfordJuniorUniversityMember bbio:StanfordLicenseAgreementMember 2017-03-01 2017-03-31 0001743881 bbio:RegularEquityProgramMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2024-06-30 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanMember 2020-04-22 2020-04-22 0001743881 2022-12-31 0001743881 bbio:QEDTherapeuticsIncMember srt:MaximumMember
bbio:EntitiesAffiliatedWithPerceptivelifeSciencesMasterFundLtdMember 2019-01-01 2019-10-31 0001743881 us-gaap:RestrictedStockMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2023-01-01 2023-06-30 0001743881 bbio:PaymentFollowingFDAApprovalOfFruseltigMember 2021-05-31 0001743881
bbio:SatisfyTaxWithholdingMember 2023-01-01 2023-03-31 0001743881 bbio:BridgeBioServicesIncMember bbio:TwoThousandNineteenEmployeeStockPurchasePlanMember us-gaap:EmployeeStockOptionMember 2019-06-22
0001743881 bbio:BridgeBioServicesIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001743881 us-gaap:USTreasuryBillSecuritiesMember us-
gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001743881 bbio:LoanAgreementMember us-gaap:PaymentInKindPIKNoteMember 2023-12-31 0001743881 bbio:LicenseAndCollaborationAgreementMember 2024-06-30
0001743881 srt:MinimumMember bbio:FinancingAgreementMember 2024-01-01 2024-06-30 0001743881 bbio:AssumedConversionOfTwoThousandTwentySevenNotesMember 2023-01-01 2023-06-30 0001743881
bbio:BridgeBioServicesIncMember bbio:MarketBasedRestrictedStockUnitsRusMember bbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMember 2023-01-01 2023-12-31 0001743881 bbio:EidosTherapeuticsIncMember
us-gaap:CommonStockMember bbio:AlexionAgreementsMember exch:XNGS 2019-09-30 0001743881 us-gaap:RestrictedStockMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember
2024-04-01 2024-06-30 0001743881 bbio:SatisfyTaxWithholdingMember us-gaap:ParentMember 2023-01-01 2023-03-31 0001743881
bbio:PrincipalValueOfTwoPointFiveZeroPercentConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2024-06-30 0001743881 bbio:SatisfyTaxWithholdingMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001743881
bbio:TheRasIncMember bbio:TransitionServiceAgreementMember bbio:BridgeBioOncologyTherapeuticsMember 2024-01-01 2024-06-30 0001743881 us-gaap:MoneyMarketFundsMember 2024-06-30
0001743881 us-gaap:EmployeeStockOptionMember us-gaap:ParentMember 2023-01-01 2023-03-31 0001743881 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001743881
bbio:RedeemableConvertibleNoncontrollingInterestsMember 2024-04-01 2024-06-30 0001743881 us-gaap:RestrictedStockUnitsRusMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2023-04-01 2023-06-30 0001743881 bbio:FoundationMedicineIncMember bbio:FoundationMedicineDiagnosticsAgreementMember
bbio:QEDTherapeuticsIncMember 2024-03-31 0001743881 bbio:QEDTherapeuticsIncMember bbio:KyowaKirinExclusiveLicenseMember 2024-02-07 0001743881 us-gaap:USTreasuryBillSecuritiesMember us-
gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001743881 bbio:FinancingAgreementMember us-gaap:SecuredOvernightFinancingRateOfOvernightIndexSwapRateMember
2024-01-17 2024-01-17 0001743881 us-gaap:ParentMember 2022-12-31 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001743881
bbio:HelsinnTherapeuticsMember 2023-04-01 2023-06-30 0001743881 bbio:OtherRSAsMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2023-04-01 2023-06-30 0001743881
bbio:TwoThousandTwentyFourFollowOnOfferingMember us-gaap:CommonStockMember 2024-03-31 0001743881 bbio:OtherConsolidatedEntitiesMember bbio:RestructuringImpairmentAndRelatedChargesMember 2024-04-01 2024-06-30
0001743881 bbio:EidosTherapeuticsIncMember bbio:TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlanMember 2024-06-30 0001743881 srt:MaximumMember
bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2020-04-22 2020-04-22 0001743881 bbio:EidosTherapeuticsIncMember
bbio:TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlanMember 2024-01-01 2024-06-30 0001743881 bbio:HelsinnTherapeuticsMember bbio:QEDTherapeuticsIncMember
bbio:AccountingStandardUpdate201818Member bbio:LicenseAndCollaborationAgreementMember 2023-04-01 2023-06-30 0001743881 us-gaap:NoncontrollingInterestMember 2024-03-31 0001743881
bbio:EidosTherapeuticsIncMember bbio:BuyerExclusiveLicenseAgreementMember 2024-06-30 0001743881 bbio:EidosTherapeuticsIncMember us-gaap:LicenseMember bbio:BuyerExclusiveLicenseAgreementMember 2024-04-01
2024-06-30 0001743881 bbio:EidosTherapeuticsIncMember bbio:LelandStanfordJuniorUniversityMember bbio:StanfordLicenseAgreementMember 2024-01-01 2024-06-30 0001743881
bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanMember 2020-11-18 2020-11-18 0001743881 bbio:FinancingAgreementMember
bbio:SoftPlusInterestMember 2024-01-17 2024-01-17 0001743881 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0001743881 srt:MaximumMember bbio:LoanAgreementMember 2021-11-01
2021-11-30 0001743881 srt:MaximumMember bbio:TwoThousandTwentyThreeAtTheMarketAgreementMember us-gaap:CommonStockMember bbio:AtTheMarketOfferingMember 2023-05-01 2023-05-31 0001743881 us-
gaap:CommonStockMember 2023-03-31 0001743881 bbio:TwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember 2021-02-02 0001743881
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2024-01-01 2024-06-30 0001743881 us-gaap:RetainedEarningsMember 2022-12-31 0001743881 bbio:BridgeBioServicesIncMember us-
gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0001743881 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31
0001743881 us-gaap:StockCompensationPlanMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001743881 bbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMember us-gaap:CommonStockMember 2024-06-30
0001743881 bbio:UnvestedMarketBasedRestrictedStockUnitMember 2023-01-01 2023-06-30 0001743881 bbio:LianBioMember bbio:BridgeBioPharmalimitedLiabilityCompanyMember 2024-03-01 2024-03-31 0001743881
bbio:SatisfyTaxWithholdingMember us-gaap:ParentMember 2024-04-01 2024-06-30 0001743881 bbio:QEDTherapeuticsIncMember bbio:LicenseAndCollaborationAgreementMember 2023-03-29 2023-03-29 0001743881 us-
gaap:RetainedEarningsMember 2023-06-30 0001743881 bbio:BridgeBioServicesIncMember srt:MaximumMember bbio:MarketBasedRestrictedStockUnitsRusMember
bbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMember 2023-01-01 2023-12-31 0001743881 bbio:ReceivableFromLicensingAndCollaborationAgreementsMember bbio:LicenseAndCollaborationAgreementMember 2023-12-31
0001743881 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001743881 srt:MinimumMember 2024-03-31 0001743881 srt:MaximumMember bbio:TrancheTwoAdvanceMember
bbio:LoanAgreementMember 2021-11-30 0001743881 bbio:LianBioMember bbio:BridgeBioPharmalimitedLiabilityCompanyMember 2024-01-01 2024-06-30 0001743881 bbio:BristolMyersSquibbCompanyMember
bbio:NavirePharmaIncMember us-gaap:SalesMember bbio:LicenseAndCollaborationAgreementMember 2023-01-01 2023-06-30 0001743881 bbio:FundingAgreementMember 2024-01-17 2024-01-17 0001743881
bbio:LianBioMember 2024-06-30 0001743881 bbio:LianBioMember srt:MaximumMember bbio:LicenseAgreementMember 2020-08-01 2020-08-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30
0001743881 2023-01-01 2023-03-31 0001743881 bbio:RedeemableConvertibleNoncontrollingInterestsMember 2023-12-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanMember us-
gaap:CommonStockMember 2023-12-31 0001743881 bbio:IncrementalTermLoanMember bbio:FinancingAgreementMember 2024-01-17 0001743881 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001743881 us-
gaap:StockCompensationPlanMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001743881 bbio:TheRasIncMember bbio:TransitionServiceAgreementMember bbio:BridgeBioOncologyTherapeuticsMember 2024-06-30
0001743881 bbio:BridgeBioServicesIncMember 2024-04-01 2024-06-30 0001743881 us-gaap:EmployeeStockOptionMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanMember 2024-01-01
2024-06-30 0001743881 us-gaap:EmployeeStockOptionMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2024-06-30 0001743881 bbio:OtherRSAsMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2024-01-01 2024-06-30 0001743881 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001743881
bbio:EidosAwardExchangePlanMember us-gaap:CommonStockMember 2021-12-31 0001743881 bbio:HelsinnTherapeuticsMember 2023-12-31 0001743881 bbio:EidosTherapeuticsIncMember
bbio:KyowaKirinExclusiveLicenseMember 2024-01-01 2024-06-30 0001743881 bbio:RestructuringImpairmentAndRelatedChargesMember 2024-04-01 2024-06-30 0001743881
bbio:AssumedConversionOffTwoThousandTwentySevenNotesMember 2024-01-01 2024-06-30 0001743881 bbio:BristolMyersSquibbCompanyMember bbio:NavirePharmaIncMember bbio:LicenseAndCollaborationAgreementMember
2024-06-30 0001743881 us-gaap:StockCompensationPlanMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001743881 bbio:HelsinnTherapeuticsMember bbio:QEDTherapeuticsIncMember
bbio:AccountingStandardUpdate201818Member bbio:LicenseAndCollaborationAgreementMember 2023-01-01 2023-06-30 0001743881 bbio:EidosTherapeuticsIncMember bbio:BuyerExclusiveLicenseAgreementMember 2024-05-31
0001743881 bbio:RedeemableConvertibleNoncontrollingInterestsMember 2022-12-31 0001743881 bbio:ReceivableFromLicensingAndCollaborationAgreementsMember bbio:LicenseAndCollaborationAgreementMember 2024-06-30
0001743881 srt:MaximumMember us-gaap:EmployeeStockOptionMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2024-01-01 2024-06-30 0001743881
bbio:ResilienceMember 2024-01-01 2024-06-30 0001743881 srt:MinimumMember bbio:LoanAgreementMember 2021-11-01 2021-11-30 0001743881 bbio:UnvestedRestrictedStockUnitMember 2023-01-01 2023-06-30
0001743881 bbio:BridgeBioOncologyTherapeuticsMember 2024-04-01 2024-06-30 0001743881 srt:MinimumMember 2024-02-01 2024-06-30 0001743881 us-gaap:StockCompensationPlanMember 2024-04-01 2024-06-30
0001743881 bbio:TwoPointFiveZeroPercentConvertibleSeniorNotesDueTwoThousandAndTwentySevenAndTwoThousandAndTwentyNineMember 2024-01-01 2024-06-30 0001743881
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2023-12-31 0001743881 bbio:BristolMyersSquibbCompanyMember bbio:NavirePharmaIncMember us-gaap:SalesMember
bbio:LicenseAndCollaborationAgreementMember 2024-01-01 2024-06-30 0001743881 bbio:FinancingAgreementMember 2024-01-01 2024-06-30 0001743881 bbio:AspaTherapeuticsIncMember bbio:ProtectAgreementMember
2023-09-01 2023-09-30 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2020-04-22 0001743881 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001743881
bbio:QEDTherapeuticsIncMember 2023-04-01 2023-06-30 0001743881 bbio:HelsinnTherapeuticsMember bbio:QEDTherapeuticsIncMember 2024-01-01 2024-06-30 0001743881 bbio:EidosTherapeuticsIncMember
bbio:CommercialProductsSupplyMember bbio:BuyerExclusiveLicenseAgreementMember 2024-01-01 2024-06-30 0001743881 bbio:OriginAndSentryTherapeuticsIncMember 2022-03-01 2022-03-31 0001743881
bbio:OtherRSAsMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2024-04-01 2024-06-30 0001743881 bbio:AccruedProfessionalAndOtherAccruedLiabilitiesMember 2023-12-31
0001743881 bbio:FoundationMedicineIncMember bbio:FoundationMedicineDiagnosticsAgreementMember 2021-05-01 2021743881 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001743881 srt:MaximumMember
bbio:ScheduledAmortizationPaymentsMember bbio:FinancingAgreementMember 2024-01-17 0001743881 bbio:BridgeBioServicesIncMember 2023-04-01 2023-06-30 0001743881 us-gaap:RetainedEarningsMember 2024-01-01
2024-03-31 0001743881 bbio:EstimatedSharesIssuableEmployeeStockPurchasePlanMember 2023-01-01 2023-06-30 0001743881 srt:MinimumMember bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2020-04-22 2020-04-22
0001743881 us-gaap:EmployeeStockOptionMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001743881 bbio:BristolMyersSquibbCompanyMember bbio:NavirePharmaIncMember
bbio:LicenseAndCollaborationAgreementMember 2024-01-01 2024-06-30 0001743881 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001743881 bbio:LoanAgreementMember 2023-01-01 2023-06-30 0001743881
bbio:EidosTherapeuticsIncMember bbio:BuyerExclusiveLicenseAgreementMember 2024-01-01 2024-06-30 0001743881 srt:MaximumMember
bbio:TwoPointFiveZeroPercentConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2020-03-09 2020-03-09 0001743881 bbio:LianBioMember
bbio:EntitiesAffiliatedWithPerceptivelifeSciencesMasterFundLtdMember bbio:BridgeBioPharmalimitedLiabilityCompanyMember 2023-01-01 2023-12-31 0001743881 bbio:LoanAgreementMember 2023-04-01 2023-06-30
0001743881 bbio:NavirePharmaIncMember bbio:LicenseAgreementMember 2022-06-01 2022-06-30 0001743881 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0001743881 us-
gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2023-12-31 0001743881 bbio:QEDTherapeuticsIncMember bbio:KyowaKirinExclusiveLicenseMember 2024-04-01 2024-06-30
0001743881 bbio:EidosTherapeuticsIncMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2024-06-30 0001743881 bbio:BridgeBioServicesIncMember 2024-01-01 2024-06-30
0001743881 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001743881 srt:MaximumMember bbio:FollowOnOfferingMember us-gaap:CommonStockMember 2023-04-03 0001743881
bbio:OtherConsolidatedEntitiesMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001743881 bbio:LoanAgreementMember us-gaap:PaymentInKindPIKNoteMember 2023-04-01 2023-06-30
0001743881 bbio:TwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember 2024-01-01 2024-06-30 0001743881 bbio:QEDTherapeuticsIncMember 2023-01-01 2023-03-31 0001743881
bbio:ScheduledAmortizationPaymentsMember bbio:FinancingAgreementMember 2024-01-17 2024-01-17 0001743881 bbio:BridgeBioServicesIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30
0001743881 bbio:TheRasIncMember bbio:BridgeBioOncologyTherapeuticsMember 2024-01-01 2024-06-30 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember us-gaap:EmployeeStockOptionMember

2020-11-10 2020-11-10 0001743881-bbio:BridgeBioServicesIncMember-bbio:TwoThousandNineteenEmployeeStockPurchasePlanMember-2023-04-01-2023-06-30 0001743881
bbio:EstimatedSharesIssuableEmployeeStockPurchasePlanMember-2024-01-01-2024-06-30 0001743881-bbio:EstimatedSharesIssuablePerformanceBasedMilestoneCompensationArrangementMember-2023-01-01-2023-06-30
0001743881-us-gaap:StockCompensationPlanMember-us-gaap:AdditionalPaidInCapitalMember-2023-01-01-2023-03-31 0001743881-bbio:OtherConsolidatedEntitiesMember-us-
gaap:SellingGeneralAndAdministrativeExpensesMember-2023-01-01-2023-06-30 0001743881-bbio:BridgeBioServicesIncMember-bbio:MarketBasedRestrictedStockUnitsRSMember-
bbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMember-2024-04-01-2024-06-30 0001743881-bbio:AsaTherapeuticsIncAndAdrenasTherapeuticsIncMember-2023-09-01-2023-09-30 0001743881-us-
gaap:NoncontrollingInterestsMember-2023-01-01-2023-03-31 0001743881-bbio:TwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember-2023-01-01-2023-06-30 0001743881-us-
gaap:EmployeeStockMember-2023-01-01-2023-03-31 0001743881-bbio:BridgeBioServicesIncMember-bbio:TwoThousandNineteenEmployeeStockPurchasePlanMember-2019-06-22-0001743881-us-
gaap:StockCompensationPlanMember-us-gaap:CommonStockMember-2023-01-01-2023-03-31 0001743881-bbio:EidosTherapeuticsIncMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2024-01-01-2024-06-30 0001743881-bbio:EidosTherapeuticsIncMember-bbio:AlexionAgreementsMember-2019-09-01-2019-09-30
0001743881-bbio:AgencyDiscountNotesMember-us-gaap:FairValueInputsLevel3Member-us-gaap:FairValueMeasurementsRecurringMember-2024-06-30 0001743881-us-gaap:AdditionalPaidInCapitalMember-2024-01-01-2024-03-31
0001743881-us-gaap:ParentMember-2023-12-31-2024-01-01 0001743881-bbio:TermLoanAfterJanuarySeventeenTwoThousandTwentyFourMember-bbio:FinancingAgreementMember-2024-01-17-2024-01-17 0001743881-us-
gaap:AccumulatedOtherComprehensiveIncomeMember-2024-01-01-2024-03-31 0001743881-bbio:EidosTherapeuticsIncMember-bbio:LelandStanfordJuniorUniversityMember-bbio:StanfordLicenseAgreementMember-2016-08-31
0001743881-bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember-2024-01-01-2024-06-30 0001743881-bbio:TwoThousandTwentyThreeAtTheMarketAgreementMember-us-gaap:CommonStockMember
bbio:AtTheMarketOfferingMember-2023-01-01-2023-12-31 0001743881-bbio:QEDTherapeuticsIncMember-bbio:EntitiesAffiliatedWithPerceptivelifeSciencesMasterFundLtdMember-2019-10-01-2019-10-31 0001743881-
srt:MaximumMember-bbio:TwoThousandTwentyFourFollowOnOfferingMember-us-gaap:CommonStockMember-2024-03-31 0001743881-bbio:TrancheOneAdvanceMember-bbio:LoanAgreementMember-2024-01-01-2024-06-30 0001743881
bbio:QEDTherapeuticsIncMember-bbio:LicenseAndCollaborationAgreementMember-2024-06-30 0001743881-bbio:RestrictedCashMember-bbio:FinancingAgreementMember-2024-06-30 0001743881
bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember-2024-01-01-2024-06-30 0001743881-bbio:RegularEquityProgramMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2023-01-01-2023-12-31 0001743881-bbio:EidosTherapeuticsIncMember-bbio:AlexionLicenseAgreementsMember-2019-09-01-2019-09-
30 0001743881-bbio:RedeemableConvertibleNoncontrollingInterestsMember-2024-03-31 0001743881-us-gaap:CommonStockMember-2023-06-30 0001743881-bbio:LoanAgreementMember-2023-12-31 0001743881
bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember-2023-12-31 0001743881-us-gaap:RestrictedStockUnitsRSUMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2023-12-31 0001743881-bbio:MaximumMember-bbio:TwoThousandTwentyThreeAtTheMarketAgreementMember-us-gaap:CommonStockMember
bbio:AtTheMarketOfferingMember-2023-01-01-2023-12-31 0001743881-us-gaap:StockCompensationPlanMember-us-gaap:ParentMember-2023-04-01-2023-06-30 0001743881-bbio:SatisfyTaxWithholdingMember-us-
gaap:AdditionalPaidInCapitalMember-2024-01-01-2024-06-30 0001743881-bbio:LoanAgreementMember-2024-06-30 0001743881-bbio:OtherConsolidatedEntitiesMember-us-gaap:ResearchAndDevelopmentExpenseMember-2024-
04-01-2024-06-30 0001743881-us-gaap:AccumulatedOtherComprehensiveIncomeMember-2023-06-30 0001743881-bbio:LoanAgreementMember-2024-04-01-2024-06-30 0001743881-bbio:QEDTherapeuticsIncMember
bbio:FoundationMedicineIncMember-bbio:FoundationMedicineDiagnosticsAgreementMember-2023-01-01-2023-06-30 0001743881-bbio:ResilienceAgreementsMember-2024-04-01-2024-06-30 0001743881
bbio:LoanAgreementMember-2024-01-17-2024-01-17 0001743881-us-gaap:ParentMember-2024-03-31 0001743881-us-gaap:AccumulatedOtherComprehensiveIncomeMember-2024-03-31 0001743881
bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember-2024-06-30 0001743881-bbio:OtherConsolidatedEntitiesMember-2024-01-01-2024-06-30 0001743881-us-
gaap:NoncontrollingInterestsMember-2024-06-30 0001743881-bbio:LianBioMember-bbio:LicenseAgreementMember-2020-08-01-2020-08-31 0001743881-bbio:FollowOnOfferingMember-us-gaap:CommonStockMember-2023-03-30
2023-03-10 0001743881-bbio:SatisfyTaxWithholdingMember-us-gaap:CommonStockMember-2024-01-01-2024-03-31 0001743881-bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2023-01-01-2023-06-30 0001743881-bbio:FinancingAgreementMember-bbio:BaseRatePlusInterestMember-2024-01-17-2024-01-17
0001743881-bbio:InterestAdjustOnTwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember-2024-06-30 0001743881-us-gaap:FairValueInputsLevel3Member-us-
gaap:FairValueMeasurementsRecurringMember-2024-06-30 0001743881-bbio:BridgeBioServicesIncMember-us-gaap:ResearchAndDevelopmentExpenseMember-2023-01-01-2023-06-30 0001743881-bbio:TheRasIncMember
bbio:BridgeBioOncologyTherapeuticsIncMember-2024-04-01-2024-06-30 0001743881-us-gaap:RetainedEarningsMember-2023-04-01-2023-06-30 0001743881-bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember-us-
gaap:RestrictedStockMember-2020-04-22-2020-04-22 0001743881-us-gaap:ParentMember-2023-03-31 0001743881-2023-09-01-2023-09-30 0001743881-bbio:EidosTherapeuticsIncMember-us-gaap:CommonStockMember
bbio:AlexionAgreementsMember-2019-09-01-2019-09-30 0001743881-bbio:TwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember-2024-04-01-2024-06-30 0001743881
bbio:BridgeBioServicesIncMember-bbio:TwoThousandNineteenEmployeeStockPurchasePlanMember-2024-01-01-2024-06-30 0001743881-bbio:BridgeBioServicesIncMember
bbio:TwoThousandNineteenEmployeeStockPurchasePlanMember-2024-06-30 0001743881-us-gaap:TreasuryStockCommonMember-2024-03-31 0001743881-bbio:AccruedCompensationAndBenefitsMember-2023-12-31 0001743881
2023-01-01-2023-12-31 0001743881-bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember-bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2024-06-30 0001743881
bbio:FoundationMedicineIncMember-bbio:FoundationMedicineDiagnosticsAgreementMember-bbio:QEDTherapeuticsIncMember-2019-11-01-2023-12-31 0001743881-us-gaap:NoncontrollingInterestsMember-2022-12-31 0001743881-us-
gaap:MoneyMarketFundsMember-us-gaap:FairValueMeasurementsRecurringMember-2023-12-31 0001743881-us-gaap:RestrictedStockMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2023-04-01-2023-06-30 0001743881-bbio:TwoThousandNineteenEmployeeStockPurchasePlanMember-2024-01-01-2024-06-30 0001743881
bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember-bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2024-01-01-2024-06-30 0001743881
bbio:BridgeBioServicesIncMember-bbio:TwoThousandNineteenEmployeeStockPurchasePlanMember-2019-06-22-2019-06-22 0001743881-bbio:OtherConsolidatedEntitiesMember-2024-04-01-2024-06-30 0001743881
bbio:BridgeBioPharmalimitedLiabilityCompanyMember-bbio:LianBioMember-bbio:EntitiesAffiliatedWithPerceptivelifeSciencesMasterFundLtdMember-2024-02-01-2024-02-31 0001743881-us-
gaap:USTreasuryBillSecuritiesMember-us-gaap:FairValueInputsLevel3Member-us-gaap:FairValueMeasurementsRecurringMember-2024-06-30 0001743881-bbio:SatisfyTaxWithholdingMember-us-gaap:ParentMember-2024-01-
01-2024-03-31 0001743881-us-gaap:AdditionalPaidInCapitalMember-2024-04-01-2024-06-30 0001743881-srt:MaximumMember-bbio:TrancheOneAdvanceMember-bbio:LoanAgreementMember-2021-11-30 0001743881
bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember-2020-02-01-2020-02-29 0001743881
bbio:TwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember-2023-06-30 0001743881-us-gaap:StockCompensationPlanMember-us-gaap:CommonStockMember-2024-04-01-2024-06-30 0001743881
us-gaap:EmployeeStockMember-us-gaap:CommonStockMember-2024-01-01-2024-03-31 0001743881-bbio:AssumedConversionOfTwoThousandTwentyNineNotesMember-2024-01-01-2024-06-30 0001743881
bbio:UnvestedPerformanceBasedRestrictedStockUnitMember-2021-01-01-2024-06-30 0001743881-us-gaap:NoncontrollingInterestsMember-2023-06-30 0001743881-bbio:LoanSecurityAgreementMember-2023-12-31 0001743881
us-gaap:MoneyMarketFundsMember-us-gaap:FairValueInputsLevel3Member-us-gaap:FairValueMeasurementsRecurringMember-2024-06-30 0001743881-bbio:EidosTherapeuticsIncMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2023-01-01-2023-12-31 0001743881-bbio:TheRasIncMember-bbio:BridgeBioOncologyTherapeuticsIncMember-2024-04-01-2024-06-30
0001743881-bbio:OtherConsolidatedEntitiesMember-us-gaap:SellingGeneralAndAdministrativeExpensesMember-2024-04-01-2024-06-30 0001743881-us-gaap:EmployeeStockMember-2024-01-01-2024-03-31 0001743881-us-
gaap:ResearchAndDevelopmentExpenseMember-2024-01-01-2024-06-30 0001743881-bbio:TwoThousandTwentyThreeAtTheMarketAgreementMember-us-gaap:CommonStockMember-bbio:AtTheMarketOfferingMember-2023-05-31
0001743881-us-gaap:TreasuryStockCommonMember-2023-12-31 0001743881-bbio:LianBioMember-bbio:EntitiesAffiliatedWithPerceptivelifeSciencesMasterFundLtdMember
bbio:BridgeBioPharmalimitedLiabilityCompanyMember-2024-02-01-2024-02-29 0001743881-bbio:FollowOnOfferingMember-us-gaap:CommonStockMember-2023-03-31 0001743881-us-gaap:RestrictedStockUnitsRSUMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2024-06-30 0001743881-bbio:TheRasIncMember-bbio:BridgeBioOncologyTherapeuticsIncMember-2024-06-30 0001743881
bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember-2023-06-30 0001743881-bbio:TwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember-2024-
06-30 0001743881-bbio:UnvestedMarketBasedRestrictedStockUnitMember-2024-01-01-2024-06-30 0001743881-us-gaap:CommonStockMember-2024-06-30 0001743881-bbio:AdrenasTherapeuticsIncMember
bbio:ProjectAgreementMember-2023-09-01-2023-09-30 0001743881-bbio:FoundationMedicineIncMember-bbio:QEDTherapeuticsIncMember-srt:MaximumMember-bbio:LicenseAndCollaborationAgreementMember-2024-01-01-2024-
06-30 0001743881-bbio:CappedCallTransactionsMember-2020-01-01-2020-12-31 0001743881-srt:MaximumMember-bbio:TwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember-2021-01-28
2021-01-28 0001743881-bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember-us-gaap:EmployeeStockOptionMember-2020-04-22-2020-04-22 0001743881-us-gaap:NoncontrollingInterestsMember-2023-04-01
2023-06-30 0001743881-bbio:BristolMyersSquibbCompanyMember-bbio:NavirePharmaIncMember-bbio:LicenseAndCollaborationAgreementMember-2023-12-31 0001743881-bbio:BristolMyersSquibbCompanyMember
bbio:NavirePharmaIncMember-us-gaap:SalesMember-bbio:LicenseAndCollaborationAgreementMember-2024-04-01-2024-06-30 0001743881
bbio:TwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember-2023-12-31 0001743881-srt:MaximumMember-2024-03-31 0001743881-us-gaap:MoneyMarketFundsMember-us-
gaap:FairValueInputsLevel3Member-us-gaap:FairValueMeasurementsRecurringMember-2024-06-30 0001743881-bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2024-04-01-2024-06-30 0001743881-bbio:AccruedProfessionalAndOtherAccruedLiabilitiesMember-2024-06-30 0001743881
bbio:FoundationMedicineIncMember-bbio:QEDTherapeuticsIncMember-srt:MinimumMember-2024-01-01-2024-06-30 0001743881-us-gaap:AdditionalPaidInCapitalMember-2022-12-31 0001743881-bbio:FollowOnOfferingMember
us-gaap:CommonStockMember-2023-03-01-2023-03-31 0001743881-us-gaap:AdditionalPaidInCapitalMember-2024-03-31 0001743881-bbio:HeislinTherapeuticsIncMember-2024-06-30 0001743881-srt:MinimumMember
bbio:FollowOnOfferingMember-us-gaap:CommonStockMember-2023-03-01-2023-03-31 0001743881-bbio:LeaseAgreementsAndLettersOfCreditMember-2023-12-31 0001743881-bbio:CommonStockOptionsIssuedAndOutstandingMember-2024-01-
01-2024-06-30 0001743881-bbio:BridgeBioServicesIncMember-bbio:TwoThousandNineteenEmployeeStockPurchasePlanMember-2024-04-01-2024-06-30 0001743881-us-gaap:MoneyMarketFundsMember-us-
gaap:FairValueInputsLevel3Member-us-gaap:FairValueMeasurementsRecurringMember-2023-12-31 0001743881-2024-01-01-2024-03-31 0001743881
bbio:TwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember-2021-01-28 0001743881-bbio:ShareRepurchaseTransactionsMember-bbio:CappedCallTransactionsMember-2020-03-04 0001743881
us-gaap:StockCompensationPlanMember-2024-01-01-2024-03-31 0001743881-us-gaap:RestrictedStockUnitsRSUMember-bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2023-01-01
2023-06-30 0001743881-us-gaap:AccountsPayableMember-2024-06-30 0001743881-bbio:BridgeBioServicesIncMember-us-gaap:SellingGeneralAndAdministrativeExpensesMember-2024-04-01-2024-06-30 0001743881-us-
gaap:RetainedEarningsMember-2024-04-01-2024-06-30 0001743881-bbio:FollowOnOfferingMember-us-gaap:CommonStockMember-2023-04-03-2023-04-03 0001743881-srt:MinimumMember-us-gaap:EmployeeStockOptionMember
2024-01-01-2024-06-30 0001743881-bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember-us-gaap:RestrictedStockMember-2024-01-01-2024-06-30 0001743881-us-gaap:NoncontrollingInterestsMember-2024-
01-01-2024-03-31 0001743881-srt:MaximumMember-bbio:OriginBioSciencesIncMember-2018-12-31 0001743881-us-gaap:CashMember-bbio:FinancingAgreementMember-2024-01-01-2024-06-30 0001743881-2023-01-01-2023-06-
30 0001743881-srt:MinimumMember-bbio:FinancingAgreementMember-2024-01-17 0001743881-srt:MaximumMember-bbio:LoanAgreementMember-2021-11-30 0001743881-us-gaap:EmployeeStockMember-us-gaap:ParentMember
2024-01-01-2024-03-31 0001743881-bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember-us-gaap:RestrictedStockMember-2023-04-01-2023-06-30 0001743881-srt:MaximumMember
bbio:FinancingAgreementMember-2024-01-01-2024-06-30 0001743881-bbio:PerformanceBasedMilestoneAwardsMember-2024-06-30 0001743881-bbio:HeislinTherapeuticsIncMember-2023-01-01-2023-06-30 0001743881-2024-01-01
2024-06-30 0001743881-bbio:LianBioMember-us-gaap:LicenseAgreementMember-bbio:LicenseAgreementMember-2021-01-01-2021-12-31 0001743881-us-gaap:AccumulatedOtherComprehensiveIncomeMember-2023-04-01-2023-06-30
0001743881-bbio:FundingAgreementMember-2024-06-30 0001743881-us-gaap:CommonStockMember-2023-12-31 0001743881-bbio:FinancingAgreementMember-2024-04-01-2024-06-30 0001743881
bbio:OtherConsolidatedEntitiesMember-us-gaap:ResearchAndDevelopmentExpenseMember-2023-01-01-2023-06-30 0001743881-bbio:BridgeBioServicesIncMember-bbio:RestructuringImpairmentAndRelatedChargesMember-
2024-01-01-2024-06-30 0001743881-srt:MaximumMember-bbio:FinancingAgreementMember-2024-01-17 0001743881-bbio:EstimatedSharesIssuablePerformanceBasedMilestoneCompensationArrangementMember-2024-01-01-2024-
06-30 0001743881-bbio:PrincipalValueAndInterestOnTwoPointFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentySevenAndTwoThousandAndTwentyNineMember-2024-06-30 0001743881
bbio:TwoPointTwoFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember-2023-04-01-2023-06-30 0001743881-us-gaap:MoneyMarketFundsMember-2023-12-31 0001743881-us-gaap:RetainedEarningsMember
2024-06-30 0001743881-bbio:SatisfyTaxWithholdingMember-us-gaap:CommonStockMember-2023-04-01-2023-06-30 0001743881-bbio:InterestTwoThousandAndTwentySevenAndTwoThousandAndTwentyNineMember-2024-06-30
0001743881-bbio:BridgeBioServicesIncMember-bbio:MarketBasedRestrictedStockUnitsRSUMember-bbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMember-2024-06-30 0001743881
bbio:DevelopmentAndManufacturingServicesAgreementMember-2023-09-01-2023-09-30 0001743881-bbio:EidosTherapeuticsIncMember-bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember
2023-12-31 0001743881-2023-04-01-2023-06-30 0001743881-us-gaap:StockCompensationPlanMember-us-gaap:ParentMember-2024-04-01-2024-06-30 0001743881-us-gaap:RestrictedStockMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2023-12-31 0001743881-bbio:AgencyDiscountNotesMember-us-gaap:FairValueInputsLevel3Member-us-
gaap:FairValueMeasurementsRecurringMember-2024-06-30 0001743881-bbio:RegularEquityProgramMember-us-gaap:RestrictedStockMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2024-01-01-2024-06-30 0001743881-bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember
bbio:PerformanceBasedStockOptionsMember-2020-11-18-2020-11-18 0001743881-us-gaap:StockCompensationPlanMember-2023-01-01-2023-03-31 0001743881-us-gaap:MoneyMarketFundsMember-us-
gaap:FairValueInputsLevel3Member-us-gaap:FairValueMeasurementsRecurringMember-2023-12-31 0001743881-us-gaap:RestrictedStockMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2024-01-01-2024-06-30 0001743881-srt:MaximumMember-bbio:FollowOnOfferingMember-us-gaap:CommonStockMember-2023-03-31
0001743881-bbio:OtherConsolidatedEntitiesMember-2023-01-01-2023-06-30 0001743881-us-gaap:EmployeeStockMember-us-gaap:CommonStockMember-2023-01-01-2023-03-31 0001743881-bbio:QEDTherapeuticsIncMember
bbio:LicenseAndCollaborationAgreementMember-2024-01-01-2024-06-30 0001743881-srt:MaximumMember-bbio:TrancheOneAdvanceMember-bbio:LoanAgreementMember-2022-05-31 0001743881
bbio:UnvestedRestrictedStockAwardMember-2023-01-01-2023-06-30 0001743881-bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2024-06-30 0001743881
bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember-bbio:PerformanceBasedRestrictedStockUnitsMember-2020-04-22-2020-04-22 0001743881-bbio:OtherConsolidatedEntitiesMember-us-
gaap:SellingGeneralAndAdministrativeExpensesMember-2024-01-01-2024-06-30 0001743881-us-gaap:NoncontrollingInterestsMember-2023-12-31 0001743881-us-gaap:RetainedEarningsMember-2024-03-31 0001743881-us-
gaap:FairValueInputsLevel3Member-us-gaap:FairValueMeasurementsRecurringMember-2023-12-31 0001743881-bbio:AccruedResearchAndDevelopmentLiabilitiesMember-2024-06-30 0001743881-bbio:InitialTermLoanMember
bbio:FinancingAgreementMember-2024-01-01-2024-06-30 0001743881-bbio:BridgeBioServicesIncMember-bbio:MarketBasedRestrictedStockUnitsRSUMember-bbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMember-
2024-01-01-2024-06-30 0001743881-us-gaap:AdditionalPaidInCapitalMember-2023-12-31 0001743881-us-gaap:StockCompensationPlanMember-2023-04-01-2023-06-30 0001743881-us-gaap:EmployeeStockOptionMember
bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember-2023-04-01-2023-06-30 0001743881-us-gaap:RestrictedStockMember-2024-01-01-2024-06-30 0001743881-us-
gaap:AccumulatedOtherComprehensiveIncomeMember-2023-01-01-2023-03-31 0001743881-bbio:OtherConsolidatedEntitiesMember-bbio:RestructuringImpairmentAndRelatedChargesMember-2024-01-01-2024-06-30 0001743881-us-
gaap:EmployeeStockOptionMember-2024-01-01-2024-06-30 0001743881-bbio:BridgeBioServicesIncMember-bbio:RestructuringImpairmentAndRelatedChargesMember-2024-04-01-2024-06-30 0001743881
bbio:BridgeBioServicesIncMember-us-gaap:SellingGeneralAndAdministrativeExpensesMember-2024-01-01-2024-06-30 0001743881-bbio:InitialTermLoanMember-bbio:FinancingAgreementMember-2024-01-17 0001743881
bbio:QEDTherapeuticsIncMember-us-gaap:LicenseMember-bbio:KyowaKirinExclusiveLicenseMember-2024-01-01-2024-06-30 0001743881-bbio:KyowaKirinExclusiveLicenseMember-2024-06-30 0001743881
bbio:PrincipalValueAndInterestOnTwoPointFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember-2024-06-30 0001743881-bbio:EidosTherapeuticsIncMember-us-gaap:LicenseMember
bbio:BaseExclusiveLicenseAgreementMember-2024-01-01-2024-06-30 0001743881-bbio:OriginAndSentynTherapeuticsIncMember-2022-03-31 0001743881-bbio:LoanAgreementMember-2022-11-30 0001743881
bbio:LoanAgreementMember-2024-01-01-2024-06-30 0001743881-bbio:PrincipalValueAndInterestOnTwoPointFivePercentConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember-2024-06-30 0001743881
bbio:UnvestedRestrictedStockUnitMember-2024-01-01-2024-06-30 0001743881-us-gaap:ParentMember-2023-01-01-2023-03-31 0001743881-bbio:SatisfyTaxWithholdingMember-us-gaap:CommonStockMember-2023-01-01-2023-
03-31 0001743881-bbio:BridgeBioServicesIncMember-bbio:MarketBasedRestrictedStockUnitsRSUMember-bbio:TwoThousandTwentyOneStockOptionAndIncentivePlanMember-2023-01-01-2023-12-31
0001743881-2024-04-01-2024-06-30 0001743881-us-gaap:StockCompensationPlanMember-us-gaap:AdditionalPaidInCapitalMember-2024-04-01-2024-06-30 0001743881
bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember-2023-01-01-2023-06-30 0001743881-bbio:TwoThousandTwentyFourFollowOnOfferingMember-us-gaap:CommonStockMember-2024-03-01-2024-03-31
0001743881-bbio:SatisfyTaxWithholdingMember-2024-04-01-2024-06-30 0001743881-us-gaap:ParentMember-2024-01-01-2024-03-31 0001743881-us-gaap:CommonStockMember-2024-03-31 0001743881
bbio:ExclusiveLicenseAgreementsWithBayerConsumerCareAndKyowaKirinColdMember-2024-01-01-2024-03-31 0001743881-bbio:AgencyDiscountNotesMember-2024-06-30 0001743881
bbio:TheRasIncMember-bbio:BridgeBioOncologyTherapeuticsIncMember-2024-05-01-2024-06-30 0001743881-us-gaap:TreasuryStockCommonMember-2023-03-31 0001743881-bbio:SatisfyTaxWithholdingMember-us-
gaap:AdditionalPaidInCapitalMember-2024-01-01-2024-03-31 0001743881-us-gaap:USTreasuryBillSecuritiesMember-us-gaap:FairValueMeasurementsRecurringMember-2023-12-31 0001743881
bbio:SatisfyTaxWithholdingMember-us-gaap:ParentMember-2023-04-01-2023-06-30 0001743881-bbio:TwoThousandNineteenInducementEquityPlansMember-us-gaap:CommonStockMember-2024-06-30 0001743881-us-
gaap:AdditionalPaidInCapitalMember-2023-01-01-2023-03-31 0001743881-srt:MinimumMember-us-gaap:EmployeeStockOptionMember-bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember
2024-01-01-2024-06-30 0001743881-bbio:LianBioMember-bbio:EquityMethodInvesteesIpoMember-2024-01-01-2024-06-30 0001743881-us-gaap:RetainedEarningsMember-2023-03-31 0001743881-us-
gaap:AccumulatedOtherComprehensiveIncomeMember-2024-04-01-2024-06-30 0001743881-bbio:EidosTherapeuticsIncMember-us-gaap:CommonStockMember-bbio:AlexionAgreementsMember-2019-09-30 0001743881-us-
gaap:USTreasuryBillSecuritiesMember-us-gaap:FairValueInputsLevel3Member-us-gaap:FairValueMeasurementsRecurringMember-2024-06-30 0001743881-bbio:LianBioMember-bbio:EquityMethodInvesteesIpoMember-2024-04-
01-2024-06-30 0001743881-bbio:LicenseAndCollaborationAgreementMember-2023-12-31 0001743881-bbio:RedeemableConvertibleNoncontrollingInterestsMember-2023-06-30 0001743881-bbio:CappedCallTransactionsMember
2020-03-04 0001743881-us-gaap:NoncontrollingInterestsMember-2023-03-31 0001743881-bbio:QEDTherapeuticsIncMember-us-gaap:LicenseMember-bbio:KyowaKirinExclusiveLicenseMember-2024-04-01-2024-06-30
0001743881-us-gaap:AccumulatedOtherComprehensiveIncomeMember-2023-03-01-2023-03-31 0001743881-us-gaap:RestrictedStockUnitsRSUMember-bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember
2024-01-01-2024-06-30 0001743881-bbio:TheRasIncMember-bbio:TransitionServiceAgreementMember-bbio:BridgeBioOncologyTherapeuticsIncMember-2024-04-01-2024-06-30 0001743881-us-
gaap:SellingGeneralAndAdministrativeExpensesMember-2024-01-01-2024-06-30 pure shares-bbio:TradingDay-bbio:Instalment iso4217:USD shares-bbio:Employee-bbio:Grantee iso4217:USD -12-31 0001743881-02
false http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-
gaap/2024#OtherAssetsNoncurrent PSD PSD PSD P3Y P3Y 0-0 true 2024-06-30 2024 false 001-38959 BridgeBio Pharma, Inc. DE 04-1850815 3160 Porter Drive Suite 250 Palo Alto CA 94304 650 391-9740 Common

[illegible]

[illegible]

width:fit-content;"/></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">47,761</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Milestone Liability</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other accrued liabilities</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued professional and other accrued liabilities</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Concentration of credit risk and other risks and uncertainties</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, receivables from license and collaboration agreements, and restricted cash. Substantially all of our cash, cash equivalents, marketable securities and restricted cash are held in financial institutions in the United States. Amounts on deposit may at times exceed federally insured limits. Although management currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced or recorded any credit losses associated with its balances as of June 30, 2024 and December 31, 2023, and for the three and six months ended June 30, 2024 and 2023.</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">We are subject to credit risk from receivables from license and collaboration agreements. We have not experienced any material losses related to receivables from individual customers or groups of customers. We also do not require any collateral. Receivables from license and collaboration agreements are recorded net of allowance for credit losses, if any.</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">We are dependent on third-party manufacturers to supply products for research and development activities in our programs. In particular, we rely and expect to continue to rely on a small number of manufacturers to supply us with our requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Use of Estimates</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to:</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Revenue from Contracts with Customers</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Basis of Presentation and Principles of Consolidation</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash, Cash Equivalents and Marketable Securities</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">We consider all highly liquid investments purchased with original maturities of</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Our marketable securities consist of high investment grade fixed income securities that are primarily invested in U.S. treasury bills. We classify our marketable securities as available-for-sale securities and report them at fair value in "Cash and cash equivalents" or "Marketable securities" on the condensed consolidated balance sheets with related unrealized gains and losses included as a component of stockholders' deficit. We classify our marketable securities as either short-term or long-term based on each instrument's underlying contractual maturity date. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity which is included in "Interest income" on the condensed consolidated statements of operations. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in "Other income (expense), net." The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Our cash, cash equivalents and marketable securities are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as commercial paper, U.S. government obligations, treasury bills, and money market funds, and places restrictions on maturities and concentrations by type and issuer.</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown on the condensed consolidated statements of cash flows.</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table></div>

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Color:<#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content>>During any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the last reported sale price of BridgeBio's common stock for at least span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content">20span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> trading days (whether or not consecutive) during a period of span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content">30span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content">130span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> percent of the conversion price on each applicable trading day, div></div>div class="item-list-element-wrapper" style="margin-left:4.53%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0,min-width:4.53%;text-align:left;">span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">4.752626672113803%display:inline-flex;justify-content:flex-start;">div style="width:100%;display:inline;">span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">During the span-style="font-size:10pt;font-family:Times New Roman;">span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> business day period after any span-style="font-size:10pt;font-family:Times New Roman;">sec-ix-hidden:f_cdi73994-c652-477b-aeb0-4e4eb15f7b65">span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> fivespan>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> consecutive trading day period (the "measurement period") in which the "trading price" (as defined in the 2020 Notes Indenture) per span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content">1.000span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> principal amount of 2020 Notes for each trading day of the measurement period was less than span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content">98span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> percent of the product of the last reported sale price of BridgeBio's common stock and the conversion rate on each such trading day, div></div>div class="item-list-element-wrapper" style="margin-left:4.53%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0,min-width:4.53%;text-align:left;">span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">4.752626672113803%display:inline-flex;justify-content:flex-start;">div style="width:100%;display:inline;">span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">Upon the occurrence of specified corporate events, as defined in the 2020 Notes Indenture, div></div>div class="item-list-element-wrapper" style="margin-left:4.53%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0,min-width:4.53%;text-align:left;">span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">4.752626672113803%display:inline-flex;justify-content:flex-start;">div style="width:100%;display:inline;">span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">On or after November 1, 2026 until the close of business on the second scheduled trading day immediately preceding the maturity date, a holder may convert all or any portion of its 2020 Notes at any time, regardless of the foregoing, p>span style="text-indent:4.53%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">The conversion rate will initially be span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content">10.3050span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> percent of BridgeBio's common stock per span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content">1.000span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> principal amount of 2020 Notes (equivalent to an initial conversion price of approximately span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content">97.04span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> percent share of BridgeBio's common stock, for a total of approximately span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content">7.792,988span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> shares). p>span style="text-indent:4.53%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity dates, span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">or if we deliver a notice of redemption, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2020 Notes in connection with such a corporate event. The maximum number of shares issuable should there be an increase in the conversion rate is span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content">11,361,551span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> shares of BridgeBio's common stock, p>span style="text-indent:4.53%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">span style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">We may not redeem the 2020 Notes prior to February 6, 2026. We may redeem for cash all or any portion of the 2020 Notes, at our option, on a redemption date occurring on or after February 6, 2026 and on or before the 41span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> scheduled trading day immediately before the maturity date, under certain circumstances. No sinking fund is provided for the Notes. If we undergo a fundamental change (as defined in the 2020 Notes Indenture), holders may require us to repurchase for cash all or any portion of their 2020 Notes at a fundamental change repurchase price equal to span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content">100span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> percent of the principal amount of the 2020 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The 2020 Notes Indenture contains customary terms and covenants, including that upon certain events of default occurring and continuing, either the 2020 Notes Trustee or the holders of not less than span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap,min-width:fit-content">16.15span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> million of debt issuance costs, which consisted of initial purchasers' discounts. This was recorded as a reduction in the carrying value of the debt on the condensed consolidated balance sheets and is amortized to interest expense using the effective interest method over the expected life of the 2020 Notes or approximately theirspan>span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> termspan>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> 2027span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> million of our 2027 Notes pursuant to an Indenture dated span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">March 9, 2020span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> million of our 2027 Notes pursuant to an Indenture dated span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">March 9, 2020span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> million of our 2027 Notes pursuant to an Indenture dated span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">March 9, 2020span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> million of our 2027 Notes pursuant to an Indenture dated span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">March 9, 2020span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> million of our 2027 Notes pursuant to an Indenture dated span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">March 9, 2020span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> million of our 2027 Notes pursuant to an Indenture dated span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">March 9, 2020span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> million of our 2027 Notes pursuant to an Indenture dated span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">March 9, 2020span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content"> million of our 2027 Notes pursuant to an Indenture dated span-style="font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content">March 9, 2020span>span-style="color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

agreed purchase price per share of common stock in the repurchases were \$.65 .75 .85 .95 1.05 1.15 1.25 1.35 1.45 1.55 1.65 1.75 1.85 1.95 2.05 2.15 2.25 2.35 2.45 2.55 2.65 2.75 2.85 2.95 3.05 3.15 3.25 3.35 3.45 3.55 3.65 3.75 3.85 3.95 4.05 4.15 4.25 4.35 4.45 4.55 4.65 4.75 4.85 4.95 5.05 5.15 5.25 5.35 5.45 5.55 5.65 5.75 5.85 5.95 6.05 6.15 6.25 6.35 6.45 6.55 6.65 6.75 6.85 6.95 7.05 7.15 7.25 7.35 7.45 7.55 7.65 7.75 7.85 7.95 8.05 8.15 8.25 8.35 8.45 8.55 8.65 8.75 8.85 8.95 9.05 9.15 9.25 9.35 9.45 9.55 9.65 9.75 9.85 9.95 10.05 10.15 10.25 10.35 10.45 10.55 10.65 10.75 10.85 10.95 11.05 11.15 11.25 11.35 11.45 11.55 11.65 11.75 11.85 11.95 12.05 12.15 12.25 12.35 12.45 12.55 12.65 12.75 12.85 12.95 13.05 13.15 13.25 13.35 13.45 13.55 13.65 13.75 13.85 13.95 14.05 14.15 14.25 14.35 14.45 14.55 14.65 14.75 14.85 14.95 15.05 15.15 15.25 15.35 15.45 15.55 15.65 15.75 15.85 15.95 16.05 16.15 16.25 16.35 16.45 16.55 16.65 16.75 16.85 16.95 17.05 17.15 17.25 17.35 17.45 17.55 17.65 17.75 17.85 17.95 18.05 18.15 18.25 18.35 18.45 18.55 18.65 18.75 18.85 18.95 19.05 19.15 19.25 19.35 19.45 19.55 19.65 19.75 19.85 19.95 20.05 20.15 20.25 20.35 20.45 20.55 20.65 20.75 20.85 20.95 21.05 21.15 21.25 21.35 21.45 21.55 21.65 21.75 21.85 21.95 22.05 22.15 22.25 22.35 22.45 22.55 22.65 22.75 22.85 22.95 23.05 23.15 23.25 23.35 23.45 23.55 23.65 23.75 23.85 23.95 24.05 24.15 24.25 24.35 24.45 24.55 24.65 24.75 24.85 24.95 25.05 25.15 25.25 25.35 25.45 25.55 25.65 25.75 25.85 25.

[illegible]

span-wrap;font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>We have entered into asset sales transactions that occurred during the three months ended March 31, 2024 for the exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd./span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>for which the Company is required to deposit span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">>75\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>of the proceeds, net of certain permitted costs, upon receipt of the upfront payments from Bayer Consumer Care AG and span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>Kyowa Kirin Co., Ltd. into the escrow accounts.span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>During the three months ended June 30, 2024, we received span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>235.0\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million in aggregate from span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>Bayer Consumer Care AG and span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>Kyowa Kirin Co., Ltd.span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>and deposited net proceeds of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>159.3\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million into the escrow accounts.span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>Refer to Note 11 for further details regarding the exclusive license agreements with Bayer Consumer Care AG and Kyowa Kirin Co., Ltd.span>span style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>The completion of the span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">>200.0\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million private equity financing with external investors of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>BBOTspan style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>was considered an asset sale transaction that was subject to a disposition fee under the Financing Agreement. Accordingly, we paid a disposition fee of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>1.1\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million to the Administrative Agent during the three months ended June 30, 2024.span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>Refer to Note 6 for further details regarding the BBOT private equity financing transaction.span>span style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>The Financing Agreement contains affirmative covenants and negative covenants applicable to the Company and its subsidiaries that are customary for financings of this type. Such covenants, among other items, limit the Company's and its subsidiaries' ability to (i) incur additional permitted indebtedness, (ii) pay dividends or make certain distributions, (iii) dispose of its and their assets, grant liens and license or permit other encumbrances on its and their assets, (iv) fundamentally alter the nature of their businesses and (v) enter into certain transactions with affiliates. The Company and the Guarantors are also required to maintain a minimum qualified cash balance of span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">>70.0\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, at all times. The Company and its subsidiaries are permitted to license their intellectual property, dispose of other assets and enter into monetization and royalty transactions, in each case, subject to satisfaction of certain terms and conditions. The Financing Agreement also includes representations, warranties, indemnities and events of default that are customary for financings of this type, including an event of default relating to a change of control of the Company. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate the Company's obligations under the Financing Agreement.span>span style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>On June 20, 2024, the Company and each of the guarantors entered into the Second Amendment to the Financing Agreement (the Financing Agreement, as amended by the Second Amendment, the "Amended Financing Agreement"). Under the Amended Financing Agreement, span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>between June 20, 2024 and through the earlier of the date the FDA approves a first NDA for acoramidis and November 30, 2024, the Company is able to request a release of funds in an aggregate amount not to exceed span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">>50\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>of the original net cash proceeds received from asset sale transactions.span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>As of June 30, 2024, span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>20.0\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million was released from the escrow accounts and classified as cash, with a remaining balance of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>139.3\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million.span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>In the escrow accounts classified as "restricted cash" on the condensed consolidated balance sheet, span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>70.0\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million plus span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>40\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, respectively, relates to amortization of debt discount and issuance costs. As of June 30, 2024, the minimum unrestricted qualified cash balance was span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>78.0\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>14.533\$/span>span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">>million, after deducting debt discount and issuance costs of </span

space:nowrap;vertical-align:bottom;"/>

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to commissions paid to KCH and offering costs of \$

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

font-family:Times New Roman;margin-bottom:0;text-align:left;"/>

[illegible]

```
<div><div style=
```


[illegible]

[illegible]

[illegible]

```


<img alt="White space: pre-wrap; min-width: fit-content;" data-bbox="113 10 886 990"/>


```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```

bottom:0;text-align:left;"/>Unvested market-based RSUs375,000
```